PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Tappero, JW; Reporter, R; Wenger, JD; Ward, BA; Reeves, MW; Missbach, TS; Plikaytis, BD; Mascola, L; Schuchat, A				Tappero, JW; Reporter, R; Wenger, JD; Ward, BA; Reeves, MW; Missbach, TS; Plikaytis, BD; Mascola, L; Schuchat, A			Meningococcal disease in Los Angeles County, California, and among men in the county jails	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTILOCUS ENZYME ELECTROPHORESIS; NEISSERIA-MENINGITIDIS; SEROGROUP-C; RISK-FACTORS; CARRIAGE; EPIDEMIC; TUBERCULOSIS; POPULATION; INFECTION; INFLUENZA	Background From January through March 1993, there were 54 cases of meningococcal disease in Los Angeles County, California, of which 9 occurred among men incarcerated in the county's jail system, which was 40 percent above capacity at the time. Several of the 45 patients from the community had had contact with men recently released from a county jail. Methods We interviewed patients from the community (n = 42) and neighborhood controls matched with the patients for age, race, and ethnic group (n = 84) about potential exposures. We collected and cultured pharyngeal swabs for Neisseria meningitidis from men entering the central jail (n = 162), men leaving the central jail (n = 379), members of the jail staff (n = 121), and patients at a community health center (n = 214). Meningococcal isolates were identified by serogrouping and multilocus enzyme electrophoresis. Results The presence of community-acquired meningococcal disease was strongly associated with exposure to a person who had been in or worked at one of the county jails (multivariate matched odds ratio, 18.5; 95 percent confidence interval, 3.8 to 90.8; P<0.001). Pharyngeal carriage of meningococcus was significantly more frequent among men released from jail (19 percent) or entering jail (17 percent) than among workers at the jails (3 percent) or community residents seen at the clinic (1 percent). Among men entering jail, those who had previously been incarcerated were more often carriers than those who had not (21 percent vs. 7 percent, P = 0.03). Of the isolates from nine community residents with serogroup C meningococcal disease, eight were the same strain as that isolated from the eight inmates with serogroup C disease. Conclusions In this outbreak of meningococcal disease in Los Angeles County, nearly half of community residents with the disease had contact with persons who had been in a county jail. The high rates of carriage among recidivists and released inmates suggest that the men became meningococcal carriers while in jail. (C) 1996, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT,CHILDHOOD & RESP DIS BRANCH,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,BIOSTAT & INFORMAT BRANCH,NATL CTR INFECT DIS,ATLANTA,GA 30333; LOS ANGELES CTY DEPT HLTH SERV,PUBL HLTH PROGRAMS & SERV,LOS ANGELES,CA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								AYCOCK WL, 1950, BACTERIOL REV, V14, P115, DOI 10.1128/MMBR.14.2.115-160.1950; BROOME CV, 1986, J ANTIMICROB CHEMOTH, V18, P25, DOI 10.1093/jac/18.Supplement_A.25; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; CAUGANT DA, 1987, J BACTERIOL, V169, P2781, DOI 10.1128/jb.169.6.2781-2792.1987; CAUGANT DA, 1994, J CLIN MICROBIOL, V32, P323, DOI 10.1128/JCM.32.2.323-330.1994; DEWALS P, 1981, J INFECTION, V3, P53, DOI 10.1016/S0163-4453(81)80009-6; FRASER PK, 1973, LANCET, V1, P1235; GLASER JB, 1993, ANN INTERN MED, V118, P139, DOI 10.7326/0003-4819-118-2-199301150-00010; GOLD R, 1978, J INFECT DIS, V137, P112, DOI 10.1093/infdis/137.2.112; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; GREENFIELD S, 1971, J INFECT DIS, V123, P67, DOI 10.1093/infdis/123.1.67; HANEBERG B, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P169; HARRISON LH, 1991, ARCH INTERN MED, V151, P1005, DOI 10.1001/archinte.151.5.1005; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; HOSPEDALES CJ, 1994, EP INT SERV 43 ANN C; Imrey PB, 1996, AM J EPIDEMIOL, V143, P624, DOI 10.1093/oxfordjournals.aje.a008792; IMREY PB, 1995, J CLIN MICROBIOL, V33, P3133, DOI 10.1128/JCM.33.12.3133-3137.1995; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; JACOBS D, 1990, 15TH P ANN SAS US GR, P1413; Jones D M, 1994, Commun Dis Rep CDR Rev, V4, pR97; KING L, 1977, JAMA-J AM MED ASSOC, V237, P791, DOI 10.1001/jama.237.8.791; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; KREMASTINOU J, 1994, SCAND J INFECT DIS, V26, P719, DOI 10.3109/00365549409008641; Le Saux N, 1992, Can J Infect Dis, V3, P60; MARKS MI, 1979, AM J EPIDEMIOL, V109, P563, DOI 10.1093/oxfordjournals.aje.a112714; Mitchell LA, 1996, J INFECT DIS, V173, P1009, DOI 10.1093/infdis/173.4.1009; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; MORROW HW, 1990, PEDIATR INFECT DIS J, V9, P394, DOI 10.1097/00006454-199006000-00005; MUNFORD RS, 1974, LANCET, V1, P1275; OLSEN SF, 1991, EPIDEMIOL INFECT, V106, P445, DOI 10.1017/S0950268800067492; REEVES MW, 1995, EMERG INFECT DIS, V1, P53, DOI 10.3201/eid0102.950203; *SAS I, 1994, MICR WIND ENV CHANG; SCHOLTEN RJPM, 1994, J INFECT DIS, V169, P673, DOI 10.1093/infdis/169.3.673; SCHWARTZ B, 1991, REV INFECT DIS, V13, pS170; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315, DOI 10.1017/S0950268800057733; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; STUART JM, 1988, COMMUNITY MED, V10, P139; STUART JM, 1989, LANCET, V2, P723, DOI 10.1016/S0140-6736(89)90781-2; THOMAS JC, 1991, AM J EPIDEMIOL, V133, P286, DOI 10.1093/oxfordjournals.aje.a115873; THOMAS JC, 1993, AM J PUBLIC HEALTH, V83, P1790, DOI 10.2105/AJPH.83.12.1790; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; WHALEN CM, 1995, JAMA-J AM MED ASSOC, V273, P390, DOI 10.1001/jama.273.5.390; WOODS TC, 1992, J CLIN MICROBIOL, V30, P132, DOI 10.1128/JCM.30.1.132-137.1992; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; 1989, MMWR-MORBID MORTAL W, V38, P635; 1989, MMWR-MORBID MORTAL W, V34, P615; 1976, JAMA-J AM MED ASSOC, V235, P261; 1995, MMWR-MORBID MORTAL W, V44, P121; 1985, MMWR-MORBID MORTAL W, V34, P255; 1992, MMWR-MORBID MORTAL W, V41, P927; 1992, MMWR-MORBID MORTAL W, V41, P507; 1989, MMWR-MORBID MORTAL W, V38, P641	53	47	52	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1996	335	12					833	840		10.1056/NEJM199609193351201	http://dx.doi.org/10.1056/NEJM199609193351201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG869	8778600				2022-12-24	WOS:A1996VG86900001
J	Bry, L; Falk, PG; Midtvedt, T; Gordon, JI				Bry, L; Falk, PG; Midtvedt, T; Gordon, JI			A model of host-microbial interactions in an open mammalian ecosystem	SCIENCE			English	Article							GERM-FREE; DIFFERENTIATION; MOUSE; INTESTINE; ECOLOGY; MICE; GLYCOSYLATION; EPITHELIUM; BACTERIA; ADHESION	The maintenance and significance of the complex populations of microbes present in the mammalian intestine are poorly understood. Comparison of conventionally housed and germ-free NMRI mice revealed that production of fucosylated glycoconjugates and an alpha 1,2-fucosyltransferase messenger RNA in the small-intestinal epithelium requires the normal microflora. Colonization of germ-free mice with Bacteroides thetaiotadmicron, a component of this flora, restored the fucosylation program, whereas an isogenic strain carrying a transposon insertion that disrupts its ability to use L-fucose as a carbon source did not. Simplified models such as this should aid the study of open microbial ecosystems.	WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; KAROLINSKA INST, DEPT MED, S-17177 STOCKHOLM, SWEDEN; KAROLINSKA INST, LAB MED MICROBIAL ECOL, S-17177 STOCKHOLM, SWEDEN	Washington University (WUSTL); Karolinska Institutet; Karolinska Institutet				Bry, Lynn/0000-0002-8792-8527	NIDDK NIH HHS [DK30292, DK37960] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037960, R37DK030292, R01DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIOL MC, 1994, BIOCHIMIE, V14, P13; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; Bry L, 1996, P NATL ACAD SCI USA, V93, P1161, DOI 10.1073/pnas.93.3.1161; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FALK P, 1994, METHOD CELL BIOL, V45, P165; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; GRANHOLM T, 1992, CYTOKINE, V4, P545, DOI 10.1016/1043-4666(92)90017-L; GUSTAFSSON BE, 1959, ANN NY ACAD SCI, V78, P17, DOI 10.1111/j.1749-6632.1959.tb53092.x; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; LENOIR D, 1995, BBA-BIOMEMBRANES, V1234, P29, DOI 10.1016/0005-2736(94)00254-M; MIDTVEDT T, 1986, MICROECOL THER, V16, P121; NORIN KE, 1985, ACTA PAEDIATR SCAND, V74, P207, DOI 10.1111/j.1651-2227.1985.tb10951.x; PUSZTAI A, 1995, GLYCOCONJUGATE J, V12, P22, DOI 10.1007/BF00731865; SALYERS AA, 1989, APPL ENVIRON MICROB, V55, P2572, DOI 10.1128/AEM.55.10.2572-2578.1989; SAVAGE DC, 1989, WENNER-GR C, V52, P3; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SHINDO K, 1976, Gastroenterologia Japonica, V11, P167; STARK PL, 1982, J MED MICROBIOL, V15, P189, DOI 10.1099/00222615-15-2-189; UMESAKI Y, 1995, MICROBIOL IMMUNOL, V39, P555, DOI 10.1111/j.1348-0421.1995.tb02242.x; USHIJIMA T, 1983, MICROBIOL IMMUNOL, V27, P985, DOI 10.1111/j.1348-0421.1983.tb02929.x; VANDERWAAIJ D, 1989, ANNU REV MICROBIOL, V43, P69, DOI 10.1146/annurev.micro.43.1.69; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97	25	458	505	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1380	1383		10.1126/science.273.5280.1380	http://dx.doi.org/10.1126/science.273.5280.1380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703071				2022-12-24	WOS:A1996VF61000040
J	Chitty, LS; Barnes, CA; Berry, C				Chitty, LS; Barnes, CA; Berry, C			Continuing with pregnancy after a diagnosis of lethal abnormality: Experience of five couples and recommendations for management	BRITISH MEDICAL JOURNAL			English	Article							LOW-RISK POPULATION; ROUTINE; ULTRASOUND				Chitty, LS (corresponding author), UCL HOSP, OBSTET HOSP, FETAL MED UNIT, LONDON WC1E 6AU, ENGLAND.			chitty, lyn/0000-0002-4857-7138				CHITTY LS, 1991, BRIT MED J, V303, P1165, DOI 10.1136/bmj.303.6811.1165; HUNFELD JAM, 1993, PRENATAL DIAG, V13, P603, DOI 10.1002/pd.1970130711; LILFORD RJ, 1994, BRIT J OBSTET GYNAEC, V101, P291, DOI 10.1111/j.1471-0528.1994.tb13612.x; MARTEAU T, 1994, J MED GENET, V31, P864, DOI 10.1136/jmg.31.11.864; SHIRLEY IM, 1992, BRIT J RADIOL, V65, P564, DOI 10.1259/0007-1285-65-775-564; WATKINS D, 1989, PRACTITIONER, V233, P990	6	54	55	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					478	480						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776321				2022-12-24	WOS:A1996VE08000028
J	Zimmerman, LB; DeJesusEscobar, JM; Harland, RM				Zimmerman, LB; DeJesusEscobar, JM; Harland, RM			The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; EARLY XENOPUS EMBRYO; NEURAL INDUCTION; VENTRALIZING FACTOR; BETA FAMILY; RECEPTOR; MESODERM; BMP-4; CELLS; DIFFERENTIATION	Signals released by the Spemann organizer of the amphibian gastrula can directly induce neural tissue from ectoderm and can dorsalize ventral mesoderm to form muscle. The secreted polypeptide noggin mimics these activities and is expressed at the appropriate time and place to participate in the organizer signal. Neural induction and mesoderm dorsalization are antagonized by bone morphogenetic proteins (BMPs), which induce epidermis and ventral mesoderm instead. Here we report that noggin protein binds BMP4 with high affinity and can abolish BMP4 activity by blocking binding to cognate cell-surface receptors. These data suggest that noggin secreted by the organizer patterns the embryo by interrupting BMP signaling.			Zimmerman, LB (corresponding author), UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [GM 49346, GM 15782] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049346, F32GM015782] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AONO A, 1995, BIOCHEM BIOPH RES CO, V210, P670, DOI 10.1006/bbrc.1995.1712; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; DALE L, 1992, DEVELOPMENT, V115, P573; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; ECONOMIDES AN, 1995, SCIENCE, V270, P1351, DOI 10.1126/science.270.5240.1351; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; HOLLEY SA, 1996, CELL, V86; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/jbc.270.10.5476; JONES CM, 1992, DEVELOPMENT, V115, P639; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LEIN P, 1995, NEURON, V15, P597, DOI 10.1016/0896-6273(95)90148-5; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LIU F, 1995, MOL CELL BIOL, V15, P3479; MAENO M, 1994, P NATL ACAD SCI USA, V91, P10260, DOI 10.1073/pnas.91.22.10260; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Moos M, 1995, DEVELOPMENT, V121, P4293; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; PLESSOW S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P280, DOI 10.1016/0167-4781(91)90026-I; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; ReemKalma Y, 1995, P NATL ACAD SCI USA, V92, P12141, DOI 10.1073/pnas.92.26.12141; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHMIDT JE, 1995, DEV BIOL, V169, P37, DOI 10.1006/dbio.1995.1124; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; VALENZUELA DM, 1995, J NEUROSCI, V15, P6077; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4	46	1313	1392	1	64	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					599	606		10.1016/S0092-8674(00)80133-6	http://dx.doi.org/10.1016/S0092-8674(00)80133-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752214	Bronze			2022-12-24	WOS:A1996VE23500010
J	Duverger, N; Tremp, G; Caillaud, JM; Emmanuel, F; Castro, G; Fruchart, JC; Steinmetz, A; Denefle, P				Duverger, N; Tremp, G; Caillaud, JM; Emmanuel, F; Castro, G; Fruchart, JC; Steinmetz, A; Denefle, P			Protection against atherogenesis in mice mediated by human apolipoprotein A-IV	SCIENCE			English	Article							HIGH-DENSITY-LIPOPROTEINS; CELL-DERIVED CHOLESTEROL; HUMAN-PLASMA; TRANSGENIC MICE; HUMAN-SERUM; ATHEROSCLEROSIS; HYPERCHOLESTEROLEMIA; ACYLTRANSFERASE; METABOLISM; ACTIVATION	Apolipoproteins ave protein constituents of plasma lipid transport particles. Human apolipoprotein A-IV (apoA-IV) was expressed in the liver of C57BL/6 mice and mice deficient in apoE, both of which are prone to atherosclerosis, to investigate whether apoA-IV protects against this disease. In transgenic C57BL/6 mice on an atherogenic diet, the serum concentration of high density lipoprotein (HDL) cholesterol increased by 35 percent, whereas the concentration of endogenous apoA-I decreased by 29 percent, relative to those in transgenic mice on a normal diet. Expression of human apoA-IV in apoE-deficient mice on a normal diet resulted in an even more severe atherogenic lipoprotein profile, without affecting the concentration of HDL cholesterol, than that in nontransgenic apoE-deficient mice. However, transgenic mice of both backgrounds showed a substantial reduction in the size of atherosclerotic lesions. Thus, apoA-IV appears to protect against atherosclerosis by a mechanism that does not involve an increase in HDL cholesterol concentration.	INST PASTEUR,INSERM 325,F-59019 LILLE,FRANCE; UNIV MARBURG,ZENTRUM INNERE MED ENDOKRINOL & STOFFWECHSEL,D-35043 MARBURG,GERMANY	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Philipps University Marburg	Duverger, N (corresponding author), RHONE POULENC RORER,GENCELL DIV,ATHEROSCLEROSIS DEPT,CTR RECH VITRY ALFORTVILLE,F-94403 VITRY SUR SEINE,FRANCE.							BEISIEGEL U, 1979, EUR J BIOCHEM, V93, P601, DOI 10.1111/j.1432-1033.1979.tb12860.x; BISGAIER CL, 1985, J LIPID RES, V26, P11; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEN CH, 1985, BIOCHIM BIOPHYS ACTA, V836, P279, DOI 10.1016/0005-2760(85)90131-6; DELALLERAMOYA M, 1994, ARTERIOSCLER THROMB, V14, P1056, DOI 10.1161/01.ATV.14.7.1056; Duverger N, 1996, CIRCULATION, V94, P713, DOI 10.1161/01.CIR.94.4.713; DUVERGER N, 1993, ARTERIOSCLER THROMB, V13, P126, DOI 10.1161/01.ATV.13.1.126; DVORIN E, 1986, J BIOL CHEM, V261, P5714; LAGROST L, 1989, J LIPID RES, V30, P1525; LEFEVRE M, 1984, J LIPID RES, V25, P1603; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; QUIAO JH, 1994, ARTERIOSCLER THROMB, V14, P1480; RADER DJ, 1993, J CLIN INVEST, V92, P1009, DOI 10.1172/JCI116606; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RYAN RO, 1990, J LIPID RES, V31, P1725; RYAN RO, 1993, J BIOL CHEM, V268, P1525; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; VONECKARDSTEIN A, 1995, ARTERIOSCL THROM VAS, V15, P1755, DOI 10.1161/01.ATV.15.10.1755; WEINBERG RB, 1992, J BIOL CHEM, V267, P8977; WEINBERG RB, 1985, J BIOL CHEM, V260, P4279; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	28	220	227	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					966	968		10.1126/science.273.5277.966	http://dx.doi.org/10.1126/science.273.5277.966			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688083				2022-12-24	WOS:A1996VC67000066
J	Cabral, JHM; Petosa, C; Sutcliffe, MJ; Raza, S; Byron, O; Poy, F; Marfatia, SM; Chishti, AH; Liddington, RC				Cabral, JHM; Petosa, C; Sutcliffe, MJ; Raza, S; Byron, O; Poy, F; Marfatia, SM; Chishti, AH; Liddington, RC			Crystal structure of a PDZ domain	NATURE			English	Article							PROTEINS; GRAPHICS; PROGRAM; ORIGIN; DHR	PDZ domains (also known as DHR domains or GLGF repeats) are similar to 90-residue repeats found in a number of proteins implicated in ion-channel and receptor clustering, and the linking of receptors to effector enzymes(1). PDZ domains are protein-recognition modules; some recognize proteins containing the consensus carboxy-terminal tripeptide motif S/TXV with high specificity(2-4). Other PDZ domains form homotypic dimers: the PDZ domain of the neuronal enzyme nitric oxide synthase binds to the PDZ domain of PSD-95, an interaction that has been implicated in its synaptic association(5). Here we report the crystal structure of the third PDZ domain of the human homologue of the Drosophila discs-large tumour-suppressor gene product, DlgA. It consists of a five-stranded antiparallel beta-barrel flanked by three alpha-helices. A groove runs over the surface of the domain, ending in a conserved hydrophobic pocket and a buried arginine; we suggest that this is the binding site for the C-terminal peptide.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; UNIV LEICESTER,DEPT NCMH,LEICESTER LE1 7RH,LEICS,ENGLAND; UNIV LEICESTER,DEPT CHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; DANA FARBER CANC INST,BOSTON,MA 02115; TUFTS UNIV,SCH MED,ST ELIZABETHS MED CTR,TUMOR CELL BIOL LAB,BOSTON,MA 02135	University of Leicester; University of Leicester; University of Leicester; Harvard University; Dana-Farber Cancer Institute; St. Elizabeth's Medical Center; Tufts University			Morais-Cabral, Joao H/J-4914-2013	Morais-Cabral, Joao H/0000-0002-4461-9716; Petosa, Carlo/0000-0002-9975-1167; Byron, Olwyn/0000-0001-7857-4520; Sutcliffe, Mike/0000-0003-0414-1700				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KNIGHT S, 1989, THESIS SWEDISH U AGR; KOMAU HC, 1995, SCIENCE, V269, P1737; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0	28	277	288	2	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					649	652		10.1038/382649a0	http://dx.doi.org/10.1038/382649a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757139				2022-12-24	WOS:A1996VC30300059
J	Cummings, DE; Brandon, EP; Planas, JV; Motamed, K; Idzerda, RL; McKnight, GS				Cummings, DE; Brandon, EP; Planas, JV; Motamed, K; Idzerda, RL; McKnight, GS			Genetically lean mice result from targeted disruption of the RII beta subunit of protein kinase A	NATURE			English	Article							BROWN ADIPOSE-TISSUE; OBESE GENE; TRANSGENIC MICE; FAT; THERMOGENESIS; RECEPTORS; WHITE	CYCLIC AMP is an important second messenger in the coordinated regulation of cellular metabolism, Its effects are mediated by cAMP-dependent protein kinase (PKA), which is assembled from two regulatory (R) and two catalytic (C) subunits, In mice there are four R genes (encoding RI alpha, RI beta, RII alpha, and RII beta) and two C genes (encoding C alpha and C beta), expressed in tissue specific patterns(1). The RII beta isoform is abundant in brown and white adipose tissue and brain, with limited expression elsewhere. To elucidate its functions, we generated RII beta knockout mice, Here we report that mutants appear healthy but have markedly diminished white adipose tissue despite normal food intake, They are protected against developing diet-induced obesity and fatty livers, Mutant brown adipose tissue exhibits a compensatory increase in RI alpha, which almost entirely replaces lost RII beta, generating an isoform switch, The holoenzyme from mutant adipose tissue binds cAMP more avidly and is more easily activated than wild-type enzyme, This causes induction of uncoupling protein and elevations of metabolic rate and body temperature, contributing to the lean phenotype. Our results demonstrate a role for the RII beta holoenzyme in regulating energy balance and adiposity.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Planas, Josep/0000-0002-6525-9617				ARNER P, 1995, NEW ENGL J MED, V333, P382, DOI 10.1056/NEJM199508103330612; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CARNEHEIM C, 1988, AM J PHYSIOL, V254, pE155, DOI 10.1152/ajpendo.1988.254.2.E155; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; JEQUIER E, 1987, BAILLIERE CLIN ENDOC, V1, P911, DOI 10.1016/S0950-351X(87)80011-3; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KOPECKY J, 1990, J BIOL CHEM, V265, P22204; KOZAK LP, 1991, GENE DEV, V5, P2256, DOI 10.1101/gad.5.12a.2256; LAFONTAN M, 1993, J LIPID RES, V34, P1057; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SCHNEIDER A, 1993, NAT GENET, V5, P381, DOI 10.1038/ng1293-381; STEIN DT, 1995, INT J OBESITY, V19, P804; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	28	346	354	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					622	626		10.1038/382622a0	http://dx.doi.org/10.1038/382622a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757131				2022-12-24	WOS:A1996VC30300051
J	Labahn, J; Scharer, OD; Long, A; EzazNikpay, K; Verdine, GL; Ellenberger, TE				Labahn, J; Scharer, OD; Long, A; EzazNikpay, K; Verdine, GL; Ellenberger, TE			Structural basis for the excision repair of alkylation-damaged DNA	CELL			English	Article							ENZYME ENDONUCLEASE-III; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 3-METHYLADENINE-DNA GLYCOSYLASE; SACCHAROMYCES-CEREVISIAE; CATALYTIC MECHANISM; ALKA GENE; CLONING; PROTEIN; CDNA	Base-excision DNA repair proteins that target alkylation damage act on a variety of seemingly dissimilar adducts, yet fail to recognize other closely related lesions. The 1.8 Angstrom crystal structure of the monofunctional DNA glycosylase AlkA (E. coli 9-methyladenine-DNA glycosylase II) reveals a large hydrophobic cleft unusually rich in aromatic residues. An Asp residue projecting into this cleft is essential for catalysis, and it governs binding specificity for mechanism-based inhibitors. We propose that AlkA recognizes electron-deficient methylated bases through pi-donor/acceptor interactions involving the electron-rich aromatic cleft. Remarkably, AlkA is similar in fold and active site location to the bifunctional glycosylase/lyase endonuclease III, suggesting the two may employ fundamentally related mechanisms for base excision.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University			Scharer, Orlando/B-8908-2008; Labahn, Jörg/G-9593-2013; Schärer, Orlando D./AAF-8613-2021	Scharer, Orlando/0000-0003-2425-2715; Labahn, Jörg/0000-0002-0648-8145; 				BERDAL KG, 1990, EMBO J, V9, P4563, DOI 10.1002/j.1460-2075.1990.tb07909.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, X PLOR VERSION 3 1 S; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; CHEN J, 1990, EMBO J, V9, P4569, DOI 10.1002/j.1460-2075.1990.tb07910.x; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; *DAR LAB, 1979, SUIT PROGR PROT CRYS; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; ENGELWARD BP, 1993, CARCINOGENESIS, V14, P175; EVANS R, 1990, VIA, V11, P134; FRIEDBERG EC, 1995, DNA REPAIR; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LAVAL J, 1977, NATURE, V269, P829, DOI 10.1038/269829a0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAIN P, 1990, ACTA CRYSTALLOGR A, V46, P372, DOI 10.1107/S0108767389012146; Mattes WB, 1996, CARCINOGENESIS, V17, P643, DOI 10.1093/carcin/17.4.643; MEMISOGLU A, 1996, IN PRESS GENE; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOROHOSHI F, 1993, J BACTERIOL, V175, P6010, DOI 10.1128/JB.175.18.6010-6017.1993; NASH HM, 1996, IN PRESS CURR BIOL; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SANTERRE A, 1994, P NATL ACAD SCI USA, V91, P2240, DOI 10.1073/pnas.91.6.2240; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SCHARER OD, 1995, J AM CHEM SOC, V117, P6623, DOI 10.1021/ja00129a039; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; THOMSON AJ, 1993, CURR BIOL, V3, P173, DOI 10.1016/0960-9822(93)90264-O; TRONRUD DE, 1995, USERS GUIDE TNT REFI; VANDUYNE GD, 1993, J MOL BIOL, V229, P104; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Zhang K. Y. J., 1990, ACTA CRYST A, VA46, P41	52	228	233	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					321	329		10.1016/S0092-8674(00)80103-8	http://dx.doi.org/10.1016/S0092-8674(00)80103-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706136	Bronze			2022-12-24	WOS:A1996UZ97200017
J	Mead, PE; Brivanlou, IH; Kelley, CM; Zon, LI				Mead, PE; Brivanlou, IH; Kelley, CM; Zon, LI			BMP-4-responsive regulation of dorsal-ventral patterning by the homeobox protein Mix.1	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; POLYMERASE CHAIN-REACTION; XENOPUS EMBRYOS; MESODERM INDUCTION; SPEMANN ORGANIZER; EXPRESSION; HOMOLOG; ACTIVIN; INVIVO; CELLS	IN an expression screen for factors that pattern or induce ventral mesoderm, we isolated a complementary DNA encoding Mix.1, a paired class homeobox gene, with no previously known function(1). Injection of Mix.1 messenger RNA results in extensive blood formation in the whole embryo and transforms dorsal mesoderm to a ventral fate. Mix.1 expression is induced by bone morphogenetic protein-4 (BMP-4), and a dominant inhibitory mutant of Mix.1 can restore a dorsal axis in embryos ventralized by ectopic BMP-4 expression. Mix.1 can form heterodimers uith the dorsalizing gene siamois, which encodes a homeodomain protein that is structurally similar to Mix.1. Furthermore, Mix.1 blocks the duplicated axis induced by ectopic siamois expression. Our findings indicate that Mix.1 participates in a BMP-4 signalling pathway to pattern ventral mesoderm, and suggest a model whereby dimerization of homeodomain proteins regulates dorsal-ventral patterning.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute			Kelley, Clair M/O-2688-2015					ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; DALE L, 1992, DEVELOPMENT, V115, P573; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLEY C, 1994, DEV BIOL, V165, P193, DOI 10.1006/dbio.1994.1246; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; LEROUX I, 1993, P NATL ACAD SCI USA, V90, P9120, DOI 10.1073/pnas.90.19.9120; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9	24	127	128	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					357	360		10.1038/382357a0	http://dx.doi.org/10.1038/382357a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684465				2022-12-24	WOS:A1996UY95000053
J	Jacobs, GH; Neitz, M; Deegan, JF; Neitz, J				Jacobs, GH; Neitz, M; Deegan, JF; Neitz, J			Trichromatic colour vision in New World monkeys	NATURE			English	Article							CONE PIGMENTS; GENETIC-BASIS; PHOTOPIGMENTS; POLYMORPHISM; GREEN; SENSITIVITY; MARMOSET	TRICHROMATIC colour vision depends on the presence of three types of cone photopigment. Trichromacy is the norm for all Old World monkeys, apes and humans, but in several genera of New World monkeys, colour vision is strikingly polymorphic(1). The difference in colour vision between these New and Old World primates results from differing arrangements of the pigment genes on the X chromosome. In Old World primates the three photopigments required for routine trichromatic colour vision are encoded by two or more X-chromosome pigment genes and an autosomal pigment gene. New World monkeys typically have only one X-chromosome pigment gene; multiple alleles allow different types of dichromatic colour vision and, in females heterozygous at this locus, variant forms of trichromatic colour vision. Here we report that multiple X-chromosome pigment genes and trichromatic colour vision are the norm for one genus of platyrrhine monkey, the howler monkey, Alouatta.	UNIV CALIF SANTA BARBARA, DEPT PSYCHOL, SANTA BARBARA, CA 93106 USA; MED COLL WISCONSIN, DEPT OPHTHALMOL, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT CELLULAR BIOL, MILWAUKEE, WI 53226 USA; CALIF STATE UNIV BAKERSFIELD, DEPT PSYCHOL, BAKERSFIELD, CA 93311 USA	University of California System; University of California Santa Barbara; Medical College of Wisconsin; Medical College of Wisconsin; California State University System; California State University Bakersfield	Jacobs, GH (corresponding author), UNIV CALIF SANTA BARBARA, NEUROSCI RES INST, SANTA BARBARA, CA 93106 USA.			Neitz, Maureen/0000-0002-5404-3343				BOWMAKER JK, 1987, PROC R SOC SER B-BIO, V231, P383, DOI 10.1098/rspb.1987.0051; BOWMAKER JK, 1991, NATO ADV SCI I A-LIF, V203, P1; CHAN T, 1992, J BIOL CHEM, V267, P9478; COTTON RGH, 1995, CURR OPIN BIOTECH, V3, P1013; DULAI KS, 1994, VISION RES, V34, P2483, DOI 10.1016/0042-6989(94)90233-X; HAGSTROM SA, 1993, INVEST OPHTH VIS SCI, V34, P809; HUNT DM, 1993, VISION RES, V33, P147, DOI 10.1016/0042-6989(93)90153-N; IBBOTSON RE, 1992, P ROY SOC B-BIOL SCI, V247, P145, DOI 10.1098/rspb.1992.0021; JACOBS GH, 1993, VISION RES, V33, P269, DOI 10.1016/0042-6989(93)90083-9; Jacobs GH, 1996, J OPT SOC AM A, V13, P641, DOI 10.1364/JOSAA.13.000641; JACOBS GH, 1993, INVEST OPHTH VIS SCI, V34, P749; JACOBS GH, 1993, BIOL REV, V68, P413, DOI 10.1111/j.1469-185X.1993.tb00738.x; JACOBS GH, 1987, P NATL ACAD SCI USA, V84, P2545, DOI 10.1073/pnas.84.8.2545; JACOBS GH, 1994, AM J PRIMATOL, V33, P217; MERBS SL, 1992, PHOTOCHEM PHOTOBIOL, V56, P869, DOI 10.1111/j.1751-1097.1992.tb09708.x; MOLLON JD, 1984, PROC R SOC SER B-BIO, V222, P373, DOI 10.1098/rspb.1984.0071; MOLLON JD, 1991, EVOLUTION EYE VISUAL, P306; NAGAMINE CM, 1989, AM J HUM GENET, V45, P337; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1984, J OPT SOC AM A, V1, P1175, DOI 10.1364/JOSAA.1.001175; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; NEITZ M, 1995, SCIENCE, V267, P1013, DOI 10.1126/science.7863325; SCHNEIDER H, 1993, MOL PHYLOGENET EVOL, V2, P225, DOI 10.1006/mpev.1993.1022; SHYUE SK, 1995, SCIENCE, V269, P1265, DOI 10.1126/science.7652574; TOVEE MJ, 1992, VISION RES, V32, P867, DOI 10.1016/0042-6989(92)90029-I; WILLIAMS AJ, 1992, EMBO J, V11, P2039, DOI 10.1002/j.1460-2075.1992.tb05261.x	26	200	204	0	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					156	158		10.1038/382156a0	http://dx.doi.org/10.1038/382156a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700203				2022-12-24	WOS:A1996UW67200046
J	Thierfelder, WE; vanDeursen, JM; Yamamoto, K; Tripp, RA; Sarawar, SR; Carson, RT; Sangster, MY; Vignali, DAA; Doherty, PC; Grosveld, GC; Ihle, JN				Thierfelder, WE; vanDeursen, JM; Yamamoto, K; Tripp, RA; Sarawar, SR; Carson, RT; Sangster, MY; Vignali, DAA; Doherty, PC; Grosveld, GC; Ihle, JN			Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells	NATURE			English	Article								SIGNAL transducers and activators of transcription (STATs) are activated by tyrosine phosphorylation in response to cytokines and mediate many of their functional responses(1-3). Statil was initially cloned as a result of its homology with Stat1 (refs 4, 5) and is widely expressed, although it is only tyrosine-phosphorylated after stimulation of T cells with interleukin (IL)-12 (refs 6, 7). IL-12 is required for the T-cell-independent induction of the cytokine interferon (IFN)-gamma, a keg step in the initial suppression of bacterial and parasitic infections. IL-12 is also important for the development of a Th1 response, which is critical for effective host defence against intracellular pathogens(8,9). To determine the function of Stat4 and its role in IL-12 signalling, we have produced mice that lack Stat4 by gene targeting. The mice were viable and fertile, with no detectable defects in haematopoiesis, However, all IL-12 functions tested were disrupted, including the induction of IFN-gamma, mitogenesis, enhancement of natural killer cytolytic function and Th1 differentiation.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, SCH MED, DEPT PATHOL, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, SCH MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; TOKYO MED & DENT UNIV, DEPT INTERNAL MED 1, BUNKYO KU, TOKYO 113, JAPAN	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Tokyo Medical & Dental University (TMDU)			Tripp, Ralph/F-5218-2011; Doherty, Peter Charles/C-4185-2013	Tripp, Ralph/0000-0002-2924-9956; Doherty, Peter Charles/0000-0002-5028-3489; Sangster, Mark/0000-0002-1599-5894				BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; DYBEDAL I, 1995, J IMMUNOL, V154, P4950; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; SALCEDO TW, 1993, J IMMUNOL, V151, P2511; SARAWAR SR, 1994, J VIROL, V68, P3112, DOI 10.1128/JVI.68.5.3112-3119.1994; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; WOLF SF, 1994, STEM CELLS, V12, P154, DOI 10.1002/stem.5530120203; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	20	931	951	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					171	174		10.1038/382171a0	http://dx.doi.org/10.1038/382171a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700208				2022-12-24	WOS:A1996UW67200051
J	Donaldson, MDC				Donaldson, MDC			Jury still out on growth hormone for normal short stature and Turner's syndrome	LANCET			English	Editorial Material											Donaldson, MDC (corresponding author), ROYAL HOSP SICK CHILDREN,GLASGOW G3 8SJ,LANARK,SCOTLAND.							CHU CE, 1995, HORM RES S1, V44, pA73; LOCHE S, 1994, J PEDIATR-US, V125, P196, DOI 10.1016/S0022-3476(94)70192-X; LYON AJ, 1985, ARCH DIS CHILD, V60, P932, DOI 10.1136/adc.60.10.932; ROSENFELD RG, 1992, J PEDIATR-US, V121, P49, DOI 10.1016/S0022-3476(05)82540-5; VANDENBROECK J, 1995, J PEDIATR-US, V127, P729, DOI 10.1016/S0022-3476(95)70161-3	5	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					3	4		10.1016/S0140-6736(05)64348-6	http://dx.doi.org/10.1016/S0140-6736(05)64348-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691928				2022-12-24	WOS:A1996UV92300003
J	Jabs, T; Dietrich, RA; Dangl, JL				Jabs, T; Dietrich, RA; Dangl, JL			Initiation of runaway cell death in an Arabidopsis mutant by extracellular superoxide	SCIENCE			English	Article							DISEASE RESISTANCE RESPONSE; SALICYLIC-ACID; ACTIVE OXYGEN; HYPERSENSITIVE RESPONSE; PHYTOPHTHORA-INFESTANS; PLANT DEFENSE; GENERATION; PATHOGENESIS; TOBACCO; H2O2	Reactive oxygen intermediates (ROIs) regulate apoptosis during normal development and disease in animals. ROIs are also implicated in hypersensitive resistance responses of plants against pathogens. Arabidopsis Isd1 mutants exhibited impaired control of cell death in the absence of pathogen and could not control the spread of cell death once it was initiated. Superoxide was necessary and sufficient to initiate lesion formation; it accumulated before the onset of cell death and subsequently in live cells adjacent to spreading Isd1 lesions, Thus, runaway cell death seen in Isd1 plants reflected abnormal accumulation of superoxide and lack of responsiveness to signals derived from it.	UNIV N CAROLINA,CURRICULA GENET & MOL BIOL,CHAPEL HILL,NC 27599; MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY	University of North Carolina; University of North Carolina Chapel Hill	Jabs, T (corresponding author), UNIV N CAROLINA,DEPT BIOL,COKER HALL 108,CB 3280,CHAPEL HILL,NC 27599, USA.							AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; AUH CK, 1995, PLANT PHYSIOL, V107, P1241, DOI 10.1104/pp.107.4.1241; BAKER CJ, 1995, ANNU REV PHYTOPATHOL, V33, P299, DOI 10.1146/annurev.py.33.090195.001503; BAKER CJ, 1991, PHYTOPATHOLOGY, V81, P1504, DOI 10.1094/Phyto-81-1504; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; DANGL JL, IN PRESS PLANT CELL; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DOKE N, 1983, PHYSIOL PLANT PATHOL, V23, P345, DOI 10.1016/0048-4059(83)90019-X; DOKE N, 1985, PHYSIOL PLANT PATHOL, V27, P311, DOI 10.1016/0048-4059(85)90044-X; DROOG FNJ, 1995, PLANT PHYSIOL, V107, P1139, DOI 10.1104/pp.107.4.1139; DWYER SC, 1995, BIOCHIM BIOPHYS ACTA, V1289, P231; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; ENYEDI AJ, 1992, CELL, V70, P879, DOI 10.1016/0092-8674(92)90239-9; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HANCOCK JT, 1987, BIOCHEM J, V242, P103, DOI 10.1042/bj2420103; Inze Dirk, 1995, Current Opinion in Biotechnology, V6, P153, DOI 10.1016/0958-1669(95)80024-7; JABS T, UNPUB; JOHAL GS, 1995, BIOESSAYS, V17, P685, DOI 10.1002/bies.950170805; Jones AM, 1996, TRENDS PLANT SCI, V1, P114, DOI 10.1016/S1360-1385(96)90005-9; KAUSS H, 1992, PLANT J, V2, P655, DOI 10.1111/j.1365-313X.1992.tb00134.x; KAUSS H, 1995, PLANT PHYSIOL, V108, P1171, DOI 10.1104/pp.108.3.1171; KIEDROWSKI S, 1992, EMBO J, V11, P4677, DOI 10.1002/j.1460-2075.1992.tb05572.x; LANGFORD AN, 1948, CAN J RES C, V26, P35, DOI 10.1139/cjr48c-006; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; May MJ, 1996, PLANT PHYSIOL, V110, P1367, DOI 10.1104/pp.110.4.1367; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; Montalbini P., 1994, Rivista di Patologia Vegetale, V4, P81; MONTALBINI P, 1992, J PHYTOPATHOL, V134, P218, DOI 10.1111/j.1439-0434.1992.tb01230.x; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; Mur LAJ, 1996, PLANT J, V9, P559, DOI 10.1046/j.1365-313X.1996.09040559.x; NEUENSCHWANDER U, UNPUB; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; RYALS J, 1994, PLANT PHYSIOL, V104, P1019; SANCHEZCASAS P, 1994, PLANT PHYSIOL, V106, P1675, DOI 10.1104/pp.106.4.1675; SCANDALIOS JG, 1993, PLANT PHYSIOL, V101, P7, DOI 10.1104/pp.101.1.7; STRELLER S, 1994, PLANTA, V192, P195, DOI 10.1007/BF01089035; UKNES S, 1993, PLANT CELL, V5, P159, DOI 10.1105/tpc.5.2.159; VERAESTRELLA R, 1993, PHYSIOL MOL PLANT P, V42, P9, DOI 10.1006/pmpp.1993.1002; WALBOT V, 1983, GENETIC ENG PLANTS, V3, P431; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; Weymann K, 1995, PLANT CELL, V7, P2013, DOI 10.1105/tpc.7.12.2013; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WONG PC, 1995, NEURON, V14, P1106; WU GS, 1995, PLANT CELL, V7, P1357, DOI 10.1105/tpc.7.9.1357	51	662	724	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1853	1856		10.1126/science.273.5283.1853	http://dx.doi.org/10.1126/science.273.5283.1853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791589				2022-12-24	WOS:A1996VJ71300043
J	Cate, JH; Gooding, AR; Podell, E; Zhou, KH; Golden, BL; Kundrot, CE; Cech, TR; Doudna, JA				Cate, JH; Gooding, AR; Podell, E; Zhou, KH; Golden, BL; Kundrot, CE; Cech, TR; Doudna, JA			Crystal structure of a group I ribozyme domain: Principles of RNA packing	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; RIBONUCLEASE-P REACTION; METAL-ION REQUIREMENTS; REV RESPONSIVE ELEMENT; GUANOSINE-BINDING-SITE; TETRAHYMENA RIBOZYME; TERTIARY STRUCTURE; CATALYTIC RNA; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE	Group I self-splicing introns catalyze their own excision from precursor RNAs by way of a two-step transesterification reaction. The catalytic core of these ribozymes is formed by two structural domains. The 2.8-angstrom crystal structure of one of these, the P4-P6 domain of the Tetrahymena thermophila intron, is described. In the 160-nucleolide domain, a sharp bend allows stacked helices of the conserved core to pack alongside helices of an adjacent region. Two specific long-range interactions clamp the two halves of the domain together. a two-Mg2+-coordinated adenosine-rich corkscrew plugs into the minor groove of a helix, and a GAAA hairpin loop binds to a conserved 11-nucleotide internal loop. Metal- and ribose-mediated backbone contacts further stabilize the close side-by-side helical packing, The structure indicates the extent of RNA packing required for the function of large ribozymes, the spliceosome, and the ribosome.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; YALE UNIV, DEPT MOL BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; UNIV COLORADO, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder; Yale University; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder				Golden, Barbara/0000-0002-9741-882X	NIGMS NIH HHS [5T32GM08283-07, GM22778-21] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008283] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; BREAKER RR, 1995, CHEM BIOL, V2, P655, DOI 10.1016/1074-5521(95)90028-4; Brunger A. T, 1993, XPLOR MANUAL VERSION; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CATE JH, IN PRESS STRUCTURE; CATE JH, UNPUB; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1993, GENE, V135, P33, DOI 10.1016/0378-1119(93)90046-6; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; COLLINS RA, 1988, NUCLEIC ACIDS RES, V16, P2705; COSTA M, 1995, EMBO J, V14, P1276, DOI 10.1002/j.1460-2075.1995.tb07111.x; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; CUENOUD B, 1995, NATURE, V375, P611, DOI 10.1038/375611a0; DOUDNA JA, 1993, P NATL ACAD SCI USA, V90, P7829, DOI 10.1073/pnas.90.16.7829; DOUDNA JA, 1995, RNA, V1, P36; Downs WD, 1996, RNA, V2, P718; FLOR PJ, 1989, EMBO J, V8, P3391, DOI 10.1002/j.1460-2075.1989.tb08503.x; GOLDEN BL, UNPUB; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HOLBROOK SR, 1977, NUCLEIC ACIDS RES, V4, P2811, DOI 10.1093/nar/4.8.2811; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; KALLENBACH NR, 1977, Q REV BIOPHYS, V10, P138, DOI 10.1017/S0033583500000202; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LAY PA, 1989, INORG CHEM, V28, P3001, DOI 10.1021/ic00314a026; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; MURPHY FL, 1994, SCIENCE, V265, P1709, DOI 10.1126/science.8085157; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SCHEVITZ RW, 1979, NATURE, V278, P188, DOI 10.1038/278188a0; SCHINDELIN H, 1995, J MOL BIOL, V249, P595, DOI 10.1006/jmbi.1995.0321; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SHEN LX, 1995, FASEB J, V9, P1023, DOI 10.1096/fasebj.9.11.7544309; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; SMITH D, 1992, J BIOL CHEM, V267, P2429; Strobel SA, 1996, BIOCHEMISTRY-US, V35, P1201, DOI 10.1021/bi952244f; VANDERHORST G, 1991, P NATL ACAD SCI USA, V88, P184, DOI 10.1073/pnas.88.1.184; WANG JF, 1992, SCIENCE, V256, P526, DOI 10.1126/science.1315076; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WANG YH, 1994, J MOL BIOL, V236, P64, DOI 10.1006/jmbi.1994.1118; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; WOO NH, 1980, NATURE, V286, P346, DOI 10.1038/286346a0; WYATT JR, 1993, RNA WORLD, P465; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848	70	1251	1278	4	167	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1996	273	5282					1678	1685		10.1126/science.273.5282.1678	http://dx.doi.org/10.1126/science.273.5282.1678			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781224				2022-12-24	WOS:A1996VH40800031
J	Parmet, WE; Daynard, RA; Gottlieb, MA				Parmet, WE; Daynard, RA; Gottlieb, MA			The physician's role in helping smoke-sensitive patients to use the Americans With Disabilities Act to secure smoke-free workplaces and public spaces	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL TOBACCO-SMOKE	Many persons suffer from a variety of conditions that render them particularly vulnerable to injuries caused by environmental tobacco smoke. Fortunately, the Americans With Disabilities Act may provide such patients with a legal right to a smoke-free environment. We examine herein how the act can be used by these patients, how the act works, and how physicians, who often advise such patients to seek smoke-free environments, can help their patients obtain the clean air to which they are entitled under law.	TOBACCO CONTROL RESOURCE CTR,BOSTON,MA 02115; NORTHEASTERN UNIV,SCH LAW,BOSTON,MA 02115	Northeastern University			Gottlieb, Mark A./ABI-1826-2020	Gottlieb, Mark A./0000-0001-8679-307X				*AM HOSP ASS, 1996, HOSP STAT 1995, P2; *AM LUNG ASS, 1995, LUNG DIS DAT 1994, P6; BORLAND R, 1995, PREV MED, V24, P56, DOI 10.1006/pmed.1995.1008; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Criteria Committee of the New York Heart Association, 1994, NOMENCLATURE CRITERI, V9th, P253; DiFranza JR, 1996, PEDIATRICS, V97, P560; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; Goldberg R J, 1993, J Cancer Educ, V8, P133; GOTTLIEB MA, 1994, ST LOUIS PUB L REV, V13, P635; Jinot J., 1992, RESP HLTH EFFECTS PA; Parmet W E, 1990, Law Med Health Care, V18, P331; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; *SOC SEC ADM, 1979, DHEW PUBL; *US DEP HHS, 1988, HLTH CONS SMOK NIC A; *US DEP HHS, 1986, 878398 CDC PHS DHHS; 1994, FED REGISTER, V59, P47570; 1993, AM REV RESPIR DIS, V147, P1056; 1995, MMWR MORB MORTAL WKL, V44	19	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					909	913						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782641				2022-12-24	WOS:A1996VF78700035
J	Pezzotti, P; Phillips, AN; Dorrucci, M; Lepri, AC; Galai, N; Vlahov, D; Rezza, G; Alliegro, B; Petrucci, A; Sinicco, A; Tarantini, G; Angarano, G; Lazzarin, A; Aiuti, F; Zaccarelli, M; Salassa, B; Castelli, F; Viale, P; Canessa, A; Barbanera, M; Ricchi, E; Ortona, L; Pristera, R; Gafa, S; Tirelli, U				Pezzotti, P; Phillips, AN; Dorrucci, M; Lepri, AC; Galai, N; Vlahov, D; Rezza, G; Alliegro, B; Petrucci, A; Sinicco, A; Tarantini, G; Angarano, G; Lazzarin, A; Aiuti, F; Zaccarelli, M; Salassa, B; Castelli, F; Viale, P; Canessa, A; Barbanera, M; Ricchi, E; Ortona, L; Pristera, R; Gafa, S; Tirelli, U			Category of exposure to HIV and age in the progression to AIDS: Longitudinal study of 1199 people with known dates of seroconversion	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED HOMOSEXUAL MEN; INTRAVENOUS-DRUG-USERS; DISEASE PROGRESSION; TRANSMISSION CATEGORY; LYMPHOCYTES; INCUBATION; RISK; SEX; SURVIVAL	Objectives-To determine whether rate of development of AIDS is affected by category of exposure to HIV and whether the more rapid development found in older subjects persists for each exposure category. Design-Longitudinal study of people with known date of seroconversion to HIV. Setting-16 HIV treatment centres throughout Italy. Subjects-1199 people infected with HIV through use of injected drugs, homosexual sex, or heterosexual sex. Main outcome measures-AIDS as defined by 1987 definition of Centers for Disease Control (including and excluding neoplasms) and by 1993 European definition. Results-225 subjects (18.8%) progressed to AIDS (Centers for Disease Control 1987 definition) during median follow up of 5.8 years. Univariate analyses showed more rapid progression to AIDS for older subjects compared with younger subjects and for homosexual men compared with other exposure categories. The age effect was of similar size in each exposure category and in men and women. In a bivariate model with age and exposure categories simultaneously included as covariates, differences by exposure category disappeared for use of injected drugs and heterosexual sex compared with homosexual sex (relative hazards 1.02 (95% confidence interval 0.71 to 1.45) and 1.07 (0.70 to 1.64) respectively), while the age effect remained (relative hazard 1.55 (1.32 to 1.83) for 10 year increase in age). Analyses using the other definitions for AIDS did not appreciably change these results. Conclusions-There was no evidence of differences in rate of development of AIDS by exposure category, while there was a strong tendency for more rapid development in older subjects for all three groups. This supports the view that external cofactors do not play major role in AIDS pathogenesis but that age is of fundamental importance.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON,ENGLAND; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,IL-91010 JERUSALEM,ISRAEL; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Hebrew University of Jerusalem; Johns Hopkins University	Pezzotti, P (corresponding author), IST SUPER SANITA,CTR OPERAT AIDS,EPIDEMIOL & BIOSTAT LAB,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		Zaccarelli, Mauro/GYV-1093-2022; Phillips, Andrew N/B-4427-2008; Castelli, Francesco/E-7045-2010; PEZZOTTI, PATRIZIO/C-6480-2016; rezza, giovanni/D-4393-2016; Galai, Noya/HII-8086-2022; DORRUCCI, MARIA/C-6485-2016	Phillips, Andrew N/0000-0003-2384-4807; PEZZOTTI, PATRIZIO/0000-0002-0805-2927; rezza, giovanni/0000-0003-0268-6790; DORRUCCI, MARIA/0000-0002-8543-6430				ANCELLEPARK R, 1993, LANCET, V341, P441, DOI 10.1016/0140-6736(93)93040-8; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; BROWN SM, 1974, ARCH INTERN MED, V134, P1001, DOI 10.1001/archinte.134.6.1001; CARRE N, 1994, AIDS, V8, P797, DOI 10.1097/00002030-199406000-00012; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; DONAHOE RM, 1986, CLIN IMMUNOL IMMUNOP, V41, P254, DOI 10.1016/0090-1229(86)90109-1; ESKILD A, 1994, SCAND J SOC MED, V4, P309; GALAI N, 1995, J ACQ IMMUN DEF SYND, V8, P66; GIESECKE J, 1988, BRIT MED J, V297, P99, DOI 10.1136/bmj.297.6641.99; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JASON J, 1989, JAMA-J AM MED ASSOC, V261, P725, DOI 10.1001/jama.261.5.725; KEET IPM, 1994, AIDS, V8, P1577, DOI 10.1097/00002030-199411000-00009; Lee E.T., 1992, STATISTICAL METHODS; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MARGOLICK JB, 1994, ARCH INTERN MED, V154, P869, DOI 10.1001/archinte.154.8.869; MARIOTTO AB, 1992, AM J EPIDEMIOL, V135, P428, DOI 10.1093/oxfordjournals.aje.a116303; MIENTJES GH, 1991, AIDS, V5, P35, DOI 10.1097/00002030-199101000-00005; OPERSKALSKI EA, 1995, J INFECT DIS, V172, P648, DOI 10.1093/infdis/172.3.648; PETERSON PK, 1990, AIDS, V4, P869, DOI 10.1097/00002030-199009000-00006; PEZZOTTI P, 1992, J ACQ IMMUN DEF SYND, V5, P745; REZZA G, 1994, HIV EPIDEMIOLOGY, P279; REZZA G, 1989, AIDS, V3, P87, DOI 10.1097/00002030-198902000-00006; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; VELLA S, 1995, AIDS, V9, P51, DOI 10.1097/00002030-199501000-00007; VEUGELERS PJ, 1994, AIDS, V8, P1471, DOI 10.1097/00002030-199410000-00015; VONOVERBECK J, 1994, AIDS, V8, P1307, DOI 10.1097/00002030-199409000-00014; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEINBERG K, 1995, NEW ENGL J MED, V332, P182, DOI 10.1056/NEJM199501193320310; 1992, AIDS, V6, P421; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1994, AIDS, V8, P911	32	91	92	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					583	586						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806246				2022-12-24	WOS:A1996VG10800015
J	Stirland, H; Husain, OAN; Butler, EB; Cater, S; Russell, KS				Stirland, H; Husain, OAN; Butler, EB; Cater, S; Russell, KS			Cervical screening in the inner cities: Is the opportunistic approach still worthwhile?	BRITISH MEDICAL JOURNAL			English	Article									WOMENS NATIONWIDE CANC CONTROL CAMPAIGN,LONDON EC2A 3AR,ENGLAND; WILSON HOSP,MERTON SUTTON & WANDSWORTH HLTH AUTHOR,MITCHAM CR4 4TP,SURREY,ENGLAND									*CANC RES CAMP, 1995, FACT SHEET 1O MARCH; HUSAIN OAN, 1990, J ROY SOC MED, V83, P319, DOI 10.1177/014107689008300515; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; *NAT COORD NETW, 1994, REP 1 5 YEARS NHS CE, P4; THORNTON J, 1989, COMMUNITY MED, V11, P290	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					600	600						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806251				2022-12-24	WOS:A1996VG10800020
J	Berg, DT; Wiley, MR; Grinnell, BW				Berg, DT; Wiley, MR; Grinnell, BW			Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator	SCIENCE			English	Article							STRUCTURAL-CHANGES; THROMBOMODULIN; BINDING; SPECIFICITY; SITE; ANTICOAGULANT; AFFINITY; ENZYME	A modulator of the enzymatic activity of human thrombin, designated LY254603, was identified that enhances the thrombin-catalyzed generation of the anticoagulant factor activated protein C, yet inhibits thrombin-dependent fibrinogen clotting, By means of mutant substrates, it was shown that LY254603 mediates the change in enzymatic substrate specificity through an alteration in thrombin's S3 substrate recognition site, a mechanism that appeared to be independent of allosteric changes induced by either sodium ions or by thrombomodulin. This compound may represent the prototype of a class of agents that specifically modulates the balance between thrombin's procoagulant and anticoagulant functions.	LILLY RES LABS,CARDIOVASC RES DIV,INDIANAPOLIS,IN 46285	Eli Lilly								AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; BERLINER LJ, 1977, BIOCHEMISTRY-US, V16, P4622, DOI 10.1021/bi00640a015; CONERY BG, 1983, BIOCHEMISTRY-US, V22, P369, DOI 10.1021/bi00271a021; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; GRIFFIN JH, 1995, NATURE, V378, P337, DOI 10.1038/378337a0; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; GRINNELL BW, 1990, PROTEIN C RELATED AN, P13; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LIU LW, 1991, J BIOL CHEM, V266, P16977; MUSCI G, 1987, J BIOL CHEM, V262, P13889; OWEN WG, 1981, J BIOL CHEM, V256, P5532; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; RICHARDSON MA, 1992, NATURE, V360, P261, DOI 10.1038/360261a0; RICHARDSON MA, 1994, PROTEIN SCI, V3, P711; SADLER JE, 1993, HAEMOSTASIS, V23, P183; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; YE J, 1991, J BIOL CHEM, V266, P23016	24	44	46	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1389	1391		10.1126/science.273.5280.1389	http://dx.doi.org/10.1126/science.273.5280.1389			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703074				2022-12-24	WOS:A1996VF61000043
J	Barr, H; Shepherd, NA; Dix, A; Roberts, DJH; Tan, WC; Krasner, N				Barr, H; Shepherd, NA; Dix, A; Roberts, DJH; Tan, WC; Krasner, N			Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX	LANCET			English	Article							ESOPHAGUS; ADENOCARCINOMA; PHOTOSENSITIZATION; ABLATION; MUCOSA; CANCER; ACID	Background High-grade dysplasia in columnar-lined (Barrett's) oesophagus presents a difficult therapeutic dilemma. Choices for management are endoscopic surveillance to detect a cancer or oesophagectomy. One carries the risk of missing invasive cancer, the other carries worrying morbidity and mortality. We have used endoscopic photodynamic therapy to eradicate high-grade dysplasia. Methods After the oral administration of 5-aminolaevulinic acid, the accumulation of the endogenously generated photosensitiser protoporphyrin IX was measured with quantitative fluorescence microscopy. Five patients with histologically confirmed high-grade dysplasia were treated with endoscopic photodynamic therapy with 630 nm laser light to activate the photosensitiser. Findings Protoporphyrin IX accumulated in the dysplastic epithelium rather than the adjacent stroma. Selective necrosis of the dysplastic epithelium in columnar-lined oesophagus occurred after light activation. High-grade dysplasia was eradicated in all patients and squamous regeneration occurred after acid suppression with a proton-pump inhibitor. There were no complications or recurrence of dysplasia after 26-44 months' endoscopic and histological follow-up. In two cases we saw non-dysplastic Barrett's epithelium underneath regenerative squamous mucosa. Interpretation High-grade dysplasia in columnar-lined oesophagus can be eradicated by endoscopic photodynamic therapy with endogenously generated PpIX. Remaining non-dysplastic Barrett's epithelium will require surveillance, but overall the technique has interrupted or delayed the worsening of the dysplasia through to carcinoma. This technique may prevent the need for surgical excision in these patients.	UNIV LEEDS,CTR PHOTOBIOL & PHOTODYNAM THERAPY,LEEDS,W YORKSHIRE,ENGLAND; AINTREE HOSP,DEPT GASTROENTEROL,LIVERPOOL,MERSEYSIDE,ENGLAND	University of Leeds; Aintree University Hospitals NHS Foundation Trust	Barr, H (corresponding author), GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTERSHIRE ROYAL & CRANFIELD UNIV INST MED SCI,GLOUCESTER GL1 3NN,ENGLAND.		Shepherd, Neil A/AAV-3565-2021					ALTORKI NK, 1991, AM J SURG, V161, P97, DOI 10.1016/0002-9610(91)90367-M; BERENSON MM, 1993, GASTROENTEROLOGY, V104, P1686, DOI 10.1016/0016-5085(93)90646-T; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; GORE S, 1993, ALIMENT PHARM THERAP, V7, P923; GRANT WE, 1993, LANCET, V342, P147, DOI 10.1016/0140-6736(93)91347-O; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; LAUKKA MA, 1995, GASTROINTEST ENDOSC, V42, P59, DOI 10.1016/S0016-5107(95)70245-8; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; Loh CS, 1996, GUT, V38, P71, DOI 10.1136/gut.38.1.71; MCFARLANE GJ, 1994, J R SOC MED, V78, P334; OVERHOLT BF, 1995, GASTROINTEST ENDOSC, V42, P64, DOI 10.1016/S0016-5107(95)70246-6; REGULA J, 1995, GUT, V36, P67, DOI 10.1136/gut.36.1.67	12	280	285	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					584	585		10.1016/S0140-6736(96)03054-1	http://dx.doi.org/10.1016/S0140-6736(96)03054-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774572				2022-12-24	WOS:A1996VF18600013
J	MacDonagh, SE; Masters, J; Helps, BA; Tookey, PA; Ades, AE; Gibb, DM				MacDonagh, SE; Masters, J; Helps, BA; Tookey, PA; Ades, AE; Gibb, DM			Descriptive survey of antenatal HIV testing in London: Policy, uptake, and detection	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSMISSION				MacDonagh, SE (corresponding author), INST CHILD HLTH,EPIDEMIOL & BIOSTAT UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.		Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387; Gibb, Diana/0000-0002-9738-5490				CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1994, GUID OFF VOL NAM HIV; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Holland F J, 1994, J Med Screen, V1, P176	4	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					532	533						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789982				2022-12-24	WOS:A1996VF29400022
J	Bleul, CC; Farzan, M; Choe, H; Parolin, C; ClarkLewis, I; Sodroski, J; Springer, TA				Bleul, CC; Farzan, M; Choe, H; Parolin, C; ClarkLewis, I; Sodroski, J; Springer, TA			The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MOLECULAR-CLONING; CHROMOSOMAL LOCALIZATION; RECEPTOR CDNA; GENE; INTERLEUKIN-8; INFECTION; SEQUENCE; PROTEINS; CELLS	CHEMOKINES are chemotactic cytokines that activate and direct the migration of leukocytes(1,2). There are two subfamilies, the CXC and the CC chemokines, We recently found that the CXC-chemokine stromal cell-derived factor-1 (SDF-1)(3,4) is a highly efficacious lymphocyte chemoattractant(5). Chemokines act on responsive leukocyte subsets through G-protein-coupled seven-transmembrane receptors', which are also used by distinct strains of HIV-1 as cofactors for viral entry. Laboratory-adapted and some T-cell-line-tropic (T-tropic) primary viruses use the orphan chemokine receptor LESTR/fusin (also known as fusin)(6-8), whereas macrophage-tropic primary HIV-1 isolates use CCR-5 and CCR-3 (refs 7-11), which are receptors for known CC chemokines, Testing of potential receptors demonstrated that SDF-1 signalled through, and hence 'adopted', the orphan receptor LESTR, which we therefore designate CXC-chemokine receptor-4 (CXCR-4). SDF-1 induced an increase in intracellular free Ca2+ and chemotaxis in CXCR-4-transfected cells. Because SDF-1 is a biological ligand for the HIV-1 entry cofactor LESTR, we tested whether it inhibited HIV-1, SDF-1 inhibited infection by T-tropic HIV-1 of HeLa-CD4 cells, CXCR-4 transfectants, and peripheral blood mononuclear cells (PBMCs), but did not affect CCR-5-mediated infection by macrophage-tropic (M-tropic) and dual-tropic primary HIV-1.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PATHO,DIV HUMAN RETROVIROL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; UNIV PADUA,INST MICROBIOL,I-35121 PADUA,ITALY; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University of Padua; University of British Columbia				Farzan, Michael/0000-0002-2990-5319				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ASJO B, 1986, LANCET, V2, P660; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BLEUL CC, IN PRESS J EXP MED; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; LOETSCHER M, IN PRESS J EXP MED; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; PAROLIN C, 1994, J VIROL, V68, P3888, DOI 10.1128/JVI.68.6.3888-3895.1994; PAROLIN C, IN PRESS J VIROL, V222; RIMLAND J, 1991, MOL PHARMACOL, V40, P869; ROTH SJ, 1995, J IMMUNOL METHODS, V100, P97; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; YENUSH L, 1994, J BIOL CHEM, V269, P100	29	1700	1807	1	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					829	833		10.1038/382829a0	http://dx.doi.org/10.1038/382829a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752280				2022-12-24	WOS:A1996VE34700053
J	Hans, D; DargentMolina, P; Schott, AM; Sebert, JL; Cormier, C; Kotzki, PO; Delmas, PD; Pouilles, JM; Breart, G; Meunier, PJ				Hans, D; DargentMolina, P; Schott, AM; Sebert, JL; Cormier, C; Kotzki, PO; Delmas, PD; Pouilles, JM; Breart, G; Meunier, PJ			Ultrasonographic heel measurements to predict hip fracture in elderly women: The EPIDOS prospective study	LANCET			English	Article							X-RAY ABSORPTIOMETRY; ULTRASOUND MEASUREMENTS; BONE-DENSITY; OS CALCIS; OSTEOPOROSIS; RISK; MASS	Background The ability of ultrasonographic measurements to discriminate between patients with hip fracture and age-matched controls has until now been tested mainly through cross-sectional studies. We report the results of a prospective study to assess the value of measurements with ultrasound in predicting the risk of hip fracture. Methods 5662 elderly women (mean age 80 . 4 years) had both baseline calcaneal ultrasonography measurements and femoral radiography (dual-photon X-ray absorptiometry, DPXA) to assess their bone quality. Follow-up every 4 months enabled us to identify incident fractures, 115 hip fractures were recorded during a mean follow-up duration of 2 years. Findings Low calcaneal ultrasonographic variables (obtained from measurements of broadband ultrasound attenuation by, and speed of sound through the bone) were able to predict an increased risk of hip fracture, with similar accuracy to low femoral bone mineral density (BMD) obtained by DPXA. The relative risk of hip fracture for 1 SD reduction was 2 . 0 (95% CI 1 . 6-2 . 4) for ultrasound attenuation and 1 . 7 (1 . 4-2 . 1) for speed of sound, compared with 1 . 9 (1 . 6-2 . 4) for BMD. After control for the femoral neck BMD, ultrasonographic variables remained predictive of hip fracture. The incidence of hip fracture among women with values above the median for both calcaneal ultrasound attenuation and femoral neck BMD was 2 . 7 per 1000 woman-years, compared with 19 . 6 per 1000 woman-years for those with values below the median for both measures. Interpretation Ultrasonographic measurements of the os calcis predict the risk of hip fracture in elderly women living at home as well as DPXA of the hip does, and the combination of both methods makes possible the identification of women at very high or very low risk of fracture.	HOP EDOUARD HERRIOT, DEPT RHUMATOL & MALAD OSSEUSES, F-69437 LYON 03, FRANCE; INSERM, U149, VILLEJUIF, FRANCE; HOP NORD AMIENS, SERV RHUMATOL, AMIENS, FRANCE; HOP COCHIN, SERV RHUMATOL, F-75674 PARIS, FRANCE; HOP LAPEYRONIE, NUCL MED SERV, MONTPELLIER, FRANCE; HOP PURPAN, SERV ENDOCRINOL, TOULOUSE, FRANCE	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Montpellier; CHU de Toulouse	Hans, D (corresponding author), HOP EDOUARD HERRIOT, INSERM, U403, PAVILLON F, F-69437 LYON 03, FRANCE.		Schott, Anne-Marie/V-7580-2018; Dargent-Molina, Patricia/N-3887-2017; Hans, Didier B/B-3208-2018	Schott, Anne-Marie/0000-0003-3337-4474; Dargent-Molina, Patricia/0000-0001-8596-6899; 				ASHMAN RB, 1984, J BIOMECH, V17, P349, DOI 10.1016/0021-9290(84)90029-0; BIOT MA, 1962, J ACOUST SOC AM, V34, P1254, DOI 10.1121/1.1918315; BOUXSEIN ML, 1995, J BONE MINER RES  S1, V10, P146; Chevalley T, 1991, Osteoporos Int, V1, P147, DOI 10.1007/BF01625444; COX DR, 1972, J R STAT SOC B, V34, P187; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7; Duboeuf F, 1991, Osteoporos Int, V1, P242; HANS D, 1994, CALCIFIED TISSUE INT, V55, P94, DOI 10.1007/BF00297182; HANS D, 1995, BONE, V16, P295, DOI 10.1016/8756-3282(94)00041-7; KAUFMAN JJ, 1993, J BONE MINER RES, V8, P517; Langton C M, 1984, Eng Med, V13, P89, DOI 10.1243/EMED_JOUR_1984_013_022_02; Langton CM, 1991, OSTEOPOROSIS INT, V1, P194; MAUTALEN C, 1995, CALCIFIED TISSUE INT, V57, P165, DOI 10.1007/BF00310252; Melton L J 3rd, 1985, Clin Geriatr Med, V1, P525; MELTON LJ, 1986, AM J EPIDEMIOL, V124, P254, DOI 10.1093/oxfordjournals.aje.a114383; MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902; PORTER RW, 1990, BMJ-BRIT MED J, V301, P638, DOI 10.1136/bmj.301.6753.638; SCHOTT AM, 1995, J BONE MINER RES, V10, P243; SCHOTT AM, 1995, J BONE MINER RES  S1, V10, P29; TURNER CH, 1995, OSTEOPOROSIS INT, V5, P130, DOI 10.1007/BF01623314; 1994, WHO TECHNICAL REPORT, V843, P1994	25	905	917	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	1996	348	9026					511	514		10.1016/S0140-6736(95)11456-4	http://dx.doi.org/10.1016/S0140-6736(95)11456-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757153				2022-12-24	WOS:A1996VD42700011
J	Merlo, J; Ranstam, J; Liedholm, H; Hedblad, B; Lindberg, G; Lindblad, U; Isacsson, SO; Melander, A; Rastam, L				Merlo, J; Ranstam, J; Liedholm, H; Hedblad, B; Lindberg, G; Lindblad, U; Isacsson, SO; Melander, A; Rastam, L			Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs: Population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; HYPERTENSION; SWEDEN; MALMO; BORN; MORTALITY	Objective-To analyse the association between use of antihypertensive treatment, diastolic blood pressure, and long term incidence of ischaemic cardiac events in elderly men. Design-Population based cohort study. Baseline examination in 1982-3 and follow up for up to 10 years. Setting-Malmo, Sweden. Subjects-484 randomly selected men born in 1914 and living in Malmo during 1982. Main outcome measures-Observational comparisons of incidence rates and rate and hazard ratios of ischaemic cardiac events (myocardial infarction or death due to chronic ischaemic cardiac disease). Results-The crude incidence rate of ischaemic cardiac events was higher in those subjects who were taking antihypertensive drugs than in those who were not (rate ratio 2.6 (95% confidence interval 1.7 to 3.9)). After adjustment for potential confounders (differences in baseline smoking habits, blood pressure, time since diagnosis of hypertension, ischaemic or other cardiovascular disease, hypercholesterolaemia, hypertriglyceridaemia, diabetes mellitus, obesity, and raised serum creatinine concentration) this rate was reduced but still raised (hazard ratio 1.9 (1.0 to 3.7)). In men with diastolic blood pressure >90 mm Hg, antihypertensive treatment was associated with a twofold increase in the incidence of ischaemic cardiac events (rate ratio 2.0 (1.1 to 3.6)), which vanished after adjustment for potential confounders (hazard ratio 1.1 (0.5 to 2.6)). In those subjects with diastolic blood pressure less than or equal to 90 mm Hg, antihypertensive treatment was associated with fourfold increase in incidence (rate ratio 3.9 (2.1 to 7.1)), which remained after adjustment for potential confounders (hazard ratio 3.8 (1.3 to 11.0)). Conclusion-Antihypertensive treatment may increase the risk of myocardial infarction in elderly men with treated diastolic blood pressures less than or equal to 90 mm Hg.	NEPI FDN,STOCKHOLM,SWEDEN; NEPI FDN,MALMO,SWEDEN; SKARABORG INST,SKOVDE,SWEDEN		Merlo, J (corresponding author), LUND UNIV,MALMO UNIV HOSP,DEPT COMMUNITY MED,S-20502 MALMO,SWEDEN.		Ranstam, Jonas/A-4386-2009; Merlo, Juan/E-2136-2011	Ranstam, Jonas/0000-0002-8287-7273; Merlo, Juan/0000-0001-8379-9708				CLAUSEN J, 1992, J HUM HYPERTENS, V6, P53; COLLINS R, 1994, TXB HYPERTENSION, P1156; CRUICKSHANK JM, 1987, LANCET, V1, P581; CUSHMAN WC, 1995, DRUG AGING, V7, P88, DOI 10.2165/00002512-199507020-00003; CUTLER JA, 1989, HYPERTENSION S1, V13, P136; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; HANSON BS, 1987, SOC SCI MED, V25, P849, DOI 10.1016/0277-9536(87)90043-8; HEDBLAD B, 1992, HYPERTENSION, V20, P32, DOI 10.1161/01.HYP.20.1.32; ISACSSON S, 1972, ACTA MED SCAND, P537; JANZON L, 1986, J EPIDEMIOL COMMUN H, V40, P174, DOI 10.1136/jech.40.2.174; KAPLAN NM, 1990, LANCET, V335, P1093; LANGER RD, 1993, HYPERTENSION, V22, P551, DOI 10.1161/01.HYP.22.4.551; LINDBLAD U, 1994, BRIT MED J, V308, P681, DOI 10.1136/bmj.308.6930.681; Rose G, 1968, CARDIOVASCULAR SURVE; THURMER HL, 1994, J HYPERTENS, V12, P481; Waaler H T, 1988, Acta Med Scand Suppl, V723, P17; YANO K, 1983, J CHRON DIS, V36, P569, DOI 10.1016/0021-9681(83)90145-5; Zanchetti A, 1993, Blood Press, V2, P86, DOI 10.3109/08037059309077535; 1995, INFORMATION MED PROD, V3, P178	19	44	44	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					457	461						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776312				2022-12-24	WOS:A1996VE08000019
J	Bostom, AG; Cupples, LA; Jenner, JL; Ordovas, JM; Seman, LJ; Wilson, PWF; Schaefer, EJ; Castelli, WP				Bostom, AG; Cupples, LA; Jenner, JL; Ordovas, JM; Seman, LJ; Wilson, PWF; Schaefer, EJ; Castelli, WP			Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger - A prospective study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRE-BETA LIPOPROTEIN; ENDOTHELIUM-DEPENDENT DILATION; LP(A) LIPOPROTEIN; MYOCARDIAL-INFARCTION; ARTERY DISEASE; HUMAN APOLIPOPROTEIN(A); GEL-ELECTROPHORESIS; LDL CHOLESTEROL; RISK; QUANTIFICATION	Objective.-To establish whether elevated lipoprotein(a) [Lp(a)], detected as a sinking pre-beta-lipoprotein band on electrophoresis of fresh plasma, is an independent risk factor for the development of premature coronary heart disease (CHD) in men. Design and Setting.-Prospective study of the Framingham offspring cohort. Participants.-A total of 2191 men aged 20 to 54 years old who were free of cardiovascular disease when they were examined between 1971 and 1975. Main Outcome Measures.-Incident CHD (myocardial infarction, coronary insufficiency, angina pectoris, or sudden cardiac death) occurring by age 55 years. Results.-After a median follow-up of 15.4 years, there were 129 CHD events. The relative risk (RR) estimates (with 95% confidence intervals [Cls]) for premature CHD derived from a proportional hazards model that included age, body mass index, and the dichotomized risk factor covariables elevated plasma Lp(a) level, total cholesterol level of 6.2 mmol/L (240 mg/dL) or more, high-density lipoprotein (HDL) level less than 0.9 mmol/L (35 mg/dL), smoking, glucose intolerance, and hypertension were as follows: elevated Lp(a) level, RR, 1.9 (95% Cl, 1.2-2.9), prevalence, 11.3%; total cholesterol level of 6.2 mmol/L or more, RR, 1.8 (95% Cl, 1.2-2.7), prevalence, 14.3%; HDL level of less than 0.9 mmol/L, RR, 1.8 (95% Cl, 1.2-2.6), prevalence, 19.2%; smoking, RR, 3.6 (95% Cl, 2.2-5.5), prevalence, 46.7%; glucose intolerance, RR, 2.7 (95% Cl, 1.4-5.3), prevalence, 2.6%; hypertension, RR, 1.2 (95% Cl, 0.8-1.8), prevalence, 26.3%. Conclusions.-Elevated plasma Lp(a) is an independent risk factor for the development of premature CHD in men, comparable in magnitude and prevalence (ie, attributable risk) to a total cholesterol level of 6.2 mmol/L (240 mg/dL) or more, or an HDL level less than 0.9 mmol/L (35 mg/dL).	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, EPIDEMIOL & BIOMETRY PROGRAM, FRAMINGHAM, MA USA; BOSTON UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL & BIOSTAT, BOSTON, MA USA; TUFTS UNIV, NEW ENGLAND MED CTR,LIPID METAB LAB,USDA, JEAN MAYER HUMAN NUTR RES CTR AGING, BOSTON, MA 02111 USA	Framingham Heart Study; Boston University; Tufts Medical Center; Tufts University; United States Department of Agriculture (USDA)	Bostom, AG (corresponding author), TUFTS UNIV, NEW ENGLAND MED CTR, VITAMIN BIOAVAILABIL LAB, USDA, BOSTON, MA 02111 USA.		Wilson, Peter W.F./J-2455-2016; Ordovas, Jose/B-8727-2013	Ordovas, Jose/0000-0002-7581-5680	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035243] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35243, HV-83-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1975, METABOLISM, V24, P1047, DOI 10.1016/0026-0495(75)90098-0; ALBERS JJ, 1974, LIPIDS, V9, P15, DOI 10.1007/BF02533209; Albers John J., 1994, Current Opinion in Lipidology, V5, P417, DOI 10.1097/00041433-199412000-00004; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ALVAREZ JJ, 1993, CLIN BIOCHEM, V26, P399, DOI 10.1016/0009-9120(93)90117-O; AVOGARO P, 1975, CLIN CHIM ACTA, V61, P239, DOI 10.1016/0009-8981(75)90413-1; BALLANTYNE D, 1973, J CLIN PATHOL, V26, P163, DOI 10.1136/jcp.26.3.163; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; BOSTOM AG, 1994, CIRCULATION, V90, P1688, DOI 10.1161/01.CIR.90.4.1688; BRECKENRIDGE WC, 1981, CLIN BIOCHEM, V14, P82, DOI 10.1016/S0009-9120(81)90755-4; BRUCKERT E, 1990, CLIN CHIM ACTA, V188, P71, DOI 10.1016/0009-8981(90)90147-K; CRAIG WY, 1992, CLIN CHEM, V38, P550; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; CUPPLES LA, NIH PUBLICATION; DAHLEN G, 1975, CLIN GENET, V8, P183; DAHLEN G, 1972, ACTA MED SCAND, P1; DAHLEN G, 1974, ACTA MED SCAND, V195, P341; EZRATTY A, 1993, BIOCHEMISTRY-US, V32, P4628, DOI 10.1021/bi00068a021; FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7; FRICK MH, 1974, ACTA MED SCAND, V195, P337; GALLE J, 1995, CIRCULATION, V92, P1582, DOI 10.1161/01.CIR.92.6.1582; GAMBERT P, 1980, CLIN CHIM ACTA, V100, P99, DOI 10.1016/0009-8981(80)90070-4; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HANSEN PR, 1994, EUR J CLIN INVEST, V24, P497, DOI 10.1111/j.1365-2362.1994.tb02381.x; HARVIE NR, 1970, P NATL ACAD SCI USA, V66, P99, DOI 10.1073/pnas.66.1.99; HEIBERG A, 1974, CLIN GENET, V5, P144; HERVIO L, 1993, BLOOD, V82, P392; HEWITT D, 1977, CLIN GENET, V11, P224; HEWITT D, 1982, CLIN GENET, V21, P301; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JENNER JL, 1993, CIRCULATION, V87, P1135, DOI 10.1161/01.CIR.87.4.1135; KAWAKAMI K, 1989, CLIN CHIM ACTA, V185, P147, DOI 10.1016/0009-8981(89)90037-5; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LEERINK CB, 1992, THROMB HAEMOSTASIS, V68, P185; LINDEN L, 1976, SCAND J CLIN LAB INV, V36, P51, DOI 10.3109/00365517609068018; LOVEJOY K, 1994, CIRCULATION, V90, P504; MAHER VMG, 1995, JAMA-J AM MED ASSOC, V274, P1771, DOI 10.1001/jama.274.22.1771; MAHER VMG, 1995, CURR OPIN LIPIDOL, V6, P229, DOI 10.1097/00041433-199508000-00007; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MCNAMARA JR, 1989, J LIPID RES, V30, P747; MORTON NE, 1978, CLIN GENET, V14, P207; NAUCK M, 1995, CLIN CHEM, V41, P731; PAGAN A, 1982, GERONTOLOGY, V28, P381; PAGAN A, 1983, J CLIN CHEM CLIN BIO, V21, P267; PEARSON TA, 1989, CIRCULATION S2, V80, P102; PETEK W, 1972, CLIN CHIM ACTA, V38, P460, DOI 10.1016/0009-8981(72)90140-4; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; RHOADS GG, 1978, AM J EPIDEMIOL, V108, P350, DOI 10.1093/oxfordjournals.aje.a112631; RIDER AK, 1970, CIRCULATION, V42, pII10; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; RIDKER PM, 1994, PRIMER PREVENTIVE CA, P205; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P86; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SAS Institute Inc, 1990, SAS STAT US GUID VER, V4; SCANU AM, 1995, CLIN CHEM, V41, P170; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SCHULTZ JS, 1968, P NATL ACAD SCI USA, V61, P963, DOI 10.1073/pnas.61.3.963; SEMAN LJ, 1994, CLIN CHEM, V40, P400; SIGURDSSON G, 1992, AM J CARDIOL, V69, P1251, DOI 10.1016/0002-9149(92)91215-P; SORENSEN KE, 1994, J CLIN INVEST, V93, P50, DOI 10.1172/JCI116983; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; WAGENKNECHT LE, 1996, CIRCULATION, V93, P635; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WALDEN CE, 1983, ARTERIOSCLEROSIS, V3, P117, DOI 10.1161/01.ATV.3.2.117; WILLIAMS RR, 1990, ARCH INTERN MED, V150, P582, DOI 10.1001/archinte.150.3.582	70	340	355	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					544	548		10.1001/jama.276.7.544	http://dx.doi.org/10.1001/jama.276.7.544			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC101	8709403				2022-12-24	WOS:A1996VC10100030
J	Watanabe, M				Watanabe, M			Reward expectancy in primate prefrontal neurons	NATURE			English	Article							UNIT-ACTIVITY; DELAYED-RESPONSE; MONKEY; CORTEX; MEMORY; PERFORMANCE; STIMULI; TASK	THE prefrontal cortex is important in the organization of goal-directed behaviour(1-3). When animals are trained to work for a particular goal or reward(4-7), reward 'expectancy' is processed by prefrontal neurons, Recent studies of the prefrontal cortex have concentrated on the role of working memory in the control of behaviour(8-10). In spatial delayed-response tasks, neurons in the prefrontal cortex shaw activity changes during the delay period between presentation of the cue and the reward(11-15), with some of the neurons being spatially specific (that is, responses vary with the cue position)(13-15). Here I report that the delay activity in prefrontal neurons is dependent also on the particular reward received for the behavioural response, and to the way the reward is given. It seems that the prefrontal cortex may monitor the outcome of goal-directed behaviour.			Watanabe, M (corresponding author), TOKYO METROPOLITAN INST NEUROSCI,DEPT PSYCHOL,MUSASHIDAI 2-6,FUCHU,TOKYO 183,JAPAN.							APICELLA P, 1992, J NEUROPHYSIOL, V68, P945, DOI 10.1152/jn.1992.68.3.945; CHATLOSH DL, 1992, LEARNING AND MEMORY : THE BEHAVIORAL AND BIOLOGICAL SUBSTRATES, P61; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster J.M., 1989, PREFRONTAL CORTEX; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; Goldman-Rakic P. S., 1987, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; HIKOSAKA O, 1989, J NEUROPHYSIOL, V61, P814, DOI 10.1152/jn.1989.61.4.814; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; Luria A. R., 2012, HIGHER CORTICAL FUNC; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; NIKI H, 1974, BRAIN RES, V70, P346, DOI 10.1016/0006-8993(74)90324-2; NIKI H, 1976, BRAIN RES, V105, P79, DOI 10.1016/0006-8993(76)90924-0; NIKI H, 1979, BRAIN RES, V171, P213, DOI 10.1016/0006-8993(79)90328-7; Peterson G.B., 1984, P135; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; SAKAGAMI M, 1994, EXP BRAIN RES, V97, P423; SCHULTZ W, 1992, J NEUROSCI, V12, P4595, DOI 10.1523/jneurosci.12-12-04595.1992; Shallice T., 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; SIRIGU A, 1995, CORTEX, V31, P301, DOI 10.1016/S0010-9452(13)80364-4; Tinklepaugh OL, 1928, J COMP PSYCHOL, V8, P197, DOI 10.1037/h0075798; TOLMAN EC, 1932, PURPOSIVE BEHAVIOR A; WATANABE M, 1992, EXP BRAIN RES, V89, P233; WATANABE M, 1989, NEUROSCI LETT, V101, P113, DOI 10.1016/0304-3940(89)90450-3; WATANABE M, 1990, EXP BRAIN RES, V80, P296	24	520	530	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					629	632		10.1038/382629a0	http://dx.doi.org/10.1038/382629a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757133				2022-12-24	WOS:A1996VC30300053
J	Yuasa, J; Hirano, S; Yamagata, M; Noda, M				Yuasa, J; Hirano, S; Yamagata, M; Noda, M			Visual projection map specified by topographic expression of transcription factors in the retina	NATURE			English	Article							FORK HEAD; CHICK; AXONS; GENE; ONCOGENE; FAMILY; ARBORIZATION; GRADIENTS; SYSTEM; BF-1	TOPOGRAPHICAL maps of neuronal connectivity occur in various brain regions(1). In the visual system of birds, retinal ganglion-cell axons from the anterior retina connect to a posterior part of the optic tectum, and posterior retinal axons connect to the anterior part, thereby establishing a point-to-point projection map(2,3). The chemoaffinity theory(4) predicts that the orderly retinotectal projection is generated by a topographical arrangement of molecules. We report here that me have found several genes topographically expressed along the nasotemporal (anterior-posterior) axis in the embryonic chicken retina. Among these, two transcriptional regulators, belonging to the winged-helix family(5) are expressed in a mutually exclusive manner in either the nasal or temporal part of the retina, Misexpression of each factor causes misprojection on the tectum along the rostrocaudal axis, showing that topographical expression of these transcription factors controls formation of the retinotectal map.	NATL INST BASIC BIOL,DIV MOL NEUROBIOL,OKAZAKI,AICHI 444,JAPAN; GRAD UNIV ADV STUDIES,DEPT MOL BIOMECH,OKAZAKI,AICHI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan			Noda, Masaharu/D-7146-2016; Yamagata, Masahito/H-6695-2016	Noda, Masaharu/0000-0002-3796-524X; Yamagata, Masahito/0000-0001-8193-2931; Yuasa-Kawada, Junichi/0000-0002-1382-3159				CHANG HW, 1995, P NATL ACAD SCI USA, V92, P447, DOI 10.1073/pnas.92.2.447; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DEITCHER DL, 1994, J NEUROSCI, V14, P486; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; DUTTING D, 1995, DEV BIOL, V167, P263, DOI 10.1006/dbio.1995.1022; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; Homburger SA, 1996, DEV DYNAM, V206, P112, DOI 10.1002/(SICI)1097-0177(199605)206:1<112::AID-AJA10>3.0.CO;2-7; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; ITASAKI N, 1991, DEVELOPMENT, V113, P1133; Itasaki N, 1996, NEURON, V16, P55, DOI 10.1016/S0896-6273(00)80023-9; KAPRIELIAN Z, 1994, BIOESSAYS, V16, P1, DOI 10.1002/bies.950160102; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LI J, 1995, CANCER RES, V55, P5540; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; MCLOON SC, 1991, J NEUROSCI, V11, P1470; MEY J, 1992, J HIRNFORSCH, V33, P673; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; Sanes J R, 1993, Curr Opin Neurobiol, V3, P67, DOI 10.1016/0959-4388(93)90037-Y; SAVITT JW, 1995, NEURON, V14, P253, DOI 10.1016/0896-6273(95)90283-X; Schwarz R, 1979, ATLAS PROTEIN SEQUEN, P353, DOI DOI 10.2307/2408678; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STAHL B, 1990, NEURON, V5, P733; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; THANOS S, 1987, J COMP NEUROL, V261, P155, DOI 10.1002/cne.902610114; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; WALTER J, 1987, DEVELOPMENT, V101, P909; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P1	30	111	117	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					632	635		10.1038/382632a0	http://dx.doi.org/10.1038/382632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757134				2022-12-24	WOS:A1996VC30300054
J	Shen, XT; Gorovsky, MA				Shen, XT; Gorovsky, MA			Linker histone H1 regulates specific gene expression but not global transcription in vivo	CELL			English	Article							TATA-BINDING PROTEIN; RNA POLYMERASE-II; TETRAHYMENA-THERMOPHILA; IN-VIVO; CRYSTAL-STRUCTURE; LARGEST SUBUNIT; CHROMATIN; SEQUENCE; CELLS; ORGANIZATION	In a linker histone H1 knockout strain (Delta H1) of Tetrahymena thermophila, the number of mature RNAs produced by genes transcribed by pol I and pol III and of most genes transcribed by pol II remains unchanged. However, H1 is required for the normal basal repression of a gene (ngoA) in growing cells but is not required for its activated expression in starved cells. Surprisingly, H1 is required for the activated expression of another gene (CyP) in starved cells but not for its repression in growing cells. Thus, H1 does not have a major effect on global transcription but can act as either a positive or negative gene-specific regulator of transcription in vivo.			Shen, XT (corresponding author), UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627, USA.			Shen, Xuetong/0000-0002-4267-5298	NIGMS NIH HHS [GM21793] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021793] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLIS CD, 1984, J CELL BIOL, V99, P1669, DOI 10.1083/jcb.99.5.1669; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AZUMA Y, 1991, NUCLEIC ACIDS RES, V19, P461, DOI 10.1093/nar/19.3.461; BANNON GA, 1983, NUCLEIC ACIDS RES, V11, P3903, DOI 10.1093/nar/11.12.3903; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; CALZONE FJ, 1983, J BIOL CHEM, V258, P6887; CECH TR, 1982, CELL NUCLEUS, P171; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKERT WA, 1978, EUR J BIOCHEM, V87, P607, DOI 10.1111/j.1432-1033.1978.tb12413.x; ENGBERG J, 1980, J MOL BIOL, V142, P289, DOI 10.1016/0022-2836(80)90274-0; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG J, 1993, CELL MOTIL CYTOSKEL, V25, P243, DOI 10.1002/cm.970250305; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; GOROVSKY MA, 1973, J PROTOZOOL, V20, P19, DOI 10.1111/j.1550-7408.1973.tb05995.x; GOROVSKY MA, 1980, ANNU REV GENET, V14, P203, DOI 10.1146/annurev.ge.14.120180.001223; GRIMES A, 1988, ANAL BIOCHEM, V172, P436, DOI 10.1016/0003-2697(88)90466-6; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAYASHI T, 1987, J BIOCHEM-TOKYO, V102, P369, DOI 10.1093/oxfordjournals.jbchem.a122063; KANDOLF H, 1994, P NATL ACAD SCI USA, V91, P7257, DOI 10.1073/pnas.91.15.7257; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KUCHINO Y, 1985, P NATL ACAD SCI USA, V82, P4758, DOI 10.1073/pnas.82.14.4758; LEWIN B, 1994, GENE, V5, P847; LI WB, 1989, NUCLEIC ACIDS RES, V17, P9621, DOI 10.1093/nar/17.23.9621; LINDER C, 1994, MOL CELL BIOL, V14, P2822, DOI 10.1128/MCB.14.4.2822; LOVE HD, 1988, MOL CELL BIOL, V8, P427, DOI 10.1128/MCB.8.1.427; MARTINDALE DW, 1983, MOL CELL BIOL, V3, P1857, DOI 10.1128/MCB.3.10.1857; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MILOSHEV G, 1994, P NATL ACAD SCI USA, V91, P11567, DOI 10.1073/pnas.91.24.11567; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PEDERSON DS, 1984, NUCLEIC ACIDS RES, V12, P3003, DOI 10.1093/nar/12.6.3003; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; SIMPSON RT, 1993, COLD SPRING HARB SYM, V58, P237, DOI 10.1101/SQB.1993.058.01.028; STARGELL LA, 1990, NUCLEIC ACIDS RES, V18, P6637, DOI 10.1093/nar/18.22.6637; STARGELL LA, 1994, MOL CELL BIOL, V14, P723, DOI 10.1128/MCB.14.1.723; WHITE EM, 1988, MOL CELL BIOL, V8, P4780, DOI 10.1128/MCB.8.11.4780; Wolffe A., 1995, CHROMATIN STRUCTURE; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; WU M, 1994, MOL CELL BIOL, V14, P10, DOI 10.1128/MCB.14.1.10; WU M, 1986, P NATL ACAD SCI USA, V83, P8674, DOI 10.1073/pnas.83.22.8674; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; ZLATANOVA J, 1992, J CELL SCI, V103, P889	49	266	268	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					475	483		10.1016/S0092-8674(00)80120-8	http://dx.doi.org/10.1016/S0092-8674(00)80120-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756729	hybrid			2022-12-24	WOS:A1996VC30900015
J	Willems, AR; Lanker, S; Patton, EE; Craig, KL; Nason, TF; Mathias, N; Kobayashi, R; Wittenberg, C; Tyers, M				Willems, AR; Lanker, S; Patton, EE; Craig, KL; Nason, TF; Mathias, N; Kobayashi, R; Wittenberg, C; Tyers, M			Cdc53 targets phosphorylated G1 cyclins for degradation by the ubiquitin proteolytic pathway	CELL			English	Article							YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; BUDDING YEAST; CONJUGATING ENZYME; GENE; MITOSIS; COMPLEX; INHIBITOR; DIVISION	In budding yeast, cell division is initiated in late Gf phase once the Cdc28 cyclin-dependent kinase is activated by the G1 cyclins Cln1, Cln2, and Cln3. The extreme instability of the Cln proteins couples environmental signals, which regulate Cln synthesis, to cell division. We isolated Cdc53 as a Cln2-associated protein and show that Cdc53 is required for Cln2 instability and ubiquitination in vivo. The Cln2-Cdc53 interaction, Cln2 ubiquitination, and Cln2 instability all depend on phosphorylation of Cln2. Cdc53 also binds the E2 ubiquitin-conjugating enzyme, Cdc34. These findings suggest that Cdc53 is a component of a. ubiquitin-protein ligase complex that targets phosphorylated G1 cyclins for degradation by the ubiquitin-proteasome pathway.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5S 1A8, CANADA; SCRIPPS RES INST, DEPT MOL & CELL BIOL, LA JOLLA, CA 92037 USA; UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Scripps Research Institute; University of Toronto; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Cold Spring Harbor Laboratory			Tyers, Michael/ABE-3194-2021		NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043487] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline; NIGMS NIH HHS [GM43487] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; Harlow E, 1988, ANTIBODIES LAB MANUA; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Kaiser C., 1994, METHODS YEAST GENETI; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MADURA K, 1993, J BIOL CHEM, V268, P12046; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIKORSKI RS, 1989, GENETICS, V122, P19; SOPTA M, 1985, J BIOL CHEM, V260, P353; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 1996, IN PRESS P NATL ACAD; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; YOON HJ, 1995, MOL CELL BIOL, V15, P4835	59	261	269	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1996	86	3					453	463		10.1016/S0092-8674(00)80118-X	http://dx.doi.org/10.1016/S0092-8674(00)80118-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756727	Bronze			2022-12-24	WOS:A1996VC30900013
J	Metzstein, MM; Hengartner, MO; Tsung, N; Ellis, RE; Horvitz, HR				Metzstein, MM; Hengartner, MO; Tsung, N; Ellis, RE; Horvitz, HR			Transcriptional regulator of programmed cell death encoded by Caenorhabditis elegans gene ces-2	NATURE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING SPECIFICITY; C-ELEGANS; CRYSTAL-STRUCTURE; BASIC REGION; PROTEIN; HLF; FUSION; E2A; DROSOPHILA	THE ces (for cell-death specification) genes of the nematode Caenorhabditis elegans the cell-death fate of individual cell types and are candidates for being the regulators of an evolutionarily conserved general pathway of programmed cell death(1-4). Here we present what we believe is the first molecular characterization of a ces gene. We cloned the gene ces-2, which is required to activate programmed cell death in the sister cells of the serotoninergic neurosecretory motor (NSM) neurons, and found that ces-2 encodes a basic region leucine-zipper (bZIP) transcription factor. The CES-2 protein is most similar to members of the PAR (proline- and acid-rich) subfamily of bZIP proteins and has DNA-binding specificity like that of PAR-family proteins. An oncogenic form of the mammalian PAR-family protein, hepatic leukaemia factor (HLF), is reported to effect programmed cell death in mammalian cells(5). On the basis of these observations, we suggest that some CES-2/PAR family transcription factors are evolutionarily conserved regulators of programmed cell death.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)			Hengartner, Michael O/A-7058-2008; Hengartner, Michael O/E-6235-2011	Hengartner, Michael/0000-0002-7584-596X				CAPOVILLA M, 1992, DEVELOPMENT, V114, P99; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ELLIS RE, 1991, DEVELOPMENT, V112, P591; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HAAS NB, 1995, MOL CELL BIOL, V15, P1923; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; HURST HC, 1994, TRANSCRIPTION FACTOR, V1; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; PU WT, 1991, MOL CELL BIOL, V11, P4918, DOI 10.1128/MCB.11.10.4918; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; YOSHIHARA T, 1995, MOL CELL BIOL, V15, P3247; ZHANG W, 1995, MOL CELL BIOL, V15, P6055	26	139	144	1	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					545	547		10.1038/382545a0	http://dx.doi.org/10.1038/382545a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700229				2022-12-24	WOS:A1996VB25800052
J	Henkemeyer, M; Orioli, D; Henderson, JT; Saxton, TM; Roder, J; Pawson, T; Klein, R				Henkemeyer, M; Orioli, D; Henderson, JT; Saxton, TM; Roder, J; Pawson, T; Klein, R			Nuk controls pathfinding of commissural axons in the mammalian central nervous system	CELL			English	Article							RECEPTOR-TYROSINE KINASE; PROTEIN; EPH; LIGAND; ELK; DROSOPHILA; CLONING; FAMILY; BRAIN; MICE	Eph family receptor tyrosine kinases have been proposed to control axon guidance and fasciculation. To address the biological functions of the Eph family member Nuk, two mutations in the mouse germline have been generated: a protein null allele (Nuk(1)) and an allele that encodes a Nuk-beta gal fusion receptor lacking the tyrosine kinase and C-terminal domains (Nuk(lacZ)). In Nuk(1) homozygous brains, the majority of axons forming the posterior tract of the anterior commissure migrate aberrantly to the floor of the brain, resulting in a failure of cortical neurons to link the two temporal lobes. These results indicate that Nuk, a receptor that binds transmembrane ligands, plays a critical and unique role in the pathfinding of specific axons in the mammalian central nervous system.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOL BIOL & CANC,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A8,CANADA; EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; European Molecular Biology Laboratory (EMBL)			Pawson, Tony J/E-4578-2013; Roder, John/G-6468-2013; Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163; Henkemeyer, Mark/0000-0002-7525-1061; ORIOLI, DONATA/0000-0002-3830-3408				BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; CALZONETTI T, 1995, DEV BIOL, V171, P615, DOI 10.1006/dbio.1995.1309; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FLETCHER FA, 1994, ONCOGENE, V9, P3241; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; His W., 1889, ABHANDL D MATH PHY K, V15, P675; Johnston JB, 1913, J COMP NEUROL, V23, P371, DOI 10.1002/cne.900230502; KATZ MJ, 1983, P NATL ACAD SCI-BIOL, V80, P5936, DOI 10.1073/pnas.80.19.5936; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; Langelaan JA, 1908, BRAIN, V31, P221, DOI 10.1093/brain/31.2.221; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; MIHALKOVICS VV, 1877, ENTWICKLUNGSGESCHICH; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; Probst M, 1901, ARCH PSYCHIAT NERVEN, V34, P709, DOI 10.1007/BF02680175; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; SILVER J, 1982, J COMP NEUROL, V210, P10, DOI 10.1002/cne.902100103; Suitsu N, 1920, J COMP NEUROL, V32, P35, DOI 10.1002/cne.900320103; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONSZILY A, 1912, A VONGRAEFES ARCH OP, V81, P67; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WURST W, 1993, GENE TARGETING PRACT; Xu QL, 1995, DEVELOPMENT, V121, P4005	40	458	468	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					35	46		10.1016/S0092-8674(00)80075-6	http://dx.doi.org/10.1016/S0092-8674(00)80075-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689685	Bronze			2022-12-24	WOS:A1996UX93400006
J	Qiu, XY; Culp, JS; DiLella, AG; Hellmig, B; Hoog, SS; Janson, CA; Smith, WW; AbdelMeguid, SS				Qiu, XY; Culp, JS; DiLella, AG; Hellmig, B; Hoog, SS; Janson, CA; Smith, WW; AbdelMeguid, SS			Unique fold and active site in cytomegalovirus protease	NATURE			English	Article							SIMPLEX VIRUS TYPE-1; CLEAVAGE SITES; PROTEINASE; SUBSTRATE; IDENTIFICATION; EXPRESSION; DOMAIN; SERINE; GENE	HUMAN herpesviruses are responsible for a variety of diseases. They are divided into three subfamilies: alpha includes herpes simplex viruses (HSV-1 and HSV-2) and varicella-zoster virus (VZV); beta includes cytomegalovirus (CMV) and human herpes-virus-6 (HHV-6); and gamma includes Epstein-Barr virus (EBV). Each virus encodes a serine protease that is essential for its replication(1-14) and is a potential target for therapeutic intervention. Human CMV is a ubiquitous opportunistic pathogen that can result in life-threatening infections in congenitally infected infants, immunocompromised individuals and immunosuppressed cancer or transplant patients(15). Here we report the crystal structure of human CMV protease at 2.5 Angstrom resolution. The structure reveals a fold that has not been reported for any other serine protease, and an active site consisting of a novel catalytic triad in which the third member is a histidine instead of an aspartic acid, or possibly a catalytic tetrad consisting of a serine, two histidines and an aspartic acid. An unusual dimer interface that is important to the protease activity has also been identified.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MACROMOL SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL GENET,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								ALFORD CA, 1990, VIROLOGY, P1981; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; CHOTHIA C, 1982, BIOCHEMISTRY-US, V21, P3955, DOI 10.1021/bi00260a009; COX GA, 1995, J VIROL, V69, P4524, DOI 10.1128/JVI.69.7.4524-4528.1995; Darke PL, 1996, J BIOL CHEM, V271, P7445, DOI 10.1074/jbc.271.13.7445; DILANNI CL, 1993, J BIOL CHEM, V268, P25449; GAO M, 1994, J VIROL, V68, P3702, DOI 10.1128/JVI.68.6.3702-3712.1994; HOLWERDA BC, 1994, J BIOL CHEM, V269, P25911; HOWARD AJ, 1994, J APPL CRYSTALLOGR A, V47, P110; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LIU FY, 1993, J VIROL, V67, P1300, DOI 10.1128/JVI.67.3.1300-1309.1993; LIU FY, 1992, P NATL ACAD SCI USA, V89, P2076, DOI 10.1073/pnas.89.6.2076; Margosiak SA, 1996, BIOCHEMISTRY-US, V35, P5300, DOI 10.1021/bi952842u; MCKEE DE, 1993, PRACTICAL PROTEIN CR; OBOYLE IL, 1993, J BIOL CHEM, V270, P4753; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PERONA JJ, 1995, PROTEIN SCI, V4, P337; STEVENS JT, 1994, EUR J BIOCHEM, V226, P361, DOI 10.1111/j.1432-1033.1994.tb20060.x; WEINHEIMER SP, 1993, J VIROL, V67, P5813, DOI 10.1128/JVI.67.10.5813-5822.1993; WELCH AR, 1995, J VIROL, V69, P341, DOI 10.1128/JVI.69.1.341-347.1995; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993	27	147	153	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					275	279		10.1038/383275a0	http://dx.doi.org/10.1038/383275a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805707				2022-12-24	WOS:A1996VH31500059
J	Luo, ZJ; Tzivion, G; Belshaw, PJ; Vavvas, D; Marshall, M; Avruch, J				Luo, ZJ; Tzivion, G; Belshaw, PJ; Vavvas, D; Marshall, M; Avruch, J			Oligomerization activates c-Raf-1 through a Ras-dependent mechanism	NATURE			English	Article							SIGNAL-TRANSDUCTION; 14-3-3 PROTEIN; KINASE RAF; BINDING; DOMAIN	THE c-Raf-1 proto-oncoprotein is a Ras-GTP-regulated protein kinase(1) that associates in situ with 14-3-3 proteins(2,3), which are naturally dimeric(4,5). In COS cells, recombinant Raf is found in oligomeric assemblies. To examine whether induced oligomerization can alter Raf kinase activity, sequences encoding the FK506-binding protein FKBP12 were fused to the amino terminus of c-Raf-1, introducing a binding site for FK506. Oligomerization of recombinant FKBP-Raf in situ, induced by the addition of the dimeric FK506 derivative FK1012A, activated Raf kinase activity at least half as well as epidermal growth factor (EGF). As with EGF, activation of FKBP-Raf by FK1012A is entirely Ras-GTP dependent. Thus oligomerization of Raf per se promotes Raf activation through a Ras-dependent mechanism.	MASSACHUSETTS GEN HOSP, MED SERV, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, DEPT CHEM & CHEM BIOL, CAMBRIDGE, MA 02138 USA; INDIANA UNIV, DEPT MED, DIV HEMATOL & ONCOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute; Harvard University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Luo, ZJ (corresponding author), MASSACHUSETTS GEN HOSP, DIABET UNIT, BOSTON, MA 02129 USA.		Luo, Zhijun/AAE-9302-2019; Tzivion, Guri/D-8954-2011	Luo, Zhijun/0000-0001-8105-5289; Vavvas, Demetrios/0000-0002-8622-6478				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BETSHAW PJ, 1996, P NATL ACAD SCI USA, V93, P4604; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; JOHNSON LN, 1996, J CELL, V85, P149; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Okada T, 1996, J BIOL CHEM, V271, P4671; Pruschy M N, 1994, Chem Biol, V1, P163, DOI 10.1016/1074-5521(94)90006-X; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	22	200	217	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1996	383	6596					181	185		10.1038/383181a0	http://dx.doi.org/10.1038/383181a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774885				2022-12-24	WOS:A1996VG14800056
J	Chen, CMA; Kraut, N; Groudine, M; Weintraub, H				Chen, CMA; Kraut, N; Groudine, M; Weintraub, H			I-mf, a novel myogenic repressor, interacts with members of the MyoD family	CELL			English	Article							LOOP-HELIX PROTEINS; TRANSCRIPTION FACTOR; XENOPUS-EMBRYOS; KAPPA-B; MUSCLE DIFFERENTIATION; NUCLEAR-LOCALIZATION; SKELETAL-MUSCLE; CELL LINEAGE; DNA-BINDING; NEURAL-TUBE	During embryogenesis, cells from the ventral and dorsal parts of the somites give rise to sclerotome and dermomyotome, respectively. Dermomyotome contains skeletal muscle precursors that are determined by the MyoD family of myogenic factors. We have isolated a novel myogenic repressor, I-mf (Inhibitor of MyoD family), which is highly expressed in the sclerotome. In contrast, MyoD family members are concentrated in the dermomyotome. We demonstrate that I-mf inhibits the transactivation activity of the MyoD family and represses myogenesis. I-mf associates with MyoD family members and retains them in the cytoplasm by masking their nuclear localization signals. I-mf can also interfere with the DNA binding activity of MyoD family members. We postulate that I-mf plays an important role in the patterning of the somite early in development.	FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104; UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,PROGRAM MOL & CELLULAR BIOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle								AOYAMA H, 1988, DEVELOPMENT, V104, P15; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; BUCKINGHAM M, 1994, CURR BIOL, V4, P61, DOI 10.1016/S0960-9822(00)00014-2; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CHEN CMA, 1996, THESIS U WASHINGTON; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; GOULDING M, 1994, DEVELOPMENT, V120, P957; HARVEY RP, 1991, P NATL ACAD SCI USA, V88, P9198, DOI 10.1073/pnas.88.20.9198; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KOPAN R, 1994, DEVELOPMENT, V120, P2385; LEE JE, 1995, SCIENCE, V268, P835; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MINER JH, 1992, DEVELOPMENT, V114, P853; MUNSTERBERG AE, 1995, DEVELOPMENT, V121, P651; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTT MO, 1991, DEVELOPMENT, V111, P1097; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; RONG PM, 1992, DEVELOPMENT, V115, P657; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SMITH TH, 1994, J CELL BIOL, V127, P95, DOI 10.1083/jcb.127.1.95; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; STERN CD, 1988, DEVELOPMENT, V104, P231; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, CELL, V66, P423, DOI 10.1016/0092-8674(81)90003-9; TAM PPL, 1994, ANAT EMBRYOL, V189, P275; TRAWICK JD, 1989, J BIOL CHEM, V264, P7005; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG YQ, 1992, DEV DYNAM, V194, P222, DOI 10.1002/aja.1001940307; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITESIDE ST, 1993, J CELL SCI, V104, P949; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	53	114	126	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					731	741		10.1016/S0092-8674(00)80148-8	http://dx.doi.org/10.1016/S0092-8674(00)80148-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797820	Bronze			2022-12-24	WOS:A1996VG37200007
J	DiazMeco, MT; Municio, MM; Frutos, S; Sanchez, P; Lozano, J; Sanz, L; Moscat, J				DiazMeco, MT; Municio, MM; Frutos, S; Sanchez, P; Lozano, J; Sanz, L; Moscat, J			The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C	CELL			English	Article							NF-KAPPA-B; ZETA-SUBSPECIES BLOCKS; XENOPUS-LAEVIS OOCYTES; TUMOR-NECROSIS-FACTOR; SPHINGOMYELIN PATHWAY; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; INTRACELLULAR RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; PHORBOL ESTERS	The atypical PKCs are involved in a number of important cellular functions, including cell proliferation. We report here that the product of the par-4 gene specifically interacts with the regulatory domains of zeta PKC and lambda/iota PKC, which dramatically inhibits their enzymatic activity. This is particularly challenging, because expression of par-4 has been shown to correlate with growth inhibition and apoptosis. Results are shown here demonstrating that the expression of par-4 in NIH-3T3 cells induces morphological changes typical of apoptosis, which are abrogated by cotransfection of either wild-type zeta PKC or lambda/iota PKC, but not by their respective kinase-inactive mutants. These findings support a role for the atypical PKC subspecies in the control of cell growth and survival.	UNIV AUTONOMA MADRID,CONSEJO SUPER INVEST CIENT,CTR BIOL MOL,MADRID 28049,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Sánchez-Gómez, Pilar/K-8256-2014; Moscat, Jorge/A-7011-2009; Lozano, José/C-2760-2014	Sánchez-Gómez, Pilar/0000-0002-0709-4973; Lozano, José/0000-0002-8187-2833; Diaz-Meco, Maria/0000-0003-0147-0998				AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Folgueira L, 1996, J VIROL, V70, P223, DOI 10.1128/JVI.70.1.223-231.1996; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MORYA S, 1996, P NATL ACAD SCI USA, V93, P151; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO Y, 1989, P NATL ACAD SCI USA, V86, P3099; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; TOKER A, 1994, J BIOL CHEM, V269, P32358; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1992, J BIOL CHEM, V267, P4799; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG ZH, 1993, J BIOL CHEM, V268, P20520; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHANG YH, 1995, ENDOCRINOLOGY, V136, P4157, DOI 10.1210/en.136.10.4157	49	325	341	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					777	786		10.1016/S0092-8674(00)80152-X	http://dx.doi.org/10.1016/S0092-8674(00)80152-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797824	Bronze			2022-12-24	WOS:A1996VG37200011
J	Sijbers, AM; deLaat, WL; Ariza, RR; Biggerstaff, M; Wei, YF; Moggs, JG; Carter, KC; Shell, BK; Evans, E; deJong, MC; Rademakers, S; deRooij, J; Jaspers, NGJ; Hoeijmakers, JHJ; Wood, RD				Sijbers, AM; deLaat, WL; Ariza, RR; Biggerstaff, M; Wei, YF; Moggs, JG; Carter, KC; Shell, BK; Evans, E; deJong, MC; Rademakers, S; deRooij, J; Jaspers, NGJ; Hoeijmakers, JHJ; Wood, RD			Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease	CELL			English	Article							NUCLEOTIDE-EXCISION-REPAIR; COMPLEMENTATION GROUP-F; SACCHAROMYCES-CEREVISIAE; PROTEINS RAD1; GENE ERCC-1; FUNCTIONAL DOMAINS; GROUP-A; RECOMBINATION; COMPLEX; PURIFICATION	Nucleotide excision repair, which is defective in xeroderma pigmentosum (XP), involves incision of a DNA strand on each side of a lesion, We isolated a human gene homologous to yeast Rad1 and found that it corrects the repair defects of XP group F as well as rodent groups 4 and 11. Causative mutations and strongly reduced levels of encoded protein were identified in XP-F patients. The XPF protein was purified from mammalian cells in a tight complex with ERCC1. This complex is a structure-specific endonuclease responsible for the 5' incision during repair. These results demonstrate that the XPF, ERCC4, and ERCC11 genes are equivalent, complete the isolation of the XP genes that form the core nucleotide excision repair system, and solve the catalytic function of the XPF-containing complex.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,CTR MED GENET,NL-3000 DR ROTTERDAM,NETHERLANDS; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	Erasmus University Rotterdam; GlaxoSmithKline; Human Genome Sciences Inc			Wood, Richard D/M-6319-2018; Hoeijmakers, Jan/AAX-6972-2021; Sijbers, Anneke/G-6661-2016; de rooij, johan/C-1325-2019	Wood, Richard D/0000-0002-9495-6892; Rodriguez Ariza, Rafael/0000-0002-0338-7306; de Laat, Wouter/0000-0002-6393-595X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; BUSCH D, 1994, MUTAGENESIS, V9, P301, DOI 10.1093/mutage/9.4.301; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FRIEDBERG EC, 1995, DNA REPAIR; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HATA H, 1991, CANCER RES, V51, P195; HOBOHM U, 1995, J MOL BIOL, V251, P390, DOI 10.1006/jmbi.1995.0442; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEHMANN AR, 1994, MUTAT RES, V315, P41, DOI 10.1016/0921-8777(94)90026-4; LIU P, 1993, MUTAGENESIS, V8, P199, DOI 10.1093/mutage/8.3.199; LIU Q, 1995, BIOTECHNIQUES, V18, P470; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; NORRIS PG, 1988, J AM ACAD DERMATOL, V18, P1185, DOI 10.1016/S0190-9622(88)70121-8; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; REYNOLDS P, 1987, MOL CELL BIOL, V7, P1012, DOI 10.1128/MCB.7.3.1012; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHNEIDER R, 1991, FEBS LETT, V283, P203, DOI 10.1016/0014-5793(91)80588-T; SEKELSKY JJ, 1995, GENETICS, V141, P619; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SUNG P, 1993, J BIOL CHEM, V268, P26391; THOMPSON LH, 1994, P NATL ACAD SCI USA, V91, P6855, DOI 10.1073/pnas.91.15.6855; TOMKINSON AE, 1994, BIOCHEMISTRY-US, V33, P5305, DOI 10.1021/bi00183a038; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; TROELSTRA C, 1992, GENOMICS, V12, P745, DOI 10.1016/0888-7543(92)90304-B; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANDUIN M, 1989, MUTAT RES, V217, P83, DOI 10.1016/0921-8777(89)90059-1; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VANVUUREN AJ, 1995, MUTAT RES-DNA REPAIR, V337, P25, DOI 10.1016/0921-8777(95)00009-9; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; WOOD RD, 1982, MUTAT RES, V95, P505, DOI 10.1016/0027-5107(82)90281-0; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; YAMAMURA K, 1989, BRIT J DERMATOL, V121, P471, DOI 10.1111/j.1365-2133.1989.tb15514.x; ZELLE B, 1980, MUTAT RES, V73, P157, DOI 10.1016/0027-5107(80)90144-X	55	420	439	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					811	822		10.1016/S0092-8674(00)80155-5	http://dx.doi.org/10.1016/S0092-8674(00)80155-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797827	Green Published, Bronze			2022-12-24	WOS:A1996VG37200014
J	Parry, RG; Crowe, A; Stevens, JM; Mason, JC; Roderick, P				Parry, RG; Crowe, A; Stevens, JM; Mason, JC; Roderick, P			Referral of elderly patients with severe renal failure: Questionnaire survey of physicians	BRITISH MEDICAL JOURNAL			English	Article							REPLACEMENT THERAPY		ST MARYS HOSP,WESSEX RENAL & TRANSPLANT UNIT,PORTSMOUTH PO3 6AD,HANTS,ENGLAND; SOUTHAMPTON GEN HOSP,WESSEX INST PUBL HLTH MED,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton								CHALLAH S, 1984, BRIT MED J, V288, P1119, DOI 10.1136/bmj.288.6424.1119; KHAN IH, 1994, Q J MED, V87, P559; MIGNON F, 1993, KIDNEY INT, V43, pS18; PONTICELLI C, 1989, Q J MED, V72, P667; WILLIAMS AJ, 1989, Q J MED, V72, P749	5	41	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					466	466						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776315				2022-12-24	WOS:A1996VE08000022
J	Tang, MX; Jacobs, D; Stern, Y; Marder, K; Schofield, P; Gurland, B; Andrews, H; Mayeux, R				Tang, MX; Jacobs, D; Stern, Y; Marder, K; Schofield, P; Gurland, B; Andrews, H; Mayeux, R			Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; PARADIGM-BASED DIAGNOSIS; E ALLELE EPSILON-4; APOLIPOPROTEIN-E; HETEROGENEOUS POPULATION; DEMENTIA; RECEPTORS; NEURONS; WOMEN	Background Oestrogen use by postmenopausal women has many health benefits, but findings on the effect of oestrogen in Alzheimer's disease are conflicting. Oestrogen promotes the growth and survival of cholinergic neurons and could decrease cerebral amyloid deposition, both of which may delay the onset or prevent Alzheimer's disease. To investigate whether use of oestrogen during the postmenopausal period affects the risk of Alzheimer's disease, we studied 1124 elderly women who were initially free of Alzheimer's disease, Parkinson's disease, and stroke, and who were taking part in a longitudinal study of ageing and health in a New York City community. Methods Relative risks and age-at-onset distributions were calculated from simple and adjusted Cox proportional hazards models. Standard annual clinical assessments and criterion-based diagnoses were used in follow-up (range 1-5 years). Findings Overall, 156 (12.5%) women reported taking oestrogen after onset of menopause. The age at onset of Alzheimer's disease was significantly later in women who had taken oestrogen than in those who did not and the relative risk of the disease was significantly reduced (9/156 [5.8%] oestrogen users vs 158/968 [16.3%] non-users; 0.40 [95% CI 0.22-0.85], p<0.01), even after adjustment for differences in education, ethnic origin, and apolipoprotein-E genotype. Women who had used oestrogen for longer than 1 year had a greater reduction in risk; none of 23 women who were taking oestrogen at study enrolment has developed Alzheimer's disease. Interpretation Oestrogen use in postmenopausal women may delay the onset and decrease the risk of Alzheimer's disease. Prospective studies are needed to establish the dose and duration of oestrogen required to provide this benefit and to assess its safety in elderly postmenopausal women.	COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,GERTRUDE H SERGIEVSKY CTR,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,TAUB CTR ALZHEIMERS DIS RES,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,DEPT NEUROL,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,DEPT PSYCHIAT,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,STROUD CTR STUDY QUAL LIFE,SCH PUBL HLTH,DIV EPIDEMIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK STATE PSYCHIAT INST,DEPT PSYCHIAT,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; New York State Psychiatry Institute			Schofield, Peter/J-7133-2013	Stern, Yaakov/0000-0001-7542-3241; Jacobs, Diane/0000-0003-0886-6784	NATIONAL INSTITUTE ON AGING [P50AG008702, R35AG010963, P01AG007232] Funding Source: NIH RePORTER; NIA NIH HHS [AG07232, AG08702, AG10963] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P205; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; BUSH TL, 1983, JAMA-J AM MED ASSOC, V249, P903, DOI 10.1001/jama.249.7.903; COLLET D, 1994, MODELLING SUVIVAL DA, P153; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; HERBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354; HIXSON J, 1991, J LIPID RES, V31, P545; HONJO H, 1995, HORM METAB RES, V27, P204, DOI 10.1055/s-2007-979941; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIRANDA RC, 1993, MOL CELL NEUROSCI, V4, P510, DOI 10.1006/mcne.1993.1063; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; PITTMAN J, 1992, ARCH NEUROL-CHICAGO, V49, P461, DOI 10.1001/archneur.1992.00530290043010; ROCCA WA, 1986, ANN NEUROL, V19, P415, DOI 10.1002/ana.410190502; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SIMPKINS JW, 1994, NEUROBIOL AGING, V15, pS195; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Singh M., 1993, Society for Neuroscience Abstracts, V19, P1254; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; TORANALLERAND CD, 1992, P NATL ACAD SCI USA, V89, P4668, DOI 10.1073/pnas.89.10.4668	28	1351	1391	2	88	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					429	432		10.1016/S0140-6736(96)03356-9	http://dx.doi.org/10.1016/S0140-6736(96)03356-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709781	Green Submitted, hybrid			2022-12-24	WOS:A1996VC67300009
J	Mirkin, CA; Letsinger, RL; Mucic, RC; Storhoff, JJ				Mirkin, CA; Letsinger, RL; Mucic, RC; Storhoff, JJ			A DNA-based method for rationally assembling nanoparticles into macroscopic materials	NATURE			English	Article							ORGANIC-SURFACES; MONOLAYERS; CATENANES; SILVER; SIZE	COLLOIDAL, particles of metals and semiconductors have potentially useful optical, optoelectronic and material properties(1-4) that derive from their small (nanoscopic) size. These properties might lead to applications including chemical sensors, spectroscopic enhancers, quantum dot and nanostructure fabrication, and microimaging methods(2-4). A great deal of control can now be exercised over the chemical composition, size and polydispersity(1,2) of colloidal particles, and many methods have been developed for assembling them into useful aggregates and materials, Here we describe a method for assembling colloidal gold nanoparticles rationally and reversibly into macroscopic aggregates. The method involves attaching to the surfaces of two batches of 13-nm gold particles non-complementary DNA oligonucleotides capped with thiol groups, which bind to gold, When we add to the solution an oligonucleotide duplex with 'sticky ends' that are complementary to the two grafted sequences, the nanoparticles self-assemble into aggregates, This assembly process can be reversed by thermal denaturation. This strategy should now make it possible to tailor the optical, electronic and structural properties of the colloidal aggregates by using the specificity of DNA interactions to direct the interactions between particles of different size and composition.			Mirkin, CA (corresponding author), NORTHWESTERN UNIV,DEPT CHEM,2145 SHERIDAN RD,EVANSTON,IL 60208, USA.		Mirkin, Chad A/E-3911-2010	Mirkin, Chad/0000-0002-6634-7627				BAIN CD, 1989, ANGEW CHEM INT EDIT, V28, P506, DOI 10.1002/anie.198905061; BASSELL GJ, 1994, J CELL BIOL, V126, P863, DOI 10.1083/jcb.126.4.863; BRUST M, 1995, ADV MATER, V7, P795, DOI 10.1002/adma.19950070907; CHEN JH, 1991, NATURE, V350, P631, DOI 10.1038/350631a0; CHEN LQ, 1994, BIOCHEMISTRY-US, V33, P13540, DOI 10.1021/bi00250a005; COLVIN VL, 1992, J AM CHEM SOC, V114, P5221, DOI 10.1021/ja00039a038; CREIGHTON JA, 1979, J CHEM SOC FARAD T 2, V75, P790, DOI 10.1039/f29797500790; DUBOIS LH, 1992, ANNU REV PHYS CHEM, V43, P437, DOI 10.1146/annurev.pc.43.100192.002253; GRABAR KC, 1995, ANAL CHEM, V67, P735, DOI 10.1021/ac00100a008; Hayat MA, 1991, COLLOIDAL GOLD PRINC; HERRLEIN MK, 1995, J AM CHEM SOC, V117, P10151, DOI 10.1021/ja00145a042; HERRON N, 1990, J AM CHEM SOC, V112, P1322, DOI 10.1021/ja00160a004; LINNERT T, 1993, J PHYS CHEM-US, V97, P679, DOI 10.1021/j100105a024; MARSH TC, 1995, NUCLEIC ACIDS RES, V23, P696, DOI 10.1093/nar/23.4.696; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MUCIC RC, 1996, J CHEM SOC CHEM COMM, P555; Schmid G., 1994, CLUSTERS COLLOIDS; SEEMAN NC, 1993, NEW J CHEM, V17, P739; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SHEKHTMAN EM, 1993, NEW J CHEM, V17, P757; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003; WANG YL, 1991, BIOCHEMISTRY-US, V30, P5667, DOI 10.1021/bi00237a005; WELLS RD, 1988, J BIOL CHEM, V263, P1095	24	5360	5620	74	2686	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					607	609		10.1038/382607a0	http://dx.doi.org/10.1038/382607a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757129				2022-12-24	WOS:A1996VC30300046
J	Strang, J; Sheridan, J; Barber, N				Strang, J; Sheridan, J; Barber, N			Prescribing injectable and oral methadone to opiate addicts: Results from the 1995 national postal survey of community pharmacies in England and Wales	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To establish the extent of prescribing injectable and oral methadone to opiate addicts and the practice characteristics and dispensing arrangements attached to these prescriptions. Design-National survey of 25% random sample of community (high street) pharmacies through postal questionnaire, with four mailings. Setting-England and Wales. Subjects-1 in 4 sample of all 10 616 community pharmacies, stratified by family health services authority. Main outcome measures-Data were collected on each prescription for controlled drugs currently being dispensed by pharmacies to misusers, describing the drug, form, dose, source (general practice or hospital; and NHS or private), and numbers of dispensing pick ups a week. Results-Methadone was the opiate most commonly dispensed to misusers (96.0% of 3846 opiate prescriptions). 79.6% of methadone prescriptions were for the oral liquid form, 11.0% for tablet, and 9.3% for injectable ampoules. More than one third of all methadone prescriptions were for weekly or fortnightly pick up, with a further third being for daily pick up. Tablets and ampoules were even less likely to be dispensed on a daily basis. Private prescriptions were significantly more likely than NHS ones to be for tablets or ampoules, to be for substantially higher daily doses, and to be collected on a weekly or fortnightly basis. Conclusions-The distinctively British practice of prescribing injectable methadone was found to be widespread and, contrary to guidance, to be as prevalent in non-specialist as specialist settings. In view of the frequent crushing and injecting of methadone tablets, clearer more authoritative guidance is needed on the contexts in which injectable methadone (tablets as well as ampoules) should be prescribed and on the responsibilities for monitoring and supervision which should be attached.	UNIV LONDON, SCH PHARM, LONDON WC1N 1AX, ENGLAND	University of London; University College London; University of London School of Pharmacy	Strang, J (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT, NATL ADDICT CTR, DE CRESPIGNY PK, DENMARK HILL, LONDON SE5 8AF, ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Sheridan, Janie/0000-0002-0312-3095				*ADV COUNC MIS DRU, 1993, AIDS DRUG MIS UPD RE; BALL JC, 1991, EFF METH MAIN TREATM; BAMMER G, 1993, ADDICTION, V88, P467; *DEP HLTH SCOTT HO, 1991, DRUG MIS DEP GUID CL; *DEP HLTH SOC SEC, 1984, GUID GOOD CLIN PRACT; DERKS JTM, 1990, DRUG MISUSE DEPENDEN, P85; *DRUG TREATM EFF T, 1996, REP DEP HLTH; FARRELL M, 1994, BMJ-BRIT MED J, V309, P997, DOI 10.1136/bmj.309.6960.997; *HOM OFF, 1994, STAT MIS DRUGS ADD N; LAUZON P, 1994, J SUBST ABUSE TREAT, V11, P457, DOI 10.1016/0740-5472(94)90099-X; MITCHESON M, 1994, HEROIN ADDICTION DRU, P178; POLKINGHORNE J, 1995, DRUG LINK        JAN, P1; Sheridan J, 1996, BRIT MED J, V313, P272, DOI 10.1136/bmj.313.7052.272; Strang J, 1994, HEROIN ADDICTION DRU, P192; Strang J., 1994, HEROIN ADDICTION DRU; STRANG J, 1989, INT REV PSYCHIATR, V1, P109; UCHTENHAGEN A, IN PRESS MED PRESCRI; WARD J, 1992, KEY ISSUES METHADONE	18	99	99	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 3	1996	313	7052					270	272		10.1136/bmj.313.7052.270	http://dx.doi.org/10.1136/bmj.313.7052.270			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VA903	8704540	Green Published			2022-12-24	WOS:A1996VA90300030
J	Russo, AA; Jeffrey, PD; Patten, AK; Massague, J; Pavletich, NP				Russo, AA; Jeffrey, PD; Patten, AK; Massague, J; Pavletich, NP			Crystal structure of the p27(Kip1) cyclin-dependent-kinase inhibitor bound to the cyclin A Cdk2 complex	NATURE			English	Article							POTENTIAL MEDIATOR; P21; PROTEINS; PROGRAM	The crystal structure of the human p27(Kip1) kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 Angstrom, p27(Kip1) binds the complex as an extended structure interacting with both cyclin A and Cdk2. On cyclin A, it binds in a groove formed by conserved cyclin box residues. On Cdk2, it binds and rearranges the amino-terminal lobe and also inserts into the catalytic cleft, mimicking ATP.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELL BIOL PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Jeffrey, Philip/0000-0002-4351-5341; Massague, Joan/0000-0001-9324-8408				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; JEFFREY PD, 1995, NATURE, V375, P159; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RUSSO AR, IN PRESS NATURE STRU; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1570; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	38	771	803	0	30	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					325	331		10.1038/382325a0	http://dx.doi.org/10.1038/382325a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684460				2022-12-24	WOS:A1996UY95000042
J	Lee, JT; Strauss, WM; Dausman, JA; Jaenisch, R				Lee, JT; Strauss, WM; Dausman, JA; Jaenisch, R			A 450 kb transgene displays properties of the mammalian X-inactivation center	CELL			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; INSITU HYBRIDIZATION; DOSAGE COMPENSATION; STEM-CELLS; MOUSE; GENE; LOCUS; DIFFERENTIATION; CONSTRUCTION; EXPRESSION	X inactivation results in inactivation of one X chromosome to compensate for gene dosage differences between mammalian females and males. It requires the X-inactivation center (Xic) and Xist in cis. We report that introducing 450 kb of murine Xic/Xist sequences onto autosomes activates female dosage compensation in male ES cells. Xist is induced upon differentiation and can be expressed from both endogenous and ectopic loci, suggesting that elements for counting and choosing Xs are present in the transgene. Differentiating transgenic ES cells undergo excessive cell death. Postnatally, Xist is expressed only from the transgene. Ectopic Xist RNA structurally associates with the autosome and may inactivate a marker gene in cis. These results argue that the Xic is contained within 450 kb and that these sequences are sufficient for chromosome counting, choosing, and initiation of X inactivation.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Lee, JT (corresponding author), MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NCI NIH HHS [R35-CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; BARR ML, 1962, ACTA CYTOL, V6, P34; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BELMONT AS, 1986, EXP CELL RES, V165, P165, DOI 10.1016/0014-4827(86)90541-0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CATTANACH BM, 1974, GENET RES, V23, P291, DOI 10.1017/S0016672300014932; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CLEMSON CM, 1996, J CELL BIOL, V132, P1; COOPER P, 1993, GENOMICS, V15, P570, DOI 10.1006/geno.1993.1109; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; COURTIER B, 1995, P NATL ACAD SCI USA, V92, P3531, DOI 10.1073/pnas.92.8.3531; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; GRAVES JAM, 1986, SOMAT CELL MOLEC GEN, V12, P275, DOI 10.1007/BF01570786; Heard E, 1996, HUM MOL GENET, V5, P441, DOI 10.1093/hmg/5.4.441; HEARD E, 1993, GENOMICS, V15, P559, DOI 10.1006/geno.1993.1108; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LEE JT, 1992, GENOMICS, V12, P526, DOI 10.1016/0888-7543(92)90444-W; LEPPIG KA, 1993, HUM MOL GENET, V2, P883, DOI 10.1093/hmg/2.7.883; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MARTIN GR, 1978, NATURE, V271, P329, DOI 10.1038/271329a0; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; Matsuura S, 1996, HUM MOL GENET, V5, P451, DOI 10.1093/hmg/5.4.451; MCGAHON AJ, 1995, CELL DEATH DIFFER, P153; MIGEON BR, 1994, TRENDS GENET, V10, P230, DOI 10.1016/0168-9525(94)90169-4; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RUSSELL LB, 1963, SCIENCE, V140, P976, DOI 10.1126/science.140.3570.976; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; STRAUSS WM, 1993, SCIENCE, V259, P1904, DOI 10.1126/science.8096090; TAI HH, 1994, SOMAT CELL MOLEC GEN, V20, P171, DOI 10.1007/BF02254758; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4	42	269	280	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					83	94		10.1016/S0092-8674(00)80079-3	http://dx.doi.org/10.1016/S0092-8674(00)80079-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689690	Bronze			2022-12-24	WOS:A1996UX93400010
J	Lee, CH; Saksela, K; Mirza, UA; Chait, BT; Kuriyan, J				Lee, CH; Saksela, K; Mirza, UA; Chait, BT; Kuriyan, J			Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain	CELL			English	Article							PROTEIN STRUCTURES; GENE; KINASES	The crystal structure of the conserved core of HIV-1 Nef has been determined in complex with the SH3 domain of a mutant Fyn tyrosine kinase (a single amino acid substitution, Arg-96 to isoleucine), to which Nef binds tightly. The conserved PxxP sequence motif of Nef, known to be important for optimal viral replication, is part of a polyproline type II helix that engages the SH3 domain in a manner resembling closely the interaction of isolated peptides with SH3 domains. The Nef-SH3 structure also reveals how high affinity and specificity in the SH3 interaction is achieved by the presentation of the PxxP motif within the context of the folded structure of Nef.	ROCKEFELLER UNIV, 1230 YORK AVE, NEW YORK, NY 10021 USA; HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute			Lee, Chi-Hon/G-9190-2012	Lee, Chi-Hon/0000-0002-6138-711X				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BOLEN JB, 1993, ONCOGENE, V8, P2025; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1992, XPLOR VERSION 3 1 MA; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; FREUND J, 1994, EUR J BIOCHEM, V223, P589, DOI 10.1111/j.1432-1033.1994.tb19029.x; FREUND J, 1994, EUR J BIOCHEM, V221, P811, DOI 10.1111/j.1432-1033.1994.tb18795.x; GOSSER YQ, 1995, STRUCTURE, V3, P1075, DOI 10.1016/S0969-2126(01)00243-X; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; GRZESIEK S, 1995, J AM CHEM SOC, V117, P9594, DOI 10.1021/ja00142a040; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SAWAI ET, 1995, J BIOL CHEM, V270, P15307, DOI 10.1074/jbc.270.25.15307; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SHUGARS DC, 1993, J VIROL, V67, P4639, DOI 10.1128/JVI.67.8.4639-4650.1993; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	40	385	397	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1996	85	6					931	942		10.1016/S0092-8674(00)81276-3	http://dx.doi.org/10.1016/S0092-8674(00)81276-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681387	Bronze			2022-12-24	WOS:A1996UR60400016
J	Nattinger, AB; Hoffmann, RG; Shapiro, R; Gottlieb, MS; Goodwin, JS				Nattinger, AB; Hoffmann, RG; Shapiro, R; Gottlieb, MS; Goodwin, JS			The effect of legislative requirements on the use of breast-conserving surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GEOGRAPHIC-VARIATION; PRACTICE GUIDELINES; CANCER-TREATMENT; MASTECTOMY; CONSENSUS; RADIOTHERAPY; PHYSICIANS; REGRESSION; RADIATION; WOMEN	Background We studied the effect of state legislation requiring the disclosure of options for the treatment of breast cancer on the use of breast-conserving surgery in clinical practice. Methods The National Cancer Institute's Surveillance, Epidemiology, and End Results registry provided data on women from 30 through 79 years of age who underwent breast-conserving surgery or mastectomy for local or regional breast cancer from 1983 through 1990. We examined the trend over time in the use of breast-conserving surgery among patients in four sites (Connecticut, Iowa, Seattle, and Utah) where there were no state laws specifically requiring the disclosure of options for the treatment of breast cancer by physicians. For four additional sites (Detroit, Atlanta, New Mexico, and Hawaii) that had such legislation, we determined whether the rate of breast-conserving surgery after the legislation was different from the expected rate. Results An attorney rated the legislation as giving most direction to physicians in Michigan, followed by Hawaii, Georgia, and New Mexico. The rate of breast-conserving surgery was up to 8.7 percent higher than expected in Detroit for six months after the passage of the Michigan law (P<0.01). The rate was up to 13.2 percent higher than expected in Hawaii for 12 months after that state's law was passed (P<0.05) and up to 6.0 percent higher than expected in Atlanta for 3 months after the passage of the Georgia law (P<0.01). After these transient increases, the surgery rates reverted to the expected levels, No significant effect was detected in New Mexico, where only a resolution without legal force was passed. Conclusions Legislation requiring physicians to disclose options for the treatment of breast cancer appeared to have only a slight and transient effect on the rate of use of breast-conserving surgery, (C) 1996, Massachusetts Medical Society.	MED COLL WISCONSIN,DEPT BIOSTAT,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT BIOETH,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT FAMILY & COMMUNITY MED,MILWAUKEE,WI 53226; UNIV TEXAS,MED BRANCH,DEPT MED,GALVESTON,TX 77550	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; University of Texas System; University of Texas Medical Branch Galveston	Nattinger, AB (corresponding author), MED COLL WISCONSIN,DEPT MED,DIV GEN INTERNAL MED,ADM OFF FMLH E,9200 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.			Nattinger, Ann/0000-0002-8189-3300	NATIONAL CANCER INSTITUTE [R01CA054676] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA54676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAY LA, 1993, EVALUATING MED CARE, P49; ANNAS GJ, 1980, HASTINGS CENT REP, V10, P27, DOI 10.2307/3561276; *BUR HLTH PROF, 1992, AR RES FILE ARF SYST; DIXON DO, 1987, STAT MED, V6, P591, DOI 10.1002/sim.4780060508; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GREER AL, 1987, JAMA-J AM MED ASSOC, V258, P2739, DOI 10.1001/jama.258.19.2739; HARRIS JR, 1985, NEW ENGL J MED, V313, P1365, DOI 10.1056/NEJM198511213132128; JENKINS GM, 1979, PRACTICAL EXPERIENCE, P104; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LANDWEHR JM, 1984, J AM STAT ASSOC, V79, P61, DOI 10.2307/2288334; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MANN BA, 1988, JAMA-J AM MED ASSOC, V259, P3413; Michalski T. A., 1995, JGIM, V10, P124; MOR V, 1989, CANCER ELDERLY APPRO, P127; *NAT CANC I, 1993, SURV PROGR CANC STAT; Nattinger AB, 1996, MED CARE, V34, P479, DOI 10.1097/00005650-199605000-00009; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; NAYFIELD SG, 1994, J NATL CANCER I, V86, P1202, DOI 10.1093/jnci/86.16.1202; PIERCE PF, 1993, NURS RES, V42, P22; SARRAZIN D, 1984, CANCER, V53, P1209, DOI 10.1002/1097-0142(19840301)53:5<1209::AID-CNCR2820530531>3.0.CO;2-Y; STUDNICKI J, 1993, CANCER, V72, P2986, DOI 10.1002/1097-0142(19931115)72:10<2986::AID-CNCR2820721021>3.0.CO;2-1; SUGARMAN J, 1991, JAMA-J AM MED ASSOC, V266, P3323, DOI 10.1001/jama.266.23.3323; TARBOX BB, 1992, AM J SURG, V164, P417, DOI 10.1016/S0002-9610(05)81172-9; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; WARD S, 1989, CANCER NURS, V12, P344	28	50	51	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1035	1040		10.1056/NEJM199610033351407	http://dx.doi.org/10.1056/NEJM199610033351407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8793929				2022-12-24	WOS:A1996VL45900007
J	Velazquez, FR; Matson, DO; Calva, JJ; Guerrero, ML; Morrow, AL; CarterCampbell, S; Glass, RI; Estes, MK; Pickering, LK; RuizPalacios, GM				Velazquez, FR; Matson, DO; Calva, JJ; Guerrero, ML; Morrow, AL; CarterCampbell, S; Glass, RI; Estes, MK; Pickering, LK; RuizPalacios, GM			Rotavirus infection in infants as protection against subsequent infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							YOUNG-CHILDREN; ESCHERICHIA-COLI; RURAL BANGLADESH; MEXICAN CHILDREN; DIARRHEA; GASTROENTERITIS; COHORT; AGE; EPIDEMIOLOGY; SEVERITY	Background Rotavirus is the leading cause of severe diarrhea in infants. To provide a base line for assessing the efficacy of rotavirus vaccines, we evaluated the protection that is conferred by natural rotavirus infection. Methods We monitored 200 Mexican infants from birth to two years of age by weekly home visits and stool collections. A physician assessed the severity of any episodes of diarrhea and collected additional stool specimens for testing by enzyme immunoassay and typing of strains. Serum collected during the first week of life and every four months thereafter was tested for antirotavirus IgA and IgG. Results A total of 316 rotavirus infections were detected on the basis of the fecal excretion of virus (56 percent) or a serologic response (77 percent), of which 52 percent were first and 48 percent repeated infections. Children with one, two, or three previous infections had progressively lower risks of both subsequent rotavirus infection (adjusted relative risk, 0.82, 0.40, and 0.34, respectively) and diarrhea (adjusted relative risk, 0.23, 0.17, and 0.08) than children who had no previous infections. No child had moderate-to-severe diarrhea after two infections, whether symptomatic or asymptomatic. Subsequent infections were significantly less severe than first infections (P=0.024), and second infections were more likely to be caused by another G type (P=0.054). Conclusions In infants, natural rotavirus infection confers protection against subsequent infection. This protection increases with each new infection and reduces the severity of the diarrhea. (C) 1996, Massachusetts Medical Society.	INST NACL NUTR SALVADOR ZUBIRAN,DEPT INFECT DIS,MEXICO CITY 14000,DF,MEXICO; EASTERN VIRGINIA MED SCH,CHILDRENS HOSP KINGS DAUGHTERS,CTR PEDIAT RES,NORFOLK,VA 23501; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; CTR DIS CONTROL & PREVENT,VIRAL GASTROENTERITIS UNIT,ATLANTA,GA 30341; BAYLOR COLL MED,DIV MOL VIROL,HOUSTON,TX 77030	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Eastern Virginia Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Centers for Disease Control & Prevention - USA; Baylor College of Medicine			Morrow, Ardythe/GQO-8482-2022; Ruiz-Palacios, Guillermo/GYQ-5462-2022		NICHD NIH HHS [HD-13201] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTLETT AV, 1987, ANNU REV MED, V38, P399, DOI 10.1146/annurev.med.38.1.399; BERNSTEIN DI, 1995, JAMA-J AM MED ASSOC, V273, P1191, DOI 10.1001/jama.273.15.1191; BERNSTEIN DI, 1991, J INFECT DIS, V164, P277, DOI 10.1093/infdis/164.2.277; BHAN MK, 1993, J INFECT DIS, V168, P282, DOI 10.1093/infdis/168.2.282; BISHOP RF, 1983, NEW ENGL J MED, V309, P72, DOI 10.1056/NEJM198307143090203; BLACK RE, 1982, AM J EPIDEMIOL, V115, P315, DOI 10.1093/oxfordjournals.aje.a113308; BLACK RE, 1981, LANCET, V1, P141; BRANDT CD, 1983, J CLIN MICROBIOL, V18, P71, DOI 10.1128/JCM.18.1.71-78.1983; CALVA JJ, 1988, LANCET, V1, P503; CARTERCAMPBELL S, 1993, THESIS HARVARD SCH P; CLAYTON D, 1985, J R STAT SOC A STAT, V148, P82, DOI 10.2307/2981943; Conner M E, 1994, Curr Top Microbiol Immunol, V185, P285; COULSON BS, 1990, J CLIN MICROBIOL, V28, P1367, DOI 10.1128/JCM.28.6.1367-1374.1990; Dean AG, 1994, EPIINFO VERSION 6 WO; DEZOYSA I, 1985, B WORLD HEALTH ORGAN, V63, P569; ESTES MK, 1989, MICROBIOL REV, V53, P410, DOI 10.1128/MMBR.53.4.410-449.1989; Fleiss JL., 1981, STAT METHODS RATES P, V2, P22; FONTEYNE J, 1978, LANCET, V1, P983; FRIEDMAN MG, 1988, J INFECT DIS, V158, P814, DOI 10.1093/infdis/158.4.814; GEORGESCOURBOT MC, 1988, ANN INST PASTEUR VIR, V139, P421, DOI 10.1016/S0769-2617(88)80077-7; GORZIGLIA M, 1990, P NATL ACAD SCI USA, V87, P7155, DOI 10.1073/pnas.87.18.7155; GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276, DOI 10.1128/JCM.28.2.276-282.1990; GRINSTEIN S, 1989, AM J EPIDEMIOL, V130, P300, DOI 10.1093/oxfordjournals.aje.a115336; GURWITH M, 1981, J INFECT DIS, V144, P218, DOI 10.1093/infdis/144.3.218; HO MS, 1988, J INFECT DIS, V158, P1112, DOI 10.1093/infdis/158.5.1112; Kapikian AZ, 1990, VIROLOGY, P1353; LINHARES AC, 1989, EPIDEMIOL INFECT, V102, P129, DOI 10.1017/S0950268800029769; LOPEZVIDA Y, 1990, J INFECT DIS, V162, P442, DOI 10.1093/infdis/162.2.442; MATA L, 1983, J INFECT DIS, V148, P452, DOI 10.1093/infdis/148.3.452; MATSON DO, 1990, J INFECT DIS, V162, P598, DOI 10.1093/infdis/162.3.598; MATSON DO, 1990, J INFECT DIS, V162, P305; Mehta C R, 1994, Stat Methods Med Res, V3, P135, DOI 10.1177/096228029400300203; ORYAN ML, 1994, J INFECT DIS, V169, P504, DOI 10.1093/infdis/169.3.504; PICKERING LK, 1988, J PEDIATR-US, V112, P361, DOI 10.1016/S0022-3476(88)80313-5; PICKERING LK, 1978, J PEDIATR-US, V93, P383, DOI 10.1016/S0022-3476(78)81142-1; PRENTICE RL, 1981, BIOMETRIKA, V68, P373, DOI 10.1093/biomet/68.2.373; REVES RR, 1989, AM J EPIDEMIOL, V130, P981, DOI 10.1093/oxfordjournals.aje.a115431; RODRIGUEZ WJ, 1978, LANCET, V2, P37; RUUSKA T, 1990, SCAND J INFECT DIS, V22, P259, DOI 10.3109/00365549009027046; VELAZQUEZ FR, 1993, PEDIATR INFECT DIS J, V12, P54, DOI 10.1097/00006454-199301000-00013; WARD RL, 1994, J INFECT DIS, V169, P900, DOI 10.1093/infdis/169.4.900; WOODS PA, 1992, J CLIN MICROBIOL, V30, P781, DOI 10.1128/JCM.30.4.781-785.1992; 1995, S PLUS WINDOWS USERS, P1; 1986, NEW VACCINE DEV ESTA, V2, P308	44	628	666	1	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1022	1028		10.1056/NEJM199610033351404	http://dx.doi.org/10.1056/NEJM199610033351404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8793926				2022-12-24	WOS:A1996VL45900004
J	Grassi, MA				Grassi, MA			The gift	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					854	854						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782618				2022-12-24	WOS:A1996VF78700002
J	King, LR				King, LR			Undescended testis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CRYPTORCHIDISM				King, LR (corresponding author), DUKE UNIV,MED CTR,SECT PEDIAT UROL,DURHAM,NC 27710, USA.							GIBBONS MD, 1979, J UROLOGY, V122, P76, DOI 10.1016/S0022-5347(17)56263-1; GIWERCMAN A, 1987, J UROLOGY, V138, P1214, DOI 10.1016/S0022-5347(17)43553-1; HREBINKO RL, 1993, J UROLOGY, V150, P458, DOI 10.1016/S0022-5347(17)35510-6; HUFF DS, 1989, J UROLOGY, V142, P546, DOI 10.1016/S0022-5347(17)38811-0; KOGAN SJ, 1990, J UROLOGY, V144, P508, DOI 10.1016/S0022-5347(17)39505-8	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					856	856		10.1001/jama.276.11.856	http://dx.doi.org/10.1001/jama.276.11.856			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782621				2022-12-24	WOS:A1996VF78700005
J	Stampfer, MJ; Krauss, RM; Ma, J; Blanche, PJ; Holl, LG; Sacks, FM; Hennekens, CH				Stampfer, MJ; Krauss, RM; Ma, J; Blanche, PJ; Holl, LG; Sacks, FM; Hennekens, CH			A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; LDL SUBCLASS PHENOTYPES; HEART-DISEASE; PLASMA TRIGLYCERIDE; APOLIPOPROTEIN-B; CHOLESTEROL; MEN; ATHEROSCLEROSIS; SUBFRACTIONS; WOMEN	Objective.-To test whether a predominance of small, dense low-density lipoprotein (LDL) particles and elevated triglyceride levels are independent risk factors for myocardial infarction (MI). Design.-Nested case-control study with prospectively collected samples. Setting.-Prospective cohort study. Participants.-Blood samples were collected at baseline (85% nonfasting samples) from 14 916 men aged 40 to 84 years in the Physicians' Health Study. Main Outcome Measurements.-Myocardial infarction diagnosed during 7 years of follow-up. Results.-Cases (n=266) had a significantly smaller LDL diameter (mean [SD], 25.6 [0.9] nm) than did controls (n=308) matched on age and smoking (mean [SD], 25.9 [8] nm; P<.001). Cases also had higher median triglyceride levels (1.90 vs 1.49 mmol/L [168 vs 132 mg/dL]; P<.001), The LDL diameter had a high inverse correlation with triglyceride level (r=-0.71), and a high direct correlation with high-density lipoprotein cholesterol (HDL-C) level (r=0.60). We observed a significant multiplicative interaction between triglyceride and total cholesterol (TC) levels (P=.01). After simultaneous adjustment for lipids and a variety of coronary risk factors, LDL particle diameter was no longer a statistically significant risk indicator, with a relative risk (RR) of 1.09 (95% confidence interval [CI], 0.85-1.40) per 0.8-nm decrease. However, triglyceride level remained significant with an RR of 1.40 (95% CI, 1.10-1.77) per 1.13 mmol/L (100-mg/dL) increase. The association between triglyceride level and MI risk appeared linear across the distribution; men in the highest quintile had a risk about 2.5 times that of those in the lowest quintile, The TC level, but not HDL-C level, also remained significant, with an RR of 1.80 (95% CI, 1.44-2.26) per 1.03-mmol/L (40-mg/dL) increase, Conclusions.-These findings indicate that nonfasting triglyceride levels appear to be a strong and independent predictor of future risk of MI, particularly when the total cholesterol level is also elevated, In contrast, LDL particle diameter is associated with risk of MI, but not after adjustment for triglyceride level. Increased triglyceride level, small LDL particle diameter, and decreased HDL-C levels appear to reflect underlying metabolic perturbations with adverse consequences for risk of MI; elevated triglyceride levels may help identify high-risk individuals.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; LAWRENCE BERKELEY NATL LAB,DEPT MOL & NUCL MED,DIV LIFE SCI,BERKELEY,CA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Stampfer, MJ (corresponding author), BRIGHAM & WOMENS HOSP,CHANNING LAB,181 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R01CA042182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42182] Funding Source: Medline; NHLBI NIH HHS [HL 34595, HL 26490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; AUSTIN MA, 1995, JAMA-J AM MED ASSOC, V273, P115, DOI 10.1001/jama.1995.03520260035025; AUSTIN MA, 1993, ARTERIOSCLER THROMB, V13, P687, DOI 10.1161/01.ATV.13.5.687; AUSTIN MA, 1988, AM J HUM GENET, V43, P838; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; BAINTON D, 1992, BRIT HEART J, V68, P60; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P187, DOI 10.1161/01.ATV.12.2.187; CASTRO GR, 1985, J CLIN INVEST, V75, P874, DOI 10.1172/JCI111786; CORESH J, 1993, J LIPID RES, V34, P1687; CRIQUI MH, 1993, NEW ENGL J MED, V328, P1220, DOI 10.1056/NEJM199304293281702; CROUSE JR, 1985, J LIPID RES, V26, P566; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; DREXEL H, 1994, CIRCULATION, V90, P2230, DOI 10.1161/01.CIR.90.5.2230; FEINGOLD KR, 1992, ARTERIOSCLER THROMB, V12, P1496, DOI 10.1161/01.ATV.12.12.1496; FISHER WR, 1983, METABOLISM, V32, P283, DOI 10.1016/0026-0495(83)90194-4; GEORGOPOULOS A, 1994, METABOLISM, V43, P1063, DOI 10.1016/0026-0495(94)90046-9; HOKANSON JE, 1993, CIRCULATION, V88, P510; KRAUSS RM, 1982, J LIPID RES, V23, P97; KRAUSS RM, 1991, AM J MED, V90, pS36, DOI 10.1016/0002-9343(91)90035-V; LAMONFAVA S, 1989, J CLIN ENDOCR METAB, V68, P191; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SACKS FM, 1995, CURR OPIN LIPIDOL, V6, P161, DOI 10.1097/00041433-199506000-00008; *SAS I INC, 1982, SAS US GUID BAS 1982; *SAS I INC, 1985, SAS US GUID STAT; SCHAEFER EJ, 1987, CIRCULATION, V76, P531; SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098; SLYPER AH, 1994, JAMA-J AM MED ASSOC, V272, P305, DOI 10.1001/jama.272.4.305; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1985, STAT MED, V4, P111, DOI 10.1002/sim.4780040202; STORER BE, 1983, APPL STAT-J ROY ST C, V32, P172; TALL A, 1986, J CLIN INVEST, V77, P1163, DOI 10.1172/JCI112417; TORNVALL P, 1991, ATHEROSCLEROSIS, V90, P67, DOI 10.1016/0021-9150(91)90245-X; TRIBBLE DL, 1992, ATHEROSCLEROSIS, V93, P189, DOI 10.1016/0021-9150(92)90255-F; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; WILLIAMS PT, 1986, METABOLISM, V35, P45, DOI 10.1016/0026-0495(86)90094-6; World Health Organization, 1971, IHD REG REP 5 WORK G; YUDKIN JS, 1993, LANCET, V342, P781; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473; 1989, NEW ENGL J MED, V329, P129; 1993, JAMA-J AM MED ASSOC, V269, P505	44	761	831	1	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					882	888		10.1001/jama.276.11.882	http://dx.doi.org/10.1001/jama.276.11.882			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782637				2022-12-24	WOS:A1996VF78700031
J	Kittner, SJ; Stern, BJ; Feeser, BR; Hebel, JR; Nagey, DA; Buchholz, DW; Earley, CJ; Johnson, CJ; Macko, RF; Sloan, MA; Wityk, RJ; Wozniak, MA				Kittner, SJ; Stern, BJ; Feeser, BR; Hebel, JR; Nagey, DA; Buchholz, DW; Earley, CJ; Johnson, CJ; Macko, RF; Sloan, MA; Wityk, RJ; Wozniak, MA			Pregnancy and the risk of stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUERPERIUM	Background It is widely believed that pregnancy increases the risk of stroke, but there are few data available to quantify that risk. Methods We identified all female patients 15 through 44 years of age in central Maryland and Washington, D.C., who were discharged from any of 46 hospitals in the study area in 1988 or 1991. Two neurologists reviewed each case, using data from the women's medical records. We determined whether the women had been pregnant at the time of the stroke or up to six weeks before it occurred. For purposes of this analysis, the six-week period after pregnancy could begin with an induced or spontaneous abortion or with the delivery of a live or stillborn child. Results Seventeen cerebral infarctions and 14 intracerebral hemorrhages occurred in women who were or had recently been pregnant (pregnancy-related strokes), and there were 175 cerebral infarctions and 48 intracerebral hemorrhages that were not related to pregnancy. For cerebral infarction, the relative risk during pregnancy, adjusted for age and race, was 0.7 (95 percent confidence interval, 0.3 to 1.6), but it increased to 8.7 for the postpartum period (after a live birth or stillbirth) (95 percent confidence interval, 4.6 to 16.7). For intracerebral hemorrhage, the adjusted relative risk was 2.5 during pregnancy (95 percent confidence interval, 1.0 to 6.4) but 28.3 for the postpartum period (95 percent confidence interval, 13.0 to 61.4). Overall, for either type of stroke during or within six weeks after pregnancy, the adjusted relative risk was 2.4 (95 percent confidence interval, 1.6 to 3.6), and the attributable, or excess, risk was 8.1 strokes per 100,000 pregnancies (95 percent confidence interval, 6.4 to 9.7). Conclusions The risks of both cerebral infarction and intracerebral hemorrhage are increased in the six weeks after delivery but nor during pregnancy itself. (C) 1996, Massachusetts Medical Society.	UNIV MARYLAND,DEPT EPIDEMIOL & PREVENT MED,BALTIMORE,MD 21201; UNIV MARYLAND,DEPT OBSTET & GYNECOL,BALTIMORE,MD 21201; JOHNS HOPKINS UNIV,DEPT NEUROL,BALTIMORE,MD 21218; SINAI HOSP,DIV NEUROL,BALTIMORE,MD 21215; EMORY UNIV,DEPT NEUROL,ATLANTA,GA 30322	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Sinai Hospital of Baltimore; Emory University	Kittner, SJ (corresponding author), UNIV MARYLAND,DEPT NEUROL,BRESSLER BLDG,RM 12-013,655 W BALTIMORE ST,BALTIMORE,MD 21201, USA.				NINDS NIH HHS [NS16332-11, K08-NS01764-01A1, K08 NS001764-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016332, P50NS016332, K08NS001764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIAS A G, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P100; ATRASH HK, 1995, OBSTET GYNECOL, V86, P700, DOI 10.1016/0029-7844(95)00200-B; Bureau of the Census, 1992, 1990 CENS POP GEN PO; CALABRESE LH, 1992, CLEV CLIN J MED, V59, P293, DOI 10.3949/ccjm.59.3.293; CROSS JN, 1968, BMJ-BRIT MED J, V3, P214, DOI 10.1136/bmj.3.5612.214; *CTR HLTH STAT, 1988, MAR VIT STAT ANN REP; CUNNINGHAM FG, 1993, WILLIAMS OBSTETRICS, P3; CUNNINGHAM FG, 1993, WILLIAMS OBSTET, P459; CUNNINGHAM FG, 1993, WILLIAMS OBSTET, P662; *DIV HLTH STAT, 1991, MAR VIT STAT ANN REP; FOULKES MA, 1988, STROKE, V19, P547, DOI 10.1161/01.STR.19.5.547; GARNER BF, 1990, J RHEUMATOL, V17, P93; GROSSET DG, 1995, J NEUROL NEUROSUR PS, V58, P129, DOI 10.1136/jnnp.58.2.129; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; IREY NS, 1973, ARCH PATHOL, V96, P227; JOHNSON CJ, 1995, STROKE, V26, P46, DOI 10.1161/01.STR.26.1.46; KITTNER SJ, 1993, STROKE J CEREBRAL CI, V0024; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; *NATL CTR HLTH STA, 1991, 1988 VIT STAT US, V1; *NATL CTR HLTH STA, 1991, 1988 VIT STAT US A, V2; *NATL CTR HLTH STA, 1995, 1991 VIT STAT US A, V2; *NATL CTR HLTH STA, 1992, TRENDS PREGN PREGN R, V41; *NATL CTR HLTH STA, 1995, 1991 VIT STAT US, V1; NENCINI P, 1988, STROKE, V19, P977, DOI 10.1161/01.STR.19.8.977; Rohr J, 1996, ARCH NEUROL-CHICAGO, V53, P603, DOI 10.1001/archneur.1996.00550070041010; Rothman K, 1986, MODERN EPIDEMIOLOGY; SHARSHAR T, 1995, STROKE, V26, P930, DOI 10.1161/01.STR.26.6.930; SIMOLKE GA, 1991, OBSTET GYNECOL, V78, P37; Stern B J, 1991, Md Med J, V40, P453; Stern B J, 1991, Md Med J, V40, P565; *US BUR CENS, 1992, CENS POP HOUS; WIEBERS DO, 1985, JAMA-J AM MED ASSOC, V254, P3055, DOI 10.1001/jama.254.21.3055	32	418	434	1	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1996	335	11					768	774		10.1056/NEJM199609123351102	http://dx.doi.org/10.1056/NEJM199609123351102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF786	8703181	Green Accepted			2022-12-24	WOS:A1996VF78600002
J	Walker, SS; Reese, JC; Apone, LM; Green, MR				Walker, SS; Reese, JC; Apone, LM; Green, MR			Transcription activation in cells lacking TAF(II)s	NATURE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN; CYCLE; GENE; COMPLEX	THE general transcription factor TFIID is composed of the TATA-box-binding protein (TBP) and a set of TBP-associated factors (TAF(II)s) (ref. 1). In vitro, TAF(II)s are required for activated transcription, and have been proposed to be obligatory targets of transcriptional activator proteins (activators)(2). The function of TAF(II)s has not been investigated systematically in vivo. A Saccharomyces cerevisiae TAF(II) complex (yTAF(II) complex) has been identified that shares functional and structural similarities with higher eukaryotic TFIID. In particular, most yTAF(II)s are the homologue of a higher eukaryotic TAF (refs 3, 4). Here we report that inactivation or depletion of six different yTAF(II)s, including the core yTAF(II) that contacts TBP, does not compromise transcriptional activation. We conclude that in vivo, activated transcription of many genes can occur in the absence of functional yTAF(II)s, and that in these instances another transcription component(s) must be the target of the activator.	UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, PROGRAM MOL MED, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; BUTT TR, 1984, P NATL ACAD SCI-BIOL, V81, P3332, DOI 10.1073/pnas.81.11.3332; CAPLEAUX E, 1989, J BIOL CHEM, V264, P7437; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Guthrie C, 1991, GUIDE YEAST GENETICS; HAMIL KG, 1988, MOL CELL BIOL, V8, P4328, DOI 10.1128/MCB.8.10.4328; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, pCH5; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LEWIN B, 1990, GENES, V4; MORTIMER RK, 1980, MICROBIOL REV, V44, P519, DOI 10.1128/MMBR.44.4.519-571.1980; NISHIMOTO T, 1982, SOMAT CELL GENET, V8, P811, DOI 10.1007/BF01543021; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WELCH MD, 1993, GENETICS, V135, P265; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	27	215	217	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1996	383	6596					185	188		10.1038/383185a0	http://dx.doi.org/10.1038/383185a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774886				2022-12-24	WOS:A1996VG14800057
J	Nakamoto, M; Cheng, HJ; Friedman, GC; McLaughlin, T; Hansen, MJ; Yoon, CH; OLeary, DDM; Flanagan, JG				Nakamoto, M; Cheng, HJ; Friedman, GC; McLaughlin, T; Hansen, MJ; Yoon, CH; OLeary, DDM; Flanagan, JG			Topographically specific effects of ELF-1 on retinal axon guidance in vitro and retinal axon mapping in vivo	CELL			English	Article							RECEPTOR TYROSINE KINASES; GROWTH CONE GUIDANCE; RETINOTECTAL PROJECTION; MOLECULES; LIGAND; RECOGNITION; EXPRESSION; MECHANISMS; COLLAPSE; CLONING	Topographic maps, which maintain the spatial order of neurons in the order of their axonal connections, are found throughout the nervous system. In the visual retinotectal projection, ELF-1, a ligand in the tectum, and its receptors in the retina show complementary gradients in expression and binding, indicating they may be positional labels for map development. Here we show that ELF-1 acts as a repellent axon guidance factor in vitro. In vivo, when the tectal ELF-1 pattern is modified by retroviral overexpression, retinal axons avoid ectopic ELF-1 patches and map to abnormally anterior positions. All these effects were seen on axons from temporal but not nasal retina, indicating that ELF-1 could determine nasal versus temporal retinotectal specificity, and providing a direct demonstration of a cell recognition molecule with topographically specific effects on neural map development.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; SALK INST BIOL STUDIES,MOL NEUROBIOL LAB,LA JOLLA,CA 92037	Harvard University; Harvard Medical School; Salk Institute			Cheng, Hwai-Jong/AAY-5067-2021; Flanagan, John/AAM-2995-2020	Cheng, Hwai-Jong/0000-0003-0647-0567; Nakamoto, Masaru/0000-0001-9356-1189	NEI NIH HHS [F32 EY06550, R01 EY07025] Funding Source: Medline; NICHD NIH HHS [R01 HD29417] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029417] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007025, F32EY006550] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BOXBERG YV, 1993, NEURON, V10, P345; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; COX EC, 1990, NEURON, V2, P31; Davenport RW, 1996, J NEUROSCI, V16, P2074; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FEKETE DM, 1993, P NATL ACAD SCI USA, V90, P2350, DOI 10.1073/pnas.90.6.2350; FRIEDMAN CG, 1996, CURR OPIN NEUROBIOL, V6, P127; FRIEDMAN GC, 1996, J NEUROSCI, V17, P5498; GARRITY PA, 1995, CELL, V83, P177, DOI 10.1016/0092-8674(95)90159-0; GIERER A, 1987, DEVELOPMENT, V101, P479; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARIS WA, 1995, NEURON, V15, P241; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNT RK, 1990, BRAIN CIRCUITS FUNCT, P19; Itasaki N, 1996, NEURON, V16, P55, DOI 10.1016/S0896-6273(00)80023-9; Kenny D, 1995, DEV BIOL, V172, P708, DOI 10.1006/dbio.1995.8083; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROSKIES A, 1995, PERSPECT DEV NEUROBI, V3, P63; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1995, DEVELOPMENT, V121, P4005	37	368	377	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					755	766		10.1016/S0092-8674(00)80150-6	http://dx.doi.org/10.1016/S0092-8674(00)80150-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797822	Bronze, Green Published			2022-12-24	WOS:A1996VG37200009
J	Emerich, C; BenJaffel, L; Clarke, JT; Prange, R; Gladstone, GR; Sommeria, J; Ballester, G				Emerich, C; BenJaffel, L; Clarke, JT; Prange, R; Gladstone, GR; Sommeria, J; Ballester, G			Evidence for supersonic turbulence in the upper atmosphere of Jupiter	SCIENCE			English	Article							LONGITUDINAL ASYMMETRY; ALPHA; BULGE	Spectra of the hydrogen Lyman alpha. (Ly-alpha) emission line profiles of the jovian dayglow, obtained by the Goddard High Resolution Spectrograph on the Hubble Space Telescope, appear complex and variable on time scales of a few minutes. Dramatic changes occur in the Ly-alpha bulge region at low latitudes, where the line profiles exhibit structures that correspond to supersonic velocities of the order of several to tens of kilometers per second, This behavior, unexpected in a planetary atmosphere, is evidence for the particularly stormy jovian upper atmosphere, not unlike a star's atmosphere.	CNRS,INST ASTROPHYS PARIS,F-75014 PARIS,FRANCE; UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; SW RES INST,SAN ANTONIO,TX 78238; ECOLE NORMALE SUPER LYON,F-69364 LYON,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; University of Michigan System; University of Michigan; Southwest Research Institute; Ecole Normale Superieure de Lyon (ENS de LYON)	Emerich, C (corresponding author), CNRS,INST ASTROPHYS SPATIALE,F-91405 ORSAY,FRANCE.		Clarke, John/C-8644-2013					ATREYA SK, 1979, GEOPHYS RES LETT, V6, P795, DOI 10.1029/GL006i010p00795; BENJAFFEL L, 1993, GEOPHYS RES LETT, V20, P747; CLARKE JT, 1980, ASTROPHYS J, V240, P696, DOI 10.1086/158277; CLARKE JT, 1991, GEOPHYS RES LETT, V18, P1935, DOI 10.1029/91GL02091; DESSLER AJ, 1981, PLANET SPACE SCI, V29, P215, DOI 10.1016/0032-0633(81)90035-0; LOUCIF ML, 1982, ASTRON ASTROPHYS, V112, P287; MAGNAN C, 1976, J QUANT SPECTROSC RA, V16, P281, DOI 10.1016/0022-4073(76)90070-4; MAGNAN C, 1985, ASTRON ASTROPHYS, V144, P186; MCGRATH MA, 1991, GEOPHYS RES LETT, V18, P1931, DOI 10.1029/91GL02545; MCGRATH MA, 1990, J GEOPHYS RES-SPACE, V95, P10365, DOI 10.1029/JA095iA07p10365; SANDEL BR, 1980, GEOPHYS RES LETT, V7, P5, DOI 10.1029/GL007i001p00005; SHEMANSKY DE, 1985, J GEOPHYS RES-SPACE, V90, P2673, DOI 10.1029/JA090iA03p02673; SKINNER TE, 1988, J GEOPHYS RES-SPACE, V93, P29, DOI 10.1029/JA093iA01p00029; SOMMERIA J, 1995, ICARUS, V119, P2	14	25	25	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1085	1087		10.1126/science.273.5278.1085	http://dx.doi.org/10.1126/science.273.5278.1085			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688090				2022-12-24	WOS:A1996VD42800031
J	Vaidya, SG; Naik, UD; Vaidya, JS				Vaidya, SG; Naik, UD; Vaidya, JS			Effect of sports sponsorship by tobacco companies on children's experimentation with tobacco	BRITISH MEDICAL JOURNAL			English	Article									GOA CANC SOC,PANAJI 403001,GOA,INDIA; TATA MEM HOSP,BOMBAY 400012,MAHARASHTRA,INDIA	Tata Memorial Centre (TMC); Tata Memorial Hospital			Vaidya, Jayant S/F-7717-2010; Vaidya, Jayant S/A-7218-2008	Vaidya, Jayant S/0000-0003-1760-1278; Vaidya, Jayant S/0000-0003-1760-1278				CHARLTON A, 1992, BRIT J CANCER, V66, P1, DOI 10.1038/bjc.1992.207; CONEY S, 1990, LANCET, V335, P342; DIFRANZA JR, 1991, JAMA-J AM MED ASSOC, V266, P3149, DOI 10.1001/jama.266.22.3149; VAIDYA SG, 1993, ASSESSMENT EFFICACY	4	36	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					400	400						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761228				2022-12-24	WOS:A1996VD20600026
J	McDonald, IG; Daly, J; Jelinek, VM; Panetta, F; Gutman, JM				McDonald, IG; Daly, J; Jelinek, VM; Panetta, F; Gutman, JM			Opening Pandora's box: The unpredictability of reassurance by a normal test result	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS; ECHOCARDIOGRAPHY; ILLNESS; MURMURS	Objectives-To determine the rate of failure of patient reassurance after a normal test result and study the determinants of failure. Design-Replicated single case study with qualitative and quantitative data analysis. Setting-University teaching hospital. Subjects-40 consecutive patients referred for echocardiography either because of symptoms (10 patients) or because of a heart murmur (30), 39 were shown to have a normal heart. Interventions-Medical consultations and semistructured patient interviews were tape recorded. Structured interviews with consultant cardiologists were recorded in survey form. Main outcome measures-Patient recall of the explanation and residual understanding, doubt, and anxiety about the heart after the test and post-test consultation. Results-All 10 patients presenting with symptoms were left with anxiety about the heart despite a normal test result and reassurance by the consultant. Of 28 patients referred because of a murmur but shown to have no heart abnormality, 20 became anxious after detection of the murmur; 11 had residual anxiety despite the normal test result. Conclusions-Reassurance of the ''worried well''-anxious patients with symptoms or patients concerned by a health query resulting from a routine medical examination or from screening-constitutes a large part of medical practice, It seems to be widely assumed that explaining that tests have shown no abnormality is enough to reassure, The results of this study refute this and emphasise the importance of personal and social factors as obstacles to reassurance.	LA TROBE UNIV,SCH SOCIOL & ANTHROPOL,MELBOURNE,VIC 3065,AUSTRALIA; ALFRED HOSP,MELBOURNE,VIC 3181,AUSTRALIA	La Trobe University; Florey Institute of Neuroscience & Mental Health	McDonald, IG (corresponding author), ST VINCENTS HOSP,CTR STUDY CLIN PRACTICE,MELBOURNE,VIC 3065,AUSTRALIA.							BASS C, 1992, AM J MED S1A, V92, P125; CACERES CA, 1967, INNOCENT MURMUR PROB, P75; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; DALY J, 1989, SOCIOL HEALTH ILL, V11, P99, DOI 10.1111/1467-9566.ep10844255; DALY JM, 1993, HLTH CARE TECHNOLOGY, V9; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P544, DOI 10.7326/0003-4819-99-4-544; FITZPATRICK R, 1981, J NEUROL NEUROSUR PS, V44, P1061, DOI 10.1136/jnnp.44.12.1061; FLETCHER RH, 1982, CLIN EPIDEMIOLOGY ES, P54; HOWELL DC, 1987, STATISTICAL METHODS; HUNT LM, 1989, SOC SCI MED, V28, P945, DOI 10.1016/0277-9536(89)90324-9; KRAMER MS, 1981, CLIN PHARMACOL THER, V29, P111, DOI 10.1038/clpt.1981.18; MCDONALD IG, 1988, J CLIN EPIDEMIOL, V41, P151, DOI 10.1016/0895-4356(88)90089-3; MeKinlay JB, 1981, RELEVANCE SOCIAL SCI, P77; NEWBURGER JW, 1983, NEW ENGL J MED, V308, P61, DOI 10.1056/NEJM198301133080201; OAKLEY CM, 1987, J ANTIMICROB CHEMOTH, V20, P99, DOI 10.1093/jac/20.suppl_A.99; PILOWSKY I, 1969, BRIT J MED PSYCHOL, V42, P347, DOI 10.1111/j.2044-8341.1969.tb02089.x; Strauss AL., 1987, QUALITATIVE ANAL SOC, Vxv, P319; TUCKETT D, 1985, M EXP APPR SHAR IDE; 1992, LANCET, V339, P525	19	143	143	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					329	332		10.1136/bmj.313.7053.329	http://dx.doi.org/10.1136/bmj.313.7053.329			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VC300	8760739	Green Published			2022-12-24	WOS:A1996VC30000017
J	Walsh, LJ; Wong, CA; Pringle, M; Tattersfield, AE				Walsh, LJ; Wong, CA; Pringle, M; Tattersfield, AE			Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							INDUCED BONE LOSS; RHEUMATOID-ARTHRITIS; STEROID OSTEOPOROSIS; REPLACEMENT THERAPY; DEPENDENT ASTHMA; CALCITONIN; PATHOGENESIS; ETIDRONATE; MANAGEMENT; FRACTURES	Objective-To determine the prevalence of continuous use of oral steroids in the general population, the conditions for which they are prescribed, and the extent to which patients taking oral steroids are taking treatment to prevent osteoporosis. Design-A cross sectional study with a four year retrospective review of drug treatment. Setting-Eight large general practices in central and southern Nottinghamshire. Subjects-A population of 65 786 patients (52% women) registered with a general practitioner during 1995. Results-303 patients (65% (197) women) aged 12-94 years were currently taking ''continuous'' (for at least three months) oral corticosteroid treatment. This figure represents 0.5% of the total population and 1.4% (245/17 114) of patients aged 55 years or more (1.7% (166/9601) of women). The usual steroid was prednisolone (97% (294/303)), the mean dose was 8.0 mg/day, and the median duration of oral steroid treatment determined in 149 patients was three years. The most common conditions for which continuous oral steroids were prescribed were rheumatoid arthritis (23% (70)), polymyalgia rheumatica (22% (66)), and asthma or chronic obstructive airways disease (19% (59)). Only 41 (14%) of the 303 patients taking oral steroids had received treatment for the prevention of osteoporosis over the past four years. Although 37 of the 41 patients were women, only 10% (18/181) of the women over 45 years taking continuous oral corticosteroids were currently taking hormone replacement therapy. Conclusions-If our figures are typical then they suggest that over 250 000 people in the United Kingdom are taking continuous oral steroids and that most of these are taking no prophylaxis against osteoporosis.	QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	Walsh, LJ (corresponding author), CITY HOSP NOTTINGHAM,DIV RESP MED,HUCKNALL RD,NOTTINGHAM NG5 1PB,ENGLAND.		Walsh, Laurence J/F-1210-2010	Walsh, Laurence J/0000-0001-5874-5687				ADACHI JD, 1994, J RHEUMATOL, V21, P1922; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; COOPER C, 1995, ANN RHEUM DIS, V54, P49, DOI 10.1136/ard.54.1.49; DIAMOND T, 1995, AM J MED, V98, P459, DOI 10.1016/S0002-9343(99)80345-3; EASTELL R, 1995, J INTERN MED, V237, P439, DOI 10.1111/j.1365-2796.1995.tb00868.x; ISAACS AJ, 1995, BRIT MED J, V311, P1399, DOI 10.1136/bmj.311.7017.1399; KANIS JA, 1993, OSTEOPOROSIS INT, V3, pS10; KHOSLA S, 1994, BONE, V15, P551, DOI 10.1016/8756-3282(94)90280-1; LUENGO M, 1994, THORAX, V49, P1099, DOI 10.1136/thx.49.11.1099; LUENGO M, 1991, THORAX, V46, P803, DOI 10.1136/thx.46.11.803; LUENGO M, 1990, AM REV RESPIR DIS, V142, P104, DOI 10.1164/ajrccm/142.1.104; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; LUKERT BP, 1992, J BONE MINER RES, V7, P1063; LUKERT BP, 1994, CHEST, V105, P1640, DOI 10.1378/chest.105.6.1640; MULDER H, 1994, BRIT J RHEUMATOL, V33, P348; REID IR, 1988, LANCET, V2, P1144; REID IR, 1989, CLIN ENDOCRINOL, V30, P83, DOI 10.1111/j.1365-2265.1989.tb03730.x; REID IR, 1988, LANCET, V1, P143; RICE P, 1994, BRIT MED J, V309, P1069, DOI 10.1136/bmj.309.6961.1069; SAMBROOK P, 1993, NEW ENGL J MED, V328, P1747, DOI 10.1056/NEJM199306173282404; Sheldon TA, 1996, BRIT MED J, V312, P296; SPECTOR TD, 1993, BRIT MED J, V307, P519, DOI 10.1136/bmj.307.6903.519; VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852; WILSON S, 1995, AIMING HLTH YEAR 200	24	291	306	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					344	346		10.1136/bmj.313.7053.344	http://dx.doi.org/10.1136/bmj.313.7053.344			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760745	Green Published			2022-12-24	WOS:A1996VC30000023
J	Silove, D; Curtis, J; Mason, C; Becker, R				Silove, D; Curtis, J; Mason, C; Becker, R			Ethical considerations in the management of asylum seekers on hunger strike	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Hunger strikes have confronted physicians with complex ethical dilemmas throughout history. Asylum seekers under threat of forced repatriation have emerged as a new category of hunger strikers, posing novel challenges for management. The management of 3 Cambodian asylum seekers on hunger strike admitted to a hospital in Sydney, New South Wales, Australia, posed important ethical dilemmas for the physicians and mental health experts involved in their care. Several factors confounded the task oi assessment and decision making, including language and cultural barriers, the patients' past exposure to persecution by authorities, and the complexities of the legal procedures being pursued. Different rules appeared to govern the actions of the hunger strikers, the medical team, and the immigration authorities, creating a ''malignant triangle'' of mounting confrontation. Recent recommendations for the management of asylum-seeking hunger strikers include the appointment of an external physician of confidence and the writing of a confidential advance directive specifying the hunger striker's wishes about resuscitation in the event of collapse. In addition, we consider the value of constituting an ad hoc ethics committee to advise the responsible physician on points of conflict in managing the hunger strike, The advantages and limitations of these proposals in relation to the particular cultural, historical, and contextual issues relevant to asylum seekers are examined herein.	PRINCE HENRY HOSP,SYDNEY,NSW,AUSTRALIA; STARTTS,SYDNEY,NSW,AUSTRALIA		Silove, D (corresponding author), UNIV NEW S WALES,LIVERPOOL HOSP,SCH PSYCHIAT,PSYCHIAT RES & TEACHING UNIT,LEVEL 4 HLTH SERV BLDG,LIVERPOOL,NSW 2170,AUSTRALIA.			Curtis, Jackie/0000-0001-6884-0098				ANNAS GJ, 1995, BRIT MED J, V311, P1114, DOI 10.1136/bmj.311.7013.1114; Becker R., 1993, PROTECTION PUNISHMEN, P81; Benatar S R, 1990, Law Med Health Care, V18, P140; BHABHA J, 1992, IMMIGRATION NATIONAL, V6, P117; Brody Baruch, 1988, LIFE DEATH DECISION; BROWN P, 1991, PSYCHIAT ETHICS, P167; GEVERS S, 1995, ASSISTANCE HUNGER ST, P23; Helton Arthur, 1993, PROTECTION PUNISHMEN, P103; *J WIER F HLTH HUM, 1995, ASS HUNG STRIK MAN P; KALK WJ, 1991, LANCET, V337, P660, DOI 10.1016/0140-6736(91)92465-E; KLEINMAN I, 1986, CAN J PSYCHIAT, V31, P313, DOI 10.1177/070674378603100405; KOS A, 1993, DRAFT GUIDELINES EVA; LOCKWOOD R, 1993, VICTORIAN BRANCH SEP, P192; MASON JK, 1987, LAW MED ETHICS, P322; MILLER R, 1991, PSYCHIAT ETHICS, P265; MILLER WP, 1987, J PRISON JAIL HLTH, V6, P40; MOORE M, 1974, LANCET, V1, P1109; MURRAY B, 1990, INT J REFUGEE LAW, V2, P620; OCONNOR A, 1988, MED SCI LAW, V28, P62, DOI 10.1177/002580248802800115; REID J, 1990, AUST NZ J PSYCHIAT, V24, P486, DOI 10.3109/00048679009062904; SILOVE D, 1993, AUST NZ J PSYCHIAT, V27, P606, DOI 10.3109/00048679309075823; SILOVE D, 1990, SOC SCI MED, V30, P417, DOI 10.1016/0277-9536(90)90344-R; SMEULERS J, 1995, ASSISTANCE HUNGER ST, P14; Strauss S A, 1991, Med Law, V10, P211; SUMMERFIELD D, 1991, LANCET, V338, P58, DOI 10.1016/0140-6736(91)90051-P; 1982, S AFR MED J, V62, P77; 1974, BRIT MED J, V2, P52	27	13	13	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					410	415						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UZ776	8683821				2022-12-24	WOS:A1996UZ77600024
J	Prasad, BVV; Rothnagel, R; Zeng, CQY; Jakana, J; Lawton, JA; Chiu, W; Estes, MK				Prasad, BVV; Rothnagel, R; Zeng, CQY; Jakana, J; Lawton, JA; Chiu, W; Estes, MK			Visualization of ordered genomic RNA and localization of transcriptional complexes in rotavirus	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; CRYOELECTRON MICROSCOPY; FUNCTIONAL IMPLICATIONS; INSECT CELLS; VIRUS; IDENTIFICATION; PROTEIN; REPLICATION; POLYMERASE; RESOLUTION	IN double-stranded-RNA (dsRNA) viruses found in animals(1), bacteria(2) and yeast(3), the genome is transcribed within the structurally intact core of the virion with extraordinary efficiency. The structural organization of the genome and the enzymes involved in the transcription inside any of these viruses, critical for understanding this process, is not known. Here we report what we believe is the first three-dimensional characterization of the viral genome and the transcription complex in a prototypical dsRNA virus. Rotavirus is a large (diameter 1,000 Angstrom) icosahedral virus composed of three capsid protein layers and 11 dsRNA segments(4-9). It is the most important cause of gastroenteritis in children, accounting for over a million deaths annually(10). We show that viral dsRNA forms a dodecahedral structure in which the RNA double helices, interacting closely with the inner capsid layer, are packed around the enzyme complex located at the icosahedral 5-fold axes. The ordered RNA accounts for about 4,500 out of a total 18,525 base pairs in the genome, the largest amount of icosahedrally ordered RNA observed in any virus structure to date. We propose that the observed organization of the dsRNA is conducive for an orchestrated movement of the RNA relative to the enzyme complex during transcription.	BAYLOR COLL MED, WM KECK CTR COMPUTAT BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV MOL VIROL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, CELL & MOL BIOL PROGRAM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Prasad, BVV (corresponding author), BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.			Prasad, B.V.Venkataram/0000-0002-1172-2071				BRINK J, 1992, ULTRAMICROSCOPY, V46, P229, DOI 10.1016/0304-3991(92)90017-E; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; COHEN J, 1977, J GEN VIROL, V36, P395, DOI 10.1099/0022-1317-36-3-395; CRAWFORD SE, 1994, J VIROL, V68, P5945, DOI 10.1128/JVI.68.9.5945-5952.1994; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; ESTES MK, 1996, VIROLOGY, P1625; FIELDS BN, 1996, VIROLOGY, P1553; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; GOTTLIEB P, 1990, J BACTERIOL, V172, P5774, DOI 10.1128/jb.172.10.5774-5782.1990; Kapikian A.Z., 1996, FIELDS VIROLOGY, P1657; LABBE M, 1994, J GEN VIROL, V75, P3423, DOI 10.1099/0022-1317-75-12-3423; LARSON SB, 1993, NATURE, V361, P179, DOI 10.1038/361179a0; Lawton JA, 1996, J STRUCT BIOL, V116, P209, DOI 10.1006/jsbi.1996.0032; LIU M, 1988, VIROLOGY, V163, P26, DOI 10.1016/0042-6822(88)90230-9; LIU M, 1992, VIROLOGY, V188, P77, DOI 10.1016/0042-6822(92)90736-9; MCKENNA R, 1992, NATURE, V355, P137, DOI 10.1038/355137a0; PRASAD BVV, 1988, J MOL BIOL, V199, P269, DOI 10.1016/0022-2836(88)90313-0; PRASAD BVV, 1990, NATURE, V343, P476, DOI 10.1038/343476a0; PRASAD BVV, 1994, ROTAVIRUSES, P9; SHATKIN AJ, 1968, P NATL ACAD SCI USA, V59, P246, DOI 10.1073/pnas.59.1.246; SHAW AL, 1993, CELL, V74, P693, DOI 10.1016/0092-8674(93)90516-S; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; VALENZUELA S, 1991, J VIROL, V65, P3964, DOI 10.1128/JVI.65.7.3964-3967.1991; WICKNER RB, 1993, J BIOL CHEM, V268, P3797; YEAGER M, 1994, EMBO J, V13, P1011, DOI 10.1002/j.1460-2075.1994.tb06349.x; ZENG CQY, 1994, VIROLOGY, V201, P55, DOI 10.1006/viro.1994.1265; Zeng CQY, 1996, J VIROL, V70, P2736, DOI 10.1128/JVI.70.5.2736-2742.1996; ZHOU ZH, 1994, J MOL BIOL, V242, P456, DOI 10.1006/jmbi.1994.1594	30	171	186	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1996	382	6590					471	473		10.1038/382471a0	http://dx.doi.org/10.1038/382471a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684490				2022-12-24	WOS:A1996VA25100063
J	Kolanus, W; Nagel, W; Schiller, B; Zeitlmann, L; Godar, S; Stockinger, H; Seed, B				Kolanus, W; Nagel, W; Schiller, B; Zeitlmann, L; Godar, S; Stockinger, H; Seed, B			alpha L beta 2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1, a cytoplasmic regulatory molecule	CELL			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; OUT SIGNAL-TRANSDUCTION; BRUTON TYROSINE KINASE; CELL-ADHESION; T-CELL; LYMPHOCYTE ADHESION; LIGAND-BINDING; GPIIB-IIIA; PH DOMAIN; PROTEIN	The avidity of integrin adhesion receptors for extracellular ligands is subject to dynamic regulation by intracellular programs that have yet to be elucidated. We describe here a protein, cytohesin-1, which specifically interacts with the intracellular portion of the integrin beta 2 chain (CD18). The molecule shows homology to the yeast SEC7 gene product and bears a pleckstrin homology (PH) domain. Overexpression of either the full-length cytohesin-1 or the SEC7 domain induces beta 2 integrin-dependent binding of Jurkat cells to ICAM-1, whereas expression of the isolated cytohesin-1 PH domain inhibits T cell receptor-stimulated adhesion. Similar inhibition is not exhibited by PH domains taken from other proteins, showing that the interaction is specific and that individual PH domains are capable of discriminating between alternative targets.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT BIOL MOL, BOSTON, MA 02114 USA; UNIV VIENNA, VIRCC, INST IMMUNOL, A-1235 VIENNA, AUSTRIA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Vienna	Kolanus, W (corresponding author), UNIV MUNICH, MOL BIOL LAB, GENZENTRUM, D-81375 MUNICH, GERMANY.		Zeitlmann, Lutz/AAF-3586-2019; Stockinger, Hannes/E-5173-2011	Stockinger, Hannes/0000-0001-6404-4430	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43031] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BAZIL V, 1990, FOLIA BIOL-PRAGUE, V36, P41; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BURN P, 1988, P NATL ACAD SCI USA, V85, P497, DOI 10.1073/pnas.85.2.497; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHEN YP, 1994, J BIOL CHEM, V269, P18307; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KASSNER PD, 1993, J EXP MED, V178, P649, DOI 10.1084/jem.178.2.649; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MEIJNE AML, 1994, J CELL SCI, V107, P2557; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	59	392	406	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 26	1996	86	2					233	242		10.1016/S0092-8674(00)80095-1	http://dx.doi.org/10.1016/S0092-8674(00)80095-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706128	Bronze			2022-12-24	WOS:A1996UZ97200009
J	Sanderson, J				Sanderson, J			The SWORD of Damocles	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; VENTRICULAR ARRHYTHMIAS; MORTALITY; AMIODARONE; PLACEBO; TRIAL				Sanderson, J (corresponding author), CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT MED, SHATIN, HONG KONG.							CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CEREMUZYNSKI L, 1992, J AM COLL CARDIOL, V20, P1056, DOI 10.1016/0735-1097(92)90357-S; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; NAVARROLOPEZ F, 1993, AM J CARDIOL, V72, P1243, DOI 10.1016/0002-9149(93)90291-J; PFISTERER ME, 1993, CIRCULATION, V87, P309, DOI 10.1161/01.CIR.87.2.309; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201	10	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	1996	348	9019					2	3		10.1016/S0140-6736(05)64347-4	http://dx.doi.org/10.1016/S0140-6736(05)64347-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691925				2022-12-24	WOS:A1996UV92300002
J	Tarn, WY; Steitz, JA				Tarn, WY; Steitz, JA			Highly diverged U4 and U6 small nuclear RNAs required for splicing rare AT-AC introns	SCIENCE			English	Article							PRE-MESSENGER-RNA; BASE-PAIRING INTERACTION; PREMESSENGER RNA; CAP STRUCTURE; ACTIVE-SITE; SPLICEOSOME; SNRNA; RIBONUCLEOPROTEIN; U2; YEAST	Removal of a rare class of metazoan precursor messenger RNA introns With AU-AC at their termini is catalyzed by a spliceosome that contains U11, U12, and U5 small nuclear ribonucleoproteins. Two previously unidentified, low-abundance human small nuclear RNAs (snRNAs), U4atac and U6atac, were characterized as associated with the AT-AC spliceosome and necessary for AT-AC intron splicing. The excision of AT-AC introns therefore requires four snRNAs not found in the major spliceosome. With the use of psoralen crosslinking, a U6atac interaction with U12 was identified that is similar to a U6-U2 helix believed to contribute to the spliceosomal active center. The conservation of only limited U6atac sequences in the neighborhood of this interaction and the potential of U6atac to base pair with the 5' splice site consensus for AT-AC introns provide support for current models of the core of the spliceosome.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06536	Howard Hughes Medical Institute; Yale University			Tarn, Woan-Yuh/N-8464-2018		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026154, R37GM026154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baserga S., 1993, RNA WORLD, P359; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; CHENG SC, 1987, GENE DEV, V1, P1047; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FABRIZIO P, 1992, NUCLEIC ACIDS RES, V20, P3659, DOI 10.1093/nar/20.14.3659; Field DJ, 1996, GENE DEV, V10, P489, DOI 10.1101/gad.10.4.489; FORTNER DM, 1994, GENE DEV, V8, P221, DOI 10.1101/gad.8.2.221; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; Gu J, 1996, NUCLEIC ACIDS RES, V24, P73, DOI 10.1093/nar/24.1.73; GUPTA S, 1990, J BIOL CHEM, V265, P19137; GUPTA S, 1990, NUCLEIC ACIDS RES, V18, P2231; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; LIU MH, 1992, NUCLEIC ACIDS RES, V20, P4299, DOI 10.1093/nar/20.16.4299; MADHANI HD, 1994, GENE DEV, V8, P1071, DOI 10.1101/gad.8.9.1071; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; Moore M., 1993, RNA WORLD, P303; Mount SM, 1996, SCIENCE, V271, P1690, DOI 10.1126/science.271.5256.1690; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; REDDY R, 1988, NUCLEIC ACIDS RES, V16, P71; REDDY R, COMMUNICATOIN; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SILLICIANO PG, 1987, CELL, V50, P585; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843; TAKAHASHI Y, 1993, MOL CELL BIOL, V13, P5613, DOI 10.1128/MCB.13.9.5613; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; TANI T, 1992, NUCLEIC ACIDS RES, V20, P2991, DOI 10.1093/nar/20.12.2991; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; TARN WY, 1995, RNA, V1, P644; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; TARN WY, UNPUB; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; WASSARMAN DA, 1993, P NATL ACAD SCI USA, V90, P7139, DOI 10.1073/pnas.90.15.7139; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377; WOLFF T, 1994, P NATL ACAD SCI USA, V91, P903, DOI 10.1073/pnas.91.3.903; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; Yan D, 1996, MOL CELL BIOL, V16, P818; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571; YU YT, 1995, RNA, V1, P46	54	156	157	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1824	1832		10.1126/science.273.5283.1824	http://dx.doi.org/10.1126/science.273.5283.1824			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791582				2022-12-24	WOS:A1996VJ71300036
J	Yu, AC; Margoliash, D				Yu, AC; Margoliash, D			Temporal hierarchical control of singing in birds	SCIENCE			English	Article							ZEBRA FINCH; CORTICAL-NEURONS; LEARNED SONG; NUCLEUS; VOCALIZATION; PLASTICITY; BEHAVIOR; MIDBRAIN; SPARROW; NETWORK	Songs of birds comprise hierarchical sets of vocal gestures. In zebra finches, songs Include notes and syllables (groups of notes) delivered in fixed sequences. During singing, premotor neurons in the forebrain nucleus HVc exhibited reliable changes In activity rates whose patterns were uniquely associated with syllable identity. Neurons in the forebrain nucleus robustus archistriatalis, which receives input from the HVc, exhibited precisely rimed and structured bursts of activity that were uniquely associated with note identity. Hence, units of vocal behavior are represented hierarchically in the avian forebrain. The representation of temporal sequences at each level of the hierarchy may be established by means of a decoding process involving Interactions of higher level input with intrinsic local circuitry. Behavior is apparently represented by precise temporal patterning of spike trains at lower levels of the hierarchy.	UNIV CHICAGO,DEPT ORGANISMAL BIOL & ANAT,CHICAGO,IL 60637; UNIV CHICAGO,COMM NEUROBIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago					NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH010151] Funding Source: NIH RePORTER; NIMH NIH HHS [1 F31 MH10151] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELES M, 1995, P NATL ACAD SCI USA, V92, P8616, DOI 10.1073/pnas.92.19.8616; AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; Anderson SE, 1996, J ACOUST SOC AM, V100, P1209, DOI 10.1121/1.415968; BAIR W, 1996, NEURAL COMPUT, V8, P1184; BERGLAND GD, 1969, IEEE SPECTRUM, V7, P41; CARR CE, 1988, P NATL ACAD SCI USA, V85, P8311, DOI 10.1073/pnas.85.21.8311; CARR CE, 1986, J NEUROSCI, V6, P107; deCharms RC, 1996, NATURE, V381, P610, DOI 10.1038/381610a0; Fetz EE, 1994, MOVEMENT CONTROL, P77; GERHARDT HC, 1978, J EXP BIOL, V74, P59; GOLLER F, 1995, NATURE, V373, P63, DOI 10.1038/373063a0; HOY RR, 1973, SCIENCE, V180, P82, DOI 10.1126/science.180.4081.82; Immelmann K., 1969, P61; KONISHI M, 1978, HDB SENSORY PHYSL, V8, P289; Lashley K., 1951, CEREBRAL MECH BEHAV, P112, DOI DOI 10.1093/RFS/HHQ153; LEWICKI MS, 1994, NEURAL COMPUT, V6, P1005, DOI 10.1162/neco.1994.6.5.1005; LLINAS R, 1990, COLD SPRING HARB SYM, V55, P933; MARLER P, 1977, SCIENCE, V198, P519, DOI 10.1126/science.198.4316.519; MARLER P, 1984, ANIM BEHAV, V32, P673, DOI 10.1016/S0003-3472(84)80143-8; MCCASLAND JS, 1981, P NATL ACAD SCI-BIOL, V78, P7815, DOI 10.1073/pnas.78.12.7815; MIDDLEBROOKS JC, 1994, SCIENCE, V264, P842, DOI 10.1126/science.8171339; MOONEY R, 1992, J NEUROSCI, V12, P2464; NOWICKI S, 1986, SCIENCE, V231, P1297, DOI 10.1126/science.3945824; PLOOG D, 1981, BRAIN RES REV, V3, P35, DOI 10.1016/0165-0173(81)90011-4; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; SELLER TJ, 1981, TRENDS NEUROSCI, V4, P301, DOI 10.1016/0166-2236(81)90094-1; SOSSINKA R, 1980, Z TIERPSYCHOL, V53, P123; SUTTER ML, 1994, J NEUROPHYSIOL, V72, P2105, DOI 10.1152/jn.1994.72.5.2105; Tinbergen, 1951, STUDY INSTINCT; TINBERGEN N, 1950, SYM SOC EXP BIOL, V4, P305; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; VICARIO DS, 1991, J NEUROBIOL, V22, P63, DOI 10.1002/neu.480220107; VU ET, 1994, J NEUROSCI, V14, P6924; WESTNEAT MW, 1993, J EXP BIOL, V182, P147; WILLIAMS H, 1993, J NEUROBIOL, V24, P903, DOI 10.1002/neu.480240704; ZANN R, 1996, ZEBRA FINCH	36	469	477	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1871	1875		10.1126/science.273.5283.1871	http://dx.doi.org/10.1126/science.273.5283.1871			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791594				2022-12-24	WOS:A1996VJ71300048
J	Kohler, M; Hirschberg, B; Bond, CT; Kinzie, JM; Marrion, NV; Maylie, J; Adelman, JP				Kohler, M; Hirschberg, B; Bond, CT; Kinzie, JM; Marrion, NV; Maylie, J; Adelman, JP			Small-conductance, calcium-activated potassium channels from mammalian brain	SCIENCE			English	Article							RAT HIPPOCAMPAL-NEURONS; ACTION-POTENTIAL REPOLARIZATION; VAGAL MOTONEURONS; AFTER-HYPERPOLARIZATION; PYRAMIDAL CELLS; ION CHANNELS; K+ CHANNELS; AFTERHYPERPOLARIZATION; CURRENTS; CA2+	Members of a previously unidentified family of potassium channel subunits were cloned from rat and human brain. The messenger RNAs encoding these subunits were widely expressed in brain with distinct yet overlapping patterns, as well as in several peripheral tissues. Expression of the messenger RNAs in Xenopus oocytes resulted in calcium-activated, voltage-independent potassium channels. The channels that formed from the various subunits displayed differential sensitivity to apamin and tubocurare. The distribution, function, and pharmacology of these channels are consistent with the SK class of small-conductance, calcium-activated potassium channels, which contribute to the afterhyperpolarization in central neurons and other cell types.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT OBSTET & GYNECOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University								ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ARTALEJO AR, 1993, PFLUG ARCH EUR J PHY, V423, P97, DOI 10.1007/BF00374966; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; DUN NJ, 1986, J PHYSIOL-LONDON, V375, P499, DOI 10.1113/jphysiol.1986.sp016130; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GELHERT DR, 1993, NEUROSCIENCE, V52, P191; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; GUSTAFSSON B, 1981, BRAIN RES, V206, P462, DOI 10.1016/0006-8993(81)90548-5; HOTSON JR, 1980, J NEUROPHYSIOL, V43, P409, DOI 10.1152/jn.1980.43.2.409; HOUAMED KM, 1991, SCIENCE, V349, P760; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; LANCASTER B, 1994, J PHYSIOL-LONDON, V475, P229, DOI 10.1113/jphysiol.1994.sp020064; LANCASTER B, 1991, J NEUROSCI, V11, P23; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PARK Y, 1994, J PHYSIOL-LONDON, V481, P555, DOI 10.1113/jphysiol.1994.sp020463; Pedarzani P, 1996, PFLUG ARCH EUR J PHY, V431, P723, DOI 10.1007/s004240050057; SAH P, 1995, J NEUROPHYSIOL, V74, P1772, DOI 10.1152/jn.1995.74.4.1772; SAH PAJ, 1992, J NEUROPHYSIOL, V68, P1834, DOI 10.1152/jn.1992.68.5.1834; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; VIANA F, 1993, J NEUROPHYSIOL, V69, P2150, DOI 10.1152/jn.1993.69.6.2150; YAROM Y, 1985, NEUROSCIENCE, V16, P719, DOI 10.1016/0306-4522(85)90090-9; ZHANG L, 1995, J PHYSIOL-LONDON, V488, P861	32	768	792	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1709	1714		10.1126/science.273.5282.1709	http://dx.doi.org/10.1126/science.273.5282.1709			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781233				2022-12-24	WOS:A1996VH40800040
J	Knight, RT				Knight, RT			Contribution of human hippocampal region to novelty detection	NATURE			English	Article							INTRACEREBRAL POTENTIALS; RECOGNITION MEMORY; PREFRONTAL CORTEX; VISUAL-STIMULI; RHESUS-MONKEY; RARE TARGET; LESIONS; WORKING; LOBE; P300	THE ability to respond to unexpected stimuli (the 'orienting response') is a fundamental characteristic of mammalian behaviour(1), but the brain mechanisms by which novelty is detected remain poorly defined. Electrophysiological recordings of scalp and intracranial event-related potentials (ERPs) have shown that novel stimuli activate a distributed network involving prefrontal and posterior association cortex(2-6). In addition, ERP(7,8) and single-neuron(9,10) recordings, as well as neuroimaging(11) and modelling(12) studies, have suggested that temporal cortical regions, including the hippocampus, are also involved. To examine further the role of the medial temporal lobe in novelty processing, I measured physiological responses to novel auditory and tactile stimuli in patients with damage to the posterior hippocampal region. In normal control subjects, unexpected novel stimuli produce a characteristic ERP signal, accompanied by an autonomic skin response. Both responses are reduced in hippocampal lesion patients, whereas the response to expected control stimuli is unaffected. Thus the hippocampal region, in addition to its known role in memory formation, is an essential component of the distributed limbic-cortical network that detects and responds to novel stimuli.			Knight, RT (corresponding author), UNIV CALIF DAVIS,CTR VET MED,CTR NEUROSCI,DEPT NEUROL,150 MUIR RD,MARTINEZ,CA 94553, USA.							BAUDENA P, 1995, ELECTROEN CLIN NEURO, V94, P251, DOI 10.1016/0013-4694(95)98476-O; COURCHESNE E, 1975, ELECTROEN CLIN NEURO, V39, P131, DOI 10.1016/0013-4694(75)90003-6; DERENZI E, 1987, BRAIN, V110, P1099, DOI 10.1093/brain/110.5.1099; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; FRIEDMAN HR, 1994, J NEUROSCI, V14, P2775; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; GUTRECHT JA, 1994, J CLIN NEUROPHYSIOL, V11, P519, DOI 10.1097/00004691-199409000-00006; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P191, DOI 10.1016/0013-4694(94)00259-N; Halgren Eric, 1995, P1137; KARIS D, 1984, COGNITIVE PSYCHOL, V16, P177, DOI 10.1016/0010-0285(84)90007-0; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; KNIGHT RT, 1989, BRAIN RES, V502, P109, DOI 10.1016/0006-8993(89)90466-6; METCALFE J, 1993, PSYCHOL REV, V100, P3, DOI 10.1037/0033-295X.100.1.3; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; ONOFRJ M, 1992, NEUROLOGY, V42, P1762, DOI 10.1212/WNL.42.9.1762; POLICH J, 1993, ELECTROEN CLIN NEURO, V86, P408, DOI 10.1016/0013-4694(93)90136-J; RENAULT B, 1982, SCIENCE, V215, P1413, DOI 10.1126/science.7063853; RICHARDSON B C, 1992, Neurology, V42, P170; Risold PY, 1996, SCIENCE, V272, P1484, DOI 10.1126/science.272.5267.1484; ROLLS ET, 1993, EXP BRAIN RES, V93, P299; Scabini D., 1993, Society for Neuroscience Abstracts, V19, P564; SOKOLOV EN, 1963, ANNU REV PHYSIOL, V25, P545, DOI 10.1146/annurev.ph.25.030163.002553; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; Tulving E, 1996, CEREB CORTEX, V6, P71, DOI 10.1093/cercor/6.1.71; Van Hoesen GW, 1996, NEUROPSYCHIATRY, P113; von Restorff H, 1933, PSYCHOL FORSCH, V18, P299, DOI 10.1007/BF02409636; VONCRAMON DY, 1988, BRAIN, V111, P1061, DOI 10.1093/brain/111.5.1061; WOODS DL, 1993, COGNITIVE BRAIN RES, V1, P227, DOI 10.1016/0926-6410(93)90007-R; YAMAGUCHI S, 1991, J NEUROSCI, V11, P2039	30	644	693	2	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					256	259		10.1038/383256a0	http://dx.doi.org/10.1038/383256a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805701				2022-12-24	WOS:A1996VH31500053
J	Ono, M; Bolland, S; Tempst, P; Ravetch, JV				Ono, M; Bolland, S; Tempst, P; Ravetch, JV			Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc gamma RIIB	NATURE			English	Article							CYTOPLASMIC DOMAIN; CELL ACTIVATION; GENERATION; RELEASE; MOTIF; PTP1C	IMMUNE complexes are potent activators of inflammatory cells, triggering effector responses through the crosslinking of Fc receptors (FcRs) such as Fc epsilon RI or Fc gamma RIII (ref, 1). On B cells and mast cells, immune complexes are also negative regulators of activation triggered by antigen and Fc receptors, a consequence of coligation of the B-cell antigen receptor or Fc epsilon RI, respectively, and the inhibitory receptor Fc gamma RIIB. Here we show that inhibitory signalling by Fc gamma RIIB does not require the SH2-domain-containing protein tyrosine phosphatase, SHP-1, in mast cells and results in the recruitment of the SH2-domain-containing inositol polyphosphate 5-phosphatase, SHIP, to the tyrosine-phosphorylated 13-amino-acid inhibitory motif of Fc gamma RIIB in both B cells and mast cells. SHIP, by hydrolysing the 5-phosphate of phosphatidylinositol(3,4,5)P-3 and inositol(1,3,4,5) P-4, suggests a mechanism by which Fc gamma RIIB can inhibit calcium influx and downstream responses triggered by immune receptors.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center			Troshina, Olga/V-8941-2018; Tamagnini, Paula/AGF-3206-2022; Ravetch, Jeffrey/Z-1596-2019; Lindblad, Peter/ABC-4091-2020; Tamagnini, Paula/A-6613-2010	Troshina, Olga/0000-0003-3319-043X; Tamagnini, Paula/0000-0003-4396-2122; Ravetch, Jeffrey/0000-0003-2024-9041; Lindblad, Peter/0000-0001-7256-0275; Tamagnini, Paula/0000-0003-4396-2122				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; DAERON M, 1992, J IMMUNOL, V149, P1365; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; Galandrini R, 1996, J EXP MED, V183, P179, DOI 10.1084/jem.183.1.179; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KATZ HR, 1992, J IMMUNOL, V148, P868; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; TOKER A, 1994, J BIOL CHEM, V269, P32358	19	632	656	2	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					263	266		10.1038/383263a0	http://dx.doi.org/10.1038/383263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805703				2022-12-24	WOS:A1996VH31500055
J	Shieh, HS; Kurumbail, RG; Stevens, AM; Stegeman, RA; Sturman, EJ; Pak, JY; Wittwer, AJ; Palmier, MO; Wiegand, RC; Holwerda, BC; Stallings, WC				Shieh, HS; Kurumbail, RG; Stevens, AM; Stegeman, RA; Sturman, EJ; Pak, JY; Wittwer, AJ; Palmier, MO; Wiegand, RC; Holwerda, BC; Stallings, WC			Three dimensional structure of human cytomegalovirus protease	NATURE			English	Article							HERPES-SIMPLEX VIRUS; MATURATIONAL PROTEINASE; INTERFACE PEPTIDES; CLEAVAGE SITES; IDENTIFICATION; RESOLUTION; GENE; REFINEMENT; EXPRESSION; SUBSTRATE	HERPESVIRUSES encode a serine protease(1,2) that specifically cleaves assembly protein(3). This protease is critical for replication(4), and represents a new target for antiviral drug design(5). Here we report the three-dimensional structure of the protease from human cytomegalovirus (hCMV) at 2.27 Angstrom resolution. The structure reveals a unique fold and new catalytic strategy for cleavage. The monomer fold of the enzyme, a seven-stranded beta-barrel encircled by a chain of helices that form the carboxy terminus of the molecule, is unrelated to those observed in classic serine proteases such as chymotrypsin and subtilisin. The serine nucleophile at position 132 is activated by two juxtaposed histidine residues at positions 63 and 157. Dimerization, which seems to be necessary for activity(6,7), is observed in the crystals. Correlations of the structure with the sequences of herpesvirus proteases(1,5,8) suggest that dimerization may confer specificity and recognition in substrate binding.	MONSANTO SEARLE,SEARLE DISCOVERY RES,DEPT INFECT DIS,ST LOUIS,MO 63198; MONSANTO SEARLE,SEARLE DISCOVERY RES,DEPT BIOL SCI,ST LOUIS,MO 63198	Monsanto; Monsanto	Shieh, HS (corresponding author), MONSANTO SEARLE,SEARLE DISCOVERY RES,DEPT MED & STRUCT CHEM,700 CHESTERFIELD PKWY N,ST LOUIS,MO 63198, USA.							BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003; BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COX GA, 1995, J VIROL, V69, P4524, DOI 10.1128/JVI.69.7.4524-4528.1995; Darke PL, 1996, J BIOL CHEM, V271, P7445, DOI 10.1074/jbc.271.13.7445; DILANNI CL, 1993, J BIOL CHEM, V268, P25449; DILANNI CL, 1994, J BIOL CHEM, V269, P12672; DIVITA G, 1995, J BIOL CHEM, V270, P28642, DOI 10.1074/jbc.270.48.28642; FUREY W, IN PRESS METHODS ENZ; GIBSON W, 1972, J VIROL, V10, P1044, DOI 10.1128/JVI.10.5.1044-1052.1972; Gibson W., 1995, PERSPECT DRUG DISCOV, V2, P413; HOLWERDA BC, 1994, J BIOL CHEM, V269, P25911; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TR, 1994, J VIROL, V68, P3742, DOI 10.1128/JVI.68.6.3742-3752.1994; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LOUTSCH JM, 1994, BIOCHEM BIOPH RES CO, V203, P472, DOI 10.1006/bbrc.1994.2206; Margosiak SA, 1996, BIOCHEMISTRY-US, V35, P5300, DOI 10.1021/bi952842u; MURZIN AG, 1994, J MOL BIOL, V236, P1382, DOI 10.1016/0022-2836(94)90065-5; OTINOWSKI Z, 1993, P CCP4 STUD WEEK DAT; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993	30	154	160	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					279	282		10.1038/383279a0	http://dx.doi.org/10.1038/383279a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805708				2022-12-24	WOS:A1996VH31500060
J	FaberLangendoen, K				FaberLangendoen, K			Weight gain in women receiving adjuvant chemotherapy for breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FaberLangendoen, K (corresponding author), UNIV MINNESOTA,DIV MED ONCOL,MINNEAPOLIS,MN 55455, USA.							CHELBOWSKI RT, 1994, CANCER, V74, P2734; CHELBOWSKI RT, 1991, BREAST CANC RES TREA, V20, P73; DEMARKWAHNEFRIED W, 1993, J CLIN ONCOL, V11, P1418, DOI 10.1200/JCO.1993.11.7.1418; HOSKIN PJ, 1992, BREAST CANCER RES TR, V22, P129, DOI 10.1007/BF01833342	4	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					855	856						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782620				2022-12-24	WOS:A1996VF78700004
J	Shen, WK; Hayes, DL; Hammill, SC; Bailey, KR; Ballard, DJ; Gersh, BJ				Shen, WK; Hayes, DL; Hammill, SC; Bailey, KR; Ballard, DJ; Gersh, BJ			Survival and functional independence after implantation of a permanent pacemaker in octogenarians and nonagenarians - A population-based study	ANNALS OF INTERNAL MEDICINE			English	Article							SICK SINUS SYNDROME; LONG-TERM SURVIVAL; ATRIOVENTRICULAR-BLOCK; HEART-BLOCK; FOLLOW-UP; PROGNOSIS; MODE; AGE	Background: The number of very elderly persons who are candidates for implantation of a permanent pacemaker is increasing, but the effect of cardiac pacing on long-term survival and functional variables has not been determined. Objective: To determine long-term survival after implantation of a permanent pacemaker in octogenarians and nonagenarians and to assess functional independence after such implantation. Design: Retrospective, population-based cohort study. Setting: Epidemiologic setting from an unselected population. Patients: 157 octogenarians and nonagenarians who initially received a pacemaker between 1962 and 1988 and were followed through 1992. Main Outcome Measures: Overall mortality rate, functional capabilities, and placement in a nursing home. Results: Observed survival in patients with heart disease was significantly worse than that in age- and sex-matched controls (P < 0.001). Observed survival in community residents without heart disease was similar to that in controls (P > 0.2). Multivariable analysis identified congestive heart failure, chronic obstructive pulmonary disease, old age, syncope, cancer, and atrioventricular block as independent predictors of increased mortality. Symptoms decreased in 118 patients (75%) after pacemaker implantation. After implantation, 70 patients (45%) were permanently placed in nursing homes; this number is similar to the estimated probability of lifetime use of nursing homes from the National Mortality Followback Survey. Dementia developed or worsened in 51 patients (32%), and orthopedic disability occurred in 41 patients (26%). Conclusions: Normal relative survival in octogenarians and nonagenarians without heart disease is reassuring; the poor prognosis in patients with heart disease warrants careful evaluation of the methods and indications for cardiac pacing. Permanent pacing alleviates bradycardia-related symptoms. Placement in a nursing home and development or worsening of cardiac, neurologic, or orthopedic disabilities frequently occur after implantation of a permanent pacemaker in the very elderly.	MAYO CLIN & MAYO FDN, DEPT HLTH SCI, ROCHESTER, MN 55905 USA	Mayo Clinic	Shen, WK (corresponding author), MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.		Ballard, David J/H-1062-2018					ALPERT MA, 1982, J CHRON DIS, V35, P341, DOI 10.1016/0021-9681(82)90005-4; ALPERT MA, 1987, AM HEART J, V113, P958, DOI 10.1016/0002-8703(87)90057-3; [Anonymous], 1964, DIS HEART BLOOD VESS; BERGSTRALH EJ, 1988, CONDITIONAL PROBABIL, P1; BREIVIK K, 1984, ACTA MED SCAND, V216, P119; CALLAHAN D, 1989, JAMA-J AM MED ASSOC, V261, P905, DOI 10.1001/jama.261.6.905; COX DR, 1972, J R STAT SOC B, V34, P187; EDHAG O, 1976, ACTA MED SCAND, V200, P457; ELIZABETH JE, 1991, POSTGRAD MED J, V67, P663, DOI 10.1136/pgmj.67.789.663; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; GINKS W, 1979, BRIT HEART J, V41, P633; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; LINDEEDELSTAM C, 1992, PACE, V15, P304, DOI 10.1111/j.1540-8159.1992.tb06500.x; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; SGARBOSSA EB, 1993, CIRCULATION, V88, P1045, DOI 10.1161/01.CIR.88.3.1045; SHEN WK, 1994, AM J CARDIOL, V74, P560, DOI 10.1016/0002-9149(94)90744-7; STRAUSS HD, 1978, PACE, V1, P458, DOI 10.1111/j.1540-8159.1978.tb03507.x; TUNG RT, 1994, AM J CARDIOL, V74, P1016, DOI 10.1016/0002-9149(94)90851-6; VANHEMEL NM, 1981, PACE, V4, P8	20	38	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					476	480		10.7326/0003-4819-125-6-199609150-00008	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779460				2022-12-24	WOS:A1996VF88200009
J	Bradley, DC; Maxwell, M; Andersen, RA; Banks, MS; Shenoy, KV				Bradley, DC; Maxwell, M; Andersen, RA; Banks, MS; Shenoy, KV			Mechanisms of heading perception in primate visual cortex	SCIENCE			English	Article							PURSUIT EYE-MOVEMENTS; CORTICAL AREAS MT; MST NEURONS; MOTION; MONKEY; DIRECTION; POSITION; IMAGE; FLOW	When we move forward while walking or driving, what we see appears to expand. The center or focus of this expansion tells us our direction of self-motion, or heading, as long as our eyes are still. However, if our eyes move, as when tracking a nearby object on the ground, the retinal image is disrupted and the focus is shifted away from the heading. Neurons in primate dorso-medial superior temporal area responded selectively to an expansion focus in a certain part of the visual field, and this selective region shifted during tracking eye movements in a way that compensated for the retinal focus shift. Therefore, these neurons account for the effect of eye movements on what we see as we travel forward through the world.	CALTECH,DIV BIOL,PASADENA,CA 91125; UNIV CALIF BERKELEY,SCH OPTOMETRY,BERKELEY,CA 94720	California Institute of Technology; University of California System; University of California Berkeley								DUFFY CJ, 1995, J NEUROSCI, V15, P5192; Freeman T. C. A., 1996, Investigative Ophthalmology and Visual Science, V37, pS454; Gibson J. J., 1950, PERCEPTION VISUAL WO; GRAZIANO MSA, 1994, J NEUROSCI, V14, P54; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; KOMATSU H, 1988, J NEUROPHYSIOL, V60, P580, DOI 10.1152/jn.1988.60.2.580; LONGUETHIGGINS HC, 1980, PROC R SOC SER B-BIO, V208, P385, DOI 10.1098/rspb.1980.0057; MACK A, 1978, VISION RES, V18, P55, DOI 10.1016/0042-6989(78)90077-9; NEWSOME WT, 1988, J NEUROPHYSIOL, V60, P604, DOI 10.1152/jn.1988.60.2.604; ROYDEN CS, 1992, NATURE, V360, P583, DOI 10.1038/360583a0; SAITO H, 1986, J NEUROSCI, V6, P145; SAKATA H, 1983, J NEUROPHYSIOL, V49, P1364, DOI 10.1152/jn.1983.49.6.1364; SHENOY KS, SOC NEUR ABSTR; Warren W. H., 1995, HDB PERCEPTION COGNI, P263, DOI [10.1016/b978-012240530-3/50010-9, DOI 10.1016/B978-012240530-3/50010-9]; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0	15	174	176	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1996	273	5281					1544	1547		10.1126/science.273.5281.1544	http://dx.doi.org/10.1126/science.273.5281.1544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8703215				2022-12-24	WOS:A1996VG59700039
J	Frade, JM; RodriguezTebar, A; Barde, YA				Frade, JM; RodriguezTebar, A; Barde, YA			Induction of cell death by endogenous nerve growth factor through its p75 receptor	NATURE			English	Article							NEUROTROPHIN RECEPTORS; CHICK-EMBRYOS; APOPTOSIS; NGF; EXPRESSION; NEURONS; RETINA; BRAIN	DURING development, neuronal survival is regulated by the limited availability of neurotrophins, which are proteins of the nerve growth factor (NGF) family. Activation of specific trk tyrosine kinase receptors by the neurotrophins blocks programmed cell death. The trkA-specific ligand NGF has also been shown to activate the non-tyrosine kinase receptor p75, a member of the tumour necrosis factor (TNF) receptor and Fas (APO-1/CD95) family. Here we report that, early in development, endogenous NGF causes the death of retinal neurons that express p75 but not trkA. These results indicate that, as with cells of the immune system, the death of neurons in the central nervous system can also be induced by ligands, and that the effect of NGF on cell fate depends on the type of receptor expressed by developing neurons.	MAX PLANCK INST PSYCHIAT,DEPT NEUROBIOCHEM,D-82152 PLANEGG,GERMANY; CSIC,INST CAJAL,E-28002 MADRID,SPAIN	Max Planck Society; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)			Barde, Yves/F-6019-2011; Frade, Jose M/E-7913-2013	Frade, Jose M/0000-0001-7067-2505; Barde, Yves/0000-0002-7627-461X				ALLENDOERFER KL, 1994, J NEUROSCI, V14, P1795; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; Bovolenta P, 1996, J NEUROSCI, V16, P4402; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CUADROS MA, 1988, ANAT EMBRYOL, V178, P543, DOI 10.1007/BF00305042; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EBENDAL T, 1986, EMBO J, V5, P1483, DOI 10.1002/j.1460-2075.1986.tb04386.x; EMFORS P, 1989, NEURON, V2, P1605; GAESE F, 1994, DEVELOPMENT, V120, P1613; GHOSH A, 1992, SCIENCE, V255, P1441, DOI 10.1126/science.1542795; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; LEIST M, 1994, J IMMUNOL, V153, P1778; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; OPPHENHEIM RW, 1991, ANN REV NEUROSCI, V14, P453; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; ROHRER H, 1988, DEVELOPMENT, V103, P545; Schropel A, 1995, MOL CELL NEUROSCI, V6, P544, DOI 10.1006/mcne.1995.0006; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; VONBARTHELD CS, 1991, J COMP NEUROL, V310, P103, DOI 10.1002/cne.903100110; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A	25	641	662	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					166	168						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774880				2022-12-24	WOS:A1996VG14800051
J	Hunt, TW; Fields, TA; Casey, PJ; Peralta, EG				Hunt, TW; Fields, TA; Casey, PJ; Peralta, EG			RCS10 is a selective activator of G alpha(i) GTPase activity	NATURE			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEIN; ALPHA; PATHWAY	POLYPEPTIDES that define a protein family termed RGS (for regulators of G-protein signalling) are encoded by the SST2 gene of the yeast Saccharomyces cerevisiae, the EGL-10 gene of the nematode Caenorhabdatis elegans, and several related mammalian genes. Genetic studies in invertebrates and mammalian cell-transfection experiments indicate that RGS proteins negatively regulate signalling pathways involving seven transmembrane receptors and heterotrimeric G proteins(1-3). However, the biochemical mechanism by which RGS proteins control these pathways is unknown. Here we report the characterization of human RGS10, a member of this protein family. Co-immunoprecipitation studies demonstrate that RGS10 associates specifically with the activated forms of two related G-protein subunits, G alpha(i3), and G alpha(z) but fails to interact with the structurally and functionally distinct G alpha(s) subunit. In vitro assays with purified proteins indicate that RGS10 increases potently and selectively the GTP hydrolytic activity of several members of the G alpha(i) family, including G alpha(i3), G alpha z and G alpha(o). These results demonstrate that RGS proteins can attenuate signalling pathways involving heterotrimeric G proteins by serving as GTPase-activating proteins for specific types of G alpha subunits.	DUKE UNIV, SCH MED, DEPT MOL CANC BIOL, DURHAM, NC 27710 USA; DUKE UNIV, SCH MED, DEPT BIOCHEM, DURHAM, NC 27710 USA; HARVARD UNIV, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Duke University; Duke University; Harvard University				Casey, Patrick/0000-0002-7366-9309				ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; AUSUBEL F, 1995, CURRENT PROTOCOLS MO, P1314; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HONG JX, 1993, J IMMUNOL, V150, P3895; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LINDER ME, 1990, J BIOL CHEM, V265, P8243; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	23	305	313	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1996	383	6596					175	177		10.1038/383175a0	http://dx.doi.org/10.1038/383175a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774883				2022-12-24	WOS:A1996VG14800054
J	Kang, HJ; Schuman, EM				Kang, HJ; Schuman, EM			A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity	SCIENCE			English	Article							LONG-TERM POTENTIATION; MESSENGER-RNA; DENTATE GYRUS; GRANULE CELLS; NITRIC-OXIDE; LATE-PHASE; CRITICAL PERIOD; NERVOUS-SYSTEM; OLFACTORY-BULB; NEURONS	Two neurotrophic factors,brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), are able to produce a long-lasting enhancement of synaptic transmission in the hippocampus. Unlike other forms of plasticity, neurotrophin-induced plasticity exhibited an immediate requirement for protein synthesis. Plasticity in rat hippocampal slices in which the synaptic neuropil was isolated from the principal cell bodies also required early protein synthesis. Thus, the neurotrophins may stimulate the synthesis of proteins in either axonal or dendritic compartments, allowing synapses to exert local control over the complement of proteins expressed at individual synaptic sites.	CALTECH,DIV BIOL 216 76,PASADENA,CA 91125	California Institute of Technology			Schuman, Erin M/D-6204-2011					ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; AMARAL D, COMMUNICATION; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DAVIS L, 1992, J NEUROSCI, V12, P4867; FEIG S, 1993, J NEUROSCI, V13, P1010; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FREY U, 1989, NEUROSCI LETT, V97, P135, DOI 10.1016/0304-3940(89)90152-3; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GIOIO AE, 1994, J NEUROCHEM, V63, P13; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Harris K. M., 1995, Society for Neuroscience Abstracts, V21, P594; IP NY, 1993, J NEUROSCI, V13, P3394; JOHNSTON HM, 1995, MOL BRAIN RES, V31, P141, DOI 10.1016/0169-328X(95)00046-U; JOHNSTON HM, 1994, J NEUROCHEM, V63, P379; JOHNSTON HM, 1994, NEUROSCI LETT, V177, P5, DOI 10.1016/0304-3940(94)90031-0; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; KANG H, IN PRESS LEARN MEM; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; KLEIMAN R, 1994, J NEUROSCI, V14, P1130, DOI 10.1523/JNEUROSCI.14-03-01130.1994; KLEIMAN R, 1990, NEURON, V5, P821, DOI 10.1016/0896-6273(90)90341-C; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; LAMBALLE F, 1994, J NEUROSCI, V14, P14; LAUTERBORN JC, 1993, NEUROREPORT, V5, P273, DOI 10.1097/00001756-199312000-00023; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; MARSH HN, 1993, J NEUROSCI, V13, P4281; Marty S, 1996, J NEUROSCI, V16, P675; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIYASHIRO K, 1994, P NATL ACAD SCI USA, V91, P10800, DOI 10.1073/pnas.91.23.10800; MOHR E, 1991, EMBO J, V10, P786; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Osten P, 1996, J NEUROSCI, V16, P2444; OTANI S, 1989, NEUROSCIENCE, V28, P519, DOI 10.1016/0306-4522(89)90001-8; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; RAO A, 1991, J NEUROSCI, V11, P2881; RASHID K, 1995, P NATL ACAD SCI USA, V92, P9495, DOI 10.1073/pnas.92.21.9495; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; STANTON PK, 1984, J NEUROSCI, V4, P3080; STEWARD O, 1982, J NEUROSCI, V2, P284; TORRE ER, 1992, J NEUROSCI, V12, P762; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; WELCHER A, UNPUB; Zhou X.-G., COMMUNICATION COMMUNICATION; ZHOU XF, 1993, BRAIN RES, V621, P189, DOI 10.1016/0006-8993(93)90106-W	56	713	727	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1402	1406		10.1126/science.273.5280.1402	http://dx.doi.org/10.1126/science.273.5280.1402			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703078				2022-12-24	WOS:A1996VF61000047
J	Kraut, R; Chia, W; Jan, LY; Jan, YN; Knoblich, JA				Kraut, R; Chia, W; Jan, LY; Jan, YN; Knoblich, JA			Role of inscuteable in orienting asymmetric cell divisions in Drosophila	NATURE			English	Article							C-ELEGANS EMBRYOS; CAENORHABDITIS-ELEGANS; CONFOCAL MICROSCOPY; SPINDLE ORIENTATION; GENETIC-CONTROL; NERVOUS-SYSTEM; PROSPERO; PROTEIN; NUMB; POLARITY	Drosophila neuroblasts and epithelial cells in the procephalic neurogenic region divide perpendicular to the surface, and segregate the proteins Numb and Prospero into the basal daughter cell. We demonstrate here that orientation of the mitotic spindle and correct localization of Numb and Prospero in these cells require the inscuteable gone. Moreover, ectopic expression of inscuteable in other epithelial cells leads to spindle reorientation. the Inscuteable protein localizes to the apical cell cortex before mitosis, suggesting that Inscuteable functions in establishing polarity for asymmetric cell division.	NATL UNIV SINGAPORE, INST MOL & CELL BIOL, SINGAPORE 119260, SINGAPORE; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOPHYS, SAN FRANCISCO, CA 94143 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco			Knoblich, Juergen A/C-2974-2015	Knoblich, Juergen A/0000-0002-6751-3404; Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chant J, 1996, CELL, V84, P187, DOI 10.1016/S0092-8674(00)80972-1; CHENG NN, 1995, GENETICS, V139, P549; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; FOE VE, 1989, DEVELOPMENT, V107, P1; HARTENSTEIN V, 1994, DEV BIOL, V165, P480, DOI 10.1006/dbio.1994.1269; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; LLOYD C, 1995, CURR BIOL, V5, P1085, DOI 10.1016/S0960-9822(95)00216-8; LUNDELL MJ, 1994, BIOTECHNIQUES, V16, P434; ORSULIC S, 1994, BIOTECHNIQUES, V16, P441; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; PRADLING A, 1986, DROSOPHILA PRACTICAL, P175; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; TORRESRUIZ RA, 1994, DEVELOPMENT, V120, P2967; TRAAS J, 1995, NATURE, V375, P676, DOI 10.1038/375676a0; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WADDLE JA, 1994, DEVELOPMENT, V120, P2317; White J, 1996, CELL, V84, P195, DOI 10.1016/S0092-8674(00)80974-5; WHITFIELD WGF, 1988, J CELL SCI, V89, P467	34	329	336	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 5	1996	383	6595					50	55		10.1038/383050a0	http://dx.doi.org/10.1038/383050a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779714				2022-12-24	WOS:A1996VF29500041
J	Schuchter, L; Schultz, DJ; Synnestvedt, M; Trock, BJ; Guerry, D; Elder, DE; Elenitsas, R; Clark, WH; Halpern, AC				Schuchter, L; Schultz, DJ; Synnestvedt, M; Trock, BJ; Guerry, D; Elder, DE; Elenitsas, R; Clark, WH; Halpern, AC			A prognostic model for predicting 10-year survival in patients with primary melanoma	ANNALS OF INTERNAL MEDICINE			English	Article							MULTIFACTORIAL ANALYSIS; THICKNESS; AREAS; RISK	Objective: To develop a prognostic model, based on clinical and pathologic data that are routinely available to the clinician, that would estimate the chance for survival of a patient with primary cutaneous melanoma after definitive surgical therapy. Design: Cohort analytical study. Setting: University medical center. Patients: 488 patients with primary cutaneous melanoma who had no apparent metastatic disease. Patients were followed prospectively for at least 10 years. An independent validation sample of 142 patients was used to assess the stability of the model. Measurements: Six clinical and pathologic variables that predict survival and are readily available to the clinician were used to develop a prediction model. The variables were tested for their association with death by using a univariate logistic regression model. Point estimates were generated for the probability of surviving melanoma at 10 years. Variables that were statistically significantly associated with survival were retained for testing in a logistic regression model. Results: 488 patients were followed prospectively for a median of 13.5 years (minimum, 10.0 years; maximum, 20.5 years). The overall 10-year survival of the study group was 78%. Four variables were found to be independent predictors of survival. Presented as adjusted odds ratios, from strongest to weakest relative predictive strength, these variables were tumor thickness (odds ratio, 50.8), site of primary melanoma (odds ratio, 4.4), age of the patient (odds ratio, 3.0), and sex of the patient (odds ratio, 2.0). The four-variable model was significantly more accurate than tumor thickness alone, particularly for predicting death. Overall, use of the model reduced the error rate of the prediction of death by 50%. Conclusions: A prognostic model that uses four readily accessible variables more accurately predicts outcome in patients with primary melanoma than does tumor thickness alone. This four-variable model can identify patients at high risk for the recurrence of disease, an identification that becomes increasingly important as adjuvant therapies are developed for treatment of melanoma.	UNIV PENN, BIOSTAT UNIT, PHILADELPHIA, PA 19104 USA; LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA; BETH ISRAEL HOSP, DEPT PATHOL, BOSTON, MA 02215 USA	University of Pennsylvania; Harvard University; Beth Israel Deaconess Medical Center				halpern, allan/0000-0001-7320-1901				BALCH CM, 1978, ANN SURG, V188, P732, DOI 10.1097/00000658-197812000-00004; BALCH CM, 1979, SURGERY, V86, P343; BERD D, 1993, ANN NY ACAD SCI, V690, P147; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Clark W H Jr, 1975, Semin Oncol, V2, P83; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; DAY CL, 1982, ANN SURG, V195, P35, DOI 10.1097/00000658-198201001-00006; Elwood J. Mark, 1994, Current Opinion in Oncology, V6, P179, DOI 10.1097/00001622-199403000-00011; HALPERN AC, 1991, ARCH DERMATOL, V127, P995, DOI 10.1001/archderm.127.7.995; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; LIVINGSTON PO, 1994, J CLIN ONCOL, V12, P1036, DOI 10.1200/JCO.1994.12.5.1036; MASRI GD, 1990, J AM ACAD DERMATOL, V22, P1042, DOI 10.1016/0190-9622(90)70149-C; VELLEMAN PF, 1981, APPLICATIONS BASICS	17	136	136	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					369	375		10.7326/0003-4819-125-5-199609010-00003	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE079	8702087				2022-12-24	WOS:A1996VE07900003
J	Duery, L				Duery, L			Santiago - Bad news travels fast in Chile?	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					605	605		10.1016/S0140-6736(05)64811-8	http://dx.doi.org/10.1016/S0140-6736(05)64811-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774580				2022-12-24	WOS:A1996VF18600030
J	Saillour, F; Dabis, F; Dupon, M; Lacoste, D; Trimoulet, P; Rispal, P; Monlun, E; Ragnaud, JM; Morlat, P; Pellegrin, JL; Fleury, H; Couzigou, P				Saillour, F; Dabis, F; Dupon, M; Lacoste, D; Trimoulet, P; Rispal, P; Monlun, E; Ragnaud, JM; Morlat, P; Pellegrin, JL; Fleury, H; Couzigou, P			Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK; SEROPREVALENCE	Objective-To evaluate the prevalence of antibodies to hepatitis C virus and serological markers for hepatitis B virus infection in patients with HIV. Design-Cross sectional survey. Setting-Aquitaine, southwestern France, 1991-94. Subjects-1935 HIV positive patients seen at least once since June 1991. Main outcome measures-Presence of antibodies to hepatitis C virus were detected by second or third generation enzyme linked immunosorbent assay (ELISA) and recombinant immunoblot assay (RIBA) and markers for hepatitis B virus detected by ELISA. Results-The prevalence was 42.5% (823) for antibodies to hepatitis C virus, 56.4 (507) for antibodies to hepatitis B core antigen, 6.9% (133) for hepatitis B surface antigen, 30.2% (584) for antibodies to hepatitis B core and surface antigen with no detectable surface antigen, 26.2% (507) for antibodies to core antigen only, and 4.8% (92) for antibodies to surface antigen only. The prevalence of antibodies to hepatitis C virus was 86.1% (726/843) in subjects who had bloodborne HIV infection and 7.3% (66/899) in those with sexually acquired infection. The prevalence of markers for hepatitis B was higher among homosexuals than in the other groups of patients, except for antibodies to surface antigen alone. The relation between markers for hepatitis B and hepatitis C virus was negative among men but positive among women. Conclusions-The results favour the hypothesis that hepatitis C virus is sexually transmitted much less commonly than either HIV or hepatitis B virus.	UNIV BORDEAUX 2,INSERM,U330,F-33076 BORDEAUX,FRANCE; CHU BORDEAUX,CTR INFORMAT & SOINS IMMUNODEFICIENCE HUMAINE,BORDEAUX,FRANCE; CHU BORDEAUX,MED VIROL LAB,BORDEAUX,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux; CHU Bordeaux			DABIS, FRANCOIS/S-9298-2019	DABIS, FRANCOIS/0000-0002-1614-8857				AOKI SK, 1993, BLOOD, V82, P100; BAATH L, 1992, J VIROL METHODS, V40, P287, DOI 10.1016/0166-0934(92)90087-T; BRICE L, 1994, SOLIDARITE SANTE, V3, P47; DABIS F, 1991, AIDS, V5, P774; DIETZMAN DE, 1977, JAMA-J AM MED ASSOC, V238, P2625, DOI 10.1001/jama.238.24.2625; ESTEBAN JI, 1989, LANCET, V2, P294; FLOMENBERG P, 1995, AIDS, V9, P97; FONG TL, 1991, HEPATOLOGY, V14, P64, DOI 10.1002/hep.1840140111; IWARSON S, 1995, CLIN INFECT DIS, V20, P1361, DOI 10.1093/clinids/20.5.1361; KLEINMAN S, 1992, TRANSFUSION, V32, P805, DOI 10.1046/j.1537-2995.1992.32993110750.x; KWO G, 1989, SCIENCE, V244, P362; LADNER J, 1992, PRESSE MED, V21, P219; LEBOVICS E, 1988, AM J GASTROENTEROL, V83, P1; LEVINE OS, 1994, EPIDEMIOL REV, V16, P418, DOI 10.1093/oxfordjournals.epirev.a036161; NUBLING CM, 1994, J MED VIROL, V44, P49, DOI 10.1002/jmv.1890440110; PILLONEL J, 1992, BEH, V39, P185; QUAN CM, 1993, CLIN INFECT DIS, V17, P117, DOI 10.1093/clinids/17.1.117; *RES NAT SANT PUBL, 1995, GROUP ACT CONC HEP C; SHEEN IS, 1992, J INFECT DIS, V165, P831, DOI 10.1093/infdis/165.5.831; SHERMAN KE, 1991, J INFECT DIS, V163, P414, DOI 10.1093/infdis/163.2.414; WRIGHT TL, 1994, HEPATOLOGY, V20, P1152	21	52	59	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					461	464						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776313	Green Published			2022-12-24	WOS:A1996VE08000020
J	Simons, AJ; Beart, RW				Simons, AJ; Beart, RW			Glyceryl trinitrate for anal fissure	LANCET			English	Editorial Material											Simons, AJ (corresponding author), UNIV SO CALIF,SCH MED,DEPT SURG,DIV COLORECTAL SURG,LOS ANGELES,CA 90033, USA.							GORFINE SR, 1995, DIS COLON RECTUM, V38, P453, DOI 10.1007/BF02148842; KLOSTERHALFEN B, 1989, DIS COLON RECTUM, V32, P43, DOI 10.1007/BF02554725; LODER PB, 1994, BRIT J SURG, V81, P1386, DOI 10.1002/bjs.1800810949; Lund JN, 1996, BRIT J SURG, V83, P776, DOI 10.1002/bjs.1800830615; SCHOUTEN WR, 1994, DIS COLON RECTUM, V37, P664, DOI 10.1007/BF02054409; Watson SJ, 1996, BRIT J SURG, V83, P771, DOI 10.1002/bjs.1800830614	6	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					491	492		10.1016/S0140-6736(05)64667-3	http://dx.doi.org/10.1016/S0140-6736(05)64667-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757148				2022-12-24	WOS:A1996VD42700006
J	Swann, PF; Waters, TR; Moulton, DC; Xu, YZ; Zheng, QG; Edwards, M; Mace, R				Swann, PF; Waters, TR; Moulton, DC; Xu, YZ; Zheng, QG; Edwards, M; Mace, R			Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine	SCIENCE			English	Article							NON-ENZYMATIC METHYLATION; ESCHERICHIA-COLI DNA; O-6-METHYLGUANINE RESIDUES; MUTATOR PHENOTYPE; DAMAGE TOLERANCE; CELLS TOLERANT; 6-THIOGUANINE; BINDING; MECHANISM; CANCER	It is proposed here that the delayed cytotoxicity of thioguanine involves the postreplicative DNA mismatch repair system. After incorporation into DNA, the thioguanine is chemically methylated by S-adenosylmethionine to form S-6-methylthioguanine. During DNA replication, the S-6-methylthioguanine directs incorporation of either thymine or cytosine into the growing DNA stand, and the resultant S-6-methylthioguanine-thymine nine-thymine pairs are recognized by the postreplicative mismatch repair system. pairs are recognized by the postreplicative mismatch repair system. Azathioprine, an immunosuppressant used in organ transplantation, is partly converted to thioguanine. Because the carcinogenicity of N-nitrosamines depends on formation of O-6-alkylguanine in DNA, the formation of the analog S-6-methylthioguanine during azathioprine treatment may partly explain the high incidence of cancer after transplantation.			Swann, PF (corresponding author), UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOL BIOL, CANC RES CAMPAIGN, NITROSAMINE INDUCED CANC GRP, LONDON WC1E 6BT, ENGLAND.		Xu, Yao/A-7700-2010	Xu, Yao/0000-0002-5713-8030				AQUILINA G, 1990, CANCER RES, V50, P4248; AQUILINA G, 1995, CANCER RES, V55, P2569; BARROWS LR, 1982, CARCINOGENESIS, V3, P349, DOI 10.1093/carcin/3.3.349; BODELL WJ, 1991, MUTAGENESIS, V6, P175, DOI 10.1093/mutage/6.3.175; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; HAWN MT, 1995, CANCER RES, V55, P3721; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; JONES M, 1981, MOL GEN GENET, V184, P562, DOI 10.1007/BF00352542; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; LENNARD L, 1985, BRIT J DERMATOL, V113, P723, DOI 10.1111/j.1365-2133.1985.tb02408.x; PENN I, 1994, CANCER DETECT PREV, V18, P241; PLANT JE, 1971, CHEM-BIOL INTERACT, V3, P337, DOI 10.1016/0009-2797(71)90013-5; RADMAN M, 1988, GENETIC RECOMBINATIO, P169; RAPPAPORT HP, 1993, BIOCHEMISTRY-US, V32, P3047, DOI 10.1021/bi00063a016; RASOULINIA A, 1994, MUTAT RES, V314, P99, DOI 10.1016/0921-8777(94)90074-4; RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x; TAN HB, 1994, BIOCHEMISTRY-US, V33, P5335, DOI 10.1021/bi00183a042; TIDD DM, 1974, CANCER RES, V34, P738; XU YZ, 1995, NUCLEOS NUCLEOT, V14, P929, DOI 10.1080/15257779508012504; XU YZ, 1992, TETRAHEDRON, V48, P1729, DOI 10.1016/S0040-4020(01)88731-7	25	329	337	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1109	1111		10.1126/science.273.5278.1109	http://dx.doi.org/10.1126/science.273.5278.1109			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688098				2022-12-24	WOS:A1996VD42800039
J	Hall, DB; Holmlin, RE; Barton, JK				Hall, DB; Holmlin, RE; Barton, JK			Oxidative DNA damage through long-range electron transfer	NATURE			English	Article							CLEAVAGE; 8-HYDROXY-2'-DEOXYGUANOSINE; INTERCALATION; RIBOFLAVIN; COMPLEXES; RESIDUES; GUANINE; BASES; SITE	The possibility has been considered for almost forty years that the DNA double helix, which contains a pi-stacked array of heterocyclic base pairs, could be a suitable medium for the migration of charge over long molecular distances(1-11). This notion of high charge mobility is a critical consideration with respect to DNA damage. We have previously found(7-10) that the DNA double helix can serve as a molecular bridge for photo-induced electron transfer between metallointercalators, with fast rates (greater than or equal to 10(10) s(-1))(10) and with quenching over a long distance (>40 Angstrom)(8). Here we use a metallointercalator to introduce a photoexcited hole into the DNA pi-stacked at a specific site in order to evaluate oxidative damage to DNA from a distance. Oligomeric DNA duplexes were prepared with a rhodium intercalator covalently attached to one end and separated spatially from 5'-GG-3' doublet sites of oxidation. Rhodium-induced photo-oxidation occurs specifically at the 5'-G in the 5'-GG-3' doublets and is observed up to 37 Angstrom away from the site of rhodium intercalation. We find that the yield of oxidative damage depends sensitively upon oxidation potential and pi-stacking, but not on distance. These results demonstrate directly that oxidative damage to DNA may be promoted from a remote site as a result of hole migration through the DNA pi-stack.	CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125	California Institute of Technology				Hall, Daniel B/0000-0002-5085-8334				ARKIN MR, IN PRESS SCIENCE; BARCISZEWSKI J, 1995, POL J CHEM, V69, P841; BARTON JK, 1986, SCIENCE, V233, P727, DOI 10.1126/science.3016894; Breslin DT, 1996, J AM CHEM SOC, V118, P2311, DOI 10.1021/ja953714w; BRUN AM, 1992, J AM CHEM SOC, V114, P3656, DOI 10.1021/ja00036a013; CHUNG MH, 1992, BIOCHEM BIOPH RES CO, V188, P1, DOI 10.1016/0006-291X(92)92341-T; CULLIS PM, 1990, J CHEM SOC FARADAY T, V86, P591, DOI 10.1039/ft9908600591; DAVID SS, 1993, J AM CHEM SOC, V115, P2984, DOI 10.1021/ja00060a060; FROMHERZ P, 1986, J AM CHEM SOC, V108, P5361, DOI 10.1021/ja00277a060; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; ITO K, 1993, J BIOL CHEM, V268, P13221; JOHANN TW, 1996, PHIL T R SOC LOND A, V354, P29; KASAI H, 1992, J AM CHEM SOC, V114, P9692, DOI 10.1021/ja00050a078; Kittler L., 1980, J ELECTROANAL CHEM I, V116, P503; MEADE TJ, 1995, ANGEW CHEM INT EDIT, V34, P352, DOI 10.1002/anie.199503521; MEI HY, 1988, P NATL ACAD SCI USA, V85, P1339, DOI 10.1073/pnas.85.5.1339; MELVIN T, 1995, PHOTOCHEM PHOTOBIOL, V61, P584, DOI 10.1111/j.1751-1097.1995.tb09873.x; MURPHY CJ, 1994, P NATL ACAD SCI USA, V91, P5315, DOI 10.1073/pnas.91.12.5315; MURPHY CJ, 1993, SCIENCE, V262, P1025, DOI 10.1126/science.7802858; PURUGGANAN MD, 1988, SCIENCE, V241, P1645, DOI 10.1126/science.3420416; RETEL J, 1993, MUTAT RES, V299, P165, DOI 10.1016/0165-1218(93)90094-T; SAITO I, 1995, J AM CHEM SOC, V117, P6406, DOI 10.1021/ja00128a050; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SITLANI A, 1992, J AM CHEM SOC, V114, P2303, DOI 10.1021/ja00033a003; SNART RS, 1968, BIOPOLYMERS, V6, P293, DOI 10.1002/bip.1968.360060304; Stemp EDA, 1996, MET IONS BIOL SYST, V33, P325; SZENTGYORGYI A, 1960, P NATL ACAD SCI USA, V46, P1444, DOI 10.1073/pnas.46.11.1444; Turro C, 1996, INORG CHIM ACTA, V243, P101, DOI 10.1016/0020-1693(95)04896-0; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; WACHTER L, 1986, NUCLEIC ACIDS RES, V14, P7985, DOI 10.1093/nar/14.20.7985	30	849	870	6	123	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					731	735		10.1038/382731a0	http://dx.doi.org/10.1038/382731a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751447				2022-12-24	WOS:A1996VD33300055
J	Shafritz, AB; Shore, EM; Gannon, FH; Zasloff, MA; Taub, R; Muenke, M; Kaplan, FS				Shafritz, AB; Shore, EM; Gannon, FH; Zasloff, MA; Taub, R; Muenke, M; Kaplan, FS			Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TGF-BETA-SUPERFAMILY; PROTEIN-4; EXPRESSION; MOUSE; INVOLVEMENT; MESODERM; PATHWAY; FAMILY; MEMBER; BMP-4	Background Fibrodysplasia ossificans progressiva is a heritable disorder of connective tissue characterized by congenital malformation of the great toes and postnatal formation of ectopic bone, Although the disorder was first described more than 300 years ago, the genetic defect and pathophysiology remain unknown. Bone morphogenetic proteins are potent bone-inducing morphogens that participate in the developmental organization of the skeleton, and increased production of one or more of these proteins has been proposed as the cause of fibrodysplasia ossificans progressiva. Methods We studied lymphoblastoid cell lines established from peripheral-blood mononuclear cells of patients with fibrodysplasia ossificans progressiva and fibroblast-like cell lines derived from lesional and nonlesional tissue. We used Northern blot analysis and ribonuclease protection assays to measure the expression of messenger RNA (mRNA) of bone morphogenetic proteins 1 to 7 and immunohistochemical analysis to examine protein expression. Results Among the bone morphogenetic proteins and mRNAs examined, only bone morphogenetic protein 4 and its mRNA were present in increased levels in cells derived from an early fibroproliferative lesion in a patient with fibrodysplasia ossificans progressiva, Bone morphogenetic protein 4 mRNA was expressed in lymphoblastoid cell lines from 26 of 32 patients with fibrodysplasia ossificans progressiva but from only 1 of 12 normal subjects (P<0.001). Bone morphogenetic protein 4 and its mRNA were detected in the lymphoblastoid cell lines from a man with fibrodysplasia ossificans progressiva and his three affected children (two girls and a boy), but not from the children's unaffected mother. No other bone morphogenetic proteins were detected. Conclusions Overexpression of a potent bone-inducing morphogen (bone morphogenetic protein 4) in lymphocytes is associated with the disabling ectopic osteogenesis of fibrodysplasia ossificans progressiva. (C) 1996, Massachusetts Medical Society.	UNIV PENN, SCH MED, DEPT ORTHOPAED SURG, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT GENET, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV HUMAN GENET & MOL BIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			Shore, Eileen/D-2593-2009	Muenke, Maximilian/0000-0002-7719-6545	NIAMS NIH HHS [R01-AR-41916] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041916] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOSTROM MPG, 1995, J ORTHOPAED RES, V13, P357, DOI 10.1002/jor.1100130309; BRIGHTON CT, 1992, CLIN ORTHOP RELAT R, V275, P287; BURING K, 1975, CLIN ORTHOP RELAT R, V110, P293; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623-199302000-00008; CONNOR JM, 1982, J BONE JOINT SURG BR, V64, P76, DOI 10.1302/0301-620X.64B1.7068725; CONNOR JM, 1993, J MED GENET, V30, P687, DOI 10.1136/jmg.30.8.687; EINHORN TA, 1995, J BONE MINER RES, V10, P1272; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; JANOFF HB, 1995, J RHEUMATOL, V22, P976; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; JONES CM, 1991, DEVELOPMENT, V111, P531; KAPLAN FS, 1990, CALCIFIED TISSUE INT, V47, P117, DOI 10.1007/BF02555995; KAPLAN FS, 1993, J BONE JOINT SURG AM, V75A, P220, DOI 10.2106/00004623-199302000-00009; KAPLAN FS, 1993, J BONE JOINT SURG AM, V75A, P1214, DOI 10.2106/00004623-199308000-00011; KAPLAN FS, IN PRESS CALIF TISSU; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1995, J CELL BIOL, V128, pU8; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; LANCHONEY TF, 1995, J PEDIATR-US, V126, P762, DOI 10.1016/S0022-3476(95)70408-6; Liebowitz David, 1993, P107; NAKASE T, 1994, J BONE MINER RES, V9, P651; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; REDDI AH, 1993, J BONE MINER RES, V8, pS499; ROCKE DM, 1994, CLIN ORTHOP RELAT R, P243; Sambrook JFE, 1989, MOL CLONING LAB MANU; SHAH PB, 1994, J BONE JOINT SURG AM, V76A, P1442, DOI 10.2106/00004623-199410000-00002; SHIMIZU K, 1994, CLIN ORTHOP RELAT R, P274; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TAKAOKA K, 1994, CLIN ORTHOP RELAT R, P269; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WATT JL, 1986, HUMAN CYTOGENETICS P, P39; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; ZECCA M, 1995, DEVELOPMENT, V121, P2265	40	283	294	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1996	335	8					555	561		10.1056/NEJM199608223350804	http://dx.doi.org/10.1056/NEJM199608223350804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD302	8678932				2022-12-24	WOS:A1996VD30200004
J	McKay, DS; Gibson, EK; ThomasKeprta, KL; Vali, H; Romanek, CS; Clemett, SJ; Chillier, XDF; Maechling, CR; Zare, RN				McKay, DS; Gibson, EK; ThomasKeprta, KL; Vali, H; Romanek, CS; Clemett, SJ; Chillier, XDF; Maechling, CR; Zare, RN			Search for past life on Mars: Possible relic biogenic activity in Martian meteorite ALH84001	SCIENCE			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; RECENT LAKE-SEDIMENTS; SNC METEORITES; MAGNETOTACTIC BACTERIA; ISOTOPIC COMPOSITION; WEATHERING PRODUCTS; MURCHISON METEORITE; SINGLE-DOMAIN; CARBON; MAGNETITE	Fresh fracture surfaces of the martian meteorite ALH84001 contain abundant polycyclic aromatic hydrocarbons (PAHs). These fresh fracture surfaces also display carbonate globules. Contamination studies suggest that the PAHs are indigenous to the meteorite. High-resolution scanning and transmission electron microscopy study of surface textures and internal structures of selected carbonate globules show that the globules contain fine-grained, secondary phases of single-domain magnetite and Fe-sulfides. The carbonate globules are similar in texture and size to some terrestrial bacterially induced carbonate precipitates. Although inorganic formation is possible, formation of the globules by biogenic processes could explain many of the observed features, including the PAHs. The PAHs, the carbonate globules, and their associated secondary mineral phases and textures could thus be fossil remains of a past martian biota.	NASA,LYNDON B JOHNSON SPACE CTR,HOUSTON,TX 77058; NASA,HOUSTON,TX 77058; MCGILL UNIV,DEPT EARTH & PLANETARY SCI,MONTREAL,PQ H3A 2A7,CANADA; UNIV GEORGIA,SAVANNAH RIVER ECOL LAB,AIKEN,SC 29802; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; McGill University; United States Department of Energy (DOE); Savannah River Ecology Laboratory; University System of Georgia; University of Georgia; Stanford University	McKay, DS (corresponding author), NASA,LYNDON B JOHNSON SPACE CTR,MAIL CODE SN,HOUSTON,TX 77058, USA.		Vali, Hojatollah/F-3511-2012; Zare, Richard N./A-8410-2009	Vali, Hojatollah/0000-0003-3464-9943; Zare, Richard/0000-0001-5266-4253				[Anonymous], 1995, GEOL SOC LOND SPEC P, DOI DOI 10.1144/GSL.SP.1995.098.01.02; Ash RD, 1996, NATURE, V380, P57, DOI 10.1038/380057a0; BAZYLINSKI DA, 1993, NATURE, V366, P218, DOI 10.1038/366218a0; BECKER, 1983, EARTH PLANET SC LETT, V69, P225; BLAKEMORE RP, 1982, ANNU REV MICROBIOL, V36, P217, DOI 10.1146/annurev.mi.36.100182.001245; BOGARD DD, 1983, SCIENCE, V221, P651, DOI 10.1126/science.221.4611.651; BOGARD DD, 1995, LUNAR PLANET SCI, V26, P143; BUCZYNSKI C, 1991, J SEDIMENT PETROL, V61, P226, DOI 10.1306/D42676DB-2B26-11D7-8648000102C1865D; BUTLER RF, 1975, J GEOPHYS RES, V80, P4049, DOI 10.1029/JB080i029p04049; Campbell I. B., 1987, Antarctica: soils, weathering processes and environment; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; CHACKO T, 1991, GEOCHIM COSMOCHIM AC, V55, P2867, DOI 10.1016/0016-7037(91)90452-B; CHANG SR, 1989, PRECAMBRIAN RES, V42, P305; CLARK ID, 1992, CHEM GEOL, V102, P217, DOI 10.1016/0009-2541(92)90157-Z; Claypool G.E., 1974, NATURAL GASES MARINE, P99, DOI DOI 10.1007/978-1-4684-2757-8_8; Clemett S. J., 1996, THESIS STANFORD U; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; CLEMETT SJ, 1996, LUNAR PLANET SCI, V26, P229; DEMITRACK A, 1985, MAGNETITE BIOMINERAL, P625; FARINA M, 1990, NATURE, V343, P256, DOI 10.1038/343256a0; FASSBINDER JWE, 1990, NATURE, V343, P161, DOI 10.1038/343161a0; FOLK RL, 1993, J SEDIMENT PETROL, V63, P990, DOI 10.1306/D4267C67-2B26-11D7-8648000102C1865D; FORTIN D, 1995, J IND MICROBIOL, V14, P178, DOI 10.1007/BF01569901; FRANKEL RB, 1991, IRON BIOMINERALIZATI; GARRELS RM, 1969, SOLUTIONS MINERALS E; Gibson E. K., 1983, Journal of Geophysical Research, V88, P912, DOI 10.1029/JB088iS02p0A912; Gladman BJ, 1996, SCIENCE, V271, P1387, DOI 10.1126/science.271.5254.1387; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; GRADY MM, 1988, GEOCHIM COSMOCHIM AC, V52, P2855, DOI 10.1016/0016-7037(88)90152-4; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; HARZMETZ CP, 1992, WORKSH MARS SURF ATM, P67; HENDRY JP, 1993, SEDIMENTOLOGY, V40, P87, DOI 10.1111/j.1365-3091.1993.tb01093.x; Hudson J.D., 1977, J GEOL SOC LOND, V133, P637, DOI DOI 10.1144/GSJGS.133.6.0637; JAGOUTZ E, 1994, METEORITICS, V29, P478; JAKOSKY BM, 1993, GEOPHYS RES LETT, V20, P1591, DOI 10.1029/93GL01598; JENSEN TE, 1983, ANAL CHEM, V55, P594, DOI 10.1021/ac00255a003; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; JULL AJT, 1996, 9601 LUN PLAN I 1, P22; KAWAMURA K, 1994, NATURWISSENSCHAFTEN, V81, P502, DOI 10.1007/s001140050116; KIRSCHVINK JL, 1984, GEOLOGY, V12, P559, DOI 10.1130/0091-7613(1984)12<559:UMIDSP>2.0.CO;2; KLEIN HP, 1995, EOS, V76, P334; KOVALENKO LJ, 1992, ANAL CHEM, V64, P682, DOI 10.1021/ac00030a021; KVENVOLDEN K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; LAFLAMME RE, 1978, GEOCHIM COSMOCHIM AC, V42, P289, DOI 10.1016/0016-7037(78)90182-5; Lovely D R, 1987, NATURE, V330, P252; MAHER BA, 1991, IRON BIOMINERALS, P179; MANN S, 1990, NATURE, V343, P258, DOI 10.1038/343258a0; MARTI K, 1995, SCIENCE, V267, P1981, DOI 10.1126/science.7701319; MARTINI AM, 1995, GEOL SOC AM ABSTR, V27, pA292; MAZUR P, 1978, SPACE SCI REV, V22, P3, DOI 10.1007/BF00215812; MCBRIDE EF, 1994, J SEDIMENT RES A, V64, P535; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MEIOSH HJ, 1984, ICARUS, V59, P234; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; MURATA KJ, 1969, US GEOL SURV PROF B, V614, P1; Nakai N., 1975, GEOCHEM J, V9, P7, DOI [10.2343/geochemj.9.7, DOI 10.2343/GEOCHEMJ.9.7]; NEALSON KH, 1994, ANNU REV MICROBIOL, V48, P311, DOI 10.1146/annurev.mi.48.100194.001523; NYQUIST LE, 1995, LUNAR PLANET SCI, V26, P1065; PACQUETTE J, IN PRESS GEOCHIM COS; PAQUETTE J, IN PRESS AM MINERAL; PERING KL, 1971, SCIENCE, V173, P237, DOI 10.1126/science.173.3993.237; PETERSEN N, 1986, NATURE, V320, P611, DOI 10.1038/320611a0; ROMANEK CS, 1992, GEOCHIM COSMOCHIM AC, V56, P419, DOI 10.1016/0016-7037(92)90142-6; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; SCHOPF JW, 1992, PROTEROZOICIMENT BIO; STANJEK H, 1994, EUR J SOIL SCI, V45, P97, DOI 10.1111/j.1365-2389.1994.tb00490.x; STEVENS TO, 1995, SCIENCE, V270, P450, DOI 10.1126/science.270.5235.450; TAYLOR RM, 1987, CLAY MINER, V22, P411, DOI 10.1180/claymin.1987.022.4.05; THOMAS KL, 1995, GEOCHIM COSMOCHIM AC, V59, P2797, DOI 10.1016/0016-7037(95)00174-X; THOMAS KL, 1995, LUNAR PLANET SCI, V26, P1409; THOMPSON JB, 1990, GEOLOGY, V18, P995, DOI 10.1130/0091-7613(1990)018<0995:CPOGCA>2.3.CO;2; Tissot B.P., 1984, PETROLEUM FORMATION, Vsecond, DOI [10.1007/978-3-642-87813-8, DOI 10.1007/978-3-642-87813-8]; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; VALI H, 1987, EARTH PLANET SC LETT, V86, P389, DOI 10.1016/0012-821X(87)90235-4; VALI H, 1989, NATURE, V339, P203, DOI 10.1038/339203a0; Vali H., 1990, IRON BIOMINERALS, P97; VELBEL MA, 1988, METEORITICS, V23, P151, DOI 10.1111/j.1945-5100.1988.tb00910.x; WAKEHAM SG, 1980, GEOCHIM COSMOCHIM AC, V44, P403, DOI 10.1016/0016-7037(80)90040-X; WAKEHAM SG, 1980, GEOCHIM COSMOCHIM AC, V44, P415, DOI 10.1016/0016-7037(80)90041-1; WATSON LL, 1994, SCIENCE, V265, P86, DOI 10.1126/science.265.5168.86; WING MR, 1991, GEOCHIM COSMOCHIM AC, V55, P2937, DOI 10.1016/0016-7037(91)90458-H; WRIGHT IP, 1993, J GEOPHYS RES-PLANET, V98, P3477, DOI 10.1029/92JE02056; YOUNGBLOOD WW, 1975, GEOCHIM COSMOCHIM AC, V39, P1303, DOI 10.1016/0016-7037(75)90137-4; Zenobi R., 1991, ADV MULTIPHOTON PROC, V7, P1; [No title captured]; [No title captured]; [No title captured]	87	1253	1304	11	530	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					924	930		10.1126/science.273.5277.924	http://dx.doi.org/10.1126/science.273.5277.924			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688069				2022-12-24	WOS:A1996VC67000052
J	Behrens, J; vonKries, JP; Kuhl, M; Bruhn, L; Wedlich, D; Grosschedl, R; Birchmeier, W				Behrens, J; vonKries, JP; Kuhl, M; Bruhn, L; Wedlich, D; Grosschedl, R; Birchmeier, W			Functional interaction of beta-catenin with the transcription factor LEF-1	NATURE			English	Article							PROTEIN-PROTEIN INTERACTIONS; TCR-ALPHA ENHANCER; XENOPUS EMBRYOS; E-CADHERIN; ACTIVATION DOMAIN; HMG DOMAIN; DNA; ARMADILLO; PLAKOGLOBIN; DROSOPHILA	THE cytoplasmic proteins beta-catenin of vertebrates and armadillo of Drosophila have two functions: they link the cadherin cell-adhesion molecules to the cytoskeleton(1-4), and they participate in the wnt/wingless signalling pathway(5-7). Here we show, in a yeast two-hybrid screen, that the architectural transcription factor LEF-1 (for lymphoid enhancer-binding factor)(8-10) interacts with beta-catenin. In mammalian cells, coexpressed LEF-1 and beta-catenin form a complex that is localized to the nucleus and can be detected by immunoprecipitation, Moreover, LEF-1 and beta-catenin form a ternary complex with DNA that displays an altered DNA bend. Microinjection of LEF-1 into Xenopus embryos induces axis duplication, which is augmented by interaction with beta-catenin. Thus beta-catenin regulates gene expression by direct interaction with transcription factors such as LEF-1, providing a molecular mechanism for the transmission of signals from cell-adhesion components or ant protein to the nucleus.	MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY; UNIV ULM,D-89081 ULM,GERMANY; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ulm University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ABERLE H, 1994, J CELL SCI, V107, P3655; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Kuhl M, 1996, MECH DEVELOP, V54, P71, DOI 10.1016/0925-4773(95)00462-9; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Miller J.H., 1972, EXPT MOL GENETICS; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	30	2503	2590	1	135	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					638	642		10.1038/382638a0	http://dx.doi.org/10.1038/382638a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757136				2022-12-24	WOS:A1996VC30300056
J	Nightingale, SL				Nightingale, SL			One-day course on clinical trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					443	443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691538				2022-12-24	WOS:A1996VA86300008
J	Evans, I				Evans, I			Amorous inclinations	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					352	352		10.1016/S0140-6736(05)64989-6	http://dx.doi.org/10.1016/S0140-6736(05)64989-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709731				2022-12-24	WOS:A1996VB42600007
J	Roberts, CW; Roberts, JW				Roberts, CW; Roberts, JW			Base-specific recognition of the nontemplate strand of promoter DNA by E-coli RNA polymerase	CELL			English	Article							AMINO-ACID SUBSTITUTIONS; -10 BINDING REGION; BACILLUS-SUBTILIS; SIGMA-FACTOR; TRANSCRIPTION INITIATION; START SITE; PROTEIN; ELONGATION; MECHANISM; COMPLEXES	RNA polymerase recognizes its promoters through base-specific interaction between defined segments of DNA and the sigma subunit of the enzyme. This interaction leads to separation of base pairs and exposure of the template strand for RNA synthesis. We show that base-specific recognition by the sigma(70) holoenzyme in this process involves primarily nontemplate strand bases in the -10 promoter region. We suggest that melting involves the persistence of these contacts as the bound duplex (closed) form is converted to the single-stranded (open) form of the enzyme-promoter complex.			Roberts, CW (corresponding author), CORNELL UNIV,BIOCHEM MOL & CELL BIOL SECT,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM21941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021941, R37GM021941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BUCK M, 1992, NATURE, V358, P422, DOI 10.1038/358422a0; BUCKLE M, 1994, TRANSCRIPTION MECH R, P207; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHEN YF, 1995, J MOL BIOL, V249, P743, DOI 10.1006/jmbi.1995.0333; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; GUO HC, 1990, THESIS CORNELL U ITH; HAWLEY DK, 1980, P NATL ACAD SCI-BIOL, V77, P6381, DOI 10.1073/pnas.77.11.6381; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Johnston D. E., 1976, RNA POLYMERASE, P413; JONES CH, 1992, J BACTERIOL, V174, P6815, DOI 10.1128/JB.174.21.6815-6821.1992; JUANG YL, 1995, BIOCHEMISTRY-US, V34, P8465, DOI 10.1021/bi00026a030; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KENNEY TJ, 1989, P NATL ACAD SCI USA, V86, P9109, DOI 10.1073/pnas.86.23.9109; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; RING BZ, 1995, THESIS CORNELL U ITH; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; TATTI KM, 1995, J BACTERIOL, V177, P6506, DOI 10.1128/jb.177.22.6506-6509.1995; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; YANG X, 1988, THESIS CORNELL U ITH; YANG XJ, 1987, GENE DEV, V1, P217, DOI 10.1101/gad.1.3.217; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	34	122	123	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					495	501						7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756731				2022-12-24	WOS:A1996VC30900017
J	Sheridan, J; Strang, J; Barber, N; Glanz, A				Sheridan, J; Strang, J; Barber, N; Glanz, A			Role of community pharmacies in relation to HIV prevention and drug misuse: Findings from the 1995 national survey in England and Wales	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To establish activity levels of community (high street) pharmacies in the provision of HIV prevention services to drug misusers and to compare these findings with the levels identified in 1988. Design-Self completion questionnaire (four mailings) to a random 1 in 4 sample of all community pharmacies, stratified by family health services authority. Setting-England and Wales. Subjects-Data provided by pharmacist in charge of the dispensary, on service provision at the pharmacy. Main outcome measures-quantitative reports of current activity levels for (a) dispensing of controlled drugs to drug misusers, (b) sale of needles and syringes, (c) needle and syringe exchange. Results-74.8% response rate (1984/2654). In 1995, 50.1% (992/1980) of pharmacies were dispensing controlled drugs (mostly methadone), compared with 23.0% (562/2457) in 1988; 34.5% (677/1962) of pharmacies were selling injecting equipment, compared with 28.0% (676/2434) in 1988; 18.9% (366/1937) were providing a needle exchange service, compared with 3.0% (65/2415) in 1988. Conclusion-Activity levels increased substantially across all three service areas. Increased activity included greater individual activity as well as higher proportions of pharmacies participating. The network of community pharmacies represents an underused point of contact for this Health of the Nation target population.	UNIV LONDON,SCH PHARM,CTR PHARM PRACTICE,LONDON WC1N 1AX,ENGLAND	University of London; University College London; University of London School of Pharmacy	Sheridan, J (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,NATL ADDICT CTR,DE CRESPIGNY PK, DENMARK HILL,LONDON SE5 8AF,ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Sheridan, Janie/0000-0002-0312-3095				*ADV COUNC MIS DRU, 1993, AIDS DRUG MIS UPD RE; Advisory Council on the Misuse of Drugs, 1988, AIDS DRUG MIS 1; *DEP HLTH, 1993, HLTH NATION KEY AREA; GLANZ A, 1989, BRIT MED J, V299, P1076, DOI 10.1136/bmj.299.6707.1076; GLANZ A, 1990, PREVENTION AIDS DRUG; *HOM OFF, 1995, STAT DRUG ADD NOT HO; Home Office, 1995, TACKLING DRUGS TOGET; MOTT J, 1994, HEROIN ADDICTION DRU, P270; Strang J, 1996, BMJ-BRIT MED J, V313, P270, DOI 10.1136/bmj.313.7052.270; 1991, PHARM J, V247, P223; 1993, PHARM J, V251, P20; 1994, PHARM J, V252, P53; 1991, PHARM J, V247, P304	13	62	63	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					272	274		10.1136/bmj.313.7052.272	http://dx.doi.org/10.1136/bmj.313.7052.272			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704541	Green Published			2022-12-24	WOS:A1996VA90300031
J	Currie, PD; Ingham, PW				Currie, PD; Ingham, PW			Induction of a specific muscle cell type by a hedgehog-like protein in zebrafish	NATURE			English	Article							MOTOR-NEURON INDUCTION; SONIC-HEDGEHOG; FLOOR PLATE; POLARIZING ACTIVITY; EXPRESSION; NOTOCHORD; AUTOPROTEOLYSIS; PATTERN; SOMITES; PRODUCT	THE notochord plays a central role in vertebrate development, acting as a signalling source that patterns the neural tube and somites(1-4). In in vitro assays, the secreted protein Sonic hedgehog mimics the inducing effects of notochord on both presomitic mesoderm and neural plate explants of amniote embryos, suggesting that both patterning activities of the notochord may be mediated by this protein in vivo(5-8). In zebrafish, however, mutants with disrupted notochord development lack a specific muscle cell type, the muscle pioneers, although they retain tile ability to induce neural differentiation, raising the possibility that neural tube and somite patterning may be mediated by distinct signals(9,10). Here we describe a new member of the hedgehog family, echidna hedgehog that is expressed exclusively in the notochord and has the ability to rescue the differentiation of muscle pioneer cells in mutants with no notochord, Moreover, we show that a combination of ectopic echidna hedgehog and sonic hedgehog expression induces supernumary muscle pioneers in wild-type embryos, suggesting that both signals act sequentially to pattern the developing somites.	IMPERIAL CANC RES FUND,MOL EMBRYOL LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Ingham, Philip W/G-9903-2011; Ingham, Philip William/AAH-5884-2020; Ingham, Philip W/E-6710-2010	Ingham, Philip W/0000-0001-8224-9958; Ingham, Philip William/0000-0001-8224-9958; Currie, Peter/0000-0001-8874-8862				BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; FELSENFELD AL, 1991, DEV BIOL, V148, P23, DOI 10.1016/0012-1606(91)90314-S; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HATTA K, 1991, DEVELOPMENT, V112, P821; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; TALBOT WS, 1995, NATURE, V378, P150, DOI 10.1038/378150a0; VANEEDEN FJM, IN PRESS DEVELOPMENT; VANSTRAATEN HWM, 1989, DEVELOPMENT, V107, P793; Weinberg ES, 1996, DEVELOPMENT, V122, P271; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	26	280	303	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					452	455		10.1038/382452a0	http://dx.doi.org/10.1038/382452a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684485				2022-12-24	WOS:A1996VA25100057
J	Zhang, DH; Nicklas, RB				Zhang, DH; Nicklas, RB			'Anaphase' and cytokinesis in the absence of chromosomes	NATURE			English	Article							SPINDLE; CELLS; KINETOCHORE; CENTROSOMES; NUCLEAR	ANAPHASE and cytokinesis are key processes in the segregation of replicated chromosomes to the daughter cell: in anaphase, chromosomes move apart; in cytokinesis, a cleavage furrow forms midway between the separate chromosomes. Some evidence suggests that chromosomes may be involved both in controlling the timing of anaphase onset(1-3) and in dictating the position of the cleavage furrow(3). Other evidence indicates that the controlling mechanisms are intrinsic to the spindle and the cell(4-7). Here we test these possibilities in grasshopper spermatocytes by observing spindles and cells after removal of chromosomes. We found that both anaphase and cytokinesis occur independently of chromosomes: stage-specific changes occur at an appropriate time and in the correct way, despite the absence of chromosomes. This finding is particularly noteworthy because chromosomes have an important impact on spindle microtubule assembly(8,9) and the timing of anaphase onset(10) in these cells.			Zhang, DH (corresponding author), DUKE UNIV,DEPT ZOOL,DURHAM,NC 27708, USA.							COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; EARNSHAW WC, 1991, COLD SH Q B, V56, P675; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LORCH IJ, 1952, Q J MICROSC SCI, V93, P475; LUCA FC, 1993, CURR BIOL, V3, P716, DOI 10.1016/0960-9822(93)90078-3; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; SLUDER G, 1993, NATO ASI SERIES H, V72, P211; WILSON EB, 1925, CELL DEV HEREDITY, P176; ZHANG DH, 1995, J CELL BIOL, V131, P1125, DOI 10.1083/jcb.131.5.1125; ZHANG DH, 1995, J CELL BIOL, V129, P1287, DOI 10.1083/jcb.129.5.1287; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	17	96	97	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					466	468		10.1038/382466a0	http://dx.doi.org/10.1038/382466a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684488				2022-12-24	WOS:A1996VA25100061
J	Ansell, P; Bull, D; Roman, E				Ansell, P; Bull, D; Roman, E			Childhood leukaemia and intramuscular vitamin K: Findings from a case-control study	BRITISH MEDICAL JOURNAL			English	Article							CANCER		RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford				Roman, Eve/0000-0001-7603-3704				DRAPER G, 1994, BRIT MED J, V308, P867, DOI 10.1136/bmj.308.6933.867; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; STILLER CA, 1995, EUR J CANCER, V202, P8	5	36	37	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					204	205		10.1136/bmj.313.7051.204	http://dx.doi.org/10.1136/bmj.313.7051.204			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696197	Green Published			2022-12-24	WOS:A1996VA12600026
J	Coetzee, T; Fujita, N; Dupree, J; Shi, R; Blight, A; Suzuki, K; Suzuki, K; Popko, B				Coetzee, T; Fujita, N; Dupree, J; Shi, R; Blight, A; Suzuki, K; Suzuki, K; Popko, B			Myelination in the absence of galactocerebroside and sulfatide: Normal structure with abnormal function and regional instability	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; BASIC-PROTEIN; RAT-BRAIN; CERAMIDE GALACTOSYLTRANSFERASE; MORPHOMETRIC ANALYSIS; PROTEOLIPID PROTEIN; GALACTOSYL CERAMIDE; DEFICIENT MICE; UDP-GALACTOSE; EXPRESSION	The vertebrate nervous system is characterized by ensheathment of axons with myelin, a multilamellar membrane greatly enriched in the galactolipid galactocerebroside (GalC) and its sulfated derivative sulfatide. We have generated mice lacking the enzyme UDP-galactose:ceramide galactosyltransferase (CGT), which is required for GalC synthesis. CGT-deficient mice do not synthesize GalC or sulfatide but surprisingly form myelin containing glucocerebroside, a lipid not previously identified in myelin. Microscopic and morphometric analyses revealed myelin of normal ultrastructural appearance, except for slightly thinner sheaths in the ventral region of the spinal cord. Nevertheless, these mice exhibit severe generalized tremoring and mild ataxia, and electrophysiological analysis showed conduction deficits consistent with reduced insulative capacity of the myelin sheath. Moreover, with age, CGT-deficient mice develop progressive hindlimb paralysis and extensive vacuolation of the ventral region of the spinal cord. These results indicate that GalC and sulfatide play important roles in myelin function and stability.	UNIV N CAROLINA,DEPT PATHOL & LAB MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT SURG,DIV NEUROSURG,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT NEUROL & PSYCHIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,PROGRAM MOL BIOL & BIOTECHNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Coetzee, T (corresponding author), UNIV N CAROLINA,CTR NEUROSCI,CHAPEL HILL,NC 27599, USA.			Popko, Brian/0000-0001-9948-2553	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024453, R01NS027336, R01NS024289, R29NS027336] Funding Source: NIH RePORTER; NINDS NIH HHS [NS24453, NS27336, NS24289] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON MB, 1965, J BIOL CHEM, V240, P2389; ADACHI M, 1972, ACTA NEUROPATHOL, V20, P22, DOI 10.1007/BF00687899; ADLKOFER K, 1995, NAT GENET, V11, P274, DOI 10.1038/ng1195-274; ALEU FP, 1963, J NEUROPATH EXP NEUR, V22, P403, DOI 10.1097/00005072-196307000-00003; BANSAL R, 1989, P NATL ACAD SCI USA, V86, P6181, DOI 10.1073/pnas.86.16.6181; BARRETT EF, 1982, J PHYSIOL-LONDON, V323, P117, DOI 10.1113/jphysiol.1982.sp014064; BEAUDET AL, 1995, METABOLIC MOL BASIS, P4599; BENJAMINS JA, 1990, ANN NY ACAD SCI, V305, P90; BLACK JA, 1990, TRENDS NEUROSCI, V13, P48, DOI 10.1016/0166-2236(90)90068-L; BLIGHT AR, 1985, NEUROSCIENCE, V15, P13, DOI 10.1016/0306-4522(85)90119-8; BOISON D, 1994, P NATL ACAD SCI USA, V91, P11709, DOI 10.1073/pnas.91.24.11709; BUSCHARD K, 1994, DIABETOLOGIA, V37, P1000; CAMPAGNONI AT, 1988, MOL NEUROBIOL, V2, P41, DOI 10.1007/BF02935632; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COETZEE T, 1996, IN PRESS GENOMICS; COSTANTI.E, 1973, J BIOL CHEM, V248, P8240; CURATOLO W, 1987, BIOCHIM BIOPHYS ACTA, V906, P137, DOI 10.1016/0304-4157(87)90009-8; DAVID G, 1995, J PHYSIOL-LONDON, V489, P141, DOI 10.1113/jphysiol.1995.sp021037; DEVRIES GH, 1972, SCIENCE, V175, P1370, DOI 10.1126/science.175.4028.1370; DORFMAN SH, 1979, BRAIN RES, V177, P105, DOI 10.1016/0006-8993(79)90921-1; DYER CA, 1989, J NEUROSCI RES, V24, P212, DOI 10.1002/jnr.490240212; DYER CA, 1988, J NEUROSCI, V8, P4307; DYER CA, 1990, J CELL BIOL, V111, P625, DOI 10.1083/jcb.111.2.625; DYER CA, 1991, J NEUROSCI RES, V30, P699, DOI 10.1002/jnr.490300414; DYER CA, 1993, MOL NEUROBIOL, V7, P1, DOI 10.1007/BF02780606; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRANKENHAEUSER B, 1963, J PHYSIOL-LONDON, V169, P431, DOI 10.1113/jphysiol.1963.sp007269; FRY JM, 1974, SCIENCE, V183, P540, DOI 10.1126/science.183.4124.540; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; HAMMARST.S, 1971, EUR J BIOCHEM, V21, P388, DOI 10.1111/j.1432-1033.1971.tb01481.x; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; IGISU H, 1983, BIOCHEM BIOPH RES CO, V110, P940, DOI 10.1016/0006-291X(83)91053-7; JANSEN R, 1989, GENE ANAL TECH, V6, P79, DOI 10.1016/0735-0651(89)90020-4; KOYNOVA R, 1995, BBA-LIPID LIPID MET, V1255, P213, DOI 10.1016/0005-2760(94)00202-A; LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0; LITTLE GJ, 1994, J ANAT, V184, P387; LONG D, 1994, J VIROL, V68, P5890, DOI 10.1128/JVI.68.9.5890-5898.1994; LUNN KF, 1995, MICROSC RES TECHNIQ, V32, P183, DOI 10.1002/jemt.1070320303; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3; MORELL P, 1969, BIOCHEMISTRY-US, V8, P506, DOI 10.1021/bi00830a008; Morell Pierre, 1994, P117; NESKOVIC NM, 1986, J NEUROCHEM, V47, P1412, DOI 10.1111/j.1471-4159.1986.tb00773.x; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Norton WT., 1984, MYELIN, P147, DOI DOI 10.1007/978-1-4757-1830-0_5; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; POPKO B, 1987, CELL, V48, P713, DOI 10.1016/0092-8674(87)90249-2; RANSCHT B, 1987, J NEUROSCI, V7, P2936; RATH EM, 1995, J NEUROSCI, V15, P7226; READHEAD C, 1987, CELL, V48, P703, DOI 10.1016/0092-8674(87)90248-0; ROACH A, 1983, CELL, V34, P799, DOI 10.1016/0092-8674(83)90536-6; ROSENBLUTH J, 1994, J NEUROCYTOL, V23, P699, DOI 10.1007/BF01181644; SCHAERENWIEMERS N, 1995, J NEUROCHEM, V65, P2267; SCHULTE S, 1993, P NATL ACAD SCI USA, V90, P10265, DOI 10.1073/pnas.90.21.10265; SHINE HD, 1992, J NEUROCHEM, V58, P342, DOI 10.1111/j.1471-4159.1992.tb09316.x; STAHL N, 1994, J NEUROSCI RES, V38, P234, DOI 10.1002/jnr.490380214; SUTCLIFFE JG, 1983, CELL, V33, P671, DOI 10.1016/0092-8674(83)90010-7; SUZUKI K, 1969, AM J PATHOL, V54, P307; TOWFIGHI J, 1974, LAB INVEST, V31, P712; Towfighi J, 1980, EXPT CLIN NEUROTOXIC, P440; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Watanabe I., 1980, EXPT CLIN NEUROTOXIC, P545; WAXMAN SG, 1993, ANN NEUROL, V33, P121, DOI 10.1002/ana.410330202; YAHI N, 1992, J VIROL, V66, P4848, DOI 10.1128/JVI.66.8.4848-4854.1992	65	479	486	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					209	219		10.1016/S0092-8674(00)80093-8	http://dx.doi.org/10.1016/S0092-8674(00)80093-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706126	Bronze			2022-12-24	WOS:A1996UZ97200007
J	Petridou, E; Trichopoulos, D; Dessypris, N; Flytzani, V; Haidas, S; Kalmanti, M; Koliouskas, D; Kosmidis, H; Piperopoulou, F; Tzortzatou, F				Petridou, E; Trichopoulos, D; Dessypris, N; Flytzani, V; Haidas, S; Kalmanti, M; Koliouskas, D; Kosmidis, H; Piperopoulou, F; Tzortzatou, F			Infant leukaemia after in utero exposure to radiation from Chernobyl	NATURE			English	Article							CHILDHOOD LEUKEMIA; REACTOR ACCIDENT; ONCOGENE; FALLOUT; BRITAIN; CANCER; SWEDEN	THERE has been no documented increase in childhood leukaemia following the Chernobyl accident. However, different forms of childhood leukaemia may not be equally susceptible to radiation carcinogenesis. Infant leukaemia is a distinct form associated with a specific genetic abnormality. Outside the former Soviet Union, contamination resulting from the Chernobyl accident has been highest in Greece and Austria and high also in the Scandinavian countries(1-4). All childhood leukaemia cases diagnosed throughout Greece since 1 January 1980 have been recorded. Here we report that infants exposed in utero to ionizing radiation from the Chernobyl accident had 2.6 limes the incidence of leukaemia compared to unexposed children (95% confidence interval, 1.4 to 5.1; P approximate to 0.003), and those born to mothers residing in regions with high radioactive fallout were at higher risk of developing infant leukaemia. No significant difference in leukaemia incidence was found among children aged 12 to 47 months. Preconceptional irradiation had no demonstrable effect on leukaemia risk at any of the studied age groups.	HARVARD UNIV,CTR CANC PREVENT,BOSTON,MA 02115; AGIA SOPHIA CHILDRENS HOSP,DEPT PAEDIAT HAEMATOL ONCOL,ATHENS 11527,GREECE; UNIV ATHENS,SCH MED,DEPT HYG & EPIDEMIOL,ATHENS 11527,GREECE; UNIV HOSP,DEPT PAEDIAT HAEMATOL ONCOL,IRAKLION 71500,GREECE; HIPPOKRATEION HOSP,DEPT PAEDIAT HAEMATOL ONCOL,THESSALONIKI 54642,GREECE; AGLAIA KYRIAKOU CHILDRENS HOSP,DEPT PAEDIAT HAEMATOL ONCOL,ATHENS 11527,GREECE; AHEPA HOSP,DEPT PAEDIAT HAEMATOL ONCOL,THESSALONIKI 54636,GREECE; UNIV ATHENS,AGIA SOPHIA CHILDRENS HOSP,DEPT PAEDIAT 1,ONCOL UNIT,ATHENS 11527,GREECE	Harvard University; The Aghia Sophia Children's Hospital; Athens Medical School; National & Kapodistrian University of Athens; University of Patras; Aristotle University of Thessaloniki; Ahepa University Hospital; National & Kapodistrian University of Athens; The Aghia Sophia Children's Hospital				PETRIDOU, ELENI/0000-0003-3695-3439				ABELIN T, 1994, SOZ PRAVENTIV MED, V39, P189, DOI 10.1007/BF01309218; AUVINEN A, 1994, BRIT MED J, V309, P151, DOI 10.1136/bmj.309.6948.151; BITHELL JF, 1975, BRIT J CANCER, V31, P271, DOI 10.1038/bjc.1975.62; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; CIMINO G, 1993, BLOOD, V82, P544; CLEARY ML, 1993, NEW ENGL J MED, V329, P958, DOI 10.1056/NEJM199309233291311; CORTES JE, 1995, CANCER-AM CANCER SOC, V76, P2393, DOI 10.1002/1097-0142(19951215)76:12<2393::AID-CNCR2820761203>3.0.CO;2-P; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; ERICSON A, 1994, ENVIRON RES, V67, P149, DOI 10.1006/enrs.1994.1070; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HJALMARS U, 1994, BRIT MED J, V309, P154, DOI 10.1136/bmj.309.6948.154; HOSHIMOTO Y, 1988, 488 RERF; *IAEA, 1992, INT CHERN PROJ TECHN; KUCHUK AA, 1994, TOXICOL LETT, V72, P213, DOI 10.1016/0378-4274(94)90031-0; MACMAHON B, 1964, NEW ENGL J MED, V270, P1082, DOI 10.1056/NEJM196405212702102; MACMAHON B, 1992, CANCER CAUSE CONTROL, V3, P283; MOLE RH, 1990, BRIT J CANCER, V62, P152, DOI 10.1038/bjc.1990.249; Monson R.R., 1984, RAD CARCINOGENESIS E, P97; PAPASTEFANOU C, 1988, J ENVIRON RADIOACTIV, V7, P49, DOI 10.1016/0265-931X(88)90041-0; PARKIN DM, 1992, EURO J CANC, V29, pA87; PETRIDOU E, 1994, SCAND J SOC MED, V22, P127, DOI 10.1177/140349489402200208; PETRIDOU E, IN PRESS BR J CANC; PUI CH, 1995, LEUKEMIA, V9, P762; ROSS JA, 1994, EPIDEMIOL REV, V16, P243, DOI 10.1093/oxfordjournals.epirev.a036153; ROTHMAN KJ, 1979, PUBLICATION NIH; *US NAT AC SCI COM, 1990, BEIR5 US NAS COMM BI; VANCHIERI C, 1992, J NATL CANCER I, V84, P1616, DOI 10.1093/jnci/84.21.1616	28	95	97	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					352	353		10.1038/382352a0	http://dx.doi.org/10.1038/382352a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684463				2022-12-24	WOS:A1996UY95000051
J	Helander, TS; Carpen, O; Turunen, O; Kovanen, PE; Vaheri, A; Timonen, T				Helander, TS; Carpen, O; Turunen, O; Kovanen, PE; Vaheri, A; Timonen, T			ICAM-2 redistributed by ezrin as a target for killer cells	NATURE			English	Article							MEMBRANE-CYTOSKELETAL LINKER; ERM FAMILY MEMBERS; PLASMA-MEMBRANE; MOLECULE; ADHESION; RECOGNITION; LYMPHOCYTES; MICROVILLI; PROTEIN; CYTOVILLIN	VERY little is known about the receptors and target molecules involved in natural killer (NK) cell activity. Here we present a model system in which interleukin-2-activated killing by NK cells depends on the intercellular adhesion molecule ICAM-2 and is regulated by the distribution of ICAM-2. The level of ICAM-2 expression in NK-sensitive and resistant cells is similar, but in sensitive cells ICAM-2 is concentrated into bud-like cellular projections known as uropods, whereas in resistant cells it is evenly distributed. The cytoskeletal-membrane linker protein ezrin is also localized in uropods. Transfection of human ezrin into NK-resistant cells induces uropod formation, redistribution of ICAM-2 and ezrin, and sensitizes target cells to interleukin-2-activated killing. These results reveal a new mechanism of target-cell recognition: cytotoxic cells recognize adhesion molecules that are already present on normal cells, but in diseased cells are concentrated into a biologically active cell-surface region by cytoskeletal reorganization. The results also highlight the importance of cytoskeletal interactions in the regulation of ICAM-2-mediated adhesive phenomena.	UNIV HELSINKI,DEPT VIROL,HAARTMANN INST,FIN-00014 HELSINKI,FINLAND	University of Helsinki	Helander, TS (corresponding author), UNIV HELSINKI,DEPT PATHOL,HAARTMANN INST,HAARTMANINKATU 3,POB 21,FIN-00014 HELSINKI,FINLAND.		Vaheri, Antti/AAV-1523-2020; Turunen, Ossi/HHN-4776-2022					ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ANDREOLI C, 1994, J CELL SCI, V107, P2509; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; CHAMBERS WH, 1995, CHEM BIOL, V2, P429, DOI 10.1016/1074-5521(95)90258-9; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; DOUGHERTY GJ, 1988, EUR J IMMUNOL, V18, P35, DOI 10.1002/eji.1830180107; DUSTIN ML, 1992, J IMMUNOL, V148, P2654; FREY JL, 1991, J EXP MED, V174, P1527, DOI 10.1084/jem.174.6.1527; GARNIWAGNER BA, 1993, J IMMUNOL, V151, P60; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GIARDINA SL, 1995, J IMMUNOL, V154, P80; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HELANDER T, 1991, J IMMUNOL, V147, P2063; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KARRE K, 1995, SCIENCE, V267, P978, DOI 10.1126/science.7863341; MALNATI MS, 1995, SCIENCE, V267, P1016, DOI 10.1126/science.7863326; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; PAKKANEN R, 1988, EUR J CELL BIOL, V46, P435; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TRINCHIERI G, 1994, J EXP MED, V180, P417, DOI 10.1084/jem.180.2.417; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; VALIANTE NM, 1993, J EXP MED, V178, P1397, DOI 10.1084/jem.178.4.1397; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	29	206	215	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					265	268		10.1038/382265a0	http://dx.doi.org/10.1038/382265a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717043				2022-12-24	WOS:A1996UX79000053
J	Vasan, S; Zhang, X; Zhang, XN; Kapurniotu, A; Bernhagen, J; Teichberg, S; Basgen, J; Wagle, D; Shih, D; Terlecky, I; Bucala, R; Cerami, A; Egan, J; Ulrich, P				Vasan, S; Zhang, X; Zhang, XN; Kapurniotu, A; Bernhagen, J; Teichberg, S; Basgen, J; Wagle, D; Shih, D; Terlecky, I; Bucala, R; Cerami, A; Egan, J; Ulrich, P			An agent cleaving glucose-derived protein crosslinks in vitro and in vivo	NATURE			English	Article							GLYCOSYLATION END-PRODUCTS; DIABETES-MELLITUS; ALZHEIMER-DISEASE; MAILLARD REACTION; GLYCATION; COLLAGEN; COMPLICATIONS; AMYLOIDOSIS; MECHANISM; RATS	GLUCOSE and other reducing sugars react with proteins by a nonenzymatic, post-translational modification process called nonenzymatic glycosylation or glycation. The sugar-derived carbonyl group adds to a free amine, forming a reversible adduct which over time rearranges to produce a class of products termed advanced-glycation end-products (AGEs). These remain irreversibly bound to macromolecules and can covalently crosslink proximate amino groups(1,2). The formation of AGEs on long-lived connective tissue and matrix components accounts largely for the increase in collagen crosslinking that accompanies normal ageing and which occurs at an accelerated rate in diabetes(3,4) AGEs can activate cellular receptors and initiate a variety of pathophysiological responses(5-9). They modify an appreciable fraction of circulating low-density lipoproteins preventing uptake of these particles by their high-affinity tissue receptors(10,11) Advanced glycation has also been implicated in the pathology of Alzheimer's disease(12,13). Because AGEs may form by a pathway involving reactive alpha-dicarbonyl intermediates(1,2,14), we investigated a potential pharmacological strategy for selectively cleaving the resultant glucose-derived protein crosslinks, We now describe a prototypic AGE crosslink 'breaker', N-phenacylthiazolium bromide (PTB), which reacts with and cleaves covalent, AGE-derived protein crosslinks. The ability of PTB to break AGE crosslinks in vivo points to the importance of an alpha-dicarbonyl intermediate in the advanced glycation pathway and offers a potential therapeutic approach for the removal of established AGE crosslinks.	PICOWER INST MED RES, MANHASSET, NY 11030 USA; ALTEON INC, RAMSEY, NJ 07446 USA; N SHORE UNIV HOSP, MANHASSET, NY 11030 USA; UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA	Northwell Health; Northwell Health; North Shore University Hospital; University of Minnesota System; University of Minnesota Twin Cities								BOCHANTIN J, 1981, EXP GERONTOL, V16, P101, DOI 10.1016/0531-5565(81)90013-9; Bucala R, 1992, Adv Pharmacol, V23, P1; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; CHEN HJC, 1993, J CARBOHYD CHEM, V12, P731; COTRAN RS, 1994, ROBBINS PATHOLOGIC B, P231; DANZE PM, 1987, CLIN CHIM ACTA, V166, P143, DOI 10.1016/0009-8981(87)90416-5; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; EBLE AS, 1983, J BIOL CHEM, V258, P9406; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; ESTENDORFER S, 1990, ANGEW CHEM INT EDIT, V29, P536, DOI 10.1002/anie.199005361; ITAKURA M, 1991, LIFE SCI, V49, P889, DOI 10.1016/0024-3205(91)90174-A; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MAKITA Z, 1992, SCIENCE, V258, P651, DOI 10.1126/science.1411574; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; Njoroge F G, 1989, Prog Clin Biol Res, V304, P85; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; UKAI OK, 1943, YAKUGAKU ZASSHI, V63, P296; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; VLASSARA H, 1995, MOL MED, V1, P447, DOI 10.1007/BF03401582; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; VOVK AI, 1985, UKR KHIM ZH+, V51, P521	27	393	432	2	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 18	1996	382	6588					275	278		10.1038/382275a0	http://dx.doi.org/10.1038/382275a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717046				2022-12-24	WOS:A1996UX79000056
J	Payne, K; Taylor, RM; Stocking, C; Sachs, GA				Payne, K; Taylor, RM; Stocking, C; Sachs, GA			Physicians' attitudes about the care of patients in the persistent vegetative state: A national survey	ANNALS OF INTERNAL MEDICINE			English	Article						knowledge, attitudes, practice; persistent vegetative state; ethics, medical; attitude toward death; life support care	COMA	Objective: To study the attitudes and beliefs of physicians who have experience caring for patients in the persistent vegetative state (PVS). Design: Mailed questionnaire survey. Participants: 500 physicians, 250 from the American Academy of Neurology and 250 from the American Medical Directors Association. Measurements: Physicians' beliefs about diagnosis of the PVS, patient awareness and suffering, treatment withdrawal, appropriate use of health maintenance and life-prolonging therapies, organ donation, lethal injection, and the treatment they would want if they were in the PVS. Results: 68% of surveyed neurologists and 60% of medical directors responded. Thirteen percent of responders believe that patients in the PVS have awareness and experience hunger and thirst; 30% believe they experience pain. Fewer than 9% believe that respiratory failure, cardiogenic shock, acute renal failure, or cancer should be aggressively treated. Eighty-nine percent believe that it is ethical to withdraw artificial hydration and nutrition. Almost two thirds of responders believe that it would be ethical to use the vital organs of patients in the PVS for transplantation, and 20% believe that it would be ethical to hasten the patient's death by lethal injection. Conclusions: When evaluating the appropriateness of treatments for patients in the PVS, neurologists and medical directors largely concur. Most physicians in both groups believe that patients in the PVS would be better off dead; that it is not necessary to provide aggressive therapeutic interventions; and that all therapeutic interventions, including artificial nutrition and hydration, can be withheld in certain circumstances. The areas of consensus are remarkable and suggest that-an ethical standard that physicians believe should be followed when caring for these patients may be emerging.	UNIV CHICAGO, MED CTR, DEPT MED, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago Medical Center			Taylor, Robert/E-4181-2011		NIA NIH HHS [AG0048] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1989, NEUROLOGY, V39, P125; [Anonymous], 1993, ANN NEUROL, V33, P386; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bernat J L, 1992, J Clin Ethics, V3, P21; BOYD K, 1991, LANCET, V337, P96; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; GALLUP G, 1991, GALLUP POLL NEWS SER, V55, P1; GERVAIS KG, 1985, REDEFINING DEATH; JENNETT B, 1972, LANCET, V1, P734; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNOX RA, 1991, BOSTON SUNDAY G 1103; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; Plows CW, 1996, JAMA-J AM MED ASSOC, V275, P443, DOI 10.1001/jama.275.6.443; TRESCH DD, 1991, J AM GERIATR SOC, V39, P17, DOI 10.1111/j.1532-5415.1991.tb05900.x; Veatch R M, 1992, J Clin Ethics, V3, P181; 1996, NEUROLOGY, V45, P1015; 1990, JAMA-J AM MED ASSOC, V263, P426	19	83	85	2	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					104	+		10.7326/0003-4819-125-2-199607150-00004	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UV921	8678363				2022-12-24	WOS:A1996UV92100007
J	Frangiskakis, JM; Ewart, AK; Morris, CA; Mervis, CB; Bertrand, J; Robinson, BF; Klein, BP; Ensing, GJ; Everett, LA; Green, ED; Proschel, C; Gutowski, NJ; Noble, M; Atkinson, DL; Odelberg, SJ; Keating, MT				Frangiskakis, JM; Ewart, AK; Morris, CA; Mervis, CB; Bertrand, J; Robinson, BF; Klein, BP; Ensing, GJ; Everett, LA; Green, ED; Proschel, C; Gutowski, NJ; Noble, M; Atkinson, DL; Odelberg, SJ; Keating, MT			LIM-kinase1 hemizygosity implicated in impaired visuospatial constructive cognition	CELL			English	Article							SUPRAVALVULAR AORTIC-STENOSIS; LONG-TERM POTENTIATION; GAMMA-MUTANT MICE; ELASTIN GENE; WILLIAMS-SYNDROME; PROTEIN; TRANSLOCATION; CHROMOSOME-7; HOMEODOMAIN; SEQUENCES	To identify genes important for human cognitive development, we studied Williams syndrome (WS), a developmental disorder that includes poor visuospatial constructive cognition. Here we describe two families with a partial WS phenotype; affected members have the specific WS cognitive profile and vascular disease, but lack other WS features. Submicroscopic chromosome 7q11.23 deletions cosegregate with this phenotype in both families. DNA sequence analyses of the region affected by the smallest deletion (83.6 kb) revealed two genes, elastin (ELN) and LIM-kinase-1 (LIMK1). The latter encodes a novel protein kinase with LIM domains and is strongly expressed in the brain. Because ELN mutations cause vascular disease but not cognitive abnormalities, these data implicate LIMK1 hemizygosity in impaired visuospatial constructive cognition.	UNIV UTAH, HLTH SCI CTR, ECCLES INST HUMAN GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, DIV CARDIOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, HUNTSMAN CANC INST, DEPT ONCOL SCI, SALT LAKE CITY, UT 84112 USA; UNIV NEVADA, SCH MED, DEPT PEDIAT, LAS VEGAS, NV 89102 USA; UNIV NEVADA, SCH MED, DEPT PATHOL, LAS VEGAS, NV 89102 USA; EMORY UNIV, DEPT PSYCHOL, ATLANTA, GA 30322 USA; INDIANA UNIV, SCH MED, DEPT PEDIAT, DIV PEDIAT CARDIOL, INDIANAPOLIS, IN 46202 USA; NATL INST HLTH, NATL CTR HUMAN GENOME RES, BETHESDA, MD 20892 USA; UNIV LONDON, INST NEUROL, DEPT CLIN NEUROL, LONDON WC1N 3BG, ENGLAND	Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Emory University; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of London; University College London	Frangiskakis, JM (corresponding author), UNIV UTAH, HLTH SCI CTR, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA.		Robinson, Byron/G-6144-2012; Toland, Amanda Ewart/E-4202-2011	Robinson, Byron/0000-0003-2618-5771; 	NHLBI NIH HHS [R01 HL4807] Funding Source: Medline; NICHD NIH HHS [R01 HD029957, R01 HD29957] Funding Source: Medline; NINDS NIH HHS [R01 NS035102, R01 NS35102] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035102] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bayley N., 1993, BAYLEY SCALES INFANT; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; Beery K. E, 1989, DEV TEST VISUAL MOTO, V3rd; Bellugi U., 1994, ATYPICAL COGNITIVE D, P23; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BUDARF ML, 1995, NAT GENET, V10, P269, DOI 10.1038/ng0795-269; Capruso D. X., 1995, CLIN NEUROPSYCHOL, P137; CHENG AK, 1995, MECH DEVELOP, V52, P187, DOI 10.1016/0925-4773(95)00400-U; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DEAR S, 1992, DNA SEQUENCE, V3, P99; DILTS CV, 1990, AM J MED GENET, P126; Elliott C. D., 1990, DIFFERENTIAL ABILITY; ENSING GJ, 1989, J AM COLL CARDIOL, V13, P413, DOI 10.1016/0735-1097(89)90520-2; EWART AK, 1994, J CLIN INVEST, V93, P1071, DOI 10.1172/JCI117057; EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11; EWART AK, 1993, P NATL ACAD SCI USA, V90, P3226, DOI 10.1073/pnas.90.8.3226; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOSTER K, 1993, ANN HUM GENET, V57, P87, DOI 10.1111/j.1469-1809.1993.tb00890.x; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GILBERTDUSSARDIER B, 1995, AM J HUM GENET, V56, P542; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HWU HR, 1986, P NATL ACAD SCI USA, V83, P3875, DOI 10.1073/pnas.83.11.3875; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LOWERY MC, 1995, AM J HUM GENET, V57, P49; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARDIS ER, 1994, NUCLEIC ACIDS RES, V22, P2173, DOI 10.1093/nar/22.11.2173; MERVIS CB, 1996, IN PRESS NEURODEVELO; MERVIS CB, 1996, RES COMMUNICATION LA; MIZUNO K, 1994, ONCOGENE, V9, P1605; MORRIS CA, 1993, AM J MED GENET, V46, P737, DOI 10.1002/ajmg.1320460634; MORRIS CA, 1988, J PEDIATR-US, V113, P318, DOI 10.1016/S0022-3476(88)80272-5; NUNOUE K, 1995, ONCOGENE, V11, P701; OLSON TM, 1995, HUM MOL GENET, V4, P1677, DOI 10.1093/hmg/4.9.1677; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; PREUS M, 1984, CLIN GENET, V25, P422, DOI 10.1111/j.1399-0004.1984.tb02011.x; PROSCHEL C, 1995, ONCOGENE, V11, P1271; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SLIGHTOM JL, 1994, GENOMICS, V20, P149, DOI 10.1006/geno.1994.1149; UDWIN O, 1987, J CHILD PSYCHOL PSYC, V28, P297, DOI 10.1111/j.1469-7610.1987.tb00212.x; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Wechsler D., 1997, WAIS 3 WECHSLER ADUL, V3rd, DOI 10.1111/j.1749-6632.1989.tb21005.x; WILKINSON DG, 1992, IN SITU HYBRIDISATIO; Xu Y, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P376	50	411	425	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					59	69		10.1016/S0092-8674(00)80077-X	http://dx.doi.org/10.1016/S0092-8674(00)80077-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689688	Bronze			2022-12-24	WOS:A1996UX93400008
J	Porcher, C; Swat, W; Rockwell, K; Fujiwara, Y; Alt, FW; Orkin, SH				Porcher, C; Swat, W; Rockwell, K; Fujiwara, Y; Alt, FW; Orkin, SH			The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages	CELL			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING MOTIF; SCL GENE-PRODUCT; CHROMOSOMAL TRANSLOCATION; FUSION TRANSCRIPT; ERYTHROID-DIFFERENTIATION; DROSOPHILA-TRITHORAX; ENHANCER-BINDING; GATA-BINDING; ES CELLS	The T cell leukemia oncoprotein SCL/tal-1, a basic-helix-loop-helix transcription factor, is required for production of embryonic red blood cells in the mouse yolk sac. To define roles in other lineages, we studied the hematopoietic potential of homozygous mutant SCL/tal-1 -/- embryonic stem cells upon in vitro differentiation and in vivo in chimeric mice. Here we show that in the absence of SCL/tal-1, hematopoiesis, including the generation of red cells, myeloid cells, megakaryocytes, mast cells, and both T and B lymphoid cells, is undetectable. These findings suggest that SCL/tal-1 functions very early in hematopoietic development, either in specification of ventral mesoderm to a blood cell fate, or in formation or maintenance of immature progenitors.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL & ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute			Porcher, Catherine/D-7026-2016					APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERGER CN, 1995, DEV BIOL, V170, P651, DOI 10.1006/dbio.1995.1244; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ERICKSON P, 1992, BLOOD, V80, P1825; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAWLEY RG, 1994, GENE THER, V1, P136; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; Hoang T, 1996, BLOOD, V87, P102; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HWANG LY, 1993, ONCOGENE, V8, P3043; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KELLER G, 1993, MOL CELL BIOL, V13, P472; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOUTHON MA, 1993, BLOOD, V81, P647; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; PEAR WS, 1996, IN PRESS METHODS MOL; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROBB L, 1995, ONCOGENE, V10, P205; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VISVADER J, 1991, ONCOGENE, V6, P187; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723; WILES MV, 1991, DEVELOPMENT, V111, P259; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	69	583	589	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					47	57		10.1016/S0092-8674(00)80076-8	http://dx.doi.org/10.1016/S0092-8674(00)80076-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689686	Bronze			2022-12-24	WOS:A1996UX93400007
J	Porter, JA; Ekker, SC; Park, WJ; vonKessler, DP; Young, KE; Chen, CH; Ma, Y; Woods, AS; Cotter, RJ; Koonin, EV; Beachy, PA				Porter, JA; Ekker, SC; Park, WJ; vonKessler, DP; Young, KE; Chen, CH; Ma, Y; Woods, AS; Cotter, RJ; Koonin, EV; Beachy, PA			Hedgehog patterning activity: Role of a lipophilic modification mediated by the carboxy-terminal autoprocessing domain	CELL			English	Article							MEMBRANE-PROTEINS; DROSOPHILA-EMBRYO	Autocatalytic processing mediated by the carboxyterminal domain of the hedgehog (hh) protein precursor (Hh) generates an amino-terminal product that accounts for all known signaling activity. The role of autoprocessing in biogenesis of the hh signal has been unclear, since a truncated unprocessed protein lacking all carboxy-terminal domain sequences retains signaling activity. Here, we present evidence that the autoprocessing reaction proceeds via an internal thioester intermediate and results in a covalent modification that increases the hydrophobic character of the signaling domain and influences its spatial and subcellular distribution. We demonstrate that truncated unprocessed amino-terminal protein causes embryonic mispatterning, even when expression is localized to cells that normally express Hh, thus suggesting a role for autoprocessing in spatial regulation of hh signaling. This type of processing also appears to operate in the biogenesis of other novel secreted proteins.	JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; NATL INST HLTH, NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20894 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Porter, JA (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA.			Ekker, Stephen/0000-0003-0726-4212				Alberts B., 1994, MOL BIOL CELL; BLACKLEDGE JA, 1995, ANAL CHEM, V67, P843, DOI 10.1021/ac00101a009; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHEVRIER MR, 1991, RAPID COMMUN MASS SP, V5, P611, DOI 10.1002/rcm.1290051209; CHU CT, 1994, LAB INVEST, V71, P792; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FIETZ MJ, 1995, CURR BIOL, V5, P643, DOI 10.1016/S0960-9822(95)00129-1; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HEUKESHOVEN J, 1985, J CHROMATOGR, V326, P91, DOI 10.1016/S0021-9673(01)87434-3; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; KOONIN EV, 1995, TRENDS BIOCHEM SCI, V20, P141, DOI 10.1016/S0968-0004(00)88989-6; Koonin EV, 1996, METHOD ENZYMOL, V266, P295; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEVINE RP, 1990, CURR TOP MICROBIOL, V153, P73; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Moore DD, 1995, GLOB MOB SURV; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROSE IA, 1983, BIOCHEMISTRY-US, V22, P4234, DOI 10.1021/bi00287a012; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	37	420	446	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					21	34		10.1016/S0092-8674(00)80074-4	http://dx.doi.org/10.1016/S0092-8674(00)80074-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689684	hybrid			2022-12-24	WOS:A1996UX93400005
J	Grubb, A; Walsh, P; Lambe, N; Murrells, T; Robinson, S				Grubb, A; Walsh, P; Lambe, N; Murrells, T; Robinson, S			Survey of British clinicians' views on management of patients in persistent vegetative state	LANCET			English	Article								Background The best care and management of patients in persistent vegetative slate (PVS) has been the subject of sustained moral and legal debate for a number of years. However, the views of clinicians in the UK involved in caring for patients in PVS are largely unknown. Methods A postal questionnaire was sent to 1882 consultant members of the British Association of Orthopaedic Surgeons, the Association of British Neurologists, the Society of British Neurosurgeons, and the British Society of Rehabilitation Medicine. Their views were sought on various aspects of the management and care of PVS, in particular the appropriateness of a decision not to treat and a decision to withdraw artificial nutrition and hydration (ANH). Findings 1027 doctors responded (55%) of whom 558 (54%) had experience of managing patients in PVS. Over 90% of responding doctors considered that it could be not to treat acute infections and other life-threatning conditions. 65% of doctors considered that withdrawal of ANH could be apporpriate. About two-thirds of doctors who thought treatment-limiting decisions could be appropriate thought that such decisions could be considered with the first 12 months of the patient being in PVS. Despite recent case law, less than half the doctors responding to the survey thought that an advance directive made by the patient should have a decisive influence in determining treatment-limiting decisions. Most doctors would like decisions about withdrawing ANH to be made in conjunction with family members and in accordance with agreed guidelines but without the need to go to court. Interpretation There is a broad consensus among doctors that treatment-limiting decisions are sometimes appropriate for patients in PVS, irrespective of whether they have experience of the condition or of the specialty to which they belong. However, two thirds of doctors said that such decisions can be considered al a time earlier than that recommended by the British Medical Association. It is not clear why some doctors thought a decision not to treat could be appropriate while a decision to withdraw ANH would not be.	UNIV LONDON KINGS COLL,NURSING RES UNIT,LONDON WC2R 2LS,ENGLAND	University of London; King's College London	Grubb, A (corresponding author), UNIV LONDON KINGS COLL,CTR MED LAW & ETH,LONDON WC2R 2LS,ENGLAND.							ANDREWS K, 1992, BRIT MED J, V305, P486, DOI 10.1136/bmj.305.6852.486; ANDREWS K, 1993, BRIT MED J, V306, P1602; [Anonymous], 1989, NEUROLOGY, V39, P125; ASHWAL S, 1992, ANN NEUROL, V32, P570, DOI 10.1002/ana.410320414; *BRIT MED ASS, 1995, ADV STAT MED TREATM; CANTOR NL, 1989, AM J LAW MED, V15, P381; Cartwright A, 1983, HLTH SURVEYS PRACTIC; CELESIA GG, 1993, ANN NEUROL, V33, P391, DOI 10.1002/ana.410330410; Dworkin R., 1993, LIFES DOMINION; *GEZ, 1994, PUBL GEZ; GIACINO GT, 1995, J HEAD TRAUMA REHABI, V10, P40; HODGES MO, 1994, ARCH INTERN MED, V154, P1013, DOI 10.1001/archinte.154.9.1013; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1992, BRIT MED J, V305, P1305, DOI 10.1136/bmj.305.6865.1305; KENNEDY I, 1993, MED LAW REV, V1, P359; Kennedy I, 1991, TREAT ME RIGHT ESSAY; KENNEDY I, 1994, MED LAW; *LAW COMM ENGL WAL, 1995, 231 LAW COMM ENGL WA; RACHELS J., 1986, END LIFE EUTHANASIA; *SCOTT LAW COMM, 1995, 151 SCOTT LAW COMM; 1994, NEW ENGL J MED, V330, P1499; 1996, J R COLL PHYSNS, V30, P119; [No title captured]; [No title captured]; 1994, NEW ENGL J MED, V330, P1572	25	49	51	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					35	40		10.1016/S0140-6736(96)02030-2	http://dx.doi.org/10.1016/S0140-6736(96)02030-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691931				2022-12-24	WOS:A1996UV92300015
J	Taback, SP; Collu, R; Deal, CL; Guyda, HJ; Salisbury, S; Dean, HJ; VanVliet, G				Taback, SP; Collu, R; Deal, CL; Guyda, HJ; Salisbury, S; Dean, HJ; VanVliet, G			Does growth-hormone supplementation affect adult height in Turner's syndrome?	LANCET			English	Article								Background By comparison with historical controls, the effect of treatment with growth hormone on adult height in Turner's syndrome was initially reported as uniformly and strongly positive. Because randomised controlled trials are not near completion, we report our experiences in an open study. Methods We examined adult height, projected attained, in 31 patients (17 treated with subcutaneous recombinant human growth hormone, up to 15 mg a week, outside of a controlled trial and 14 untreated contemporaries). Findings Contingency table analysis of attained versus projected height showed significantly higher values in treated patients although only 4 of 17 had final heights of 5 cm or more over projection, Patients' and treatment variables (height, bone-age delay, oestrogen replacement) that interfere with adult height projection confounded the analysis of adult height data. Interpretation Girls with Turner's syndrome should be counselled cautiously about the expectation of a strongly positive effect of treatment on adult height. Completion of the randomised controlled trials to adult height is needed to establish the effect of growth-hormone supplementation on adult height in Turner's syndrome and the psychological effect of treatment.	HOP ST JUSTINE, MONTREAL, PQ H3T 1C5, CANADA; MONTREAL CHILDRENS HOSP, SERV ENDOCRINOL, MONTREAL, PQ H3H 1P3, CANADA; IZAAK WALTON KILLAM HOSP CHILDREN, HALIFAX, NS B3J 3G9, CANADA; WINNIPEG CHILDRENS HOSP, WINNIPEG, MB, CANADA	Universite de Montreal; McGill University; Dalhousie University; University of Manitoba; Children's Hospital Research Institute of Manitoba								CHU CE, 1995, HORM RES S1, V44, pA73; CIANFARANI S, 1994, LANCET, V344, P114, DOI 10.1016/S0140-6736(94)91288-2; Greulich WW, 1959, RADIOGRAPHIC ATLAS S; LYON AJ, 1985, ARCH DIS CHILD, V60, P932, DOI 10.1136/adc.60.10.932; RANKE MB, 1983, EUR J PEDIATR, V141, P81, DOI 10.1007/BF00496795; ROSENFELD RG, 1995, P 8 ANN INV M NAT CO, P16; Ross JL, 1996, J CLIN ENDOCR METAB, V81, P926, DOI 10.1210/jc.81.3.926; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; Taback SP, 1995, INT CONGR SER, V1089, P183; Tanner J., 1994, DIAGNOSIS TREATMENT, V4th ed., P154; VANDENBROECK, 1995, J PEDIATR, V127, P729	12	53	54	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	1996	348	9019					25	27		10.1016/S0140-6736(96)01267-6	http://dx.doi.org/10.1016/S0140-6736(96)01267-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691926				2022-12-24	WOS:A1996UV92300011
J	Ng, M; DiazBenjumea, FJ; Vincent, JP; Wu, J; Cohen, SM				Ng, M; DiazBenjumea, FJ; Vincent, JP; Wu, J; Cohen, SM			Specification of the wine by localized expression of wingless protein	NATURE			English	Article							HALTERE DEVELOPMENT; DROSOPHILA EMBRYO; DISC; MUTATION; SYSTEM; CELLS; GENES	LIMB development in Drosophila depends on subdivision of the limb primordia into functional units called compartments(1-4). Cell interactions across compartment boundaries establish pattern-organizing centres that control growth and specify cell fates along the anteroposterior (AP) and dorsoventral (DV) axes of the limbs(2,3,5-9). AP sub,division of the disc primordia is inherited from the embryonic ectoderm(10). DV subdivision of the wine; disc occurs during the second larval instar through localized expression of the apterous protein (Apterous) in dorsal cells(2,11). A third major subdivision of the wing disc into wing and body-wall compartments also occurs in the second instar(1). Here we show that specification of the wing primordium in early second instar depends on activity of the AP patterning system but not the DV system. These results define two distinct roles for the wingless gene: a primary role in specifying the wing primordium. and a subsequent role mediating the patterning activities of the DV compartment boundary(9,12,13).	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY; MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	European Molecular Biology Laboratory (EMBL); MRC Laboratory Molecular Biology; Baylor College of Medicine			Cohen, Stephen M/G-9930-2011; Diaz-Benjumea, Fernando/K-7667-2014	Cohen, Stephen M/0000-0003-2858-9163; Diaz-Benjumea, Fernando/0000-0003-3007-2489				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Lawrence PA, 1995, DEVELOPMENT, V121, P4303; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NG M, 1995, DEVELOPMENT, V121, P589; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; ZECCA M, 1995, DEVELOPMENT, V121, P2265	25	177	179	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					316	318		10.1038/381316a0	http://dx.doi.org/10.1038/381316a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692268				2022-12-24	WOS:A1996UM40300054
J	Yang, J; Zimmerly, S; Perlman, PS; Lambowitz, AM				Yang, J; Zimmerly, S; Perlman, PS; Lambowitz, AM			Efficient integration of an intron RNA into double-stranded DNA by reverse splicing	NATURE			English	Article							YEAST MITOCHONDRIA; INVITRO; RIBOZYME	SOME group introns are mobile elements as well as catalytic RNAs(1,2). Introns aI1 and aI2 found in the gene COX1 in yeast mitochondria encode reverse transcriptases which promote site-specific insertion of the intron into intronless alleles ('housing')(3-6). For aI2 this predominantly occurs by reverse transcription of unspliced precursor RNA st a break in double. strand DNA made by an endonuclease encoded by the intron(7). The aI2 endonuclease involves both the excised intron RNA, which cleaves the DNA's sense strand by partial reverse splicing; and the intron-encoded reverse transcriptase which cleaves the antisense strand(8). Here we show that aI1 encodes an analogous endonuclease specific for a different target site compatible with the different exon-binding sequences of the intron RNA. Over half of aI1 undergoes complete reverse splicing in vitro, thus integrating linear intron RNA directly into the DNA. This unprecedented reaction has implications for both intron mobility and evolution, and potential genetic engineering applications.	OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT BIOCHEM MED,COLUMBUS,OH 43210; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								HEBBAR SK, 1992, NUCLEIC ACIDS RES, V20, P1747, DOI 10.1093/nar/20.7.1747; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; Meunier B, 1990, STRUCTURE FUNCTION B, P169; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; MORL M, 1990, NUCLEIC ACIDS RES, V18, P6545, DOI 10.1093/nar/18.22.6545; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	17	133	148	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					332	335		10.1038/381332a0	http://dx.doi.org/10.1038/381332a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692273				2022-12-24	WOS:A1996UM40300059
J	Croft, P; Pope, D; Silman, A				Croft, P; Pope, D; Silman, A			The clinical course of shoulder pain: Prospective cohort study in primary care	BRITISH MEDICAL JOURNAL			English	Article							DISORDERS		UNIV MANCHESTER,ARC,EPIDEMIOL RES UNIT,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester	Croft, P (corresponding author), UNIV KEELE,POSTGRAD MED SCH,IND & COMMUNITY HLTH RES CTR,STOKE ON TRENT ST4 7QB,STAFFS,ENGLAND.		Pope, Daniel P/C-3054-2014	Pope, Daniel/0000-0003-2694-5478				BADLEY EM, 1992, ANN RHEUM DIS, V51, P366, DOI 10.1136/ard.51.3.366; CHARD MD, 1991, ARTHRITIS RHEUM-US, V34, P766, DOI 10.1002/art.1780340619; CROFT P, 1994, ANN RHEUM DIS, V53, P525, DOI 10.1136/ard.53.8.525; HART FD, 1984, PRACTICAL PROBLEMS R; PATRICK DL, 1981, HLTH CARE PHYSICALLY	5	183	185	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					601	602						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806252				2022-12-24	WOS:A1996VG10800021
J	Mulcahy, HE; Croke, DT; Farthing, MJG				Mulcahy, HE; Croke, DT; Farthing, MJG			Cancer and mutant DNA in blood plasma	LANCET			English	Editorial Material									ROYAL COLL SURGEONS IRELAND,DEPT BIOCHEM,DUBLIN 2,IRELAND	Royal College of Surgeons - Ireland	Mulcahy, HE (corresponding author), ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT,DEPT GASTROENTEROL,LONDON EC1M 6BQ,ENGLAND.			mulcahy, hugh/0000-0002-7087-6177; Croke, David/0000-0003-2718-3583				ANKER P, 1975, CANCER RES, V35, P2375; Chen XQ, 1996, NAT MED, V2, P1033; FOURNIE GJ, 1995, CANC LETT, P221; LEON SA, 1977, CANCER RES, V37, P646; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; STROUN M, 1987, EUR J CANCER CLIN ON, V23, P707, DOI 10.1016/0277-5379(87)90266-5; STROUN M, 1989, ONCOLOGY, V46, P318	7	21	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					628	628		10.1016/S0140-6736(05)65067-2	http://dx.doi.org/10.1016/S0140-6736(05)65067-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782747				2022-12-24	WOS:A1996VF60900002
J	Chen, P; Tsuge, H; Almassy, RJ; Gribskov, CL; Katoh, S; Vanderpool, DL; Margosiak, SA; Pinko, C; Matthews, DA; Kan, CC				Chen, P; Tsuge, H; Almassy, RJ; Gribskov, CL; Katoh, S; Vanderpool, DL; Margosiak, SA; Pinko, C; Matthews, DA; Kan, CC			Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad	CELL			English	Article							ASSEMBLY PROTEIN; CLEAVAGE SITES; SUBSTRATE; IDENTIFICATION; PRECURSOR; RELEASE	Proteolytic processing of capsid assembly protein precursors by herpesvirus proteases is essential for virion maturation. A 2.5 Angstrom crystal structure of the human cytomegalovirus protease catalytic domain has been determined by X-ray diffraction. The structure defines a new class of serine protease with respect to global-fold topology and has a catalytic triad consisting of Ser-132, His-63, and His-157 in contrast with the Ser-His-Asp triads found in other serine proteases. However, catalytic machinery for activating the serine nucleophile and stabilizing a tetrahedral transition state is oriented similarly to that for members of the trypsin-like and subtilisin-like serine protease families. Formation of the active dimer is mediated primarily by burying a helix of one protomer into a deep cleft in the protein surface of the other.	JAPAN TOBACCO INC,CENT PHARMACEUT RES INST,TAKATSUKI,OSAKA 569,JAPAN	Japan Tobacco Inc.	Chen, P (corresponding author), AGOURON PHARMACEUT,3565 GEN ATOM COURT,SAN DIEGO,CA 92121, USA.		Tsuge, Hideaki/ABF-6424-2021	Tsuge, Hideaki/0000-0003-0166-9163				Baum EZ, 1996, BIOCHEMISTRY-US, V35, P5838, DOI 10.1021/bi952996+; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; COX GA, 1995, J VIROL, V69, P4524, DOI 10.1128/JVI.69.7.4524-4528.1995; Darke PL, 1996, J BIOL CHEM, V271, P7445, DOI 10.1074/jbc.271.13.7445; DILANNI CL, 1994, J BIOL CHEM, V269, P12672; EFIMOV AV, 1992, FEBS LETT, V298, P261, DOI 10.1016/0014-5793(92)80072-O; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GARAVITO RM, 1977, BIOCHEMISTRY-US, V16, P5065, DOI 10.1021/bi00642a019; GIBSON W, 1990, J VIROL, V64, P1241, DOI 10.1128/JVI.64.3.1241-1249.1990; Gibson W., 1995, PERSPECT DRUG DISCOV, V2, P413; Gold E, 1982, VIRAL INFECT HUMANS, P167; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TR, 1994, J VIROL, V68, P3742, DOI 10.1128/JVI.68.6.3742-3752.1994; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; Margosiak SA, 1996, BIOCHEMISTRY-US, V35, P5300, DOI 10.1021/bi952842u; MATUSICKKUMAR L, 1995, J VIROL, V69, P7113, DOI 10.1128/JVI.69.11.7113-7121.1995; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PINKO C, 1995, J BIOL CHEM, V270, P23634, DOI 10.1074/jbc.270.40.23634; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; VINOD VS, 1994, J BIOL CHEM, V269, P14337; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WELCH AR, 1991, J VIROL, V65, P4091, DOI 10.1128/JVI.65.8.4091-4100.1991; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993	28	149	156	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					835	843		10.1016/S0092-8674(00)80157-9	http://dx.doi.org/10.1016/S0092-8674(00)80157-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797829	Bronze			2022-12-24	WOS:A1996VG37200016
J	Hollfelder, F; Kirby, AJ; Tawfik, DS				Hollfelder, F; Kirby, AJ; Tawfik, DS			Off-the-shelf proteins that rival tailor-made antibodies as catalysts	NATURE			English	Article							GENERAL ACID CATALYSIS; ENOL ETHER HYDROLYSIS; HUMAN-SERUM ALBUMIN; PROTON-TRANSFER; ACETAL HYDROLYSIS; ENZYME; CARBON	MIMICKING the efficiency of enzyme catalysis Is a daunting challenge, An enzyme selectively binds and stabilizes the transition state(s) for a particular reaction(1,2). Artificial host systems can bind ground states just as efficiently(3), and rate enhancements comparable to those in enzymatic reactions can be achieved by bringing catalytic and substrate groups together in intramolecular reactions, But the combination of selective binding and efficient catalysis remains elusive, The best enzyme mimics currently known are catalytic antibodies(5,6), They bind transition-state analogues with high affinity, but their catalytic efficiency generally falls far short of that of enzymes(4,8), Thorn et al.(9) recently described an antibody that catalyses the eliminative ring-opening of a benzisoxazole ''exceptionally efficiently'' using carboxylate as the general base, raising the intriguing possibility that this high efficiency derives from precise positioning of catalytic and substrate groups(10). Here we show that familiar 'off-the-shelf' proteins-serum albumins-catalyse the same reaction at similar rates, using a lysine side-chain amino group as the catalytic general base, Comparisons suggest that formal general base catalysis is of only modest efficiency in both systems, and that the antibody catalysis Is boosted by a non-specific medium effect.	UNIV CAMBRIDGE,CHEM LAB,CAMBRIDGE CB2 1EW,ENGLAND	University of Cambridge				Hollfelder, Florian/0000-0002-1367-6312				BEHR JP, 1994, LOCK KEY PRINCIPLE; BENKOVIC SJ, 1992, ANNU REV BIOCHEM, V61, P29; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CASEY ML, 1973, J ORG CHEM, V38, P2294, DOI 10.1021/jo00953a006; DEMPSEY WB, 1962, J BIOL CHEM, V237, P1113; EISENTHAL R, 1993, ENZYME ASSAYS; Fersht A., 1985, ENZYME STRUCTURE MEC; HO XM, 1992, NATURE, V358, P209; KEMP DS, 1995, NATURE, V373, P196, DOI 10.1038/373196a0; KEMP DS, 1975, J AM CHEM SOC, V97, P7312, DOI 10.1021/ja00858a018; Kirby A.J., 1980, ADV PHYS ORG CHEM, V17, P183; Kirby AJ, 1996, ACTA CHEM SCAND, V50, P203, DOI 10.3891/acta.chem.scand.50-0203; Kirby AJ, 1996, ANGEW CHEM INT EDIT, V35, P707; KIRBY AJ, 1994, J CHEM SOC PERK T 2, P649, DOI 10.1039/p29940000649; KIRBY AJ, 1989, J CHEM SOC PERK T 2, P907, DOI 10.1039/p29890000907; KIRBY AJ, 1994, J CHEM SOC CHEM COMM, P707, DOI 10.1039/c39940000707; KIRBY AJ, 1994, J CHEM SOC PERK T 2, P643, DOI 10.1039/p29940000643; MEANS GE, 1975, BIOCHEMISTRY-US, V14, P4989, DOI 10.1021/bi00693a031; MENGER FM, 1987, J AM CHEM SOC, V109, P3145, DOI 10.1021/ja00244a047; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SERGEEVA MV, IN PRESS ISR J CHEM; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; Tawfik Dan S., 1994, Molecular Biotechnology, V1, P87, DOI 10.1007/BF02821512; TAYLOR RP, 1973, J AM CHEM SOC, V95, P5819, DOI 10.1021/ja00798a093; TAYLOR RP, 1975, J AM CHEM SOC, V97, P1943, DOI 10.1021/ja00840a056; TAYLOR RP, 1975, J AM CHEM SOC, V97, P1934, DOI 10.1021/ja00840a055; THOM SN, 1995, NATURE, V273, P228	29	149	149	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					60	63		10.1038/383060a0	http://dx.doi.org/10.1038/383060a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779715				2022-12-24	WOS:A1996VF29500044
J	Yool, AJ; Stamer, WD; Regan, JW				Yool, AJ; Stamer, WD; Regan, JW			Forskolin stimulation of water and cation permeability in aquaporin1 water channels	SCIENCE			English	Article							XENOPUS OOCYTES; PROTEIN; CHIP; CDNA; CAMP	Aquaporin1, a six-transmembrane domain protein, is a water channel present in many fluid-secreting and -absorbing cells. In Xenopus oocytes injected with aquaporin1 complementary RNA, the application of forskolin or cyclic 8-bromo- adenosine 3',5'-monophosphate increased membrane permeability to water and triggered a cationic conductance. The cationic conductance was also induced by direct injection of protein kinase A (PKA) catalytic subunit, reduced by the kinase inhibitor H7, and blocked by HgCl2, an inhibitor of aquaporin1. The cationic permeability of the aquaporin1 channel is activated by a cyclic adenosine monophosphate-dependent mechanism that may involve direct or indirect phosphorylation by PKA.	UNIV ARIZONA,DEPT PHARMACOL,TUCSON,AZ 85724; UNIV ARIZONA,DEPT PHARMACOL & TOXICOL,TUCSON,AZ 85721; UNIV ARIZONA,DEPT PHYSIOL,PROGRAM NEUROSCI,TUCSON,AZ 85721	University of Arizona; University of Arizona; University of Arizona	Yool, AJ (corresponding author), UNIV ARIZONA,DEPT PHYSIOL,TUCSON,AZ 85724, USA.		Yool, Andrea/AAK-9907-2020	Yool, Andrea/0000-0003-1283-585X	NATIONAL EYE INSTITUTE [R29EY009355] Funding Source: NIH RePORTER; NEI NIH HHS [EY09355] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; CHANG XB, 1993, J BIOL CHEM, V268, P11304; FISCHBARG J, 1989, P NATL ACAD SCI USA, V86, P8397, DOI 10.1073/pnas.86.21.8397; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; MACEY RI, 1984, AM J PHYSIOL, V246, pC195, DOI 10.1152/ajpcell.1984.246.3.C195; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; RICH DP, 1993, J BIOL CHEM, V268, P20259; STAMER WD, 1994, INVEST OPHTH VIS SCI, V35, P3867; Stamer WD, 1995, CURR EYE RES, V14, P1095, DOI 10.3109/02713689508995815; YOOL AJ, UNPUB; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243; ZHANG RB, 1993, J CELL BIOL, V120, P359, DOI 10.1083/jcb.120.2.359	20	143	145	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1216	1218		10.1126/science.273.5279.1216	http://dx.doi.org/10.1126/science.273.5279.1216			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703053				2022-12-24	WOS:A1996VE47600036
J	Bult, CJ; White, O; Olsen, GJ; Zhou, LX; Fleischmann, RD; Sutton, GG; Blake, JA; FitzGerald, LM; Clayton, RA; Gocayne, JD; Kerlavage, AR; Dougherty, BA; Tomb, JF; Adams, MD; Reich, CI; Overbeek, R; Kirkness, EF; Weinstock, KG; Merrick, JM; Glodek, A; Scott, JL; Geoghagen, NSM; Weidman, JF; Fuhrmann, JL; Nguyen, D; Utterback, TR; Kelley, JM; Peterson, JD; Sadow, PW; Hanna, MC; Cotton, MD; Roberts, KM; Hurst, MA; Kaine, BP; Borodovsky, M; Klenk, HP; Fraser, CM; Smith, HO; Woese, CR; Venter, JC				Bult, CJ; White, O; Olsen, GJ; Zhou, LX; Fleischmann, RD; Sutton, GG; Blake, JA; FitzGerald, LM; Clayton, RA; Gocayne, JD; Kerlavage, AR; Dougherty, BA; Tomb, JF; Adams, MD; Reich, CI; Overbeek, R; Kirkness, EF; Weinstock, KG; Merrick, JM; Glodek, A; Scott, JL; Geoghagen, NSM; Weidman, JF; Fuhrmann, JL; Nguyen, D; Utterback, TR; Kelley, JM; Peterson, JD; Sadow, PW; Hanna, MC; Cotton, MD; Roberts, KM; Hurst, MA; Kaine, BP; Borodovsky, M; Klenk, HP; Fraser, CM; Smith, HO; Woese, CR; Venter, JC			Complete genome sequence of the methanogenic archaeon, Methanococcus jannaschii	SCIENCE			English	Article							TRANSFER-RNA SYNTHETASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ADENOSINE-TRIPHOSPHATASE; METHANOTHERMUS-FERVIDUS; NUCLEOTIDE-SEQUENCE; RIBOSOMAL-PROTEINS; DNA-POLYMERASES; CELL-DIVISION; GENE	The complete 1.66-megabase pair genome sequence of an autotrophic archaeon, Methanococcus jannaschii, and its 58- and 16-kilobase pair extrachromosomal elements have been determined by whole-genome random sequencing. A total of 1738 predicted protein-coding genes were identified; however, only a minority of these (38 percent) could be assigned a putative cellular role with high confidence. Although the majority of genes related to energy production, cell division, and metabolism in M. jannaschii are most similar to those found in Bacteria, most of the genes involved in transcription, translation, and replication in M. jannaschii are more similar to those found in Eukaryotes.	INST GENOM RES,ROCKVILLE,MD 20850; UNIV ILLINOIS,DEPT MICROBIOL,CHAMPAIGN,IL 61801; ARGONNE NATL LAB,DIV MATH & COMP SCI,ARGONNE,IL 60439; SUNY BUFFALO,DEPT MICROBIOL,BUFFALO,NY 14214; GEORGIA INST TECHNOL,SCH BIOL,ATLANTA,GA 30332; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205	J. Craig Venter Institute; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Energy (DOE); Argonne National Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University System of Georgia; Georgia Institute of Technology; Johns Hopkins University			Wood, David W/B-2992-2012	Fraser, Claire/0000-0003-1462-2428; Blake, Judith/0000-0001-8522-334X; Kerlavage, Anthony/0000-0002-3954-9653	NIGMS NIH HHS [GM00783] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1995, NATURE, V377, P3; BELAY N, 1984, NATURE, V312, P286, DOI 10.1038/312286a0; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BLAAT M, 1994, A LEEWENHOEK, V66, P187; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; COOPER AA, 1995, TRENDS BIOCHEM SCI, V20, P351, DOI 10.1016/S0968-0004(00)89075-1; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DEPOUPLANA R, 1996, P NATL ACAD SCI USA, V93, P166; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; EBERHART CG, 1995, DEVELOPMENT, V121, P3477; FAGUY DM, 1994, CAN J MICROBIOL, V40, P67, DOI 10.1139/m94-011; FELSENFELD G, 1957, J AM CHEM SOC, V79, P2023, DOI 10.1021/ja01565a074; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FOX GE, 1977, P NATL ACAD SCI USA, V74, P4537, DOI 10.1073/pnas.74.10.4537; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HAMILTON PT, 1985, MOL GEN GENET, V200, P47, DOI 10.1007/BF00383311; HARTMANN E, 1989, ARCH MICROBIOL, V151, P274, DOI 10.1007/BF00413142; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HIRATA R, 1990, J BIOL CHEM, V265, P6726; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JIANG XM, 1991, MOL MICROBIOL, V5, P695, DOI 10.1111/j.1365-2958.1991.tb00741.x; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; KAINE BP, 1989, J BACTERIOL, V171, P4261, DOI 10.1128/JB.171.8.4261-4266.1989; KALMOKOFF ML, 1992, ARCH MICROBIOL, V157, P481; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KEELING P, IN PRESS SYST APPL M; KLENK HP, 1994, CURR BIOL, V4, P920, DOI 10.1016/S0960-9822(00)00206-2; KOPKE AKE, 1989, CAN J MICROBIOL, V35, P11; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; LANZENDORFER M, 1994, SYST APPL MICROBIOL, V16, P656; LECHNER K, 1989, J MOL EVOL, V29, P20, DOI 10.1007/BF02106178; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; LOGAN DT, 1995, EMBO J, V14, P4156, DOI 10.1002/j.1460-2075.1995.tb00089.x; LUTKENHAUS J, 1993, CURR OPIN GENET DEV, V3, P783, DOI 10.1016/S0959-437X(05)80099-1; MARTIN N, 1976, J MOL BIOL, V101, P285, DOI 10.1016/0022-2836(76)90148-0; MARTIN NC, 1977, BIOCHEMISTRY-US, V16, P4672, DOI 10.1021/bi00640a022; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MOJICA FJM, 1995, MOL MICROBIOL, V17, P85, DOI 10.1111/j.1365-2958.1995.mmi_17010085.x; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PIETROKOVSKI S, 1994, PROTEIN SCI, V3, P2340, DOI 10.1002/pro.5560031218; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; Rothfield LI, 1996, CELL, V84, P183, DOI 10.1016/S0092-8674(00)80971-X; SANDMAN K, 1990, P NATL ACAD SCI USA, V87, P5788, DOI 10.1073/pnas.87.15.5788; SCHON A, 1988, BIOCHIMIE, V70, P391, DOI 10.1016/0300-9084(88)90212-X; Su┬ll D., 1995, TRNA STRUCTURE BIOSY; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; UEMORI T, 1995, J BACTERIOL, V177, P2164, DOI 10.1128/jb.177.8.2164-2177.1995; WAGNER EA, 1995, J BACTERIOL, V177, P5179; WALLACE JC, 1992, COMPUT APPL BIOSCI, V8, P249; WHITBREAD LA, 1995, GENE, V155, P113, DOI 10.1016/0378-1119(94)00925-I; WILCOX M, 1969, EUR J BIOCHEM, V11, P405, DOI 10.1111/j.1432-1033.1969.tb00788.x; Williams N, 1996, SCIENCE, V272, P481, DOI 10.1126/science.272.5261.481; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; WOESE CR, 1985, BACTERIA, V8; WOOD HG, 1986, TRENDS BIOCHEM SCI, V11, P14, DOI 10.1016/0968-0004(86)90223-9; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; ZHAO HX, 1988, ARCH MICROBIOL, V150, P178, DOI 10.1007/BF00425159; ZILLIG W, 1989, ENDOCYT CELL RES, V6, P1	67	2184	4090	6	167	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1058	1073		10.1126/science.273.5278.1058	http://dx.doi.org/10.1126/science.273.5278.1058			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688087				2022-12-24	WOS:A1996VD42800028
J	Mainen, ZF; Sejnowski, TJ				Mainen, ZF; Sejnowski, TJ			Influence of dendritic structure on firing pattern in model neocortical neurons	NATURE			English	Article							RAT VISUAL-CORTEX; PYRAMIDAL NEURONS; SODIUM-CHANNELS; MORPHOLOGY; CELLS; ELECTROPHYSIOLOGY; SPIKING; LAYER-5	NEOCORTICAL neurons display a wide range of dendritic morphologies, ranging from compact arborizations to highly elaborate branching patterns(1). In vitro electrical recordings from these neurons have revealed a correspondingly diverse range of intrinsic firing patterns, including non-adapting, adapting and bursting types(2,3). This heterogeneity of electrical responsivity has generally been attributed to variability in the types and densities of ionic channels. We show here, using compartmental models of reconstructed cortical neurons, that an entire spectrum of firing patterns can be reproduced in a set of neurons that share a common distribution of ion channels and differ only in their dendritic geometry. The essential behaviour of the model depends on partial electrical coupling of fast active conductances localized to the soma and axon and slow active currents located throughout the dendrites, and can be reproduced in a two-compartment model. The results suggest a causal relationship for the observed correlations between dendritic structure and firing properties(3-7) and emphasize the importance of active dendritic conductances in neuronal function(8-10).	SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, COMPUTAT NEUROBIOL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego			Sejnowski, Terrence/AAV-5558-2021	Mainen, Zachary/0000-0001-7913-9109				AGMON A, 1992, J NEUROSCI, V12, P319; ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; Azouz R, 1996, J PHYSIOL-LONDON, V492, P211, DOI 10.1113/jphysiol.1996.sp021302; CHAGNACAMITAL Y, 1990, J COMP NEUROL, V296, P598, DOI 10.1002/cne.902960407; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; FRANCESCHETTI S, 1995, BRAIN RES, V696, P127, DOI 10.1016/0006-8993(95)00807-3; GRANIT R, 1963, J PHYSL, V168, P100; GUTFREUND Y, 1995, J PHYSIOL-LONDON, V483, P621, DOI 10.1113/jphysiol.1995.sp020611; Hamill OP, 1991, CEREB CORTEX, V1, P48, DOI 10.1093/cercor/1.1.48; Hines M, 1993, NEURAL SYSTEMS ANAL, P127; KANDEL ER, 1961, J NEUROPHYSIOL, V24, P243, DOI 10.1152/jn.1961.24.3.243; KASPER EM, 1994, J COMP NEUROL, V339, P475, DOI 10.1002/cne.903390403; KIM HG, 1993, J NEUROSCI, V13, P5301, DOI 10.1523/JNEUROSCI.13-12-05301.1993; LARKMAN AU, 1992, J COMP NEUROL, V323, P137, DOI 10.1002/cne.903230202; Mainen ZF, 1995, NEURON, V15, P1427, DOI 10.1016/0896-6273(95)90020-9; MASON A, 1990, J NEUROSCI, V10, P1415; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; Peters A, 1984, CEREBRAL CORTEX, V1; Pinsky P F, 1994, J Comput Neurosci, V1, P39, DOI 10.1007/BF00962717; RAPP M, IN PRESS P NATL ACAD; REUVENI I, 1993, J NEUROSCI, V13, P4609; SCHWINDT PC, 1988, J NEUROPHYSIOL, V59, P424, DOI 10.1152/jn.1988.59.2.424; SLOPER JJ, 1979, PHILOS T R SOC B, V285, P173, DOI 10.1098/rstb.1979.0004; STORM JF, 1990, PROG BRAIN RES, V83, P161; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; TURNER RW, 1994, J NEUROSCI, V14, P6453; WOLLNER DA, 1986, P NATL ACAD SCI USA, V83, P8424, DOI 10.1073/pnas.83.21.8424; Yang CR, 1996, J NEUROSCI, V16, P1904; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4	30	888	899	3	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 25	1996	382	6589					363	366		10.1038/382363a0	http://dx.doi.org/10.1038/382363a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684467				2022-12-24	WOS:A1996UY95000055
J	Miller, B				Miller, B			Tuberculin skin testing of hospital workers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Miller, B (corresponding author), CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,ATLANTA,GA 30341, USA.							BURWEN DE, 1994, AM J RESP CRIT CAR S, V149, pA856; *CDCP, 1996, REP TUB US 1995; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; 1994, MMWR MORB MORTAL S13, V43, P1	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					855	855						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782619				2022-12-24	WOS:A1996VF78700003
J	Gordon, SM; Carlyn, CJ; Doyle, LJ; Knapp, CC; Longworth, DL; Hall, GS; Washington, JA				Gordon, SM; Carlyn, CJ; Doyle, LJ; Knapp, CC; Longworth, DL; Hall, GS; Washington, JA			The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: Epidemiology and risk factors	ANNALS OF INTERNAL MEDICINE			English	Article							FIELD GEL-ELECTROPHORESIS; RESISTANCE; OFLOXACIN; NORFLOXACIN; CRITERIA; STRAINS	Background: Until 1992, almost all strains of Neisseria gonorrhoeae that had been tested in the United States were susceptible to fluoroquinolones, including ciprofloxacin. However, among men with urethral gonococcal infections who attended one sexually transmitted disease clinic in Cleveland, Ohio, the prevalence of gonococci with decreased susceptibility to ciprofloxacin increased from 2% in 1991 to 16% in 1994. Objective: To describe the emergence of and risk factors for gonococcal urethritis caused by gonococci with decreased susceptibility to ciprofloxacin. Resistance to ciprofloxacin was considered to be decreased if the mean inhibitory concentration was at least 0.12 mu g/mL and was less than or equal to 0.25 mu g/mL; this definition did not equate with the definition of clinical resistance. Design: Case-control study. Setting: An urban sexually transmitted disease clinic. Participants: 51 case-patients and 106 controls. Measurements: Pulsed-field gel electrophoresis was used to identify individual genotypes of ciprofloxacin-resistant and ciprofloxacin-susceptible isolates. Results: 55 of the 746 isolates of N. gonorrhoeae that were tested (7.4%) had decreased susceptibility to ciprofloxacin, and the prevalence of N. gonorrhoeae with decreased susceptibility significantly increased during the study period. Case-patients were significantly less likely to have gram-negative diplococci seen on microscopic examination of urethral discharge (P less than or equal to 0.01) and were less likely to be treated for gonococcal urethritis than were controls (P less than or equal to 0.001). Molecular typing suggested the spread of a single genotype of N. gonorrhoeae. Conclusions: Strains of gonococci with decreased susceptibility to ciprofloxacin appear to have become endemic in Cleveland, Ohio. The clinical significance of these isolates is not clear, but the potential for the emergence of clinically important resistance may preclude the use of fluoroquinolones as an alternative treatment for uncomplicated gonorrhea.	CLEVELAND CLIN FDN, DEPT PATHOL & LAB MED, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation	Gordon, SM (corresponding author), CLEVELAND CLIN FDN, DEPT INFECT DIS, 9500 EUCLID AVE, MAILSTOP S-32, CLEVELAND, OH 44195 USA.							[Anonymous], 1993, MMWR Recomm Rep, V42, P1; BIRLEY H, 1994, GENITOURIN MED, V70, P292; CARLYN CJ, 1995, ANTIMICROB AGENTS CH, V39, P1606, DOI 10.1128/AAC.39.7.1606; GORDON SM, 1993, CLIN INFECT DIS, V17, P462, DOI 10.1093/clinids/17.3.462; Gorwitz Rachel J., 1993, Morbidity and Mortality Weekly Report, V42, P29; JEPHCOTT AE, 1990, LANCET, V335, P165, DOI 10.1016/0140-6736(90)90035-4; KAM KM, 1995, GENITOURIN MED, V71, P141; KNAPP JS, 1994, ANTIMICROB AGENTS CH, V38, P2194, DOI 10.1128/AAC.38.9.2194; KNAPP JS, 1995, ANTIMICROB AGENTS CH, V39, P2442, DOI 10.1128/AAC.39.11.2442; MORELLO JA, 1991, MANUAL CLIN MICROBIO, P248; *NAT COMM CLIN LAB, 1994, M10055 NAT COMM CLIN; National Committee for Clinical Laboratory standards, 1993, M7A3 NAT COMM CLIN L; RICHARD P, 1994, CLIN INFECT DIS, V19, P54, DOI 10.1093/clinids/19.1.54; TAPSALL JW, 1992, MED J AUSTRALIA, V156, P143; TARTAGLIONE TA, 1990, SEXUALLY TRANSMITTED, P993; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; XIA MS, 1995, J INFECT DIS, V171, P455, DOI 10.1093/infdis/171.2.455; YEUNG KH, 1990, LANCET, V336, P759, DOI 10.1016/0140-6736(90)92261-F; 1994, MMWR-MORBID MORTAL W, V43, P325; 1995, MMWR-MORBID MORTAL W, V44, P761; 1987, MMWR MORTAL WKLY S5, V36, pS1	21	37	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					465	470		10.7326/0003-4819-125-6-199609150-00006	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779458				2022-12-24	WOS:A1996VF88200007
J	Warren, JB; Higenbottam, T				Warren, JB; Higenbottam, T			Caution with use of inhaled nitric oxide	LANCET			English	Editorial Material									UNIV SHEFFIELD,DEPT MED & PHARMACOL,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND	University of Sheffield	Warren, JB (corresponding author), ST THOMAS HOSP,DEPT PHARMACOL,LONDON,ENGLAND.							Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BEBERA JA, 1996, LANCET, V347, P436; BIHARI D, 1987, NEW ENGL J MED, V317, P394; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; JAI L, 1996, NATURE, V380, P221; KINSELLA JP, 1992, LANCET, V340, P436; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROSSIANT R, 1993, NEW ENGL J MED, V328, P299; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; YOSHIDA K, 1983, INT ARCH OCC ENV HEA, V52, P103, DOI 10.1007/BF00405415; 1996, CURR PROBL PHARMACOV, V22, P8	11	43	46	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					629	630		10.1016/S0140-6736(05)65068-4	http://dx.doi.org/10.1016/S0140-6736(05)65068-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782748				2022-12-24	WOS:A1996VF60900003
J	McAlindon, TE; Felson, DT; Zhang, YQ; Hannan, MT; Aliabadi, P; Weissman, B; Rush, D; Wilson, PWF; Jacques, P				McAlindon, TE; Felson, DT; Zhang, YQ; Hannan, MT; Aliabadi, P; Weissman, B; Rush, D; Wilson, PWF; Jacques, P			Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study	ANNALS OF INTERNAL MEDICINE			English	Article							OSTEO-ARTHRITIS; RADIOGRAPHIC PROGRESSION; PHYSICAL-ACTIVITY; JOINT SPACE; BONE; HEALTH; QUESTIONNAIRE; DISEASE; WOMEN; HIP	Background: Evidence suggests that pathophysiologic processes in bone are important determinants of outcome in osteoarthritis of the knee. Low intake and low serum levels of vitamin D may compromise favorable responses of bone to osteoarthritis, predisposing patients to progression. Objective: To determine whether dietary intake and serum levels of vitamin D would predict the incidence and progression of osteoarthritis of the knee in participants of the Framingham Study. Design: Prospective observational study. Setting: The Framingham Study. Participants: Participants in the Framingham Heart Study who had knee radiography at examinations 18 (done between 1983 and 1985) and 22 (done between 1992 and 1993) and received interim assessments of vitamin D intake and serum levels. Measurements: Intake of vitamin D and serum levels of 25-hydroxyvitamin D, calculated on the basis of dietary habits and supplement use as reported on a questionnaire, were evaluated at examination 20 (1988 to 1989). Knee radiographs were given scores for global severity of osteoarthritis, using a modification of the scale of Kellgren and Lawrence (range, 0 to 4), and for the presence of osteophytes and joint-space narrowing (range, 0 to 3). Covariates measured at examinations 18 and 20 were age, sex, body mass index, weight change, injury, physical activity, health status, bone mineral density, and energy intake. Results: 556 participants (mean age at baseline +/- SD, 70.3 +/- 4.5 years) had complete assessments. Incident osteoarthritis occurred in 75 knees; progressive osteoarthritis occurred in 62 knees. Serum levels of vitamin D were modestly correlated with vitamin D intake (r = 0.24). Risk for progression increased threefold in participants in the middle and lower tertiles for both vitamin D intake (odds ratio for the lower compared with the upper tertile, 4.0 [95% Cl, 1.4 to 11.6]) and serum levels of vitamin D (odds ratio for the lower compared with the upper tertilee, 2.9 [Cl, 1.0 to 8.2]). Low serum levels of vitamin D also predicted loss of cartilage, as assessed by loss of joint space (odds ratio, 2.3 [Cl, 0.9 to 5.5]) and osteophyte growth (odds ratio, 3.1 [Cl, 1.3 to 7.5]). Incident osteoarthritis of the knee occurring after baseline was not consistently related to either intake or serum levels of vitamin D. Conclusions: Low intake and low serum levels of vitamin D each appear to be associated with an increased risk for progression of osteoarthritis of the knee.	FRAMINGHAM STUDY, FRAMINGHAM, MA 01701 USA; TUFTS UNIV, USDA, CTR HUMAN NUTR, BOSTON, MA 02111 USA; BRIGHAM & WOMENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA	Tufts University; United States Department of Agriculture (USDA); Harvard University; Brigham & Women's Hospital	McAlindon, TE (corresponding author), BOSTON UNIV, MED CTR, ARTHRIT CTR, ROOM A203, 80 E CONCORD ST, BOSTON, MA 02118 USA.		Wilson, Peter W.F./J-2455-2016	Felson, David/0000-0002-2668-2447; Zhang, Yuqing/0000-0001-7954-1149	NATIONAL INSTITUTE ON AGING [R01AG009300] Funding Source: NIH RePORTER; NIAMS NIH HHS [ARZ0613] Funding Source: Medline; NIA NIH HHS [R0-1 AG09300] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS JS, 1982, NEW ENGL J MED, V306, P722, DOI 10.1056/NEJM198203253061206; ALTMAN RD, 1987, ARTHRITIS RHEUM-US, V30, P1214, DOI 10.1002/art.1780301103; [Anonymous], 1990, NUTR EPIDEMIOLGY; ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; CORVOL MT, 1981, ANN ENDOCRINOL-PARIS, V42, P482; DEDRICK DK, 1993, ARTHRITIS RHEUM, V36, P1460, DOI 10.1002/art.1780361019; DEQUEKER J, 1995, J RHEUMATOL, V22, P98; DIEPPE P, 1993, ANN RHEUM DIS, V52, P557, DOI 10.1136/ard.52.8.557; FELSON DT, 1995, ARTHRITIS RHEUM-US, V38, P1500, DOI 10.1002/art.1780381017; FELSON DT, 1990, RHEUM DIS CLIN N AM, V16, P499; GRANT MD, 1995, J CLIN EPIDEMIOL, V48, P375, DOI 10.1016/0895-4356(94)00143-E; HANNAN MT, 1993, J RHEUMATOL, V20, P704; HANNAN MT, 1992, J BONE MINER RES, V7, P547; HORDON LD, 1992, ANN RHEUM DIS, V51, P823, DOI 10.1136/ard.51.6.823; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; Kellgren JH, 1963, EPIDEMIOLOGY CHRONIC; KIEL DP, 1995, NUTR ASSESSMENT ELDE, P277; LAYTON MW, 1988, ARTHRITIS RHEUM-US, V31, P1400, DOI 10.1002/art.1780311109; LEDINGHAM J, 1995, ANN RHEUM DIS, V54, P53, DOI 10.1136/ard.54.1.53; LEDINGHAM J, 1993, ANN RHEUM DIS, V52, P263, DOI 10.1136/ard.52.4.263; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MCALINDON T, 1990, BRIT J RHEUMATOL, V29, P471; McAlindon TE, 1996, ARTHRITIS RHEUM-US, V39, P648, DOI 10.1002/art.1780390417; MILGRAM JW, 1983, CLIN ORTHOP RELAT R, V173, P293; PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014; PERRY GH, 1972, ANN RHEUM DIS, V31, P440, DOI 10.1136/ard.31.6.440; POTTENGER LA, 1990, ARTHRITIS RHEUM-US, V33, P853, DOI 10.1002/art.1780330612; RADIN EL, 1986, CLIN ORTHOP RELAT R, P34; RADIN EL, 1970, ARTHRITIS RHEUM, V13, P400, DOI 10.1002/art.1780130406; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SMYTHE HA, 1987, J RHEUMATOL, V14; SPECTOR TD, 1994, ANN RHEUM DIS, V53, P565, DOI 10.1136/ard.53.9.565; Willett W, 1990, NUTRITIONAL EPIDEMIO; Willett W, 1990, NUTR EPIDEMIOLOGY, P92; WRIGHT V, 1989, BRIT MED J, V299, P1476, DOI 10.1136/bmj.299.6714.1476; 1976, BRIT MED J, V2, P4	38	301	318	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					353	359		10.7326/0003-4819-125-5-199609010-00001	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE079	8702085				2022-12-24	WOS:A1996VE07900001
J	Rooke, J; Pan, D; Xu, T; Rubin, GM				Rooke, J; Pan, D; Xu, T; Rubin, GM			KUZ, a conserved metalloprotease-disintegrin protein with two roles in Drosophila neurogenesis	SCIENCE			English	Article							PLATELET-AGGREGATION INHIBITOR; SPERM-EGG FUSION; CELL FATE; SENSORY BRISTLES; VENOM; MELANOGASTER; NOTCH; RECOMBINASE; PRECURSOR; SEQUENCE	During neurogenesis in Drosophila both neurons and nonneuronal cells are produced from a population of initially equivalent cells. The kuzbanian (kuz) gene described here is essential for the partitioning of neural and nonneuronal cells during development of both the central and peripheral nervous systems in Drosophila. Mosaic analyses indicated that kuz is required for cells to receive signals inhibiting the neural fate. These analyses further revealed that the development of a neuron requires a kuz-mediated positive signal from neighboring cells. The kuz gene encodes a metalloprotease-disintegrin protein with a highly conserved bovine homolog, raising the possibility that kuz homologs may act in similar processes during mammalian neurogenesis.	YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT GENET, NEW HAVEN, CT 06536 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, BERKELEY, CA 94720 USA	Yale University; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley				Rubin, Gerald/0000-0001-8762-8703				ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; AU LC, 1991, BIOCHEM BIOPH RES CO, V181, P585, DOI 10.1016/0006-291X(91)91230-A; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BOUROUIS M, 1989, NATURE, V341, P442, DOI 10.1038/341442a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J. A., 1993, DEV DROSOPHILA MELAN, VII, P1091; CHOU TB, 1992, GENETICS, V131, P643; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HOWARD L, 1995, METHOD ENZYMOL, V248, P388; JAN YN, 1993, DEV DROSOPHILA MELAN, V2, P1207; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; NEEPER MP, 1990, NUCLEIC ACIDS RES, V18, P4255, DOI 10.1093/nar/18.14.4255; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824; RICHELLE J, 1979, DEV BIOL, V70, P418, DOI 10.1016/0012-1606(79)90036-8; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; SHEBUSKI RJ, 1989, J BIOL CHEM, V264, P21550; SIMPSON P, 1990, DEVELOPMENT, V110, P927; SIMPSON P, 1990, DEVELOPMENT, V109, P509; STUTTEM I, 1991, DEVELOPMENT, P39; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; VANDERVORST P, 1980, NATURE, V286, P65, DOI 10.1038/286065a0; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; XU T, 1993, DEVELOPMENT, V117, P1223; XU T, 1990, GENETICS, V126, P665; XU T, 1994, METHOD CELL BIOL, V44, P655, DOI 10.1016/S0091-679X(08)60937-1; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0	36	295	306	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1996	273	5279					1227	1231		10.1126/science.273.5279.1227	http://dx.doi.org/10.1126/science.273.5279.1227			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703057				2022-12-24	WOS:A1996VE47600040
J	Oberlin, E; Amara, A; Bachelerie, F; Bessia, C; Virelizier, JL; ArenzanaSeisdedos, F; Schwartz, O; Heard, JM; ClarkLewis, I; Legler, DF; Loetscher, M; Baggiolini, M; Moser, B				Oberlin, E; Amara, A; Bachelerie, F; Bessia, C; Virelizier, JL; ArenzanaSeisdedos, F; Schwartz, O; Heard, JM; ClarkLewis, I; Legler, DF; Loetscher, M; Baggiolini, M; Moser, B			The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1	NATURE			English	Article							CHEMOTACTIC CYTOKINES; MOLECULAR-CLONING; RECEPTOR; INTERLEUKIN-8; MIP-1-ALPHA; MIP-1-BETA; SEQUENCE; PROTEINS; RANTES	A PUTATIVE chemokine receptor that we previously cloned and termed LESTR(1) has recently been shown to function as a co-receptor (termed fusin) for lymphocyte-tropic HIV-1 strains(2), Cells expressing CD4 became permissive to infection with T-cell-line-adapted HIV-1 strains of the syncytium-inducing phenotype after transfection with LESTR/fusin complementary DNA, We report here the identification of a human chemokine of the CXC type, stromal cell-derived factor 1 (SDF-1), as the natural ligand for LESTR/fusin, and we propose the term CXCR-4 for this receptor, in keeping with the new chemokine-receptor nomenclature, SDF-1 activates Chinese hamster ovary (CHO) cells transfected with CXCR-4 cDNA as well as blood leukocytes and lymphocytes. In cell lines expressing CXCR-4 and CD4, and in blood lymphocytes, SDF-1 is a powerful inhibitor of infection by lymphocyte-tropic HIV-1 strains, whereas the CC chemokines RANTES, MIP-1 alpha and MIP-1 beta, which were shown previously to prevent infection with primary, monocyte-tropic viruses(3), are inactive, In combination with CC chemokines, which block the infection with monocyte/macrophage-tropic viruses, SDF-1 could help to decrease virus load and prevent the emergence of the syncytium-inducing viruses which are characteristic of the late stages of AIDS(4).	INST PASTEUR,UNITE IMMUNOL VIRALE,F-75724 PARIS 15,FRANCE; INST PASTEUR,LAB RETROVIRUS & TRANSFERT GENET,F-75724 PARIS 15,FRANCE; UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BERN,THEODOR KOCHER INST,BERN 9,SWITZERLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of British Columbia; University of Bern			AMARA, Ali/ABX-9903-2022; BACHELERIE, FRANCOISE/F-8823-2013; Oberlin, Estelle/M-4915-2018; Amara, Ali/E-8803-2017; Arenzana-Seisdedos, Fernando/E-5835-2016; Schwartz, Olivier/AAZ-3765-2021	BACHELERIE, FRANCOISE/0000-0002-0399-3277; Oberlin, Estelle/0000-0002-8200-9548; Schwartz, Olivier/0000-0002-0729-1475; Moser, Bernhard/0000-0002-4354-4572; AMARA, Ali/0000-0002-0283-1815; Legler, Daniel F./0000-0001-8610-4764				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BLEUL CC, IN PRESS J EXP MED; CANN AJ, 1990, J VIROL, V64, P4735, DOI 10.1128/JVI.64.10.4735-4742.1990; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLOTTA F, 1984, J IMMUNOL, V132, P936; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Jacque JM, 1996, J VIROL, V70, P2930; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; VANTSCHAMER V, 1986, NATURE, V324, P369; Weiss RA, 1996, SCIENCE, V272, P1885, DOI 10.1126/science.272.5270.1885; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564	26	1440	1511	0	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					833	835		10.1038/382833a0	http://dx.doi.org/10.1038/382833a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752281	Green Submitted			2022-12-24	WOS:A1996VE34700054
J	vanderBom, JG; Bots, ML; Haverkate, F; Slagboom, PE; Meijer, P; deJong, PTVM; Hofman, A; Grobbee, DE; Kluft, C				vanderBom, JG; Bots, ML; Haverkate, F; Slagboom, PE; Meijer, P; deJong, PTVM; Hofman, A; Grobbee, DE; Kluft, C			Reduced response to activated protein C is associated with increased risk for cerebrovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article						cerebrovascular disorders; protein C; blood coagulation disorders; factor V; thrombophlebitis	COAGULATION-FACTOR-V; POOR ANTICOAGULANT RESPONSE; TRANSIENT ISCHEMIC ATTACKS; VENOUS THROMBOSIS; MYOCARDIAL-INFARCTION; RESISTANCE; MUTATION; STROKE; ROTTERDAM; LEIDEN	Background: Resistance to activated protein C (APC), which results from various factors, including a mutation in the gene for coagulant factor V, has been associated with increased risk for venous thrombosis. However, its relation to arterial disease is sti II not well defined. Objective: To investigate the association of both response to APC and the factor V Leiden mutation with arterial disease. Design: Population-based case-control study. Setting: A district of Rotterdam, the Netherlands. Participants: 115 patients with a history of myocardial infarction; 112 patients with a history of stroke, transient ischemic attack, or both; and 222 age-matched controls without arterial disease chosen from among 7983 persons in the Rotterdam Study cohort. Patients using anticoagulant drugs were excluded. Measurements: Response to APC was determined in double-centrifuged platelet-poor plasma. Patients were genotyped for the Arg 506 to Gln mutation in the gene for coagulant factor V. Results: The prevalence of cerebrovascular disease increased gradually and corresponded to a decreasing response to APC (odds ratio per 1-unit decrease of response to APC 1.43 [95% CI, 1.12 to 1.81], adjusted for age and sex). Adjustment for the factor V mutation did not change the findings. We found no association between response to APC and myocardial infarction or between factor V mutation and cerebrovascular disease or myocardial infarction. Conclusions: Low response to APC is associated with an increased risk for cerebrovascular disease but not with an increased risk for myocardial infarction, independent of the factor V Leiden mutation. The association between the factor V Leiden mutation and cerebrovascular disease or myocardial infarction remains to be determined.	ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, NL-3000 DR ROTTERDAM, NETHERLANDS; NETHERLANDS OPHTHALM RES INST, NL-1100 AC AMSTERDAM, NETHERLANDS; TNO, GAUBIUS INST CARDIOVASC RES, LEIDEN, NETHERLANDS	Erasmus University Rotterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Netherlands Organization Applied Science Research			Grobbee, Diederick/C-7651-2014; Slagboom, P. Eline/R-4790-2016; van der Bom, Johanna G./G-1965-2018	Grobbee, Diederick/0000-0003-4472-4468; Slagboom, P. Eline/0000-0002-2875-4723; van der Bom, Johanna G./0000-0001-9095-2475				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOTS ML, 1993, LANCET, V341, P1232, DOI 10.1016/0140-6736(93)91144-B; CATTO A, 1995, ARTERIOSCL THROM VAS, V15, P783, DOI 10.1161/01.ATV.15.6.783; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; FON EA, 1994, STROKE, V25, P282, DOI 10.1161/01.STR.25.2.282; FUJIMURA H, 1995, THROMB HAEMOSTASIS, V74, P1381; HALBMAYER WM, 1994, BLOOD COAGUL FIBRIN, V5, P51, DOI 10.1097/00001721-199402000-00008; HERMAN B, 1982, STROKE, V13, P629, DOI 10.1161/01.STR.13.5.629; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HORVAT R, 1993, EUR J CELL BIOL, V61, P299; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KONTULA K, 1995, THROMB HAEMOSTASIS, V73, P558; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KOUDSTAAL PJ, 1994, CEREBROVASC DIS, V4, P40, DOI 10.1159/000108560; MARZ W, 1995, LANCET, V345, P526, DOI 10.1016/S0140-6736(95)90626-6; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MIETTINEN OS, 1985, THEORETICAL EPIDEMIO, P231; Qizilbash N, 1995, LANCET, V346, P1647; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; SAMANI NJ, 1994, LANCET, V344, P1709, DOI 10.1016/S0140-6736(94)90495-2; SIDELMANN J, 1995, THROMB HAEMOSTASIS, V74, P993; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; VANBEMMEL JH, 1990, METHOD INFORM MED, V29, P346; VANDERBOM JG, 1994, FIBRINOLYSIS, V8, P157, DOI 10.1016/0268-9499(94)90283-6; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503	28	114	115	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					265	+		10.7326/0003-4819-125-4-199608150-00002	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678388				2022-12-24	WOS:A1996VB68000005
J	Nightingale, SL				Nightingale, SL			FDA conference on human subject protection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					443	443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691538				2022-12-24	WOS:A1996VA86300005
J	PascualLeone, A; Rubio, B; Pallardo, F; Catala, MD				PascualLeone, A; Rubio, B; Pallardo, F; Catala, MD			Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression	LANCET			English	Article								Background Lesion and neuroimaging studies suggest that left prefrontal lobe dysfunction is pathophysiologically linked to depression. Rapid-rate transcranial magnetic stimulation (rTMS) to prefrontal lateralised effect on mood In normal several preliminary studies suggest a beneficial effect of rTMS on depression. However, adequately controlled studies have not been conducted. Methods We have studied the effects of focal rTMS on the depressive symptoms in 17 patients with medication-resistant depression of psychotic subtype. The study was designed as a multiple cross-over, randomised placebo-controlled trial. Sham rTMS and stimulation of different cortical areas were used as controls. Findings Left dorsolateral prefrontal cortex rTMS resulted in a significant decrease in scores on the Hamilton depression rating scale HDRS (from 25.2 to 13.8) and the self-rated Beck questionnaire BQ (from 47.9 to 25.7). 11 of the 17 patients showed pronounced improvement that lasted for about 2 weeks after 5 days of daily rTMS sessions. No patient experienced any significant undesirable side-effects. Interpretation Our findings emphasise the role of the left dorsolateral prefrontal cortex in depression, and suggest that rTMS of the left dorsolateral prefrontal cortex might become a safe, non-convulsive alternative to electroconvulsive treatment in depression.	CSIC,INST RAMON Y CAJAL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC)	PascualLeone, A (corresponding author), UNIV VALENCIA,DEPT FISIOL,UNIDAD NEUROBIOL,AVE BLASCO IBANEZ 17,E-46010 VALENCIA,SPAIN.		Pascual-Leone, Alvaro/AAC-5101-2019; Pallardo, Federico V./T-1156-2017	Pascual-Leone, Alvaro/0000-0001-8975-0382; Pallardo, Federico V./0000-0003-3715-1980; Rubio, Belen/0000-0003-0858-1842				BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; COHEN LG, 1990, ELECTROEN CLIN NEURO, V75, P350, DOI 10.1016/0013-4694(90)90113-X; GEORGE MS, 1995, NEUROREPORT, V6, P1853, DOI 10.1097/00001756-199510020-00008; GEORGE MS, 1994, CONVULSIVE THER, V10, P251; George MS, 1994, DEPRESSION, V2, P59, DOI [DOI 10.1002/DEPR.3050020202, 10.1002/depr.3050020202]; GRISARU N, 1994, EUR NEUROPSYCHOPHARM, V4, P287; HAMILTON M, 1961, BR J SOC CLIN PSYCHO, V4, P561; HOFLICH G, 1993, HUM PSYCHOPHARM CLIN, V8, P361, DOI 10.1002/hup.470080510; KOLBINGER HM, 1995, HUM PSYCHOPHARM CLIN, V10, P305, DOI 10.1002/hup.470100408; PascualLeone A, 1996, NEUROLOGY, V46, P499, DOI 10.1212/WNL.46.2.499; PASCUALLEONE A, 1994, NEUROREPORT, V5, P2517, DOI 10.1097/00001756-199412000-00028; PASCUALLEONE A, 1993, ELECTROEN CLIN NEURO, V89, P120, DOI 10.1016/0168-5597(93)90094-6; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; PASCUALLEONE A, IN PRESS HDB NEUROPS, V10; PAZZAGLIA PJ, 1993, PSYCHIAT RES, V49, P257, DOI 10.1016/0165-1781(93)90066-P; ROTH BJ, 1991, ELECTROEN CLIN NEURO, V81, P47, DOI 10.1016/0168-5597(91)90103-5; SACKEIM HA, 1994, CONVULSIVE THER, V10, P255; TOFTS PS, 1990, PHYS MED BIOL, V35, P1119, DOI 10.1088/0031-9155/35/8/008; Wassermann EM, 1996, NEUROIMAGE, V3, P1, DOI 10.1006/nimg.1996.0001; WILLIAMS WA, 1995, NEUROLOGY S4, V5, pA168; 1985, JAMA-J AM MED ASSOC, V254, P2103	21	883	926	3	199	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					233	237		10.1016/S0140-6736(96)01219-6	http://dx.doi.org/10.1016/S0140-6736(96)01219-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684201				2022-12-24	WOS:A1996UZ28600012
J	Shibasaki, F; Price, ER; Milan, D; McKeon, F				Shibasaki, F; Price, ER; Milan, D; McKeon, F			Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4	NATURE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CYCLOSPORINE-A; ACTIVATION; PROTEIN; DOMAIN; IDENTIFICATION; COMPLEXES; FAR1	A NEW facet of calcium signallin involves the nuclear import of the NF-AT transcription factors from their dormant position in the cytoplasm(1-3). The protein phosphatase calcineurin appears to play an essential role in activating NF-AT nuclear import, as the calcineurin inhibitors cyclosporin A and FK506 block dephosphorylation and nuclear import of NF-AT (refs 4-7). Here we show that calcium signalling induces an association between NF-AT4 and calcineurin, and that these molecules are transported, as a complex, to the nucleus, where calcineurin continues to dephosphorylate NF-AT4. We propose that a nuclear complex of NF-AT4 and calcineurin maintains calcium signalling by counteracting a vigorous nuclear NF-AT kinase.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274	26	436	451	1	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					370	373		10.1038/382370a0	http://dx.doi.org/10.1038/382370a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684469				2022-12-24	WOS:A1996UY95000057
J	Eom, SH; Wang, JM; Steitz, TA				Eom, SH; Wang, JM; Steitz, TA			Structure of Taq polymerase with DNA at the polymerase active site	NATURE			English	Article							I KLENOW FRAGMENT; ESCHERICHIA-COLI; EXONUCLEASE ACTIVITY; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; PROTEIN	THE DNA polymerase from Thermus aquaticus (Tag polymerase) is homologous to Escherichia coli DNA polymerase I (Pol I) and likewise has domains responsible for DNA polymerase and 5' nuclease activities(1,2). The structures of the polymerase domains of Tag polymerase and of the Klenow fragment (KF) of Pol I are almost identical, whereas the structure of a vestigial editing 3'-5' exonuclease domain of Tag polymerase that lies between the other two domains is dramatically altered, resulting in the absence of this activity in the thermostable enzyme(2). The structures have been solved for editing complexes between KF and single-stranded DNA(3,4) and for duplex DNA with a 3' overhanging single strand(5), but not for a complex containing duplex DNA at the polymerase active-site, Here we present the co-crystal structure of Taq polymerase with a blunt-ended duplex DNA bound to the polymerase active-site cleft; the DNA neither bends nor goes through the large polymerase cleft, and the structural form of the bound DNA is between the B and A forms. A wide minor groove allows access to protein side chains that hydrogen-bond to the N3 of purines and the O2 of pyrimidines at the blunt-end terminus. Part of the DNA bound to the polymerase site shares a common binding site with DNA bound to the exonuclease site, but they are translated relative to each other by several angstroms along their helix axes.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06520; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06520	Yale University; Yale University; Howard Hughes Medical Institute; Yale University			Steitz, Thomas A./C-6559-2009					ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRUNGER AT, 1992, XPLOR VERSION 3 1; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CONNER BN, 1982, NATURE, V295, P294, DOI 10.1038/295294a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GEORGIADIS MM, 1995, STRUCTURE, V3, P879, DOI 10.1016/S0969-2126(01)00223-4; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; STEITZ TA, 1987, COLD SPRING HARB SYM, V52, P465, DOI 10.1101/SQB.1987.052.01.053; STEITZ TA, 1992, BIOL ORG MACROMOLECU, P45; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339	30	292	313	4	101	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					278	281		10.1038/382278a0	http://dx.doi.org/10.1038/382278a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717047				2022-12-24	WOS:A1996UX79000057
J	Lamaze, C; Chuang, TH; Terlecky, LJ; Bokoch, GM; Schmid, SL				Lamaze, C; Chuang, TH; Terlecky, LJ; Bokoch, GM; Schmid, SL			Regulation of receptor-mediated endocytosis by Rho and Rac	NATURE			English	Article							GTP-BINDING PROTEIN; GDP-DISSOCIATION INHIBITOR; CELLS	PINOCYTOSIS and membrane ruffling are among the earliest and most dramatic cellular responses to stimulation by growth factors or other mitogens(1). The small Ras-related G proteins Rho and Rac have a regulatory role in membrane ruffling(1-3) and activated Rho has been shown to stimulate pinocytosis when microinjected into Xenopus oocytes(4). In contrast to these well established effects of Rho and Rac on plasma membrane morphology and bulk pinocytosis, there has been no evidence for their involvement in the regulation of receptor-mediated endocytosis in clathrin-coated pits. Here we show that activated Rho and Rac inhibit transferrin-receptor-mediated endocytosis when expressed in intact cells. Furthermore, we have reconstituted these effects in a cell-free system and established that Rho and Rac can regulate clathrin-coated vesicle formation.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Lamaze, Christophe/M-4912-2017; Chuang, Tsung-Hsien/F-9679-2010	Schmid, Sandra/0000-0002-1690-7024; LAMAZE, Christophe/0000-0001-5430-2707				AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUANG TH, 1993, J BIOL CHEM, V268, P775; CLAQUE MJ, 1995, FEBS LETT, V367, P272; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; SMYTHE E, 1992, METHOD ENZYMOL, V219, P223; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; UEDA T, 1990, J BIOL CHEM, V265, P9373; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; XU XM, 1994, J BIOL CHEM, V269, P23569; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	30	326	330	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					177	179		10.1038/382177a0	http://dx.doi.org/10.1038/382177a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700210				2022-12-24	WOS:A1996UW67200053
J	Corral, J; Lavenir, I; Impey, H; Warren, AJ; Forster, A; Larson, TA; Bell, S; McKenzie, ANJ; King, G; Rabbitts, TH				Corral, J; Lavenir, I; Impey, H; Warren, AJ; Forster, A; Larson, TA; Bell, S; McKenzie, ANJ; King, G; Rabbitts, TH			An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes	CELL			English	Article							11Q23 CHROMOSOMAL TRANSLOCATIONS; PROLINE-RICH PROTEIN; DROSOPHILA-TRITHORAX; ALL-1 GENE; STEM-CELLS; MLL GENE; BREAKPOINT; PRODUCT; INT-2	Homologous recombination in embryonal stem cells has been used to produce a fusion oncogene, thereby mimicking chromosomal translocations that frequently result in formation of tumor-specific fusion oncogenes in human malignancies. AF9 sequences were fused into the mouse MII gene so that expression of the MII-AF9 fusion gene occurred from endogenous MII transcription control elements, as in t(9;11) found in human leukemias. Chimeric mice carrying the fusion gene developed tumors, which were restricted to acute myeloid leukemias despite the widespread activity of the MII promoter. Onset of perceptible disease was preceded by expansion of ES cell derivatives in peripheral blood. This novel use of homologous recombination formally proves that chromosomal translocations contribute to malignancy and provides a general strategy to create fusion oncogenes for studying their role in tumorigenesis.			Corral, J (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		; Rabbitts, Terence/D-6262-2016	Corral, Javier/0000-0003-0288-1107; Rabbitts, Terence/0000-0002-4982-2609				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; DEAR TN, 1995, DEVELOPMENT, V121, P2909; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; IIDA S, 1993, ONCOGENE, V8, P3085; LOCOCO F, 1993, CANCER RES, V53, P3800; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MANSOUR SL, 1990, P NATL ACAD SCI USA, V87, P7688, DOI 10.1073/pnas.87.19.7688; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Papaioannou V., 1993, Gene targeting: a practical approach., P107; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	27	424	435	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					853	861		10.1016/S0092-8674(00)81269-6	http://dx.doi.org/10.1016/S0092-8674(00)81269-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681380	Bronze			2022-12-24	WOS:A1996UR60400009
J	Herbst, R; Carroll, PM; Allard, JD; Schilling, J; Raabe, T; Simon, MA				Herbst, R; Carroll, PM; Allard, JD; Schilling, J; Raabe, T; Simon, MA			Daughter of sevenless is a substrate of the phosphotyrosine phosphatase corkscrew and functions during sevenless signaling	CELL			English	Article							RECEPTOR TYROSINE KINASE; GUANINE-NUCLEOTIDE EXCHANGE; GROWTH-FACTOR RECEPTOR; GENE-PRODUCT; PROTEIN; ACTIVATION; DROSOPHILA; PHOSPHORYLATION; RAS1; TRANSDUCTION	The SH2 domain-containing phosphotyrosine phosphatase Corkscrew (CSW) is an essential component of the signaling pathway initiated by the activation of the sevenless receptor. tyrosine kinase (SEV) during Drosophila eye development We have used genetic and biochemical approaches to identify a substrate for CSW. Expression of a catalytically inactive CSW was used to trap CSW in a complex with a 115 kDa tyrosine-phosphorylated substrate. This substrate was purified and identified as the product of the daughter of sevenless (dos) gene. Mutations of dos were identified in a screen for dominant mutations which enhance the phenotype caused by overexpression of inactive CSW during photoreceptor development. Analysis of dos mutations indicates that DOS is a positive component of the SEV signaling pathway and suggests that DOS dephosphorylation by CSW may be a key event during signaling by SEV.	SUGEN INC,REDWOOD CITY,CA 94063; UNIV WURZBURG,THEODOR BOVERI INST BIOWISSENSCH,LEHRSTUHL GENET,D-97074 WURZBURG,GERMANY	University of Wurzburg	Herbst, R (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NATIONAL EYE INSTITUTE [R01EY009845] Funding Source: NIH RePORTER; NEI NIH HHS [1RO1EY9845] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLARD JD, 1996, DEVELOPMENT, V122, P1125; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HERBST R, 1995, ONCOGENE, V10, P369; HSU JC, 1994, GENE DEV, V8, P2176, DOI 10.1101/gad.8.18.2176; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	44	194	196	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					899	909		10.1016/S0092-8674(00)81273-8	http://dx.doi.org/10.1016/S0092-8674(00)81273-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681384	Bronze			2022-12-24	WOS:A1996UR60400013
J	Kim, TK; Maniatis, T				Kim, TK; Maniatis, T			Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway	SCIENCE			English	Article							KAPPA-B-ALPHA; INDUCED PHOSPHORYLATION; DEGRADATION; PROTEIN; PROTEOLYSIS; SIGNAL; TYROSINE; TRANSCRIPTION; END	STAT proteins (signal transducers and activators of transcription) are latent cytoplasmic transcription factors that are phosphorylated by Janus kinases in response to cytokines. Phosphorylated STAT proteins translocate to the nucleus, where they transiently turn on specific sets of cytokine-inducible genes. The mechanism that controls the amounts of activated STAT proteins is not understood. STAT1 proteins activated by interferon-gamma treatment in HeLa cells were shown to be stabilized by a proteasome inhibitor and ubiquitinated in vivo. Thus, the amount of activated STAT1 may be negatively regulated by the ubiquitin-proteasome pathway.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020642, R01AI020642] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20642] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; HASPEL RL, IN PRESS EMBO J; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JENTSCH S, 1992, ANNU REV GENET, V26, P177; Kim T. J., UNPUB; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SALMA SR, 1994, MOL CELL BIOL, V14, P7953; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	28	346	361	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1717	1719		10.1126/science.273.5282.1717	http://dx.doi.org/10.1126/science.273.5282.1717			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781235				2022-12-24	WOS:A1996VH40800042
J	Wolfe, S				Wolfe, S			Drug advertisements that go straight to the hippocampus	LANCET			English	Editorial Material											Wolfe, S (corresponding author), PUBL CITIZENS HLTH RES GRP,1600 20TH ST NW,WASHINGTON,DC 20009, USA.							AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; *HLTH CAR COMM, 1989, EFF J ADV MARK SHAR; KESSLER DA, 1992, ANN INTERN MED, V116, P950, DOI 10.7326/0003-4819-116-11-950; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912	4	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					632	632		10.1016/S0140-6736(05)65071-4	http://dx.doi.org/10.1016/S0140-6736(05)65071-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782751				2022-12-24	WOS:A1996VF60900006
J	Kumagai, A; Dunphy, WG				Kumagai, A; Dunphy, WG			Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts	SCIENCE			English	Article							CELL-CYCLE REGULATION; PROTEIN-KINASE; CDC25 PHOSPHATASE; MITOTIC SPINDLE; DROSOPHILA POLO; MITOSIS; PHOSPHORYLATION; ACTIVATION; PHOSPHOPROTEINS; LOCALIZATION	Cdc2, the cyclin-dependent kinase that controls mitosis, is negatively regulated by phosphorylation on its threonine-14 and tyrosine-15 residues, Cdc25, the phosphatase that dephosphorylates both of these residues, undergoes activation and phosphorylation by multiple kinases at mitosis. Plx1, a kinase that associates with and phosphorylates the amino-terminal domain of Cdc25, was purified extensively from Xenopus egg extracts. Cloning of its complementary DNA revealed that Plx1 is related to the Polo family of protein kinases. Recombinant Plx1 phosphorylated Cdc25 and stimulated its activity in a purified system. Cdc25 phosphorylated by Plx1 reacted strongly with MPM-2, a monoclonal antibody to mitotic phosphoproteins. These studies indicate that Plx1 may participate in control of mitotic progression.			Kumagai, A (corresponding author), CALTECH, HOWARD HUGHES MED INST, DIV BIOL, 216-76, PASADENA, CA 91125 USA.							BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; KUMAGAI A, UNPUB; LEE KS, 1995, MOL CELL BIOL, V15, P7143; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VANDRE DD, 1991, J CELL SCI, V98, P577; Wang Y., 1993, PROTEIN PHOSPHORYLAT, P121; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	32	473	483	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 6	1996	273	5280					1377	1380		10.1126/science.273.5280.1377	http://dx.doi.org/10.1126/science.273.5280.1377			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703070				2022-12-24	WOS:A1996VF61000039
J	Gerstner, W; Kempter, R; vanHemmen, JL; Wagner, H				Gerstner, W; Kempter, R; vanHemmen, JL; Wagner, H			A neuronal learning rule for sub-millisecond temporal coding	NATURE			English	Article							COCHLEAR NUCLEUS; BARN OWL; BRAIN; CELLS; REPRESENTATION; INTEGRATION; HIPPOCAMPUS; CODES	A PARADOX that exists in auditory and electrosensory neural systems(1,2) is that they encode behaviourally relevant signals in the range of a few microseconds with neurons that are at least one order of magnitude slower, The importance of temporal coding in neural information processing is not clear yet(3-8), A central question is whether neuronal firing can be more precise than the time constants of the neuronal processes involved(9), Here we address this problem using the auditory system of the barn owl as an example, We present a modelling study based on computer simulations of a neuron in the laminar nucleus. Three observations explain the paradox. First, spiking of an 'integrate-and-fire' neuron driven by excitatory postsynaptic potentials with a width at half-maximum height of 250 mu s, has an accuracy of 25 mu s if the presynaptic signals arrive coherently. Second, the necessary degree of coherence in the signal arrival times can be attained during ontogenetic development by virtue of an unsupervised hebbian learning rule, Learning selects connections with matching delays from a broad distribution of axons with random delays, Third, the learning rule also selects the correct delays from two independent groups of inputs, for example, from the left and right ear.	TECH UNIV MUNICH,DEPT PHYS,D-85747 GARCHING,GERMANY; TECH UNIV MUNICH,FAK CHEM & BIOL,D-85747 GARCHING,GERMANY	Technical University of Munich; Technical University of Munich			Wagner, Hermann/G-5454-2012	Wagner, Hermann/0000-0002-8191-7595				Abeles M, 1994, MODELS NEURAL NETWOR, P121, DOI [10.1007/978-1-4612-4320-5_3, DOI 10.1007/978-1-4612-4320-5_3]; BERNANDER O, 1991, P NATL ACAD SCI USA, V88, P11569, DOI 10.1073/pnas.88.24.11569; BIALEK W, 1991, SCIENCE, V252, P1854, DOI 10.1126/science.2063199; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRAITENBERG V, 1993, NETWORK-COMP NEURAL, V4, P11, DOI 10.1088/0954-898X/4/1/002; CARR CE, 1993, ANNU REV NEUROSCI, V16, P223, DOI 10.1146/annurev.ne.16.030193.001255; CARR CE, 1990, J NEUROSCI, V10, P3227; CARR CE, 1995, ADV HEARING RES, P24; DEBANNE D, 1994, P NATL ACAD SCI USA, V91, P1148, DOI 10.1073/pnas.91.3.1148; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GOLDBERG JM, 1969, J NEUROPHYSIOL, V32, P613, DOI 10.1152/jn.1969.32.4.613; HEBB DO, 1949, ORG BEHAVIOR; Heiligenberg W., 1991, NEURAL NETS ELECT FI; HERZ AV, 1989, BIOL CYBERN, V60, P457, DOI 10.1007/BF00204701; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; JEFFRESS LA, 1948, J COMP PHYSIOL PSYCH, V41, P35, DOI 10.1037/h0061495; KNUDSEN EI, 1979, J COMP PHYSIOL, V133, P1, DOI 10.1007/BF00663105; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MANIS PB, 1991, J NEUROSCI, V11, P2865; Markram Henry, 1995, Society for Neuroscience Abstracts, V21, P2007; MOISEFF A, 1981, J COMP PHYSIOL, V144, P299, DOI 10.1007/BF00612561; OERTEL D, 1983, J NEUROSCI, V3, P2043; REYES AD, 1994, J NEUROSCI, V14, P5352; Reyes AD, 1996, J NEUROSCI, V16, P993; SALINAS E, 1994, J COMPUT NEUROSCI, V1, P87; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; Softky W R, 1995, Curr Opin Neurobiol, V5, P239, DOI 10.1016/0959-4388(95)80032-8; SOFTKY WR, 1993, J NEUROSCI, V13, P334; SULLIVAN WE, 1984, J NEUROSCI, V4, P1787; YIN TCT, 1990, J NEUROPHYSIOL, V64, P465, DOI 10.1152/jn.1990.64.2.465	30	745	767	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					76	78		10.1038/383076a0	http://dx.doi.org/10.1038/383076a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779718	Green Submitted			2022-12-24	WOS:A1996VF29500050
J	Maguire, CP; Kirby, M; Coen, R; Coakley, D; Lawlor, BA; ONeill, D				Maguire, CP; Kirby, M; Coen, R; Coakley, D; Lawlor, BA; ONeill, D			Family members' attitudes toward telling the patient with Alzheimer's disease their diagnosis	BRITISH MEDICAL JOURNAL			English	Article											Maguire, CP (corresponding author), ST JAMES HOSP,MERCERS INST RES AGING,DUBLIN 8,IRELAND.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				BAHRO M, 1995, J AM GERIATR SOC, V43, P41, DOI 10.1111/j.1532-5415.1995.tb06240.x; DRICKAMER MA, 1992, NEW ENGL J MED, V326, P947, DOI 10.1056/NEJM199204023261410; MICHON A, 1994, J NEUROL NEUROSUR PS, V57, P805, DOI 10.1136/jnnp.57.7.805; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; ROHDE K, 1995, J AM GERIATR SOC, V43, P187, DOI 10.1111/j.1532-5415.1995.tb06388.x	5	107	107	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					529	530		10.1136/bmj.313.7056.529	http://dx.doi.org/10.1136/bmj.313.7056.529			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VF294	8789979	Green Published			2022-12-24	WOS:A1996VF29400019
J	Meredith, S; Watson, JM; Citron, KM; Cockcroft, A; Darbyshire, JH				Meredith, S; Watson, JM; Citron, KM; Cockcroft, A; Darbyshire, JH			Are healthcare workers in England and Wales at increased risk of tuberculosis?	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether healthcare workers in England and Wales are at increased risk of tuberculosis and to examine the frequency of drug resistance in this population. Design-Comparison of notification rates by occupation obtained from national tuberculosis notification surveys in 1988 and 1993, with denominators from the 1991 census. Subjects-People with notified tuberculosis in professional and associate professional occupations from the two surveys. Main outcome measures-Rates of notified tuberculosis in health professionals (mainly doctors) and health associate professionals (mainly nurses) compared with rates in other professional and associate professional occupations, adjusted for ethnic group, sex, and age. Results-119 cases of tuberculosis were identified in healthcare workers, including 61 nurses and 42 doctors. The crude notification rate in healthcare workers was 11.8 per 100 000 per year (95% confidence interval 9.8 to 14.1) compared with 3.3 per 100 000 per year (2.9 to 3.6) in other professional and associate professional occupations; rate ratios were higher (range 1.7 to 3.2) in all ethnic groups. The relative risk adjusted for ethnic group, sex, and age was 2.4 (95% confidence interval 2.0 to 3.0), slightly higher for health professionals (2.7 (1.9 to 3.8)) than for associate professionals (2.0 (1.5 to 2.6)). No multiple drug resistant strains of tuberculosis were identified in healthcare workers. Conclusions-Better detection and notification of cases of tuberculosis in healthcare workers may account for some of the apparent increased risk, but these findings imply that tuberculosis remains a hazard for healthcare workers and highlight the importance of ensuring that occupational health monitoring and protection workers are not neglected.	UNIV LONDON, COLL MED, DEPT EPIDEMIOL & MED STAT, LONDON E1 4NS, ENGLAND; PUBL HLTH LAB SERV, CTR COMMUNICABLE DIS SURVEILLANCE, LONDON NW9 5EQ, ENGLAND; ROYAL BROMPTON HOSP, LONDON SW3 6NP, ENGLAND; UNIV LONDON ROYAL FREE HOSP, LONDON NW3 2QG, ENGLAND; UCL, SCH MED, MRC, HIV CLIN TRIALS CTR, LONDON WC1E 6AU, ENGLAND	University of London; Public Health England; Royal Brompton Hospital; University of London; University College London; Medical Research Council Clinical Trials Unit; University of London; University College London; UCL Medical School								ABRUZZI WA, 1953, NEW ENGL J MED, V248, P722, DOI 10.1056/NEJM195304232481705; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; CAPEWELL S, 1988, TUBERCLE, V69, P113, DOI 10.1016/0041-3879(88)90073-6; CHILDRESS WG, 1951, JAMA-J AM MED ASSOC, V146, P1188, DOI 10.1001/jama.1951.03670130010004; *COMP RES CTR, 1992, STAT REF MAN REL 3 0; DANIELS M, 1948, TUBERCULOSIS YOUNG A, V2; *EMPL DEP GROUP OF, 1990, STAND OCC CLASS; HARRINGTON JM, 1976, BRIT MED J, V1, P759, DOI 10.1136/bmj.1.6012.759; Hayward A C, 1995, Commun Dis Rep CDR Rev, V5, pR29; HEIMBECK J., 1936, Tubercle, V18, P97, DOI 10.1016/S0041-3879(36)80249-9; LOUGHREY C, 1992, American Review of Respiratory Disease, V145, pA103; LUNN JA, 1989, J SOC OCCUP MED, V39, P30; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206; MEREDITH SK, 1992, THORAX, V47, P770; MIKOL EX, 1952, AM REV TUBERC PULM, V66, P16; *OFF POP CENS SURV, 1994, 1991 CENS EC ACT GRE; REID DD, 1957, BMJ-BRIT MED J, V2, P10, DOI 10.1136/bmj.2.5035.10; SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012; SHELDON CD, 1992, THORAX, V47, P1015, DOI 10.1136/thx.47.12.1015; SKINNER C, 1994, THORAX, V49, P1193, DOI 10.1136/thx.49.12.1193; Warburton A R, 1993, Commun Dis Rep CDR Rev, V3, pR175; WATSON JM, 1995, THORAX, V50, pP442	23	43	43	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					522	525						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789976	Green Published			2022-12-24	WOS:A1996VF29400016
J	Cuttler, L; Silvers, JB; Singh, J; Marrero, U; Finkelstein, B; Tannin, G; Neuhauser, D				Cuttler, L; Silvers, JB; Singh, J; Marrero, U; Finkelstein, B; Tannin, G; Neuhauser, D			Short stature and growth hormone therapy - A national study of physician recommendation patterns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SHORT CHILDREN; FINAL HEIGHT; DEFICIENCY; CHILDHOOD; GH	Objective.-To determine current expert opinion and recommendations regarding the controversial issue of the use of growth hormone (GH) to treat short children who do not have classical GH deficiency (non-GHD children). Study Design.-Analysis of a national survey mailed to 534 US physician experts on the management of short stature (pediatric endocrinologists) with a response rate of 81.3%. Main Outcome Measure.-The experts' GH treatment recommendations. Results.-The physicians reported that approximately 58% of their current patients undergoing GH therapy have classical GH deficiency, while 42% have other conditions. The proportion of physicians who recommended GH treatment of short non-GHD children ranged from 1% to 74% over all case scenarios presented. The likelihood of GH being recommended depended on the physiological growth characteristics of the child tie, the child's height, growth rate, and predicted adult height), contingency factors tie, strong family wishes or a reduction in GH cost), and physician beliefs tie, the impact of short stature on well-being, the effectiveness of GH therapy), Each of these factors exerted highly significant, independent, and additive effects on decisions to recommend GH. Conclusion.-Our results indicate that many pediatric endocrinologists consider GH treatment appropriate for selected short non-GHD children, going beyond current Food and Drug Administration-approved indications for GH. Decisions to recommend GH for a non-GHD child rest on a combination of medical, social, and perceptual factors; variations in treatment patterns stem from variations in these influences. Future GH use will likely be determined not only by the results of controlled trials, but also by family preferences, producer pricing, and physician perceptions of the value of height and GH therapy.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PEDIAT, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT EPIDEMIOL & BIOSTAT, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, WEATHERHEAD SCH MANAGEMENT, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University								ALLEN DB, 1990, J PEDIATR-US, V117, P16, DOI 10.1016/S0022-3476(05)82438-2; [Anonymous], 1978, MAIL TELEPHONE SURVE; AUGUST GP, 1990, J PEDIATR-US, V116, P899, DOI 10.1016/S0022-3476(05)80647-X; BAYLEY N, 1952, J PEDIATR-US, V40, P423, DOI 10.1016/S0022-3476(52)80205-7; BIERICH JR, 1992, ACTA ENDOCRINOL-COP, V127, P392, DOI 10.1530/acta.0.1270392; CARA JF, 1990, PEDIATR CLIN N AM, V37, P1229; CHIPMAN JJ, 1993, HORM RES, V39, P18, DOI 10.1159/000182761; CUTTLER L, 1987, Pediatrician, V14, P109; DARENDELILER F, 1990, HORM RES, V128, P33; FRASIER SD, 1990, J CLIN ENDOCR METAB, V71, P269, DOI 10.1210/jcem-71-2-269; FURLANETTO RW, 1995, J PEDIATR-US, V127, P857; GERTNER JM, 1984, J PEDIATR-US, V104, P172, DOI 10.1016/S0022-3476(84)80987-7; GORMAN C, 1995, TIME            0410, P60; GUYDA HJ, 1994, TRENDS ENDOCRIN MET, V5, P334, DOI 10.1016/1043-2760(94)90163-5; HAMILTON J, 1990, BUSINESS WEEK   0730, P66; HAMILTON J, 1990, BUSINESS WEEK   0730, P69; HILTS PJ, 1992, NY TIMES        0514, pD7; HILTS PJ, 1992, NY TIMES        0514, pD4; HINTZ R, 1995, PEDIATR RES, V37, pA91; HINTZ RL, 1992, HORM RES, V38, P44, DOI 10.1159/000182569; HOPWOOD NJ, 1993, J PEDIATR-US, V123, P215, DOI 10.1016/S0022-3476(05)81691-9; Hosmer D, 1989, APPL LOGISTIC REGRES, P148; KAPLAN SL, 1993, ADV INTERNAL MED, V38, P287; KAPLOWITZ PB, 1995, J PEDIATR-US, V126, P478, DOI 10.1016/S0022-3476(95)70475-2; LANTOS J, 1989, JAMA-J AM MED ASSOC, V261, P1020, DOI 10.1001/jama.261.7.1020; LIN TH, 1989, J PEDIATR-US, V115, P57, DOI 10.1016/S0022-3476(89)80329-4; LIPPE BM, 1993, RECENT PROG HORM RES, V48, P179; MCPHERSON K, 1994, J EPIDEMIOL COMMUN H, V48, P6, DOI 10.1136/jech.48.1.6; MOORE KC, 1993, J PEDIATR-US, V122, P687, DOI 10.1016/S0022-3476(06)80005-3; OMEARA JJ, 1994, NEW ENGL J MED, V330, P1864, DOI 10.1056/NEJM199406303302605; QUAID KA, 1993, AM J MED GENET, V45, P41, DOI 10.1002/ajmg.1320450112; RANKE MB, 1993, ACTA PAEDIATR, V82, P82, DOI 10.1111/j.1651-2227.1993.tb12936.x; ROSENBLOOM AL, 1990, CLIN PEDIATR, V29, P288, DOI 10.1177/000992289002900507; ROSENFELD RG, 1995, J CLIN ENDOCR METAB, V80, P1532, DOI 10.1210/jc.80.5.1532; ROSENFELD RG, 1992, ACTA PAEDIATR, V81, P3; ROSENFIELD RL, 1995, ENDOCRINOLOGY, P2549; RUVALCABA RHA, 1993, CLIN PEDIATR, V32, P292, DOI 10.1177/000992289303200507; SILINK M, 1992, Journal of Pediatric Endocrinology, V5, P43; TANNER JM, 1985, J PEDIATR-US, V107, P317, DOI 10.1016/S0022-3476(85)80501-1; THOMSETT M, 1993, MED J AUSTRALIA, V158, P802, DOI 10.5694/j.1326-5377.1993.tb137664.x; UNDERWOOD LE, 1992, HOSP PRACT, V27, P192; VANVLIET G, 1983, NEW ENGL J MED, V309, P1016; VIMPANI GV, 1977, BMJ-BRIT MED J, V2, P427, DOI 10.1136/bmj.2.6084.427; WEISS R, 1994, WASHINGTON POST 0315; WENNBERG JE, 1991, JAMA-J AM MED ASSOC, V265, P1306, DOI 10.1001/jama.265.10.1306; ZADIK Z, 1992, J PEDIATR-US, V121, P44, DOI 10.1016/S0022-3476(05)82539-9; 1994, MED LETT        0902, V36, P77	47	83	84	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					531	537		10.1001/jama.276.7.531	http://dx.doi.org/10.1001/jama.276.7.531			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC101	8709401				2022-12-24	WOS:A1996VC10100028
J	Evans, E; Bowman, H; Leung, A; Needham, D; Tirrell, D				Evans, E; Bowman, H; Leung, A; Needham, D; Tirrell, D			Biomembrane templates for nanoscale conduits and networks	SCIENCE			English	Article							FILLING CARBON NANOTUBES; MEMBRANE; TUBULES; TETHER; GIANT	Long nanotubes of fluid-lipid bilayers can be used to create templates for photochemical polymerization into solid-phase conduits and networks. Each nanotube is pulled from a micropipette-held feeder vesicle by mechanical retraction of the vesicle after molecular bonding to a rigid substrate. The caliber of the tube is controlled precisely in a range from 20 to 200 nanometers merely by setting the suction pressure in the micropipette. Branched conduits can be formed by coalescing separate nanotubes drawn serially from the feeder vesicle surface. Single nanotubes and nanotube junctions can be linked together between bonding sites on a surface to create a functionalized network. After assembly, the templates can be stabilized by photoinitiated radical cross-linking of macromonomers contained in the aqueous solution confined by the lipid bilayer boundary.	UNIV BRITISH COLUMBIA,DEPT PATHOL,VANCOUVER,BC V6T 1W5,CANADA; UNIV MASSACHUSETTS,DEPT POLYMER SCI & ENGN,AMHERST,MA 01003; DUKE UNIV,DEPT MECH ENGN & MAT SCI,DURHAM,NC 27708	University of British Columbia; University of Massachusetts System; University of Massachusetts Amherst; Duke University	Evans, E (corresponding author), UNIV BRITISH COLUMBIA,DEPT PHYS,6224 AGR RD,VANCOUVER,BC V6T 1W5,CANADA.			Needham, David/0000-0002-0082-9148				ANSETH KS, 1995, MACROMOLECULES, V28, P2491, DOI 10.1021/ma00111a050; ARCHIBALD DD, 1993, NATURE, V364, P430, DOI 10.1038/364430a0; BARAL S, 1993, CHEM MATER, V5, P145, DOI 10.1021/cm00026a001; BO L, 1989, BIOPHYS J, V55, P509, DOI 10.1016/S0006-3495(89)82844-9; CHOPRA NG, 1995, SCIENCE, V269, P966, DOI 10.1126/science.269.5226.966; Eaton DF, 1986, ADV PHOTOCHEM, V13, P427; EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094; EVANS E, 1994, CHEM PHYS LIPIDS, V73, P39, DOI 10.1016/0009-3084(94)90173-2; HEATH JR, 1993, CHEM PHYS LETT, V208, P263, DOI 10.1016/0009-2614(93)89073-Q; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; HOCHMUTH RM, 1982, BIOPHYS J, V39, P71, DOI 10.1016/S0006-3495(82)84492-5; HOCHMUTH RM, 1983, SCIENCE, V220, P101, DOI 10.1126/science.6828875; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; LAGO RM, 1995, J CHEM SOC CHEM COMM, P1355, DOI 10.1039/c39950001355; NEEDHAM D, 1988, BIOCHEMISTRY-US, V27, P8261, DOI 10.1021/bi00421a041; NEEDHAM D, 1993, METHOD ENZYMOL, V220, P111, DOI 10.1016/0076-6879(93)20078-H; SCHNUR JM, 1993, SCIENCE, V262, P1669, DOI 10.1126/science.262.5140.1669; TSANG SC, 1994, NATURE, V372, P159, DOI 10.1038/372159a0; WHITESIDES GM, 1995, SCI AM, V273, P146; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; Yeung A. K. C., 1994, THESIS U BRIT COLUMB; ZAKRZEWSKI A, 1987, TETRAHEDRON, V43, P4507, DOI 10.1016/S0040-4020(01)86891-5	22	195	198	2	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					933	935		10.1126/science.273.5277.933	http://dx.doi.org/10.1126/science.273.5277.933			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688071				2022-12-24	WOS:A1996VC67000054
J	Day, JH; Grant, AD; Doherty, JF; Chiodini, PL; Wright, SG				Day, JH; Grant, AD; Doherty, JF; Chiodini, PL; Wright, SG			Schistosomiasis in travellers returning from sub-Saharan Africa	BRITISH MEDICAL JOURNAL			English	Article									HOSP TROP DIS,LONDON NW1 0PE,ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine								BLANCHARD TJ, 1993, LANCET, V341, P959, DOI 10.1016/0140-6736(93)91249-L; HARRIES AD, 1986, LANCET, V1, P86; JORDAN P, 1993, HUMAN SCHISTOSOMIASI, P16; WHITWORTH JAG, 1993, BRIT MED J, V307, P936, DOI 10.1136/bmj.307.6909.936-c	4	36	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					268	269		10.1136/bmj.313.7052.268	http://dx.doi.org/10.1136/bmj.313.7052.268			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704539	Green Published			2022-12-24	WOS:A1996VA90300028
J	Shaham, S; Horvitz, HR				Shaham, S; Horvitz, HR			An alternatively spliced C-elegans ced-4 RNA encodes a novel cell death inhibitor	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; BCL-2 HOMOLOG BAK; GENE CED-3; IL-1-BETA-CONVERTING ENZYME; APOPTOSIS; PROTEIN; INDUCTION; SURVIVAL; PROTOONCOGENE; CLONING	The C. elegans gene ced-4 is essential for programmed cell death. We report that ced-4 encodes two transcripts and that whereas the major transcript can cause programmed cell death, the minor transcript can act oppositely and prevent programmed cell death, thus defining a novel class of cell death inhibitors. That ced-4 has both cell-killing and cell-protective functions is consistent with previous genetic studies. Our results suggest that the dual protective and killer functions of the C. elegans bcl-2-like gene ced-9 are mediated by inhibition of the killer and protective ced-4 functions, respectively. We propose that a balance between opposing ced-4 functions influences the decision of a cell to live or to die by programmed cell death and that both ced-9 and ced-4 protective functions are required to prevent programmed cell death.	MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)								BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRENNER S, 1974, GENETICS, V77, P71; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Cortazzo M, 1996, CANCER RES, V56, P1199; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EMMONS SW, 1988, NEMATODE CAENORHABDI, P47; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HORVITZ HR, 1979, MOL GEN GENET, V175, P129, DOI 10.1007/BF00425528; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TRENT C, 1983, GENETICS, V104, P619; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	44	124	133	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					201	208		10.1016/S0092-8674(00)80092-6	http://dx.doi.org/10.1016/S0092-8674(00)80092-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706125	Bronze			2022-12-24	WOS:A1996UZ97200006
J	Cowing, D; Kenyon, C				Cowing, D; Kenyon, C			Correct Hox gene expression established independently of position in Caenorhabditis elegans	NATURE			English	Article							C-ELEGANS; HOMEOBOX GENES; BODY REGION; CELL FATES; EMBRYO; POLARITY; GLP-1	THE Hox genes are expressed in a conserved sequence of spatial domains along the anteroposterior (A/P) body axes of many organisms(1). In Drosophila, position-specific signals located along the A/P axis establish the pattern of Hox gene expression(2-4). In the nematode Caenorhabditis elegans, it is not known how the pattern of Hox gene expression is established, C. elegans uses lineal control mechanisms and local cell interactions to specify early blastomere identities(5,6). However, many cells expressing the same Hox gene are unrelated by lineage, suggesting that, as in Drosophila, domains of Hox gene expression may be defined by cell-extrinsic A/P positional signals. To test this, we have investigated whether posterior mesodermal and ectodermal cells will express their normal posterior Hox gene when they are mispositioned in the anterior. Surprisingly, we find that correct Hox gene expression does not depend on cell position, but is highly correlated with cell lineage, Thus, although the most striking feature of Hox gene expression is its positional specificity, in C. elegans the pattern is achieved, at least in part, by a lineage-specific control system that operates without regard to A/P position.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								CHALFIE M, 1994, SCIENCE, V263; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; COWING DW, 1992, DEVELOPMENT, V116, P481; Dustin P., 1984, MICROTUBULES; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; HUTTER H, 1995, DEVELOPMENT, V121, P1559; HUTTER H, 1994, DEVELOPMENT, V120, P2051; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McGinnis W, 1990, Adv Genet, V27, P363; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MOSKOWITZ IPG, 1994, DEVELOPMENT, V120, P3325; NARDELLIHAEFLIGER D, 1994, DEVELOPMENT, V120, P1839; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; PRIESS JR, 1994, CURR OPIN GENET DEV, V4, P563, DOI 10.1016/0959-437X(94)90073-C; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SALSER SJ, 1993, GENE DEV, V7, P1714, DOI 10.1101/gad.7.9.1714; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WOOD WB, 1994, TRENDS GENET, V10, P49, DOI 10.1016/0168-9525(94)90148-1	23	37	38	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					353	356		10.1038/382353a0	http://dx.doi.org/10.1038/382353a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684464				2022-12-24	WOS:A1996UY95000052
J	Aramayo, R; Metzenberg, RL				Aramayo, R; Metzenberg, RL			Meiotic transvection in fungi	CELL			English	Article							DROSOPHILA-ZESTE PROTEIN; WHITE GENE-EXPRESSION; NEUROSPORA-CRASSA; TRANS-INACTIVATION; PAIRING DEPENDENCE; ULTRABITHORAX GENE; MOLECULAR ANALYSIS; BITHORAX COMPLEX; SELF-ASSOCIATION; BROWN GENE	The Neurospora crassa Asm-1(+) (ascospore maturation 1) gene encodes an abundant nucleus-localized protein required for formation of female structures and for ascospore maturation. Deletion mutants of Asm-1(+) are ''ascus-dominant,'' i.e., when crossed to wild type, neither Asm-1(+) nor Asm-1(Delta) spores mature. To explain this behavior, we considered three models: an effect of reduced dosage of the gene product, failure of internuclear communication, and failure of transvection (regulation dependent on pairing of alleles). We found that for proper regulation of subsequent sexual sporulation, Asm-1(+) must be in proximity, probably paired, to its allelic counterpart in the zygote: i.e., transvection must occur. Disruption of pairing causes failure of ascospore progeny to mature. Transvection in Neurospora, unlike in Drosophila, occurs immediately before meiosis, and can be demonstrated between wildtype alleles.	UNIV WISCONSIN,DEPT BIOMOL CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Aramayo, Rodolfo/0000-0001-9702-6204	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM008995, R01GM008995] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08995] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAMAYO R, 1996, IN PRESS FUNGAL GENE, V43; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BABU P, 1987, MOL GEN GENET, V210, P557, DOI 10.1007/BF00327212; BENSON M, 1988, EMBO J, V7, P3907, DOI 10.1002/j.1460-2075.1988.tb03277.x; BESTOR TH, 1994, DEV GENET, V15, P458, DOI 10.1002/dvg.1020150603; BICKEL S, 1990, EMBO J, V9, P2959, DOI 10.1002/j.1460-2075.1990.tb07488.x; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BISTIS GN, 1983, EXP MYCOL, V7, P292, DOI 10.1016/0147-5975(83)90051-8; BISTIS GN, 1981, MYCOLOGIA, V73, P959, DOI 10.2307/3759806; BOLLMANN J, 1991, PLANT CELL, V3, P1327, DOI 10.1105/tpc.3.12.1327; BROCKMAN HE, 1963, AM J BOT, V50, P709, DOI 10.2307/2440049; CHEN JD, 1992, MOL CELL BIOL, V12, P598, DOI 10.1128/MCB.12.2.598; CHEN JD, 1993, EMBO J, V12, P2061, DOI 10.1002/j.1460-2075.1993.tb05855.x; COEN ES, 1988, EMBO J, V7, P877, DOI 10.1002/j.1460-2075.1988.tb02891.x; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DAVISON D, 1985, GENETICS, V110, P479; de TERRA NOEL, 1963, AMER JOUR BOT, V50, P669; DREESEN TD, 1991, GENE DEV, V5, P331, DOI 10.1101/gad.5.3.331; ELLIS N, 1989, TRENDS GENET, V5, P406, DOI 10.1016/0168-9525(89)90199-6; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; GEYER PK, 1988, P NATL ACAD SCI USA, V85, P3938, DOI 10.1073/pnas.85.11.3938; GEYER PK, 1990, EMBO J, V9, P2247, DOI 10.1002/j.1460-2075.1990.tb07395.x; GEYER PK, 1986, EMBO J, V5, P2657, DOI 10.1002/j.1460-2075.1986.tb04548.x; GLASS NL, 1988, SCIENCE, V241, P570, DOI 10.1126/science.2840740; GLASS NL, 1990, P NATL ACAD SCI USA, V87, P4912, DOI 10.1073/pnas.87.13.4912; GRIFFITHS AJF, 1978, GENETICS, V88, P239; GUBB D, 1990, GENETICS, V126, P167; HAZELRIGG T, 1992, GENETICS, V130, P125; HENIKOFF S, 1989, P NATL ACAD SCI USA, V86, P6704, DOI 10.1073/pnas.86.17.6704; HENIKOFF S, 1994, GENETICS, V138, P1; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOPMANN R, 1995, GENETICS, V139, P815; JACK JW, 1979, P NATL ACAD SCI USA, V76, P1368, DOI 10.1073/pnas.76.3.1368; JACOBSON DJ, 1992, FUNGAL GENET NEWSL, V39, P24; JUDD BH, 1988, CELL, V53, P841, DOI 10.1016/S0092-8674(88)90209-7; KASSIS JA, 1991, GENETICS, V128, P751; KLAR AJS, 1980, GENETICS, V94, P597; LANEY JD, 1992, GENE DEV, V6, P1531, DOI 10.1101/gad.6.8.1531; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MARTINEZLABORDA A, 1992, EMBO J, V11, P3645, DOI 10.1002/j.1460-2075.1992.tb05449.x; MATHOG D, 1990, GENETICS, V125, P371; METZENBERG RL, 1988, FUNGAL GENET NEWSL, V35, P28; MICOL JL, 1988, P NATL ACAD SCI USA, V85, P1146, DOI 10.1073/pnas.85.4.1146; MICOL JL, 1990, GENETICS, V126, P365; Murray J. C., 1959, Proceedings of the IX International Botanical Congress, Montreal, August 19-29, 1959., V2, pp; MURRAY JAY C., 1962, CANADIAN JOUR BOT, V40, P337; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; PERKINS DD, 1982, MICROBIOL REV, V46, P426, DOI 10.1128/MMBR.46.4.426-570.1982; PERKINS DD, 1962, NEUROSPORA NEWSL, V2, P14; PERKINS DD, 1984, NEUROSPORA NEWSL, V31, P41; Perkins DD., 1988, FUNGAL GENET NEWSL, V35, P29; PERKINS DD, 1966, NEUROSPORA NEWSL, V9, P11; PETERSON KM, 1994, MOL GEN GENET, V242, P717, DOI 10.1007/BF00283427; PHILLEY ML, 1994, GENETICS, V137, P715; QIAN S, 1992, GENETICS, V131, P79; RAJU NB, 1977, EXP MYCOL, V1, P152, DOI 10.1016/S0147-5975(77)80040-6; RAJU NB, 1980, EUR J CELL BIOL, V23, P208; RAJU NB, 1992, MYCOL RES, V96, P241, DOI 10.1016/S0953-7562(09)80934-9; RAJU NB, 1988, MYCOLOGIA, V80, P825, DOI 10.2307/3807561; RUSSELL PJ, 1972, GENETICS, V71, P233; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SMOLIKUTLAUT SM, 1987, GENETICS, V116, P285; SPRINGER ML, 1993, BIOESSAYS, V15, P365, DOI 10.1002/bies.950150602; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TIMBERLAKE W E, 1986, P343; TURNER BC, 1977, GENETICS, V85, P439; WESTERGAARD M, 1947, AM J BOT, V34, P573, DOI 10.2307/2437339; WU CT, 1989, TRENDS GENET, V5, P189, DOI 10.1016/0168-9525(89)90074-7; WU CT, 1993, J CELL BIOL, V120, P587, DOI 10.1083/jcb.120.3.587	72	146	155	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					103	113		10.1016/S0092-8674(00)80081-1	http://dx.doi.org/10.1016/S0092-8674(00)80081-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689677	Bronze			2022-12-24	WOS:A1996UX93400012
J	Raabe, T; RiesgoEscovar, J; Liu, XD; Bausenwein, BS; Deak, P; Maroy, P; Hafen, E				Raabe, T; RiesgoEscovar, J; Liu, XD; Bausenwein, BS; Deak, P; Maroy, P; Hafen, E			DOS, a novel pleckstrin homology domain-containing protein required for signal transduction between sevenless and RAS1 in Drosophila	CELL			English	Article							RECEPTOR TYROSINE KINASE; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOTYROSINE PHOSPHATASE; 2ND CHROMOSOME; EYE; ACTIVATION; MELANOGASTER; LIGAND; TORSO; PHOSPHORYLATION	The specification of the R7 photoreceptor cell in the developing eye of Drosophila is dependent upon activation of the Sevenless (SEV) receptor tyrosine kinase. By screening for mutations that suppress signaling via a constitutively activated SEV protein, we have identified a novel gene, daughter of sevenless (dos). DOS is required not only for signal transduction via SEV but also in other receptor tyrosine kinase signaling pathways throughout development. The presence of an amino-terminally located pleckstrin homology domain and many potential tyrosine phosphorylation sites suggests that DOS functions as an adaptor protein able to interact with multiple signaling molecules. Our genetic analysis demonstrates that DOS functions upstream of Ras1 and defines a signaling pathway that is independent of direct binding of the DRK SH2/SH3 adaptor protein to the SEV receptor tyrosine kinase.	UNIV WURZBURG, THEODOR BOVERI INST BIOWISSENSCH, LEHRSTUHL GENET, D-97074 WURZBURG, GERMANY; ATTILA JOZSEF UNIV, DEPT GENET, H-6701 SZEGED, HUNGARY	University of Wurzburg; Szeged University	Raabe, T (corresponding author), UNIV ZURICH, INST ZOOL, WINTERTHURERSTR 190, CH-8057 ZURICH, SWITZERLAND.		Deák, Péter/M-5674-2018; Deak, Peter/F-7751-2012	Deak, Peter/0000-0002-8849-0352				Allard JD, 1996, DEVELOPMENT, V122, P1137; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; CHOU TB, 1993, DEVELOPMENT, V119, P1359; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAFEN E, 1993, DEVELOPMENT, P41; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SIMON MA, 1994, DEV BIOL, V166, P431, DOI 10.1006/dbio.1994.1327; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STERN MJ, 1994, DEV BIOL, V166, P443, DOI 10.1006/dbio.1994.1328; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SZABAD J, 1989, GENETICS, V122, P823; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; TOROK T, 1993, GENETICS, V135, P71; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wolff Tanya, 1993, P1277; XU T, 1993, DEVELOPMENT, V117, P1223; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	55	179	181	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1996	85	6					911	920		10.1016/S0092-8674(00)81274-X	http://dx.doi.org/10.1016/S0092-8674(00)81274-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681385	Bronze, Green Accepted			2022-12-24	WOS:A1996UR60400014
J	Arieli, A; Sterkin, A; Grinvald, A; Aertsen, A				Arieli, A; Sterkin, A; Grinvald, A; Aertsen, A			Dynamics of ongoing activity: Explanation of the large variability in evoked cortical responses	SCIENCE			English	Article							PRIMARY VISUAL-CORTEX; ELECTRICAL-ACTIVITY; ORIENTATION DISCRIMINATION; SINGLE CELLS; NEURONS; MONKEY; BRAIN; CAT; PATTERNS; PERFORMANCE	Evoked activity in the mammalian cortex and the resulting behavioral responses exhibit a large variability to repeated presentations of the same stimulus. This study examined whether the variability can be attributed to ongoing activity, Ongoing and evoked spatiotemporal activity patterns in the cat visual cortex were measured with real-time optical imaging; local field potentials and discharges of single neurons were recorded simultaneously, by electrophysiological techniques. The evoked activity appeared deterministic, and the variability resulted from the dynamics of ongoing activity, presumably reflecting the instantaneous state of cortical networks, In spite of the large variability, evoked responses in single trials could be predicted by linear summation of the deterministic response and the preceding ongoing activity, Ongoing activity must play an important role in cortical function and cannot be ignored in exploration of cognitive processes.			Arieli, A (corresponding author), WEIZMANN INST SCI, DEPT NEUROBIOL, POB 26, IL-76100 REHOVOT, ISRAEL.							ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; ARIELI A, 1995, J NEUROPHYSIOL, V73, P2072, DOI 10.1152/jn.1995.73.5.2072; Arieli A., 1995, Society for Neuroscience Abstracts, V21, P772; ARIELI A, 1992, INFORMATION PROCESSI, P123; ARIELI A, IN PRESS SOC NEUR AB; BLAIR W, 1994, SOC NEUR ABSTR, V20, P1279; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; COOPER R, 1965, ELECTROEN CLIN NEURO, V18, P217, DOI 10.1016/0013-4694(65)90088-X; Creutzfeldt O., 1974, HDB ELECTROENCEPHALO, V2C, P5; Elul R, 1971, Int Rev Neurobiol, V15, P227; FERSTER D, 1995, SCIENCE, V270, P756, DOI 10.1126/science.270.5237.756; GEISLER WS, 1995, VISION RES, V35, P2723, DOI 10.1016/0042-6989(95)00029-Y; GERSTEIN GL, 1960, SCIENCE, V131, P1811, DOI 10.1126/science.131.3416.1811; GEVINS AS, 1980, CRC CR REV BIOM ENG, V4, P113; GRATTON G, 1995, PSYCHOPHYSIOLOGY, V32, P292, DOI 10.1111/j.1469-8986.1995.tb02958.x; GRINVALD A, 1994, J NEUROSCI, V14, P2545; GRINVALD A, 1982, J PHYSIOL-LONDON, V333, P269, DOI 10.1113/jphysiol.1982.sp014453; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; GRINVALD A, 1984, NATURE, V308, P848, DOI 10.1038/308848a0; HARTVEIT E, 1994, J NEUROPHYSIOL, V72, P1278, DOI 10.1152/jn.1994.72.3.1278; HEGGELUND P, 1978, EXP BRAIN RES, V32, P197; Holt Gary R., 1995, Society for Neuroscience Abstracts, V21, P22; JOHN ER, 1972, SCIENCE, V177, P850, DOI 10.1126/science.177.4052.850; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Mechler F., 1995, Society for Neuroscience Abstracts, V21, P22; ORBACH HS, 1985, J NEUROSCI, V5, P1886; Regan D., 1989, HUMAN BRAIN ELECTROP; ROSENBLITH WA, 1959, PROCESSING NEUROELEC; SCHILLER PH, 1976, BRAIN RES, V105, P347, DOI 10.1016/0006-8993(76)90432-7; SCOBEY RP, 1989, EXP BRAIN RES, V77, P398, DOI 10.1007/BF00274997; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; Shadlen MN, 1996, J NEUROSCI, V16, P1486; SHAW GL, 1982, EXP NEUROL, V77, P324, DOI 10.1016/0014-4886(82)90249-7; SNOWDEN RJ, 1992, EXP BRAIN RES, V88, P389, DOI 10.1007/BF02259114; SOFTKY WR, 1993, J NEUROSCI, V13, P334; STERKIN A, UNPUB; VOGELS R, 1989, EXP BRAIN RES, V77, P432, DOI 10.1007/BF00275002; WHEAT HE, 1995, J NEUROSCI, V15, P5582	38	1235	1251	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	1996	273	5283					1868	1871		10.1126/science.273.5283.1868	http://dx.doi.org/10.1126/science.273.5283.1868			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791593				2022-12-24	WOS:A1996VJ71300047
J	Farrar, MA; AlberolaIla, J; Perlmutter, RM				Farrar, MA; AlberolaIla, J; Perlmutter, RM			Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization	NATURE			English	Article							BINDS COUMARIN DRUGS; NIH 3T3 CELLS; PROTEIN-KINASE; PLASMA-MEMBRANE; DNA GYRASE; SIGNAL-TRANSDUCTION; IN-VITRO; RAS; PHOSPHORYLATION; SUBDOMAIN	THE Raf-1 serine/threonine kinase is a key component of the MAP kinase cascade(1-3), regulating both proliferation and commitment to cell fate(4,5). Raf activation is stimulated following its translocation to the plasma membrane, a process that ordinarily requires interaction with the membrane-localized GTPase, Ras-GTP(6-10). To investigate the mechanisms underlying Raf activation, we have developed a coumermycin-induced chemical dimerization method. We find that dimerization is by itself sufficient, in the absence of any membrane components, both to activate a modified Raf protein and to stimulate the MAP kinase cascade appropriately. As Ras-GTP-induced membrane localization increases the effective intracellular Ras concentration, our results indicate that homotypic oligomerization may ordinarily act to promote Raf activation in vivo.	UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM & MED MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle			Farrar, Michael A/M-7802-2013	Farrar, Michael/0000-0002-5569-0366; alberola-ila, Jose/0000-0003-2439-553X				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; GILBERT EJ, 1994, MOL MICROBIOL, V12, P365, DOI 10.1111/j.1365-2958.1994.tb01026.x; GODFREY JC, 1972, ADV APPL MICROBIOL, V15, P653; GONZALEZ AL, 1995, TRENDS GENET, V11, P216, DOI 10.1016/S0168-9525(00)89051-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SEGER R, 1994, J BIOL CHEM, V269, P25699; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	28	266	289	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					178	181		10.1038/383178a0	http://dx.doi.org/10.1038/383178a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774884				2022-12-24	WOS:A1996VG14800055
J	Kanter, MH; vanMaanen, D; Anders, KH; Castro, F; Mya, WW; Clark, K				Kanter, MH; vanMaanen, D; Anders, KH; Castro, F; Mya, WW; Clark, K			Preoperative autologous blood donations before elective hysterectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALLOGENEIC TRANSFUSION; SURGERY; CONTROVERSIES; SCHEDULE; MEDICINE	Objective.-To determine whether preoperative autologous blood donation is justified for patients undergoing elective abdominal or vaginal hysterectomy. Design.-Retrospective cohort study. Patients and Setting.-A total of 263 consecutive patients admitted for elective abdominal or vaginal hysterectomy to a community health maintenance organization hospital during 1993 and 1994. Main Outcome Measures.-Evaluation of transfusion rates for patients who did and did not donate autologous blood; determination of any risk factors that would predict the need for transfusion; and evaluation of the need for transfusion based on chart review. Results.-Of 263 patients, 26 received a blood transfusion. The major risk factor identified for transfusion was the donation of autologous blood. Of 140 patients who donated autologous blood, 25 were transfused, whereas just 1 patient of 123 who did not donate autologous blood was transfused (P<.001). Patients who donated autologous blood had significantly lower mean admission hemoglobin level than patients who did not donate (119 g/L vs 132 g/L; P<.05); logistic regression showed that autologous donation was an independent risk factor for transfusion. Conclusion.-For hysterectomy patients, donation of autologous blood causes anemia and is associated with a more liberal transfusion policy. These 2 factors result in a markedly increased incidence of transfusion with its associated risks. Elimination of preoperative autologous donation for these patients should not result in frequent exposure to allogeneic blood.	KAISER PERMANENTE MED CTR,PANORAMA CITY,CA; UNIV CALIF LOS ANGELES,DEPT PATHOL & LAB MED,LOS ANGELES,CA	Kaiser Permanente; University of California System; University of California Los Angeles	Kanter, MH (corresponding author), KAISER PERMANENTE MED CTR,DEPT PATHOL,5601 DE SOTO AVE,WOODLAND HILLS,CA 91365, USA.		kanter, michael howard/W-2753-2019					ATLAS SJ, 1994, TRANSFUSION, V34, P386, DOI 10.1046/j.1537-2995.1994.34594249048.x; AXELROD FB, 1989, TRANSFUSION, V29, P677, DOI 10.1046/j.1537-2995.1989.29890020438.x; COHEN JA, 1995, TRANSFUSION, V35, P640, DOI 10.1046/j.1537-2995.1995.35895357894.x; ETCHASON J, 1995, NEW ENGL J MED, V332, P719, DOI 10.1056/NEJM199503163321106; FRIEDMAN BA, 1976, TRANSFUSION, V16, P380; GIORDANO GF, 1991, TRANSFUSION, V31, P509, DOI 10.1046/j.1537-2995.1991.31691306247.x; GOODNOUGH LT, 1992, VOX SANG, V63, P96, DOI 10.1111/j.1423-0410.1992.tb02493.x; GOULD SA, 1995, TRANSFUSION, V35, P446, DOI 10.1046/j.1537-2995.1995.35595259156.x; KRUSKALL MS, 1988, AUTOLOGOUS BLOOD TRA, P151; MILLER RD, 1995, TRANSFUSION, V35, P450, DOI 10.1046/j.1537-2995.1995.35595259157.x; OWINGS DV, 1989, JAMA-J AM MED ASSOC, V262, P1963; PARSLOE MRJ, 1990, BRIT J ANAESTH, V64, P634, DOI 10.1093/bja/64.5.634; POPOVSKY MA, 1995, TRANSFUSION, V35, P734, DOI 10.1046/j.1537-2995.1995.35996029156.x; POPOVSKY MA, 1992, AM J CLIN PATHOL, V97, P297, DOI 10.1093/ajcp/97.3.297; RENNER SW, 1992, ARCH PATHOL LAB MED, V116, P613; SILVERGLEID AJ, 1991, TRANSFUSION, V31, P99, DOI 10.1046/j.1537-2995.1991.31291142959.x; TOY PTCY, 1992, TRANSFUSION, V32, P562, DOI 10.1046/j.1537-2995.1992.32692367202.x; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TOY PTCY, 1992, TRANSFUSION, V32, P63, DOI 10.1046/j.1537-2995.1992.32192116435.x; WALKER RH, 1987, AM J CLIN PATHOL, V88, P374, DOI 10.1093/ajcp/88.3.374; WASMAN J, 1987, JAMA-J AM MED ASSOC, V258, P3135, DOI 10.1001/jama.258.21.3135; 1986, JAMA-J AM MED ASSOC, V256, P2378; 1995, TRANSFUSION, V35, P703	23	72	73	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 11	1996	276	10					798	801		10.1001/jama.276.10.798	http://dx.doi.org/10.1001/jama.276.10.798			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF219	8769589				2022-12-24	WOS:A1996VF21900026
J	Hausladen, A; Privalle, CT; Keng, T; DeAngelo, J; Stamler, JS				Hausladen, A; Privalle, CT; Keng, T; DeAngelo, J; Stamler, JS			Nitrosative stress: Activation of the transcription factor OxyR	CELL			English	Article							NITRIC-OXIDE; ESCHERICHIA-COLI; OXIDATIVE-STRESS; SERUM-ALBUMIN; SALMONELLA-TYPHIMURIUM; S-NITROSOTHIOLS; SOXR PROTEIN; GLUTATHIONE; RESISTANCE; REDUCTASE	Hydrogen peroxide (H2O2) imposes an oxidative stress to Escherichia coli that is manifested by oxidation of glutathione and related redox-sensitive targets. OxyR is a thiol-containing transcriptional activator whose oxidation controls the expression of genes involved in H2O2 detoxification. Here we report that certain S-nitrosothiols (RSNOs) impose what we term a ''nitrosative stress'' to E. coli, evidenced by lowering of intracellular thiol and the transcriptional activation of OxyR by S-nitrosylation. This cellular and genetic response determines the metabolic fate of RSNOs and thereby contributes to bacterial rescue from stasis. Our studies reveal that signaling by S-nitrosylation can extend to the level of transcription and describe a metabolic pathway that constitutes an adaptation to nitrosative stress.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; APEX BIOSCI INC, RES TRIANGLE PK, NC 27709 USA	Duke University; Duke University				Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HL02582, HL52529] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002582, R01HL052529] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; CASELLI A, 1994, J BIOL CHEM, V269, P24878; CASTELLANI AG, 1955, APPL MICROBIOL, V3, P154, DOI 10.1128/AEM.3.3.154-159.1955; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; FEELLSCH M, 1996, METHODS NITRIC OXIDE; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HAJJAR DP, 1995, J AM CHEM SOC, V117, P3340, DOI 10.1021/ja00117a004; HAN J, 1995, BIOL NITRIC OXIDE, V4, P114; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; INCZE K, 1974, APPL MICROBIOL, V27, P202, DOI 10.1128/AEM.27.1.202-205.1974; JI XB, 1989, BIOCHEM ARCH, V5, P61; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; JOHNSTON MA, 1971, CAN INST F SCI TEC J, V4, P179, DOI 10.1016/S0008-3860(71)74226-3; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LITTLE C, 1969, EUR J BIOCHEM, V10, P533, DOI 10.1111/j.1432-1033.1969.tb00721.x; LOEWEN PC, 1984, J BACTERIOL, V157, P622, DOI 10.1128/JB.157.2.622-626.1984; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MIRNA A, 1969, FLEISCHWIRTSCHAFT, V10, P1361; Mohr S, 1996, J BIOL CHEM, V271, P4209; MORRIS SL, 1981, J BACTERIOL, V148, P465, DOI 10.1128/JB.148.2.465-471.1981; MORRIS SL, 1984, J BIOL CHEM, V259, P3590; MUKHOPADHYAY S, 1994, J BACTERIOL, V176, P2300, DOI 10.1128/JB.176.8.2300-2307.1994; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PRIVALLE CT, 1988, J BIOL CHEM, V263, P4274; PRIVALLE CT, 1990, J BIOL CHEM, V265, P21966; RICHTER HE, 1981, BIOCHEM BIOPH RES CO, V100, P1039, DOI 10.1016/0006-291X(81)91928-8; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; ROMAN R, 1973, CAN J CHEM, V51, P588, DOI 10.1139/v73-089; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STORZ G, 1994, METHOD ENZYMOL, V234, P217; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; WROTHINGTON V, 1993, WORTHINGTON ENZYME M, P293; WU J, 1995, J BIOL CHEM, V270, P10323, DOI 10.1074/jbc.270.17.10323	68	296	312	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1996	86	5					719	729		10.1016/S0092-8674(00)80147-6	http://dx.doi.org/10.1016/S0092-8674(00)80147-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797819	Bronze			2022-12-24	WOS:A1996VG37200006
J	Roest, HP; vanKlaveren, J; deWit, J; vanGurp, CG; Koken, MHM; Vermey, M; vanRoijen, JH; Hoogerbrugge, JW; Vreeburg, JTM; Baarends, WM; Bootsma, D; Grootegoed, JA; Hoeijmakers, JHJ				Roest, HP; vanKlaveren, J; deWit, J; vanGurp, CG; Koken, MHM; Vermey, M; vanRoijen, JH; Hoogerbrugge, JW; Vreeburg, JTM; Baarends, WM; Bootsma, D; Grootegoed, JA; Hoeijmakers, JHJ			Inactivation of the HR6B ubiquitin-conjugating DNA repair enzyme in mice causes male sterility associated with chromatin modification	CELL			English	Article							MOUSE Y-CHROMOSOME; N-END RULE; GENE RAD6; SACCHAROMYCES-CEREVISIAE; ACTIVATING ENZYME-E1; INFERTILE MEN; PROTEIN; YEAST; SPERMATOGENESIS; DEGRADATION	The ubiquitin-conjugating yeast enzyme RAD6 and its human homologs hHR6A and hHR6B are implicated in postreplication repair and damage-induced mutagenesis, The yeast protein is also required for sporulation and may modulate chromatin structure via histone ubiquitination. We report the phenotype of the first animal mutant in the ubiquitin pathway: inactivation of the hHR6B-homologous gene in mice causes male infertility. Derailment of spermatogenesis becomes overt during the postmeiotic condensation of chromatin in spermatids. These findings provide a parallel between yeast sporulation and mammalian spermatogenesis and strongly implicate hHR6-dependent ubiquitination in chromatin remodeling. Since heterozygous male mice and even knockout female mice are completely normal and fertile and thus able to transmit the defect, similar hHR6B mutations may cause male infertility in man.	ERASMUS UNIV ROTTERDAM, FAC MED & HLTH SCI, DEPT ENDOCRINOL & REPROD, NL-3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, FAC MED & HLTH SCI, DEPT PATHOL, NL-3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam	Roest, HP (corresponding author), ERASMUS UNIV ROTTERDAM, FAC MED & HLTH SCI, MGC, DEPT CELL BIOL & GENET, NL-3000 DR ROTTERDAM, NETHERLANDS.		koken, marcel/J-8154-2012; koken, marcel/N-1349-2019; Hoeijmakers, Jan/AAX-6972-2021	koken, marcel/0000-0002-0839-0125; 				AGELL N, 1988, BIOCHEM J, V250, P883, DOI 10.1042/bj2500883; AGELL N, 1983, FEBS LETT, V155, P209, DOI 10.1016/0014-5793(82)80604-2; AITKEN RJ, 1995, HUM REPROD, V10, P248, DOI 10.1093/oxfordjournals.humrep.a135922; ALFONSO PJ, 1993, BIOL REPROD, V48, P522, DOI 10.1095/biolreprod48.3.522; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Balhorn R., 1989, P366; BROCK WA, 1980, P NATL ACAD SCI-BIOL, V77, P371, DOI 10.1073/pnas.77.1.371; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEVAILLIER P, 1987, LANCET, V2, P806; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEYEBRA L, 1993, J BIOL CHEM, V268, P10553; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DULLAART J, 1975, J REPROD FERTIL, V43, P189, DOI 10.1530/jrf.0.0430189; FORESTA C, 1992, INT J ANDROL, V15, P330, DOI 10.1111/j.1365-2605.1992.tb01132.x; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDKNOPF IL, 1980, BIOCHEM BIOPH RES CO, V96, P1724, DOI 10.1016/0006-291X(80)91373-X; GORCZYCA W, 1993, CANCER RES, V53, P1945; HENDRIKSEN PJM, 1995, DEV BIOL, V170, P730, DOI 10.1006/dbio.1995.1252; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KISTLER WS, 1989, HISTONES OTHER BASIC, P331; KOKEN M, 1991, P NATL ACAD SCI USA, V88, P3832, DOI 10.1073/pnas.88.9.3832; Koken MHM, 1996, DEV BIOL, V173, P119, DOI 10.1006/dbio.1996.0011; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; MADURA K, 1993, J BIOL CHEM, V268, P12046; Meistrich M., 1989, HISTONES OTHER BASIC, P165; MEISTRICH ML, 1992, MOL REPROD DEV, V31, P170, DOI 10.1002/mrd.1080310303; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; MONTELONE BA, 1981, MOL GEN GENET, V184, P410, DOI 10.1007/BF00352514; NICKEL BE, 1987, BIOCHEMISTRY-US, V26, P4417, DOI 10.1021/bi00388a034; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; PETERSON MW, 1992, J APPL PHYSIOL, V72, P236, DOI 10.1152/jappl.1992.72.1.236; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; RHIM JA, 1995, BIOL REPROD, V52, P20, DOI 10.1095/biolreprod52.1.20; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROLLER ML, 1995, MAMM GENOME, V6, P305; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THORNE AW, 1987, EMBO J, V6, P1005, DOI 10.1002/j.1460-2075.1987.tb04852.x; UNNI E, 1995, MOL REPROD DEV, V42, P210, DOI 10.1002/mrd.1080420210; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; WONG TW, 1973, ARCH PATHOL, V95, P151; ZHOU XY, 1995, GENE DEV, V9, P2623, DOI 10.1101/gad.9.21.2623	55	326	351	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1996	86	5					799	810		10.1016/S0092-8674(00)80154-3	http://dx.doi.org/10.1016/S0092-8674(00)80154-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797826	Green Published, Bronze			2022-12-24	WOS:A1996VG37200013
J	Levinsky, NG				Levinsky, NG			The purpose of advance medical planning - Autonomy for patients or limitation of care?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NURSING-HOME RESIDENTS; CARDIOPULMONARY-RESUSCITATION; PREFERENCES; LIFE; DIRECTIVES; PHYSICIANS; DECISIONS				Levinsky, NG (corresponding author), BOSTON UNIV,MED CTR,88 E NEWTON ST,BOSTON,MA 02118, USA.							ANGELL M, 1991, NEW ENGL J MED, V325, P511, DOI 10.1056/NEJM199108153250712; Annas GJ, 1995, HASTINGS CENT REP, V25, pS12, DOI 10.2307/3527850; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BROWN NK, 1979, NEW ENGL J MED, V300, P1246, DOI 10.1056/NEJM197905313002204; Callahan D., 1987, MED GOALS AGEING SOC; CAPRON AM, 1994, HASTINGS CENT REP, V24, P42; Finucane TE, 1996, AM J MED, V100, P126, DOI 10.1016/S0002-9343(97)89449-1; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIESINGER GO, 1995, AM J MED, V99, P13, DOI 10.1016/S0002-9343(99)80098-9; GERETY MB, 1993, J AM GERIATR SOC, V41, P953, DOI 10.1111/j.1532-5415.1993.tb06761.x; GILLICK MR, 1995, ANN INTERN MED, V123, P621, DOI 10.7326/0003-4819-123-8-199510150-00009; HIRSCH CH, 1995, GERIATRICS, V50, P26; KONG D, 1995, BOSTON GLOBE    1120, P10; LEVINSKY NG, 1990, NEW ENGL J MED, V322, P1813, DOI 10.1056/NEJM199006213222512; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; NOYES R, 1977, J AM GERIATR SOC, V25, P470, DOI 10.1111/j.1532-5415.1977.tb00810.x; OBRIEN LA, 1995, JAMA-J AM MED ASSOC, V274, P1775, DOI 10.1001/jama.274.22.1775; PARIS JJ, 1990, NEW ENGL J MED, V322, P1012, DOI 10.1056/NEJM199004053221420; Phillips RS, 1996, AM J MED, V100, P128, DOI 10.1016/S0002-9343(97)89450-8; RETTIG RA, 1991, KIDNEY FAILURE FEDER, P89; ROTHMAN D, 1991, STRANGERS BEDSIDE; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TENO JM, 1994, J CLIN ETHIC, V5, P23; 1995, JAMA-J AM MED ASSOC, V274, P1591	27	42	42	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1996	335	10					741	743		10.1056/NEJM199609053351012	http://dx.doi.org/10.1056/NEJM199609053351012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VH266	8703178				2022-12-24	WOS:A1996VH26600012
J	Cui, W; Fowlis, DJ; Bryson, S; Duffie, E; Ireland, H; Balmain, A; Akhurst, RJ				Cui, W; Fowlis, DJ; Bryson, S; Duffie, E; Ireland, H; Balmain, A; Akhurst, RJ			TGF beta 1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice	CELL			English	Article							TRANSFORMING GROWTH FACTOR-BETA-1; HUMAN BREAST-CANCER; KERATIN GENE-EXPRESSION; FACTOR RECEPTOR LIGANDS; FACTOR TYPE-BETA; MOUSE SKIN; TGF-BETA; FACTOR-ALPHA; EPITHELIAL-CELLS; II RECEPTOR	TGF beta 1 has been implicated in cell cycle control and carcinogenesis. To address the exact function of TGF beta 1 in skin carcinogenesis in vivo, mice with TGF beta 1 expression targeted to keratinocytes were subjected to long-term chemical carcinogenesis treatment. TGF beta 1 showed biphasic action during multistage skin carcinogenesis, acting early as a tumor suppressor but later enhancing the malignant phenotype. The transgenics were more resistant to induction of benign skin tumors than controls, but the malignant conversion rate was vastly increased. There was also a higher incidence of spindle cell carcinomas, which expressed high levels of endogenous TGF beta 3, suggesting that TGF beta 1 elicits an epithelial-mesenchymal transition in vivo and that TGF beta 3 might be involved in maintenance of the spindle cell phenotype. The action of TGF beta 1 in enhancing malignant progression may mimic its proposed function in modulating epithelial cell plasticity during embryonic development.	UNIV GLASGOW, DEPT MED GENET, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV GLASGOW, DEPT MED ONCOL, CANC RES CAMPAIGN, BEATSON LABS, GLASGOW G12 8QQ, LANARK, SCOTLAND	University of Glasgow; Beatson Institute; University of Glasgow			Cui, Wei/AAD-1690-2019	AKHURST, ROSEMARY/0000-0002-4474-9668; Cui, Wei/0000-0003-2019-380X				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; AKHURST RJ, 1990, DEVELOPMENT, V108, P645; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102; ANZANO MA, 1982, CANCER RES, V42, P4776; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; BATTIFORA H, 1976, CANCER, V37, P2275, DOI 10.1002/1097-0142(197605)37:5<2275::AID-CNCR2820370518>3.0.CO;2-3; BERGMANN M, 1951, CANCER, V4, P919, DOI 10.1002/1097-0142(195109)4:5<919::AID-CNCR2820040505>3.0.CO;2-W; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; BURSCH W, 1993, BRIT J CANCER, V67, P531, DOI 10.1038/bjc.1993.98; Cano A, 1996, INT J CANCER, V65, P254; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHAKRABARTY S, 1992, INT J CANCER, V50, P968, DOI 10.1002/ijc.2910500624; CHANG HL, 1993, CANCER RES, V53, P4391; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHENG C, 1993, CELL GROWTH DIFFER, V4, P317; CUI W, 1995, GENE DEV, V9, P945, DOI 10.1101/gad.9.8.945; CUI W, 1994, CANCER RES, V54, P5831; CUI W, 1996, IN PRESS GROWTH FACT; DERYNCK R, 1987, CANCER RES, V47, P707; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DIXON MJ, 1991, ANAT EMBRYOL, V184, P83, DOI 10.1007/BF01744264; DLUGOSZ AA, 1995, CANCER RES, V55, P1883; EVANS HL, 1980, CANCER-AM CANCER SOC, V45, P2687, DOI 10.1002/1097-0142(19800515)45:10<2687::AID-CNCR2820451034>3.0.CO;2-R; FALCIONI R, 1994, EXP CELL RES, V210, P113, DOI 10.1006/excr.1994.1017; FITZPATRICK DR, 1990, DEVELOPMENT, V109, P585; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; FOWLIS DJ, 1992, CELL GROWTH DIFFER, V3, P81; Fowlis DJ, 1996, CELL GROWTH DIFFER, V7, P679; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; GOMELLA LG, 1989, CANCER RES, V49, P6972; GOMEZ M, 1992, EXP CELL RES, V201, P250, DOI 10.1016/0014-4827(92)90272-A; GORSCH SM, 1992, CANCER RES, V52, P6949; HADDOW S, 1991, ONCOGENE, V6, P1465; HEINO J, 1989, J BIOL CHEM, V264, P21806; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; JIRTLE RL, 1993, CANCER RES, V53, P3849; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; JOUANNEAU J, 1991, CANCER CELL-MON REV, V3, P525; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KEMP CJ, 1994, QUANT BIOL, V59, P427; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; KRIEG P, 1991, MOL CARCINOGEN, V4, P129, DOI 10.1002/mc.2940040208; LENVENTON GS, 1981, CANCER, V48, P994; LIN JK, 1992, CANCER RES, V52, P385; MANNING AM, 1991, ONCOGENE, V6, P1471; MAREEL M, 1993, INT J DEV BIOL, V37, P227; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MILLAN FA, 1991, DEVELOPMENT, V111, P131; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; NELSON KG, 1982, CANCER RES, V42, P4176; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; PELTON RW, 1990, DEV BIOL, V141, P456, DOI 10.1016/0012-1606(90)90401-4; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; POTTS JD, 1989, DEV BIOL, V134, P392, DOI 10.1016/0012-1606(89)90111-5; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1990, TRANSFORMING GROWTH, P419; ROOP DR, 1988, CANCER RES, V48, P3245; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SAMUEL SK, 1992, EMBO J, V11, P1599, DOI 10.1002/j.1460-2075.1992.tb05205.x; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SIEWEKE MH, 1990, SCIENCE, V248, P1656, DOI 10.1126/science.2163544; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TENNENBAUM T, 1992, CANCER RES, V52, P2966; TENNENBAUM T, 1993, CANCER RES, V53, P4803; TERZAGHIHOWE M, 1989, CARCINOGENESIS, V10, P973, DOI 10.1093/carcin/10.6.973; TOFTGARD R, 1985, CANCER RES, V45, P5845; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VALLES AM, 1991, EXP SUPPL, V59, P17; WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WINTER H, 1980, CARCINOGENESIS, V1, P391, DOI 10.1093/carcin/1.5.391; WU JE, 1994, DEV DYNAM, V199, P292, DOI 10.1002/aja.1001990405; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255	93	497	537	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 23	1996	86	4					531	542		10.1016/S0092-8674(00)80127-0	http://dx.doi.org/10.1016/S0092-8674(00)80127-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752208	Bronze			2022-12-24	WOS:A1996VE23500004
J	Piccolo, S; Sasai, Y; Lu, B; DeRobertis, EM				Piccolo, S; Sasai, Y; Lu, B; DeRobertis, EM			Dorsoventral patterning in xenopus: Inhibition of ventral signals by direct binding of Chordin to BMP-4	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; GROWTH-FACTOR-BETA; DROSOPHILA EMBRYO; SPEMANN ORGANIZER; NEURAL INDUCTION; MARGINAL ZONE; RECEPTOR; MESODERM; NOGGIN; GENES	Chordin (Chd) is an abundant protein secreted by Spemann organizer tissue during gastrulation. Chd antagonizes signaling by mature bone morphogenetic proteins (BMPs) by blocking binding to their receptors. Recombinant Xenopus Chd binds to BMP-4 with high affinity (K-D 3 x 10(-10) M), binding specifically to BMPs but not to activin or TGF-beta 1. Chd protein is able to dorsalize mesoderm and to neuralize ectoderm in Xenopus gastrula explants at 1 nM. We propose that the noncell-autonomous effects of Spemann's organizer on dorsoventral patterning are executed in part by diffusible signals that directly bind to and neutralize ventral BMPs during gastrulation.			Piccolo, S (corresponding author), UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT BIOL CHEM,LOS ANGELES,CA 90095, USA.			De Robertis, Edward/0000-0002-7843-1869; PICCOLO, STEFANO/0000-0002-2037-0004	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, R01HD021502] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21502-11, R37 HD021502-13, R37 HD021502, R01 HD021502] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AONO A, 1995, BIOCHEM BIOPH RES CO, V210, P670, DOI 10.1006/bbrc.1995.1712; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOUWMEESTER T, 1996, IN PRESS NATURE; DALE L, 1987, DEVELOPMENT, V100, P279; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V269, P6259; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; DEROBERTIS EM, 1995, NATURE, V374, P407, DOI 10.1038/374407a0; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HAMBERGER V, 1988, HERITAGE EXPT EMBRYO; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; HAZAMA M, 1995, BIOCHEM BIOPH RES CO, V209, P859, DOI 10.1006/bbrc.1995.1578; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; HOLLEY SA, 1996, CELL, V86; JONES CM, 1992, DEVELOPMENT, V115, P639; JONS CM, 1996, DEVELOPMENT, V122, P1545; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; LAMB TM, 1995, DEVELOPMENT, V121, P3627; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASUHARA K, 1995, BONE, V16, P91, DOI 10.1016/S8756-3282(94)00014-X; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; ReemKalma Y, 1995, P NATL ACAD SCI USA, V92, P12141, DOI 10.1073/pnas.92.26.12141; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schmidt J, 1995, DEVELOPMENT, V121, P4319; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XU RH, 1995, BIOCHEM BIOPH RES CO, V212, P212, DOI 10.1006/bbrc.1995.1958; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; ZIMMERMAN LB, 1996, CELL	48	905	943	2	54	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					589	598		10.1016/S0092-8674(00)80132-4	http://dx.doi.org/10.1016/S0092-8674(00)80132-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752213	Green Accepted, Bronze			2022-12-24	WOS:A1996VE23500009
J	Nightingale, SL				Nightingale, SL			Quality of mammography facilities improved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, JAMA-J AM MED ASSOC, V271, P179; 1995, JAMA-J AM MED ASSOC, V273, P1897	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					443	443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691538				2022-12-24	WOS:A1996VA86300007
J	Stevenson, WG; Ridker, PM				Stevenson, WG; Ridker, PM			Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; SIGNAL-AVERAGED ELECTROCARDIOGRAM; VENTRICULAR ENLARGEMENT TRIAL; THROMBOLYTIC THERAPY; PROGNOSTIC-SIGNIFICANCE; LATE POTENTIALS; PREDICTION; VARIABLES; EVENTS; TACHYCARDIA	Because survivors of myocardial infarction are at risk for ventricular arrhythmias and sudden death, physicians must decide whether to refer these patients to specialists for arrhythmia assessment and therapy, However, this decision is complex as few randomized data are available concerning either diagnostic or therapeutic options, Therefore, we modeled the potential impact of current arrhythmia detection and management strategies on mortality in survivors of myocardial infarction with reduced left ventricular function who are managed in a contemporary manner. Based on recent data we estimated that the mortality for myocardial infarction survivors with left ventricular ejection fraction less than 0.40 is 20% over 3.5 years and that half of the deaths are sudden. The sensitivity and specificity of a Holter electrocardiogram (EGG), a signal-averaged EGG, and an invasive electrophysiology study for predicting sudden death were obtained from a literature review of trials published after 1990 that included more than 300 patients, A series of models were constructed to predict mortality achieved by different arrhythmia management strategies that reduced sudden death by 50% and 75%-reductions estimated to be within the range for amiodarone and implantable defibrillators. We found that, when routinely applied to all infarct survivors with depressed ventricular function, a therapy that reduces sudden death by 50% with 1% fatal adverse effects (potentially amiodarone) saves approximately 1 life for every 25 patients treated. Therapy that reduces sudden death by 75% with 2% fatal adverse effects (potentially implantable defibrillators) saves 1 life for every 14 patients treated, Using Holter ECG recordings, a signal-averaged EGG, or an invasive electrophysiology study to select higher-risk groups, 1 life can be saved for every 4 to 11 patients treated, and the negative impact of adverse effects can be reduced, However, to achieve this benefit, additional and potentially invasive arrhythmia testing must be applied to 28 to 47 patients for each life saved. Thus, with contemporary management of acute myocardial infarction, the risk of sudden death for survivors is sufficiently low that broad application of available antiarrhythmic therapies has limited potential for further improving survival, particularly if therapy also has significant adverse effects, Thus, routine referral to arrhythmia specialists is not warranted for the majority of infarct survivors and should be largely reserved for patients with serious, symptomatic arrhythmias.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School								BOURKE JP, 1991, J AM COLL CARDIOL, V18, P780, DOI 10.1016/0735-1097(91)90802-G; DECHILLOU C, 1991, J AM COLL CARDIOL, V18, P1638, DOI 10.1016/0735-1097(91)90496-V; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; FARRELL TG, 1991, J AM COLL CARDIOL, V18, P687, DOI 10.1016/0735-1097(91)90791-7; GANG ES, 1989, NEW ENGL J MED, V321, P712, DOI 10.1056/NEJM198909143211104; GREENE HL, 1989, AM J CARDIOL, V63, P1, DOI 10.1016/0002-9149(89)91065-5; KERSSCHOT IE, 1986, J AM COLL CARDIOL, V7, P1234, DOI 10.1016/S0735-1097(86)80141-3; KOSTIS JB, 1987, J AM COLL CARDIOL, V10, P231, DOI 10.1016/S0735-1097(87)80001-3; MAGGIONI AP, 1993, CIRCULATION, V87, P312, DOI 10.1161/01.CIR.87.2.312; MCCLEMENTS BM, 1993, J AM COLL CARDIOL, V21, P1419, DOI 10.1016/0735-1097(93)90319-V; MOYE LA, 1991, AM J CARDIOL, V68, pD70; NADEMANEE K, 1993, CIRCULATION, V88, P764, DOI 10.1161/01.CIR.88.2.764; NEWMAN D, 1992, AM J CARDIOL, V69, P899, DOI 10.1016/0002-9149(92)90789-2; ODEMUYIWA O, 1993, AM HEART J, V125, P1597, DOI 10.1016/0002-8703(93)90746-V; PEDERSEN TR, 1994, LANCET, V344, P1383; PEDRETTI R, 1993, AM J CARDIOL, V71, P1131, DOI 10.1016/0002-9149(93)90635-P; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; POWELL AC, 1993, CIRCULATION, V88, P1083, DOI 10.1161/01.CIR.88.3.1083; RICHARDS DAB, 1991, CIRCULATION, V83, P756, DOI 10.1161/01.CIR.83.3.756; SAGER PT, 1988, J AM COLL CARDIOL, V12, P19, DOI 10.1016/0735-1097(88)90350-6; SOGAARD P, 1994, CIRCULATION, V90, P101; SWEENEY MO, 1994, CIRCULATION, V89, P1851, DOI 10.1161/01.CIR.89.4.1851; WHITE HD, 1994, CIRCULATION, V89, P61, DOI 10.1161/01.CIR.89.1.61; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; ZAREMBSKI DG, 1993, ARCH INTERN MED, V153, P2661, DOI 10.1001/archinte.153.23.2661; ZIPES DP, 1994, CIRCULATION, V89, P2934, DOI 10.1161/01.CIR.89.6.2934	26	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					481	485		10.1001/jama.276.6.481	http://dx.doi.org/10.1001/jama.276.6.481			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691557				2022-12-24	WOS:A1996VA86300037
J	Nakajima, T; Fukamizu, A; Takahashi, J; Gage, FH; Fisher, T; Blenis, J; Montminy, MR				Nakajima, T; Fukamizu, A; Takahashi, J; Gage, FH; Fisher, T; Blenis, J; Montminy, MR			The signal-dependent coactivator CBP is a nuclear target for pp90(RSK)	CELL			English	Article							NERVE GROWTH-FACTOR; TRANSCRIPTION FACTOR CREB; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; BINDING PROTEIN CREB; PC12 CELLS; KINASE-II; PHOSPHORYLATION; INSULIN; CAMP; ACTIVATION	We have examined the mechanism by which growth factor-mediated induction of the Ras pathway interferes with signaling via the second messenger cAMP. Activation of cellular Ras with insulin or NGF stimulated recruitment of the S6 kinase pp90(RSK) to the signal-dependent coactivator CBP. Formation of the pp90(RSK)-CBP complex occurred with high stoichiometry and persisted for 6-8 hr following growth factor addition. pp90(RSK) specifically recognized the E1A-binding domain of the coactivator CBP. In addition, like E1A, binding of pp90(RSK) to CBP was sufficient to repress transcription of cAMP-responsive genes via the cAMP-inducible factor CREB. By contrast with its effects on the cAMP pathway, formation of the pp90(RSK)-CBP complex was required for induction of Ras-responsive genes. These results provide a demonstration of cross-coupling between two signaling pathways that occurs at the level of a signal-dependent coactivator.	FDN MED RES,PEPTIDE BIOL LABS,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,GENET LAB,LA JOLLA,CA 92037	Salk Institute	Nakajima, T (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,JOSLIN DIABET CTR,BOSTON,MA 02215, USA.				NCI NIH HHS [CA 54418] Funding Source: Medline; NIA NIH HHS [AG 06088] Funding Source: Medline; NIGMS NIH HHS [GM 37828] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037828, R37GM037828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARANY Z, 1995, NATURE, V374, P8184; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FISHER T, 1996, IN PRESS MOL CELL BI; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JHUN BH, 1994, J BIOL CHEM, V269, P5699; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LUNBLAD JR, 1995, NATURE, V374, P85; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MONTMINY MR, 1986, J NEUROSCI, V6, P803; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; Parker D, 1996, MOL CELL BIOL, V16, P694; QUINN PG, 1994, J BIOL CHEM, V269, P14375; QUINN PG, 1993, J BIOL CHEM, V268, P16999; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	39	231	243	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					465	474		10.1016/S0092-8674(00)80119-1	http://dx.doi.org/10.1016/S0092-8674(00)80119-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756728	Bronze			2022-12-24	WOS:A1996VC30900014
J	Blair, PS; Fleming, PJ; Bensley, D; Smith, I; Bacon, C; Taylor, E; Berry, J; Golding, J; Tripp, J; Anson, L; Sodzi, R; Thompson, R; Wood, S; Ahronson, C; Cansfield, L; Davis, C; Griffin, M; Johnson, P; Lovelock, L; Middleton, L; Mueller, P; Stephenson, S; Taylor, D; Wright, L; Laws, C; McCabe, R				Blair, PS; Fleming, PJ; Bensley, D; Smith, I; Bacon, C; Taylor, E; Berry, J; Golding, J; Tripp, J; Anson, L; Sodzi, R; Thompson, R; Wood, S; Ahronson, C; Cansfield, L; Davis, C; Griffin, M; Johnson, P; Lovelock, L; Middleton, L; Mueller, P; Stephenson, S; Taylor, D; Wright, L; Laws, C; McCabe, R			Smoking and the sudden infant death syndrome: Results from 1993-5 case-control study for confidential inquiry into stillbirths and deaths in infancy	BRITISH MEDICAL JOURNAL			English	Article							SLEEPING POSITION; MATERNAL SMOKING; RISK	Objective-To investigate the effects of exposure to tobacco smoke and of parental consumption of alcohol and illegal drugs as risk factors for the sudden infant death syndrome after a national risk reduction campaign which included advice on prenatal and postnatal avoidance of tobacco smoke. Design-Two year population based case-control study. Parental interviews were conducted for each infant who died and four controls matched for age and date of interview. Setting-Three regions in England with a total population of 17 million people. Subjects-195 babies who died and 780 matched controls. Results-More index than control mothers (62.6% v 25.1%) smoked during pregnancy (multivariate odds ratio = 2.10; 95% confidence interval 1.24 to 3.54). Paternal smoking had an additional independent effect when other factors were controlled for (2.50; 1.48 to 4.22). The risk of death rose with increasing postnatal exposure to tobacco smoke, which had an additive effect among those also exposed to maternal smoking during pregnancy (2.93; 1.56 to 5.48). The population attributable risk was over 61%, which implies that the numbers of deaths from the syndrome could be reduced by almost two third if parents did not smoke. Alcohol use was higher among index than control mothers but was strongly correlated with smoking and on multivariate analysis was not found to have any additional independent effect. Illegal drug use was more common among the index parents, and paternal use of illegal drugs remained significant in the multivariate model (4.68; 1.56 to 14.05). Conclusions-This study confirms the increased risk of the sudden infant death syndrome associated with maternal smoking during pregnancy and shows evidence that household exposure to tobacco smoke has an independent additive effect. Parental drug misuse has an additional small but significant effect.	ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,FDN STUDY INFANT DEATHS RES UNIT,BRISTOL BS2 8BJ,AVON,ENGLAND; NHS EXECUT,OPERAT RES DIV,LEEDS LS2 9UA,W YORKSHIRE,ENGLAND; NUFFIELD INST HLTH,LEEDS LS2 9PL,W YORKSHIRE,ENGLAND; FRIARAGE HOSP,NORTHALLERTON DL6 1JG,N YORKSHIRE,ENGLAND; SHEFFIELD CHILDRENS HOSP,SHEFFIELD S10 2TH,S YORKSHIRE,ENGLAND; UNIV BRISTOL,ST MICHAELS HOSP,BRISTOL BS2 8EG,AVON,ENGLAND; ROYAL DEVON & EXETER HOSP,POSTGRAD MED SCH,DEPT CHILD HLTH,EXETER EX2 5DW,DEVON,ENGLAND	Bristol Royal Hospital For Children; University of Bristol; University of Leeds; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Bristol; University of Exeter			Fleming, Peter J/A-9081-2010; Blair, Peter S/C-1213-2009; Fleming, Peter/O-3231-2019	Fleming, Peter J/0000-0003-2521-5764; Fleming, Peter/0000-0003-2521-5764; Blair, Peter/0000-0002-7832-8087; Golding, Jean/0000-0003-2826-3307				BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; ENGELBERTS A, 1991, THSIS AMSTERDAM; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; GILBERT RE, 1990, BMJ-BRIT MED J, V300, P1237, DOI 10.1136/bmj.300.6734.1237; GILBERT RE, 1992, ARCH DIS CHILD, V67, P272; HAGLUND B, 1990, AM J PUBLIC HEALTH, V80, P29, DOI 10.2105/AJPH.80.1.29; HOFFMAN HJ, 1988, SUDDEN INFANT DEATH, P153; KLONOFFCOHEN HS, 1995, JAMA-J AM MED ASSOC, V273, P795, DOI 10.1001/jama.273.10.795; LI DK, 1991, AM J EPIDEMIOL, V134, P958, DOI 10.1093/oxfordjournals.aje.a116180; MCGLASHAN ND, 1989, SOC SCI MED, V29, P1015, DOI 10.1016/0277-9536(89)90059-2; MICHELL EA, 1992, J PAEDIAT CHILD HL S, V28, pS3; Mitchell E. A., 1995, P114; MITCHELL EA, 1993, PEDIATRICS, V91, P893; NAEYE RL, 1976, AM J DIS CHILD, V130, P1207, DOI 10.1001/archpedi.1976.02120120041005; *NAT ADV BODY CESD, 1996, 1994 NAT ADV BOD CES; NICHOLL J, 1992, EFFECTS SMOKING FETU; SCHOENDORF KC, 1992, PEDIATRICS, V90, P905; Wigfield R., 1995, P124; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282	20	232	239	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					195	198		10.1136/bmj.313.7051.195	http://dx.doi.org/10.1136/bmj.313.7051.195			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696194	Green Published			2022-12-24	WOS:A1996VA12600020
J	Fleming, PJ; Blair, PS; Bacon, C; Bensley, D; Smith, I; Taylor, E; Berry, J; Golding, J; Tripp, JZ; Anson, L; Sodzi, R; Thompson, R; Wood, S; Ahronson, C; Cansfield, L; Davis, C; Griffin, M; Johnson, P; Lovelock, L; Middleton, L; Mueller, P; Stephenson, S; Taylor, D; Wright, L; Laws, C; McCabe, R				Fleming, PJ; Blair, PS; Bacon, C; Bensley, D; Smith, I; Taylor, E; Berry, J; Golding, J; Tripp, JZ; Anson, L; Sodzi, R; Thompson, R; Wood, S; Ahronson, C; Cansfield, L; Davis, C; Griffin, M; Johnson, P; Lovelock, L; Middleton, L; Mueller, P; Stephenson, S; Taylor, D; Wright, L; Laws, C; McCabe, R			Environment of infants during sleep and risk of the sudden infant death syndrome: Results of 1993-5 case-control study for confidential inquiry into stillbirths and deaths in infancy	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSITION	Objective-To investigate the role of sleeping arrangements as risk factors for the sudden infant death syndrome after a national risk reduction campaign. Design-Two year population based case-control study. Parental interviews were conducted for each infant who died and for four controls matched for age and date of interview. Setting-Three regions in England with a total population of 17 million people. Subjects-195 babies who died and 780 matched controls. Results-Prone and side sleeping positions both carried increased risks of death compared with supine when adjusted for maternal age, parity, gestation, birth weight, exposure to smoke, and other relevant factors in the sleeping environment (multivariate odds ratio = 9.00 (95% confidence interval 2.84 to 28.47) and 1.84 (1.02 to 3.31), respectively). The higher incidence of side rather than prone sleeping led to a higher population attributable risk (side 18.4%, prone 14.2%). More of the infants who died were found with bed covers over their heads (21.58; 6.21 to 74.99). The use of a dummy had an apparent protective effect (0.38; 0.21 to 0.70). Bed sharing for the whole night was a significant risk factor for infants whose mothers smoked (9.25; 2.31 to 34.02). No protective effect of breast feeding could be identified on multivariate analysis. Conclusions-This study confirms the importance of certain risk factors for the sudden infant death syndrome and identifies others-for example, covers over the head, side sleeping position-which may be amenable to change by educating and informing parents and health care professionals.	FRIARAGE HOSP, NORTHALLERTON DL6 1JG, N YORKSHIRE, ENGLAND; NHS EXECUT, OPERAT RES DIV, LEEDS LS2 9UA, W YORKSHIRE, ENGLAND; NUFFIELD INST HLTH, LEEDS LS2 9PL, W YORKSHIRE, ENGLAND; SHEFFIELD CHILDRENS HOSP, SHEFFIELD S10 2TH, S YORKSHIRE, ENGLAND; UNIV BRISTOL, ST MICHAELS HOSP, BRISTOL BS2 8EG, AVON, ENGLAND; ROYAL DEVON & EXETER HOSP, POSTGRAD MED SCH, DEPT CHILD HLTH, EXETER EX2 5DW, DEVON, ENGLAND	University of Leeds; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Bristol; University of Exeter	Fleming, PJ (corresponding author), ROYAL HOSP SICK CHILDREN, INST CHILD HLTH, FDN STUDY INFANT DEATHS RES UNIT, BRISTOL BS2 8BJ, AVON, ENGLAND.		Blair, Peter S/C-1213-2009; Fleming, Peter/O-3231-2019; Fleming, Peter J/A-9081-2010	Fleming, Peter/0000-0003-2521-5764; Fleming, Peter J/0000-0003-2521-5764; Reis, AlessanRSS/0000-0001-8486-7469; Blair, Peter/0000-0002-7832-8087; Golding, Jean/0000-0003-2826-3307				BARROS FC, 1995, PEDIATRICS, V95, P497; BLAIR P, 1995, LANCET, V345, P720, DOI 10.1016/S0140-6736(95)90891-9; Blair PS, 1996, BRIT MED J, V313, P195, DOI 10.1136/bmj.313.7051.195; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CORDNER SM, 1992, SUDDEN INFANT DEATH; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FLEMING PJ, 1993, ACTA PAEDIATR, V82, P57, DOI 10.1111/j.1651-2227.1993.tb12878.x; FORD RPK, 1993, INT J EPIDEMIOL, V22, P885, DOI 10.1093/ije/22.5.885; GILBERT RE, 1995, BMJ-BRIT MED J, V310, P88, DOI 10.1136/bmj.310.6972.88; GILBERT RE, 1992, ARCH DIS CHILD, V67, P272; KLONOFFCOHEN H, 1995, BMJ-BRIT MED J, V311, P1269, DOI 10.1136/bmj.311.7015.1269; *MICR CORP, 1995, FOX PRO; MITCHELL EA, 1993, ARCH DIS CHILD, V68, P501, DOI 10.1136/adc.68.4.501; *NAT ADV BOD CESDI, 1996, 1994 NAT ADV BOD CES; Norvenius S G, 1987, Acta Paediatr Scand Suppl, V333, P1; SAS, 1989, SAS US GUID; SCRAGG R, 1993, BMJ-BRIT MED J, V307, P1312, DOI 10.1136/bmj.307.6915.1312; TAYLOR EM, 1990, ARCH DIS CHILD, V65, P535, DOI 10.1136/adc.65.5.535; Wigfield R., 1995, P124; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282	20	309	314	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 27	1996	313	7051					191	195		10.1136/bmj.313.7051.191	http://dx.doi.org/10.1136/bmj.313.7051.191			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696193	Green Published			2022-12-24	WOS:A1996VA12600019
J	Malkovsky, M				Malkovsky, M			HLA and natural history of HIV infection	LANCET			English	Editorial Material											Malkovsky, M (corresponding author), UNIV WISCONSIN,SCH MED,DEPT MED MICROBIOL & IMMUNOL,MADISON,WI 53706, USA.			Malkovsky, Miroslav/0000-0002-5056-5224				BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; HEENEY JL, 1995, IMMUNOL TODAY, V16, P515, DOI 10.1016/0167-5699(95)80043-3; Hill AVS, 1996, NAT MED, V2, P395, DOI 10.1038/nm0496-395; HUANG YX, 1995, J VIROL, V69, P93, DOI 10.1128/JVI.69.1.93-100.1995; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; LEELAYUWAT C, 1993, HUM IMMUNOL, V38, P30, DOI 10.1016/0198-8859(93)90517-5; MALKOVSKY M, 1996, INT ANTIVIRAL NEWS, V4, P7; McNeil AJ, 1996, QJM-INT J MED, V89, P177; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; RICE WG, 1996, INT ANTIVIRAL NEWS, V4, P3	12	18	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					142	143						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684150				2022-12-24	WOS:A1996UX78900005
J	Bhanot, P; Brink, M; Samos, CH; Hsieh, JC; Wang, YS; Macke, JP; Andrew, D; Nathans, J; Nusse, R				Bhanot, P; Brink, M; Samos, CH; Hsieh, JC; Wang, YS; Macke, JP; Andrew, D; Nathans, J; Nusse, R			A new member of the frizzled family from Drosophila functions as a Wingless receptor	NATURE			English	Article							SEGMENT POLARITY GENE; HOMEOTIC GENES; SPATIAL EXPRESSION; ARMADILLO PROTEIN; CELL; EMBRYOS; HOMOLOG; ENCODES; SIGNAL; MELANOGASTER	Receptors for Wingless and other signalling molecules of the Wnt gene family have yet to be identified. We show here that cultured Drosophila cells transfected with a novel member of the frizzled gene family in Drosophila, Dfz2, respond to added Wingless protein by elevating the level of the Armadillo protein. Moreover, Wingless binds to Drosophila or human cells expressing Dfz2. These data demonstrate that Dfz2 functions as a Wingless receptor, and they imply, in general, that Frizzled proteins are receptors for the Wnt signalling molecules.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT BIOL,STANFORD,CA 94305	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Stanford University; Stanford University				Nathans, Jeremy/0000-0001-8106-5460				ADLER PN, 1990, GENETICS, V126, P401; ADLER PN, 1987, DEV GENET, V8, P99, DOI 10.1002/dvg.1020080206; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CARAS IW, 1989, SCIENCE, V243, P1196, DOI 10.1126/science.2466338; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; EISENBERG LM, 1992, DEV BIOL, V154, P73, DOI 10.1016/0012-1606(92)90049-M; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRABA Y, 1995, DEVELOPMENT, V121, P209; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; HERMAN MA, 1994, DEVELOPMENT, V120, P1035; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MATHIES LD, 1994, DEVELOPMENT, V120, P2799; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PEEL DJ, 1992, ROUX ARCH DEV BIOL, V201, P120, DOI 10.1007/BF00420423; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; REUTER R, 1990, DEVELOPMENT, V110, P1031; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; RUSSELL J, 1992, DEVELOPMENT, V115, P475; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; THEISEN H, 1994, DEVELOPMENT, V120, P347; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wang YS, 1996, J BIOL CHEM, V271, P4468; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; ZHENG L, 1995, DEVELOPMENT, V121, P3045	50	1179	1235	1	76	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					225	230		10.1038/382225a0	http://dx.doi.org/10.1038/382225a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717036				2022-12-24	WOS:A1996UX79000040
J	Ascherio, A; Rimm, EB; Giovannucci, EL; Spiegelman, D; Stampfer, M; Willett, WC				Ascherio, A; Rimm, EB; Giovannucci, EL; Spiegelman, D; Stampfer, M; Willett, WC			Dietary fat and risk of coronary heart disease in men: Cohort follow up study in the United States	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FOOD FREQUENCY QUESTIONNAIRE; FACTOR INTERVENTION TRIAL; SERUM-LIPIDS; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; ALCOHOL-CONSUMPTION; 10-YEAR MORTALITY; ACIDS; CHOLESTEROL; DEATH	Objective-To examine the association between fat intake and the incidence of coronary heart disease in men of middle age and older. Design-Cohort questionnaire study of men followed up for six years from 1956. Setting-The health professionals follow up study in the United States. Subjects-43 757 health professionals aged 40 to 75 years free of diagnosed cardiovascular disease or diabetes in 1956. Main outcome measure e-Incidence of acute myocardial infarction or coronary death. Results-During follow up 734 coronary events were documented, including 505 non-fatal myocardial infarctions and 229 deaths. After age and several corollary risk factors were controlled for significant positive associations were observed between intake of saturated far and risk of coronary disease. For men in the Pop versus the lowest fifth of saturated fat intake (median = 14.8% v 5.7% of energy) the multivariate relative risk for myocardial infarction was 1.22 (95% confidence interval 0.96 to 1.56) and for fatal coronary heart disease was 2.21 (1.38 to 3.54). After adjustment for intake of fibre the risks were 0.96 (0.73 to 1.27) and 1.72 (1.01 to 2.90), respectively. Positive associations between intake of cholesterol and risk of coronary heart disease were similarly attenuated after adjustment for fibre intake. intake; of linolenic acid was inversely associated with risk of myocardial infarction; this association became significant only after adjustment for non-dietary risk factors and was strengthened after adjustment for total fat intake (relative risk 0.41 for a 1% increase in energy, P for trend <0.01). Conclusions-These data do not support the strong association between intake of saturated fat and risk of coronary heart disease suggested by international comparisons. They are compatible, however, with the hypotheses that saturated fat and cholesterol intakes affect the risk of coronary heart disease as predicted by their effects on blood cholesterol concentration. They also support a specific preventive effect of linolenic acid intake.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	Ascherio, A (corresponding author), HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA.				NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARO A, 1995, LANCET, V345, P273, DOI 10.1016/S0140-6736(95)90273-2; ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAYRON S, 1966, J LIPID RES, V7, P103; DAYTON S, 1969, CIRCULATION, V40, pII1; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; FEHILY AM, 1993, BRIT J NUTR, V69, P303, DOI 10.1079/BJN19930035; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; GABH Rose, 1982, WHO MONOGRAPH SERIES; GARCIAPALMIERI MR, 1980, AM J CLIN NUTR, V33, P1818, DOI 10.1093/ajcn/33.8.1818; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GOLDBOURT U, 1993, CARDIOLOGY, V82, P100, DOI 10.1159/000175862; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON T, 1981, CIRCULATION, V63, P500, DOI 10.1161/01.CIR.63.3.500; Grundy S. M., 1982, CIRCULATION, V65, P839, DOI DOI 10.1161/01.CIR.65.5.839; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; HJERMANN I, 1981, LANCET, V2, P1303; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; KATO H, 1973, AM J EPIDEMIOL, V97, P372, DOI 10.1093/oxfordjournals.aje.a121518; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KROMHOUT D, 1982, LANCET, V2, P518; KROMHOUT D, 1984, AM J EPIDEMIOL, V119, P733, DOI 10.1093/oxfordjournals.aje.a113794; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCGEE DL, 1984, AM J EPIDEMIOL, V119, P667, DOI 10.1093/oxfordjournals.aje.a113788; MCKEIGUE P, 1994, LANCET, V343, P1445, DOI 10.1016/S0140-6736(94)92575-5; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; OWREN PA, 1965, ANN INTERN MED, V63, P167, DOI 10.7326/0003-4819-63-2-167; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROBERTS TL, 1995, LANCET, V345, P278, DOI 10.1016/S0140-6736(95)90274-0; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Rothman K, 1986, MODERN EPIDEMIOLOGY; SANDKER GW, 1993, EUR J CLIN NUTR, V47, P201; SCRIMSHA.NS, 1968, LAB INVEST, V18, P623; SHEKELLE RB, 1989, LANCET, V1, P1177; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722; WILLETT WC, IN PRESS PREVENTION	58	529	548	0	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	1996	313	7049					84	90		10.1136/bmj.313.7049.84	http://dx.doi.org/10.1136/bmj.313.7049.84			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688759	Green Submitted, Green Published			2022-12-24	WOS:A1996UX69800022
J	Kaplan, MH; Sun, YL; Hoey, T; Grusby, MJ				Kaplan, MH; Sun, YL; Hoey, T; Grusby, MJ			Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice	NATURE			English	Article							STIMULATORY FACTOR	INTERACTIONS between cytokine and receptor lead to the activation of multiple signalling molecules, including the family of signal transducer and activator of transcription (STAT) proteins(1,2). Stat4 is one member of this family(3,4), and is activated only in response to the cytokine interleukin(IL)-12, (refs 5, 6). By gene targeting, we have generated mice deficient in Stat4 to determine whether the function of this transcription factor is redundant with other signalling molecules activated by IL-12. IL-12-induced increases in the production of interferon(IFN)-gamma cellular proliferation and natural killer (NK) cell cytotoxicity are abrogated in lymphocytes from Statil-deficient mice. The development of Th1 cells in response to either IL-12 or Listeria monocytogenes is also impaired in the absence of Stat4. Furthermore, Stat4-deficient lymphocytes demonstrate a propensity towards the development of Th2 cells. These results demonstrate that Stat4 is essential for mediating responses to IL-12 in lymphocytes, and regulating the differentiation of both Th1 and Th2 cells.	HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115; TULARIK INC,S SAN FRANCISCO,CA 94080; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School				Kaplan, Mark/0000-0002-2923-8245				BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEBLAKERHOHE DF, 1995, CELL IMMUNOL, V165, P33, DOI 10.1006/cimm.1995.1184; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SWAIN SL, 1990, J IMMUNOL, V145, P3796; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	22	1022	1052	2	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					174	177		10.1038/382174a0	http://dx.doi.org/10.1038/382174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700209				2022-12-24	WOS:A1996UW67200052
J	Kim, J; Sebring, A; Esch, JJ; Kraus, ME; Vorwerk, K; Magee, J; Carroll, SB				Kim, J; Sebring, A; Esch, JJ; Kraus, ME; Vorwerk, K; Magee, J; Carroll, SB			Integration of positional signals and regulation of wing formation and identity by Drosophila vestigial gene	NATURE			English	Article							HEDGEHOG; ENCODES; CELLS; DISC	Appendage formation is organized by signals from discrete sources that presumably act upon downstream genes to control growth and patterning. The Drosophila vestigial gene is selectively required for wing-cell proliferation, and is sufficient to induce outgrowths of wing tissue from eyes, legs and antennae. Different signals activate separate enhancers to control vestigial expression: first, in the dorsal/ventral organizer through the Notch pathway, and subsequently, in the developing wing blade by decapentaplegic and a signal from the dorsal/ventral organizer. Signal integration must be a general feature of genes like vestigial, that regulate growth or patterning along more than one axis.	UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706; UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAPDEVILA J, 1994, EMBO J, V6, P715; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; deCelis JF, 1996, DEVELOPMENT, V122, P359; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; DIPASQUALE A, 1952, RO IST IONB SCI LE 3, V85, P241; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Meinhardt H., 1991, Seminars in Developmental Biology, V2, P129; MORIMURA S, IN PRESS DEV BIOL; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OUWENEEL WJ, 1970, GENETICA, V41, P1, DOI 10.1007/BF00958890; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; SANICOLA M, 1995, GENETICS, V139, P745; SIMPSON P, 1981, DEV BIOL, V84, P206, DOI 10.1016/0012-1606(81)90384-5; SPREICHER S, 1994, DEVELOPMENT, V120, P535; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; XU T, 1993, DEVELOPMENT, V117, P1223; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZECCA M, 1995, DEVELOPMENT, V121, P2265	52	406	412	0	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					133	138		10.1038/382133a0	http://dx.doi.org/10.1038/382133a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700202				2022-12-24	WOS:A1996UW67200039
J	Sintchak, MD; Fleming, MA; Futer, O; Raybuck, SA; Chambers, SP; Caron, PR; Murcko, MA; Wilson, KP				Sintchak, MD; Fleming, MA; Futer, O; Raybuck, SA; Chambers, SP; Caron, PR; Murcko, MA; Wilson, KP			Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid	CELL			English	Article							HUMAN IMP DEHYDROGENASE; HUMAN NORMAL LYMPHOCYTES; GMP REDUCTASE; 5'-MONOPHOSPHATE DEHYDROGENASE; CELL LINES; EXPRESSION; INHIBITORS; GENE; PROLIFERATION; SEQUENCE	The structure of inosine-5'-monophosphate dehydrogenase (IMPDH) in complex with IMP and mycophenolic acid (MPA) has been determined by X-ray diffraction. IMPDH plays a central role in B and T lymphocyte replication. MPA is a potent IMPDH inhibitor and the active metabolite of an immunosuppressive drug recently approved for the treatment of allograft rejection. IMPDH comprises two domains: a core domain, which is an alpha/beta barrel and contains the active site, and a flanking domain. The complex, in combination with mutagenesis and kinetic data, provides a structural basis for understanding the mechanism of IMPDH activity and indicates that MPA inhibits IMPDH by acting as a replacement for the nicotinamide portion of the nicotinamide adenine dinucleotide cofactor and a catalytic water molecule.			Sintchak, MD (corresponding author), VERTEX PHARMACEUT INC, 40 ALLSTON ST, CAMBRIDGE, MA 02139 USA.							Allison A C, 1977, Ciba Found Symp, P207; ALLISON AC, 1975, LANCET, V2, P1179; ALLISON AC, 1993, IMMUNOL REV, V136, P5, DOI 10.1111/j.1600-065X.1993.tb00652.x; ANDREWS SC, 1988, BIOCHEM J, V255, P35, DOI 10.1042/bj2550035; ANTONINO LC, 1994, BIOCHEMISTRY-US, V33, P1760, DOI 10.1021/bi00173a019; ARTIS DR, 1995, Patent No. 22538; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BORK P, 1995, PROTEIN SCI, V4, P268; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; CARR SF, 1993, J BIOL CHEM, V268, P27286; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COLLART FR, 1990, BLOOD, V75, P570; COLLART FR, 1992, CANCER RES, V52, P5826; COLLART FR, 1988, J BIOL CHEM, V263, P15769; COONEY D, 1987, BIOCHIM BIOPHYS ACTA, V916, P89, DOI 10.1016/0167-4838(87)90214-7; CRABTREE GW, 1971, CANCER RES, V31, P985; DAYTON JS, 1994, J IMMUNOL, V152, P984; FLEMING MA, 1996, IN PRESS BIOCHEMISTR; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; FUREY W, 1996, IN PRESS MACROMOLECU; GIBLETT ER, 1972, LANCET, V2, P1067; Gosio B., 1896, RIV DIGIENE SANITA P, V7, P825; HAGER PW, 1995, BIOCHEM PHARMACOL, V49, P1323, DOI 10.1016/0006-2952(95)00026-V; HARRISON W, 1972, J CHEM SOC PERK T 2, P1542, DOI 10.1039/p29720001542; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; HODGES SD, 1989, J BIOL CHEM, V264, P18137; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; HOLMES EW, 1974, BIOCHIM BIOPHYS ACTA, V364, P209, DOI 10.1016/0005-2744(74)90006-0; HUETEPEREZ JA, 1995, BIOCHEMISTRY-US, V34, P13889, DOI 10.1021/bi00042a021; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KONNO Y, 1991, J BIOL CHEM, V266, P506; LEE HJ, 1985, CANCER RES, V45, P5512; LIGHTFOOT T, 1994, BBA-GENE STRUCT EXPR, V1217, P156, DOI 10.1016/0167-4781(94)90029-9; Link JO, 1996, J AM CHEM SOC, V118, P2091, DOI 10.1021/ja9534056; Makara GM, 1996, J MED CHEM, V39, P1236, DOI 10.1021/jm950600m; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; NAGAI M, 1991, CANCER RES, V51, P3886; NAGAI M, 1992, CANCER RES, V52, P258; NAKAMURA H, 1992, LEUKEMIA RES, V16, P561, DOI 10.1016/0145-2126(92)90002-O; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NATSUMEDA Y, 1988, CANCER RES, V48, P507; NATSUMEDA Y, 1993, ANN NY ACAD SCI, V696, P88; NIJKAMP HJJ, 1967, BIOCHIM BIOPHYS ACTA, V145, P31, DOI 10.1016/0005-2787(67)90651-X; Rashtchian A, 1992, PCR Methods Appl, V2, P124; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; SENDA M, 1994, LIFE SCI, V54, P1917, DOI 10.1016/0024-3205(94)90150-3; SHAW LM, 1995, THER DRUG MONIT, V17, P690, DOI 10.1097/00007691-199512000-00025; SJOGEN EB, 1995, Patent No. 22535; SNYDER FF, 1972, BIOCHEM PHARMACOL, V21, P2351, DOI 10.1016/0006-2952(72)90386-3; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; SPECTOR T, 1979, J BIOL CHEM, V254, P2308; Wang W, 1996, BIOCHEMISTRY-US, V35, P95, DOI 10.1021/bi951499q; WEBER G, 1983, CANCER RES, V43, P3466; WOLFENDEN R, 1991, ACCOUNTS CHEM RES, V24, P209, DOI 10.1021/ar00007a004; WU YD, 1995, J AM CHEM SOC, V117, P4100, DOI 10.1021/ja00119a026; Xiang BS, 1996, J BIOL CHEM, V271, P1435, DOI 10.1074/jbc.271.3.1435	58	368	390	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1996	85	6					921	930		10.1016/S0092-8674(00)81275-1	http://dx.doi.org/10.1016/S0092-8674(00)81275-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681386	Bronze			2022-12-24	WOS:A1996UR60400015
J	Yang, YP; Wilson, JM				Yang, YP; Wilson, JM			CD40 ligand-dependent T cell activation: Requirement of B7-CD28 signaling through CD40	SCIENCE			English	Article							X-LINKED IMMUNODEFICIENCY; HYPER-IGM SYNDROME; MICE; GENE; DEFICIENT; EXPRESSION	The role of CD40 ligand (CD40L) in the primary activation of T cells is not clear. The cellular and humoral immune responses to adenoviral vectors in a murine model of liver-directed gene transfer were studied to define the mechanisms responsible for CD40L-dependent T cell priming. CD40L-deficient mice did not develop effective cytotoxic T cells to transduced hepatocytes, and T cell-dependent B cell responses were absent. Full reconstitution of cellular and humoral immunity was achieved in CD40L-deficient mice by administration of an activating antibody to CD40 that increased expression of B7.2 on spleen cells. Wild-type mice could be made nonresponsive to vector by administration of antibodies to B7. Thus, CD40L-dependent activation of T cells occurs through signaling of CD40 in the antigen-presenting cell to enhance requisite costimulatory pathways that include B7.	WISTAR INST ANAT & BIOL,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MOL & CELLULAR ENGN,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania; University of Pennsylvania			Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ALLISON JP, 1995, SCIENCE, V270, P932, DOI 10.1126/science.270.5238.932; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; HASBOLD J, 1994, EUR J IMMUNOL, V24, P1835, DOI 10.1002/eji.1830240817; Kamanaka M, 1996, IMMUNITY, V4, P275, DOI 10.1016/S1074-7613(00)80435-5; KAY MA, 1995, NAT GENET, V11, P191, DOI 10.1038/ng1095-191; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; LI QT, 1993, HUM GENE THER, V4, P403, DOI 10.1089/hum.1993.4.4-403; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; WU Y, 1995, CURR BIOL, V5, P1303, DOI 10.1016/S0960-9822(95)00257-0; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Yang YP, 1996, J VIROL, V70, P6370, DOI 10.1128/JVI.70.9.6370-6377.1996; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1995, NAT MED, V1, P890, DOI 10.1038/nm0995-890; YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4; ZSENGELLER ZK, 1995, HUM GENE THER, V6, P457, DOI 10.1089/hum.1995.6.4-457	24	351	364	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1862	1864		10.1126/science.273.5283.1862	http://dx.doi.org/10.1126/science.273.5283.1862			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791591				2022-12-24	WOS:A1996VJ71300045
J	Staessen, JA				Staessen, JA			Potential adverse effects of blood pressure lowering - J-curve revisited	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION				Staessen, JA (corresponding author), KATHOLIEKE UNIV LEUVEN,DEPT CARDIOL,B-3000 LOUVAIN,BELGIUM.		Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				CARLSSON A, 1993, STROKE, V24, P195, DOI 10.1161/01.STR.24.2.195; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; KANNEL WB, 1980, AM J CARDIOL, V45, P326, DOI 10.1016/0002-9149(80)90654-2; Merlo J, 1996, BRIT MED J, V313, P457; Rodgers A, 1996, BRIT MED J, V313, P147, DOI 10.1136/bmj.313.7050.147; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; WITTEMAN JCM, 1994, LANCET, V343, P504, DOI 10.1016/S0140-6736(94)91459-1	9	15	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					696	697		10.1016/S0140-6736(05)65599-7	http://dx.doi.org/10.1016/S0140-6736(05)65599-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806284				2022-12-24	WOS:A1996VG37400003
J	Beckwith, SVW; Sargent, AI				Beckwith, SVW; Sargent, AI			Circumstellar disks and the search for neighbouring planetary systems	NATURE			English	Review							T-TAURI STARS; MAIN-SEQUENCE STARS; YOUNG STELLAR OBJECTS; ACCRETION DISKS; BETA-PICTORIS; BROWN DWARF; HL-TAURI; UNSEEN COMPANIONS; INFRARED-SPECTRA; MOLECULAR CLOUDS	The recent discoveries of planets orbiting several 'mature' stars bring new life to the question of just how common other planetary systems might be. Observations of very young stars provide a way to address this question and suggest that a significant number of such stars harbour conditions appropriate for the formation of planetary systems like our own.	CALTECH,OWENS VALLEY RADIO OBSERV 10524,PASADENA,CA 91125	California Institute of Technology	Beckwith, SVW (corresponding author), MAX PLANCK INST ASTRON,KONIGSTUHL 17,D-69117 HEIDELBERG,GERMANY.							ADAMS FC, 1986, ASTROPHYS J, V308, P836, DOI 10.1086/164555; ADAMS FC, 1988, ASTROPHYS J, V326, P865, DOI 10.1086/166144; AGLADZE NI, 1994, NATURE, V372, P243, DOI 10.1038/372243a0; ALCOCK C, 1993, NATURE, V365, P619; ANDRE P, 1994, ASTROPHYS J, V420, P837, DOI 10.1086/173608; ANGEL JRP, 1994, NATURE, V368, P203, DOI 10.1038/368203a0; AUBOURG E, 1993, NATURE, V365, P623, DOI 10.1038/365623a0; AUMANN HH, 1984, ASTROPHYS J, V278, pL23, DOI 10.1086/184214; Backman D. E., 1993, PROTOSTARS PLANETS, P1253; BAHCALL JN, 1994, ASTROPHYS J, V435, pL51, DOI 10.1086/187592; BASRI G, IN PRESS ASTROPHYS J; BECKWITH S, 1986, ASTROPHYS J, V309, P755, DOI 10.1086/164645; BECKWITH SVW, 1990, ASTRON J, V99, P924, DOI 10.1086/115385; BECKWITH SVW, 1991, ASTROPHYS J, V381, P250, DOI 10.1086/170646; BERTOUT C, 1989, ANNU REV ASTRON ASTR, V27, P351; BODENHEIMER P, 1995, ANNU REV ASTRON ASTR, V33, P199; BOSS AP, 1993, ASTROPHYS J, V411, pL99, DOI 10.1086/186922; BOSS AP, 1988, ASTROPHYS J, V331, P370, DOI 10.1086/166563; BURROWS A, 1993, REV MOD PHYS, V65, P301, DOI 10.1103/RevModPhys.65.301; BURROWS C, IN PRESS ASTROPHYS J; Butler RP, 1996, ASTROPHYS J, V464, pL153, DOI 10.1086/310102; CAMERON AGW, 1988, ANNU REV ASTRON ASTR, V26, P441; COHEN M, 1989, ASTROPHYS J, V339, P455, DOI 10.1086/167310; DUQUENNOY A, 1991, ASTRON ASTROPHYS, V248, P485; DUTREY A, 1994, ASTRON ASTROPHYS, V286, P149; ELSASSER H, 1978, ASTRON ASTROPHYS, V70, pL3; Guillot T, 1996, ASTROPHYS J, V459, pL35, DOI 10.1086/309935; HARTMANN L, 1991, ASTRON J, V101, P1050, DOI 10.1086/115747; JENSEN ELN, 1994, ASTROPHYS J, V429, pL29, DOI 10.1086/187405; KNACKE RF, 1993, ASTROPHYS J, V418, P440, DOI 10.1086/173405; KOEMER DW, 1995, ASTRON J, V109, P2138; LADA CJ, 1993, ASTROPHYS J, V408, P471, DOI 10.1086/172605; LADD EF, 1993, ASTROPHYS J, V410, P168, DOI 10.1086/172735; LAGAGE PO, 1994, NATURE, V369, P628, DOI 10.1038/369628a0; LATHAM DW, 1989, NATURE, V339, P38, DOI 10.1038/339038a0; LAY OP, 1994, ASTROPHYS J, V434, pL75, DOI 10.1086/187578; MANNINGS V, 1994, MON NOT R ASTRON SOC, V267, P361, DOI 10.1093/mnras/267.2.361; Marcel G., 1994, BOTTOM MAIN SEQUENCE, P99; Marcy GW, 1996, ASTROPHYS J, V464, pL147, DOI 10.1086/310096; MARSH KA, 1992, ASTROPHYS J, V395, pL115, DOI 10.1086/186501; MAYOR M, 1995, NATURE, V378, P355, DOI 10.1038/378355a0; MCCAUGHREAN MJ, 1996, C R ASTRON J, V111, P1977; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MIZUNO H, 1988, ASTRON ASTROPHYS, V195, P183; MIZUNO H, 1980, PROG THEOR PHYS, V64, P544, DOI 10.1143/PTP.64.544; MUNDY LG, IN PRESS ASTROPHYS J; NAKAJIMA T, 1995, NATURE, V378, P463, DOI 10.1038/378463a0; ODELL CR, 1994, ASTROPHYS J, V436, P194, DOI 10.1086/174892; OSSENKOPF V, 1994, ASTRON ASTROPHYS, V291, P943; OSTERLOH M, 1995, ASTROPHYS J, V439, P288, DOI 10.1086/175172; PACZYNSKI B, 1986, ASTROPHYS J, V304, P1, DOI 10.1086/164140; PARRY IR, 1995, C SER ASTRON SOC PAC, V84, P124; POLLACK JB, 1994, ASTROPHYS J, V421, P615, DOI 10.1086/173677; REBOLO R, 1995, NATURE, V377, P129, DOI 10.1038/377129a0; Safronov V S., 1969, EVOLUTION PROTOPLANE; SAITO M, 1995, ASTROPHYS J, V453, P384, DOI 10.1086/176398; SARGENT AI, 1987, ASTROPHYS J, V323, P294, DOI 10.1086/165827; SARGENT AI, 1991, ASTROPHYS J, V382, pL31, DOI 10.1086/186207; SCHOPF JW, 1992, MAJOR EVENTS HIST LI, P235; SHKLOVSKIL IS, 1996, INTELLIGENT LIFE UNI; SHU F, 1993, PROTOSTARS PLANETS, V3, P3; SHU FH, 1987, ANNU REV ASTRON ASTR, V25, P23, DOI 10.1146/annurev.aa.25.090187.000323; SKRUTSKIE MF, 1990, ASTRON J, V99, P1187, DOI 10.1086/115407; SKUTSKIE MF, 1991, ASTRON J, V102, P1749; SMITH BA, 1984, SCIENCE, V226, P1421, DOI 10.1126/science.226.4681.1421; STAUFFER JR, 1994, ASTRON J, V108, P155, DOI 10.1086/117053; STAUFFER JR, 1994, ASTRON J, V108, P1375, DOI 10.1086/117159; STEVENSON DJ, 1982, PLANET SPACE SCI, V30, P755, DOI 10.1016/0032-0633(82)90108-8; STROM KM, 1989, ASTRON J, V97, P1451, DOI 10.1086/115085; STROM KM, 1995, ASTROPHYS J, V438, P813, DOI 10.1086/175125; Strom S. E., 1993, PROTOSTARS PLANETS, P837; UDALSKI A, 1994, ASTROPHYS J, V426, pL69, DOI 10.1086/187342; WALTER FM, 1988, ASTRON J, V96, P297, DOI 10.1086/114809; Weidenschilling S.J., 1993, PROTOSTARS PLANETS, P1031; WEIDENSCHILLING SJ, 1987, GERL BEITR GEOPHYS, V96, P21; WETHERILL GW, 1990, ANNU REV EARTH PL SC, V18, P205, DOI 10.1146/annurev.ea.18.050190.001225; WETHERILL GW, 1993, ICARUS, V106, P190, DOI 10.1006/icar.1993.1166; WETHERILL GW, 1991, SCIENCE, V253, P535, DOI 10.1126/science.253.5019.535; WOLSZCZAN A, 1992, NATURE, V355, P145, DOI 10.1038/355145a0; Wood J. A., 1988, METEORITES EARLY SOL, P329; ZUCKERMAN B, 1995, NATURE, V373, P494, DOI 10.1038/373494a0; ZUCKERMAN B, 1993, ASTROPHYS J, V414, P793, DOI 10.1086/173123	82	229	231	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					139	144		10.1038/383139a0	http://dx.doi.org/10.1038/383139a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774877				2022-12-24	WOS:A1996VG14800042
J	Barth, DS; MacDonald, KD				Barth, DS; MacDonald, KD			Thalamic modulation of high-frequency oscillating potentials in auditory cortex	NATURE			English	Article							MEDIAL GENICULATE-BODY; EVOKED-POTENTIALS; RAT; PROJECTIONS; CONNECTIONS; NEURONS; ACTIVATION; ANATOMY	PERHAPS the most widely recognized but least understood electrophysiological activity of the cerebral cortex is its characteristic electrical oscillations. Recently, there have been efforts to understand the mechanisms underlying high-frequency gamma oscillations (similar to 40 Hz) because they may coordinate sensory processing between populations of cortical cells(1,2), High-resolution cortical recordings show that gamma oscillations are constrained to sensory cortex(3-5) that they occur independently in auditory and somatosensory cortex(4), and that they are phase-locked between primary and secondary sensory cortex(5). As yet, the mechanism of their neurogenesis is unknown(2). Whereas cortical neurons can produce gamma oscillations without subcortical input(6-9), they may also be modulated by the thalamus(10) and basal forebrain(11). Here we report that the neural generator of gamma oscillations in auditory cortex seems to be intracortical, serving to synchronize interactions between the primary and secondary areas. The acoustic thalamus directly modulates these oscillations, which are inhibited by stimulation of the dorsal and ventral divisions of the medial geniculate nucleus (MGd and MGv) and evoked by stimulation of the adjacent posterior intralaminar nucleus (PIL).			Barth, DS (corresponding author), UNIV COLORADO,DEPT PSYCHOL,CAMPUS BOX 345,BOULDER,CO 80309, USA.							ARNAULT P, 1987, J COMP NEUROL, V258, P463, DOI 10.1002/cne.902580313; ARNAULT P, 1990, J COMP NEUROL, V302, P110, DOI 10.1002/cne.903020109; Basar E, 1992, INDUCED RHYTHMS BRAI; BRETT B, 1994, BRAIN RES, V647, P65, DOI 10.1016/0006-8993(94)91399-4; DI S, 1992, J NEUROPHYSIOL, V68, P425, DOI 10.1152/jn.1992.68.2.425; FRANOWICZ MN, 1995, J NEUROPHYSIOL, V74, P96, DOI 10.1152/jn.1995.74.1.96; GUTFREUND Y, 1995, J PHYSIOL-LONDON, V483, P621, DOI 10.1113/jphysiol.1995.sp020611; Kolb B, 1990, CEREBRAL CORTEX RAT, P21; LEDOUX JE, 1987, J COMP NEUROL, V264, P123, DOI 10.1002/cne.902640110; LEDOUX JE, 1985, J COMP NEUROL, V242, P182, DOI 10.1002/cne.902420204; LLINAS RR, 1991, P NATL ACAD SCI USA, V88, P897, DOI 10.1073/pnas.88.3.897; MACDONALD KD, 1995, BRAIN RES, V694, P1, DOI 10.1016/0006-8993(95)00662-A; MACDONALD KD, IN PRESS J NEUROPHYS; METHERATE R, 1992, J NEUROSCI, V12, P4701; MOREST DK, 1986, ADV ANAT EMBRYOL CEL, V97, P1; PATTERSON H, 1977, THESIS U BOSTON; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; SILVA LR, 1991, SCIENCE, V251, P432, DOI 10.1126/science.1824881; Singer W., 1994, LARGE SCALE NEURONAL, P201; STERIADE M, 1993, NEUROSCIENCE, V56, P1, DOI 10.1016/0306-4522(93)90556-U; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; Steriade M, 1996, J NEUROSCI, V16, P2788; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0	23	119	123	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					78	81		10.1038/383078a0	http://dx.doi.org/10.1038/383078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779725				2022-12-24	WOS:A1996VF29500051
J	Best, S; LeTissier, P; Towers, G; Stoye, JP				Best, S; LeTissier, P; Towers, G; Stoye, JP			Positional cloning of the mouse retrovirus restriction gene Fv1	NATURE			English	Article							MURINE LEUKEMIA VIRUSES; LOCUS AFFECTING RESISTANCE; HOST-RANGE; WILD MOUSE; MOLECULAR CLONES; CELL-CULTURES; HUMAN DNA; FV-1; YEAST; INVITRO	VERTEBRATE evolution has taken place against a background of constant retrovirus infection, and much of the mammalian genome consists of endogenous retrovirus-like elements(1). Several host genes have evolved to control retrovirus replication(3), including Friend-virus-susceptibility-1, Fv1, on mouse chromosome 4 (refs 3, 4). The Fv1 gene acts on murine leukaemia virus at a stage after entry into the target cell but before integration and formation of the provirus(5). Although restriction is not absolute, Fv1 prevents or delays spontaneous or experimentally induced viral tumours(2), In vitro, Fv1 restriction leads to an apparent 50-1,000 fold reduction in viral titre(6). Genetic evidence implicates a direct interaction between the Fv1 gene product and a component of the viral preintegration complex, the capsid protein CA (refs 7-9), We have now cloned Fv1: the gene appears to be derived from the gag region of an endogenous retrovirus unrelated to murine leukaemia virus, implying that the Fv1 protein and its target mag share functional similarities despite the absence of nucleotide-sequence homology.	NATL INST MED RES, DIV VIROL, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research			Towers, Greg J/H-8892-2012; Le Tissier, Paul/G-3079-2011; Best, Steve/A-7531-2012	Towers, Gregory/0000-0002-7707-0264; Le Tissier, Paul/0000-0002-7220-5705; Stoye, Jonathan/0000-0003-3377-323X	Medical Research Council [MC_U117570590] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BALTIMORE D, 1985, CELL, V40, P481, DOI 10.1016/0092-8674(85)90190-4; BOONE LR, 1983, J VIROL, V48, P110, DOI 10.1128/JVI.48.1.110-119.1983; BOONE LR, 1989, J VIROL, V63, P2592, DOI 10.1128/JVI.63.6.2592-2597.1989; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BURKE DT, 1991, MAMM GENOME, V1, P65, DOI 10.1007/BF00350849; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; CORDONNIER A, 1995, J VIROL, V69, P5890, DOI 10.1128/JVI.69.9.5890-5897.1995; DURANTROISE G, 1981, VIROLOGY, V112, P795, DOI 10.1016/0042-6822(81)90329-9; FRANKEL WN, 1989, J VIROL, V63, P1763, DOI 10.1128/JVI.63.4.1763-1774.1989; GARDNER MB, 1991, TRENDS GENET, V7, P22, DOI 10.1016/0168-9525(91)90017-K; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; GUIGO R, 1992, J MOL BIOL, V226, P141, DOI 10.1016/0022-2836(92)90130-C; HARTLEY JW, 1970, J VIROL, V5, P221, DOI 10.1128/JVI.5.2.221-225.1970; HOLLAND CA, 1985, J VIROL, V53, P152, DOI 10.1128/JVI.53.1.152-157.1985; Jolicoeur P, 1979, Curr Top Microbiol Immunol, V86, P67; KOZAK CA, 1987, J VIROL, V61, P3082, DOI 10.1128/JVI.61.10.3082-3088.1987; KOZAK CA, 1985, J VIROL, V55, P281, DOI 10.1128/JVI.55.2.281-285.1985; LANDER MR, 1984, J VIROL, V52, P695, DOI 10.1128/JVI.52.2.695-698.1984; LILLY F, 1970, J NATL CANCER I, V45, P163; Morgan BA, 1996, P NATL ACAD SCI USA, V93, P2801, DOI 10.1073/pnas.93.7.2801; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PINCUS T, 1975, VIROLOGY, V65, P333, DOI 10.1016/0042-6822(75)90039-2; PRYCIAK PM, 1992, J VIROL, V66, P5959, DOI 10.1128/JVI.66.10.5959-5966.1992; REIN A, 1982, VIROLOGY, V120, P251, DOI 10.1016/0042-6822(82)90024-1; ROMMELAERE J, 1979, CELL, V16, P43, DOI 10.1016/0092-8674(79)90186-7; ROWE WP, 1973, J EXP MED, V137, P850, DOI 10.1084/jem.137.3.850; SRIVASTAVA AK, 1991, GENE, V103, P53, DOI 10.1016/0378-1119(91)90390-W; STEEVES R, 1977, ANNU REV GENET, V11, P277, DOI 10.1146/annurev.ge.11.120177.001425; STOYE JP, 1995, MAMM GENOME, V6, P31, DOI 10.1007/BF00350890	30	377	382	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 29	1996	382	6594					826	829		10.1038/382826a0	http://dx.doi.org/10.1038/382826a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752279				2022-12-24	WOS:A1996VE34700052
J	Feldman, HI; Kinosian, M; Bilker, WB; Simmons, C; Holmes, JH; Pauly, MV; Escarce, JJ				Feldman, HI; Kinosian, M; Bilker, WB; Simmons, C; Holmes, JH; Pauly, MV; Escarce, JJ			Effect of dialyzer reuse on survival of patients treated with hemodialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY; MORBIDITY; DIALYSIS	Objective-To evaluate the impact of dialyzer reuse on the survival of US hemodialysis patients. Study Design and Participants.-Nonconcurrent cohort study of 27938 patients beginning hemodialysis in the United Stales in 1986 and 1987. Main Outcome Measure.-Patient survival. Results-Dialysis in freestanding facilities reprocessing dialyzers with the combination of peracetic and acetic acids was associated with greater mortality than treatment in facilities not reprocessing dialyzers (rate ratio [RR], 1.10, 95% confidence interval [CI], 1.02-1.18; P=.02) In contrast, there was no significant difference between survival in freestanding facilities reprocessing dialyzers with either formaldehyde (RR, 1.03, 95% CI, 0.96-1.10; P=.45) or glutaraldehyde (RR, 1.13, 95% CI, 0.95-1.35; P=.18) and survival in freestanding facilities not reprocessing dialyzers. Among freestanding facilities reprocessing dialyzers, use of peracetic/acetic acid was associated with a higher rate of death than use of formaldehyde (RR=1.08, 95% CI, 1.01-1.14, P=.02). There was no statistical difference between survival in hospital-based facilities reprocessing dialyzers with either peracetic/acetic acid (RR=0.95, 95% CI, 0.85-1.06; P=.40), formaldehyde (RR=1.06, 95% CI, 0.98-1.15; P=.12), or glutaraldehyde (RR=1.09, 95% CI, 0.71-1.67; P=.70) and survival in hospital-based facilities not reprocessing dialyzers. In addition, choice of sterilant was not associated with a statistically significant difference in survival among hospital-based facilities reprocessing dialyzers. Conclusions.-Dialysis in freestanding facilities reprocessing dialyzers with peracetic/acetic acid may be associated with worse survival than dialysis in freestanding facilities not reprocessing dialyzers or in those reprocessing with formaldehyde. We were unable to determine whether these relationships arose from greater comorbidity among patients treated in facilities using peracetic/acetic acid, poor quality of dialysis procedures in these facilities, or direct toxicity of peracetic/acetic acid. These findings raise important concerns about potentially avoidable mortality among US hemodialysis patients treated in dialysis facilities reprocessing hemodialyzers.	UNIV PENN,MED CTR,CTR CLIN EPIDEMIOL & BIOSTAT,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MED,RENAL ELECTROLYTE & HYPERTENS DIV,PHILADELPHIA,PA 19104; UNIV PENN,WHARTON SCH,DEPT HLTH CARE SYST,PHILADELPHIA,PA 19104; UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Feldman, HI (corresponding author), UNIV PENN,MED CTR,DEPT BIOSTAT & EPIDEMIOL,423 SERV DR,720 BLOCKLEY HALL,PHILADELPHIA,PA 19104, USA.		Bilker, Warren/AAS-3515-2021		NIDDK NIH HHS [DK-97006, DK-45191] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045191] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COX DR, 1972, J R STAT SOC B, V34, P187; DOR A, 1992, MED CARE, V30, P879, DOI 10.1097/00005650-199210000-00001; EFRON B, 1992, MONOGRAPH SOC IND AP, V38; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HAKIM RM, 1980, T AM SOC ART INT ORG, V26, P159; HELD PJ, 1994, AM J KIDNEY DIS, V23, P692, DOI 10.1016/S0272-6386(12)70280-9; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HELD PJ, 1992, OP M FOOD DRUG ADM O; *HLTH CAR FIN ADM, 1989, HCFA PUBL; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEE ET, 1980, STAT MODELS SURVIVAL, P250; POLLAK VE, 1986, NEPHRON, V42, P217, DOI 10.1159/000183670; Rettig RA, 1991, KIDNEY FAILURE FEDER; SHUSTERMAN NH, 1989, AM J KIDNEY DIS, V14, P81, DOI 10.1016/S0272-6386(89)80181-7; THOMSEN BL, 1992, STAT MED, V11, P1528; THOMSEN BL, 1991, STAT MED, V10, P733, DOI 10.1002/sim.4780100508; TOKARAS JI, 1992, NATL SURVEILLANCE DI; Tokars J I, 1993, ASAIO J, V39, P71, DOI 10.1097/00002480-199301000-00016; WING AJ, 1978, BRIT MED J, V2, P853, DOI 10.1136/bmj.2.6141.853	19	81	83	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1996	276	8					620	625		10.1001/jama.276.8.620	http://dx.doi.org/10.1001/jama.276.8.620			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC853	8773634				2022-12-24	WOS:A1996VC85300028
J	Maly, P; Thall, AD; Petryniak, B; Rogers, GE; Smith, PL; Marks, RM; Kelly, RJ; Gersten, KM; Cheng, GY; Saunders, TL; Camper, SA; Camphausen, RT; Sullivan, FX; Isogai, Y; Hindsgaul, O; vonAndrian, UH; Lowe, JB				Maly, P; Thall, AD; Petryniak, B; Rogers, GE; Smith, PL; Marks, RM; Kelly, RJ; Gersten, KM; Cheng, GY; Saunders, TL; Camper, SA; Camphausen, RT; Sullivan, FX; Isogai, Y; Hindsgaul, O; vonAndrian, UH; Lowe, JB			The alpha(1,3)Fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis	CELL			English	Article							SIALYL-LEWIS-X; ELAM-1-DEPENDENT CELL-ADHESION; ENDOTHELIAL-DERIVED LIGAND; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; MONOCLONAL-ANTIBODY; MESENTERIC VENULES; EXPRESSION CLONING; MOLECULAR-CLONING; DEFICIENT MICE; MOUSE	alpha(1,3)Fucosylated oligosaccharides represent components of leukocyte counterreceptors for E- and P-selectins and of L-selectin ligands expressed by lymph node high endothelial venules (HEV). The identity of the alpha(1,3)fucosyltransferase(s) required for their expression has been uncertain, as has a requirement for alpha(1,3)fucosylation in HEV L-selectin ligand activity. We demonstrate here that mice deficient in alpha(1,3)fucosyltransferase Fuc-TVII exhibit a leukocyte adhesion deficiency characterized by absent leukocyte E- and P-selectin ligand activity and deficient HEV L-selectin ligand activity. Selectin ligand deficiency is distinguished by blood leukocytosis, impaired leukocyte extravasation in inflammation, and faulty lymphocyte homing. These observations demonstrate an essential role for Fuc-TVII in E-, P-, and L-selectin ligand biosynthesis and imply that this locus can control leukocyte trafficking in health and disease.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; GENET INST INC,CAMBRIDGE,MA 02140; LA JOLLA CANC RES CTR,BURNHAM INST,LA JOLLA,CA 92119	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Sanford Burnham Prebys Medical Discovery Institute	Maly, P (corresponding author), UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109, USA.		von Andrian, Ulrich H/A-5775-2008; Malý, Petr/H-5962-2014	Malý, Petr/0000-0001-8118-0581; Camper, Sally/0000-0001-8556-3379; Saunders, Thom/0000-0003-2015-101X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047455] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47455] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIGNER S, 1995, INT IMMUNOL, V7, P1557, DOI 10.1093/intimm/7.10.1557; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BARRESI F, 1995, J CARBOHYD CHEM, V14, P1043, DOI 10.1080/07328309508005396; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CROMMIE D, 1995, J BIOL CHEM, V270, P22614, DOI 10.1074/jbc.270.38.22614; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HART PH, 1986, INFECT IMMUN, V51, P936, DOI 10.1128/IAI.51.3.936-941.1986; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HESTDAL K, 1991, J IMMUNOL, V147, P22; ITO K, 1994, GLYCOCONJUGATE J, V11, P232, DOI 10.1007/BF00731223; JOHNSONTIDEY RR, 1994, AM J PATHOL, V144, P952; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEY K, 1991, CIRC RES, V69, P1034, DOI 10.1161/01.RES.69.4.1034; LEY K, 1991, BLOOD, V77, P2553; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LOWE JB, 1996, IN PRESS SELECTINS I; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NOLTE D, 1994, AM J PHYSIOL-HEART C, V267, pH1637, DOI 10.1152/ajpheart.1994.267.4.H1637; OBESO J, 1990, LAB INVEST, V63, P259; PALCIC MM, 1994, METHOD ENZYMOL, V247, P215; PALCIC MM, 1989, CARBOHYD RES, V190, P1, DOI 10.1016/0008-6215(89)84141-2; PEMBERTON M, 1993, J IMMUNOL, V150, P5104; Phillips ML, 1995, J CLIN INVEST, V96, P2898, DOI 10.1172/JCI118361; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; PRIES AR, 1988, INT J MICROCIRC, V7, P327; ROSEN SD, 1989, J IMMUNOL, V142, P1985; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; Smith PL, 1996, J BIOL CHEM, V271, P8250, DOI 10.1074/jbc.271.14.8250; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; WATT SM, 1980, J HISTOCHEM CYTOCHEM, V28, P934, DOI 10.1177/28.9.7410816; WELLER A, 1992, J BIOL CHEM, V267, P15176; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176	54	640	660	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					643	653		10.1016/S0092-8674(00)80137-3	http://dx.doi.org/10.1016/S0092-8674(00)80137-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752218	Bronze			2022-12-24	WOS:A1996VE23500014
J	Uckun, FM; Waddick, KG; Mahajan, S; Jun, X; Takata, M; Bolen, J; Kurosaki, T				Uckun, FM; Waddick, KG; Mahajan, S; Jun, X; Takata, M; Bolen, J; Kurosaki, T			BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells	SCIENCE			English	Article							PROTEIN-TYROSINE KINASES; X-LINKED AGAMMAGLOBULINEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PRIMARY CLONOGENIC BLASTS; LYN-DEFICIENT MICE; SRC-FAMILY; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-2; HEMATOPOIETIC-CELLS	Bruton's tyrosine kinase (BTK) is a member of the SRC-related TEC family of protein tyrosine kinases (PTKs). DT-40 lymphoma B cells, rendered BTK-deficient through targeted disruption of the btk gene by homologous recombination knockout, did not undergo radiation-induced apoptosis, but cells with disrupted lyn or syk genes did. Introduction of the wild-type, or a SRC homology 2 domain or a plecstrin homology domain mutant (but not a kinase domain mutant), human btk gene into BTK-deficient cells restored the apoptotic response to radiation. Thus, BTK is the PTK responsible for triggering radiation-induced apoptosis of lymphoma B cells, and its kinase domain is indispensable for the apoptotic response.	YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; DNAX RES INST MOL & CELLULAR BIOL INC,PALO ALTO,CA 94304	Yale University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Uckun, FM (corresponding author), UNIV MINNESOTA,MOL SIGNAL TRANSDUCT LAB,BIOTHERAPY INST,ROSEVILLE,MN 55113, USA.		Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Uckun, Fatih M./0000-0001-9334-183X; Takata, Minoru/0000-0002-4926-3675	NATIONAL CANCER INSTITUTE [R01CA042633, R01CA042111] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA-42633, R01-CA-42111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CONLEY ME, 1994, CURR OPIN GENET DEV, V4, P401, DOI 10.1016/0959-437X(94)90028-0; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DELBUONO BJ, 1989, J CELL PHYSIOL, V138, P61, DOI 10.1002/jcp.1041380110; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; FADOK VA, 1992, J IMMUNOL, V148, P2207; GIBSON S, 1993, BLOOD, V82, P1561; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; JI L, 1995, BIOCHEM BIOPH RES CO, V212, P640, DOI 10.1006/bbrc.1995.2017; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAW DA, 1993, CURR BIOL, V3, P654; LEE E, 1994, BIOCHEM BIOPH RES CO, V202, P128, DOI 10.1006/bbrc.1994.1902; LIU YO, 1994, BIOCHEM PHARMACOL, V48, P1265; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MESSINGER Y, IN PRESS CLIN CANC R; MIGITA K, 1994, J IMMUNOL, V153, P3457; MOWER DA, 1994, J IMMUNOL, V152, P4832; MYERS DE, 1995, P NATL ACAD SCI USA, V92, P1; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SAFFRAN DC, 1994, NEW ENGL J MED, V330, P1488, DOI 10.1056/NEJM199405263302104; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAKATA M, IN PRESS J EXP MED; TAKATA M, UNPUB; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; Uckun FM, 1996, J BIOL CHEM, V271, P6389, DOI 10.1074/jbc.271.11.6389; UCKUN FM, 1993, J CLIN INVEST, V91, P1044, DOI 10.1172/JCI116261; UCKUN FM, 1993, CANCER RES, V53, P1431; UCKUN FM, 1995, BLOOD, V85, P2817, DOI 10.1182/blood.V85.10.2817.bloodjournal85102817; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; UCKUN FM, UNPUB; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WAADDICK KG, 1995, BLOOD, V86, P4228; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; ZHU QL, 1994, J EXP MED, V180, P461, DOI 10.1084/jem.180.2.461	78	161	212	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1096	1100		10.1126/science.273.5278.1096	http://dx.doi.org/10.1126/science.273.5278.1096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688094				2022-12-24	WOS:A1996VD42800035
J	Wang, SX; Mure, M; Medzihradszky, KF; Burlingame, AL; Brown, DE; Dooley, DM; Smith, AJ; Kagan, HM; Klinman, JP				Wang, SX; Mure, M; Medzihradszky, KF; Burlingame, AL; Brown, DE; Dooley, DM; Smith, AJ; Kagan, HM; Klinman, JP			A crosslinked cofactor in lysyl oxidase: Redox function for amino acid side chains	SCIENCE			English	Article							RESONANCE RAMAN-SPECTROSCOPY; TOPA QUINONE COFACTOR; PYRROLOQUINOLINE QUINONE; PYRIDOXAL-PHOSPHATE; PROSTHETIC GROUP; MENKES SYNDROME; CROSS-LINKING; ACTIVE-SITE; ENZYME; MECHANISM	A previously unknown redox cofactor has been identified in the active site of lysyl oxidase from the bovine aorta. Edman sequencing, mass spectrometry, ultraviolet-visible spectra, and resonance Raman studies showed that this cofactor is a quinone. Its structure is derived from the crosslinking of the epsilon-amino group of a peptidyl lysine with the modified side chain of a tyrosyl residue, and it has been designated lysine tyrosylquinone. This quinone appears to be the only example of a mammalian cofactor formed from the crosslinking of two amino acid side chains, This discovery expands the range of known quino-cofactor structures and has implications for the mechanism of their biogenesis.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143; MONTANA STATE UNIV,DEPT CHEM & BIOCHEM,BOZEMAN,MT 59717; STANFORD UNIV,MED CTR,BECKMAN CTR,STANFORD,CA 94305; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Montana State University System; Montana State University Bozeman; Stanford University; Boston University					NCRR NIH HHS [P41 RR01614] Funding Source: Medline; NIGMS NIH HHS [GM39296, GM27659] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039296, R01GM027659] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN G, 1989, SEQUENCING PROTEINS, P58; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; BIRD TA, 1982, BIOCHEM BIOPH RES CO, V108, P1172, DOI 10.1016/0006-291X(82)92124-6; BUFFONI F, 1981, ITAL J BIOCHEM, V30, P179; BUFFONI F, 1966, PHARMACOL REV, V18, P1163; BURBELO PD, 1986, COLLAGEN REL RES, V6, P153; BYERS PH, 1980, NEW ENGL J MED, V303, P61, DOI 10.1056/NEJM198007103030201; CAI DY, 1994, J BIOL CHEM, V269, P32039; CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; Carr S. A, 1996, MASS SPECTROMETRY BI, P546; CHOI YH, 1995, J BIOL CHEM, V270, P4712, DOI 10.1074/jbc.270.9.4712; CRONSHAW AD, 1993, MATRIX, V13, P255, DOI 10.1016/S0934-8832(11)80009-0; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; GACHERU SN, 1989, J BIOL CHEM, V264, P12963; HAMILTON GA, 1981, COPPER PROTEINS; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KAGAN HM, 1995, J CELL BIOCHEM, V59, P329, DOI 10.1002/jcb.240590305; KAGAN HM, 1979, BIOCHEM J, V177, P203, DOI 10.1042/bj1770203; KAGAN HM, 1993, PRINCIPLES APPLICATI, P173; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176; KIVIRIKKO KI, 1987, CONNECTIVE TISSUE DI; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; KNOWLES PF, 1987, BIOCHEM J, V241, P603, DOI 10.1042/bj2410603; KNOWLES PF, 1984, COPPER PROTEINS COPP, V2, P103; KUIVANIEMI H, 1985, AM J HUM GENET, V37, P798; KUIVANIEMI H, 1982, J CLIN INVEST, V69, P730, DOI 10.1172/JCI110503; KUIVANIEMI H, 1984, J BIOL CHEM, V259, P6996; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MCINTIRE WS, 1991, SCIENCE, V252, P817, DOI 10.1126/science.2028257; MOOG RS, 1986, P NATL ACAD SCI USA, V83, P8435, DOI 10.1073/pnas.83.22.8435; MU D, 1992, J BIOL CHEM, V267, P7979; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; MURE M, 1995, J AM CHEM SOC, V117, P8707, DOI 10.1021/ja00139a003; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; PAZ MA, 1991, J BIOL CHEM, V266, P689; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; ROWE DW, 1977, J BIOL CHEM, V252, P939; ROYCE PM, 1980, BIOCHEM J, V192, P579, DOI 10.1042/bj1920579; SALISBURY SA, 1979, NATURE, V280, P843, DOI 10.1038/280843a0; SANDBERG LB, 1981, NEW ENGL J MED, V304, P566, DOI 10.1056/NEJM198103053041004; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; SUVA RH, 1978, BIOCHEMISTRY-US, V17, P3538, DOI 10.1021/bi00610a018; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; VANDERMEER RA, 1986, BIOCHEM J, V239, P789, DOI 10.1042/bj2390789; VANDERMEER RA, 1989, FEBS LETT, V254, P99, DOI 10.1016/0014-5793(89)81017-8; WANG SG, UNPUB; WILLIAMS MA, 1985, ANAL BIOCHEM, V149, P430, DOI 10.1016/0003-2697(85)90594-9; WILLIAMSON PR, 1986, BIOCHEM J, V235, P597, DOI 10.1042/bj2350597; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P6302; YASUNOBU KT, 1976, MOL CELL BIOCHEM, V13, P3, DOI 10.1007/BF01732392	55	301	328	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1078	1084		10.1126/science.273.5278.1078	http://dx.doi.org/10.1126/science.273.5278.1078			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688089				2022-12-24	WOS:A1996VD42800030
J	Ryan, RM; Maduako, K; White, C; East, CA				Ryan, RM; Maduako, K; White, C; East, CA			Routine monitoring of all postoperative outcomes at one year: Longitudinal study at the royal national throat, nose and ear hospital	BRITISH MEDICAL JOURNAL			English	Article									ROYAL NATL THROAT NOSE & EAR HOSP,LONDON WC1X 8DA,ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London								FRATER A, 1995, OUTCOMES BRIEFING, V3, P25; MCDOWELL I, 1987, GUIDE RATING SCALES; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; ROSENBERG W, 1995, BMJ-BRIT MED J, V310, P1122, DOI 10.1136/bmj.310.6987.1122; RYAN RM, 1994, ANN R COLL SURG ENGL, V76, P75	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					403	403						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761231				2022-12-24	WOS:A1996VD20600029
J	Berman, DM; Wilkie, TM; Gilman, AG				Berman, DM; Wilkie, TM; Gilman, AG			GAIP and RGS4 are GTPase-activating proteins for the G(i) subfamily of G protein alpha subunits	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; FACTOR PHEROMONES; CRYSTAL-STRUCTURE; CHOLERA-TOXIN; HUMAN GENE; A-FACTOR; TRANSDUCIN; HYDROLYSIS; MECHANISM	A novel class of regulators of G protein signaling (RGS) proteins has been identified recently. Genetic evidence suggests that RGS proteins inhibit G protein-mediated signaling at the level of the receptor-G protein interaction or the G protein alpha subunit itself. We have found that two RGS family members, GAlP and RGS4, are GTPase-activating proteins (GAPs), accelerating the rate of GTP hydrolysis by G(i alpha 1) at least 40-fold. All G(i) subfamily members assayed were substrates for these GAPs; (s alpha)was not. RGS4 activates the GTPase activity of certain G(i alpha 1) mutants (e.g., R178C), but not others (e.g., Q204L). The GAP activity of RGS proteins is consistent with their proposed role as negative regulators of G protein-mediated signaling.			Berman, DM (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				NIDDK NIH HHS [DK47890] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HONG JX, 1993, J IMMUNOL, V150, P3895; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEE E, 1992, J BIOL CHEM, V267, P1212; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAGES F, 1993, J BIOL CHEM, V268, P26358; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Roush W, 1996, SCIENCE, V271, P1056, DOI 10.1126/science.271.5252.1056; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANDOP C, 1984, J BIOL CHEM, V259, P696; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WILKIE T M, 1991, Methods (Orlando), V2, P32, DOI 10.1016/S1046-2023(05)80123-9	49	647	656	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1996	86	3					445	452		10.1016/S0092-8674(00)80117-8	http://dx.doi.org/10.1016/S0092-8674(00)80117-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756726	Bronze			2022-12-24	WOS:A1996VC30900012
J	Bilwes, AM; denHertog, J; Hunter, T; Noel, JP				Bilwes, AM; denHertog, J; Hunter, T; Noel, JP			Structural basis for inhibition of receptor protein-tyrosine phosphatase-alpha by dimerization	NATURE			English	Article							CRYSTAL-STRUCTURE; RECOGNITION; LIGAND; PHOSPHORYLATION; ENVIRONMENT; SYSTEM; 1B	RECEPTOR-LIKE protein-tyrosine phosphatases (RPTPs), like their non-receptor counterparts, regulate the level of phosphotyrosine-containing proteins derived from the action of protein-tyrosine kinases(1). RPTPs are type-I integral membrane proteins which contain one or two catalytic domains in their cytoplasmic region(2). It is not known whether extracellular ligands regulate the activity of RPTPs. Here we describe the crystal structure of the membrane-proximal catalytic domain (D1) of a typical RPTP, murine RPTP alpha. Significant structural deviations from the PTP1B fold reside within the amino-terminal hells-turn-helix segment of RPTP alpha D1 (residues 214 to 242) and a distinctive two stranded beta-sheet formed between residues 211-213 and 458-461. The turn of the N-terminal segment inserts into the active site of a dyad-related D1 monomer. On the basis of two independent crystal structures, sequence alignments, and the reported biological activity of EGF receptor/CD45 chimaeras(3), we propose that dimerization and active-site blockage is a physiologically important mechanism for downregulating the catalytic activity of RPTP alpha and other RBTPs.	SALK INST BIOL STUDIES,STRUCT BIOL LAB,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,MOL BIOL & VIROL LAB,LA JOLLA,CA 92037; NETHERLANDS INST DEV BIOL,NL-3584 CT UTRECHT,NETHERLANDS	Salk Institute; Salk Institute; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)			Noel, Joseph P/A-9459-2009	Bilwes Crane, Alexandrine/0000-0001-9922-0692				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRUNGER AT, 1992, XPLOR VERSION 3 1; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GOLDSTEIN BJ, 1995, PHOSPHOPROTEIN PHOSP, V1; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P127; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; Schmitz K. S., 1990, INTRO DYNAMIC LIGHT; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; WILD DL, 1995, J MOL GRAPHICS, V13, P291, DOI 10.1016/0263-7855(95)00068-2; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	28	282	288	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					555	559		10.1038/382555a0	http://dx.doi.org/10.1038/382555a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700232				2022-12-24	WOS:A1996VB25800055
J	Morris, JZ; Tissenbaum, HA; Ruvkun, G				Morris, JZ; Tissenbaum, HA; Ruvkun, G			A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans	NATURE			English	Article							CONTROLLING DAUER FORMATION; PROTEIN-KINASE; INTERACTING GENES; 3-KINASE; WORTMANNIN; CELLS; INHIBITION; RECEPTOR; SUBUNIT; DAF-2	A PHEROMONE-INDUCED neurosecretory pathway in Caenorhabditis elegans triggers developmental arrest and an increase in longevity at the dauer diapause stage. The gene age-1 is required for non-dauer development and normal senescence. age-1 encodes a homologue of mammalian phosphatidylinositol-3-OH kinase (PI(3)K) catalytic subunits. Lack of both maternal and zygotic age-1 activity causes dauer formation, whereas animals with maternal but not zygotic age-1 activity develop as non-dauers that live more than twice as long as normal. These data suggest that phosphatidylinositol signalling mediated by AGE-1 protein controls lifespan and the dauer diapause decision.	MASSACHUSETTS GEN HOSP,DEPT MOL BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DORMAN JB, 1995, GENETICS, V141, P1399; Finch CE, 1990, LONGEVITY SENESCENCE; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRIEDMAN DB, 1988, GENETICS, V118, P75; GOTTLIEB S, 1994, GENETICS, V137, P107; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KLASS MR, 1983, MECH AGEING DEV, V22, P279, DOI 10.1016/0047-6374(83)90082-9; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; OKADA T, 1994, J BIOL CHEM, V269, P3563; PONS S, 1995, MOL CELL BIOL, V15, P4453; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; RIDDLE DL, 1988, DAUER LARVA NEMATODE, P393; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SATO Y, 1994, GEN COMP ENDOCR, V96, P27, DOI 10.1006/gcen.1994.1156; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; THOMAS JH, 1993, GENETICS, V134, P1105; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; VOWELS JJ, 1992, GENETICS, V130, P105; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	30	659	688	1	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					536	539		10.1038/382536a0	http://dx.doi.org/10.1038/382536a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700226				2022-12-24	WOS:A1996VB25800049
J	Duke, C; Kovar, IZ				Duke, C; Kovar, IZ			HIV and the paediatrician as the child's advocate	LANCET			English	Article							TRANSMISSION; INFECTION; DELIVERY		CHELSEA & WESTMINSTER HOSP,LONDON SW10 9NH,ENGLAND	Imperial College London								BLANCHE S, 1994, NEW ENGL J MED, V330, P308, DOI 10.1056/NEJM199402033300502; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *GEN MED COUNC, 1995, DUT DOCT HIV AIDS CL; Kennedy I, 1994, MED LAW TEXT MAT; NEWELL ML, 1994, LANCET, V343, P1464; RHODEN NK, 1986, CALIF LAW REV, V74, P1951, DOI 10.2307/3480420; 1995, COMM DIS REP CDR WKL, V5, P111; 1991, MMWR-MORBID MORTAL W, V40, P1; 1994, MMWR-MORBID MORTAL W, V43, P285	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					247	249		10.1016/S0140-6736(96)00428-X	http://dx.doi.org/10.1016/S0140-6736(96)00428-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684204				2022-12-24	WOS:A1996UZ28600015
J	Bai, C; Sen, P; Hofmann, K; Ma, L; Goebl, M; Harper, JW; Elledge, SJ				Bai, C; Sen, P; Hofmann, K; Ma, L; Goebl, M; Harper, JW; Elledge, SJ			SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ANAPHASE TRANSITION; BUDDING YEAST; PROTEIN; KINASE; DESTRUCTION; INHIBITOR; PATHWAY; MITOSIS; COMPLEX	We have identified the yeast and human homologs of the SKP1 gene as a suppressor of cdc4 mutants and as a cyclin F-binding protein. Skp1p indirectly binds cyclin A/Cdk2 through Skp2p, and directly binds Skp2p, cyclin F, and Cdc4p through a novel structural motif called the F-box. SKP1 is required for ubiquitin-mediated proteolysis of Cln2p, Clb5p, and the Cdk inhibitor Sic1p, and provides a link between these molecules and the proteolysis machinery. A large number of proteins contain the F-box motif and are thereby implicated in the ubiquitin pathway. Different skp1 mutants arrest cells in either G1 or G2, suggesting a connection between regulation of proteolysis in different stages of the cycle.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; SWISS INST EXPTL CANC RES,BIOINFORMAT GRP,CH-1066 LAUSANNE,SWITZERLAND; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Swiss Institute Experimental Cancer Research; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute			Hofmann, Kay/D-6714-2011	Hofmann, Kay/0000-0002-2289-9083; Harper, Jeffrey/0000-0002-6944-7236	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044664, R37GM044664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER; NIA NIH HHS [AG11085] Funding Source: Medline; NIGMS NIH HHS [GM44664] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; BANERJEE A, 1993, J BIOL CHEM, V270, P26209; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CONNELLY C, 1996, IN PRESS CELL, V86; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FLICK JS, 1991, MOL CELL BIOL, V11, P5101, DOI 10.1128/MCB.11.10.5101; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LIU HP, 1992, GENETICS, V132, P665; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; THOMAS D, 1995, MOL CELL BIOL, V15, P6526; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	38	1148	1236	7	67	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					263	274		10.1016/S0092-8674(00)80098-7	http://dx.doi.org/10.1016/S0092-8674(00)80098-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706131	Bronze			2022-12-24	WOS:A1996UZ97200012
J	Yamagata, Y; Kato, M; Odawara, K; Tokuno, Y; Nakashima, Y; Matsushima, N; Yasumura, K; Tomita, K; Ihara, K; Fujii, Y; Nakabeppu, Y; Sekiguchi, M; Fujii, S				Yamagata, Y; Kato, M; Odawara, K; Tokuno, Y; Nakashima, Y; Matsushima, N; Yasumura, K; Tomita, K; Ihara, K; Fujii, Y; Nakabeppu, Y; Sekiguchi, M; Fujii, S			Three-dimensional structure of a DNA repair enzyme, 3-methyladenine DNA glycosylase II, from Escherichia coli	CELL			English	Article							BASE-EXCISION-REPAIR; TATA-BINDING PROTEIN; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ALKA GENE; ENDONUCLEASE-III; 3-DIMENSIONAL STRUCTURE; STACKING INTERACTION; ADAPTIVE RESPONSE; ALKYLATING-AGENTS	The three-dimensional structure of Escherichia coli 3-methyladenine DNA glycosylase II, which removes numerous alkylated bases from DNA, was solved at 2.3 Angstrom resolution. The enzyme consists of three domains: one alpha + beta fold domain with a similarity to one-half of the eukaryotic TATA box-binding protein, and two all alpha-helical domains similar to those of Escherichia coli endonuclease III with combined N-glycosylase/abasic lyase activity. Mutagenesis and model-building studies suggest that the active site is located in a cleft between the two helical domains and that the enzyme flips the target base out of the DNA duplex into the active-site cleft. The structure of the active site implies broad substrate specificity and simple N-glycosylase activity.	KYUSHU UNIV,MED INST BIOREGULAT,HIGASHI KU,FUKUOKA 812,JAPAN	Kyushu University	Yamagata, Y (corresponding author), OSAKA UNIV,FAC PHARMACEUT SCI,SUITA,OSAKA 565,JAPAN.		Yamagata, Yoshiki/T-6489-2019; Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X; Ihara, Kenji/0000-0002-8831-1991				ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; BERDAL KG, 1990, EMBO J, V9, P4563, DOI 10.1002/j.1460-2075.1990.tb07909.x; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; BJORAS M, 1995, BIOCHEMISTRY-US, V34, P4577, DOI 10.1021/bi00014a010; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRUNGER AT, 1993, X PLOR VERSION 3 1; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CHEN J, 1990, EMBO J, V9, P4569, DOI 10.1002/j.1460-2075.1990.tb07910.x; FINNIN MS, 1994, P NATL ACAD SCI USA, V91, P10972, DOI 10.1073/pnas.91.23.10972; FLORES TP, 1994, PROTEIN ENG, V7, P31, DOI 10.1093/protein/7.1.31; FRIEDBERG EC, 1995, DNA REPAIR; IHARA K, 1994, MOL GEN GENET, V243, P379; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOW YW, 1994, ANN NY ACAD SCI, V726, P178, DOI 10.1111/j.1749-6632.1994.tb52812.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; MATIJASEVIC Z, 1992, P NATL ACAD SCI USA, V89, P9331, DOI 10.1073/pnas.89.19.9331; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOORE MH, 1994, EMBO J, V13, P1495, DOI 10.1002/j.1460-2075.1994.tb06410.x; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MOROHOSHI F, 1993, J BACTERIOL, V175, P6010, DOI 10.1128/JB.175.18.6010-6017.1993; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3723; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3730; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; SAKUMI K, 1986, J BIOL CHEM, V261, P5761; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SANTERRE A, 1994, P NATL ACAD SCI USA, V91, P2240, DOI 10.1073/pnas.91.6.2240; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; STEIGEMANN W, 1985, PROTEIN; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; VICKERS MA, 1993, P NATL ACAD SCI USA, V90, P3437, DOI 10.1073/pnas.90.8.3437; VRIELINK A, 1994, EMBO J, V13, P3413, DOI 10.1002/j.1460-2075.1994.tb06646.x; XIAO W, 1994, YEAST, V10, P687, DOI 10.1002/yea.320100513; YAMAGATA Y, 1988, J MOL BIOL, V204, P1055, DOI 10.1016/0022-2836(88)90063-0; YAMAGATA Y, 1994, CHEM PHARM BULL, V42, P2385; YAMAMOTO Y, 1979, MOL GEN GENET, V171, P251, DOI 10.1007/BF00267579	58	131	133	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					311	319		10.1016/S0092-8674(00)80102-6	http://dx.doi.org/10.1016/S0092-8674(00)80102-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706135	Bronze			2022-12-24	WOS:A1996UZ97200016
J	Kipreos, ET; Lander, LE; Wing, JP; He, WW; Hedgecock, EM				Kipreos, ET; Lander, LE; Wing, JP; He, WW; Hedgecock, EM			cul-1 is required for cell cycle exit in C-elegans and identifies a novel gene family	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SACCHAROMYCES-CEREVISIAE; SEQUENCE; GENOME; FIBROBLASTS; LINEAGES; PROJECT; PHASE; G(1)	The gene cul-1 (formerly lin-19) is a negative regulator of the cell cycle in C. elegans. Null mutations cause hyperplasia of all tissues. cul-1 is required for developmentally programmed transitions from the G1 phase of the cell cycle to the G0 phase or the apoptotic pathway. Moreover, the mutant phenotype suggests that G1-to-S phase progression is accelerated, overriding mechanisms for mitotic arrest and producing abnormally small cells. Significantly, diverse aspects of cell fate and differentiation are unaffected in cul-1 mutants. cul-1 represents a conserved family of genes, designated cullins, with at least five members in nematodes, six in humans, and three in budding yeast.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; HUMAN GENOME SCI INC, ROCKVILLE, MD 20850 USA	Johns Hopkins University; GlaxoSmithKline; Human Genome Sciences Inc					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026295, R01NS026295] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26295] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; BURNATOWSKAHLEDIN MA, 1995, AM J PHYSIOL-RENAL, V268, pF1198, DOI 10.1152/ajprenal.1995.268.6.F1198; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEDGECOCK EM, 1985, DEV BIOL, V107, P128, DOI 10.1016/0012-1606(85)90381-1; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KIMBLE J, 1984, DEV BIOL, V105, P234, DOI 10.1016/0012-1606(84)90279-3; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Mello C, 1995, METHOD CELL BIOL, P452; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sambrook J., 1989, MOL CLONING; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SINGH RN, 1978, NEMATOLOGICA, V24, P63, DOI 10.1163/187529278X00074; SULSTON J, 1975, J COMP NEUROL, V163, P215, DOI 10.1002/cne.901630207; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Sulston J., 1988, NEMATODE CAENORHABDI, P415; Sulston J, 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; Swofford D., 1998, PAUP PHYLOGENETIC AN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	47	387	411	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 14	1996	85	6					829	839		10.1016/S0092-8674(00)81267-2	http://dx.doi.org/10.1016/S0092-8674(00)81267-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681378	hybrid			2022-12-24	WOS:A1996UR60400007
J	PerezTerzic, C; Pyle, J; Jaconi, M; StehnoBittel, L; Clapham, DE				PerezTerzic, C; Pyle, J; Jaconi, M; StehnoBittel, L; Clapham, DE			Conformational states of the nuclear pore complex induced by depletion of nuclear Ca2+ stores	SCIENCE			English	Article							CALCIUM; TRANSPORT; GLYCOPROTEIN; MICROSCOPY; DIFFUSION; ENVELOPE; CELLS	The nuclear pore complex (NPC) is essential for the transit of molecules between the cytoplasm and nucleoplasm of a cell and until recently was thought to allow intermediate-sized molecules (relative molecular mass of similar to 10,000) to diffuse freely across the nuclear envelope. However, the depletion of calcium from the nuclear envelope of Xenopus laevis oocytes was shown to regulate the passage of intermediate-sized molecules. Two distinct conformational stales of the NPC were observed by field emission scanning electronmicroscopy and atomic force microscopy. A central plug occluded the NPC channel after nuclear calcium stores had been depleted and free diffusion of intermediate-sized molecules had been blocked. Thus, the NPC conformation appears to gate molecular movement across the nuclear envelope.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Clapham, David/R-5974-2019; Jaconi, Marisa EE/J-4392-2013	Jaconi, Marisa/0000-0002-2004-8226; Stehno-Bittel, Lisa/0000-0002-8879-6124; Clapham, David/0000-0002-4459-9428				AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; AKEY CW, 1995, J MOL BIOL, V248, P2732; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MAK DOD, 1994, J BIOL CHEM, V269, P29375; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; UNWIN PNT, 1982, J CELL BIOL, V93, P63, DOI 10.1083/jcb.93.1.63	21	156	158	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1875	1877		10.1126/science.273.5283.1875	http://dx.doi.org/10.1126/science.273.5283.1875			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791595				2022-12-24	WOS:A1996VJ71300049
J	Kessler, DA; Witt, AM; Barnett, PS; Zeller, MR; Natanblut, SL; Wilkenfeld, JP; Lorraine, CC; Thompson, LJ; Schultz, WB				Kessler, DA; Witt, AM; Barnett, PS; Zeller, MR; Natanblut, SL; Wilkenfeld, JP; Lorraine, CC; Thompson, LJ; Schultz, WB			The Food and Drug Administration's regulation of tobacco products	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENCE; CHILDREN				Kessler, DA (corresponding author), US FDA,OFF COMMISSIONER,5600 FISHERS LN,HF-1,ROCKVILLE,MD 20857, USA.							AFRICK J, 1986, COMMUNICATION    WIN, P2; *AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P159; *AMA, 1993, 1993 AMA POL COMP, P35; BAVLEY A, 1966, Patent No. 3280823; Benowitz N L, 1990, NIDA Res Monogr, V99, P12; COTTLER LB, 1993, ADDICTION, V88, P689, DOI 10.1111/j.1360-0443.1993.tb02082.x; DAGNOLI J, 1990, ADVERTISING AGE 0212, P31; *DEP HHS, 1994, PREV TOB US YOUNG PE, P249; *DEP HLTH HUM SERV, 1994, PREV TOB US YOUNG PE, P80; *DEP HLTH HUM SERV, 1988, HLTH CONS SMOK NIC A, P7; *DEP HLTH HUM SERV, 1988, DHHS CDC PUBL, P13; *DEP HLTH HUM SERV, 1994, DHHS PUBL, P89; *DEP HLTH HUM SERV, 1994, SN017001004910 DEP H, P5; *DEP HLTH HUM SERV, 1994, PREV TOB US YOUNG PE; *DEP HLTH HUM SERV, 1986, PUBL DEP HLTH HUM SE, P4; *DEP HLTH HUM SERV, 1994, PREV TOB US YOUNG PE, P65; *DEP HLTH HUM SERV, 1988, DHHS PUBL, P274; DIFRANZA JR, 1990, JAMA-J AM MED ASSOC, V263, P2784, DOI 10.1001/jama.263.20.2784; DUNN WL, 1974, COMMUNICATION   0509; DUNN WL, 1972, MOTIVES INCENTIVES C, P5; ELLIS C, 1962, SMOKING HLTH POLICY, P4; ERICKSEN MP, 1995, TOBACCO MORTALITY ES; *FED REP BRAZ MIN, 1993, PUBL FED REP BRAZ MI; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; *GH GALL INT I, 1992, TEEN ATT BEH TOB REP, P17; HARSHBARGER S, 1996, PROPOSED REGULATIONS; HILTS PJ, 1994, NY TIMES        0507; *HLTH WELF CAN HLT, 1989, TOB NIC ADD COMM REP, pR5; HUGHES JR, 1987, AM J PSYCHIAT, V144, P205; *I MED, 1994, GROW TOB FREE PREV N, P215; *I MED, 1994, GROW TOB FREE PREV N, P3; *I MED, 1994, GROW TOB FREE PREV N; JOHNSTON LD, 1994, NIH PUBLICATION, P9; KESSLER DA, 1994, AGENCYS RESPONSE COA; Levin Gary, 1992, ADVERTISING AGE 0427, P12; *MED RES COUNC, 1994, MRC FIELD REV DRUG D, P11; *NAT AUT MERCH ASS, 1989, FIND STUD TEEN CIG S; *OUTD ADV ASS AM, OUTD ITS NOT MED ITS; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P61, DOI 10.1001/jama.261.1.61; SENKUS M, 1976, SOME EFFECTS SMOKING, P4; SLADE J, 1994, 9 WORLD C TOB HLTH; TEAGUE CE, 1972, COMMUNICATION   0414; TEINOWITZ I, 1993, ADVERTISING AGE 0426, P46; TEINOWITZ I, 1993, ADVERTISING AGE 0426, P3; *U MICH NEWS INF S, 1995, SMOK RAT CLIMB AM TE; WAKEHAM H, 1969, COMMUNICATION   1126, P240; *WHO, 1992, ICD 10 CLASS MENT BE, P76; WOODY GE, 1993, ADDICTION, V88, P1573, DOI 10.1111/j.1360-0443.1993.tb03144.x; YEAMAN AY, 1963, BATCO RES C JUL 17, P4; 1995, FED REGISTER, V60, P41625; 1995, FED REGISTER, V62, P41737; 1995, FED REGISTER, V60, P41453; 1994, MMWR-MORBID MORTAL W, V43, P925; 1996, FED REGISTER, V61, P44396; 1993, MMWR-MORBID MORTAL W, V42, P645; 1994, MMWR-MORBID MORTAL W, V43, P577; 1995, FED REGISTER, V60, P41314; 1996, FED REGISTER, V61, P11419; 1996, ROLLING STONE   0307, P12; 1995, FED REGISTER, V60, P41701; 1988, CHEM BIOL STUDIES NE; 1995, FED REGISTER, V60, P41723; 1996, ROLLING STONE   0307, P13	63	95	96	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1996	335	13					988	994		10.1056/NEJM199609263351321	http://dx.doi.org/10.1056/NEJM199609263351321			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VK148	8782508	Bronze			2022-12-24	WOS:A1996VK14800035
J	Hiller, MM; Finger, A; Schweiger, M; Wolf, DH				Hiller, MM; Finger, A; Schweiger, M; Wolf, DH			ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; DEPENDENT PROTEOLYSIS; MULTIUBIQUITIN CHAIN; YEAST PROTEASOME; CELL; LOCALIZATION; MEMBRANE; GENE; RESISTANCE	Secretion of proteins is initiated by their uptake into the endoplasmic reticulum (ER), which possesses a proteolytic system able to degrade misfolded and nonassembled proteins. The ER degradation system was studied with yeast mutants defective in the breakdown of a mutated soluble vacuolar protein, carboxypeptidase yscY (CPYstar). The ubiquitin-conjugating enzyme Ubc7p participated in the degradation process, which was mediated by the cytosolic 26S proteasome. It is likely that CPYstar entered the ER, was glycosylated, and was then transported back out of the ER lumen to the cytoplasmic side of the organelle, where it was conjugated with ubiquitin and degraded.	UNIV STUTTGART, INST BIOCHEM, D-70569 STUTTGART, GERMANY	University of Stuttgart								ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1994, CELLULAR PROTEOLYTIC, V15, P137; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; EGNER R, 1995, MOL CELL BIOL, V15, P5879; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Guthrie C, 1991, METHODS ENZYMOL, V194; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HILT W, 1993, J BIOL CHEM, V268, P3479; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; PALMER A, 1994, EUR J CELL BIOL, V64, P163; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RIVETT AJ, 1993, CURR BIOL, V3, P127, DOI 10.1016/0960-9822(93)90173-L; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; ROMISCH K, 1992, P NATL ACAD SCI USA, V89, P7227, DOI 10.1073/pnas.89.15.7227; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; SCHWARTZ AL, 1988, EMBO J, V7, P2961, DOI 10.1002/j.1460-2075.1988.tb03158.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SPORMANN DO, 1992, J BIOL CHEM, V267, P8021; VALLON U, 1994, PROTOPLASMA, V182, P15, DOI 10.1007/BF01403684; VASSAL A, 1992, BIOCHIM BIOPHYS ACTA, V1132, P211, DOI 10.1016/0167-4781(92)90015-R; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5	46	595	601	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1725	1728		10.1126/science.273.5282.1725	http://dx.doi.org/10.1126/science.273.5282.1725			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781238				2022-12-24	WOS:A1996VH40800045
J	Kohda, D; Morton, CJ; Parkar, AA; Hatanaka, H; Inagaki, FM; Campbell, ID; Day, AJ				Kohda, D; Morton, CJ; Parkar, AA; Hatanaka, H; Inagaki, FM; Campbell, ID; Day, AJ			Solution structure of the link module: A hyaluronan-binding domain involved in extracellular matrix stability and cell migration	CELL			English	Article							CARTILAGE PROTEOGLYCAN CORE; NUCLEAR-MAGNETIC-RESONANCE; E-SELECTIN; TERTIARY STRUCTURE; CRYSTAL-STRUCTURE; PROTEIN; ACID; CD44; SPECTROSCOPY; RECEPTOR	Link modules are hyaluronan-binding domains found in proteins involved in the assembly of extracellular matrix, cell adhesion, and migration. The solution structure of the Link module from human TSG-6 was determined and found to consist of two alpha helices and two antiparallel beta sheets arranged around a large hydrophobic core. This defines the consensus fold for the Link module superfamily, which includes CD44, cartilage link protein, and aggrecan. The TSG-6 Link module was shown to interact with hyaluronan, and a putative binding surface was identified on the structure. A structural database search revealed close similarity between the Link module and the C-type lectin domain, with the predicted hyaluronan-binding site at an analogous position to the carbohydrate-binding pocket in E-selectin.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,OXFORD CTR MOL SCI,OXFORD OX1 3QU,ENGLAND; TOKYO METROPOLITAN INST MED SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Oxford; University of Oxford; Tokyo Metropolitan Institute of Medical Science			Morton, Craig/GON-8638-2022; Kohda, Daisuke/I-4990-2019; Day, Anthony/O-1658-2015	Morton, Craig/0000-0001-5452-5193; Kohda, Daisuke/0000-0001-8234-3776; Day, Anthony/0000-0002-1415-3134; Parkar, Ashfaq/0000-0003-0173-0673	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BORK P, 1995, TRENDS BIOCH S, V2; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P531; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHRISTNER JE, 1977, BIOCHEM J, V167, P711, DOI 10.1042/bj1670711; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; DOEGE K, 1987, J BIOL CHEM, V262, P17757; FOSANG AJ, 1990, MATRIX, V10, P306, DOI 10.1016/S0934-8832(11)80186-1; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARDINGHAM TE, 1976, BIOCHEM J, V157, P127, DOI 10.1042/bj1570127; HARDINGHAM TE, 1973, BIOCHEM J, V135, P905, DOI 10.1042/bj1350905; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HATANAKA H, 1994, J MOL BIOL, V240, P155, DOI 10.1006/jmbi.1994.1429; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; HOLM L, 1992, PROTEIN SCI, V1, P1691, DOI 10.1002/pro.5560011217; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JUTILA MA, 1994, J IMMUNOL, V153, P3917; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KOGAN TP, 1995, J BIOL CHEM, V270, P14047, DOI 10.1074/jbc.270.23.14047; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; LYON M, 1986, BIOCHIM BIOPHYS ACTA, V881, P22, DOI 10.1016/0304-4165(86)90092-9; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; Maier R, 1996, ARTHRITIS RHEUM, V39, P552, DOI 10.1002/art.1780390403; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; MORGELIN M, 1988, BIOCHEM J, V253, P175; MORGELIN M, 1995, BIOCHEM J, V307, P595; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; NEAME PJ, 1986, J BIOL CHEM, V261, P3519; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; POUYANI T, 1994, BIOCONJUGATE CHEM, V5, P370, DOI 10.1021/bc00028a015; RAUCH U, 1992, J BIOL CHEM, V267, P19536; SHARON N, 1993, TRENDS BIOCHEM SCI, V18, P221, DOI 10.1016/0968-0004(93)90193-Q; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; SURI AK, 1993, J MAGN RESON SER B, V101, P320, DOI 10.1006/jmrb.1993.1050; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; VARELAS JB, 1995, ARCH BIOCHEM BIOPHYS, V321, P21, DOI 10.1006/abbi.1995.1363; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YU Q, 1995, BIOTECHNIQUES, V19, P122; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	66	247	260	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					767	775		10.1016/S0092-8674(00)80151-8	http://dx.doi.org/10.1016/S0092-8674(00)80151-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797823	Bronze			2022-12-24	WOS:A1996VG37200010
J	Laufer, TM; DeKoning, J; Markowitz, JS; Lo, D; Glimcher, LH				Laufer, TM; DeKoning, J; Markowitz, JS; Lo, D; Glimcher, LH			Unopposed positive selection and autoreactivity in mice expressing class II MHC only on thymic cortex	NATURE			English	Article							CD4+ T-CELLS; TRANSGENIC MICE; NEGATIVE SELECTION; EPITHELIAL-CELLS; CLONAL DELETION; ANTIGEN; MOLECULES; MEDULLA; DIFFERENTIATION; APOPTOSIS	THE normal development of T cells in the thymus requires both positive and negative selection. During positive selection, thymocytes mature only if their T-cell receptors react with some specificity to host major histocompatibility complex (MHC) and host peptides. During negative selection, thymocytes die if their T-cell receptors react with too high an affinity to the presenting cell, self MHC, and peptides to which they are exposed. These two processes are important for the development of the T-cell repertoire and the acquisition of self-tolerance, but their precise location and temporal relationship are not known. We have used the keratin 14 (K14) promoter to re-express a class II MHC antigen (I-A(b)) in class II-negative mice. The transgenic I-A molecule is expressed only on thymic cortical epithelium; thymic medullary epithelium and bone-marrow-derived cells are I-A negative. CD4(+) cells are positively selected in K14 mice, but clonal deletion does not occur in K14 mice or in reIB-negative mice, which lack a thymic medulla. The K14 CD4 cells are autoreactive, as they proliferate extensively to and specifically lyse I-A(b)-positive target cells. These autoreactive cells make up 5% of the peripheral CD4 T cells, providing an estimate of the minimal frequency of positively selected cells that must subsequently undergo negative selection for self-tolerance to be preserved, Thus positive and negative selection occur in anatomically distinct sites.	HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Scripps Research Institute								ANDERSON G, 1994, J EXP MED, V179, P2027, DOI 10.1084/jem.179.6.2027; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; BURKLY LC, 1993, J IMMUNOL, V151, P3954; COSGROVE D, 1992, INT IMMUNOL, V4, P707, DOI 10.1093/intimm/4.6.707; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DIGHE AS, 1995, IMMUNITY, V3, P657, DOI 10.1016/1074-7613(95)90136-1; GLIMCHER LH, 1981, J EXP MED, V154, P1652, DOI 10.1084/jem.154.5.1652; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HENGARTNER H, 1988, NATURE, V336, P388, DOI 10.1038/336388a0; HOFFMANN MW, 1995, P NATL ACAD SCI USA, V92, P9851, DOI 10.1073/pnas.92.21.9851; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; POIRIER G, 1994, IMMUNITY, V1, P385, DOI 10.1016/1074-7613(94)90069-8; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TASWELL C, 1981, J IMMUNOL, V126, P1614; VANEWIJK W, 1988, CELL, V53, P357, DOI 10.1016/0092-8674(88)90156-0; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WIDERA G, 1987, CELL, V51, P175, DOI 10.1016/0092-8674(87)90145-0	24	325	332	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					81	85		10.1038/383081a0	http://dx.doi.org/10.1038/383081a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779719				2022-12-24	WOS:A1996VF29500052
J	Rimm, EB; Katan, MB; Ascherio, A; Stampfer, MJ; Willett, WC				Rimm, EB; Katan, MB; Ascherio, A; Stampfer, MJ; Willett, WC			Relation between intake of flavonoids and risk for coronary heart disease in male health professionals	ANNALS OF INTERNAL MEDICINE			English	Article							POTENTIALLY ANTICARCINOGENIC FLAVONOIDS; FOOD FREQUENCY QUESTIONNAIRE; ALCOHOL-CONSUMPTION; MEN; REPRODUCIBILITY; NETHERLANDS; VALIDITY	Objective: Flavonols and flavones are subgroups of flavonoids and are found in tea, vegetables, fruits, and red wine. Because they have antioxidant properties, we investigated whether intake of these dietary compounds is associated with a lower risk for fatal and nonfatal coronary heart disease. Design: Prospective cohort study. Setting: United States. Patients: 34 789 male health professionals, 40 to 75 years of age, who responded to a questionnaire in 1986. Measurements: In 1986 and 1990, detailed, 131-item questionnaires were used to assess dietary intake of flavonols and flavones. Results: Between 1986 and 1992, 496 patients received a new diagnosis of nonfatal myocardial infarction. The relative risk for nonfatal myocardial infarction was 1.08 (95% Cl, 0.81 to 1.43) for the highest (median, 40.0 mg/d) compared with the lowest (median, 7.1 mg/d) quintiles for intake of flavonols and flavones after adjustment for age, obesity, smoking, intake of vitamin E, intake of alcohol, diabetes, hypertension, hypercholesterolemia, and family history of coronary heart disease. Among the 4814 men who reported that they had previously had coronary heart disease, we found a modest but nonsignificant inverse association between in-take of flavonols and flavones and subsequent coronary mortality rates (relative risk, 0.63 [Cl, 0.33 to 1.20] for the highest compared with the lowest quintile for intake of flavonoids). Conclusion: The data do not support a strong inverse association between intake of flavonoids and total coronary heart disease, but they do not exclude the possibility that flavonoids have a protective effect in men with established coronary heart disease.	AGR UNIV WAGENINGEN, DEPT HUMAN NUTR, NL-6703 HD WAGENINGEN, NETHERLANDS; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Wageningen University & Research; Harvard University; Brigham & Women's Hospital	Rimm, EB (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.							ASCHERIO A, 1994, CIRCULATION, V89, P969, DOI 10.1161/01.CIR.89.3.969; ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; *CONS FOOD EC I, 1989, COMP FOODS; DEWHALLEY CV, 1990, BIOCHEM PHARMACOL, V39, P1743, DOI 10.1016/0006-2952(90)90120-A; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P2379, DOI 10.1021/jf00024a011; HERTOG MGL, 1993, J AGR FOOD CHEM, V41, P1242, DOI 10.1021/jf00032a015; HOLLMAN PCH, 1995, AM J CLIN NUTR, V62, P1276, DOI 10.1093/ajcn/62.6.1276; KLEIJNEN J, 1992, LANCET, V340, P1136, DOI 10.1016/0140-6736(92)93158-J; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; LANDOLFI R, 1984, BIOCHEM PHARMACOL, V33, P1525, DOI 10.1016/0006-2952(84)90423-4; MIDDLETON E, 1992, BIOCHEM PHARMACOL, V43, P1167, DOI 10.1016/0006-2952(92)90489-6; NEGRESALVAYRE A, 1992, FREE RADICAL BIO MED, V12, P101, DOI 10.1016/0891-5849(92)90002-X; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; RIMM EB, 1992, ALCOHOL AND CARDIOVASCULAR DISEASE, P1; Rose G, 1982, CARDIOVASCULAR SURVE; Rothman K, 1986, MODERN EPIDEMIOLOGY; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366	30	433	446	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1996	125	5					384	389		10.7326/0003-4819-125-5-199609010-00005	http://dx.doi.org/10.7326/0003-4819-125-5-199609010-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE079	8702089				2022-12-24	WOS:A1996VE07900005
J	Lenton, SW; Sidebotham, PD				Lenton, SW; Sidebotham, PD			Incidence of adverse reactions after administration of high dose diphtheria with tetanus vaccine to school leavers: Retrospective questionnaire study	BRITISH MEDICAL JOURNAL			English	Article							ADULTS		UNIV SOUTHAMPTON,SCH MED,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Southampton	Lenton, SW (corresponding author), BATH & W COMMUNITY NHS TRUST,DEPT CHILD HLTH,BATH BA1 3QE,AVON,ENGLAND.		Sidebotham, Peter D/E-3011-2010	Sidebotham, Peter D/0000-0003-4891-6926				*DEP HLTH, 1994, 942 PL CMO DEP HLTH; MIDDAUGH JP, 1979, AM J PUBLIC HEALTH, V69, P246, DOI 10.2105/AJPH.69.3.246; MORTIMER J, 1986, LANCET, V2, P1182; MYERS MG, 1982, JAMA-J AM MED ASSOC, V248, P2478, DOI 10.1001/jama.248.19.2478; SCHEIBEL I, 1948, ACTA PATHOL MIC SC, V25, P319	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					533	534						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VF294	8789983	Green Published			2022-12-24	WOS:A1996VF29400023
J	Wright, CM; Corbett, SS; Drewett, RF				Wright, CM; Corbett, SS; Drewett, RF			Sex differences in weight in infancy and the British 1990 national growth standards	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine if there is a sex difference in infancy in the new British national standards for weight (based on data from 1990). Design-Weight data in a birth cohort were compared with the 1990 standards and Tanner and Whitehouse (1966) standards up to age 12 months. Setting-Newcastle upon Tyne. Subjects-3418 term infants. Results-Our cohort showed a mean difference in standard deviation scores of 0.42 between boys and girls (P<0.0001) when compared with the 1990 standards. Two and a half times as many girls as boys had weights below the 3rd centile during the first year, with an equivalent excess of boys above the 97th centile (P<0.0001). Similar results were found with Tanner and Whitehouse standards. Conclusions-These differences could result in substantial sex bias in the identification of poor growth in early childhood. The standards need modification.	UNIV DURHAM, DEPT PSYCHOL, DURHAM DH1 3LE, ENGLAND	Durham University	Wright, CM (corresponding author), UNIV NEWCASTLE UPON TYNE, DEPT CHILD HLTH, GATESHEAD NE8 3EB, TYNE & WEAR, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOYCE L, 1993, GROWTH PROGRAM VERSI; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; SAVAGE S, IN PRESS P NUTR SOC; SKUSE D, 1994, EUR J CLIN NUTR, V48, pS113; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; WRIGHT CM, 1993, ARCH DIS CHILD, V69, P420, DOI 10.1136/adc.69.4.420; WRIGHT CM, 1994, ACTA PAEDIATR, V83, P351, DOI 10.1111/j.1651-2227.1994.tb18118.x	7	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 31	1996	313	7056					513	514						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789973	Green Published			2022-12-24	WOS:A1996VF29400013
J	Geyer, S; Ledberg, A; Schleicher, A; Kinomura, S; Schormann, T; Burgel, U; Klingberg, T; Larsson, J; Zilles, K; Roland, PE				Geyer, S; Ledberg, A; Schleicher, A; Kinomura, S; Schormann, T; Burgel, U; Klingberg, T; Larsson, J; Zilles, K; Roland, PE			Two different areas within the primary motor cortex of man	NATURE			English	Article							OWL MONKEYS; 2 REPRESENTATIONS; ORGANIZATION; HAND; CONNECTIONS; MOVEMENTS; INPUT; M1	THE primary motor area (M1) of mammals has long been considered to be structurally and functionally homogeneous(1-5). This area corresponds to Brodmann's cytoarchitectural area 4. A few reports shoeing that arm and hand are doubly represented in M1 of macaque monkeys(6,7) and perhaps man(8) and that each subarea has separate connections from somatosensory areas, have, with a few exceptions(9-12), gone largely unnoticed, Here we show that area 4 in man can be subdivided into areas '4 anterior' (4a) and '4 posterior' (4p) on the basis of both quantitative cytoarchitecture and quantitative distributions of transmitter-binding sites. We also show by positron emission tomography that two representations of the fingers exist, one in area 4a and one in area 4p, Roughness discrimination activated area 4p significantly more than a control condition of self-generated movements, We therefore suggest that the primary motor area is subdivided on the basis of anatomy, neurochemistry and function.	UNIV DUSSELDORF, DEPT NEUROANAT, D-40001 DUSSELDORF, GERMANY; UNIV DUSSELDORF, C&O VOGT INST BRAIN RES, D-40001 DUSSELDORF, GERMANY; KAROLINSKA INST, DEPT NEUROSCI, DIV HUMAN BRAIN RES, S-17177 STOCKHOLM, SWEDEN	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Karolinska Institutet			Zilles, Karl/J-9704-2013; Zilles, Karl/Y-3784-2019	Zilles, Karl/0000-0001-9296-9959; Zilles, Karl/0000-0002-4705-4175; Klingberg, Torkel/0000-0002-3175-2171; Ledberg, Anders/0000-0003-3827-8721				Brodmann, 1909, VERGLEICHENDE LOKALI; FOERSTER O, 1936, HDB NEUROLOGIE, P1; Fritsch G, 1870, ARCH ANAT PHYSL WISS, V37, P300, DOI 10.1007/bf01759916; KAWASHIMA R, 1995, NEUROREPORT, V6, P238, DOI 10.1097/00001756-199501000-00003; KUNESCH E, 1989, EXP BRAIN RES, V78, P539; MAHALANOBIS P. C., 1949, Sankhya. The Indian Journal of Statistics, V9, P89; MATELLI M, 1989, J COMP NEUROL, V280, P468, DOI 10.1002/cne.902800311; MERKER B, 1983, J NEUROSCI METH, V9, P235, DOI 10.1016/0165-0270(83)90086-9; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; ROLAND E, 1976, ARCH NEUROL-CHICAGO, V33, P551; Roland P. E., 1993, Human Brain Mapping, V1, P3, DOI 10.1002/hbm.460010103; Roland P E, 1994, Hum Brain Mapp, V1, P173, DOI 10.1002/hbm.460010303; ROLAND PE, 1994, TRENDS NEUROSCI, V17, P458, DOI 10.1016/0166-2236(94)90131-7; ROLAND PE, 1987, BRAIN RES REV, V12, P1, DOI 10.1016/0165-0173(87)90017-8; SCHLEICHER A, 1990, J MICROSC-OXFORD, V157, P367, DOI 10.1111/j.1365-2818.1990.tb02971.x; SCHORMANN T, 1995, IEEE T MED IMAGING, V14, P25, DOI 10.1109/42.370399; Schormann T., 1993, Bioimaging, V1, P119, DOI 10.1002/1361-6374(199306)1:2<119::AID-BIO6>3.3.CO;2-Y; SEITZ RJ, 1991, EUR J NEUROSCI, V3, P481, DOI 10.1111/j.1460-9568.1991.tb00835.x; STEPNIEWSKA I, 1993, J COMP NEUROL, V330, P238, DOI 10.1002/cne.903300207; STEPNIEWSKA I, 1994, J COMP NEUROL, V349, P558, DOI 10.1002/cne.903490405; STEPNIEWSKA I, 1994, J COMP NEUROL, V349, P536, DOI 10.1002/cne.903490404; STRICK PL, 1982, J NEUROPHYSIOL, V48, P150, DOI 10.1152/jn.1982.48.1.150; STRICK PL, 1982, J NEUROPHYSIOL, V48, P139, DOI 10.1152/jn.1982.48.1.139; WOOLSEY CN, 1950, RES PUBL ASSOC RES N, V30, P238; Zilles K, 1995, AUTORADIOGRAPHY CORR, P277	25	484	485	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 29	1996	382	6594					805	807		10.1038/382805a0	http://dx.doi.org/10.1038/382805a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752272				2022-12-24	WOS:A1996VE34700045
J	Silver, R; LeSauter, J; Tresco, PA; Lehman, MN				Silver, R; LeSauter, J; Tresco, PA; Lehman, MN			A diffusible coupling signal from the transplanted suprachiasmatic nucleus controlling circadian locomotor rhythms	NATURE			English	Article							NEURAL TRANSPLANT; HAMSTERS; RESTORATION; BEHAVIOR; LESIONS; SYSTEM; SCN	THE mammalian suprachiasmatic nuclei (SCN) transmit signals to the rest of the brain, organizing circadian rhythms throughout the body(1-4), Transplants of the SCN restore circadian activity rhythms to animals whose own SCN have been ablated(5-9). The nature of the coupling signal from the grafted SCN to the host brain is not known, although it has been presumed that functional recovery requires re-establishment of appropriate synaptic connections. We have isolated SCN tissue from hamsters within a semipermeable polymeric capsule before transplantation, thereby preventing neural outgrowth but allowing diffusion of humoral signals, Here we show that the transplanted SCN, like neural pacemakers of Drosophila(10) and silkmoths(11), can sustain circadian activity rhythms by means of a diffusible signal.	COLUMBIA UNIV,DEPT PSYCHOL,NEW YORK,NY 10027; UNIV UTAH,DEPT BIOENGN,SALT LAKE CITY,UT 84112; UNIV CINCINNATI,COLL MED,DEPT CELL BIOL NEUROBIOL & ANAT,CINCINNATI,OH 45267	Columbia University; Utah System of Higher Education; University of Utah; University System of Ohio; University of Cincinnati	Silver, R (corresponding author), COLUMBIA UNIV BARNARD COLL,DEPT PSYCHOL,3009 BROADWAY,NEW YORK,NY 10027, USA.		Lehman, Michael/ABC-9076-2020; Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Silver, Rae/0000-0001-8633-739X; Lehman, Michael/0000-0002-9076-5108				AEBISCHER P, 1991, BIOMATERIALS, V12, P50, DOI 10.1016/0142-9612(91)90132-T; AGUILARROBLERO R, 1994, EXP NEUROL, V130, P250, DOI 10.1006/exnr.1994.1203; BITTMAN EL, 1993, NEUR ABSTR, V19; DECOURSEY PJ, 1989, BRAIN RES, V500, P263, DOI 10.1016/0006-8993(89)90322-3; HAKIM H, 1991, J BIOL RHYTHM, V6, P97, DOI 10.1177/074873049100600201; HANDLER AM, 1979, NATURE, V279, P236, DOI 10.1038/279236a0; HONMA K, 1984, AM J PHYSIOL, V246, P949; INOUYE ST, 1979, P NATL ACAD SCI USA, V76, P5962, DOI 10.1073/pnas.76.11.5962; Klein D.C., 1991, SUPRACHIASMATIC NUCL; LEHMAN MN, 1987, J NEUROSCI, V7, P1626; LESAUTER J, 1994, RESTOR NEUROL NEUROS, V6, P135, DOI 10.3233/RNN-1994-6207; MAHE V, 1995, PRESSE MED, V24, P1041; MORIN LP, 1994, BRAIN RES REV, V67, P102; MOSKO S, 1978, P NATL ACAD SCI USA, V75, P6243, DOI 10.1073/pnas.75.12.6243; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; RUSAK B, 1977, J COMP PHYSIOL, V118, P145, DOI 10.1007/BF00611819; SILVER R, 1990, BRAIN RES, V525, P45, DOI 10.1016/0006-8993(90)91319-C; SOLLARS PJ, 1995, J NEUROSCI, V15, P2109, DOI 10.1523/JNEUROSCI.15-03-02109.1995; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; Tresco P A, 1992, Cell Transplant, V1, P255; TRUMAN JW, 1970, SCIENCE, V167, P1624, DOI 10.1126/science.167.3925.1624; TUREK FW, 1995, NEUROSCI BIOBEHAV R, V19, P53, DOI 10.1016/0149-7634(94)00030-5; VOGELBAUM MA, 1992, J NEUROSCI, V12, P3619	24	551	568	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					810	813		10.1038/382810a0	http://dx.doi.org/10.1038/382810a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752274				2022-12-24	WOS:A1996VE34700047
J	Yang, YM; Dowling, J; Yu, QC; Kouklis, P; Cleveland, DW; Fuchs, E				Yang, YM; Dowling, J; Yu, QC; Kouklis, P; Cleveland, DW; Fuchs, E			An essential cytoskeletal linker protein connecting actin microfilaments to intermediate filaments	CELL			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; BULLOUS PEMPHIGOID ANTIGEN; DYSTONIA-MUSCULORUM; AXONAL-TRANSPORT; MOUSE MODEL; GENE; IDENTIFICATION; NEUROFILAMENTS; EXPRESSION; PLECTIN	Typified by rapid degeneration of sensory neurons, dystonia musculorum mice have a defective BPAG1 gene, known to be expressed in epidermis. We report a neuronal splice form, BPAG1n, which localizes to sensory axons. Both isoforms have a coiled-coil rod, followed by a carboxy domain that associates with intermediate filaments. However, the amino terminus of BPAG1n differs from BPAG1e in that it contains a functional actin-binding domain. In transfected cells, BPAG1n coaligns neurofilaments and microfilaments, establishing this as a cytoskeletal protein interconnecting actin and intermediate filament cytoskeletons. In BPAG1 null mice, axonal architecture is markedly perturbed, consistent with a failure to tether neurofilaments to the actin cytoskeleton and underscoring the physiological relevance of this protein.	UNIV CALIF SAN DIEGO,DEPT MED,LUDWIG INST CANC RES,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LUDWIG INST CANC RES,LA JOLLA,CA 92093	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Yang, YM (corresponding author), UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOL GENET & CELL BIOL,CHICAGO,IL 60637, USA.		Cleveland, Don/AAN-9783-2021; Fuchs, Elaine/G-1565-2016	Cleveland, Don/0000-0002-1934-3682; Kouklis, Panos/0000-0003-0378-5619	NIAMS NIH HHS [R01-AR27883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; BROWN A, 1995, GENOMICS, V29, P777, DOI 10.1006/geno.1995.9936; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; CAMPBELL RM, 1992, NEURON, V9, P693, DOI 10.1016/0896-6273(92)90032-9; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; Duchen L W, 1976, Adv Neurol, V14, P353; DURHAM HD, 1992, J NEUROPATH EXP NEUR, V51, P287, DOI 10.1097/00005072-199205000-00007; FATH KR, 1988, J CELL BIOL, V107, P613, DOI 10.1083/jcb.107.2.613; Foisner R, 1995, J STRUCT BIOL, V115, P304, DOI 10.1006/jsbi.1995.1055; FOISNER R, 1991, P NATL ACAD SCI USA, V88, P3812, DOI 10.1073/pnas.88.9.3812; FRAPPIER T, 1992, EUR J BIOCHEM, V205, P85, DOI 10.1111/j.1432-1033.1992.tb16754.x; GREEN KJ, 1992, INT J BIOL MACROMOL, V14, P145, DOI 10.1016/S0141-8130(05)80004-2; GRIFFITH LM, 1978, J CELL BIOL, V78, P958, DOI 10.1083/jcb.78.3.958; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HOPKINSON SB, 1994, BIOCHEM J, V300, P851, DOI 10.1042/bj3000851; KOTHARY R, 1988, NATURE, V335, P435, DOI 10.1038/335435a0; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; LASEK RJ, 1976, CELL MOTILITY, V3, P1021; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; Minichiello L, 1995, DEVELOPMENT, V121, P4067; NEMHAUSER I, 1985, BRAIN RES, V334, P47, DOI 10.1016/0006-8993(85)90566-9; PAGGI P, 1987, J NEUROSCI, V7, P2397; SEIFERT GJ, 1992, EUR J CELL BIOL, V59, P138; SOTELO C, 1988, NEUROSCIENCE, V27, P403, DOI 10.1016/0306-4522(88)90277-1; STANLEY JR, 1993, ADV IMMUNOL, V53, P291, DOI 10.1016/S0065-2776(08)60503-9; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; SUGI T, 1989, J CLIN INVEST, V84, P1050, DOI 10.1172/JCI114266; TAMAI K, 1993, J CLIN INVEST, V92, P814, DOI 10.1172/JCI116655; TSUKITA S, 1986, J CELL BIOL, V102, P1710, DOI 10.1083/jcb.102.5.1710; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yang XW, 1996, DEVELOPMENT, V122, P555; ZELENA J, 1974, CELL TISSUE RES, V153, P115	38	263	267	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					655	665		10.1016/S0092-8674(00)80138-5	http://dx.doi.org/10.1016/S0092-8674(00)80138-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752219	Bronze			2022-12-24	WOS:A1996VE23500015
J	Alivisatos, AP; Johnsson, KP; Peng, XG; Wilson, TE; Loweth, CJ; Bruchez, MP; Schultz, PG				Alivisatos, AP; Johnsson, KP; Peng, XG; Wilson, TE; Loweth, CJ; Bruchez, MP; Schultz, PG			Organization of 'nanocrystal molecules' using DNA	NATURE			English	Article							QUANTUM DOTS; PARTICLES; CLUSTERS; CDS; COLLOIDS; STATE; TIO2	PATTERNING matter on the nanometre scale is an important objective of current materials chemistry and physics. It is driven by both the need to further miniaturize electronic components and the fact that at the nanometre scale, materials properties are strongly size-dependent and thus can be tuned sensitively(1). In nanoscale crystals, quantum size effects and the large number of surface atoms influence the, chemical, electronic, magnetic and optical behaviour(2-4). 'Top-down' (for example, lithographic) methods for nanoscale manipulation reach only to the upper end of the nanometre regime(5); but whereas 'bottom-up' wet chemical techniques allow for the preparation of monodisperse, defect-free crystallites just 1-10 nm in size(6-10), ways to control the structure of nanocrystal assemblies are scarce. Here we describe a strategy for the synthesis of 'nanocrystal molecules', in which discrete numbers of gold nanocrystals are organized into spatially defined structures based on Watson-Crick base-pairing interactions. We attach single-stranded DNA oligonucleotides of defined length and sequence to individual nanocrystals, and these assemble into dimers and trimers on addition of a complementary single-stranded DNA template, We anticipate that this approach should allow the construction of more complex two- and three-dimensional assemblies.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY NATL LAB,INST MOL DESIGN,BERKELEY,CA 94701	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Alivisatos, AP (corresponding author), UNIV CALIF BERKELEY,DEPT CHEM,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.		johnsson, kai/P-4222-2014; Bruchez, Marcel P/C-2271-2009; peng, xiaogang/R-6184-2016; Alivisatos, Paul/N-8863-2015	johnsson, kai/0000-0002-8002-1981; Bruchez, Marcel P/0000-0002-7370-4848; peng, xiaogang/0000-0002-5606-8472; Alivisatos, Paul/0000-0001-6895-9048				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Andres RP, 1996, SCIENCE, V272, P1323, DOI 10.1126/science.272.5266.1323; BAWENDI MG, 1990, ANNU REV PHYS CHEM, V41, P477, DOI 10.1146/annurev.pc.41.100190.002401; BENTZON MD, 1989, PHILOS MAG B, V60, P169, DOI 10.1080/13642818908211188; BRUST M, 1995, ADV MATER, V7, P795, DOI 10.1002/adma.19950070907; COVIN VL, 1992, J AM CHEM SOC, V114, P5221; FENDLER JH, 1995, ADV MATER, V7, P607, DOI 10.1002/adma.19950070703; GOPIDAS KR, 1990, J PHYS CHEM-US, V94, P6435, DOI 10.1021/j100379a051; Guzelian AA, 1996, J PHYS CHEM-US, V100, P7212, DOI 10.1021/jp953719f; HANEDA K, 1987, CAN J PHYS, V65, P1233, DOI 10.1139/p87-198; HERRON N, 1993, SCIENCE, V259, P1426, DOI 10.1126/science.259.5100.1426; Klein DL, 1996, APPL PHYS LETT, V68, P2574, DOI 10.1063/1.116188; LAWLESS D, 1995, J PHYS CHEM-US, V99, P10329, DOI 10.1021/j100025a040; LITTAU KA, 1993, J PHYS CHEM-US, V97, P1224, DOI 10.1021/j100108a019; Maniatis T, 1989, DECONTAMINATION DILU; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; NIEMEYER CM, 1994, NUCLEIC ACIDS RES, V22, P5530, DOI 10.1093/nar/22.25.5530; PAG X, UNPUB ANGEW CHEM; PENG XG, 1992, J PHYS CHEM-US, V96, P3412, DOI 10.1021/j100187a043; PESCHEL S, 1995, ANGEW CHEM INT EDIT, V34, P1442, DOI 10.1002/anie.199514421; SCHMID G, 1992, CHEM REV, V92, P1709, DOI 10.1021/cr00016a002; SEEMAN NC, 1993, MATER RES SOC SYMP P, V292, P123; SPANHEL L, 1987, J AM CHEM SOC, V109, P6632, DOI 10.1021/ja00256a012; TOLBERT SH, 1995, ANNU REV PHYS CHEM, V46, P595, DOI 10.1146/annurev.pc.46.100195.003115; VOSSMEYER T, 1995, SCIENCE, V267, P1476, DOI 10.1126/science.267.5203.1476; WAUGH FR, 1995, PHYS REV LETT, V75, P705, DOI 10.1103/PhysRevLett.75.705; WELLER H, 1993, ANGEW CHEM INT EDIT, V32, P41, DOI 10.1002/anie.199300411; Whetten RL, 1996, ADV MATER, V8, P428, DOI 10.1002/adma.19960080513; ZUCKERMANN R, 1987, NUCLEIC ACIDS RES, V15, P5305, DOI 10.1093/nar/15.13.5305	30	2495	2629	16	999	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					609	611		10.1038/382609a0	http://dx.doi.org/10.1038/382609a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757130	Green Submitted			2022-12-24	WOS:A1996VC30300047
J	Sperling, MR; OConnor, MJ; Saykin, AJ; Plummer, C				Sperling, MR; OConnor, MJ; Saykin, AJ; Plummer, C			Temporal lobectomy for refractory epilepsy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURGICAL-TREATMENT; LOBE EPILEPSY; RESECTIVE SURGERY; FOLLOW-UP; SEIZURES; PREDICTION; RISK; AGE	Objective.-To examine the long-term effectiveness of anterior temporal lobectomy for refractory epilepsy with regard to seizure control and related medical and psychosocial measures and to determine how patterns of early seizure recurrence relate to long-term prognosis. Design.-cohort of patients prospectively followed up for 5 years after surgery. Setting.-Tertiary care comprehensive epilepsy center. Patients.-Eighty-nine patients with medically refractory epilepsy who were consecutively treated with anterior temporal lobectomy between 1986 and 1990. All patients had noninvasive preoperative evaluations, and 31 were evaluated with intracranial electrodes prior to surgery. Main Outcome Measures.-Postoperative seizure frequency, neuropsychologic function, mortality, and postoperative employment status. Results.-Five years after surgery, 62 patients (70%) were seizure free, 8 (9%) had seizures on fewer than 3 days per year or exclusively had nocturnal seizures, 10 (11%) had greater than 80% reduction in seizure frequency, 5 (6%) had less than 80% reduction in seizure frequency, and 4 (4%) died of causes unrelated to surgery. The proportion of patients in each outcome class remained stable throughout the 5-year period, Fifty-five percent of seizure recurrences happened within 6 months of surgery, and 93% occurred within 2 years after surgery. Outcome at 1 year related only moderately well to outcome at 5 years, No significant cognitive or linguistic deficits occurred. All patients who died had persistent seizures after surgery, Underemployment and unemployment declined significantly after surgery, with improvement noted in seizure-free patients. Conclusions.-Temporal lobectomy provides sustained seizure relief over 5 years to most patients who have surgery. Outcome at 2 years predicts long-term outcome. A seizure-free state is associated with reduced mortality and increased employment. Mere reduction in seizure frequency is not associated with improvement in those measures.	UNIV PENN,GRAD HOSP,DEPT NEUROL,PHILADELPHIA,PA 19146; UNIV PENN,GRAD HOSP,DIV NEUROSURG,PHILADELPHIA,PA 19146; DARTMOUTH COLL,DEPT PSYCHIAT,HANOVER,NH	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Dartmouth College	Sperling, MR (corresponding author), UNIV PENN,GRAD HOSP,COMPREHENS EPILEPSY CTR,1800 LOMBARD ST,PHILADELPHIA,PA 19146, USA.		Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS014867, P01NS014867, R01NS028813] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28813, NS14867] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENGZON ARA, 1968, NEUROLOGY, V18, P717, DOI 10.1212/WNL.18.8.717; BERKOVIC SF, 1995, NEUROLOGY, V45, P1358, DOI 10.1212/WNL.45.7.1358; Bonis A, 1980, Acta Neurochir Suppl (Wien), V30, P55; CAHAN LD, 1984, CLEVELAND CLIN Q, V51, P313, DOI 10.3949/ccjm.51.2.313; CHOVAZ CJ, 1994, SEIZURE, V3, P171, DOI 10.1016/S1059-1311(05)80185-2; DIKMEN S, 1980, J NERV MENT DIS, V168, P236, DOI 10.1097/00005053-198004000-00008; Dodrill Carl B., 1993, P263; DODRILL CB, 1986, ANN NEUROL, V20, P2, DOI 10.1002/ana.410200103; ELWES RDC, 1991, J NEUROL NEUROSUR PS, V54, P200, DOI 10.1136/jnnp.54.3.200; ELWES RDC, 1991, J NEUROL NEUROSUR PS, V54, P949, DOI 10.1136/jnnp.54.11.949; Engel Jerome Jr., 1993, P23; Engel Jr J., 1987, SURG TREATMENT EPILE, P553; FALCONER MA, 1963, J NEUROL NEUROSUR PS, V26, P154, DOI 10.1136/jnnp.26.2.154; GOLDRING S, 1984, J NEUROSURG, V60, P457, DOI 10.3171/jns.1984.60.3.0457; GULDVOG B, 1994, EPILEPSIA, V35, P540, DOI 10.1111/j.1528-1157.1994.tb02474.x; GULDVOG B, 1994, EPILEPSIA, V35, P554, DOI 10.1111/j.1528-1157.1994.tb02475.x; Hauser W, 1990, EPILEPSY FREQUENCY C; JENSEN I, 1976, ACTA NEUROL SCAND, V53, P335, DOI 10.1111/j.1600-0404.1976.tb04353.x; JOHNSTON SC, 1995, ANN NEUROL, V37, P531, DOI 10.1002/ana.410370416; KING DW, 1986, NEUROLOGY, V36, P334, DOI 10.1212/WNL.36.3.334; MIZRAHI EM, 1990, EPILEPSIA, V31, P302, DOI 10.1111/j.1528-1157.1990.tb05380.x; PAILLAS JE, 1983, SURG NEUROL, V20, P189, DOI 10.1016/0090-3019(83)90051-4; RASMUSSEN TB, 1983, EPILEPSIA, V24, pS65, DOI 10.1111/j.1528-1157.1983.tb04645.x; RODIN E, 1972, EPILEPSIA, V13, P149, DOI 10.1111/j.1528-1157.1972.tb04562.x; ROUGIER A, 1992, J NEUROL NEUROSUR PS, V55, P762, DOI 10.1136/jnnp.55.9.762; SAYKIN AJ, 1995, EPILEPSIA, V36, P1071, DOI 10.1111/j.1528-1157.1995.tb00464.x; SAYKIN AJ, 1992, NEUROPSYCHOLOGY EPIL, P63; SMITH DF, 1991, EPILEPSY RES, V9, P231, DOI 10.1016/0920-1211(91)90057-M; SPERLING MR, 1986, ANN NEUROL, V20, P57, DOI 10.1002/ana.410200110; SPERLING MR, 1995, NEUROLOGY, V45, P970, DOI 10.1212/WNL.45.5.970; SPERLING MR, 1994, NEUROLOGY, V44, P2325, DOI 10.1212/WNL.44.12.2325; SPERLING MR, 1992, NEUROLOGY, V42, P416, DOI 10.1212/WNL.42.2.416; SPERLING MR, 1989, NEUROLOGY, V39, P1487; STAFINIAK P, 1990, NEUROLOGY, V40, P1509, DOI 10.1212/WNL.40.10.1509; TAYLOR DC, 1987, SURG TREATMENT EPILE, P485; Van Buren J M, 1975, Adv Neurol, V8, P155; VICKREY BG, 1995, ANN NEUROL, V37, P158, DOI 10.1002/ana.410370205; WALCZAK TS, 1990, NEUROLOGY, V40, P413, DOI 10.1212/WNL.40.3_Part_1.413; WINGKUN EC, 1991, EPILEPSIA, V32, P851, DOI 10.1111/j.1528-1157.1991.tb05541.x	39	234	238	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					470	475		10.1001/jama.276.6.470	http://dx.doi.org/10.1001/jama.276.6.470			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691555				2022-12-24	WOS:A1996VA86300035
J	Lee, DH; Granja, JR; Martinez, JA; Severin, K; Ghadiri, MR				Lee, DH; Granja, JR; Martinez, JA; Severin, K; Ghadiri, MR			A self-replicating peptide	NATURE			English	Article							COILED-COILS; HEXADEOXYNUCLEOTIDE; PROTEINS; SYSTEM; ARCHITECTURE; STABILITY; MECHANISM; LINKAGE; MODEL	THE production of amino acids and their condensation to polypeptides under plausibly prebiotic conditions have long been known(1,2). But despite the central importance of molecular self-replication in the origin of life, the feasibility of peptide self-replication has not been established experimentally(3-6). Here we report an example of a self-replicating peptide. We show that a 32-residue alpha-helical peptide based on the leucine-zipper domain of the yeast transcription factor GCN4 can act autocatalytically in templating its own synthesis by accelerating the thioester-promoted amide-bond condensation of 15- and 17-residue fragments in neutral, dilute aqueous solutions. The self-replication process displays parabolic growth pattern with the initial rates of product formation correlating with the square-root of initial template concentration.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute			Granja, Juan R/P-7646-2014	Granja, Juan R/0000-0002-5842-7504; Severin, Kay/0000-0003-2224-7234				BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; DYSON FJ, 1982, J MOL EVOL, V18, P344, DOI 10.1007/BF01733901; Fox S. W., 1977, MOL EVOLUTION ORIGIN; GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; KAUFFMAN SA, 1986, J THEOR BIOL, V119, P1, DOI 10.1016/S0022-5193(86)80047-9; KOBAYASHI K, 1995, ANGEW CHEM INT EDIT, V34, P95, DOI 10.1002/anie.199500951; LI T, 1994, NATURE, V369, P218, DOI 10.1038/369218a0; Miller S. L., 1974, ORIGINS LIFE EARTH; NOWICK JS, 1991, J AM CHEM SOC, V113, P8831, DOI 10.1021/ja00023a036; OPARIN A. I., 1965, ADVANCE ENZYMOL, V27, P347; ORGEL LE, 1992, NATURE, V358, P203, DOI 10.1038/358203a0; PITSCH S, 1995, HELV CHIM ACTA, V78, P1621, DOI 10.1002/hlca.19950780702; SIEVERS D, 1994, NATURE, V369, P221, DOI 10.1038/369221a0; TJIVIKUA T, 1990, J AM CHEM SOC, V112, P1249, DOI 10.1021/ja00159a057; von Kiedrowski G., 1993, BIOORG CHEM FRONT, V3, P113; VONKIEDROWSKI G, 1991, ANGEW CHEM INT EDIT, V30, P423, DOI 10.1002/anie.199104231; VONKIEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P932, DOI 10.1002/anie.198609322; VONKIEDROWSKI G, 1989, ANGEW CHEM INT EDIT, V28, P1235, DOI 10.1002/anie.198912351; WINTNER EA, 1995, J ORG CHEM, V60, P7997, DOI 10.1021/jo00129a046; WINTNER EA, 1994, J AM CHEM SOC, V116, P8877, DOI 10.1021/ja00099a003; ZHOU NE, 1992, BIOCHEMISTRY-US, V31, P5739, DOI 10.1021/bi00140a008; ZIELINSKI WS, 1987, NATURE, V327, P346, DOI 10.1038/327346a0	25	481	500	4	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 8	1996	382	6591					525	528		10.1038/382525a0	http://dx.doi.org/10.1038/382525a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700225				2022-12-24	WOS:A1996VB25800045
J	Treue, S; Maunsell, JHR				Treue, S; Maunsell, JHR			Attentional modulation of visual motion processing in cortical areas MT and MST	NATURE			English	Article							POSTERIOR PARIETAL CORTEX; SUPERIOR TEMPORAL SULCUS; FUNCTIONAL-PROPERTIES; FOCAL ATTENTION; MACAQUE MONKEY; NEURONS; V1; CONNECTIONS; RESPONSES; FIELD	THE visual system is constantly inundated with information received by the eyes, only a fraction of which seems to reach visual awareness. This selection process is one of the functions ascribed to visual attention(1-6). Although many studies have investigated the role of attention in shaping neuronal representations in the visual cortex, few have focused on attentional modulation of neuronal signals related to visual motion. Here we report that the responses of direction-selective neurons in monkey visual cortex are greatly influenced by attention, and that this modulation occurs as early in the cortical hierarchy as the level of the middle temporal visual area (MT). Our finding demonstrates a stronger and earlier influence of attention on motion processing along the dorsal visual pathway than previously recognized.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine	Treue, S (corresponding author), UNIV TUBINGEN,DEPT NEUROL,COGNIT NEUROSCI LAB,MORGENSTELLE 15,D-72076 TUBINGEN,GERMANY.		Maunsell, John/G-5702-2010	Maunsell, John/0000-0003-0018-4439	NEI NIH HHS [R01 EY005911] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSEN R, 1990, Society for Neuroscience Abstracts, V16, P7; ASSAD JA, 1995, NATURE, V373, P518, DOI 10.1038/373518a0; BROADBENT DE, 1982, ACTA PSYCHOL, V50, P253, DOI 10.1016/0001-6918(82)90043-9; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DUBNER R, 1971, BRAIN RES, V35, P528, DOI 10.1016/0006-8993(71)90494-X; ERIKSEN CW, 1986, PERCEPT PSYCHOPHYS, V40, P225, DOI 10.3758/BF03211502; FERRERA VP, 1994, J NEUROSCI, V14, P6171; James W., 1980, PRINCIPLES PSYCHOL, V1st; JULESZ B, 1984, DYNAMIC ASPECTS NEOC, P585; LOGOTHETIS NK, 1994, VISUAL DETECTION MOT, P177; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MAUNSELL JHR, 1983, J NEUROSCI, V3, P2563; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2178; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; MOUNTCASTLE VB, 1981, J NEUROSCI, V1, P1218; NEWSOME WT, 1988, J NEUROPHYSIOL, V60, P604, DOI 10.1152/jn.1988.60.2.604; OCRAVEN KM, 1995, INVEST OPHTH VIS SCI, V36, pS856; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Recanzone G. H., 1993, Society for Neuroscience Abstracts, V19, P973; SNOWDEN RJ, 1991, J NEUROSCI, V11, P2768; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; UNGERLEIDER LG, 1986, J COMP NEUROL, V248, P147, DOI 10.1002/cne.902480202; VANESSEN DC, 1981, J COMP NEUROL, V199, P293, DOI 10.1002/cne.901990302	26	763	775	1	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					539	541		10.1038/382539a0	http://dx.doi.org/10.1038/382539a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700227	Green Published			2022-12-24	WOS:A1996VB25800050
J	Rahhal, FM; Arevalo, JF; delaPaz, EC; Munguia, D; Azen, SP; Freeman, WR				Rahhal, FM; Arevalo, JF; delaPaz, EC; Munguia, D; Azen, SP; Freeman, WR			Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS - A preliminary report	ANNALS OF INTERNAL MEDICINE			English	Article						cytomegalovirus retinitis; acquired immunodeficiency syndrome; cidofovir; injections, intravitreous	RHEGMATOGENOUS RETINAL-DETACHMENT; GANCICLOVIR; FOSCARNET; (S)-1-(3-HYDROXY-2-PHOSPHONYLMETHOXYPROPYL)CYTOSINE; THERAPY	Background: Cytomegalovirus retinitis remains a major cause of illness in patients with the acquired immunodeficiency syndrome (AIDS), and existing therapies for this condition are relatively ineffective and toxic. Objective: To evaluate the efficacy of intravitreous cidofovir injections alone for initial and maintenance therapy for cytomegalovirus retinitis. Design: Prospective, nonrandomized, consecutive case series. Setting: University ophthalmology referral clinic. Patients: 22 patients with AIDS and cytomegalovirus retinitis. In 15 of 32 affected eyes, intravitreous cidofovir was administered as the initial treatment for cytomegalovirus retinitis (group A); 17 eyes had previously been treated with intravenous therapy (group B). Intervention: All eyes were intravitreously injected with 20 mu g of cidofovir at 5- to 6-week intervals. No patient in either group received systemic anticytomegalovirus therapy at-any time during the study period. Measurements: Healing of retinitis was defined as resolution of retinal opacification and cessation of border progression. Progression, the primary end point, was defined as 750 microns of border progression or development of a new lesion. Results: The mean duration of follow-up was 15.3 weeks (range, 5 to 44 weeks). Of the eyes with active retinitis, 100% (95% CI, 87% to 100%) healed in response to the initial injection. In two eyes (6%; CI, 0% to 15%), two episodes of retinitis progression occurred (one in each eye). Both of these eyes were in a patient with clinically resistant retinitis. In 3% of eyes (CI, 0% to 9%). the retina became detached. Mild iritis developed after 14% of the injections that had been preceded by prophylaxis with oral probenecid. Irreversible, visually significant hypotonia developed in one eye. Conclusion: Treatment and subsequent maintenance of cytomegalovirus retinitis with 20 mu g of intravitreously injected cidofovir, given at 5- to 6-week intervals, is safe and highly effective.	UNIV SO CALIF, SCH MED, DEPT PREVENT MED, DIV BIOMETRY, LOS ANGELES, CA 90033 USA; UNIV CALIF SAN DIEGO, SCH MED, SAN DIEGO, CA 92103 USA	University of Southern California; University of California System; University of California San Diego				Arevalo Suarez, Fernando Antonio/0000-0002-4114-5949	PHS HHS [E707366] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANAND R, 1993, ARCH OPHTHALMOL-CHIC, V111, P223, DOI 10.1001/archopht.1993.01090020077027; COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348; DECLERCQ E, 1986, NATURE, V323, P464, DOI 10.1038/323464a0; DIAZLLOPIS M, 1994, BRIT J OPHTHALMOL, V78, P120, DOI 10.1136/bjo.78.2.120; FANNING MM, 1990, J ACQ IMMUN DEF SYND, V3, P472; FLORESAGUILAR M, 1993, OPHTHALMOLOGY, V100, P1022; FREEMAN WR, 1993, AM J OPHTHALMOL, V116, P713, DOI 10.1016/S0002-9394(14)73471-3; FREEMAN WR, 1992, OPHTHALMOLOGY, V99, P466; HEINEMANN MH, 1989, ARCH OPHTHALMOL-CHIC, V107, P1767, DOI 10.1001/archopht.1989.01070020849025; HENDERLY DE, 1987, OPHTHALMOLOGY, V94, P425; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401; JABS DA, 1994, OPHTHALMOLOGY, V101, P1250; KIRSCH LS, 1995, OPHTHALMOLOGY, V102, P533, DOI 10.1016/S0161-6420(95)30985-2; KIRSH LS, 1995, AM J OPHTHALMOL, V119, P466, DOI 10.1016/S0002-9394(14)71233-4; KORETZ SH, 1986, NEW ENGL J MED, V314, P801, DOI 10.1056/NEJM198603273141301; KUPPERMANN BD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1359, DOI 10.1001/archopht.1993.01090100067029; LESAR TS, 1985, DRUG INTEL CLIN PHAR, V19, P642, DOI 10.1177/106002808501900905; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; NEYTS J, 1990, VIROLOGY, V179, P41, DOI 10.1016/0042-6822(90)90271-R; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PALESTINE AG, 1986, AM J OPHTHALMOL, V101, P95, DOI 10.1016/0002-9394(86)90470-8; SNOECK R, 1988, ANTIMICROB AGENTS CH, V32, P1839, DOI 10.1128/AAC.32.12.1839; *STUD OC COMPL AID, 1995, HPMPC PER CMV RET TR; 1992, CONTROLLED CLIN TRIA, V13, P22	25	53	54	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					98	+		10.7326/0003-4819-125-2-199607150-00003	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678386				2022-12-24	WOS:A1996UV92100006
J	Bostrom, H; Willetts, K; Pekny, M; Leveen, P; Lindahl, P; Hedstrand, H; Pekna, M; Hellstrom, M; GebreMedhin, S; Schalling, M; Nilsson, M; Kurland, S; Tornell, J; Heath, JK; Betsholtz, C				Bostrom, H; Willetts, K; Pekny, M; Leveen, P; Lindahl, P; Hedstrand, H; Pekna, M; Hellstrom, M; GebreMedhin, S; Schalling, M; Nilsson, M; Kurland, S; Tornell, J; Heath, JK; Betsholtz, C			PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis	CELL			English	Article							GROWTH-FACTOR-A; ALPHA-RECEPTOR; MOUSE EMBRYOS; EXPRESSION; CELLS; CHAIN; PREIMPLANTATION; EMBRYOGENESIS; LOCALIZATION; MUTATION	A mouse platelet-derived growth factor A chain (PDGF-A) null allele is shown to be homozygous lethal, with two distinct restriction points, one prenatally before E10 and one postnatally. Postnatally surviving PDGF-A-deficient mice develop lung emphysema secondary to the failure of alveolar septation. This is apparently caused by the loss of alveolar myofibroblasts and associated elastin fiber deposits. PDGF alpha receptor-positive cells in the lung having the location of putative alveolar myofibroblast progenitors were specifically absent in PDGF-A null mutants. We conclude that PDGF-A is crucial for alveolar myofibroblast ontogeny. We have previously shown that PDGF-B is required in the ontogeny of kidney mesangial cells. The PDGFs therefore appear to regulate the generation of specific populations of myofibroblasts during mammalian development. The two PDGF null phenotypes also reveal analogous morphogenetic functions for myofibroblast-type cells in lung and kidney organogenesis.	GOTHENBURG UNIV,DEPT PHYSIOL,S-41390 GOTHENBURG,SWEDEN; UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; KAROLINSKA HOSP,DEPT MOLEC MED,NEUROGENET UNIT,S-17176 STOCKHOLM,SWEDEN	University of Gothenburg; University of Birmingham; University of Oxford; Karolinska Institutet; Karolinska University Hospital	Bostrom, H (corresponding author), GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN.		Pekna, Marcela/AAM-3261-2021; Ehrencrona, Hans/Q-4621-2019; Pekna, Marcela/AAM-3249-2021; Ehrencrona, Hans/M-5619-2014; Schalling, Martin/F-1518-2015	Pekna, Marcela/0000-0003-2734-8237; Ehrencrona, Hans/0000-0002-5589-3622; Pekna, Marcela/0000-0003-2734-8237; Ehrencrona, Hans/0000-0002-5589-3622; Schalling, Martin/0000-0001-5011-2922; Hellstrom, Mats/0000-0002-7088-9533				ADAMSON IYR, 1985, EXP LUNG RES, V8, P261, DOI 10.3109/01902148509087808; ADLER KB, 1989, LAB INVEST, V60, P473; ATALIOTIS P, 1995, DEVELOPMENT, V121, P3099; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; Betsholtz C, 1995, INT J DEV BIOL, V39, P817; BRODY AR, 1991, CHEST, V99, pS50, DOI 10.1378/chest.99.3_Supplement.50S; DAMIANO VV, 1979, AM J PATHOL, V96, P439; DUTTLINGER R, 1995, P NATL ACAD SCI USA, V92, P3754, DOI 10.1073/pnas.92.9.3754; EMERY JL, 1970, RESPIRATION, V27, P41, DOI 10.1159/000192718; FUKUDA Y, 1983, AM J ANAT, V167, P405, DOI 10.1002/aja.1001670402; GRUNEBERG H, 1960, GENET RES, V1, P69, DOI 10.1017/S0016672300000094; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1993, GROWTH FACTORS, V8, P245, DOI 10.3109/08977199308991570; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KAPANCI Y, 1974, J CELL BIOL, V60, P375, DOI 10.1083/jcb.60.2.375; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LESLIE KO, 1990, DIFFERENTIATION, V44, P143, DOI 10.1111/j.1432-0436.1990.tb00547.x; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; NOGUCHI A, 1989, EXP LUNG RES, V4, P537; ORRURTREGER A, 1992, DEVELOPMENT, V115, P1045; ORRURTREGER A, 1992, DEVELOPMENT, V115, P289; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PALMIERI SL, 1992, MECH DEVELOP, V39, P181, DOI 10.1016/0925-4773(92)90045-L; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAMACHANDRAN RK, 1995, DEV DYNAM, V204, P77, DOI 10.1002/aja.1002040110; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; Rorsman F, 1992, GROWTH FACTORS, V6, P303, DOI 10.3109/08977199209021542; Rubin E, 1988, PATHOLOGY, P1444; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SCHURCH W, 1992, HISTOLOGY PATHOLOGIS, P109; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SHINBROT E, 1994, DEV DYNAM, V199, P169, DOI 10.1002/aja.1001990302; SMITH A, 1978, WOLFE MED ATLASES, V18; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; [No title captured]	41	624	635	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					863	873		10.1016/S0092-8674(00)81270-2	http://dx.doi.org/10.1016/S0092-8674(00)81270-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681381	Bronze			2022-12-24	WOS:A1996UR60400010
J	Tong, L; Qian, CG; Massariol, MJ; Bonneau, PR; Cordingley, MG; Lagace, L				Tong, L; Qian, CG; Massariol, MJ; Bonneau, PR; Cordingley, MG; Lagace, L			A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease	NATURE			English	Article							SUBSTRATE; PROTEINS	HUMAN cytomegalovirus (hCMV), a herpesvirus, infects up to 70% of the general population in the United States and can cause morbidity and mortality in immunosuppressed individuals (organ-transplant recipients and AIDS patients) and congenitally infected newborns(1). hCMV protease is essential for the production of mature infectious virions, as it performs proteolytic processing near the carboxy terminus (M-site) of the viral assembly protein precursor (for a review, see ref. 2). hCMV protease is a serine protease(2), although it has little homology to other clans of serine proteases(2,3). Here we report the crystal structure of hCMV pretense at 2.0 Angstrom resolution, and show that it possesses a new polypeptide backbone fold. Ser 132 and His 63 are found in close proximity in the active site, confirming earlier biochemical and mutagenesis studies(2). The structure suggests that the third member of the triad is probably His 157. A dimer of the protease with an extensive interface is found in the crystal structure. This structure information will help in the design and optimization of inhibitors against herpesvirus proteases.	BIOMEGA BOEHRINGER INGELHEIM RES INC,LAVAL,PQ H7S 2G5,CANADA	Boehringer Ingelheim	Tong, L (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC,90 E RIDGE POB 368,RIDGEFIELD,CT 06877, USA.			Tong, Liang/0000-0002-0563-6468				BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Darke PL, 1996, J BIOL CHEM, V271, P7445, DOI 10.1074/jbc.271.13.7445; FIELDS BN, 1990, VIROLOGY, V2, pCH64; Gibson Wade, 1995, Perspectives in Drug Discovery and Design, V2, P413, DOI 10.1007/BF02172034; HALL DL, 1995, J BIOL CHEM, V270, P22697, DOI 10.1074/jbc.270.39.22697; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Margosiak SA, 1996, BIOCHEMISTRY-US, V35, P5300, DOI 10.1021/bi952842u; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PINKO C, 1995, J BIOL CHEM, V270, P23634, DOI 10.1074/jbc.270.40.23634; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; TONG L, 1993, J APPL CRYSTALLOGR, V26, P15, DOI 10.1107/S0021889892007295; TONG L, 1993, J APPL CRYSTALLOGR, V26, P748, DOI 10.1107/S0021889893005631; YAMAMOTO A, 1992, BIOCHEMISTRY-US, V31, P11305, DOI 10.1021/bi00161a007	23	162	167	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					272	275		10.1038/383272a0	http://dx.doi.org/10.1038/383272a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805706				2022-12-24	WOS:A1996VH31500058
J	Chen, HL; Chang, MH; Ni, YH; Hsu, HY; Lee, PI; Lee, CY; Chen, DS				Chen, HL; Chang, MH; Ni, YH; Hsu, HY; Lee, PI; Lee, CY; Chen, DS			Seroepidemiology of hepatitis B virus infection in children - Ten years of mass vaccination in Taiwan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIGEN CARRIER MOTHERS; PROGRAM; INFANTS; EFFICACY; TAIPEI	Objective.-To study the seroepidemiology of hepatitis B virus (HBV) infection in children 10 years after a mass hepatitis B vaccination program was begun in Taiwan. Design.-Cross-sectional seroprevalence survey. Setting.-Cheng-Chung/Chung-Cheng District, Taipei, Taiwan, 1994. Subjects and Methods.-Serum samples from 1515 healthy children younger than 12 years were tested for HBV markers. The results were compared with a baseline seroepidemiologic study conducted just before the vaccination program was launched in 1984 and with a subsequent study in 1989 in the same area. Main Results.-Eighty-seven percent of the children had received at least 3 doses of HBV vaccine. The overall prevalence rate of hepatitis B surface antigenemia decreased from 9.8% in 1984 to 1.3% in 1994. A statistically significant decrease was observed in every age group from 1 to 10 years. The overall prevalence rate of hepatitis B core antibody was 26% in 1984, 15% in 1989, and 4.0% in 1994. This suggests that the risk of horizontal HBV infection has decreased overtime, not only because of the protective effect of the vaccine but also because the infection source has diminished. A high prevalence rate of hepatitis B surface antibody (79%) was noted in 1994 as anticipated. Conclusions.-The Taiwanese mass vaccination program has protected most children younger than 10 years from becoming carriers, reducing both perinatal and horizontal HBV transmission. Mass HBV vaccination has proved to be a successful method to control HBV infection in this hyperendemic area.	NATL TAIWAN UNIV HOSP, DEPT PEDIAT, TAIPEI 10016, TAIWAN; NATL TAIWAN UNIV HOSP, DEPT INTERNAL MED, TAIPEI 10016, TAIWAN	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital				LEE, PING-ING/0000-0002-7299-2825; Chang, Mei Hwei/0000-0002-3648-9261; Hsu, Hong-Yuan/0000-0002-5720-4835; LEE, CHIN-YUN/0000-0002-3938-377X; CHEN, DING-SHINN/0000-0001-7791-6154; Ni, Yen-Hsuan/0000-0002-1158-5249				BEASLEY RP, 1982, HEPATOLOGY, V2, pS21; BEASLEY RP, 1981, LANCET, V2, P1129; Chen D S, 1978, Taiwan Yi Xue Hui Za Zhi, V77, P263; Chen D S, 1982, Taiwan Yi Xue Hui Za Zhi, V81, P1357; Chen D-S, 1987, NEOPLASMS LIVER, P71; CHEN DS, 1987, JAMA-J AM MED ASSOC, V257, P2597; *DEP HLTH EX YUAN, 1984, HLTH STAT VIT STAT R, V2, P44; HSU HM, 1988, JAMA-J AM MED ASSOC, V260, P2231, DOI 10.1001/jama.260.15.2231; HSU HY, 1986, J MED VIROL, V18, P301, DOI 10.1002/jmv.1890180402; LEE PI, 1995, J PEDIATR-US, V126, P716, DOI 10.1016/S0022-3476(95)70398-5; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; SUNG JL, 1980, SCAND J GASTROENTERO, V15, P321, DOI 10.3109/00365528009181477; SUNG JL, 1984, CHINESE J GASTROENTE, V1, P1; TSEN YJ, 1991, J MED VIROL, V34, P96, DOI 10.1002/jmv.1890340205; WONG WCW, 1994, VACCINE, V12, P229, DOI 10.1016/0264-410X(94)90199-6	15	269	277	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					906	908		10.1001/jama.276.11.906	http://dx.doi.org/10.1001/jama.276.11.906			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782640				2022-12-24	WOS:A1996VF78700034
J	Irwin, K; Olivo, N; Schable, CA; Weber, JT; Janssen, R; Ernst, J; BekoeTabiri, S; Benjamin, F; Carniciu, S; Chavaria, C; Chiriboga, V; Disla, M; Fernandez, A; Ganea, C; Martinez, G; Parsons, R; Rosario, F; Rothman, W; Santos, W; Shulman, R; Vasquez, Y; Brown, K; Cowart, F; Daugharty, A; Edeline, M; Lewis, E; McRae, B; Raimondi, V; Wells, L; Winter, R; Minor, P				Irwin, K; Olivo, N; Schable, CA; Weber, JT; Janssen, R; Ernst, J; BekoeTabiri, S; Benjamin, F; Carniciu, S; Chavaria, C; Chiriboga, V; Disla, M; Fernandez, A; Ganea, C; Martinez, G; Parsons, R; Rosario, F; Rothman, W; Santos, W; Shulman, R; Vasquez, Y; Brown, K; Cowart, F; Daugharty, A; Edeline, M; Lewis, E; McRae, B; Raimondi, V; Wells, L; Winter, R; Minor, P			Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article							TESTS	Background: The delay between collection of blood samples and availability of test results may be as long as 3 weeks and is one barrier to the acceptance of voluntary testing for human immunodeficiency virus (HIV) infection. Serologic tests that provide results rapidly could overcome this barrier, but the accuracy and reliability of rapid tests have not been well characterized in the United States. Objective: To evaluate, in a ''real world'' setting, the performance characteristics of a rapid HIV assay that reduces the need for patients to return for counseling after the test. Design: Testing of HIV antibodies by rapid and nonrapid assays and survey about risk behaviors for HIV. Setting: A hospital in Bronx, New York, with a high prevalence of HIV-seropositive patients. Patients: 837 patients who were not known to be infected with HIV, had not been admitted for conditions related to the acquired immunodeficiency syndrome, and agreed to participate in HIV testing and an interview. Measurements: Sensitivity and specificity of a rapid HIV antibody assay based on comparisons with nonrapid assay and Western blot assay. Results: According to nonrapid assays, 5.4% of patients were infected with HIV. The rapid assay was highly accurate in this sample overall: Its sensitivity was 1.00, its specificity was 0.991, its positive predictive value was 0.865, and its negative predictive value was 1.00. The assay was also highly accurate in various subgroups. Conclusions: Accurate, rapid tests for HIV infection may enhance testing programs by preventing the need for delayed counseling of seronegative patients and by providing preliminary results to seropositive patients. These preliminary results may encourage patients to return for confirmatory test results and to adopt risk-reducing behaviors sooner.			Irwin, K (corresponding author), CTR DIS CONTROL & PREVENT, DIV HIV AIDS PREVENT, MAILSTOP E-45, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.		Rosario, Fredrick Joseph/I-2835-2019		PHS HHS [U64/CCU206797] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM MED ASS, 1994, DIG HIV AIDS POL; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; *DIV HIV PREV AIDS, 1992, COMM NEED IND; Farnham PG, 1996, PUBLIC HEALTH REP, V111, P44; FERRERA C, 1993, 9 INT C AIDS BERL; FLEMING DW, 1987, JAMA-J AM MED ASSOC, V258, P785, DOI 10.1001/jama.258.6.785; HARDY LM, 1991, HIV SCREENING PREGNA; IRWIN KL, 1996, 11 INT C AIDS VANC; KASSLER WJ, 1995, J CLIN MICROBIOL, V33, P2899, DOI 10.1128/JCM.33.11.2899-2902.1995; KASSLER WJ, 1994, 10 INT C AIDS YOK; KLINE RL, 1993, 9 INT C AIDS BERL; MALONE JD, 1993, J ACQ IMMUN DEF SYND, V6, P115; MOORE JD, 1986, NEW ENGL J MED, V314, P1387; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; SAS Institute, 1990, SAS STAT US GUID VER; SCHABLE C, 1994, LANCET, V344, P1333, DOI 10.1016/S0140-6736(94)90695-5; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; WHITE LJ, 1988, ANN INTERN MED, V108, P460, DOI 10.7326/0003-4819-108-3-460; 1987, MMWR-MORBID MORTAL W, V36, P509	20	40	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					471	475		10.7326/0003-4819-125-6-199609150-00007	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779459				2022-12-24	WOS:A1996VF88200008
J	Sirigu, A; Duhamel, JR; Cohen, L; Pillon, B; Dubois, B; Agid, Y				Sirigu, A; Duhamel, JR; Cohen, L; Pillon, B; Dubois, B; Agid, Y			The mental representation of hand movements after parietal cortex damage	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; MOTOR IMAGERY; APRAXIA; MODEL	Recent neuroimagery findings showed that the patterns of cerebral activation during the mental rehearsal of a motor act are similar to those produced by its actual execution. This concurs with the notion that part of the distributed neural activity taking place during movement involves internal simulations, but it is not yet clear what specific contribution the different brain areas involved bring to this process. Here, patients with lesions restricted to the parietal cortex were found to be impaired selectively at predicting, through mental imagery, the time necessary to perform differentiated finger movements and visually guided pointing gestures, in comparison to normal individuals and to a patient with damage to the primary motor area, These results suggest that the parietal cortex is important for the ability to generate mental movement representations.	COLL FRANCE, CNRS, LAB PHYSIOL PERCEPT ACT, F-75006 PARIS, FRANCE; HOP LA PITIE SALPETRIERE, F-75013 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Sirigu, A (corresponding author), INSERM, U289, 47 BLVD HOP, F-75013 PARIS, FRANCE.		Sirigu, Angela/L-4683-2017; Duhamel, Jean-René/M-4723-2017	Duhamel, Jean-René/0000-0003-0210-1027; cohen, laurent/0000-0002-5010-9085				ANNETT J, 1995, NEUROPSYCHOLOGIA, V33, P1395, DOI 10.1016/0028-3932(95)00072-B; CLARK MA, 1994, BRAIN, V117, P1093, DOI 10.1093/brain/117.5.1093; DECETY J, 1989, BRAIN COGNITION, V11, P87, DOI 10.1016/0278-2626(89)90007-9; DECETY J, 1989, BEHAV BRAIN RES, V34, P35, DOI 10.1016/S0166-4328(89)80088-9; DECETY J, 1991, BEHAV BRAIN RES, V42, P1, DOI 10.1016/S0166-4328(05)80033-6; DECETY J, 1994, NATURE, V371, P600, DOI 10.1038/371600a0; DOMINEY P, 1995, NEUROPSYCHOLOGIA, V33, P727, DOI 10.1016/0028-3932(95)00008-Q; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FITTS PM, 1954, J EXP PSYCHOL, V47, P381, DOI 10.1037/h0055392; FUJITA M, 1982, BIOL CYBERN, V45, P195, DOI 10.1007/BF00336192; GESCHWIN.N, 1965, BRAIN, V88, P585, DOI 10.1093/brain/88.3.585; HEILMAN KM, 1982, NEUROLOGY, V32, P342, DOI 10.1212/WNL.32.4.342; INGVAR DH, 1977, ANN NEUROL, V2, P230, DOI 10.1002/ana.410020309; Ito M, 1984, CEREBELLUM NEURAL CO; JEANNEROD M, 1986, BEHAV BRAIN RES, V19, P99, DOI 10.1016/0166-4328(86)90008-2; JORDAN MI, 1992, COGNITIVE SCI, V16, P307, DOI 10.1207/s15516709cog1603_1; Kosslyn S. M., 1994, IMAGE BRAIN; LANG W, 1994, NEUROREPORT, V5, P921, DOI 10.1097/00001756-199404000-00017; LEONE AP, 1995, J NEUROPHYSIOL, V67, P1114; MacKenzie C. L., 1994, THE GRASPING HAND; MELVILLJONES G, 1985, ADAPTIVE MECH GAZE C; OPTICAN LM, 1982, FUNCTIONAL BASIS OCU, P423; PARSONS LM, 1994, J EXP PSYCHOL HUMAN, V20, P709, DOI 10.1037/0096-1523.20.4.709; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P118, DOI 10.1152/jn.1980.43.1.118; ROTHI LJG, 1991, COGN NEUROPSYCHOL, V8, P443, DOI 10.1080/02643299108253382; Sakata Hideo, 1994, Current Opinion in Neurobiology, V4, P847, DOI 10.1016/0959-4388(94)90133-3; SIRIGU A, 1995, CORTEX, V31, P41, DOI 10.1016/S0010-9452(13)80104-9; SIRIGU A, 1995, NEUROREPORT, V6, P997, DOI 10.1097/00001756-199505090-00012; STEPHAN KM, 1995, J NEUROPHYSIOL, V73, P373, DOI 10.1152/jn.1995.73.1.373; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931	30	607	622	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 13	1996	273	5281					1564	1568		10.1126/science.273.5281.1564	http://dx.doi.org/10.1126/science.273.5281.1564			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VG597	8703221				2022-12-24	WOS:A1996VG59700045
J	Fiedler, K; Veit, M; Stamnes, MA; Rothman, JE				Fiedler, K; Veit, M; Stamnes, MA; Rothman, JE			Bimodal interaction of coatomer with the p24 family of putative cargo receptors	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; TRANSPORT VESICLES; COATED VESICLES; INTRACELLULAR-TRANSPORT; BETA-COP; GOLGI; MEMBRANE; GLYCOPROTEIN; RETENTION	Cytoplasmic domains of members of the p24 family of putative cargo receptors were shown to bind to coatomer, the coat protein of COPI-coated transport vesicles. Domains that contained dilysine endoplasmic reticulum retrieval signals bound the alpha-, beta'-, and epsilon-COP subunits of coatomer, whereas other p24 domains bound the beta-, gamma-, and zeta-COP subunits and required a phenylalanine-containing motif, Transit of a CD8-p24 chimera from the endoplasmic reticulum through the Golgi complex was slowed when the phenylalanine motif was mutated, suggesting that this motif may function as an anterograde transport signal. The either-or bimodal binding of coatomer to p24 tails suggests models for how coatomer can potentially package retrograde-directed and anterograde-directed cargo into distinct COPI-coated vesicles.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center			Veit, Michael/G-6492-2010	Fiedler, Klaus/0000-0001-9398-1116; Stamnes, Mark/0000-0002-5869-7985; Veit, Michael/0000-0002-7638-1829				BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; DUDEN R, 1994, J BIOL CHEM, V269, P24486; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; WADA I, 1991, J BIOL CHEM, V266, P19599; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	32	278	281	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 6	1996	273	5280					1396	1399		10.1126/science.273.5280.1396	http://dx.doi.org/10.1126/science.273.5280.1396			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703076				2022-12-24	WOS:A1996VF61000045
J	Olsen, EJ; Davis, AM; Clayton, RN; Mayeda, TK; Moore, CB; Steele, IM				Olsen, EJ; Davis, AM; Clayton, RN; Mayeda, TK; Moore, CB; Steele, IM			A silicate inclusion in Puente del Zacate, a IIIA iron meteorite	SCIENCE			English	Article							IAB	The IIIA and IIIB iron meteorites are considered to have formed in the cores of asteroids. A silicate inclusion within the IIIA meteorite Puente del Zacate consisting of olivine (Fa(4)), low-calcium pyroxene (Fs(6)Wo(1)), chromium diopside (Fs(3)Wo(47)), plagioclase (An(14)Or(4)), graphite, troilite, chromite, daubreelite, and iron metal resembles inclusions in IAB iron meteorites. The oxygen isotopic composition of the Puente del Zacate inclusion is like chromite and phosphate inclusions in other IIIA and IIIB irons. The Puente del Zacate inclusion may have been derived from the lower mantle of the IIIAB parent asteroid.	UNIV CHICAGO,ENRICO FERMI INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CHEM,CHICAGO,IL 60637; ARIZONA STATE UNIV,CTR METEORITE STUDIES,TEMPE,AZ 85287; UNIV CHICAGO,DEPT GEOPHYS SCI,ENRICO FERMI INST,CHICAGO,IL 60637	University of Chicago; University of Chicago; Arizona State University; Arizona State University-Tempe; University of Chicago	Olsen, EJ (corresponding author), UNIV CHICAGO,DEPT GEOPHYS SCI,5734 S ELLIS AVE,CHICAGO,IL 60637, USA.			Davis, Andrew/0000-0001-7955-6236				Buchwald V., 1975, HDB IRON METEORITES, P1426; BUNCH TE, 1970, CONTRIB MINERAL PETR, V25, P297, DOI 10.1007/BF00399290; CHOI BG, 1995, GEOCHIM COSMOCHIM AC, V59, P593, DOI 10.1016/0016-7037(94)00384-X; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; KRACHER A, 1985, P LUNAR PLANET SCI C, V15, pC689; MEIBOM A, 1995, METEORITICS, V30, P544; OLSEN E, 1966, GEOCHIM COSMOCHIM AC, V30, P459, DOI 10.1016/0016-7037(66)90057-3; OLSEN E, 1994, LUNAR PLANET SCI, V25, P1025; OSLEN E, 1993, METEORITICS, V28, P415; ZINNER E, 1986, INT J MASS SPECTROM, V69, P17, DOI 10.1016/0168-1176(86)87039-2	10	4	4	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1365	1367		10.1126/science.273.5280.1365	http://dx.doi.org/10.1126/science.273.5280.1365			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703065				2022-12-24	WOS:A1996VF61000034
J	Socie, G; Mary, JY; deGramont, A; Rio, B; Leporrier, M; Rose, C; Heudier, P; Rochant, H; Cahn, JY; Gluckman, E				Socie, G; Mary, JY; deGramont, A; Rio, B; Leporrier, M; Rose, C; Heudier, P; Rochant, H; Cahn, JY; Gluckman, E			Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; PIG-A GENE; APLASTIC-ANEMIA; HEMOGLOBINURIA PNH; SOMATIC MUTATIONS; ANCHOR	Background Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired disorder of haematopoietic stem cells. Although knowledge about the pathophysiology of the disease is increasing, no multivariate analysis of factors influencing survival has been undertaken, mainly because the disease is rare. We undertook such an investigation. Methods Data were collected on 220 patients with PNH diagnosed over a 46-year period (1950-1995) from participating French centres. Diagnosis of the disease required, at least, an unequivocally positive Ham's test. Findings The Kaplan-Meier survival estimate was 65% (SE 4) at 10 years and 48% (6) at 15 years after diagnosis. 8-year cumulative incidence rates of the main complications (pancytopenia, thrombosis, and myelodysplastic syndrome) were 15% (3), 28% (4), and 5% (2), respectively. Demographic data, presenting features, initial treatment, complications, and causes of death were similar to those previously reported, In multivariate analysis, seven factors were significantly associated with survival in patients with PNH. Poor survival was associated with the occurrence of thrombosis as a complication (relative risk 10.2 [95% CI 6-17], p<0.0001), evolution to pancytopenia (5.5 [2.8-11], p<0.0001), myelodysplastic syndrome or acute leukaemia (19.1 [7.3-50], p<0.001), age over 55 years at diagnosis (4 [2.4-6.9], p<0.0001), need for additional treatment (2.1 [1.3-3.6], p<0.003), and thrombocytopenia at diagnosis (2.2 [1.3-3.8, p<0.003). Better survival was shown for patients in whom aplastic anaemia antedated PNH (0.32 [0.14-0.72], p<0.02). Factors associated in multivariate analysis with a high risk of thrombosis during the disease course were thrombosis at diagnosis (5.1 [2.5-10.6], p=0.0002), age over 54 years (2.6 [1.5-4.6, p=0.0014), and infection at diagnosis (2.6 [1.3-5.2], p=0.0099). The risk factors for progression to pancytopenia were absence at diagnosis of anaemia (4.03 [1.3-12.2], p=0.03) and neutropenia (2.45 [1.1-5.7], p=0.03). The risk factors for development of myelodysplastic syndrome or acute leukaemia were abdominal pain crisis at presentation (10.5 [2.5-44.0], p=0.004) and year of diagnosis after 1983 (8.45 [1.8-40.7], p=0.004). Interpretation This large number of cases permitted a detailed analysis of prognostic factors for the first time, in this rare disease. Estimates of PNH prognostic factors may serve as baseline data in the assessment of current and future treatments for this disease.Interpretation This large number of cases permitted a detailed analysis of prognostic factors for the first time, in this rare disease. Estimates of PNH prognostic factors may serve as baseline data in the assessment of current and future treatments for this disease.	UNIV PARIS 07,INSERM,U444,CTR BIOINFORMAT,PARIS,FRANCE; HOP ST ANTOINE,SERV MED INTERNE ONCOL,F-75571 PARIS,FRANCE; HOP HOTEL DIEU,SERV HEMATOL,PARIS,FRANCE; CTR HOSP REG & UNIV CAEN,CAEN,FRANCE; HOP C HURIEZ,LILLE,FRANCE; HOP CIMIEZ,F-06003 NICE,FRANCE; HOP HENRI MONDOR,F-94010 CRETEIL,FRANCE; HOP J MINJOZ,BESANCON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite de Lille - ISITE; CHU Lille; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite de Franche-Comte; CHU Besancon	Socie, G (corresponding author), HOP ST LOUIS,SERV GREFFE MOELLE,F-75475 PARIS 10,FRANCE.		eliane, Gluckman/AAA-5024-2021					ALTMAN DG, 1994, STAT MED, V13, P301, DOI 10.1002/sim.4780130402; ANTIN JH, 1985, BLOOD, V66, P1247; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; Byar DP., 1988, CANC CLIN TRIALS MET, P423; Cox D. R., 1984, ANAL SURVIVAL DATA; DACIE JV, 1967, HAEMOLYTIC ANAEMIA 4, P1128; DACIE JV, 1972, SER HAEMATOL, V3, P3; DEGRAMONT A, 1985, REV MED INTERNE, V6, P477, DOI 10.1016/S0248-8663(85)80028-X; FORMAN K, 1984, ACTA HAEMATOL-BASEL, V71, P217, DOI 10.1159/000206591; FUJIOKA S, 1989, ACTA HAEMATOL JAPON, V52, P1386; GRISCELLIBENNACEUR A, 1995, BLOOD, V85, P1354, DOI 10.1182/blood.V85.5.1354.bloodjournal8551354; GROSBY WH, 1953, BLOOD, V8, P769; HARTMANN RC, 1972, SER HAEMATOL, V3, P42; HILLMEN P, 1995, NEW ENGL J MED, V333, P1253, DOI 10.1056/NEJM199511093331904; KAWAHARA K, 1992, AM J HEMATOL, V39, P283, DOI 10.1002/ajh.2830390409; LEWIS SM, 1967, BRIT J HAEMATOL, V13, P236, DOI 10.1111/j.1365-2141.1967.tb08736.x; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PEYTREMANN R, 1972, SER HAEMATOL, V3, P115; PRAMOONJAGO P, 1995, BLOOD, V86, P1736, DOI 10.1182/blood.V86.5.1736.bloodjournal8651736; ROSSE WF, 1995, PRINCIPLES PRACTICE, P367; ROTOLI B, 1989, SEMIN HEMATOL, V26, P201; SASO R, 1995, EXP HEMATOL, V23, P866; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SPATHSCHWALBE E, 1995, DEUT MED WOCHENSCHR, V120, P1027, DOI 10.1055/s-2008-1055440; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TICHELLI A, 1994, LEUKEMIA LYMPHOMA, V12, P167, DOI 10.3109/10428199409059587; VANKAMP H, 1995, BRIT J HAEMATOL, V89, P79, DOI 10.1111/j.1365-2141.1995.tb08907.x; WARE RE, 1991, NEW ENGL J MED, V325, P91; YEH ETH, 1994, J CLIN INVEST, V93, P2305, DOI 10.1172/JCI117234	29	351	376	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					573	577		10.1016/S0140-6736(95)12360-1	http://dx.doi.org/10.1016/S0140-6736(95)12360-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774569				2022-12-24	WOS:A1996VF18600010
J	Bartley, M; Owen, C				Bartley, M; Owen, C			Relation between socioeconomic status, employment, and health during economic change, 1973-93	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; MEN; UNEMPLOYMENT	Objective-To investigate the association between the national unemployment rate and class differences in the relation between health and employment during the period 1973-93. Design-Data from general household surveys, 1973-93. Comparison of rates of employment, unemployment, and economic inactivity among those with and without limiting longstanding illness in different socioeconomic groups and how these varied over 20 years. Subjects-All men aged 20-59 years in each survey between 1973 and 1993. Main outcome measures-Change over time in class specific rates of employment, unemployment, and economic inactivity in those with and without limiting longstanding illness. Results-Men in socioeconomic groups 1 and 2 with no longstanding illness experienced little decrease in their chances of being in paid employment as the general unemployment rate rose. Those most affected were men in manual groups with limiting longstanding illness. The likelihood of paid employment was affected far less by such illness in non-manual than in manual groups. In group 1 about 85% of men with such illness were in paid employment in 1979 and 75% by 1993; in group 4 the equivalent proportions were 70% and 40%. In men in manual groups with limiting longstanding illness there was no sign of employment rates rising again as the economy recovered. Conclusion-Socioeconomic status makes large difference to the impact of illness on the ability to remain in paid employment, and this impact increases as unemployment rises. Men with chronic illness in manual occupations were not drawn back into the labour force during the economic recovery of the late 1980s.	UNIV LONDON,INST EDUC,THOMAS CORAM RES UNIT,LONDON WC1H 0AA,ENGLAND	University of London; University College London; UCL Institute of Education	Bartley, M (corresponding author), CITY UNIV LONDON,SOCIAL STAT RES UNIT,LONDON EC1V 0HB,ENGLAND.		Owen, Charlie/C-4457-2008	Owen, Charlie/0000-0002-4560-7477				ARBER S, 1987, BRIT MED J, V294, P1069, DOI 10.1136/bmj.294.6579.1069; ATKINSON AB, 1993, AGE WORK SOCIAL SECU; BLANE D, 1986, J ROYAL STAT SOC A, V159, P77; BLANE D, 1993, MED SOCIOLOGY RES CH; CARPENTER LM, 1987, BRIT J IND MED, V44, P289; *CENTR STAT OFF, 1994, SOC TRENDS 1992; Dale A., 1988, DOING SECONDARY ANAL; DUNNELL K, 1995, POPULATION TRENDS, V82, P12; FOX AJ, 1976, BR J PREV SOC MED, V9, P80; FOX AJ, 1982, LONGITUDINAL STUDY S; GOLDBLATT P, 1990, OPCS SERIES LS, V6; Hannay D R, 1978, J R Coll Gen Pract, V28, P492; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; IVERSEN I, 1989, BRIT MED J, V295, P879; LAST JM, 1963, LANCET, V2, P28; LAWLOR J, 1990, EMPLOYMENT GAZET DEC, P601; McMichael AJ, 1976, J OCCUP MED, V17, P126; NICKELL S, 1995, OXFORD REV ECON POL, V11, P40, DOI 10.1093/oxrep/11.1.40; PIACHAUD D, 1986, J SOC POLICY, V15, P145, DOI 10.1017/S0047279400001641; SHAPER AG, 1984, BRIT HEART J, V51, P606; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595	21	175	177	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					445	449						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VE080	8776309				2022-12-24	WOS:A1996VE08000016
J	Walt, RP				Walt, RP			Metronidazole-resistant H-pylori - Of questionable clinical importance	LANCET			English	Editorial Material											Walt, RP (corresponding author), BIRMINGHAM HEARTLANDS HOSP,DEPT GASTROENTEROL,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND.							BANATVALA N, 1994, GUT, V35, P1562, DOI 10.1136/gut.35.11.1562; Ching CK, 1996, GUT, V38, P675, DOI 10.1136/gut.38.5.675; DeKoster E, 1996, GASTROENTEROLOGY, V110, pA93; Lopez-Brea M., 1995, Gut, V37, pA97; REDDY R, 1966, GASTROENTEROLOGY, V110, pA238; WALT R, 1986, LANCET, V1, P489	6	26	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					489	490		10.1016/S0140-6736(05)64665-X	http://dx.doi.org/10.1016/S0140-6736(05)64665-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757146				2022-12-24	WOS:A1996VD42700004
J	Urbina, JA; Payares, G; Molina, J; Sanoja, C; Liendo, A; Lazardi, K; Piras, MM; Piras, R; Perez, N; Wincker, P; Ryley, JF				Urbina, JA; Payares, G; Molina, J; Sanoja, C; Liendo, A; Lazardi, K; Piras, MM; Piras, R; Perez, N; Wincker, P; Ryley, JF			Cure of short- and long-term experimental Chagas' disease using D0870	SCIENCE			English	Article							TRYPANOSOMA SCHIZOTRYPANUM CRUZI; TRIAZOLE D0870; BLOOD-SAMPLES; IN-VITRO; KETOCONAZOLE; EPIMASTIGOTES; INVITRO; TRYPANOSOMA-(SCHIZOTRYPANUM)-CRUZI; CHEMOTHERAPY; COMBINATIONS	Chagas' disease, a protozoan infection by the kinetoplastid Trypanosoma cruzi, constitutes a major public health problem in Latin America. With the use of mouse models of both short- and long-term forms of the disease, the efficacy of D0870, a bis-triazole derivative, was tested. D0870 was able to prevent death and induced parasitological cure in 70 to 90 percent of animals, in both the short- and long-term disease. In contrast, currently used drugs such as nifurtimox or ketoconazole prolonged survival but did not induce significant curing effects. D0870 may be useful in the treatment of human long-term Chagas' disease, a condition that is currently incurable.	CENT UNIV VENEZUELA,FAC CIENCIAS,DEPT PARASITOL,INST ZOOL TROP,CARACAS 1040,VENEZUELA; CTR MED DOCENTE LA TRINIDAD,UNIDAD INVEST,CARACAS 1080,VENEZUELA; UNIV MONTPELLIER,FAC MED,LAB GENOME PARASITES,F-34000 MONTPELLIER,FRANCE	University of Central Venezuela; Universite de Montpellier	Urbina, JA (corresponding author), INST VENEZOLANO INVEST CIENT,LAB QUIM BIOL,CTR BIOQUIM & BIOFIS,APARTADO 21827,CARACAS 1020A,VENEZUELA.							ATKINSON BA, 1994, ANTIMICROB AGENTS CH, V38, P1604, DOI 10.1128/AAC.38.7.1604; BRENER Z, 1993, MEM I OSWALDO CRUZ, V88, P149, DOI 10.1590/S0074-02761993000100023; BRITTO C, 1993, MEM I OSWALDO CRUZ, V88, P171, DOI 10.1590/S0074-02761993000100030; CLEMONS KV, 1994, J MED VET MYCOL, V32, P323; CLEMONS KV, 1995, ANTIMICROB AGENTS CH, V39, P778, DOI 10.1128/AAC.39.3.778; de Maio A., 1984, Acta Cientifica Venezolana, V35, P136; DECASTRO SL, 1993, ACTA TROP, V53, P83, DOI 10.1016/0001-706X(93)90021-3; DEWIT S, 1995, ICAAC ABSTR, V35, pF97; GOAD LJ, 1989, MOL BIOCHEM PARASIT, V32, P179, DOI 10.1016/0166-6851(89)90069-8; KARYOTAKIS NC, 1995, ANTIMICROB AGENTS CH, V39, P571, DOI 10.1128/AAC.39.2.571; LARRALDE G, 1988, ACTA CIENT VENEZ, V39, P140; LAZARDI K, 1991, ANTIMICROB AGENTS CH, V35, P736, DOI 10.1128/AAC.35.4.736; MALDONADO RA, 1993, ANTIMICROB AGENTS CH, V37, P1353, DOI 10.1128/AAC.37.6.1353; MCCABE R, 1988, J INFECT DIS, V158, P1408, DOI 10.1093/infdis/158.6.1408; MOREIRA AAB, 1992, REV I MED TROP, V34, P177, DOI 10.1590/S0036-46651992000200015; Rassi A, 1992, CHAGAS DIS AM TYP IT, P237; RILEY JF, 1988, ANN NY ACAD SCI, V544, P310; URBINA JA, 1991, ANTIMICROB AGENTS CH, V35, P730, DOI 10.1128/AAC.35.4.730; Urbina JA, 1996, CHEMOTHERAPY, V42, P294, DOI 10.1159/000239458; URBINA JA, 1993, ANTIMICROB AGENTS CH, V37, P580, DOI 10.1128/AAC.37.3.580; URBINA JA, 1995, MOL BIOCHEM PARASIT, V73, P199, DOI 10.1016/0166-6851(95)00117-J; URBINA JA, 1988, ANTIMICROB AGENTS CH, V32, P1237, DOI 10.1128/AAC.32.8.1237; VANDENBOSSCHE H, 1992, RECENT PROGRESS IN ANTIFUNGAL CHEMOTHERAPY, P25; VANDENBOSSCHE H, 1995, MODERN SELECTIVE FUN, P431; WARDLE HM, 1995, ANTIMICROB AGENTS CH, V39, P868, DOI 10.1128/AAC.39.4.868; WINCKER P, 1994, AM J TROP MED HYG, V51, P771, DOI 10.4269/ajtmh.1994.51.771; *WORLD BANK, 1993, 1993 WORLD BANK WORL; YAMADA H, 1993, ANTIMICROB AGENTS CH, V37, P2412, DOI 10.1128/AAC.37.11.2412	28	161	164	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					969	971		10.1126/science.273.5277.969	http://dx.doi.org/10.1126/science.273.5277.969			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688084				2022-12-24	WOS:A1996VC67000067
J	Atkins, MC; Carlin, EM; Emery, VC; Griffiths, PD; Boag, F				Atkins, MC; Carlin, EM; Emery, VC; Griffiths, PD; Boag, F			Fluctuations of HIV load in semen of HIV positive patients with newly acquired sexually transmitted diseases	BRITISH MEDICAL JOURNAL			English	Article									ROYAL CHELSEA & WESTMINSTER HOSP,DEPT GENITOURINARY MED,LONDON SW10 9TH,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT VIROL,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Emery, Vincent/G-8928-2013	Emery, Vincent/0000-0001-5893-9756				ERON J, 1996, JAMA-J AM MED ASSOC, V275, P38; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; VERNAZZA PL, 1994, AIDS, V8, P1325, DOI 10.1097/00002030-199409000-00017; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607	5	52	54	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					341	342		10.1136/bmj.313.7053.341	http://dx.doi.org/10.1136/bmj.313.7053.341			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760742	Green Published			2022-12-24	WOS:A1996VC30000020
J	Jiang, J; Struhl, G				Jiang, J; Struhl, G			Complementary and mutually exclusive activities of Decapentaplegic and Wingless organize axial patterning during Drosophila leg development	CELL			English	Article							SEGMENT-POLARITY GENE; PROTEIN-KINASE-A; SIGNALING PATHWAY; IMAGINAL DISKS; LIMB DEVELOPMENT; VERTEBRATE LIMB; THICK VEINS; I RECEPTORS; WNT GENES; HEDGEHOG	Growth and patterning of the Drosophila leg are organized by three secreted proteins: Hedgehog (Hh), Wingless (Wg), and Decapentaplegic (Dpp). Hh is secreted by posterior cells; it acts at short range to induce dorsal anterior cells to secrete Dpp and ventral anterior cells to secrete Wg. Here we show that the complementary patterns of dpp and wg expression are maintained by mutual repression: Dpp signaling blocks wg transcription, whereas Wg signaling attenuates dpp transcription. We also show that this mutual repression is essential for normal axial patterning because it ensures that the dorsalizing and ventralizing activities of Dpp and Wg are restricted to opposite sides of the leg primordium and meet only at the center of the primordium to distalize the appendage.			Jiang, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT GENET & DEV,NEW YORK,NY 10032, USA.							BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPBELL G, 1995, DEVELOPMENT, V121, P619; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CHOU TB, 1992, GENETICS, V131, P643; COHEN B, 1993, DEVELOPMENT, V117, P597; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GUILLEN I, 1995, DEVELOPMENT, V121, P3447; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; POSAKONY LG, 1991, MECH DEVELOP, V33, P69; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; ROELINK H, 1995, CURR OPIN NEUROBIOL, V6, P33; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1995, DEVELOPMENT, V121, P3359; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; THEISEN H, 1994, DEVELOPMENT, V120, P347; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; XU T, 1993, DEVELOPMENT, V117, P1223; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZECCA M, 1995, DEVELOPMENT, V121, P2265	60	152	153	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					401	409		10.1016/S0092-8674(00)80113-0	http://dx.doi.org/10.1016/S0092-8674(00)80113-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756722	hybrid			2022-12-24	WOS:A1996VC30900008
J	Galaktionov, K; Chen, XC; Beach, D				Galaktionov, K; Chen, XC; Beach, D			Cdc25 cell-cycle phosphatase as a target of c-myc	NATURE			English	Article							DNA-BINDING; ORNITHINE DECARBOXYLASE; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; MAX; PROTEIN; TRANSFORMATION; ACTIVATION; EXPRESSION; ONCOGENES	The product of the proto-oncogene c-myc, in partnership with Max, forms a transcription factor that can promote either oncogenic transformation or apoptosis. The Myc/Max heterodimer binds to elements in the cdc25A gene and activates transcription. Like myc, cdc25A, itself a proto-oncogene, can induce apoptosis in cells depleted of growth factor, and Myc-induced apoptosis also requires cdc25A. These findings indicate that cdc25A is a physiologically relevant transcriptional target of c-myc.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute								ALBRECHT M, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH S, 1992, ONCOGENE, V7, P775; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOMKAMM GW, 1987, ADV VIRAL ONCOL, V7, P173; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KAKIZUKA A, 1992, GENE DEV, V6, P578, DOI 10.1101/gad.6.4.578; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, REV BIOCH, V61, P809; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Penn L J, 1990, Semin Cancer Biol, V1, P69; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WATERS CM, 1991, ONCOGENE, V6, P797	50	640	666	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 8	1996	382	6591					511	517		10.1038/382511a0	http://dx.doi.org/10.1038/382511a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700224				2022-12-24	WOS:A1996VB25800041
J	Inaba, T; Inukai, T; Yoshihara, T; Seyschab, H; Ashmun, RA; Canman, CE; Laken, SJ; Kastan, MB; Look, AT				Inaba, T; Inukai, T; Yoshihara, T; Seyschab, H; Ashmun, RA; Canman, CE; Laken, SJ; Kastan, MB; Look, AT			Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor	NATURE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; PROGRAMMED CELL-DEATH; DNA-BINDING; E2A GENE; BCL-2; SURVIVAL; ELEGANS; PROTEIN; FUSION; HLF	THE E2A-HLF (for hepatic leukaemia factor) fusion gene, formed by action of the t(17;19) (q22;p13) chromosomal translocation, drives the leukaemic transformation of early B-cell precursors(1-4), but the mechanism of this activity remains unknown. Here we report that human leukaemia cells carrying the translocation t(17;19) rapidly died by apoptosis when programmed to express a dominant-negative suppressor of the fusion protein E2A-HLF, indicating that the chimaeric oncoprotein probably affects cell survival rather than cell growth. Moreover, when introduced into murine pro-B lymphocytes, the oncogenic E2A-HLF fusion protein reversed both interleukin-3-dependent and p53-mediated apoptosis. The close homology of the basic region/leucine zipper (bZIP) DNA-binding and dimerization domain of HLF to that of the CES-2 cell death specification protein of Caenorhabditis elegans(5) suggests a model of leukaemogenesis in which E2A-HLF blocks an early step within an evolutionarily conserved cell-death pathway(6-9).	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21287 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University; Johns Hopkins Medicine				, Christine/0000-0001-8892-7430				ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hunger SP, 1996, BLOOD, V87, P1211, DOI 10.1182/blood.V87.4.1211.bloodjournal8741211; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; HUNGER SP, 1994, MOL CELL BIOL, V14, P5986, DOI 10.1128/MCB.14.9.5986; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; KORSMEYER SJ, 1992, BLOOD, V80, P879; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8	26	115	115	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					541	544		10.1038/382541a0	http://dx.doi.org/10.1038/382541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700228				2022-12-24	WOS:A1996VB25800051
J	Hanoch, J; Feigin, E; Pikarsky, A; Kugel, C; Rivkind, A				Hanoch, J; Feigin, E; Pikarsky, A; Kugel, C; Rivkind, A			Stab wounds associated with terrorist activities in Israel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELECTIVE MANAGEMENT; INJURY; EXPERIENCE; VICTIMS; CHEST	Objective.-To describe injuries resulting from terrorist-associated knife stabbings. Design.-Retrospective case series. Setting.-Israel (population 5.5 million). Subjects.-Israeli victims (N=154) of knife stabbings on nationalistic basis (the intifada) between July 1987 and April 1994. Results.-A total of 125 men and 29 women sustained stab wounds associated with terrorist activities. The median age was 28 years (range, 12-92 years), and 99 victims were aged 18 to 35 years. Seventy percent (108 patients) of the stabbing events occurred between 7 AM and 11 AM. The 154 victims sustained a total of 327 stab wounds, the median number of injuries was 2 per person (range, 1-28), and 68 individuals (44%) sustained more than 1 stab wound. The chest was the most commonly involved site (146 wounds), with the right posterior chest stabbed in 71 patients. The knife penetrated the heart in 20 patients and penetrated the peritoneal cavity in 29 patients. Overall, 29 patients (19%) had superficial injuries, 86 (56%) had internal organ injuries that mandated operative interventions, and 39 died (overall mortality, 25.3%). Conclusions.-Unlike other civilian stabbings, wounds resulting from terrorist-associated stabbings represent severe and highly lethal injuries.	HADASSAH UNIV HOSP,TRAUMA UNIT,DEPT SURG,IL-91120 JERUSALEM,ISRAEL; TEL AVIV UNIV,INST FORENS MED,IL-69978 TEL AVIV,ISRAEL	Hebrew University of Jerusalem; Tel Aviv University								*AM COLL SURG COMM, 1988, ADV TRAUM LIF SUPP, P3; DONCHIN Y, 1994, J TRAUMA, V37, P552, DOI 10.1097/00005373-199410000-00006; FLETCHER TB, 1989, RADIOLOGY, V173, P621, DOI 10.1148/radiology.173.3.2813764; FULLUM TM, 1990, J NATL MED ASSOC, V82, P109; GOODMAN RA, 1986, AM J PUBLIC HEALTH, V76, P144, DOI 10.2105/AJPH.76.2.144; ITANI KMF, 1992, J TRAUMA, V32, P302, DOI 10.1097/00005373-199203000-00007; KRESSEL GM, 1981, MURDER NAME FAMILY H; LAMBRIANIDES AL, 1984, INJURY, V15, P300, DOI 10.1016/0020-1383(84)90050-0; LEE WC, 1984, ANN SURG, V199, P549, DOI 10.1097/00000658-198405000-00009; MARIADASON JG, 1988, ANN SURG, V207, P335, DOI 10.1097/00000658-198803000-00019; PAPPE I, 1993, PROFILE STABBER DEPR; ROBIN AP, 1989, J TRAUMA, V29, P1684, DOI 10.1097/00005373-198912000-00018; SHAFTAN GW, 1960, AM J SURG, V99, P657, DOI 10.1016/0002-9610(60)90010-6; SHORR RM, 1988, ARCH SURG-CHICAGO, V123, P1141; SIEGEL JH, 1987, TRAUMA EMERGENCY SUR, P1; SIRINEK KR, 1990, ARCH SURG-CHICAGO, V125, P844; STEBBINGS WSL, 1987, POSTGRAD MED J, V63, P81, DOI 10.1136/pgmj.63.736.81; SWANN IJ, 1985, ARCH EMERG MED, V2, P31; THORESEN SO, 1986, FORENSIC SCI INT, V31, P181, DOI 10.1016/0379-0738(86)90186-6; WALTON CB, 1989, J TRAUMA, V29, P99, DOI 10.1097/00005373-198901000-00021	20	26	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					388	390		10.1001/jama.276.5.388	http://dx.doi.org/10.1001/jama.276.5.388			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ776	8683817				2022-12-24	WOS:A1996UZ77600020
J	Ohta, K; Yamada, T; Nakanishi, K; Kohno, K; Akiyama, M; Kawabe, R				Ohta, K; Yamada, T; Nakanishi, K; Kohno, K; Akiyama, M; Kawabe, R			Detection of molecular gas in the quasar BR1202-0725 at redshift z=4.69	NATURE			English	Article							LYMAN-ALPHA SYSTEM; CO EMISSION; IRAS F10214+4724; GALAXY; SEARCH	ALTHOUGH great efforts(1-8) have been made to locate molecular gas-the material out of which stars form-in the early Universe, there have been only two firm detections at high redshift. Both are gravitationally lensed objects at redshift z approximate to 2.5 (refs 9-14). Here we report the detection of CO emission from the radio-quite quasar BR1202 - 0725, which is at redshift z approximate to 4.69. From the observed CO luminosity, we estimate that almost 10(11) solar masses of molecular hydrogen are associated with the quasar; this is comparable to the stellar mass of a present-day luminous galaxy. Our results suggest that BR1202 - 0725 is a massive galaxy, in which the gas is largely concentrated in the central region, and that it is currently undergoing a large burst of star formation.	UNIV HAWAII,INST ASTRON,HONOLULU,HI 96822; INST PHYS & CHEM RES,COSM RADIAT LAB,WAKO,SAITAMA 35101,JAPAN; NATL ASTRON OBSERV,NOBEYAMA RADIO OBSERV,MINAMISA KU,NAGANO 38413,JAPAN; UNIV TOKYO,DEPT ASTRON,TOKYO 113,JAPAN	University of Hawaii System; RIKEN; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); University of Tokyo	Ohta, K (corresponding author), KYOTO UNIV,DEPT ASTRON,KYOTO 60601,JAPAN.			Nakanishi, Kouichiro/0000-0002-6939-0372				Arimoto N, 1996, PUBL ASTRON SOC JPN, V48, P275, DOI 10.1093/pasj/48.2.275; ATHANASSOULA E, 1987, ASTRON ASTROPHYS, V179, P23; BARVAINIS R, 1994, NATURE, V371, P586, DOI 10.1038/371586a0; BARVAINIS R, IN PRESS INT ASTR UN, V170; BROADHURST T, 1995, ASTROPHYS J, V450, pL41, DOI 10.1086/316774; BROWN RL, 1993, ASTROPHYS J, V412, pL21, DOI 10.1086/186930; BROWN RL, 1992, ASTROPHYS J, V397, pL19, DOI 10.1086/186534; BROWN RL, 1991, ASTRON J, V102, P1956, DOI 10.1086/116017; Evans AS, 1996, ASTROPHYS J, V457, P658, DOI 10.1086/176761; FRAYER DT, 1994, ASTROPHYS J, V433, pL5, DOI 10.1086/187534; HU CM, 1996, ASTROPHYS J, V459, pL53; IRWIN M, 1991, ASTR SOC P, V21, P117; ISAAK KG, 1994, MON NOT R ASTRON SOC, V269, pL28, DOI 10.1093/mnras/269.1.L28; KAWABE R, 1992, ASTROPHYS J, V397, pL23, DOI 10.1086/186535; KORMENDY J, 1992, ASTROPHYS J, V390, pL53, DOI 10.1086/186370; MCMAHON RG, 1994, MON NOT R ASTRON SOC, V267, pL9, DOI 10.1093/mnras/267.1.L9; Ohta K, 1995, PUBL ASTRON SOC JPN, V47, P739; OHTA K, 1994, PUBL ASTRON SOC JPN, V46, pL163; Petitjean P, 1996, NATURE, V380, P411, DOI 10.1038/380411a0; SILK J, 1983, NATURE, V301, P574, DOI 10.1038/301574a0; SOLOMON PM, 1992, NATURE, V356, P318, DOI 10.1038/356318a0; SOLOMON PM, 1992, ASTROPHYS J, V398, pL29, DOI 10.1086/186569; STORRIELOMBARDI LJ, IN PRESS ASTROPHYS J; TSUBOI M, 1994, PUBL ASTRON SOC JPN, V46, pL179; WIKLIND T, 1994, ASTRON ASTROPHYS, V288, pL41; WRIGHT EL, 1991, ASTROPHYS J, V381, P200, DOI 10.1086/170641; YAMADA T, 1995, ASTRON J, V110, P1564, DOI 10.1086/117629; YAMADA T, 1995, ASTROPHYS J, V438, pL5, DOI 10.1086/187701; YAMADA T, 1995, ASTRON J, V110, P1572	29	151	151	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					426	428		10.1038/382426a0	http://dx.doi.org/10.1038/382426a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684482				2022-12-24	WOS:A1996VA25100048
J	Parsonnet, J; Harris, RA; Hack, HM; Owens, DK				Parsonnet, J; Harris, RA; Hack, HM; Owens, DK			Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials	LANCET			English	Article							INFECTION; POPULATION; EPIDEMIOLOGY; ERADICATION; EFFICACY; RISK; AGE	Background It is unknown whether eradication of Helicobacter pyiori infection prevents development of gastric adenocarcinoma. To determine whether screening and treatment trials are warranted, we conducted a cost-effectiveness analysis to estimate the costs and benefits associated with screening for H pylori at age 50 and treating those individuals infected with antibiotics. Methods We compared two interventions: (1) screen for H pylori and treat those with a positive rest, and (2) do not screen and do not treat. Estimates of risks and costs were obtained by review of published reports. Since the efficacy of H pyiori therapy in cancer prevention is unknown, we did sensitivity analyses, varying this estimate widely. In our base-case analysis, we assumed that H pylori treatment prevented 30% of attributable gastric cancers. Findings In the base-case analysis, 11 646 000 persons in the US would be screened and 4 658 400 treated, at a cost of $996 million. Cost-effectiveness was $25 000 per year of life saved, Cost-effectiveness was sensitive to the efficacy of the cancer prevention strategy. At low efficacy rates (<10%), the screening programme was more expensive (>$75 000 per year of life saved), In a high-risk group such as Japanese-Americans, however, screening and treatment required less than $50 000 per year of life saved, even at 5% treatment efficacy. Interpretation Screening and treatment for H pyiori infection is potentially cost-effective in the prevention of gastric cancer, particularly in high-risk populations. Cancer prevention trials are strongly recommended.	STANFORD UNIV,SCH MED,DEPT HLTH RES & POLICY,STANFORD,CA 94305; VET ADM PALO ALTO HLTH CARE SYST,SECT GEN MED,PALO ALTO,CA	Stanford University	Parsonnet, J (corresponding author), STANFORD UNIV,SCH MED,DEPT MED,HRP BLDG,ROOM T225,STANFORD,CA 94305, USA.			Parsonnet, Julie/0000-0001-7342-5366				ASAKA M, 1992, GASTROENTEROLOGY, V102, P760, DOI 10.1016/0016-5085(92)90156-S; BAKER MS, 1989, CANCER CARE AND COST, P127; BELL GD, 1993, Q J MED, V86, P743; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; FELDMAN RA, 1995, ALIMENT PHARM THER, V9, P21; FORMAN D, 1994, LANCET, V343, P243, DOI 10.1016/S0140-6736(94)91034-0; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; Hahn B., 1992, ANN EXPENSES SOURCES; HAHN RA, 1995, EPIDEMIOLOGY, V6, P350, DOI 10.1097/00001648-199507000-00004; *HLTH CAR CONS AM, 1995, PHYS FEE COD GUID; HORNBERGER JC, 1995, STAT MED, V14, P2249, DOI 10.1002/sim.4780142008; *IARC WORK GROUP E, 1994, SCHIST LIV FLUK HEL, P177; Labenz J., 1995, Gut, V37, pA41; *MED EC CO INC, 1995, REDB UPD; MITCHELL HM, 1993, J PEDIATR GASTR NUTR, V16, P120, DOI 10.1097/00005176-199302000-00004; PARSONNET J, 1993, GASTROENTEROL CLIN N, V22, P89; PARSONNET J, 1995, ALIMENT PHARM THERAP, V9, P45; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Perkins C, 1993, CANC INCIDENCE MORTA; Replogle ML, 1996, INT J EPIDEMIOL, V25, P210, DOI 10.1093/ije/25.1.210; RUSSELL LB, 1989, SCIENCE, V246, P892, DOI 10.1126/science.2510299; SIPPONEN P, 1991, J GASTROEN HEPATOL, V6, P244, DOI 10.1111/j.1440-1746.1991.tb01472.x; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; THIJS JC, 1993, SCAND J GASTROENTERO, V28, P934, DOI 10.3109/00365529309098287; *US BUR CENS, 1993, STAT ABSTR US, P86; VILLAKO K, 1981, ANN CLIN RES, V13, P114; YOUSFI MM, 1995, ALIMENT PHARM THERAP, V9, P209; ZHENG TZ, 1993, CANCER, V72, P330, DOI 10.1002/1097-0142(19930715)72:2<330::AID-CNCR2820720205>3.0.CO;2-L; 1994, JAMA-J AM MED ASSOC, V272, P65	30	272	282	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					150	154		10.1016/S0140-6736(96)01501-2	http://dx.doi.org/10.1016/S0140-6736(96)01501-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684154				2022-12-24	WOS:A1996UX78900009
J	Okada, F				Okada, F			Kampo medicine, a source of drugs waiting to be exploited	LANCET			English	Editorial Material											Okada, F (corresponding author), OKAJIMA NEUROPSYCHIAT CLIN,HIGASHI KU,SAPPORO,HOKKAIDO 065,JAPAN.							BABA S, 1995, CLIN OTOLARYNGOL, V88, P389; HIRAYAMA C, 1989, Gastroenterologia Japonica, V24, P715; HIZAWA N, 1994, INTERNAL MED, V33, P337, DOI 10.2169/internalmedicine.33.337; *JAP MIN HLTH WELF, 1992, STAT PROD PHARM IND; *JAP MIN HLTH WELF, 1992, 15 JAP MIN HLTH WELF; KIMURA I, 1993, ANN NY ACAD SCI, V685, P529, DOI 10.1111/j.1749-6632.1993.tb35916.x; Miyoshi A, 1994, GASTROENTEROLOGY, V18, P299; WOMIOKA H, 1992, SAISHIN IGAKU, V47, P1342; 1991, NIHON KEIZAI SH 1214	9	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					5	6		10.1016/S0140-6736(05)64351-6	http://dx.doi.org/10.1016/S0140-6736(05)64351-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691936				2022-12-24	WOS:A1996UV92300006
J	Muchmore, SW; Sattler, M; Liang, H; Meadows, RP; Harlan, JE; Yoon, HS; Nettesheim, D; Chang, BS; Thompson, CB; Wong, SL; Ng, SC; Fesik, SW				Muchmore, SW; Sattler, M; Liang, H; Meadows, RP; Harlan, JE; Yoon, HS; Nettesheim, D; Chang, BS; Thompson, CB; Wong, SL; Ng, SC; Fesik, SW			X-ray and NMR structure of human Bcl-x(L), an inhibitor of programmed cell death	NATURE			English	Article							DIPHTHERIA-TOXIN; ASSIGNMENTS; MODELS	THE Bcl-2 family of proteins regulate programmed cell death by an unknown mechanism(1). Here we describe the crystal and solution structures of a Bcl-2 family member, Bcl-x(L) (ref. 2). The structures consist of two central, primarily hydrophobic alpha-helices, which are surrounded by amphipathic helices. A 60-residue loop connecting helices alpha 1 and alpha 2 was found to be flexible and non-essential for anti-apoptotic activity. The three functionally important Bcl-2 homology regions (BH1, BH2 and BH3)(3-5) are in close spatial proximity and form an elongated hydrophobic cleft that may represent the binding site for other Bcl-2 family members. The arrangement of the alpha-helices in Bcl-x(L) is reminiscent of the membrane translocation domain of bacterial toxins, in particular diphtheria toxin and the colicins(6). The structural similarity may provide a clue to the mechanism of action of the Bcl-2 family of proteins.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,PROT CRYSTALLOG,ABBOTT PK,IL 60064; ABBOTT LABS,DIV PHARMACEUT DISCOVERY,NMR RES,ABBOTT PK,IL 60064; ABBOTT LABS,DIV PHARMACEUT DISCOVERY,RES COMP & INFORMAT SCI,ABBOTT PK,IL 60064; ABBOTT LABS,DIV PHARMACEUT DISCOVERY,AGING & DEGENERAT DIS RES,ABBOTT PK,IL 60064; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET,CHICAGO,IL 60637; UNIV CHICAGO,DEPT CELL BIOL,CHICAGO,IL 60637	Abbott Laboratories; Abbott Laboratories; Abbott Laboratories; Abbott Laboratories; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Muchmore, SW (corresponding author), ABBOTT LABS,PROT CRYSTALLOG,ABBOTT PK,IL 60064, USA.		Sattler, Michael/C-1169-2010; Yoon, Ho Sup/A-2193-2011; Sattler, Michael/A-2407-2012	Yoon, Ho Sup/0000-0002-8243-3904; Sattler, Michael/0000-0002-1594-0527				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bomer C, 1994, J CELL BIOL, V126, P1059; BOYD JM, 1995, ONCOGENE, V11, P1921; BRUNGER AT, 1992, X PLOR 3 1; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; FANG W, 1994, J IMMUNOL, V153, P4388; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LOGAN TM, 1992, FEBS LETT, V314, P413, DOI 10.1016/0014-5793(92)81517-P; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; REED RJ, 1986, ACTA CRYSTALLOGR A, V42, P140; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; *SERC DAR LAB, 1979, CCP4 SUIT PROGR PROT; VUISTER GW, 1994, J AM CHEM SOC, V116, P9206, DOI 10.1021/ja00099a041; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	30	1251	1341	1	100	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					335	341		10.1038/381335a0	http://dx.doi.org/10.1038/381335a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692274	Green Accepted			2022-12-24	WOS:A1996UM40300060
J	Kane, MA				Kane, MA			Global status of hepatitis B immunisation	LANCET			English	Editorial Material							VACCINATION				Kane, MA (corresponding author), WHO,EXPANDED PROGRAMME IMMUNISAT,CH-1211 GENEVA 27,SWITZERLAND.							ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; CHEN DS, 1996, 9 TRIENN INT S VIR H, P41; COURSAGET P, 1993, HEPATITIS B VACCINES, P209; MANGTANI P, 1995, J EPIDEMIOL COMMUN H, V49, P238, DOI 10.1136/jech.49.3.238; MARGOLIS HS, 1995, JAMA-J AM MED ASSOC, V274, P1201, DOI 10.1001/jama.274.15.1201; VANDAMME P, 1995, VACCINE, V13, pS54; WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6; *WORLD BANK, 1993, 1993 WORLD BANK, P72	8	129	135	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					696	696		10.1016/S0140-6736(05)65598-5	http://dx.doi.org/10.1016/S0140-6736(05)65598-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806283				2022-12-24	WOS:A1996VG37400002
J	Jacobson, JL; Jacobson, SW				Jacobson, JL; Jacobson, SW			Intellectual impairment in children exposed to polychlorinated biphenyls in utero	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-MILK; YOUNG-CHILDREN; LEAD-EXPOSURE; PCB EXPOSURE; CONTAMINANTS; DIOXINS; DDE; AGE	Background In utero exposure to polychlorinated biphenyls, a ubiquitous environmental contaminant, has been linked to adverse effects on neurologic and intellectual function in infants and young children. We assessed whether these effects persist through school age and examined their importance in the acquisition of reading and arithmetic skills. Methods We tested 212 children, recruited as newborns to overrepresent infants born to women who had eaten Lake Michigan fish contaminated with polychlorinated biphenyls, A battery of IQ and achievement tests was administered when the children were 11 years of age, Concentrations of polychlorinated biphenyls in maternal serum and milk at delivery were slightly higher than in the general population. A composite measure of prenatal exposure was derived from concentrations in umbilical-cord serum and maternal serum and milk. Results Prenatal exposure to polychlorinated biphenyls was associated with tower full-scale and verbal IQ scores after control for potential confounding variables such as socioeconomic status (P = 0.02). The strongest effects related to memory and attention. The most highly exposed children were three times as likely to have low average IQ scores (P < 0.001) and twice as likely to be at least two years behind in reading comprehension (P = 0.03). Although larger quantities of polychlorinated biphenyls are transferred by breast-feeding than in utero, there were deficits only in association with transplacental exposure, suggesting that the developing fetal brain is particularly sensitive to these compounds. Conclusions In utero exposure to polychlorinated biphenyls in concentrations slightly higher than those in the general population can have a long-term impact on intellectual function. (C) 1996, Massachusetts Medical Society.			Jacobson, JL (corresponding author), WAYNE STATE UNIV,DEPT PSYCHOL,71 W WARREN AVE,DETROIT,MI 48202, USA.		Fahimifar, Sepideh/M-5303-2019		NIEHS NIH HHS [R01-ES05843] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANNAU Z, 1986, NEUROBEHAVIORAL TOXI, P153; BELLINGER DC, 1992, PEDIATRICS, V90, P855; CHEN YCJ, 1992, JAMA-J AM MED ASSOC, V268, P3213, DOI 10.1001/jama.268.22.3213; DIETRICH KN, 1993, NEUROTOXICOL TERATOL, V15, P37, DOI 10.1016/0892-0362(93)90043-N; DOBSON S, 1993, POLYCHLORINATED BIPH; DVORCHIK BH, 1981, DRUG METABOLISM IMMA, P145; FEIN GG, 1984, J PEDIATR-US, V105, P315, DOI 10.1016/S0022-3476(84)80139-0; GLADEN BC, 1988, J PEDIATR-US, V113, P991, DOI 10.1016/S0022-3476(88)80569-9; JACOBSON JL, 1990, J PEDIATR-US, V116, P38, DOI 10.1016/S0022-3476(05)81642-7; JACOBSON JL, 1990, NEUROTOXICOL TERATOL, V12, P319, DOI 10.1016/0892-0362(90)90050-M; JACOBSON JL, 1989, AM J PUBLIC HEALTH, V79, P1401, DOI 10.2105/AJPH.79.10.1401; JACOBSON JL, IN PRESS NEUROTOXICO; JACOBSON SW, 1985, CHILD DEV, V56, P853, DOI 10.2307/1130097; JENSEN AA, 1987, SCI TOTAL ENVIRON, V64, P259, DOI 10.1016/0048-9697(87)90250-6; KAUFMAN AS, 1975, J CONSULT CLIN PSYCH, V43, P135, DOI 10.1037/h0076502; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KOOPMANESSEBOOM C, 1994, PEDIATR RES, V36, P468, DOI 10.1203/00006450-199410000-00009; KUZMA JW, 1981, NEUROBEH TOXICOL TER, V3, P211; LEVIN ED, 1988, ARCH TOXICOL, V62, P267, DOI 10.1007/BF00332486; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LILIENTHAL H, 1991, FUND APPL TOXICOL, V17, P368, DOI 10.1016/0272-0590(91)90226-T; NEEDHAM LL, 1981, J ASSOC OFF ANA CHEM, V64, P1131; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; ROGAN WJ, 1988, SCIENCE, V241, P334, DOI 10.1126/science.3133768; ROGAN WJ, 1986, AM J PUBLIC HEALTH, V76, P172, DOI 10.2105/AJPH.76.2.172; ROGAN WJ, 1986, J PEDIATR-US, V109, P335, DOI 10.1016/S0022-3476(86)80397-3; Sattler JM, 1992, ASSESSMENT CHILDRENS; SAWYER LD, 1978, J ASSOC OFF ANA CHEM, V61, P272; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Swain W. R., 1983, PCBS HUMAN ENV CONSE, P11; TANABE S, 1988, ENVIRON POLLUT, V50, P5, DOI 10.1016/0269-7491(88)90183-2; Weschler D., 1991, WECHSLER INTELLIGENC; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; WOODBURY DM, 1974, DRUGS DEV BRAIN, V8, P259	34	848	871	0	66	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1996	335	11					783	789		10.1056/NEJM199609123351104	http://dx.doi.org/10.1056/NEJM199609123351104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF786	8703183				2022-12-24	WOS:A1996VF78600004
J	Weiss, A; Keshet, I; Razin, A; Cedar, H				Weiss, A; Keshet, I; Razin, A; Cedar, H			DNA demethylation in vitro: Involvement of RNA	CELL			English	Article							MOUSE EMBRYO; NUCLEAR EXTRACTS; GENE-EXPRESSION; CPG ISLAND; ACTIN GENE; APRT GENE; METHYLATION; CELLS; 5-METHYLCYTOSINE; DIFFERENTIATION	An in vitro system for studying DNA demethylation has been established using extracts from tissue culture cells, this reaction, which is unusually resistant to proteinase K, takes place through the removal of a 5-methylcytosine nucleotide unit from the DNA substrate end its conversion to an RNase-sensitive form. It is likely that this represents the in vivo mechanism, as well, Since extracts from L8 mybolasts specifically demethylate an alpha-actin gene, while extracts from F9 teratocarcinoma cells specifically demodify the Aprt CpG island. After pretreatment with proteinase K, these extracts demethylate both genes equally, suggesting that gene specificity may be controlled by protein factors.			Weiss, A (corresponding author), HEBREW UNIV JERUSALEM,SCH MED,DEPT CELLULAR BIOCHEM,IL-91120 JERUSALEM,ISRAEL.							BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; GRIFFIN EA, 1995, CHEM BIOL, V2, P761, DOI 10.1016/1074-5521(95)90104-3; GRUENBAUM Y, 1981, FEBS LETT, V123, P67; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; Jahner D., 1984, DNA METHYLATION BIOC, P189; Jones PA, 1984, DNA METHYLATION BIOC, P165; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; KAFRI T, 1993, P NATL ACAD SCI USA, V90, P10558, DOI 10.1073/pnas.90.22.10558; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KIRILLOV A, 1996, IN PRESS NATURE GENE, V13; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LOWY I, 1980, CELL, V22, P817, DOI 10.1016/0092-8674(80)90558-9; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MONK M, 1987, DEVELOPMENT, V99, P371; MORI M, 1992, CELL, V70, P803; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; POLLACK Y, 1980, P NATL ACAD SCI-BIOL, V77, P6463, DOI 10.1073/pnas.77.11.6463; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SALUZ HP, 1986, P NATL ACAD SCI USA, V83, P7167, DOI 10.1073/pnas.83.19.7167; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; STEIN R, 1982, P NATL ACAD SCI USA, V80, P2422; SULLIVAN CH, 1986, P NATL ACAD SCI USA, V83, P329; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x; Yeivin A, 1993, EXS, V64, P523; YISRAELI J, 1986, CELL, V46, P409, DOI 10.1016/0092-8674(86)90661-6; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6	39	171	183	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					709	718		10.1016/S0092-8674(00)80146-4	http://dx.doi.org/10.1016/S0092-8674(00)80146-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797818	Bronze			2022-12-24	WOS:A1996VG37200005
J	Chen, JY; Clifford, J; Zusi, C; Starrett, J; Tortolani, D; Ostrowski, J; Reczek, PR; Chambon, P; Gronemeyer, H				Chen, JY; Clifford, J; Zusi, C; Starrett, J; Tortolani, D; Ostrowski, J; Reczek, PR; Chambon, P; Gronemeyer, H			Two distinct actions of retinoid-receptor ligands	NATURE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; LIGATION-MEDIATED PCR; PML-RAR-ALPHA; T(1517) TRANSLOCATION; RESPONSE PATHWAYS; INVIVO; TRANSACTIVATION; TRANSCRIPTION; CELLS	SIGNALLING by all-trans retinoic acid is mediated through RXR-RAR retinoid receptor heterodimers(1,2), in which RXR has been considered to act as a transcriptionally silent partner(3-5), However, we show here that in cultured NB4 (ref. 6) human acute promyelocytic leukaemia(7-9) cells treated with either an RAR-alpha-selective agonist alone, or certain RAR-alpha antagonists in combination with an RXR agonist, receptor-DNA binding is induced in vivo, resulting in expression of the target genes of retinoic acid as well as acute promyelocytic leukaemia protein (PML) relocation to nuclear bodies(10-12) and differentiation before apoptosis, These results indicate that RAR-alpha ligands can induce two separate events: one enables RXR-RAR-alpha heterodimers to bind to DNA in vivo and allows RXR agonists to act; the other induces transcriptional activity of RAR-alpha. The availability of receptor-specific synthetic retinoids that can induce distinct receptor functions has potential in extending the therapeutic repertoire of retinoids.	COLL FRANCE, INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM, ULP, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; BRISTOL MYERS SQUIBB CO, PHARMACEUT RES INST, BUFFALO, NY 14213 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Bristol-Myers Squibb			Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/G-6240-2011	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449				Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; Blanco JCG, 1996, GENES CELLS, V1, P209, DOI 10.1046/j.1365-2443.1996.d01-229.x; CHAMBON P, IN PRESS FASEB J; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CLIFFORD J, IN PRESS EMBO J; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GRONEMEYER H, 1985, PROTIEN PROFILE, V2, P1173; Kersten S, 1996, BIOCHEMISTRY-US, V35, P3816, DOI 10.1021/bi952737k; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LANOTTE M, 1991, BLOOD, V77, P1080; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGY L, 1995, MOL CELL BIOL, V15, P3540; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	28	178	183	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 29	1996	382	6594					819	822		10.1038/382819a0	http://dx.doi.org/10.1038/382819a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752277				2022-12-24	WOS:A1996VE34700050
J	Ho, SN; Biggar, SR; Spencer, DM; Schreiber, SL; Crabtree, GR				Ho, SN; Biggar, SR; Spencer, DM; Schreiber, SL; Crabtree, GR			Dimeric ligands define a role for transcriptional activation domains in reinitiation	NATURE			English	Article							RNA-POLYMERASE-II; PREINITIATION COMPLEX; FACTOR ATF; IN-VIVO; PROTEIN; PROMOTER; BINDING; RECRUITMENT; CALCINEURIN; INITIATION	EUKARYOTIC transcriptional activators mediate transcriptional induction through stabilization of the preinitiation complex(1-4), probably through direct interactions with basal transcription factors(5-7). In vitro studies on the role of an activator in the maintenance of on-going transcription (reinitiation) hare been contradictory, suggesting that, after formation of a preinitiation complex, an activator may(8) or may not(9) be necessary for transcription to be maintained, We have developed a means of regulating transcription in living cells through the use of both homodimeric and heterodimerizing synthetic ligands that allow the ligand-dependent association and disassociation of a transcriptional activation domain with a promoter. Here we report that maintaining the transcription of endogenous genes in vivo, in both yeast and human cells, requires the continuous presence of the activation domain. The use of synthetic ligands as a transcriptional on-off switch represents a powerful means of controlling the transcription in vitro and in vivo for both experimental and therapeutic purposes.	STANFORD UNIV,SCH MED,BECKMAN CTR MOL & GENET MED,HOWARD HUGHES MED INST,DEPT PATHOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,BECKMAN CTR MOL & GENET MED,HOWARD HUGHES MED INST,DEPT DEV BIOL,STANFORD,CA 94305; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Harvard University								BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JOHNSTON M, 1994, MOL CELL BIOL, V14, P3834, DOI 10.1128/MCB.14.6.3834; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; RIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231; RIVERA, IN PRESS NATURE MED; ROBERTS SGE, 1995, CURR BIOL, V5, P508, DOI 10.1016/S0960-9822(95)00103-5; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SZENTIRMAY MN, 1993, EMBO J, V12, P4677, DOI 10.1002/j.1460-2075.1993.tb06156.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TIJIAN R, 1994, CELL, V77, P5; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	31	215	245	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					822	826		10.1038/382822a0	http://dx.doi.org/10.1038/382822a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752278				2022-12-24	WOS:A1996VE34700051
J	Norris, JM; Beaty, B; Klingensmith, G; Yu, LP; Hoffman, M; Chase, HP; Erlich, HA; Hamman, RF; Eisenbarth, GS; Rewers, M				Norris, JM; Beaty, B; Klingensmith, G; Yu, LP; Hoffman, M; Chase, HP; Erlich, HA; Hamman, RF; Eisenbarth, GS; Rewers, M			Lack of association between early exposure to cow's milk protein and beta-cell autoimmunity - Diabetes autoimmunity study in the young (DAISY)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECALL BIAS; IDENTICAL-TWINS; IDDM; ANTIBODIES; MELLITUS; RISK; PREDICTION; POPULATION; PREGNANCY; ACCURACY	Objective.-To examine whether infant dietary exposure to cow's milk is associated with beta-cell autoimmunity (BCA), an early predictor of insulin-dependent diabetes mellitus (IDDM). Setting.-Denver, Cole. Design.-Cross-sectional with retrospective analysis. Participants.-Between January 1994 and December 1995, 253 children from 171 families of persons with IDDM were screened for BCA, All children were between the ages of 9 months and 7 years. Main Outcome Measures.-BCA was defined as elevated levels of insulin autoantibody, glutamic acid decarboxylase autoantibody, or insulinoma-associated islet tyrosine phosphatases autoantibody (IA-2) above the 99th percentile of 198 normal subjects. Results.-Eighteen cases of BCA were detected; 153 unrelated autoantibody-negative children were selected from the cohort as controls, There were no differences in the proportion of cases and controls who were exposed to cow's milk or foods containing cow's milk or to cereal, fruit and vegetable, or meat protein by 3 months or by 6 months of age. Children with BCA were breast-fed for a slightly longer duration than controls (median duration 10 vs 8 months, P=.07). Conclusions.-These data suggest that early exposure to cow's milk or other dietary protein is not associated with BCA, This calls into question the importance of cow's milk avoidance as a preventive measure for IDDM.	BARBARA DAVIS CTR CHILDHOOD DIABET,DENVER,CO; ROCHE MOL SYST INC,DEPT HUMAN GENET,ALAMEDA,CA	Roche Holding	Norris, JM (corresponding author), UNIV COLORADO,SCH MED,DEPT PREVENT MED & BIOMETR,4200 E 9TH AVE,BOX C-245,DENVER,CO 80262, USA.				NIDDK NIH HHS [R01 DK-32493] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032493] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON MA, 1993, NEW ENGL J MED, V329, P1853, DOI 10.1056/NEJM199312163292505; BINGLEY PJ, 1994, DIABETES, V43, P1304, DOI 10.2337/diabetes.43.11.1304; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BRANDT LPA, 1992, AM J EPIDEMIOL, V135, P302, DOI 10.1093/oxfordjournals.aje.a116284; DAHLQUIST GG, 1995, DIABETES CARE, V18, P852, DOI 10.2337/diacare.18.6.852; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; DORMAN JS, 1995, NIH PUBLICATION, P165; DREWS CD, 1990, INT J EPIDEMIOL, V19, P405, DOI 10.1093/ije/19.2.405; FELDMAN Y, 1989, TERATOLOGY, V40, P37, DOI 10.1002/tera.1420400106; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; GIANANI R, 1995, DIABETES, V44, P1340, DOI 10.2337/diabetes.44.11.1340; GRUBIN CE, 1994, DIABETOLOGIA, V37, P344, DOI 10.1007/BF00408469; HAMMAN RF, 1990, DIABETES CARE, V13, P499, DOI 10.2337/diacare.13.5.499; HUTTLY SRA, 1990, AM J EPIDEMIOL, V132, P572, DOI 10.1093/oxfordjournals.aje.a115693; JOHNSTON C, 1989, DIABETOLOGIA, V32, P382, DOI 10.1007/BF00277263; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; KHOURY MJ, 1993, AM J EPIDEMIOL, V137, P1241, DOI 10.1093/oxfordjournals.aje.a116626; KOSTRABA JN, 1993, DIABETES, V42, P288, DOI 10.2337/diabetes.42.2.288; KOSTRABA JN, 1992, DIABETES CARE, V15, P626, DOI 10.2337/diacare.15.5.626; MARTIKAINEN A, 1996, P 1 WORLD C PREV DIA; Norris JM, 1996, EPIDEMIOLOGY, V7, P87, DOI 10.1097/00001648-199601000-00015; OLEARY LA, 1991, DIABETES RES CLIN PR, V14, P183, DOI 10.1016/0168-8227(91)90019-A; PILCHER C C, 1991, Diabetes Research and Clinical Practice, V14, pS82; Rewers M, 1996, DIABETOLOGIA, V39, P807, DOI 10.1007/s001250050514; Vaarala O, 1996, DIABETES, V45, P178, DOI 10.2337/diabetes.45.2.178; Vaarala O, 1995, J ALLERGY CLIN IMMUN, V96, P917, DOI 10.1016/S0091-6749(95)70229-6; VARDI P, 1987, DIABETES, V36, P1286, DOI 10.2337/diabetes.36.11.1286; Verge CF, 1996, DIABETES, V45, P926, DOI 10.2337/diabetes.45.7.926; VERGE CF, 1995, DIABETES, V44, P1176, DOI 10.2337/diabetes.44.10.1176; WERLER MM, 1989, AM J EPIDEMIOL, V129, P415, DOI 10.1093/oxfordjournals.aje.a115145	30	131	133	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1996	276	8					609	614		10.1001/jama.276.8.609	http://dx.doi.org/10.1001/jama.276.8.609			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC853	8773632				2022-12-24	WOS:A1996VC85300026
J	Yan, SD; Chen, X; Fu, J; Chen, M; Zhu, HJ; Roher, A; Slattery, T; Zhao, L; Nagashima, M; Morser, J; Migheli, A; Nawroth, P; Stern, D; Schmidt, AM				Yan, SD; Chen, X; Fu, J; Chen, M; Zhu, HJ; Roher, A; Slattery, T; Zhao, L; Nagashima, M; Morser, J; Migheli, A; Nawroth, P; Stern, D; Schmidt, AM			RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease	NATURE			English	Article							GLYCATION END-PRODUCTS; CELL-ADHESION MOLECULE-1; NEURITE OUTGROWTH; BINDING-PROTEINS; OXIDANT STRESS; NEUROLOGICAL DISEASE; ENDOTHELIAL-CELLS; MICROGLIAL CELLS; TAU-PROTEIN; RECEPTOR	Amyloid-beta peptide is central to the pathology of Alzheimer's disease, because it is neurotoxic-directly by inducing oxidant stress, and indirectly by activating microglia. A specific cell-surface acceptor site that could focus its effects on target cells has been postulated but not identified. Here we present evidence that the receptor for advanced glycation end products' (RAGE) is such a receptor, and that it mediates effects of the peptide on neurons and microglia. increased expression of RAGE in Alzheimer's disease brain indicates that it is relevant to the pathogenesis of neuronal dysfunction and death.	COLUMBIA UNIV COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & MED,NEW YORK,NY 10032; SUN HLTH RES INST,SUN CITY,AZ 85372; BERLEX BIOSCI,RICHMOND,CA 94804; UNIV TURIN,I-10126 TURIN,ITALY; UNIV HEIDELBERG,DEPT MED,D-69115 HEIDELBERG,GERMANY	Columbia University; Columbia University; Banner Research; Banner Health; Banner Sun Health Research Institute; University of Turin; Ruprecht Karls University Heidelberg	Yan, SD (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,630 W 168TH ST,NEW YORK,NY 10032, USA.		Fu, Jin/A-3510-2012					ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; BRETT J, 1993, AM J PATHOL, V143, P1699; DAVIS JB, 1992, BIOCHEM BIOPH RES CO, V189, P1096, DOI 10.1016/0006-291X(92)92317-Q; DENNERY PA, 1990, AM J RESP CELL MOL, V3, P137, DOI 10.1165/ajrcmb/3.2.137; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; FRASER PE, 1993, J NEUROCHEM, V61, P298, DOI 10.1111/j.1471-4159.1993.tb03568.x; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GUMKOWSKI F, 1987, BLOOD VESSELS, V24, P11; HAASS C, 1994, CELL, V7, P1039; HARRIS ME, 1995, EXP NEUROL, V131, P193, DOI 10.1016/0014-4886(95)90041-1; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P7508, DOI 10.1073/pnas.90.16.7508; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; KOO EH, 1993, P NATL ACAD SCI USA, V90, P4748, DOI 10.1073/pnas.90.10.4748; KOSIK KS, 1994, J CELL BIOL, V127, P1501, DOI 10.1083/jcb.127.6.1501; MATTSON MP, 1995, BRAIN RES, V676, P219, DOI 10.1016/0006-8993(95)00148-J; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; NEEPER M, 1992, J BIOL CHEM, V267, P14998; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIKE CJ, 1993, J NEUROSCI, V13, P1676; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1993, J CLIN INVEST, V91, P2155, DOI 10.1172/JCI116442; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368; STRITTMATTER WJ, 1993, EXP NEUROL, V122, P327, DOI 10.1006/exnr.1993.1132; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; TROJANOWSKI JQ, 1994, AM J PATHOL, V144, P449; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; YAN SD, 1994, J BIOL CHEM, V269, P9889; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YAVIN E, 1974, J CELL BIOL, V62, P540, DOI 10.1083/jcb.62.2.540	45	1687	1798	4	140	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					685	691		10.1038/382685a0	http://dx.doi.org/10.1038/382685a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751438				2022-12-24	WOS:A1996VD33300040
J	Howard, AD; Feighner, SD; Cully, DF; Arena, JP; Liberator, PA; Rosenblum, CI; Hamelin, M; Hreniuk, DL; Palyha, OC; Anderson, J; Paress, PS; Diaz, C; Chou, M; Liu, KK; McKee, KK; Pong, SS; Chaung, LY; Elbrecht, A; Dashkevicz, M; Heavens, R; Rigby, M; Sirinathsinghji, DJS; Dean, DC; Melillo, DG; Patchett, AA; Nargund, R; Griffin, PR; DeMartino, JA; Gupta, SK; Schaeffer, JM; Smith, RG; VanderPloeg, LHT				Howard, AD; Feighner, SD; Cully, DF; Arena, JP; Liberator, PA; Rosenblum, CI; Hamelin, M; Hreniuk, DL; Palyha, OC; Anderson, J; Paress, PS; Diaz, C; Chou, M; Liu, KK; McKee, KK; Pong, SS; Chaung, LY; Elbrecht, A; Dashkevicz, M; Heavens, R; Rigby, M; Sirinathsinghji, DJS; Dean, DC; Melillo, DG; Patchett, AA; Nargund, R; Griffin, PR; DeMartino, JA; Gupta, SK; Schaeffer, JM; Smith, RG; VanderPloeg, LHT			A receptor in pituitary and hypothalamus that functions in growth hormone release	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS RNA; XENOPUS-OOCYTES; ARCUATE NUCLEUS; EXPRESSION; CLONING; SECRETAGOGUE; HEXAPEPTIDE; AVERMECTIN; PEPTIDE-6; AEQUORIN	Small synthetic molecules termed growth hormone secretagogues (GHSs) act on the pituitary gland and the hypothalamus to stimulate and amplify pulsatile growth hormone (GH) release. A heterotrimeric GTP-binding protein (G protein)-coupled receptor (GPC-R) of the pituitary and arcuate ventro-medial and infundibular hypothalamus of swine and humans was cloned and was shown to be the target of the GHSs. On the basis of its pharmacological and molecular characterization, this GPC-R defines a neuroendocrine pathway for the control of pulsatile GH release and supports the notion that the GHSs mimic an undiscovered hormone.	MERCK RES LABS,RAHWAY,NJ 07065; MERCK SHARP & DOHME LTD,NEUROSCI RES CTR,HARLOW CM20 2QR,ESSEX,ENGLAND	Merck & Company; Merck & Company								ARENA JP, 1992, MOL BRAIN RES, V15, P339, DOI 10.1016/0169-328X(92)90127-W; ARENA JP, 1991, MOL PHARMACOL, V40, P368; BOWERS CY, 1984, ENDOCRINOLOGY, V114, P1537, DOI 10.1210/endo-114-5-1537; BOWERS CY, 1994, J CLIN ENDOCR METAB, V79, P940, DOI 10.1210/jc.79.4.940; BRESSONBEPOLDIN L, 1994, CELL CALCIUM, V15, P247, DOI 10.1016/0143-4160(94)90064-7; BUTTON D, 1993, CELL CALCIUM, V14, P663, DOI 10.1016/0143-4160(93)90091-J; CHENG K, 1991, ENDOCRINOLOGY, V129, P3337; CHENG K, 1989, ENDOCRINOLOGY, V124, P2791; CHOMCZYNSKI P, 1995, ANAL BIOCHEM, V225, P163, DOI 10.1006/abio.1995.1126; DICKSON SL, 1995, J ENDOCRINOL, V146, P519, DOI 10.1677/joe.0.1460519; FROHMAN LA, 1987, ENDOCRINOL METAB, P264; GERTZ BJ, 1993, J CLIN ENDOCR METAB, V77, P1393, DOI 10.1210/jc.77.5.1393; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRYGORCZYK R, IN PRESS J NEUROSCI; HERRINGTON J, 1994, ENDOCRINOLOGY, V135, P1100, DOI 10.1210/en.135.3.1100; HOWARD A, UNPUB; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; Kriegler M., 1990, GENE TRANSFER EXPRES; LEI T, 1995, J MOL ENDOCRINOL, V14, P135, DOI 10.1677/jme.0.0140135; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Pong SS, 1996, MOL ENDOCRINOL, V10, P57, DOI 10.1210/me.10.1.57; PONG SS, 1993, P 75 M END SOC END S, P172; REINHART J, 1992, J BIOL CHEM, V267, P21281; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; SIRINATHSINGHJI DJ, UNPUB; SIRINATHSINGHJI DJS, 1995, NEUROREPORT, V6, P1989, DOI 10.1097/00001756-199510010-00009; SIRINATHSINGHJI DJS, 1990, NEUROSCIENCE, V34, P675, DOI 10.1016/0306-4522(90)90174-3; SIRINATHSINGHJI DS, 1993, MOL IMAGING NEUROSCI, P43; SMITH RG, 1993, SCIENCE, V260, P1640, DOI 10.1126/science.8503009; Smith RG, 1996, RECENT PROG HORM RES, V51, P261; WU D, 1992, J BIOL CHEM, V266, P9309	31	1665	1756	3	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					974	977		10.1126/science.273.5277.974	http://dx.doi.org/10.1126/science.273.5277.974			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688086				2022-12-24	WOS:A1996VC67000069
J	Nagasawa, T; Hirota, S; Tachibana, K; Takakura, N; Nishikawa, S; Kitamura, Y; Yoshida, N; Kikutani, H; Kishimoto, T				Nagasawa, T; Hirota, S; Tachibana, K; Takakura, N; Nishikawa, S; Kitamura, Y; Yoshida, N; Kikutani, H; Kishimoto, T			Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1	NATURE			English	Article							MURINE EMBRYO; RXR-ALPHA; C-KIT; GENE; MORPHOGENESIS; REQUIREMENT; RECEPTORS; LINEAGES; CLONING; HEART	THE chemokines are a large family of small, structurally related cytokines(1,2). The physiological importance of most members of this family has yet to be elucidated, although some are inducible inflammatory mediators that determine leukocyte chemotaxis(1-5). Pre-B-cell growth-stimulating factor/stromal cell-derived factor-1 (PBSF/SDF-1) is a member of the CXC group of chemokines(6,7). PBSF/SDF-1 stimulates proliferation of B-cell progenitors in vitro(6) and is constitutively expressed in bone-marrow-derived stromal cells(6,7). Here we investigate the physiological roles of PBSF/SDF-1 by generating mutant mice with a targeted disruption of the gene encoding PBSF/SDF-1, We found that mite lacking PBSF/SDF-1 died perinatally and that although the numbers of B-cell progenitors in mutant embryos were severely reduced in fetal liver and bone marrow, myeloid progenitors were reduced only in the hone marrow but not in the fetal liver, indicating that PBSF/SDF-1 is responsible for B-cell lymphopoiesis and bone-marrow myelopoiesis. In addition, the mutants had a cardiac ventricular septal defect, Hence, we have shown that the chemokine PBSF/SDF-1 has several essential functions in development.	OSAKA UNIV,INST MOL & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,SUITA,OSAKA 565,JAPAN; KYOTO UNIV,FAC MED,DEPT MOL GENET,SAKYO KU,KYOTO 606,JAPAN; OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University; Kyoto University; Osaka University	Nagasawa, T (corresponding author), OSAKA MED CTR MATERNAL & CHILD HLTH,RES INST,DEPT IMMUNOL,840 MURODO CHO,IZUMI,OSAKA 59002,JAPAN.		Kikutani, Hitoshi/C-9525-2009; Kishimoto, Tadamitsu/C-8470-2009	Nagasawa, Takashi/0000-0002-1085-0960				CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; Delassus S, 1996, IMMUNITY, V4, P97, DOI 10.1016/S1074-7613(00)80302-7; FREEDENJEFFRY U, 1995, J EXP MED, V181, P1519; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; HARDY RR, 1991, P NATL ACAD SCI USA, V88, P11550, DOI 10.1073/pnas.88.24.11550; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KUNKEL SL, 1995, IMMUNOL TODAY, V16, P559, DOI 10.1016/0167-5699(95)80076-X; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; MOORE MW, 1995, SCIENCE, V269, P1591, DOI 10.1126/science.269.5230.1591; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; OGAWA M, 1993, DEVELOPMENT, V117, P1089; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PESHON J, 1994, J EXP MED, V180, P1955; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TAVASSOLI M, 1991, BLOOD CELLS, V1, P269; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	25	1904	2017	0	53	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					635	638		10.1038/382635a0	http://dx.doi.org/10.1038/382635a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757135				2022-12-24	WOS:A1996VC30300055
J	Nightingale, SL				Nightingale, SL			T-PA approved for acute ischemic stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					443	443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691538				2022-12-24	WOS:A1996VA86300006
J	Cairns, A; Roberts, ISD; Benbow, EW				Cairns, A; Roberts, ISD; Benbow, EW			Characteristics of fatal methadone overdose in Manchester, 1985-94	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MAINTENANCE TREATMENT; DEPENDENCE		UNIV MANCHESTER, DEPT PATHOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND; MANCHESTER ROYAL INFIRM, DEPT HISTOPATHOL, MANCHESTER M13 9WL, LANCS, ENGLAND	University of Manchester; University of Manchester								CAPLEHORN J, 1995, BMJ-BRIT MED J, V310, P463, DOI 10.1136/bmj.310.6977.463; Clark J C, 1995, J Clin Forensic Med, V2, P143, DOI 10.1016/1353-1131(95)90082-9; FARRELL M, 1994, BMJ-BRIT MED J, V309, P997, DOI 10.1136/bmj.309.6960.997; FARRELL M, 1994, BRIT MED J, V308, P609, DOI 10.1136/bmj.308.6929.609; *OFF POP CENS SURV, 1987, MORT STAT INJ POIS	5	64	65	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 3	1996	313	7052					264	265		10.1136/bmj.313.7052.264	http://dx.doi.org/10.1136/bmj.313.7052.264			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704535	Green Published			2022-12-24	WOS:A1996VA90300024
J	DuranTauleria, E; Rona, RJ; Chinn, S; Burney, P				DuranTauleria, E; Rona, RJ; Chinn, S; Burney, P			Influence of ethnic group on asthma treatment in children in 1990-1: National cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; HOSPITAL ADMISSIONS; HEALTH; TRENDS; POPULATION; INCREASE; SEVERITY; GROWTH; HEIGHT; RATES	Objective-To examine the extent to which the prescription of drugs for asthma adhered to recommended guidelines in 1990-1 and to assess the influence of ethnic group on prescription. Design-Cross sectional. Setting-Primary schools in England and Scotland in 1990-1. Subjects-Children aged mainly 5-11 years. The representative samples included 10 628 children. The inner city sample included 7049 children, 4866 (69%) from ethnic minority groups. For the prevalence estimation 14 490 children were included in the analysis (82% of the eligible children). For the treatment analysis a subgroup of 5494 children with respiratory symptoms was selected. Main outcome measures-Prevalence of respiratory symptoms and drugs commonly prescribed for asthma, method of administration, inappropriate treatment, and odds ratios to assess the effect of ethnic group on rate of prescription and method of administration. Results-Children with respiratory symptoms in the inner city sample were less likely to be diagnosed as having asthma. Of children with reported asthma attacks, those in inner city areas had a higher risk of not having been prescribed any drug for asthma (odds ratio 1.87 (95% confidence interval 1.26 to 2.77). Overall, 773 (75%) of these children had received a beta(2) agonist, 259 (25%) had received steroids, 148 (14%) had received sodium cromoglycate, and 194 (19%) had received no drug treatment in the previous year. When prescribed, beta(2) agonists were inhaled in 534 (69%) of cases, and this percentage was even lower in ethnic minority groups. Children of Afro-Caribbean and Indian subcontinent origin who had asthma were less likely to receive beta(2) agonists, and those from the Indian subcontinent were less likely to receive anti-inflammatory drugs. Antibiotics were less prescribed and antitussives more prescribed in children from ethnic minority groups than in white children. Conclusion-In 1990-1 the risk of underdiagnosis and undertreatment of asthma was higher in children from ethnic minority groups. The implementation of indicators and targets to monitor inequalities in the treatment of asthma in ethnic groups could improve equity and effectiveness in the NHS.			DuranTauleria, E (corresponding author), UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND.		Rona, Roberto J/C-2348-2011	Rona, Roberto/0000-0003-3739-5571; Burney, Peter/0000-0001-8635-5678				ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; BALARAJAN R, 1989, BRIT MED J, V299, P958, DOI 10.1136/bmj.299.6705.958; BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; BOSCO LA, 1993, CHEST, V104, P1727, DOI 10.1378/chest.104.6.1727; British Thoracic Society (BTS), 1993, THORAX, V48, pS1; BURNEY PGJ, 1991, BRIT MED J, V303, P571, DOI 10.1136/bmj.303.6802.571; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; GARRETT JE, 1989, NEW ZEAL MED J, V102, P121; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GILL PS, 1995, BRIT MED J, V310, P890, DOI 10.1136/bmj.310.6984.890; HILL RA, 1989, ARCH DIS CHILD, V64, P246, DOI 10.1136/adc.64.2.246; KUN HY, 1993, MED J AUSTRALIA, V159, P312, DOI 10.5694/j.1326-5377.1993.tb137867.x; MITCHELL EA, 1991, SOC SCI MED, V32, P831, DOI 10.1016/0277-9536(91)90309-Z; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; Osborn A.F., 1984, SOCIAL LIFE BRITAINS; PEAT JK, 1989, CLIN EXP ALLERGY, V19, P299, DOI 10.1111/j.1365-2222.1989.tb02387.x; PHIN S, 1993, MED J AUSTRALIA, V159, P662, DOI 10.5694/j.1326-5377.1993.tb138080.x; RONA RJ, 1986, ANN HUM BIOL, V13, P453, DOI 10.1080/03014468600008631; RONA RJ, 1977, ANN HUM BIOL, V4, P501, DOI 10.1080/03014467700002511; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174; THOMPSON R, 1993, NEW ZEAL MED J, V106, P81; VOLLMER WM, 1993, AM REV RESPIR DIS, V147, P347, DOI 10.1164/ajrccm/147.2.347; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WARNER JO, 1995, BRIT MED J, V311, P663, DOI 10.1136/bmj.311.7006.663; WILSON SR, 1993, MED CARE, V31, pMS49; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 1992, ARCH DIS CHILD, V67, P240	28	54	54	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 20	1996	313	7050					148	152		10.1136/bmj.313.7050.148	http://dx.doi.org/10.1136/bmj.313.7050.148			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY921	8688777	Green Published			2022-12-24	WOS:A1996UY92100020
J	Stratford, KJ; TarczyHornoch, K; Martin, KAC; Bannister, NJ; Jack, JJB				Stratford, KJ; TarczyHornoch, K; Martin, KAC; Bannister, NJ; Jack, JJB			Excitatory synaptic inputs to spiny stellate cells in cat visual cortex	NATURE			English	Article							ORIENTATION SELECTIVITY; GENICULOCORTICAL AFFERENTS; NEURONS; TRANSMISSION; PROJECTIONS; MONKEY	IN layer 4 of cat visual cortex, the monocular, concentric receptive fields of thalamic neurons, which relay retinal input to the cortex, are transformed into 'simple' cortical receptive fields that are binocular and selective for the precise orientation, direction of motion, and size of the visual stimulus(1). These properties are thought to arise from the pattern of connections from thalamic neurons(1-6), although anatomical studies show that most excitatory inputs to layer 4 simple cells are from recurrently connected circuits of cortical neurons(7-9). We examined single fibre inputs to spiny stellate neurons in slices of cat visual cortex, and conclude that thalamocortical synapses are powerful and the responses they evoke are unusually invariant for central synapses. However, the responses to intracortical inputs, although less invariant, are strong enough to provide most of the excitation to simple tells in vivo. Our results suggest that the recurrent excitatory circuits of cortex may amplify the initial feedforward thalamic signal, subserving dynamic modifications of the functional properties of cortical neurons(10-12).	ETH ZURICH,INST NEUROINFORMAT,CH-8006 ZURICH,SWITZERLAND; UNIV ZURICH,CH-8006 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Stratford, KJ (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.			Tarczy-Hornoch, Kristina/0000-0001-6881-0382	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; ANDERSON JC, 1994, J COMP NEUROL, V341, P25, DOI 10.1002/cne.903410104; ANDREASEN M, 1994, J NEUROPHYSIOL, V72, P326, DOI 10.1152/jn.1994.72.1.326; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; Das A, 1996, NEURON, V16, P477, DOI 10.1016/S0896-6273(00)80067-7; DOUGLAS RJ, 1995, SCIENCE, V269, P981, DOI 10.1126/science.7638624; Everitt B. S., 1993, CLUSTER ANAL; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P233, DOI 10.1113/jphysiol.1985.sp015822; Ferster D, 1996, NATURE, V380, P249, DOI 10.1038/380249a0; GAREY LJ, 1971, PROC R SOC SER B-BIO, V179, P41, DOI 10.1098/rspb.1971.0080; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GRIEVE KL, 1991, EXP BRAIN RES, V87, P521; HESTRIN S, 1993, NEURON, V11, P1083, DOI 10.1016/0896-6273(93)90221-C; HIRSCH JA, 1995, J PHYSIOL-LONDON, V483, P183, DOI 10.1113/jphysiol.1995.sp020577; Hubel D, 1996, NATURE, V380, P197, DOI 10.1038/380197a0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JACK JJB, 1975, ELECTRIC CURRENT FLO; LEVAY S, 1976, BRAIN RES, V113, P1, DOI 10.1016/0006-8993(76)90002-0; LUND JS, 1979, J COMP NEUROL, V184, P599, DOI 10.1002/cne.901840402; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MASON A, 1991, J NEUROSCI, V11, P72; PETERS A, 1993, CEREB CORTEX, V3, P69, DOI 10.1093/cercor/3.1.69; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; SCLAR G, 1982, EXP BRAIN RES, V46, P457; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; STEVENS CF, 1994, LARGE SCALE NEURONAL, P239; VOLGUSHEV M, 1995, EUR J NEUROSCI, V7, P1751, DOI 10.1111/j.1460-9568.1995.tb00695.x	29	325	328	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					258	261		10.1038/382258a0	http://dx.doi.org/10.1038/382258a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717041				2022-12-24	WOS:A1996UX79000051
J	Fox, NC; Freeborough, PA; Rossor, MN				Fox, NC; Freeborough, PA; Rossor, MN			Visualisation and quantification of rates of atrophy in Alzheimer's disease	LANCET			English	Article							TOMOGRAPHY; MATTER; BRAIN	Background Definitive diagnosis of Alzheimer's disease requires histological examination of brain tissue. In life, brain atrophy can be visualised by computed tomography or magnetic resonance (MR) imaging, but the atrophy due to the disease is difficult to distinguish from that caused by normal ageing. We have investigated use of accurate positional matching (registration) and digital subtraction of serially acquired MR brain scans to allow determination of rates of global and regional atrophy. Methods This technique was applied to eleven patients with clinically diagnosed Alzheimer's disease and eleven age-matched controls. Each individual had two scans approximately 1 year apart; scan intervals were matched between the groups. Findings The median rate atrophy was significantly greater in the Alzheimer's disease group than in the control group (12 . 3 [range 5 . 8 to 23 . 6] vs 0 . 3 (-1 . 2 to 1 . 7) mL per year; p<0 . 0001). There was no overlap between the groups. Furthermore, three non-demented individuals at risk of familiar Alzheimer's disease had scans 6-14 months apart and showed greater rates of volume loss than the controls; these three individuals have subsequently developed symptoms. Interpretation This technique may be useful for the diagnosis of Alzheimer's disease, the assessment of disease progression, and the evaluation of potential treatments.	NATL HOSP NEUROL & NEUROSURG,DEMENTIA RES GRP,LONDON WC1N 3BG,ENGLAND; ST MARYS HOSP,IMPERIAL COLL,SCH MED,LONDON,ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Imperial College London			Fox, Nick C/AAE-1849-2021; Rossor, Martin/C-1598-2008; Fox, Nick C/B-1319-2009	Fox, Nick C/0000-0002-6660-657X; Fox, Nick C/0000-0002-6660-657X; Rossor, Martin/0000-0001-8215-3120				CONVIT A, 1995, LANCET, V345, P266, DOI 10.1016/S0140-6736(95)90265-1; Convit Antonio, 1993, Psychiatric Quarterly (New York), V64, P371, DOI 10.1007/BF01064929; DAVIS PC, 1995, NEUROLOGY, V45, P178, DOI 10.1212/WNL.45.1.178; DAVIS PC, 1992, NEUROLOGY, V42, P1676, DOI 10.1212/WNL.42.9.1676; DECARLI C, 1990, NEUROLOGY, V40, P872, DOI 10.1212/WNL.40.6.872; DECARLI C, 1995, PSYCHIAT RES, V57, P119, DOI 10.1016/0165-1781(95)02651-C; DELEON MJ, 1989, AM J ROENTGENOL, V152, P1257, DOI 10.2214/ajr.152.6.1257; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox NC, 1996, ANN NY ACAD SCI, V777, P226, DOI 10.1111/j.1749-6632.1996.tb34423.x; FOX NC, 1996, P INT SOC MAGNETIC R, V1, P234; FOX NC, 1995, NEUROBIOLOGY ALZHEIM, P269; FREEBOROUGH PA, 1996, P EUROGRAPHICS UK C, V2, P261; FREEBOROUGH PA, 1996, P INT SOC MAGNETIC R, V1, P34; HAJNAL JV, 1995, J COMPUT ASSIST TOMO, V19, P289, DOI 10.1097/00004728-199503000-00022; HAJNAL JV, 1995, J COMPUT ASSIST TOMO, V19, P677, DOI 10.1097/00004728-199509000-00001; IKEDA M, 1994, NEURORADIOLOGY, V36, P7, DOI 10.1007/BF00599184; JOBST KA, 1994, LANCET, V343, P829, DOI 10.1016/S0140-6736(94)92028-1; JOBST KA, 1992, LANCET, V340, P1179; KENNEDY AM, 1995, NEUROSCI LETT, V186, P17, DOI 10.1016/0304-3940(95)11270-7; KILLIANY RJ, 1993, ARCH NEUROL-CHICAGO, V50, P949, DOI 10.1001/archneur.1993.00540090052010; LEHERICY S, 1994, AM J NEURORADIOL, V15, P927; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MURPHY DGM, 1992, ARCH NEUROL-CHICAGO, V49, P839, DOI 10.1001/archneur.1992.00530320063013; NEWMAN SK, 1994, J NEUROL NEUROSUR PS, V57, P967, DOI 10.1136/jnnp.57.8.967; RUSINEK H, 1991, RADIOLOGY, V178, P109, DOI 10.1148/radiology.178.1.1984287; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	26	285	288	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					94	97		10.1016/S0140-6736(96)05228-2	http://dx.doi.org/10.1016/S0140-6736(96)05228-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676724				2022-12-24	WOS:A1996UW67300012
J	Hahn, H; Wicking, C; Zaphiropoulos, PG; Gailani, MR; Shanley, S; Chidambaram, A; Vorechovsky, I; Holmberg, E; Unden, AB; Gillies, S; Negus, K; Smyth, I; Pressman, C; Leffell, DJ; Gerrard, B; Goldstein, AM; Dean, M; Toftgard, R; ChenevixTrench, G; Wainwright, B; Bale, AE				Hahn, H; Wicking, C; Zaphiropoulos, PG; Gailani, MR; Shanley, S; Chidambaram, A; Vorechovsky, I; Holmberg, E; Unden, AB; Gillies, S; Negus, K; Smyth, I; Pressman, C; Leffell, DJ; Gerrard, B; Goldstein, AM; Dean, M; Toftgard, R; ChenevixTrench, G; Wainwright, B; Bale, AE			Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome	CELL			English	Article							TUMOR SUPPRESSOR GENE; GORLIN SYNDROME; COLORECTAL TUMORIGENESIS; POINT MUTATIONS; SEGMENT; PROTEIN; RETINOBLASTOMA; POLARITY; POLYMORPHISMS; ASSOCIATION	The nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant disorder characterized by multiple basal cell carcinomas (BCCs), pits of the palms and soles, jaw keratocysts, a variety of other tumors, and developmental abnormalities. NBCCS maps to chromosome 9q22.3. Familial and sporadic BCCs display loss of heterozygosity in this region, consistent with the gene being a tumor suppressor. A human sequence (PTC) with strong homology to the Drosophila segment polarity gene, patched, was isolated from a YAC and cosmid contig of the NBCCS region. Mutation analysis revealed alterations of PTC in NBCCS patients and in related tumors. We propose that a reduction in expression of the patched gene can lead to the developmental abnormalities observed in the syndrome and that complete loss of patched function contributes to transformation of certain cell types.	NCI,VIRAL CARCINOGENESIS LAB,HUMAN GENET SECT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,INTRAMURAL RES SUPPORT PROGRAM,FREDERICK,MD 21702; NCI,GENET EPIDEMIOL BRANCH,BETHESDA,MD 20852; KAROLINSKA INST,NOVUM,DEPT BIOSCI,CTR NUTR & TOXICOL,S-14157 HUDDINGE,SWEDEN; KAROLINSKA HOSP,DEPT DERMATOL,S-17176 STOCKHOLM,SWEDEN; ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA; YALE UNIV,SCH MED,DEPT PEDIAT,NEW HAVEN,CT 06250; YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06250; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06250	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Yale University; Yale University; Yale University	Hahn, H (corresponding author), UNIV QUEENSLAND,CTR CELLULAR & MOLEC BIOL,ST LUCIA,QLD 4072,AUSTRALIA.		Chenevix-Trench, Georgia/AAV-2014-2020; Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Wicking, Carol/J-1814-2014	Chenevix-Trench, Georgia/0000-0002-1878-2587; Dean, Michael C/0000-0003-2234-0631; Wicking, Carol/0000-0002-7225-3803; Smyth, Ian/0000-0002-1727-7829; Zaphiropoulos, Peter/0000-0003-4298-3861; Wainwright, Brandon/0000-0003-0406-2092	NCI NIH HHS [K11CA60199, R01CA57605, P30CA16359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA060199, R01CA057605, P30CA016359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DE, 1967, AM J HUM GENET, V19, P12; BALE SJ, 1991, AM J MED GENET, V40, P206, DOI 10.1002/ajmg.1320400217; BASTER K, 1994, NATURE, V368, P208; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EVANS DGR, 1993, J MED GENET, V30, P460, DOI 10.1136/jmg.30.6.460; EVANS DGR, 1991, BRIT J CANCER, V64, P959, DOI 10.1038/bjc.1991.435; FARNDON PA, 1992, LANCET, V339, P581, DOI 10.1016/0140-6736(92)90868-4; FARNDON PA, 1994, GENOMICS, V23, P486, DOI 10.1006/geno.1994.1528; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Gailani MR, 1996, J NATL CANCER I, V88, P349, DOI 10.1093/jnci/88.6.349; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P765; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; GUTIERREZ MM, 1986, J AM ACAD DERMATOL, V15, P1023, DOI 10.1016/S0190-9622(86)70266-1; HAHN H, 1996, IN PRESS J BIOL CHEM, V271; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOLMBERG E, 1996, IN PRESS BR J CANC; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PERICAKVANCE MA, 1995, ANN HUM GENET, V59, P2347; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; REIS A, 1992, LANCET, V339, P617, DOI 10.1016/0140-6736(92)90903-G; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SHANLEY S, 1994, AM J MED GENET, V50, P282, DOI 10.1002/ajmg.1320500312; SHANLEY SM, 1995, HUM MOL GENET, V4, P129; SMITH MW, 1994, NAT GENET, V7, P40, DOI 10.1038/ng0594-40; SPRINGATE JE, 1986, J PEDIATR SURG, V21, P908, DOI 10.1016/S0022-3468(86)80023-9; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; VALDES JM, 1994, P NATL ACAD SCI USA, V91, P5377, DOI 10.1073/pnas.91.12.5377; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5; WICKING C, 1994, GENOMICS, V22, P505, DOI 10.1006/geno.1994.1423	64	1538	1606	0	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					841	851		10.1016/S0092-8674(00)81268-4	http://dx.doi.org/10.1016/S0092-8674(00)81268-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681379	hybrid			2022-12-24	WOS:A1996UR60400008
J	Muzio, M; Chinnaiyan, AM; Kischkel, FC; ORourke, K; Shevchenko, A; Ni, J; Scaffidi, C; Bretz, JD; Zhang, M; Gentz, R; Mann, M; Krammer, PH; Peter, ME; Dixit, VM				Muzio, M; Chinnaiyan, AM; Kischkel, FC; ORourke, K; Shevchenko, A; Ni, J; Scaffidi, C; Bretz, JD; Zhang, M; Gentz, R; Mann, M; Krammer, PH; Peter, ME; Dixit, VM			FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex	CELL			English	Article							CELL-SURFACE ANTIGEN; MASS-SPECTROMETRY; FAS ANTIGEN; GENE CED-3; APOPTOSIS; RECEPTOR; ENZYME; PURIFICATION; INDUCTION; ENCODES	To identify CAP3 and CAP4 components of the CD95 (Fas/APO-1) death-inducing signaling complex, we utilized nano-electrospray tandem mass spectrometry, a recently developed technique to sequence femtomole quantities of polyacrylamide gel-separated proteins. Interestingly, CAP4 encodes a novel 55 kDa protein, designated FLICE, which has homology to both FADD and the ICE/CED-3 family of cysteine proteases. FLICE binds to the death effector domain of FADD and upon overexpression induces apoptosis that is blocked by the ICE family inhibitors, CrmA and z-VAD-fmk. CAP3 was identified as the FLICE prodomain which likely remains bound to the receptor after proteolytic activation. Taken together, this is unique biochemical evidence to link a death receptor physically to the proapoptotic proteases of the ICE/CED-3 family.	GERMAN CANC RES CTR,TUMORIMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; EUROPEAN MOLEC BIOL LAB,PROT & PEPTIDE GRP,D-69012 HEIDELBERG,GERMANY; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); GlaxoSmithKline; Human Genome Sciences Inc	Muzio, M (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109, USA.		Mann, Matthias/A-3454-2013; Muzio, Marta/J-9360-2018; Watzl, Carsten/B-4911-2013; dixit, vishva m/A-4496-2012	Mann, Matthias/0000-0003-1292-4799; Muzio, Marta/0000-0002-7761-759X; Watzl, Carsten/0000-0001-5195-0995; dixit, vishva m/0000-0001-6983-0326; Peter, Marcus Ernst/0000-0003-3216-036X				BAGLIONI C, 1992, TUMOR NECROSIS FACTO, P425; BERKE G, 1995, IMMUNOL TODAY, V16, P343, DOI 10.1016/0167-5699(95)80152-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUAN H, 1996, IN PRESS J BIOL CHEM; DUAN H, 1996, J BIOL CHEM, V271, P35013; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; OEHM A, 1992, J BIOL CHEM, V267, P10709; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PETER ME, 1995, CELL DEATH DIFFER, V2, P163; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; QUAN LT, 1996, IN PRESS P NATL ACAD, V93; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TEWARI M, 1995, MODULAR TEXTS MOL C, P107; THOMBERRY NA, 1992, NATURE, V356, P768; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WILM M, 1996, ANAL CHEM, V66, P1; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	74	2695	2823	5	127	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					817	827		10.1016/S0092-8674(00)81266-0	http://dx.doi.org/10.1016/S0092-8674(00)81266-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681377	Bronze			2022-12-24	WOS:A1996UR60400006
J	Daniels, SE; Bhattacharrya, S; James, A; Leaves, NI; Young, A; Hill, MR; Faux, JA; Ryan, GF; leSouef, PN; Lathrop, GM; Musk, AW; Cookson, WOCM				Daniels, SE; Bhattacharrya, S; James, A; Leaves, NI; Young, A; Hill, MR; Faux, JA; Ryan, GF; leSouef, PN; Lathrop, GM; Musk, AW; Cookson, WOCM			A genome-wide search for quantitative trait loci underlying asthma	NATURE			English	Article							FC-EPSILON-RI; IMMUNOGLOBULIN-E; POPULATION-SAMPLE; GENETIC-LINKAGE; IGE LEVELS; SERUM IGE; CHROMOSOME-11Q; ATOPY; POLYMORPHISM; ALLERGENS	ASTHMA now affects one child in seven in the United Kingdom(1). Most cases (95%) of childhood asthma are associated with atopy, the immunoglobulin E (IgE)-mediated familial syndrome of allergic asthma, eczema and rhinitis. Segregation analysis has consistently suggested the presence of major genes influencing atopy and IgE levels(2-4), with the expectation that these genes may be identified by positional cloning or the examination of candidate genes. Here we report the results of a genome wide search for linkage to one qualitative and four quantitative traits associated with allergic (atopic) asthma. We have identified six potential linkages (P < 0.001), five of which are to quantitative traits. Monte Carlo simulations show that 1.6 false-positive linkages at this level of significance would be expected from the data. One linkage, to chromosome 11q13, has been established previously(5). Three of the new loci show evidence of linkage to a second panel of families, in which maternal effects and pleiotropy of linked phenotypes are seen. The results demonstrate the extent and the complexity of the genetic predisposition to asthma.	UNIV OXFORD,WELLCOME TRUST CTR HUMAN GENET DIS,OXFORD OX3 7BN,ENGLAND; SIR CHARLES GAIRDNER HOSP,DEPT RESP MED,PERTH,WA,AUSTRALIA; RADCLIFFE INFIRM,CTSU,OXFORD OX2 6HE,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; PRINCESS MARGARET HOSP CHILDREN,UNIV DEPT PAEDIAT,PERTH,WA,AUSTRALIA	University of Oxford; Wellcome Centre for Human Genetics; University of Western Australia; Radcliffe Infirmary; University of Oxford; University of Oxford; University of Western Australia			Hill, Michael/C-4861-2008; Le Souef, Peter N/H-5256-2014; Cookson, William/HHC-1790-2022	Le Souef, Peter/0000-0003-0930-1654	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABERG N, 1993, CLIN EXP ALLERGY, V23, P829, DOI 10.1111/j.1365-2222.1993.tb00260.x; BORECKI I B, 1985, Genetic Epidemiology, V2, P327, DOI 10.1002/gepi.1370020402; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COLLEE JM, 1993, LANCET, V342, P936, DOI 10.1016/0140-6736(93)91988-X; COOKSON WOCM, 1988, LANCET, V1, P86; COOKSON WOCM, 1989, LANCET, V1, P1292; DIZIER MH, 1995, GENET EPIDEMIOL, V12, P93, DOI 10.1002/gepi.1370120109; EIBERG H, 1985, CYTOGENET CELL GENET, V40, P622; GERRARD JW, 1978, AM J HUM GENET, V30, P46; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; HERWERDEN L, 1995, LANCET, V346, P1262; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; HODGE S E, 1984, Genetic Epidemiology, V1, P109, DOI 10.1002/gepi.1370010203; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; KUEHR J, 1993, CLIN EXP ALLERGY, V23, P600, DOI 10.1111/j.1365-2222.1993.tb00900.x; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; MYERS DA, 1994, GENOMICS, V23, P464; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; OCONNOR GT, 1994, AM J RESP CRIT CARE, V149, pS21, DOI 10.1164/ajrccm/149.2_Pt_2.S21; PEAT JK, 1987, CLIN ALLERGY, V17, P271; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SHIRAKAWA T, 1994, CLIN GENET, V46, P125; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236	30	628	652	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					247	250		10.1038/383247a0	http://dx.doi.org/10.1038/383247a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805698				2022-12-24	WOS:A1996VH31500050
J	Wyttenbach, RA; May, ML; Hoy, RR				Wyttenbach, RA; May, ML; Hoy, RR			Categorical perception of sound frequency by crickets	SCIENCE			English	Article							FLYING CRICKETS; SPEECH-PERCEPTION; TELEOGRYLLUS-OCEANICUS; CALLING SONG; DISCRIMINATION; ULTRASOUND; PHONOTAXIS; ATTRACTION; AVOIDANCE; STIMULI	Partitioning continuously varying stimuli into categories is a fundamental problem of perception. One solution to this problem, categorical perception, is known primarily from human speech, but also occurs in other modalities and in some mammals and birds. Categorical perception was tested in crickets by using two paradigms of human psychophysics, labeling and habituation-dishabituation. The results show that crickets divide sound frequency categorically between attractive (<16 kilohertz) and repulsive (>16 kilohertz) sounds. There is sharp discrimination between these categories but no discrimination between different frequencies of ultrasound. This demonstration of categorical perception in an invertebrate suggests that categorical perception may be a basic and widespread feature of sensory systems, from humans to invertebrates.	CORNELL UNIV,NEUROBIOL & BEHAV SECT,ITHACA,NY 14853	Cornell University			Galantucci, Bruno/E-5770-2010	Wyttenbach, Robert/0000-0002-1681-9729	NIMH NIH HHS [K05-MH1148] Funding Source: Medline; OMHHE CDC HHS [T32-MN15793] Funding Source: Medline; ODCDC CDC HHS [R01-CD00103] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001148] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); OMHHE CDC HHS; ODCDC CDC HHS; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Boynton Robert M, 1975, HDB PERCEPTION, V5, P301; DOOLING RJ, 1990, PERCEPT PSYCHOPHYS, V47, P568, DOI 10.3758/BF03203109; EHRET G, 1987, CATEGORICAL PERCEPTI, pCH10; Herrnstein R. J., 1984, ANIMAL COGNITION, P233; KUHL PK, 1978, J ACOUST SOC AM, V63, P905, DOI 10.1121/1.381770; KUHL PK, 1981, J ACOUST SOC AM, V70, P340, DOI 10.1121/1.386782; LIBERMAN AM, 1961, J EXP PSYCHOL, V61, P379, DOI 10.1037/h0049038; LIBERMAN AM, 1967, PSYCHOL REV, V74, P431, DOI 10.1037/h0020279; LIBERSAT F, 1994, J COMP PHYSIOL A, V174, P485, DOI 10.1007/BF00191714; MATTINGLY IG, 1972, AM SCI, V60, P327; MAY ML, 1990, J EXP BIOL, V151, P485; MAY ML, 1988, J COMP PHYSIOL A, V164, P243, DOI 10.1007/BF00603954; MAY ML, 1991, J EXP BIOL, V159, P489; MILLER CL, 1976, J SPEECH HEAR RES, V19, P578, DOI 10.1044/jshr.1903.578; MILLER JD, 1976, J ACOUST SOC AM, V60, P410, DOI 10.1121/1.381097; MOISEFF A, 1978, P NATL ACAD SCI USA, V75, P4052, DOI 10.1073/pnas.75.8.4052; MORSE PA, 1975, PERCEPT PSYCHOPHYS, V17, P9, DOI 10.3758/BF03203991; NELSON DA, 1989, SCIENCE, V244, P976, DOI 10.1126/science.2727689; NOLEN TG, 1986, J COMP PHYSIOL A, V159, P423, DOI 10.1007/BF00604163; PASTORE RE, 1977, J EXP PSYCHOL HUMAN, V3, P686, DOI 10.1037/0096-1523.3.4.686; POLLACK GS, 1982, J COMP PHYSIOL, V146, P207, DOI 10.1007/BF00610239; POLLACK GS, 1981, J COMP PHYSIOL, V144, P367, DOI 10.1007/BF00612568; Rosch E., 1978, COGNITION CATEGORIZA, P27, DOI DOI 10.1037/0012-1649.16.5.391; STUDDERTKENNEDY M, 1970, PSYCHOL REV, V77, P234, DOI 10.1037/h0029078	24	146	149	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1996	273	5281					1542	1544		10.1126/science.273.5281.1542	http://dx.doi.org/10.1126/science.273.5281.1542			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8703214				2022-12-24	WOS:A1996VG59700038
J	Watson, N; Linder, ME; Druey, KM; Kehrl, JH; Blumer, KJ				Watson, N; Linder, ME; Druey, KM; Kehrl, JH; Blumer, KJ			RGS family members: GTPase-activating proteins for heterotrimeric G-protein alpha-subunits	NATURE			English	Article							LIPID MODIFICATIONS; CRYSTAL-STRUCTURE; BETA-GAMMA; MECHANISM; HYDROLYSIS; TRANSDUCIN; DEACTIVATION; DESENSITIZATION; INCREASES; AFFINITY	SIGNALLING pathways using heterotrimeric guanine-nucleotide-binding-proteins (G proteins) trigger physiological responses elicited by hormones, neurotransmitters and sensory stimuli(1,2) GTP binding activates G proteins by dissociating G alpha from G beta gamma subunits, and GTP hydrolysis by G alpha subunits deactivates G proteins by allowing heterotrimers to reform. However, deactivation of G-protein signalling pathways in vivo can occur 10- to 100-fold faster than the rate of GTP hydrolysis of G alpha subunits in vitro(3-8), suggesting that GTPase-activating proteins (GAPs) deactivate G alpha subunits. Here we report that RGS(9,10) (for regulator of G-protein signalling) proteins are GAPs for G alpha subunits. RGS1, RGS4 and GAIP (for G alpha-interacting protein(17)) bind specifically and tightly to G alpha(i) and G alpha(o) in cell membranes treated with GDP and AIF(4)(-), and are GAPs for G alpha(i), G alpha(o) and transducin alpha-subunits, but not for G alpha(s). Thus, these RGS proteins are likely to regulate a subset of the G-protein signalling pathways in mammalian cells. Our results provide insight into the mechanisms that govern the duration and specificity of physiological responses elicited by G-protein-mediated signalling pathways.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Linder, Maurine/AAU-9999-2021; Blumer, Kendall J/C-5268-2012; Kehrl, John/AAE-6292-2019	Linder, Maurine/0000-0003-2202-9712; Kehrl, John/0000-0002-6526-159X				ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; Breer H, 1992, Curr Opin Neurobiol, V2, P439, DOI 10.1016/0959-4388(92)90177-M; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DOHLMAN HG, 1996, J MOL CELL BIOL, V16, P5194; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HONG JX, 1993, J IMMUNOL, V150, P3895; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Pan JY, 1996, J BIOL CHEM, V271, P1322, DOI 10.1074/jbc.271.3.1322; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SHUI Z, 1995, J PHYSIOL-LONDON, V487, P359, DOI 10.1113/jphysiol.1995.sp020885; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; VUONG TM, 1990, NATURE, V346, P71, DOI 10.1038/346071a0; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	30	472	476	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					172	175		10.1038/383172a0	http://dx.doi.org/10.1038/383172a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774882				2022-12-24	WOS:A1996VG14800053
J	Annas, GJ				Annas, GJ			The promised end - Constitutional aspects of physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; Baron CH, 1996, HARVARD J LEGIS, V33, P1; Cantor NL, 1996, KENNEDY INST ETHIC J, V6, P107; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Glantz L H, 1987, Law Med Health Care, V15, P231; Kamisar Yale, 1995, Univ Detroit Mercy Law Rev, V72, P735; Preston T. A., 1996, J PHARM CARE PAIN SY, V4, P183; Sontag S, 1988, AIDS ITS METAPHORS; *STAT TASK FORC LI, 1994, DEATH SOUGHT ASS SUI; Wolf S M, 1989, Hastings Cent Rep, V19, P13, DOI 10.2307/3561964; 1995, JAMA-J AM MED ASSOC, V274, P1591	12	36	36	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					683	687		10.1056/NEJM199608293350924	http://dx.doi.org/10.1056/NEJM199608293350924			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VD425	8687526	Green Published			2022-12-24	WOS:A1996VD42500030
J	Macarthur, C; Macarthur, A; Weeks, S				Macarthur, C; Macarthur, A; Weeks, S			Accuracy of recall of back pain after delivery	BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM BACKACHE; EPIDURAL-ANESTHESIA; CHILDBIRTH		WOMENS COLL HOSP,TORONTO,ON M5S 1B2,CANADA; ROYAL VICTORIA HOSP,MONTREAL,PQ H3A 1A1,CANADA	University of Toronto; University Toronto Affiliates; Womens College Hospital; McGill University; Royal Victoria Hospital	Macarthur, C (corresponding author), HOSP SICK CHILDREN,DIV GEN PAEDIAT,PAEDIAT OUTCOMES RES TEAM,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.		MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158				COUGHLIN SS, 1990, J CLIN EPIDEMIOL, V43, P87, DOI 10.1016/0895-4356(90)90060-3; Fleiss JL., 1981, STAT METHODS RATES P, V2, P22; MACARTHUR A, 1995, BRIT MED J, V311, P1336, DOI 10.1136/bmj.311.7016.1336; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; RUSSELL R, 1993, BRIT MED J, V306, P1299, DOI 10.1136/bmj.306.6888.1299	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					467	467						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776316				2022-12-24	WOS:A1996VE08000023
J	Deschamps, MM; Pape, JW; Hafner, A; Johnson, WD				Deschamps, MM; Pape, JW; Hafner, A; Johnson, WD			Heterosexual transmission of HIV in Haiti	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; WOMAN SEXUAL TRANSMISSION; COUPLES; RISK; SEROCONVERSION; HEMOPHILIA; INFECTION; BEHAVIOR; PARTNERS; MEN	Background: Despite the importance of human immunodeficiency virus (HIV) transmission through heterosexual contact, the incidence of HIV infection in heterosexual cohorts has not been well studied, particularly in the developing world. Objective: To 1) determine the incidence of HIV infection in discordant heterosexual couples (couples in which one partner had HIV infection and the other did not) in Haiti and 2) assess risk factors for and methods of preventing HIV infection. Design: Prospective study. Setting: National Institute for Laboratory Research, Port-au-Prince, Haiti. Participants: 475 HIV-infected patients and their noninfected regular sex partners. Measurements: Patients and their partners were evaluated at 3- to 6-month intervals for HIV infection, sexually transmitted diseases, and sexual practices. The efficacy of counseling and provision of free condoms was also evaluated. Results: Among the 177 couples who remained sexually active during the prospective study period, 20 seroconversions to HIV positivity occurred, for an incidence rate of 5.4 per 100 person-years (95% CI 5.16 to 5.64 per 100 person-years). Thirty-eight couples (21.5%) discontinued sexual activity during the study. Only 1 seroconversion occurred among the 42 sexually active couples (23.7% of the 177 sexually active couples) who always used condoms. In contrast, the incidence in sexually active couples who infrequently used or did not use condoms was 6.8 per 100 person-years (CI, 6.49 to 7.14 per 100 person-years). Transmission of HIV was associated with genital ulcer disease, syphilis, and vaginal or penile discharge in the HIV-negative partner and with syphilis in the HIV-infected partner. Conclusion: Counseling and the provision of free condoms contributed to the institution of safe sex practices or abstinence in 45% of discordant heterosexual couples. However, 55% of couples reported that they continued to have unprotected sex, resulting in an incidence of HIV infection of 6.8 per 100 person-years.	CORNELL UNIV MED COLL, DIV INT MED & INFECT DIS, NEW YORK, NY 10021 USA; GHESKIO, PORT AU PRINCE, HAITI	Cornell University					FIC NIH HHS [D43 TW00018] Funding Source: Medline; NIAID NIH HHS [R37 AI22624] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022624] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; BULTERYS M, 1989, LANCET, V2, P977; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; DEVINCENZI I, 1992, BRIT MED J, V304, P809; DEVINCENZI I, 1989, BRIT MED J, V298, P411; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; JOHNSON AM, 1988, AIDS S1, V2, P549; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; LAGA M, 1994, AIDS, V8, P5119; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; Pape JW, 1988, BAILLIERE CLIN TROP, V3, P31; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; RAGNI MV, 1989, J ACQ IMMUN DEF SYND, V2, P557; SARACCO A, 1993, J ACQ IMMUN DEF SYND, V6, P497; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414; 1987, MMWR-MORBID MORTAL W, V36, pSU	20	107	110	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					324	330		10.7326/0003-4819-125-4-199608150-00011	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB680	8678397	Green Published			2022-12-24	WOS:A1996VB68000014
J	Schacker, T; Collier, AC; Hughes, J; Shea, T; Corey, L				Schacker, T; Collier, AC; Hughes, J; Shea, T; Corey, L			Clinical and epidemiologic features of primary HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus infections; human immunodeficiency virus seropositivity; sexual partners; sex behavior; sexually transmitted diseases, viral	HUMAN-IMMUNODEFICIENCY-VIRUS; HOMOSEXUAL BISEXUAL MEN; SEXUAL-BEHAVIOR; ORAL INTERCOURSE; RISK-FACTORS; SEROCONVERSION; PLASMA; TYPE-1; TRANSMISSION; COHORT	Background: The acute clinical events surrounding the acquisition of human immunodeficiency virus (HIV) have not been well characterized. Objective: To further define the clinical and epidemiologic presentation of primary HIV infection. Design: Descriptive cohort study. Setting: University research clinic. Patients: 46 adults (43 men and 3 women) with primary HIV infection who enrolled in the study a median of 51 days after HIV seroconversion. Measurements: Documentation of recent HIV seroconversion. Standardized collection of demographic characteristics and sexual contact history, results of tests for HIV RNA, HIV culture, and T-cell subsets. Results: 41 of 46 patients (89%) developed an acute retroviral syndrome. Primary HIV infection was infrequently diagnosed at the initial medical encounter, even in persons enrolled in routine HIV screening programs. Median numbers of sexual partners 6 months and 1 month before acquisition of HIV were three and one, respectively; 21 patients (46%) reported having had only one partner in the month before seroconversion. Of the 12 patients who could identify the precise date of and activity leading to seroconversion, 4 reported having only oral-genital contact. Conclusions: Primary HIV infection causes a recognizable clinical syndrome that is often underdiagnosed, even in persons enrolled in a program of routine surveillance for HIV infection. Frequency of sexual contact and overall numbers of sexual partners in this group of homosexual men who acquired HIV were markedly lower than those seen a decade ago. Acquisition of HIV does occur, even in persons with relatively few sexual partners. Increased attention to oral-genital contact as a means of acquiring HIV appears to be warranted.	UNIV WASHINGTON, DIV VIROL, SEATTLE, WA 98144 USA	University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27757, AI-45206] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COLLIER AC, 1990, NEW ENGL J MED, V323, P1015, DOI 10.1056/NEJM199010113231502; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172; HENRARD DR, 1994, TRANSFUSION, V34, P376, DOI 10.1046/j.1537-2995.1994.34594249046.x; KEET IPM, 1992, AIDS, V6, P223, DOI 10.1097/00002030-199202000-00014; KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008; KINGSLEY LA, 1987, LANCET, V1, P345; LANE HC, 1991, AM J PUBLIC HEALTH, V81, P658, DOI 10.2105/AJPH.81.5.658; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; LO B, 1989, ANN INTERN MED, V110, P727; LOES SK, 1995, NEW ENGL J MED, V333, P408; MAAYAN S, 1993, ISRAEL J PSYCHIAT, V30, P150; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MURRAY AB, 1991, LANCET, V338, P830, DOI 10.1016/0140-6736(91)90726-6; PACHL C, 1995, J ACQ IMMUN DEF SYND, V8, P446, DOI 10.1097/00042560-199504120-00003; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; PIATAK M, 1993, LANCET, V341, P1099, DOI 10.1016/0140-6736(93)92463-4; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; ROZENBAUM W, 1988, LANCET, V1, P1395; SCHECHTER MT, 1988, AM J PUBLIC HEALTH, V78, P1535, DOI 10.2105/AJPH.78.12.1535; SCHWARCZ SK, 1995, AM J EPIDEMIOL, V142, P314, DOI 10.1093/oxfordjournals.aje.a117637; SEAGE GR, 1993, AM J EPIDEMIOL, V137, P899, DOI 10.1093/oxfordjournals.aje.a116751; SINICCO A, 1993, J ACQ IMMUN DEF SYND, V6, P575; STEVENS CE, 1986, JAMA-J AM MED ASSOC, V255, P2167, DOI 10.1001/jama.255.16.2167; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; VANGRIENSVEN GJP, 1989, BMJ-BRIT MED J, V298, P218, DOI 10.1136/bmj.298.6668.218; VANGRIENSVEN GJP, 1987, AM J EPIDEMIOL, V125, P1048, DOI 10.1093/oxfordjournals.aje.a114620; VANGRIENSVEN GJP, 1988, AM J PUBLIC HEALTH, V78, P1575, DOI 10.2105/AJPH.78.12.1575; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; WINKELSTEIN W, 1988, AM J PUBLIC HEALTH, V78, P1472, DOI 10.2105/AJPH.78.11.1472	32	513	526	2	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1996	125	4					257	+		10.7326/0003-4819-125-4-199608150-00001	http://dx.doi.org/10.7326/0003-4819-125-4-199608150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VB680	8678387				2022-12-24	WOS:A1996VB68000004
J	Greer, DL				Greer, DL			Treatment of symptom-free carriers in management of tinea capitis	LANCET			English	Editorial Material							STATE; EPIDEMIOLOGY; SCALP				Greer, DL (corresponding author), LOUISIANA STATE UNIV,DEPT DERMATOL,NEW ORLEANS,LA 70112, USA.							BABEL DE, 1989, J AM ACAD DERMATOL, V21, P1209, DOI 10.1016/S0190-9622(89)70331-5; BABEL DE, 1990, MYCOPATHOLOGIA, V109, P69, DOI 10.1007/BF00436787; FRIEDEN IJ, 1994, J AM ACAD DERMATOL, V31, pS42, DOI 10.1016/S0190-9622(08)81266-2; HOWARD R, 1995, SEMIN DERMATOL, V14, P2, DOI 10.1016/S1085-5629(05)80032-X; MACKENZIE D.W.R., 1961, SABOURAUDIA, V1, P58; NEIL G, 1990, PEDIATR INFECT DIS J, V9, P57, DOI 10.1097/00006454-199001000-00013; WILLIAMS JV, 1995, PEDIATRICS, V96, P265	7	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					350	351		10.1016/S0140-6736(05)64987-2	http://dx.doi.org/10.1016/S0140-6736(05)64987-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709729				2022-12-24	WOS:A1996VB42600005
J	Hedstrom, J; Sainio, V; Kemppainen, E; Haapiainen, R; Kivilaakso, E; Schroder, T; Leinonen, J; Stenman, UH				Hedstrom, J; Sainio, V; Kemppainen, E; Haapiainen, R; Kivilaakso, E; Schroder, T; Leinonen, J; Stenman, UH			Serum complex of trypsin 2 and alpha(1) antitrypsin as diagnostic and prognostic marker of acute pancreatitis: Clinical study in consecutive patients	BRITISH MEDICAL JOURNAL			English	Article							PERITONEAL-LAVAGE; SEVERITY; ASSAYS; TRIAL	Objective-To estimate the usefulness of serum concentrations of the complex of trypsin 2 and alpha(1) antitrypsin in diagnosing and assessing the severity of acute pancreatitis in comparison with serum C reactive protein, amylase, and trypsinogen 2 concentrations (reference markers). Design-Markers were measured in consecutive patients admitted with acute abdominal pain that was either due to pancreatitis or to other disease unrelated to the pancreas (controls). Setting-Department of surgery of a teaching hospital in Helsinki. Subjects-110 patients with acute pancreatitis and 66 with acute abdominal diseases of extrapancreatic origin. On the basis of the clinical course, acute pancreatitis was classified as mild (82 patients) or severe (28 patients). Main outcome measures-Clinical diagnosis of acute pancreatitis and severity of the disease. Results-At admission all patients with acute pancreatitis had clearly raised concentrations of trypsin 2-alpha(1) antitrypsin complex (32 mu g/l), whereas only three of the controls had such values. Of the markers studied, trypsin 2-alpha(1) antitrypsin complex had the largest area under the receiver operating curve, both in differentiating acute pancreatitis from extrapancreatic disease and in differentiating mild from severe disease. Conclusions-Of the markers studied, trypsin 2-alpha(1) antitrypsin complex was the most accurate in differentiating between acute pancreatitis and extrapancreatic disease and in predicting a severe course for acute pancreatitis.	HELSINKI UNIV,CENT HOSP,DEPT CLIN CHEM,FIN-00290 HELSINKI,FINLAND; HELSINKI UNIV,CENT HOSP,DEPT SURG 2,FIN-00290 HELSINKI,FINLAND; HELSINKI UNIV,CENT HOSP,DEPT SURG,FIN-00290 HELSINKI,FINLAND	University of Helsinki; University of Helsinki; University of Helsinki								BLOCK S, 1986, GUT, V27, P1035, DOI 10.1136/gut.27.9.1035; BORGSTROM A, 1978, EUR J CLIN INVEST, V8, P379, DOI 10.1111/j.1365-2362.1978.tb00868.x; CORFIELD AP, 1985, GUT, V26, P724, DOI 10.1136/gut.26.7.724; DAMMANN HG, 1980, LANCET, V2, P860; DURIE PR, 1982, J PEDIATR GASTR NUTR, V1, P337, DOI 10.1097/00005176-198201030-00010; FISCHER CL, 1976, AM J CLIN PATHOL, V66, P840; GUDGEON AM, 1990, LANCET, V335, P4, DOI 10.1016/0140-6736(90)90135-R; HEDSTROM J, 1994, CLIN CHEM, V40, P1761; IMRIE CW, 1978, BRIT J SURG, V65, P337, DOI 10.1002/bjs.1800650514; ITKONEN O, 1990, J LAB CLIN MED, V115, P712; KIVISAARI L, 1984, GASTROINTEST RADIOL, V9, P27, DOI 10.1007/BF01887796; KOIVUNEN E, 1990, CANCER RES, V50, P2375; LASSON A, 1984, SCAND J GASTROENTERO, V19, P779, DOI 10.1080/00365521.1984.12005808; LEVITT RG, 1978, RADIOLOGY, V126, P149, DOI 10.1148/126.1.149; MAYER AD, 1985, NEW ENGL J MED, V312, P399, DOI 10.1056/NEJM198502143120703; OHISSON K, 1988, ACTA GASTROENTEROL B, V51, P3; OHLSSON K, 1975, GASTROENTEROLOGY, V69, P668; RANSON JHC, 1978, ANN SURG, V187, P565, DOI 10.1097/00000658-197805000-00016; SALT WB, 1976, MEDICINE, V55, P269, DOI 10.1097/00005792-197607000-00001; STEINBERG WM, 1985, ANN INTERN MED, V102, P576, DOI 10.7326/0003-4819-102-5-576; WILLIAMSON RCN, 1984, GUT, V25, P1331, DOI 10.1136/gut.25.12.1331; ZWEIG MH, 1993, CLIN CHEM, V39, P561	22	73	74	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 10	1996	313	7053					333	337		10.1136/bmj.313.7053.333	http://dx.doi.org/10.1136/bmj.313.7053.333			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760740	Green Published			2022-12-24	WOS:A1996VC30000018
J	Smith, IE				Smith, IE			Prophylactic cranial irradiation for small-cell lung cancer	LANCET			English	Editorial Material											Smith, IE (corresponding author), ROYAL MARSDEN NHS TRUST,LUNG UNIT,DOWNS RD,SUTTON SM2 5PT,SURREY,ENGLAND.							GREGOR A, 1996, P AN M AM SOC CLIN, V15, P381; HARDY J, 1990, BRIT J CANCER, V62, P684, DOI 10.1038/bjc.1990.357; JOHNSON BE, 1985, J CLIN ONCOL, V3, P1659, DOI 10.1200/JCO.1985.3.12.1659; KOMAKI R, 1993, P AN M AM SOC CLIN, V12, P1084; LUCAS CF, 1986, CANCER TREAT REP, V70, P565; Work E, 1996, EUR J CANCER, V32A, P772, DOI 10.1016/0959-8049(95)00597-8	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					350	350		10.1016/S0140-6736(05)64986-0	http://dx.doi.org/10.1016/S0140-6736(05)64986-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709728				2022-12-24	WOS:A1996VB42600004
J	Steigman, DM				Steigman, DM			Is it ''urban'' or is it ''asthma''?	LANCET			English	Editorial Material									ST VINCENT HOSP,WORCESTER,MA 01606		Steigman, DM (corresponding author), FALLON CLIN INC,DEPT PULM,WORCESTER,MA 01606, USA.							GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; Hartert TV, 1996, AM J MED, V100, P386, DOI 10.1016/S0002-9343(97)89513-7; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546, DOI 10.1093/oxfordjournals.aje.a117470; *US DHHS, 1991, DHHS PUBL	4	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					143	144		10.1016/S0140-6736(05)66107-7	http://dx.doi.org/10.1016/S0140-6736(05)66107-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684151				2022-12-24	WOS:A1996UX78900006
J	Ahima, RS; Prabakaran, D; Mantzoros, C; Qu, DQ; Lowell, B; MaratosFlier, E; Flier, JS				Ahima, RS; Prabakaran, D; Mantzoros, C; Qu, DQ; Lowell, B; MaratosFlier, E; Flier, JS			Role of leptin in the neuroendocrine response to fasting	NATURE			English	Article							FOOD-DEPRIVATION; SECRETION; RAT	A TOTAL deficiency in or resistance to the protein leptin causes severe obesity(1-4). As leptin levels rise with increasing adiposity in rodents(5) and man(6,7), it is proposed to act as a negative feedback 'adipostatic signal' to brain centres controlling energy homeostasis, limiting obesity in times of nutritional abundance(1,3). Starvation is also a threat to homeostasis that triggers adaptive responses(8-12), but whether leptin plays a role in the physiology of starvation is unknown. Leptin concentration falls during starvation(13) and totally leptin-deficient ob/ob mice have neuroendocrine abnormalities similar to those of starvation(14), suggesting that this may be the case. Here we show that preventing the starvation-induced fall in leptin with exogenous leptin substantially blunts the changes in gonadal, adrenal and thyroid axes in male mice, and prevents the starvation-induced delay in ovulation in female mice. In contrast, leptin repletion during this period of starvation has little or no effect on body weight, blood glucose or ketones. We propose that regulation of the neuroendocrine system during starvation could be the main physiological role of leptin.	BETH ISRAEL HOSP,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.			Mantzoros, Christos/Y-2902-2019; Flier, jeffrey/AAG-6223-2019; Ahima, Rexford/W-1394-2019					BATES GW, 1985, CLIN OBSTET GYNECOL, V28, P632; BRAY GA, 1990, FRONT NEUROENDOCRIN, V11, P128; BRONSON FH, 1985, BIOL REPROD, V33, P660, DOI 10.1095/biolreprod33.3.660; CAHILL GF, 1966, J CLIN INVEST, V45, P1751, DOI 10.1172/JCI105481; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHEBAB FF, 1996, NAT GENET, V12, P318; CONNORS JM, 1985, ENDOCRINOLOGY, V117, P900, DOI 10.1210/endo-117-3-900; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; COOPER RL, 1984, ENDOCRINOLOGY, V114, P391, DOI 10.1210/endo-114-2-391; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Pierroz DD, 1996, ENDOCRINOLOGY, V137, P3, DOI 10.1210/en.137.1.3; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; SCHREIHOFER DA, 1993, ENDOCRINOLOGY, V132, P1890, DOI 10.1210/en.132.5.1890; SCHWARTZ MW, 1995, AM J PHYSIOL-REG I, V269, pR949, DOI 10.1152/ajpregu.1995.269.5.R949; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; WHITE J D, 1990, Molecular and Cellular Neuroscience, V1, P41; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	24	2523	2580	5	166	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					250	252		10.1038/382250a0	http://dx.doi.org/10.1038/382250a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717038				2022-12-24	WOS:A1996UX79000048
J	Dernburg, AF; Sedat, JW; Hawley, RS				Dernburg, AF; Sedat, JW; Hawley, RS			Direct evidence of a role for heterochromatin in meiotic chromosome segregation	CELL			English	Article							DROSOPHILA-MELANOGASTER FEMALES; KINESIN-LIKE PROTEIN; SYNAPTONEMAL COMPLEX; ACHIASMATE SEGREGATION; RECOMBINATION NODULES; WILD-TYPE; DISTRIBUTIVE SEGREGATION; GENETIC-ANALYSIS; SATELLITE DNA; MICROSCOPY	We have investigated the mechanism that enables achiasmate chromosomes to segregate from each other at meiosis I in D. melanogaster oocytes. Using novel cytological methods, we asked whether nonexchange chromosomes are paired prior to disjunction. Our results show that the heterochromatin of homologous chromosomes remains associated throughout prophase until metaphase I regardless of whether they undergo exchange, suggesting that homologous recognition can lead to segregation even in the absence of chiasmata. However, partner chromosomes lacking homology do not pair prior to disjunction. Furthermore, euchromatic synapsis is not maintained throughout prophase. These observations provide a physical demonstration that homologous and heterologous achiasmate segregations occur by different mechanisms and establish a role for heterochromatin in maintaining the alignment of chromosomes during meiosis.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF DAVIS, SECT MOL & CELLULAR BIOL, DEPT GENET, DAVIS, CA 95616 USA	University of California System; University of California San Francisco; University of California System; University of California Davis				Hawley, R. Scott/0000-0002-6478-0494; Dernburg, Abby/0000-0001-8037-1079				ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Bridges CB, 1925, GENETICS, V10, P418; BRITTNACHER JG, 1989, GENETICS, V121, P739; CARMENA M, 1993, J CELL SCI, V105, P41; CARPENTER AT, 1973, GENETICS, V73, P393; CARPENTER ATC, 1975, CHROMOSOMA, V51, P157, DOI 10.1007/BF00319833; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1981, CHROMOSOMA, V83, P59, DOI 10.1007/BF00286016; CARPENTER ATC, 1979, GENETICS, V92, P511; Chen H, 1996, J STRUCT BIOL, V116, P56, DOI 10.1006/jsbi.1996.0010; COMINGS DE, 1980, HUM GENET, V53, P131, DOI 10.1007/BF00273484; DEMBURG AF, 1996, CELL, V85, P745; DREIBIN RA, 1986, COMPUT GRAPH, V22, P65; GERSHENSON S, 1940, VIDENSK AKAD NAUK UR, V3, P3; Grell R. F., 1976, GENET BIOL DROSOPHIL, VIa, P435; GRELL RF, 1962, P NATL ACAD SCI USA, V48, P165, DOI 10.1073/pnas.48.2.165; GRELL RF, 1962, GENETICS, V50, P150; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; HAWLEY RS, 1993, ANNU REV GENET, V27, P281; HAWLEY RS, 1993, TRENDS GENET, V9, P310; HAWLEY RS, 1992, DEV GENET, V13, P440, DOI 10.1002/dvg.1020130608; Heitz E, 1928, JAHRB WISS BOT, V69, P762; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; HSIEH T, 1979, J MOL BIOL, V135, P465, DOI 10.1016/0022-2836(79)90447-9; King R. C., 1970, OVARIAN DEV DROSOPHI; LINDSLEY DL, 1992, GENOME DROSOPHILIA M; LOHE AR, 1993, GENETICS, V134, P1149; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MAHOWALD AP, 1970, ROUX ARCH DEV BIOL, V165, P8; MAHOWALD AP, 1980, GENET BIOL DROSOPHIL, P141; MAKUNIN IV, 1995, DOKL AKAD NAUK+, V344, P266; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; Merriam J., 1968, DROS INFORM SERV, V43, P64; NICKLAS RB, 1977, PHILOS T ROY SOC B, V277, P267, DOI 10.1098/rstb.1977.0017; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; NOKKALA S, 1976, HEREDITAS, V83, P265; NOVITSKI E, 1964, GENETICS, V50, P1449; NOVITSKI E, 1981, GENETICS, V98, P257; NOVITSKI E, 1976, GENET BIOL DROSOPHIL, P562; OTOUSA J, 1982, GENETICS, V102, P503; PARDUE ML, 1977, CHROMOSOMA, V63, P135, DOI 10.1007/BF00292726; PARDUE ML, 1990, CHROMOSOMA, V100, P3, DOI 10.1007/BF00337597; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PIMPINELLI S, 1989, GENETICS, V121, P765; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; PURO J, 1977, CHROMOSOMA, V63, P273, DOI 10.1007/BF00327454; Rabl C, 1885, MORPHOL JB, V10, P214; SANDLER L, 1956, GENETICS, V41, P189; Sturtevant AH, 1936, GENETICS, V21, P554; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; Weinstein A, 1936, GENETICS, V21, P155; WHYTE WL, 1993, GENETICS, V134, P825; WOLF KW, 1994, BIOESSAYS, V16, P107, DOI 10.1002/bies.950160207; WU CI, 1988, CELL, V54, P179, DOI 10.1016/0092-8674(88)90550-8; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZITRON AE, 1989, GENETICS, V122, P801	60	293	297	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					135	146		10.1016/S0092-8674(00)80084-7	http://dx.doi.org/10.1016/S0092-8674(00)80084-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689681	Bronze			2022-12-24	WOS:A1996UX93400015
J	Penton, A; Hoffmann, FM				Penton, A; Hoffmann, FM			Decapentaplegic restricts the domain of wingless during Drosophila limb patterning	NATURE			English	Article							IMAGINAL DISKS; GENE; EXPRESSION	SIGNALLING proteins in the BMP-decapentaplegic (dpp), WNT-wingless (wg) and Shh-hedgehog (hh) families have been implicated in Limb and appendage development in both invertebrates and vertebrates(1-3), In Drosophila, dpp protein (Dpp) induces distal outgrowth and patterning of legs and wings, but the molecular responses to Dpp are not well characterized(4-9). Analysis of clones mutant for the Dpp receptors encoded by punt or thickveins (tkv) reveals that repression of wg expression is one critical function of Dpp signalling in leg and wing discs. Distal clones that lie on the anterior edge of the anterior-posterior compartment boundary ectopically express wg and cause pattern abnormalities, suggesting that Dpp represses Hh activation of wg in the distal primordia of the leg and wing. By repressing Hg expression in the leg, Dpp signalling limits the region that responds to high levels of Wg and Dpp to the site of distal outgrowth. Such negative regulatory feedback loops between signalling molecules are likely to be critical for limb patterning in other species.	UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,GENET LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Hoffmann, F. Michael/0000-0002-2770-9656				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPBELL G, 1995, DEVELOPMENT, V121, P619; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; INGHAM PW, 1993, DEVELOPMENT, V117, P283; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; WILDER EL, 1995, DEVELOPMENT, V121, P477; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; XU T, 1993, DEVELOPMENT, V117, P1223; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X; ZECCA M, 1995, DEVELOPMENT, V121, P2265	29	92	93	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					162	165		10.1038/382162a0	http://dx.doi.org/10.1038/382162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700205				2022-12-24	WOS:A1996UW67200048
J	Catanzaro, A				Catanzaro, A			Value of direct amplified test for diagnosis of tuberculosis	LANCET			English	Editorial Material											Catanzaro, A (corresponding author), UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92103, USA.							BATES JH, 1979, CHEST, V76, P757, DOI 10.1378/chest.76.6.757; Catanzaro A., 1994, Tubercle and Lung Disease, V75, P36, DOI 10.1016/0962-8479(94)90814-1; CHIN DP, 1995, AM J RESP CRIT CARE, V151, P1872, DOI 10.1164/ajrccm.151.6.7767534; Condos R, 1996, LANCET, V347, P1082, DOI 10.1016/S0140-6736(96)90281-0; Pfyffer GE, 1996, J CLIN MICROBIOL, V34, P834, DOI 10.1128/JCM.34.4.834-841.1996; SMALL PM, 1993, J CLIN MICROBIOL, V31, P1677, DOI 10.1128/JCM.31.7.1677-1682.1993	6	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1500	1501		10.1016/S0140-6736(96)90666-2	http://dx.doi.org/10.1016/S0140-6736(96)90666-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684097				2022-12-24	WOS:A1996UN47300005
J	Chambers, CD; Johnson, KA; Dick, LM; Felix, RJ; Jones, KL				Chambers, CD; Johnson, KA; Dick, LM; Felix, RJ; Jones, KL			Birth outcomes in pregnant women taking fluoxetine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXPOSURE; NEWBORN	Background Although fluoxetine is the most frequently prescribed antidepressant drug in the United States, its safety in pregnant women has nor been established. Methods From 1989 through 1995, we prospectively identified 228 pregnant women taking fluoxetine. We compared the outcomes of their pregnancies with those of 254 women identified in a similar manner who were not taking fluoxetine. Results The rate of spontaneous pregnancy loss did not differ significantly between the women treated with fluoxetine and the control women (10.5 percent and 9.1 percent, respectively), nor was the rate of major structural anomalies significantly different (5.5 percent vs. 4.0 percent). Among the 97 infants exposed to fluoxetine who were evaluated for minor anomalies, the incidence of three or more minor anomalies was significantly higher than among 153 similarly examined control infants (15.5 percent vs. 6.5 percent, P=0.03). As compared with the 101 infants exposed to fluoxetine only during the first and second trimesters, the 73 infants exposed during the third trimester had higher rates of premature delivery (relative risk, 4.8; 95 percent confidence interval, 1.1 to 20.8), admission to special-care nurseries (relative risk, 2.6; 95 percent confidence interval, 1.1 to 6.9), and poor neonatal adaptation, including respiratory difficulty, cyanosis on feeding, and jitteriness (relative risk, 8.7; 95 percent confidence interval, 2.9 to 26.6). Birth weight was also lower and birth length shorter in infants exposed to fluoxetine late in gestation. Conclusions Women who take fluoxetine during pregnancy do not have an increased risk of spontaneous pregnancy loss or major fetal anomalies, but women who take fluoxetine in the third trimester are at increased risk for perinatal complications. (C) 1996, Massachusetts Medical Society.	UNIV CALIF SAN DIEGO, MED CTR, DEPT PEDIAT 8446, DIV DYSMORPHOL & TERATOL, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego				Chambers, Christina D/0000-0003-4675-7722				ABRAMS, 1986, AM J OBSTET GYNECOL, V155, P918; ABRAMS BF, 1986, AM J OBSTET GYNECOL, V154, P503, DOI 10.1016/0002-9378(86)90591-0; BERKOWITZ GS, 1993, EPIDEMIOL REV, V15, P414, DOI 10.1093/oxfordjournals.epirev.a036128; GOLDSTEIN DJ, 1995, J CLIN PSYCHOPHARM, V15, P417, DOI 10.1097/00004714-199512000-00005; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; Hollingshead AB, 1965, 2 FACTOR INDEX SOCIA; LEPPIG KA, 1987, J PEDIATR-US, V110, P531, DOI 10.1016/S0022-3476(87)80543-7; MARDEN PM, 1964, J PEDIATR-US, V64, P357, DOI 10.1016/S0022-3476(64)80188-8; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; ROSA F, 1994, REPROD TOXICOL, V8, P531, DOI 10.1016/0890-6238(94)90036-1; VORHEES CV, 1994, FUND APPL TOXICOL, V23, P194, DOI 10.1006/faat.1994.1098; WALSHSUKYS MC, 1993, CLIN PERINATOL, V20, P127, DOI 10.1016/S0095-5108(18)30415-9; 1995, DRUG FACTS COMP	13	538	544	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1010	1015		10.1056/NEJM199610033351402	http://dx.doi.org/10.1056/NEJM199610033351402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8793924				2022-12-24	WOS:A1996VL45900002
J	Lerer, LB; Matzopoulos, R				Lerer, LB; Matzopoulos, R			Meeting the challenge of railway injury in a South African city	LANCET			English	Article							SUICIDE; EPIDEMIOLOGY; FATALITIES	Background Efficient and safe transport infrastructure is vital for economic growth in developing countries. The city of Cape Town, South Africa, has an extensive rail network with high levels of injury and violence. We investigated the reporting and frequency of railway injuries and examined their reduction through a range of interventions. Methods We analysed railway injury and death reporting by Cape Town's rail utility, state mortuaries, and a regional trauma survey. The data were obtained over 2.5 years, and the use of more than one data source was necessary to increase the size of the data pool and to determine underreporting. Findings There were 379 railway-related deaths and 505 serious injuries during the study period. Most deaths (190) were train-pedestrian collisions, and the fatality rate on the metropolitan lines was about 60 per 100 million passenger journeys. There was substantial under-reporting by the rail utility of both fatal (20% under-reported) and non-fatal injuries (at least 24%). Many injuries occurred during peak commuting times and alcohol played an important part, especially in pedestrian fatalities. Interpretation Our results demonstrate the importance of a comprehensive, sustainable railway injury surveillance system to promote safety engineering and law enforcement in a metropolitan rail system.			Lerer, LB (corresponding author), MRC,COMMUNITY HLTH RES GRP,POB 19070,ZA-7505 TYGERBERG,SOUTH AFRICA.		Matzopoulos, Richard/AAL-9965-2021	Matzopoulos, Richard/0000-0001-9063-6210				BESKOW J, 1994, SOC SCI MED, V38, P447, DOI 10.1016/0277-9536(94)90446-4; *BRIT MED ASS, 1987, BRIT MED ASS GUID, P82; CINA SJ, 1994, J FORENSIC SCI, V39, P668; CLARKE RV, 1994, SOC SCI MED, V38, P443, DOI 10.1016/0277-9536(94)90445-6; DEKOCK C, 1993, FOCUS, V2, P8; HADDON W, 1980, PUBLIC HEALTH REP, V95, P411; LERER LB, 1995, 1994 S AFR MED RES C; MONK M, 1987, EPIDEMIOL REV, V9, P51, DOI 10.1093/oxfordjournals.epirev.a036308; ODONNELL I, 1994, SOC SCI MED, V38, P409, DOI 10.1016/0277-9536(94)90440-5; ODONNELL I, 1994, SOC SCI MED, V38, P437, DOI 10.1016/0277-9536(94)90444-8; PIRIE GH, 1991, APARTHEID CITY URBAN, P172; SCHMIDTKE A, 1994, SOC SCI MED, V38, P419, DOI 10.1016/0277-9536(94)90441-3; SINGER M, 1988, S AFR MED J, V73, P87; SONNECK G, 1994, SOC SCI MED, V38, P453, DOI 10.1016/0277-9536(94)90447-2; SYMONDS RL, 1994, SOC SCI MED, V38, P431, DOI 10.1016/0277-9536(94)90443-X; Tshabangu Mango, 1978, STAFFRIDER, V1, P27; *URB PROBL RES UN, 1990, 43 UPRU; WARD NJ, 1995, ACCIDENT ANAL PREV, V27, P185, DOI 10.1016/0001-4575(94)00057-S; *WORLD BANK, 1933, 1993 WORLD BANK	19	32	33	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					664	666		10.1016/S0140-6736(96)02100-9	http://dx.doi.org/10.1016/S0140-6736(96)02100-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782759				2022-12-24	WOS:A1996VF60900014
J	Kawabata, S; Tsutsumi, R; Kohara, A; Yamaguchi, T; Nakanishi, S; Okada, M				Kawabata, S; Tsutsumi, R; Kohara, A; Yamaguchi, T; Nakanishi, S; Okada, M			Control of calcium oscillations by phosphorylation of metabotropic glutamate receptors	NATURE			English	Article							PROTEIN-KINASE-C; INOSITOL TRISPHOSPHATE; SUBSTRATE-SPECIFICITY; SIGNAL TRANSDUCTION; PHORBOL ESTERS; HAMSTER EGGS; CELLS; EXPRESSION; ACTIVATION; ASTROCYTES	STIMULATION of two metabotropic glutamate-receptor subtypes, mGluR1 and mGluR5, triggers the release of Ca2+ from intracellular stores through the inositol-(1,4,5)trisphosphate (InsP(3)) pathway(1-3). Here rye report that glutamate induces single-peaked intracellular Ca2+ mobilization in mGluR1 alpha-transfected cells but elicits Ca2+ oscillations in mGluR5a-transfected cells, The response patterns of the intracellular Ca2+ increase depend upon the identity of a single amino acid, aspartate (at position 854) or threonine (at position 840), located within the G-protein-interacting domains of mGluR1 alpha and mGluR5a, respectively, Pharmacological and peptide mapping analyses indicated that phosphorylation of the threonine residue at position 840 of mGluR5a by protein kinase C (PKC) is responsible for the generation of Ca2+ oscillations in mGluR5a-expressing cells, To our knowledge this is the first evidence that PKC phosphorylation of G-protein-coupled receptors is important in producing oscillations in intracellular Ca2+ signalling.	YAMANOUCHI PHARMACEUT CO LTD,NEUROSCI & GASTROINTESTINAL RES LAB,INST DRUG DISCOVERY RES,TSUKUBA,IBARAKI 305,JAPAN; KYOTO UNIV,FAC MED,DEPT BIOL SCI,KYOTO 606,JAPAN	Astellas Pharmaceuticals; Kyoto University								ABE T, 1992, J BIOL CHEM, V267, P13361; ALALUF S, 1995, FEBS LETT, V367, P301, DOI 10.1016/0014-5793(95)00575-T; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; CARTER WG, 1995, BIOCHEMISTRY-US, V34, P9488, DOI 10.1021/bi00029a025; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; GRYKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HOUSE C, 1987, J BIOL CHEM, V262, P772; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MILLER S, 1995, J NEUROSCI, V15, P6103; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; OGURA A, 1990, J BIOL CHEM, V265, P3577; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; SHIGEMOTO R, 1993, NEUROSCI LETT, V163, P53, DOI 10.1016/0304-3940(93)90227-C; SKOGLUND G, 1988, CANCER RES, V48, P3168; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; SWANN K, 1989, EMBO J, V8, P3711, DOI 10.1002/j.1460-2075.1989.tb08546.x; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315	29	240	243	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					89	92		10.1038/383089a0	http://dx.doi.org/10.1038/383089a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779726				2022-12-24	WOS:A1996VF29500054
J	Moazed, D; Johnson, AD				Moazed, D; Johnson, AD			A deubiquitinating enzyme interacts with SIR4 and regulates silencing in S-cerevisiae	CELL			English	Article							UBIQUITIN-PROTEASOME PATHWAY; NF-KAPPA-B; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; CHROMOSOME SEGREGATION; TRANSCRIPTIONAL STATES; MULTIPROTEIN COMPLEX; BINDING-PROTEIN; MATING LOCI; HISTONE H3	The SIR2, SIR3, and SIR4 proteins are required for silencing of transcription at the silent mating type loci and at telomeres in yeast. Using protein affinity chromatography, we show that SIR2, SIR3, and two proteins of 69 and 110 kDa tightly associate with SIR4. Surprisingly, the 110 kDa SIR4-binding protein is identical to UBP3, one of several previously described yeast enzymes that deubiquitinate target proteins. Deletion of the UBP3 gene results in markedly improved silencing of genes inserted either near a telomere or at one of the silent mating type loci, indicating that UBP3 is an inhibitor of silencing. We discuss possible roles for UBP3 in controlling the activity or assembly of the SIR protein complex.			Moazed, D (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL,SAN FRANCISCO,CA 94143, USA.							ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Broach J.R., 1992, MOL CELLULAR BIOL SA, P583; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DIFFLEY JFX, 1989, NATURE, V342, P24, DOI 10.1038/342024a0; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GALL JG, 1971, CHROMOSOMA, V33, P319; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; JONES EW, 1984, ANNU REV GENET, V18, P233, DOI 10.1146/annurev.ge.18.120184.001313; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KELLUM R, 1995, J CELL SCI, V108, P1419; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LOO S, 1995, GENETICS, V141, P889; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RHODE PR, 1989, GENE DEV, V3, P1926, DOI 10.1101/gad.3.12a.1926; RINE J, 1987, GENETICS, V116, P9; Sandell L L, 1992, Trends Cell Biol, V2, P10, DOI 10.1016/0962-8924(92)90138-D; SHEI GJ, 1995, MOL CELL BIOL, V15, P3496; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spofford J. B., 1976, GENET BIOL DROSOPHIL, V1c, P955; SPRADLING A, 1987, ANNU REV GENET, V21, P373, DOI 10.1146/annurev.ge.21.120187.002105; SPRAGUE G F JR, 1991, P77; SWERDLOW PS, 1990, MOL CELL BIOL, V10, P4905, DOI 10.1128/MCB.10.9.4905; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; VARSHAVSKY A, 1987, BIOCHEM SOC T, V15, P815, DOI 10.1042/bst0150815; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WHITEWAY M, 1987, MOL CELL BIOL, V7, P3713, DOI 10.1128/MCB.7.10.3713; WILEY EA, 1995, GENETICS, V139, P67	65	211	215	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					667	677		10.1016/S0092-8674(00)80139-7	http://dx.doi.org/10.1016/S0092-8674(00)80139-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752220	Bronze			2022-12-24	WOS:A1996VE23500016
J	Sowers, MF; Hollis, BW; Shapiro, B; Randolph, J; Janney, CA; Zhang, DW; Schork, MA; Crutchfield, M; Stanczyk, F; RussellAulet, M				Sowers, MF; Hollis, BW; Shapiro, B; Randolph, J; Janney, CA; Zhang, DW; Schork, MA; Crutchfield, M; Stanczyk, F; RussellAulet, M			Elevated parathyroid hormone-related peptide associated with lactation and bone density loss	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTPARTUM WOMEN; MINERAL CONTENT; MAMMARY TISSUE; MILK CALCIUM; PROTEIN; PREGNANCY; TURNOVER; HYPERCALCEMIA; CONSERVATION; METABOLISM	Objective.-To investigate the hypothesis that parathyroid hormone-related peptide (PTHrP) may be involved with bone loss and recovery as a means of providing adequate calcium and phosphate to infants. Design.-An 18-month prospective cohort study. Setting.-General community setting with recruitment occurring at birthing education classes. Participants.-Volunteer sample of 115 postpartum healthy women aged 20 to 40 years, and 0 or 1 parity prior to parturition with no intent to breast-feed or intent to breast-feed at least 6 months. Main Outcome Measures.-Parathyroid hormone-related peptide, prolactin, estradiol, 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D, femoral bone mineral density, and bone turnover markers were measured in 115 postpartum women at 2 weeks, 2 months, 4 months, 6 months, 12 months, and 18 months postpartum. Lumbar bone mineral density was measured at 2 weeks, 6 months, 12 months, and 18 months postpartum. Results.-Elevated PTHrP values were significantly associated (P<.001) with breast-feeding status, elevated prolactin levels, and lower serum estradiol levels, conditions occurring during lactation, Furthermore, elevated PTHrP levels were negatively and significantly associated (P<.01) over time with bone mineral density change at both the spine and the femoral neck, even after accounting for prolactin levels, breast-feeding status, return of menstruation, estradiol levels, PTH levels, 1,25-dihydroxyvitamin D levels, dietary calcium intake, physical activity, and body size. Conclusion.-These data clearly support the hypothesis that PTHrP is an alternative mechanism associated with bone loss and recovery during and subsequent to lactation.	UNIV MICHIGAN, DEPT BIOSTAT, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT OBSTET & GYNECOL, ANN ARBOR, MI 48109 USA; MED UNIV S CAROLINA, DEPT PEDIAT, CHARLESTON, SC 29425 USA; UNIV SO CALIF, SCH MED, DEPT OBSTET & GYNECOL, LOS ANGELES, CA 90033 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Medical University of South Carolina; University of Southern California	Sowers, MF (corresponding author), UNIV MICHIGAN, SCH PUBL HLTH,DEPT EPIDEMIOL,109 OBSERV,ROOM 3037, SPH-1, ANN ARBOR, MI 48109 USA.			Randolph, John/0000-0003-4901-7711	NIAMS NIH HHS [R29 AR39651, R01 AR41310] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041310, R29AR039651] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ATKINSON P J, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P555; BAIRD DT, 1979, J CLIN ENDOCR METAB, V49, P500, DOI 10.1210/jcem-49-4-500; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BROMMAGE R, 1985, AM J PHYSIOL, V248, pE182, DOI 10.1152/ajpendo.1985.248.2.E182; BUDAYR AA, 1989, P NATL ACAD SCI USA, V86, P7183, DOI 10.1073/pnas.86.18.7183; CAIRD LE, 1994, CLIN ENDOCRINOL, V41, P739, DOI 10.1111/j.1365-2265.1994.tb02788.x; CANALIS E, 1990, ENDOCRINOLOGY, V126, P1806, DOI 10.1210/endo-126-4-1806; CHAN GM, 1987, AM J CLIN NUTR, V46, P319, DOI 10.1093/ajcn/46.2.319; CROSS NA, 1995, AM J CLIN NUTR, V61, P514, DOI 10.1093/ajcn/61.3.514; Diggle PJ, 2002, ANAL LONGITUDINAL DA; DOBNIG H, 1995, J CLIN ENDOCR METAB, V80, P3699, DOI 10.1210/jc.80.12.3699; DRINKWATER BL, 1991, BONE MINER, V14, P153, DOI 10.1016/0169-6009(91)90092-E; GARNER SC, 1990, J BONE MINER RES, V5, P69, DOI 10.1002/jbmr.5650050111; GREER FR, 1982, AM J CLIN NUTR, V86, P431; GRILL V, 1992, CLIN ENDOCRINOL, V37, P405, DOI 10.1111/j.1365-2265.1992.tb02350.x; HAYSLIP CC, 1989, OBSTET GYNECOL, V73, P588; KENT GN, 1990, J BONE MINER RES, V5, P361, DOI 10.1002/jbmr.5650050409; KENT GN, 1991, MINER ELECTROL METAB, V17, P1; KHOSLA S, 1990, MAYO CLIN PROC, V65, P1408, DOI 10.1016/S0025-6196(12)62164-8; LAMKE B, 1977, ACTA OBSTET GYN SCAN, V56, P217, DOI 10.3109/00016347709162123; LAW FMK, 1991, J ENDOCRINOL, V128, P21, DOI 10.1677/joe.0.1280021; PRENTICE A, 1995, AM J CLIN NUTR, V62, P58, DOI 10.1093/ajcn/62.1.58; RATCLIFFE WA, 1992, J ENDOCRINOL, V133, P87, DOI 10.1677/joe.0.1330087; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; *SAS I INC, 1992, P229 SAS; SAS Institute, 1990, SAS STAT US GUID VER; SOWERS M, 1995, J CLIN ENDOCR METAB, V80, P2210, DOI 10.1210/jc.80.7.2210; SOWERS M, 1995, OBSTET GYNECOL, V85, P285, DOI 10.1016/0029-7844(94)00351-D; SOWERS M, 1993, JAMA-J AM MED ASSOC, V269, P3130, DOI 10.1001/jama.269.24.3130; SPECKER BL, 1994, AM J CLIN NUTR, V59, P593, DOI 10.1093/ajcn/59.3.593; STIEGLER C, 1995, J BONE MINER RES, V10, P751; THIEDE MA, 1989, MOL ENDOCRINOL, V3, P1443, DOI 10.1210/mend-3-9-1443; THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653; THOMAS ML, 1991, P SOC EXP BIOL MED, V196, P214, DOI 10.3181/00379727-196-43182; UZAWA T, 1995, BONE, V16, P477; VARGAS SJ, 1992, J BONE MINER RES, V7, P971; WADA S, 1992, INTERNAL MED, V31, P968, DOI 10.2169/internalmedicine.31.968; ZARATE A, 1987, J STEROID BIOCHEM, V27, P1023, DOI 10.1016/0022-4731(87)90185-3; ZHANG D, 1996, INT BIOM SOC E N AM; ZINAMAN MJ, 1995, J CLIN ENDOCR METAB, V80, P2088, DOI 10.1210/jc.80.7.2088	41	170	174	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 21	1996	276	7					549	554		10.1001/jama.276.7.549	http://dx.doi.org/10.1001/jama.276.7.549			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC101	8709404				2022-12-24	WOS:A1996VC10100031
J	McKeganey, N; Forsyth, A; Barnard, M; Hay, G				McKeganey, N; Forsyth, A; Barnard, M; Hay, G			Designer drinks and drunkenness amongst a sample of Scottish schoolchildren	BRITISH MEDICAL JOURNAL			English	Article											McKeganey, N (corresponding author), UNIV GLASGOW,CTR DRUG MISUSE RES,GLASGOW G12 8RT,LANARK,SCOTLAND.		Hay, Gordon/K-3310-2015; Forsyth, Alasdair John/ABG-3968-2021	Hay, Gordon/0000-0002-8346-9618; 				Barnard M, 1996, DRUG-EDUC PREV POLIC, V3, P81, DOI 10.3109/09687639609019313; Carstairs V., 1991, DEPRIVATION HLTH SCO; *HLTH ED AUT, 1995, YOUNG AD HLTH LIF AL; *ROYAL COLL PHYS R, 1995, ALC YOUNG	4	39	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					401	401						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761229				2022-12-24	WOS:A1996VD20600027
J	Sim, BC; Zerva, L; Greene, MI; Gascoigne, NRJ				Sim, BC; Zerva, L; Greene, MI; Gascoigne, NRJ			Control of MHC restriction by TCR V-alpha CDR1 and CDR2	SCIENCE			English	Article							T-CELL RECEPTOR; ANTIGEN RECEPTOR; TRANSGENIC MICE; POSITIVE SELECTION; NEGATIVE SELECTION; EXPRESSION; LYMPHOCYTES; RECOGNITION; MOLECULES; ANTIBODY	Individual T cell receptor (TCR) V-alpha elements are expressed preferentially in CD4 or CD8 peripheral T cell subsets. The closely related V(alpha)3.1 and V(alpha)3.2 elements show reciprocal selection into CD4 and CD8 subsets, respectively. Transgenic mice expressing site-directed mutants of a V alpha 3.1 gene were used to show that individual residues in either the complementarity-determining region 1 (CDR1) or CDR2 were sufficient to change selection from the CD4 subset to the CD8 subset. Thus, the germline-encoded V-alpha elements are a major influence on major histocompatibility class complex (MHC) restriction, most likely by a preferential interaction with one or the other class of MHC molecule.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; UNIV PENN, DEPT PATHOL, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048002] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM48002] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arden Bernhard, 1995, Immunogenetics, V42, P501; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CARBONE FR, 1992, INT IMMUNOL, V4, P861, DOI 10.1093/intimm/4.8.861; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DERSIMONIAN H, 1991, J EXP MED, V174, P639, DOI 10.1084/jem.174.3.639; DIANZANI U, 1992, J IMMUNOL, V148, P678; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Gascoigne Nicholas R. J., 1995, P288; JAMESON SC, 1991, J IMMUNOL, V147, P3185; JAMESON SC, 1990, J IMMUNOL, V145, P1324; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; JANEWAY CA, 1996, SEMIN IMMUNOL, V8, P109; JOUVINMARCHE E, 1990, EMBO J, V9, P2141, DOI 10.1002/j.1460-2075.1990.tb07383.x; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KOUSKOFF V, 1995, J IMMUNOL METHODS, V180, P273, DOI 10.1016/0022-1759(95)00002-R; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; RUSSELL JH, 1990, J IMMUNOL, V144, P3318; SAOUAF SJ, 1994, TRANSGENICS, V1, P185; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TOMONARI K, 1992, IMMUNOGENETICS, V35, P291; UTSUNOMIYA Y, 1989, J IMMUNOL, V143, P2602; VONBOEHMER H, 1991, J EXP MED, V174, P1001, DOI 10.1084/jem.174.5.1001	29	138	140	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					963	966		10.1126/science.273.5277.963	http://dx.doi.org/10.1126/science.273.5277.963			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688082				2022-12-24	WOS:A1996VC67000065
J	Finter, NB				Finter, NB			The naming of cats - And alpha-interferons	LANCET			English	Editorial Material							CARCINOID-TUMORS; ANTIBODIES				Finter, NB (corresponding author), TIDESWELL,9 BURNTWOOD RD,SEVENOAKS TN13 1PS,KENT,ENGLAND.							Allen G, 1996, J INTERF CYTOK RES, V16, P181, DOI 10.1089/jir.1996.16.181; ANTONELLI G, 1991, J INFECT DIS, V163, P882, DOI 10.1093/infdis/163.4.882; Bacon B. R., 1995, Hepatology, V22, p152A; FINTER N B, 1991, Journal of Interferon Research, P185; GRANDER D, 1990, LANCET, V336, P337, DOI 10.1016/0140-6736(90)91879-F; HAWKINS MJ, 1984, J CLIN ONCOL, V2, P221, DOI 10.1200/JCO.1984.2.3.221; HENCO K, 1985, J MOL BIOL, V185, P227, DOI 10.1016/0022-2836(85)90401-2; Hopps H. E., 1985, INTERFERON, V4, P121; OBERG KE, 1994, J INTERFERON RES, V14, P215, DOI 10.1089/jir.1994.14.215; PESTKA S, 1995, EPIDERMAL GROWTH FAC, P163; Phillips, 1985, LARGE SCALE MAMMALIA, P87, DOI 10.1016/B978-0-12-250430-3.50012-X; STRANDER H, 1966, ANN MED EXP BIOL FEN, V44, P265; VONWUSSOW P, 1994, J INTERFERON RES, V14, P217, DOI 10.1089/jir.1994.14.217	13	10	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					348	349		10.1016/S0140-6736(05)64985-9	http://dx.doi.org/10.1016/S0140-6736(05)64985-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709727				2022-12-24	WOS:A1996VB42600003
J	ToozsHobson, P; Cardozo, L				ToozsHobson, P; Cardozo, L			Controversies in management - Hormone replacement therapy for all? Universal prescription is desirable	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL WOMEN; ESTROGEN THERAPY; BREAST-CANCER; DISEASE; METAANALYSIS; RISK		UNIV LONDON KINGS COLL, SCH MED & DENT, DEPT OBSTET & GYNAECOL, UROGYNAECOL UNIT, LONDON SE5 8RX, ENGLAND	University of London; King's College London				Toozs-Hobson, Philip/0000-0002-1859-9934				ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; COWAN WK, 1991, BRIT J CANCER, V64, P780, DOI 10.1038/bjc.1991.398; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; FERGUSON KJ, 1989, ARCH INTERN MED, V149, P133, DOI 10.1001/archinte.149.1.133; GRADY D, 1991, AM J EPIDEMIOL, V134, P1396, DOI 10.1093/oxfordjournals.aje.a116043; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRIFFITHS F, 1995, FAM PRACT, V12, P54, DOI 10.1093/fampra/12.1.54; HENDERSON BE, 1986, AM J OBSTET GYNECOL, V154, P1181, DOI 10.1016/0002-9378(86)90696-4; KLEMI PJ, 1992, BRIT MED J, V304, P467, DOI 10.1136/bmj.304.6825.467; Leather A. T., 1993, P291; LEATHER AT, 1990, BRIT J OBSTET GYNAEC, V97, P1071, DOI 10.1111/j.1471-0528.1990.tb02491.x; LOBO RA, 1995, AM J OBSTET GYNECOL, V173, P982, DOI 10.1016/0002-9378(95)90247-3; NACHIGALL RG, 1989, OBSTET GYNECOL, V75, P77; NORMAN SG, 1994, BRIT J OBSTET GYNAEC, V101, P879, DOI 10.1111/j.1471-0528.1994.tb13549.x; OHKURA T, 1995, DEMENTIA, V6, P99, DOI 10.1159/000106929; Paganini-Hill A, 1995, Int J Fertil Menopausal Stud, V40 Suppl 1, P54; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; PURDIE DW, 1995, BRIT J OBSTET GYNAEC, V102, P735, DOI 10.1111/j.1471-0528.1995.tb11433.x; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; *US DEPT HHS, 1980, VIT STAT US	21	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 10	1996	313	7053					350	351		10.1136/bmj.313.7053.350	http://dx.doi.org/10.1136/bmj.313.7053.350			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760747	Green Published			2022-12-24	WOS:A1996VC30000025
J	Tomee, JFC; Mannes, GPM; vanderBij, W; vanderWerf, TS; deBoer, WJ; Koeter, GH; Kauffman, HF				Tomee, JFC; Mannes, GPM; vanderBij, W; vanderWerf, TS; deBoer, WJ; Koeter, GH; Kauffman, HF			Serodiagnosis and monitoring of Aspergillus infections after lung transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLICATIONS; RECIPIENTS; DIAGNOSIS; REJECTION; DISEASE	Objective: To determine whether quantification of specific antifungal antibody responses in serum can provide supplemental information for the diagnosis of Aspergillus fumigatus infections and the monitoring of antifungal treatment in patients after lung transplantation. Design: Retrospective study. Setting: Center for lung transplantation, University Hospital Groningen, the Netherlands. Patients: 4 patients with proven A. fumigatus infections after lung transplantation and fatal outcome. Measurements: The IgG antibody response specific for A. fumigatus antigens was measured by enzyme-linked immunosorbent assay and was compared with radiographic features, cytologic findings, microbiological cultures, and clinical diagnosis. Results: Increasing IgG antibody responses specific for A. fumigatus antigens closely paralleled cytologic or microbiological identification of A. fumigatus from bronchoalveolar ravage fluid and decrease of lung function. Increasing specific IgG antibody responses were found to precede radiographic identification of lung cavitation by 1 to 2 weeks, precede the diagnosis of aspergillosis by 2 to 20 weeks, and detect fungal reinfection. In most cases, successful antifungal treatment decreased specific IgG antibody response. A decrease in specific IgG antibody response correlated with the inability to culture or identify A. fumigatus in bronchoalveolar lavage fluid and with radiographic and clinical improvement. Conclusions: Specific IgG antibody responses in serum correlate with radiographic, cytologic, and microbiological findings and with the clinical diagnosis of A. fumigatus infections in patients who have had lung transplantation. Increased IgG antibody responses in serum may provide important information that is helpful in the diagnosis and early treatment of pulmonary fungal infections and in monitoring antifungal treatment.	UNIV GRONINGEN HOSP, DEPT ALLERGOL, CLIN INTERNAL MED, NL-9713 GZ GRONINGEN, NETHERLANDS; UNIV GRONINGEN HOSP, DEPT PULM, CLIN INTERNAL MED, NL-9713 GZ GRONINGEN, NETHERLANDS; UNIV GRONINGEN HOSP, DEPT CARDIOTHORAC SURG, NL-9713 GZ GRONINGEN, NETHERLANDS	University of Groningen; University of Groningen; University of Groningen				van der Werf, Tjip/0000-0002-4824-1642				BECKER FS, 1994, AM J RESP CRIT CARE, V150, P159, DOI 10.1164/ajrccm.150.1.8025743; BROOKS RG, 1985, AM J MED, V79, P412, DOI 10.1016/0002-9343(85)90027-0; DUMMER JS, 1986, TRANSPLANTATION, V41, P725, DOI 10.1097/00007890-198606000-00012; DUNCAN SR, 1992, AM REV RESPIR DIS, V146, P1419, DOI 10.1164/ajrccm/146.6.1419; EGAN TM, 1992, ANN THORAC SURG, V53, P590, DOI 10.1016/0003-4975(92)90316-V; FLUME PA, 1994, AM J RESP CRIT CARE, V149, P1601, DOI 10.1164/ajrccm.149.6.7516251; HIGENBOTTAM T, 1988, TRANSPLANTATION, V46, P532, DOI 10.1097/00007890-198810000-00013; KRAMER MR, 1993, ARCH INTERN MED, V153, P2010, DOI 10.1001/archinte.153.17.2010; MAURER JR, 1992, CHEST, V101, P1056, DOI 10.1378/chest.101.4.1056; MCDOUGALL JC, 1993, ANN THORAC SURG, V56, P176, DOI 10.1016/0003-4975(93)90433-I; MEDINA LS, 1994, AM J ROENTGENOL, V162, P969, DOI 10.2214/ajr.162.4.8141028; MILLET B, 1989, AM REV RESPIR DIS, V140, P62, DOI 10.1164/ajrccm/140.1.62; Paradis I L, 1993, Semin Respir Infect, V8, P207; SMYTH RL, 1989, RESP MED, V83, P459, DOI 10.1016/S0954-6111(89)80126-X; TOMEE JF, IN PRESS AM J RESP C; TOMEE JFC, 1994, J ALLERGY CLIN IMMUN, V93, P768, DOI 10.1016/0091-6749(94)90257-7; TOMEE JFC, 1995, AM J RESP CRIT CARE, V151, P199, DOI 10.1164/ajrccm.151.1.7812553; VANDERGIESSEN M, 1990, CLIN EXP IMMUNOL, V80, P56; WEILAND D, 1983, ANN SURG, V198, P622, DOI 10.1097/00000658-198311000-00011; WILKES DS, 1995, AM J RESP CELL MOL, V13, P621, DOI 10.1165/ajrcmb.13.5.7576699	20	30	33	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					197	201		10.7326/0003-4819-125-3-199608010-00006	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686977				2022-12-24	WOS:A1996UZ28700005
J	Ronsmans, C; Islam, T; Bennish, ML				Ronsmans, C; Islam, T; Bennish, ML			Medical practitioners' knowledge of dysentery treatment in Bangladesh	BRITISH MEDICAL JOURNAL			English	Article							HEALTH		INT CTR DIARRHOEAL DIS RES,DHAKA,BANGLADESH; GONOSHASTHAYA KENDRA,SAVAR,BANGLADESH; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DEPT PAEDIAT,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DEPT MED,BOSTON,MA 02111	International Centre for Diarrhoeal Disease Research (ICDDR); Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University								BENNISH ML, 1992, CLIN INFECT DIS, V14, P1055, DOI 10.1093/clinids/14.5.1055; GUYON AB, 1994, B WORLD HEALTH ORGAN, V72, P265; RONSMANS C, 1988, LANCET, V2, P552; RONSMANS C, 1991, REV INFECT DIS, V13, pS351; 1994, UPDATE, V16, P1	5	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					205	206		10.1136/bmj.313.7051.205	http://dx.doi.org/10.1136/bmj.313.7051.205			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696198	Green Published			2022-12-24	WOS:A1996VA12600027
J	Brown, JR; Ye, H; Bronson, RT; Dikkes, P; Greenberg, ME				Brown, JR; Ye, H; Bronson, RT; Dikkes, P; Greenberg, ME			A defect in nurturing in mice lacking the immediate early gene fosB	CELL			English	Article							OLFACTORY BULB REMOVAL; MEDIAL PREOPTIC AREA; MATERNAL-BEHAVIOR; C-FOS; POSTPARTUM RATS; DIFFERENTIAL EXPRESSION; SIGNALING PATHWAYS; OXYTOCIN; BINDING; MOUSE	Although expression of the Fos family of transcription factors is induced by environmental stimuli that trigger adaptive neuronal responses, evidence that Fos family members mediate these responses is lacking. To address this issue, mice were generated with an inactivating mutation in the fosB gene. fosB mutant mice are profoundly deficient in their ability to nurture young animals but are normal with respect to other cognitive and sensory functions. The nurturing defect is likely due to the absence of FosB in the preoptic area, a region of the hypothalamus that is critical for nurturing. These observations suggest that a transcription factor controls a complex behavior by regulating a specific neuronal circuit and indicate that nurturing in mammals has a genetic component.	HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA; TUFTS UNIV, SCH VET MED, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA	Harvard University; Harvard Medical School; Tufts University	Brown, JR (corresponding author), HARVARD UNIV, SCH MED, CHILDRENS HOSP, DIV NEUROSCI, BOSTON, MA 02115 USA.				NCI NIH HHS [CA43855] Funding Source: Medline; NICHD NIH HHS [P30-HD18655] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ANUMAN M, 1995, BEH NEUROSCI, V109, P135; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BARNETT SA, 1970, REPRODUCTION BREEDIN; BRIDGES RS, 1994, PSYCHONEUROENDOCRINO, V19, P611, DOI 10.1016/0306-4530(94)90045-0; BRIDGES RS, 1994, ACTA PAEDIATR, V83, P33, DOI 10.1111/j.1651-2227.1994.tb13263.x; CALAMANDREI G, 1994, BEHAV NEUROSCI, V108, P113, DOI 10.1037/0735-7044.108.1.113; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEMMER J, 1993, MOL BRAIN RES, V17, P279, DOI 10.1016/0169-328X(93)90012-E; FAHRBACH SE, 1985, NEUROENDOCRINOLOGY, V40, P526, DOI 10.1159/000124125; FLEMING AS, 1994, BEHAV NEUROSCI, V108, P724, DOI 10.1037/0735-7044.108.4.724; FLEMING AS, 1990, BEHAV NEURAL BIOL, V53, P64, DOI 10.1016/0163-1047(90)90814-M; FLEMING AS, 1992, BEHAV NEURAL BIOL, V57, P177, DOI 10.1016/0163-1047(92)90122-K; FLEMING AS, 1974, J COMP PHYSIOL PSYCH, V86, P221, DOI 10.1037/h0035937; FLEMING AS, 1980, PHYSIOL BEHAV, V25, P731, DOI 10.1016/0031-9384(80)90377-7; FLEMING AS, 1994, PSYCHONEUROENDOCRINO, V19, P429, DOI 10.1016/0306-4530(94)90030-2; FLEMING AS, 1983, PHYSIOL BEHAV, V31, P503, DOI 10.1016/0031-9384(83)90073-2; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GANDELMA.R, 1971, SCIENCE, V171, P210, DOI 10.1126/science.171.3967.210; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GRIFF IC, 1995, CELL, V83, P407, DOI 10.1016/0092-8674(95)90118-3; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; JIRIKBABB P, 1984, BEHAV NEURAL BIOL, V40, P170, DOI 10.1016/S0163-1047(84)90267-X; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEPRI JJ, 1985, PHYSIOL BEHAV, V35, P809, DOI 10.1016/0031-9384(85)90416-0; LEREA LS, 1993, NEURON, V10, P31, DOI 10.1016/0896-6273(93)90239-N; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LUCKMAN SM, 1995, BRAIN RES, V669, P115, DOI 10.1016/0006-8993(94)01271-I; MALENFANT SA, 1991, PHYSIOL BEHAV, V49, P289, DOI 10.1016/0031-9384(91)90045-P; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Moore DD, 1995, GLOB MOB SURV; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NOIROT E, 1969, ANIM BEHAV, V17, P542, DOI 10.1016/0003-3472(69)90161-4; NOIROT E, 1969, ANIM BEHAV, V17, P547, DOI 10.1016/0003-3472(69)90162-6; NUMAN M, 1994, ACTA PAEDIATR, V83, P19, DOI 10.1111/j.1651-2227.1994.tb13261.x; NUMAN M, 1988, BEHAV NEUROSCI, V102, P381, DOI 10.1037/0735-7044.102.3.381; ORPEN BG, 1987, PHYSIOL BEHAV, V40, P47, DOI 10.1016/0031-9384(87)90184-3; PEDERSEN CA, 1985, NEUROPEPTIDES, V6, P175, DOI 10.1016/0143-4179(85)90108-8; PEDERSEN CA, 1982, SCIENCE, V216, P648, DOI 10.1126/science.7071605; PEDERSEN CA, 1994, BEHAV NEUROSCI, V108, P1163, DOI 10.1037/0735-7044.108.6.1163; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROSENBLATT JS, 1988, PSYCHONEUROENDOCRINO, V13, P29, DOI 10.1016/0306-4530(88)90005-4; ROSENBLATT JS, 1994, ACTA PAEDIATR, V83, P3, DOI 10.1111/j.1651-2227.1994.tb13259.x; ROZEN F, 1995, P NATL ACAD SCI USA, V92, P200, DOI 10.1073/pnas.92.1.200; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SIDIS Y, 1994, ENDOCRINOLOGY, V134, P1979, DOI 10.1210/en.134.4.1979; SMOTHERMAN WP, 1974, BEHAV BIOL, V12, P55, DOI 10.1016/S0091-6773(74)91026-8; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANLEENGOED E, 1987, J ENDOCRINOL, V112, P275, DOI 10.1677/joe.0.1120275; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Watanabe Y, 1996, J NEUROSCI, V16, P3827; WISDOM R, 1993, MOL CELL BIOL, V13, P2635, DOI 10.1128/MCB.13.5.2635; WYSOCKI CJ, 1977, BEHAV GENET, V7, P171, DOI 10.1007/BF01066005; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZHUGE R, 1995, MOL REPROD DEV, V41, P20, DOI 10.1002/mrd.1080410105	61	263	268	1	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 26	1996	86	2					297	309		10.1016/S0092-8674(00)80101-4	http://dx.doi.org/10.1016/S0092-8674(00)80101-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706134	Bronze			2022-12-24	WOS:A1996UZ97200015
J	Crompton, T; Gilmour, KC; Owen, MJ				Crompton, T; Gilmour, KC; Owen, MJ			The MAP kinase pathway controls differentiation from double-negative to double-positive thymocyte	CELL			English	Article							RECEPTOR-BETA-CHAIN; ACTIVATED PROTEIN-KINASE; T-CELL DEVELOPMENT; NIH 3T3 CELLS; ALLELIC EXCLUSION; DEFICIENT MICE; ALPHA-BETA; SIGNAL-TRANSDUCTION; MUTANT MICE; LYMPHOCYTES	T cell development is regulated at two major control points where maturation, proliferation, and antigen receptor gene rearrangement are coordinated. Progression through these developmental control points is dependent upon the expression of different forms of the T cell receptor. Here we show that the MAP kinase cascade is a regulator of the differentiation of immature thymocytes from double-negative to double-positive cell, most probably acting as a transducer of pre-T cell receptor signaling. Furthermore, this study demonstrates the use of retrovirus-mediated gene transfer in fetal thymic organ culture in the analysis of thymic development in mutant mice, an alternative to transgenesis by oocyte injection.			Crompton, T (corresponding author), IMPERIAL CANC RES FUND,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.			Crompton, Tessa/0000-0002-8973-4021				ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON SJ, 1994, ADV IMMUNOL, V56, P151, DOI 10.1016/S0065-2776(08)60451-4; ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CROMPTON T, 1994, EUR J IMMUNOL, V25, P1903; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; GILMOUR KC, 1994, P NATL ACAD SCI USA, V91, P6850, DOI 10.1073/pnas.91.15.6850; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; GUIDOS CJ, 1995, J EXP MED, V181, P1187, DOI 10.1084/jem.181.3.1187; Jenkinson E J, 1990, Semin Immunol, V2, P51; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KINGSTON R, 1985, NATURE, V317, P811, DOI 10.1038/317811a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEVELT CN, 1995, EUR J IMMUNOL, V25, P1257, DOI 10.1002/eji.1830250519; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SEGER R, 1994, J BIOL CHEM, V269, P25699; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; VONBOEHMER H, 1995, CLIN IMMUNOL IMMUNOP, V76, P145; WALLACE VA, 1995, EUR J IMMUNOL, V25, P1312, DOI 10.1002/eji.1830250527	44	183	184	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					243	251		10.1016/S0092-8674(00)80096-3	http://dx.doi.org/10.1016/S0092-8674(00)80096-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706129	Bronze			2022-12-24	WOS:A1996UZ97200010
J	Grubb, NR; OCarroll, R; Cobbe, SM; Sirel, J; Fox, KAA				Grubb, NR; OCarroll, R; Cobbe, SM; Sirel, J; Fox, KAA			Chronic memory impairment after cardiac arrest outside hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEARTSTART SCOTLAND; DEFIBRILLATION; SURVIVAL; EMERGENCY; IMPACT	Objectives-To evaluate the nature, prevalence, and severity of chronic memory deficit in patients resuscitated after cardiac arrest outside hospital and to determine whether such deficits are related to duration of cardiac arrest. Design-Case-control study. Subjects-35 survivors of cardiac arrest outside hospital and 35 controls matched for age and sex who had had acute myocardial infarction without cardiac arrest. Main outcome measures-Subjects assessed at least two months after index event for affective state (hospital anxiety and depression scale), premorbid intelligence (national adult reading test), short term recall (digit recall test), and episodic long term memory (Rivermead behavioural memory test). Results-Cases and controls showed no difference in short term recall. Cases scored lower on Rivermead test than controls (mean (SD) score out of 24 points: 17.4 (5.4) v 21.8 (2.0), P<0.001), particularly in subtests relating to verbal and spatial memory. Moderate or severe impairment was found in 37% of cases and in no controls. Severity of impairment of memory correlated significantly with measures of duration of cardiac arrest. This deficit was not significantly associated with subjects' age, interval from index event to assessment, occupation, measures of comorbidity, social deprivation, anxiety or depression scores, or estimated premorbid intelligence. Conclusions-Clinically important impairment of memory was common after cardiac arrest outside hospital. Improvement in response times of emergency services could reduce the severity of such deficits. With an increasing numbers of people expected to survive cardiac arrest outside hospital, rehabilitation of those with memory deficit merits specific attention.	UNIV EDINBURGH, CARDIOVASC RES UNIT, EDINBURGH, MIDLOTHIAN, SCOTLAND; ROYAL EDINBURGH & ASSOCIATED HOSP, MRC, BRAIN METAB UNIT, EDINBURGH, MIDLOTHIAN, SCOTLAND; GLASGOW ROYAL INFIRM, DEPT MED CARDIOL, GLASGOW G4 0SF, LANARK, SCOTLAND	University of Edinburgh; Royal Infirmary of Edinburgh; University of Glasgow			O'Carroll, Ronan E/A-5040-2009; Fox, keith A A/I-3742-2013	O'Carroll, Ronan E/0000-0002-5130-291X; Fox, Keith/0000-0002-0140-2752				[Anonymous], 1991, NEUROPSYCHOL REHABIL, DOI DOI 10.1080/09602019108401386; BASS E, 1985, ANN INTERN MED, V103, P920, DOI 10.7326/0003-4819-103-6-920; BEURET P, 1993, RESUSCITATION, V25, P171, DOI 10.1016/0300-9572(93)90093-6; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; Carstairs V., 1991, DEPRIVATION HLTH SCO; COBB LA, 1992, CIRCULATION, V85, P98; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; COLQUHOUN M, 1995, ABC RESUSCITATION, P56; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; DILLER L, 1976, CLIN PSYCHOL, V19, P13; Dougherty C M, 1994, Am J Crit Care, V3, P145; FRICCHIONE GL, 1989, AM HEART J, V117, P1411, DOI 10.1016/0002-8703(89)90457-2; GRUBB NR, 1995, LANCET, V346, P417, DOI 10.1016/S0140-6736(95)92784-0; GULY UM, 1995, BRIT MED J, V310, P1091, DOI 10.1136/bmj.310.6987.1091; HAMER DW, 1993, RESUSCITATION, V26, P31, DOI 10.1016/0300-9572(93)90160-R; HERLITZ J, 1994, EUR HEART J, V15, P1628, DOI 10.1093/oxfordjournals.eurheartj.a060445; Hillis Michael, 1993, Journal of Emergency Medicine, V11, P245; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; POWELL J, 1993, BRIT J CLIN PHARMACO, V35, P105, DOI 10.1111/j.1365-2125.1993.tb05675.x; SEDGWICK ML, 1993, RESUSCITATION, V26, P75, DOI 10.1016/0300-9572(93)90166-N; SQUIRE LR, 1990, J NEUROSCI, V10, P3106; STERN TA, 1987, AM J CARDIOL, V60, P59; TORPPEDERSEN C, 1991, RESUSCITATION, V21, P283, DOI 10.1016/0300-9572(91)90053-2; TOWNES BD, 1989, J THORAC CARDIOV SUR, V98, P774; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; WECHSLE D, 1987, WECHSLER MEMORY SCAL; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Wilson B., 1992, CLIN MANAGEMENT MEMO; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	29	90	92	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	1996	313	7050					143	146		10.1136/bmj.313.7050.143	http://dx.doi.org/10.1136/bmj.313.7050.143			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UY921	8688775	Green Published			2022-12-24	WOS:A1996UY92100018
J	Hansot, E				Hansot, E			A letter from a patient's daughter	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Hansot, E (corresponding author), STANFORD UNIV, DEPT POLIT SCI,MED CTR,DIV PULM & CRIT CARE MED, MC 5236,300 PASTEUR DR, ROOM H3151, STANFORD, CA 94305 USA.								0	26	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1996	125	2					149	151		10.7326/0003-4819-125-2-199607150-00016	http://dx.doi.org/10.7326/0003-4819-125-2-199607150-00016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV921	8678372				2022-12-24	WOS:A1996UV92100017
J	Rybin, V; Ullrich, O; Rubino, M; Alexandrov, K; Simon, I; Seabra, MC; Goody, R; Zerial, M				Rybin, V; Ullrich, O; Rubino, M; Alexandrov, K; Simon, I; Seabra, MC; Goody, R; Zerial, M			GTPase activity of Rab5 acts as a timer for endocytic membrane fusion	NATURE			English	Article							GDP-DISSOCIATION INHIBITOR; ELONGATION-FACTOR-TU; NUCLEOTIDE EXCHANGE; BINDING PROTEINS; ENDOSOME FUSION; INVITRO; ASSOCIATION; REGULATOR; EFFECTOR; PATHWAY	THE GTPase cycle is a versatile regulatory mechanism directing many cell functions(1), and Rab family members use it to regulate intracellular transport(2-4). Current models propose that GTP hydrolysis by Rah proteins is either required for membrane fusion or occurs afterwards to allow recycling of the protein(1-4). To measure the GTPase activity of Rab5 in endocytic membrane fusion(5), we engineered a mutant that preferentially binds xanthosine 5'-triphosphate (XTP), Rab5(D136N) and monitored the kinetics of [alpha(32)P]-XTP hydrolysis in situ during endosome fusion in vitro. Surprisingly, nucleotide hydrolysis occurred even in the absence of membrane fusion, indicating that membrane-bound Rab5 undergoes futile cycles of GTP (XTP) binding and hydrolysis. Nucleotide triphosphate hydrolysis by Rab5 is not conditional on membrane Fusion and is reduced by its effector Rabaptin-5 (ref. 6). Our data reveal that the GTP cycle of Rab proteins differs from that of other GTPases (for example, EF-Tu) and indicate that GTP hydrolysis acts as a timer that determines the frequency of membrane docking/fusion events.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY; UNIV MAINZ,INST BIOCHEM,D-55128 MAINZ,GERMANY; MAX PLANCK INST MOL PHYSIOL,D-44139 DORTMUND,GERMANY; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235	European Molecular Biology Laboratory (EMBL); Johannes Gutenberg University of Mainz; Max Planck Society; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019; Alexandrov, Kirill/A-5830-2013; Goody, Roger S/J-8845-2014	Seabra, Miguel C/0000-0002-6404-4892; Alexandrov, Kirill/0000-0002-0957-6511; Goody, Roger S/0000-0002-0772-0444				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HUBER LA, 1994, P NATL ACAD SCI USA, V91, P7874, DOI 10.1073/pnas.91.17.7874; JONES S, 1995, J CELL BIOL, V130, P1051, DOI 10.1083/jcb.130.5.1051; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SIMON I, IN PRESS J BIOL CHEM; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P245, DOI 10.1016/0968-0004(94)90149-X; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	30	267	271	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					266	269		10.1038/383266a0	http://dx.doi.org/10.1038/383266a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805704				2022-12-24	WOS:A1996VH31500056
J	Kehoe, DM; Grossman, AR				Kehoe, DM; Grossman, AR			Similarity of a chromatic adaptation sensor to phytochrome and ethylene receptors	SCIENCE			English	Article							CYANOBACTERIUM FREMYELLA-DIPLOSIPHON; RESOLVED ENERGY-TRANSFER; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; 2-COMPONENT REGULATORS; PORPHYRIDIUM-CRUENTUM; GENE; ARABIDOPSIS; PHYCOBILISOMES; PROTEINS	Complementary chromatic adaptation in cyanobacteria acts through photoreceptors to control the biosynthesis of light-harvesting complexes. The mutant FdBk, which appears black, cannot chromatically adapt and may contain a lesion in the apparatus that senses light quality, The complementing gene identified here, rcaE, encodes a deduced protein in which the amino-terminal region resembles the chromophore attachment domain of phytochrome photoreceptors and regions of plant ethylene receptors; the carboxyl-terminal half is similar to the histidine kinase domain of two-component sensor kinases.			Kehoe, DM (corresponding author), CARNEGIE INST WASHINGTON,DEPT PLANT BIOL,290 PANAMA ST,STANFORD,CA 94305, USA.							ALLEN MM, 1968, J BACTERIOL, V96, P836, DOI 10.1128/JB.96.3.836-841.1968; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRUNS BU, 1989, J BACTERIOL, V171, P901, DOI 10.1128/jb.171.2.901-908.1989; CASEY E, 1996, THESIS STANFORD U; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHIANG GG, 1992, PLANT PHYSIOL BIOCH, V30, P315; CHIANG GG, 1992, P NATL ACAD SCI USA, V89, P9415, DOI 10.1073/pnas.89.20.9415; CLACK T, 1994, PLANT MOL BIOL, V25, P413, DOI 10.1007/BF00043870; COBLEY JG, 1993, PLASMID, V30, P90, DOI 10.1006/plas.1993.1037; COBLEY JG, 1983, J BACTERIOL, V153, P1486, DOI 10.1128/JB.153.3.1486-1492.1983; DEMARSAC NT, 1993, FEMS MICROBIOL LETT, V104, P119; DEMARSAC NT, 1983, B I PASTEUR, V81, P201; Engelmann T.W., 1902, ARCH ANAT PHYSL, P333; FAY P, 1987, CYANOBACTERIA, P69; FEDERSPIEL NA, 1990, J BACTERIOL, V172, P4072, DOI 10.1128/jb.172.7.4072-4081.1990; Gaidukov N., 1903, BER DEUT BOT GES, V21, P517; GAIDUKOV N, 1904, BER DEUT BOT GES, V22, P23; GLAZER AN, 1985, ANNU REV BIOPHYS BIO, V14, P47, DOI 10.1146/annurev.biophys.14.1.47; GLAZER AN, 1989, J BIOL CHEM, V264, P1; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Kehoe David M., 1994, Seminars in Cell Biology, V5, P303, DOI 10.1006/scel.1994.1037; KEHOE DM, UNPUB; KEHOE DM, 1995, PHOTOSYNTHESIS LIGHT, V3, P501; KENDRICK RE, 1994, PHOTOMORPHOGENEIS PL; LOMAX TL, 1987, J BACTERIOL, V169, P2675, DOI 10.1128/jb.169.6.2675-2684.1987; OELMULLER R, 1988, PLANT PHYSIOL, V88, P1084, DOI 10.1104/pp.88.4.1084; OELMULLER R, 1988, PLANT PHYSIOL, V88, P1077, DOI 10.1104/pp.88.4.1077; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PORTER G, 1978, BIOCHIM BIOPHYS ACTA, V501, P232, DOI 10.1016/0005-2728(78)90029-4; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; SEARLE GFW, 1978, BIOCHIM BIOPHYS ACTA, V501, P246, DOI 10.1016/0005-2728(78)90030-0; SEKI T, 1987, J BACTERIOL, V169, P2913, DOI 10.1128/jb.169.7.2913-2916.1987; THUMMLER F, 1995, FEBS LETT, V357, P149, DOI 10.1016/0014-5793(94)01327-W; WANNER BL, 1994, PHOSPHATE IN MICROORGANISMS, P215; WANNER BL, 1992, J BACTERIOL, V174, P2124, DOI 10.1128/JB.174.7.2124-2130.1992; WANNER BL, 1992, FEMS MICROBIOL LETT, V100, P133, DOI 10.1111/j.1574-6968.1992.tb05694.x; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807	40	299	314	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1409	1412		10.1126/science.273.5280.1409	http://dx.doi.org/10.1126/science.273.5280.1409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703080				2022-12-24	WOS:A1996VF61000049
J	Carmeliet, P; Mackman, N; Moons, L; Luther, T; Gressens, P; VanVlaenderen, I; Demunck, H; Kasper, M; Breier, G; Evrard, P; Muller, M; Risau, W; Edgington, T; Collen, D				Carmeliet, P; Mackman, N; Moons, L; Luther, T; Gressens, P; VanVlaenderen, I; Demunck, H; Kasper, M; Breier, G; Evrard, P; Muller, M; Risau, W; Edgington, T; Collen, D			Role of tissue factor in embryonic blood vessel development	NATURE			English	Article							DEFICIENT MICE; MOUSE EMBRYOS; EXPRESSION; CELLS; HEMATOPOIESIS	TISSUE factor, a member of the cytokine-receptor superfamily and high-affinity receptor and cofactor for plasma factor VII/VIIa (ref, 1), is the primary cellular initiator of blood coagulation. It is involved in thrombosis and inflammation associated with sepsis, atherosclerosis and cancer(2), and can participate in other cellular processes including intracellular signalling(3), metastasis(4), tumour-associated angiogenesis(5), and embryogenesis(6). Here we report that inactivation of the tissue factor gene (TF) results in abnormal circulation from yolk sac to embryo beyond embryonic day 8.5, leading to embryo wasting and death, Vitelline vessels from null mice were deficient in smooth-muscle a-actin-expressing mesenchymal cells, which participate in organization of the vessel wall, This implies that tissue factor has a role in blood-vessel development.	CATHOLIC UNIV LEUVEN VIB, CTR TRANSGENE TECHNOL & GENE THERAPY, B-3000 LOUVAIN, BELGIUM; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; TECH UNIV DRESDEN, INST PATHOL, D-01307 DRESDEN, GERMANY; HOP ROBERT DEBRE, LAB NEUROL DEV, F-75019 PARIS, FRANCE; UNIV HOSP LEUVEN, LAB EXPT HEMATOL, B-3000 LOUVAIN, BELGIUM; MAX PLANCK INST PHYSIOL & CLIN RES, WG KERCKHOFF INST, ABT MOL ZELLBIOL, D-6350 BAD NAUHEIM, GERMANY	Flanders Institute for Biotechnology (VIB); KU Leuven; Scripps Research Institute; Scripps Research Institute; Technische Universitat Dresden; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; KU Leuven; University Hospital Leuven; Universite Catholique Louvain; Max Planck Society			gressens, pierre/M-7557-2017; Breier, Georg/E-3580-2016; Carmeliet, Peter/AAQ-5140-2020	gressens, pierre/0000-0002-0909-4221; Breier, Georg/0000-0002-9467-780X; Carmeliet, Peter/0000-0001-7961-1821; Mackman, Nigel/0000-0002-9170-7700; Moons, Lieve (Godelieve)/0000-0003-0186-1411	NHLBI NIH HHS [P01 HL16411] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTIERI DC, 1995, FASEB J, V9, P860; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHEN BY, 1991, TERATOLOGY, V44, P581, DOI 10.1002/tera.1420440511; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; GRESSENS P, 1992, J NEUROPATH EXP NEUR, V51, P206, DOI 10.1097/00005072-199203000-00010; HUME DA, 1995, BRIT J HAEMATOL, V90, P939, DOI 10.1111/j.1365-2141.1995.tb05220.x; KASPER M, 1995, HISTOCHEM CELL BIOL, V104, P397, DOI 10.1007/BF01458134; Luther T, 1996, AM J PATHOL, V149, P101; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; NEHLS V, 1993, HISTOCHEMISTRY, V99, P1, DOI 10.1007/BF00268014; RICKLES FR, 1992, CANCER METAST REV, V11, P237, DOI 10.1007/BF01307180; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Sato Y, 1996, THROMB HAEMOSTASIS, V75, P389; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	23	564	581	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					73	75		10.1038/383073a0	http://dx.doi.org/10.1038/383073a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779717				2022-12-24	WOS:A1996VF29500049
J	Lipp, MM; Lee, KYC; Zasadzinski, JA; Waring, AJ				Lipp, MM; Lee, KYC; Zasadzinski, JA; Waring, AJ			Phase and morphology changes in lipid monolayers induced by SP-B protein and its amino-terminal peptide	SCIENCE			English	Article							AIR-WATER-INTERFACE; PULMONARY SURFACTANT; LUNG SURFACTANT; SP-C; DIPALMITOYLPHOSPHATIDYLCHOLINE; TRANSITIONS; DOMAINS; SHAPES; FILM	Both human lung surfactant protein, SP-B, and its amino-terminal peptide, SP-B-1-25, inhibit the formation of condensed phases in monolayers of palmitic acid, resulting new fluid phase. This fluid phase forms a network, separating condensed-phase domains at coexistence. The network persists to high surface pressures, altering the nucleation, growth, and morphology of monolayer collapse structures, leading to lower surface tensions on compression and more reversible respreading on expansion. The network is stabilized by the low line tension between the fluid phase and the condensed phase as confirmed by the formation of ''stripe'' phases.	UNIV CALIF SANTA BARBARA,DEPT CHEM ENGN,SANTA BARBARA,CA 93106; UNIV CALIF LOS ANGELES,HARBOR MED CTR,PERINATAL LABS,LOS ANGELES,CA 90059; MARTIN LUTHER KING JR DREW UNIV MED CTR,LOS ANGELES,CA 90059	University of California System; University of California Santa Barbara; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center					NHLBI NIH HHS [HL55534, HL51177-02] Funding Source: Medline; NIGMS NIH HHS [GM 50483] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S15GM050483] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON AW, 1990, PHYSICAL CHEM SURFAC; AVERY ME, 1959, AM J DIS CHILD, V97, P917; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; CHUNG JB, 1990, LANGMUIR, V6, P1647, DOI 10.1021/la00101a005; COCKSHUTT AM, 1991, BIOCHIM BIOPHYS ACTA, V1085, P248, DOI 10.1016/0005-2760(91)90101-M; DICKSTEIN AJ, 1993, SCIENCE, V261, P1012, DOI 10.1126/science.261.5124.1012; FIELDS C G, 1991, Peptide Research, V4, P95; Gordon LM, 1996, PROTEIN SCI, V5, P1662, DOI 10.1002/pro.5560050820; HAGWOOD S, 1987, P NATL ACAD SCI USA, V84, P66; HUNTER RJ, 1992, FDN COLLOID SCI, V1, pCH5; KNOBLER CM, 1992, ANNU REV PHYS CHEM, V43, P207, DOI 10.1146/annurev.pc.43.100192.001231; Lee K. T., UNPUB; LEE KYC, 1993, J PHYS CHEM-US, V97, P9532, DOI 10.1021/j100139a044; LONGO ML, 1993, SCIENCE, V261, P453, DOI 10.1126/science.8332910; LONGO ML, 1992, BIOPHYS J, V63, P760, DOI 10.1016/S0006-3495(92)81643-0; LONGO ML, 1993, THESIS U CALIFORNIA; MATHIALAGAN N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P121, DOI 10.1016/0005-2760(90)90140-S; MCCONNELL HM, 1991, ANNU REV PHYS CHEM, V42, P171, DOI 10.1146/annurev.physchem.42.1.171; MCCONNELL HM, 1988, J PHYS CHEM-US, V92, P4520, DOI 10.1021/j100326a053; MCCONNELL HM, 1984, NATURE, V310, P47; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P441, DOI 10.1146/annurev.pc.41.100190.002301; Nag K, 1996, BIOPHYS J, V71, P246, DOI 10.1016/S0006-3495(96)79221-4; PEREZGIL J, 1995, BIOCHEMISTRY-US, V34, P3964, DOI 10.1021/bi00012a014; PEREZGIL J, 1992, BIOPHYS J, V63, P197, DOI 10.1016/S0006-3495(92)81582-5; POST A, 1995, MOL MEMBR BIOL, V12, P93, DOI 10.3109/09687689509038502; SARIN VK, 1990, P NATL ACAD SCI USA, V87, P2633, DOI 10.1073/pnas.87.7.2633; SEEGER W, 1992, AM J PHYSIOL, V262, pL286, DOI 10.1152/ajplung.1992.262.3.L286; SEELIG J, 1995, MOL MEMBR BIOL, V12, P51, DOI 10.3109/09687689509038495; SEUL M, 1995, SCIENCE, V267, P476, DOI 10.1126/science.267.5197.476; SEUL M, 1990, PHYS REV LETT, V64, P1903, DOI 10.1103/PhysRevLett.64.1903; SEUL M, 1993, PHYS REV LETT, V70, P1658, DOI 10.1103/PhysRevLett.70.1658; Shapiro D. L, 1989, SURFACTANT REPLACEME; SMITH RD, 1980, J COLLOID INTERF SCI, V74, P273, DOI 10.1016/0021-9797(80)90190-3; SOLL RF, 1992, RESIDENT STAFF PHYSI, V38, P19; STINE KJ, 1992, LANGMUIR, V8, P2509, DOI 10.1021/la00046a026; WHITSETT JA, 1986, PEDIATR RES, V20, P460, DOI 10.1203/00006450-198605000-00016; XU S, 1982, J COLLOID INTERF SCI, V89, P581, DOI 10.1016/0021-9797(82)90213-2; YU SH, 1992, BIOCHIM BIOPHYS ACTA, V1126, P26, DOI 10.1016/0005-2760(92)90212-E; YU SH, 1986, BIOCHEM J, V236, P85, DOI 10.1042/bj2360085	39	163	167	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1196	1199		10.1126/science.273.5279.1196	http://dx.doi.org/10.1126/science.273.5279.1196			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703046				2022-12-24	WOS:A1996VE47600029
J	Fullner, KJ; Lara, JC; Nester, EW				Fullner, KJ; Lara, JC; Nester, EW			Pilus assembly by Arobacterium T-DNA transfer genes	SCIENCE			English	Article							AGROBACTERIUM-TUMEFACIENS; BACTERIAL CONJUGATION; VIRULENCE; PLANT; MUTATIONS; OPERON	Agrobacterium tumefaciens can genetically transform eukaryotic cells, In many bacteria, pill are required for interbacterial DNA transfer. The formation of pill by Agrobacterium required induction of tumor-inducing (Ti) plasmid-encoded virulence genes and growth at low temperature, Agenetic analysis demonstrated that virA, virG, virB1 through virB11, and virD4 are the only Ti plasmid genes necessary for pilus assembly, The loss and gain of pill in various mutants correlated with the loss and gain of transferred DNA (T-DNA) transfer functions, which is consistent with the view that Agrobacterium pill are required for transfer of DNA to plant cells in a process similar to that of conjugation.	UNIV WASHINGTON, DEPT MICROBIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BOT, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Satchell, Karla/GSN-3100-2022		NIGMS NIH HHS [GM32618] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032618] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEIJERSBERGEN A, 1992, SCIENCE, V256, P1324, DOI 10.1126/science.256.5061.1324; BERGER BR, 1994, J BACTERIOL, V176, P3646, DOI 10.1128/JB.176.12.3646-3660.1994; BINNS KJ, 1995, UNPUB, V177, P4890; BRADLEY DE, 1978, PLASMID, V1, P376, DOI 10.1016/0147-619X(78)90053-7; BRADLEY DE, 1980, PLASMID, V4, P155, DOI 10.1016/0147-619X(80)90005-0; BUNDOCK P, 1995, EMBO J, V14, P3206, DOI 10.1002/j.1460-2075.1995.tb07323.x; CANGELOSI GA, 1991, METHOD ENZYMOL, V204, P384; CHRISTIE PJ, 1988, J BACTERIOL, V170, P2659, DOI 10.1128/jb.170.6.2659-2667.1988; DALE EM, 1993, J BACTERIOL, V175, P887, DOI 10.1128/JB.175.3.887-891.1993; DEFEYTER R, 1990, GENE, V88, P65, DOI 10.1016/0378-1119(90)90060-5; Frost LS., 1993, BACTERIAL CONJUGATIO, P189; Fullner KJ, 1996, J BACTERIOL, V178, P1498, DOI 10.1128/jb.178.6.1498-1504.1996; FULLNER KJ, 1994, MOL GEN GENET, V245, P705; GRIMSLEY N, 1989, MOL GEN GENET, V217, P309, DOI 10.1007/BF02464898; HAASE J, 1995, J BACTERIOL, V177, P4779, DOI 10.1128/jb.177.16.4779-4791.1995; Heath J.D., 1995, 2 COMPONENT SIGNAL T, P367; LESSL M, 1994, CELL, V77, P321, DOI 10.1016/0092-8674(94)90146-5; MAHER D, 1993, J BACTERIOL, V175, P2175, DOI 10.1128/JB.175.8.2175-2183.1993; MATTHYSSE AG, 1983, J BACTERIOL, V154, P906, DOI 10.1128/JB.154.2.906-915.1983; PAZOUR GJ, 1992, J BACTERIOL, V174, P4169, DOI 10.1128/jb.174.12.4169-4174.1992; Piers KL, 1996, P NATL ACAD SCI USA, V93, P1613, DOI 10.1073/pnas.93.4.1613; POHLMAN RF, 1994, MOL MICROBIOL, V14, P655, DOI 10.1111/j.1365-2958.1994.tb01304.x; Riker AJ, 1926, J AGRIC RES, V32, P0083; SCIAKY D, 1978, PLASMID, V1, P238, DOI 10.1016/0147-619X(78)90042-2; SHIRASU K, 1993, FEMS MICROBIOL LETT, V111, P287, DOI 10.1111/j.1574-6968.1993.tb06400.x; STEPHENS KM, 1995, J BACTERIOL, V177, P27, DOI 10.1002/path.1711770106; Sundberg C, 1996, J BACTERIOL, V178, P1207, DOI 10.1128/jb.178.4.1207-1212.1996; Tummuru MKR, 1995, MOL MICROBIOL, V18, P867, DOI 10.1111/j.1365-2958.1995.18050867.x; WATERS VL, 1992, J BACTERIOL, V174, P6666, DOI 10.1128/JB.174.20.6666-6673.1992; WATSON B, 1975, J BACTERIOL, V123, P255, DOI 10.1128/JB.123.1.255-264.1975; WILLETTS N, 1981, GENET RES, V37, P311, DOI 10.1017/S0016672300020310; Winans SC, 1996, TRENDS MICROBIOL, V4, P64, DOI 10.1016/0966-842X(96)81513-7; WINANS SC, 1987, NUCLEIC ACIDS RES, V15, P825, DOI 10.1093/nar/15.2.825; ZAMBRYSKI P, 1991, MOBILE DNA, P309; ZUPAN JR, 1995, PLANT PHYSIOL, V107, P1041, DOI 10.1104/pp.107.4.1041	35	181	211	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 23	1996	273	5278					1107	1109		10.1126/science.273.5278.1107	http://dx.doi.org/10.1126/science.273.5278.1107			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688097				2022-12-24	WOS:A1996VD42800038
J	ElKhoury, J; Hickman, SE; Thomas, CA; Cao, L; Silverstein, SC; Loike, JD				ElKhoury, J; Hickman, SE; Thomas, CA; Cao, L; Silverstein, SC; Loike, JD			Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils	NATURE			English	Article							ALZHEIMER-DISEASE; FLUOROMETRIC ASSAY; BASEMENT-MEMBRANE; END-PRODUCTS; CONGO RED; MACROPHAGES; NEUROTOXICITY; ACTIVATION; PROTEIN; REGION	A PATHOLOGICAL hallmark of Alzheimer's disease is the senile plaque, containing beta-amyloid fibrils, microglia and astrocytes(1). beta-amyloid fibrils exert a cytotoxic effect on neurons(2), and stimulate microglia to produce neurotoxins, such as reactive oxygen species(3,4). Mononuclear phagocytes, including microglia, express scavenger receptors that mediate endocytosis of oxidized low-density lipoproteins(5), and adhesion to glucose-modified extracellular matrix proteins(6). Here we report that class A scavenger receptors mediate adhesion of rodent microglia and human monocytes to beta-amyloid fibril-coated surfaces leading to secretion of reactive oxygen species and cell immobilization. Thus, class A scavenger receptors are potential therapeutic targets in Alzheimer's disease.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University	ElKhoury, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032, USA.			El Khoury, Joseph/0000-0003-1498-1703				AKESON AL, 1993, J IMMUNOL METHODS, V163, P181, DOI 10.1016/0022-1759(93)90121-M; AUSUBEL FM, 1993, CURR PROT MOL BIOL, V1, P921; BELL MD, 1994, J NEUROCYTOL, V23, P605, DOI 10.1007/BF01191555; Christie RH, 1996, AM J PATHOL, V148, P399; ELGHETANY MT, 1989, ANN CLIN LAB SCI, V19, P190; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; GIULIAN D, 1986, J NEUROSCI, V6, P2163; HARTUNG HP, 1986, LAB INVEST, V55, P209; JIANG HX, 1994, J IMMUNOL, V152, P5050; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LOIKE JD, 1995, J EXP MED, V181, P1763, DOI 10.1084/jem.181.5.1763; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; NARINDRASORASAK S, 1995, LAB INVEST, V72, P272; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; WAN CP, 1993, J IMMUNOL METHODS, V159, P131, DOI 10.1016/0022-1759(93)90150-6; WISNIEWSKI HM, 1989, J NEUROPATH EXP NEUR, V48, P606	23	626	649	0	31	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					716	719						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751442				2022-12-24	WOS:A1996VD33300050
J	Nelson, JR; Lawrence, CW; Hinkle, DC				Nelson, JR; Lawrence, CW; Hinkle, DC			Deoxycytidyl transferase activity of yeast REV1 protein	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE; MUTAGENESIS	MUTAGENESIS induced by DNA damage in Sacchalamyces cerevisiae requires the products of the REV1, REV3 and REV7 genes(1), The Rev3 and Rev7 proteins are subunits of DNA polymerase-zeta(2) (Pol-zeta), an enzyme whose sole function appears to be translesion synthesis(3). Rev1 protein has weak homology with UmuC protein(4), which facilitates translesion synthesis in Escherichia coli by an unknown mechanism. We show here that Rev1 protein has a deoxycytidyl transferase activity which transfers a dCMP residue from dCTP to the 3' end of a DNA primer in a template-dependent reaction. Efficient transfer occurred opposite a template abasic site, but similar to 20% transfer also occurred opposite a template guanine and similar to 10% opposite adenine or uracil; less than or equal to 1% was seen opposite thymine or cytosine. Insertion of cytosine opposite an abasic site produced a terminus that was extended efficiently by Pol-zeta, but not by yeast Poi-alpha.	UNIV ROCHESTER,DEPT BIOPHYS,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14642	University of Rochester; University of Rochester								ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; GIBBS PEM, 1995, J MOL BIOL, V251, P229, DOI 10.1006/jmbi.1995.0430; GIBBS PEM, 1995, NUCLEIC ACIDS RES, V23, P1919, DOI 10.1093/nar/23.11.1919; GIBBS PEM, 1993, J BACTERIOL, V175, P2607, DOI 10.1128/JB.175.9.2607-2612.1993; LARIMER FW, 1989, J BACTERIOL, V171, P230, DOI 10.1128/jb.171.1.230-237.1989; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ratliff R.L., 1981, ENZYMES, VXIV, P105	10	499	504	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					729	731		10.1038/382729a0	http://dx.doi.org/10.1038/382729a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751446				2022-12-24	WOS:A1996VD33300054
J	Samson, M; Libert, F; Doranz, BJ; Rucker, J; Liesnard, C; Farber, CM; Saragosti, S; Lapoumeroulie, C; Cognaux, J; Forceille, C; Muyldermans, G; Verhofstede, C; Burtonboy, G; Georges, M; Imai, T; Rana, S; Yi, YJ; Smyth, RJ; Collman, RG; Doms, RW; Vassart, G; Parmentier, M				Samson, M; Libert, F; Doranz, BJ; Rucker, J; Liesnard, C; Farber, CM; Saragosti, S; Lapoumeroulie, C; Cognaux, J; Forceille, C; Muyldermans, G; Verhofstede, C; Burtonboy, G; Georges, M; Imai, T; Rana, S; Yi, YJ; Smyth, RJ; Collman, RG; Doms, RW; Vassart, G; Parmentier, M			Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELLS; ACTIVATION; CLONING	HIV-1 and related viruses require co-receptors, in addition to CD4, to infect target cells. The chemokine receptor CCR-5 (ref. 1) was recently demonstrated to be a co-receptor for macrophage-tropic (M-tropic) HIV-1 strains(2-6), and the orphan(7) receptor LESTR (also called fusin) allows infection by strains adapted for growth in transformed T-cell lines (T-tropic strains). Here we show that a mutant allele of CCR-5 is present at a high frequency in caucasian populations (allele frequency, 0.092), but is absent in 'black populations from Western and Central Africa and Japanese populations. A 32-base-pair deletion within the coding region results in a frame shift, and generates a non-functional receptor that does not support membrane fusion or infection by macrophage- and dual-tropic HIV-1 strains. In a cohort of HIV-1-infected caucasian subjects, no individual homozygous for the mutation was found, and the frequency of heterozygotes was 35% lower than in the general population. White blood cells from an individual homozygous for the null allele were found to be highly resistant to infection by M-tropic HIV-1 viruses, confirming that CCR-5 is the major cc-receptor for primary HIV-1 strains, The lower frequency of heterozygotes in seropositive patients may indicate partial resistance.	FREE UNIV BRUSSELS,IRIBHN,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,SERV GENET MED,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,SERV VIROL,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,SERV IMMUNODEFICIENCES,B-1070 BRUSSELS,BELGIUM; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; HOP COCHIN,INST COCHIN GENET MOL,F-75014 PARIS,FRANCE; HOP ROBERT DEBRE,INSERM,U120,F-75935 PARIS,FRANCE; UNIV LIEGE,BELGIAN AIDS REFERENCE LABS,B-4000 LIEGE,BELGIUM; UNIV LIEGE,FAC VET MED,DEPT GENET,B-4000 LIEGE,BELGIUM; NAGOYA UNIV,SCH MED,DEPT SURG 2,NAGOYA,AICHI 466,JAPAN; UNIV PENN,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Pennsylvania; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Liege; University of Liege; Nagoya University; University of Pennsylvania			Lapoumeroulie, Claudine/P-3515-2018; Samson, Michel/F-8356-2013; Muyldermans, Gaetan/AAE-7235-2020	Parmentier, Marc/0000-0001-8081-4685; LAPOUMEROULIE, Claudine/0000-0001-6665-3598				AGUILARCORDOVA E, 1994, AIDS RES HUM RETROV, V10, P295, DOI 10.1089/aid.1994.10.295; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DETELS R, 1994, J ACQ IMMUN DEF SYND, V7, P1263; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; DRAJIC T, 1996, NATURE, V381, P667; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; JAZIN EE, 1993, REGUL PEPTIDES, V47, P247, DOI 10.1016/0167-0115(93)90392-L; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SPIRA AI, 1995, J VIROL, V69, P422, DOI 10.1128/JVI.69.1.422-429.1995; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TAYLOR R, 1994, J NIH RES, V6, P29; WAINBERG MA, 1987, CLIN EXP IMMUNOL, P136; WILLIAMS LM, 1991, VIROLOGY, V184, P723, DOI 10.1016/0042-6822(91)90442-E	24	2323	2455	3	158	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					722	725		10.1038/382722a0	http://dx.doi.org/10.1038/382722a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751444				2022-12-24	WOS:A1996VD33300052
J	Beelman, CA; Stevens, A; Caponigro, G; LaGrandeur, TE; Hatfield, L; Fortner, DM; Parker, R				Beelman, CA; Stevens, A; Caponigro, G; LaGrandeur, TE; Hatfield, L; Fortner, DM; Parker, R			An essential component of the decapping enzyme required for normal rates of mRNA turnover	NATURE			English	Article							TRANSLATIONAL TERMINATION CODON; MESSENGER-RNA DECAY; SACCHAROMYCES-CEREVISIAE; YEAST; DEADENYLATION; DEGRADATION; TRANSCRIPT; PROTEIN; GENE; IDENTIFICATION	A MAJOR pathway of messenger RNA degradation in eukaryotic cells is initiated by shortening of the poly(A) tail, which, at least in yeast, triggers a decapping reaction, thereby exposing the mRNA to 5' --> 3' degradation(1-4). Decapping is the key step in this decay pathway because the transcript body is rapidly degraded following decapping. Accordingly, decapping is the site of numerous controls, including inhibition of decapping by the poly(A) tail(3,4) and modulation of mRNA decapping rate by specific sequences(3-5). Moreover, a specialized decay pathway that degrades aberrant transcripts triggers rapid mRNA decapping independently of poly(A)-tail shortening(6). We have identified a yeast gene, termed DCP1, that encodes the decapping enzyme, or an essential component of a decapping complex. The protein Dcp1 is required for the normal decay of many unstable and stable yeast mRNAs, as well as mRNAs that are decapped independently of deadenylation. These results indicate that mRNA-specific rates of decapping, and thus decay, will result from differences in the interaction of the DCP1 decapping enzyme with individual transcripts.	UNIV ARIZONA,HOWARD HUGHES MED INST,TUCSON,AZ 85721; UNIV ARIZONA,DEPT MOL & CELLULAR BIOL,TUCSON,AZ 85721; OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831	Howard Hughes Medical Institute; University of Arizona; University of Arizona; United States Department of Energy (DOE); Oak Ridge National Laboratory								BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CUI Y, 1995, GENE DEV, V9, P423, DOI 10.1101/gad.9.4.423; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; HATFIELD L, IN PRESS MOL CELL BI; HE F, 1995, GENE DEV, V9, P437, DOI 10.1101/gad.9.4.437; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; JOHNSON AW, 1991, J BIOL CHEM, V266, P14046; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; MANDART E, 1995, MOL CELL BIOL, V15, P6979; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; PELTZ SW, 1994, PROG NUCLEIC ACID RE, V47, P271, DOI 10.1016/S0079-6603(08)60254-8; STEVENS A, 1988, MOL CELL BIOL, V8, P2005, DOI 10.1128/MCB.8.5.2005	21	272	277	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					642	646		10.1038/382642a0	http://dx.doi.org/10.1038/382642a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757137				2022-12-24	WOS:A1996VC30300057
J	Ring, BZ; Yarnell, WS				Ring, BZ; Yarnell, WS			Function of E-coli RNA polymerase sigma factor sigma(70) in promoter-proximal pausing	CELL			English	Article							ESCHERICHIA-COLI; TRANSCRIPTION INITIATION; TERNARY COMPLEXES; DNA; SUBUNIT; SPECIFICITY; RECOGNITION; ELONGATION; SEQUENCES; BINDING	The sigma factor sigma(70) of E. coli RNA polymerase acts not only in initiation, but also at an early stage of elongation to induce a transcription pause, and simultaneously to allow the phage lambda gene Q transcription antiterminator to act. We identify the signal in DNA that induces early pausing to be a version of the sigma(70) -10 promoter consensus, and we show that sigma(70) is both necessary for pausing and present in the paused transcription complex. Regions 2 and 3 of sigma(70) suffice to induce pausing. Since pausing is induced by the nontemplate DNA strand of the open transcription bubble, we conclude that RNA polymerase containing sigma(70) carries out base-specific recognition of the nontemplate strand as single stranded DNA. We suggest that sigma(70) remains bound to core RNA polymerase when the -10 promoter contacts are broken, and then moves to the pause-inducing sequence.			Ring, BZ (corresponding author), CORNELL UNIV,BIOCHEM MOL & CELL BIOL SECT,ITHACA,NY 14853, USA.				PHS HHS [21941] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AIYAR SE, 1994, J BIOL CHEM, V269, P13179; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1969, J BIOL CHEM, V244, P6160; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DEBOER HA, 1979, CELL, V17, P201, DOI 10.1016/0092-8674(79)90308-8; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; GOLIGER JA, 1989, J MOL BIOL, V210, P461, DOI 10.1016/0022-2836(89)90123-X; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; GUO HC, 1990, J BACTERIOL, V173, P1554; GUO HC, 1990, THESIS CORNELL U ITH; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Johnston D. E., 1976, RNA POLYMERASE, P413; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KEILTY S, 1987, J BIOL CHEM, V262, P6389; KENNEY TJ, 1989, P NATL ACAD SCI USA, V86, P9109, DOI 10.1073/pnas.86.23.9109; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; RIGGS DL, 1986, P NATL ACAD SCI USA, V83, P9333, DOI 10.1073/pnas.83.24.9333; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; RING BZ, 1995, THESIS CORNELL U ITH; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; SHIMAMOTO N, 1986, J BIOL CHEM, V261, P1859; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; STRANEY DC, 1987, J MOL BIOL, V193, P279, DOI 10.1016/0022-2836(87)90219-1; TRAVERS AA, 1980, J BACTERIOL, V141, P973, DOI 10.1128/JB.141.2.973-976.1980; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; YANG X, 1988, THESIS CORNELL U ITH; YANG XJ, 1989, J MOL BIOL, V210, P453, DOI 10.1016/0022-2836(89)90122-8; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	41	173	179	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					485	493		10.1016/S0092-8674(00)80121-X	http://dx.doi.org/10.1016/S0092-8674(00)80121-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756730	hybrid			2022-12-24	WOS:A1996VC30900016
J	Faden, RR; Feinberg, KR; Glatstein, E; Lederer, SE; Macklin, R; Norris, LL; Oleinick, NL; Royal, HD; Russell, PK; Stevenson, MA; Thomas, DC; Tuckson, RV				Faden, RR; Feinberg, KR; Glatstein, E; Lederer, SE; Macklin, R; Norris, LL; Oleinick, NL; Royal, HD; Russell, PK; Stevenson, MA; Thomas, DC; Tuckson, RV			Research ethics and the medical profession - Report of the advisory committee on human radiation experiments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFORMED CONSENT; PHASE-I; TRIALS	The Advisory Committee on Human Radiation Experiments was convened by President Clinton in January 1994 in response to allegations of unethical practices in radiation experiments involving human subjects that were sponsored by the US government between 1944 and 1974. The committee's Final Report was released in October 1995. In addition to analyzing the history of the ethics of medical research involving human subjects, the committee reviewed current federal policies and procedures for protection of human subjects. In this article, the committee's findings are discussed as they relate to the patient-physician relationship, the issue of trust, and the specific role of the physician-investigator in all types of human experimentation. The committee found evidence of discussion of the conduct of human research at the highest levels of the government and within the medical profession, particularly with regard to risk, during the 1940s and 1950s. However, in both federal policy and professional practice, requirements for consent were more likely to apply to ''healthy volunteers'' than to patient-subjects (ie, those with disease or illness). Today, consensus exists that duties to obtain informed consent apply to all human subjects, whether healthy or sick, regardless of the risk or potential for medical benefit from participation in the research and regardless of the nature of sponsorship or funding (eg, federal, military, or private). Based on a finding of serious deficiencies in the current system of protections for human subjects, the committee offers a number of recommendations, including changes in institutional review boards, in the interpretation of ethics rules and policies; in oversight, accountability, and sanctions for ethics violation: and in compensation for research injuries. More than public policy changes, however, the committee recommends that the medical profession intensify its commitment to the ethics of research involving human subjects.	GEORGETOWN UNIV,KENNEDY INST ETH,WASHINGTON,DC 20057; KENNETH R FEINBERG & ASSOCIATES,WASHINGTON,DC; UNIV PENN,PHILADELPHIA,PA 19104; YALE UNIV,SCH LAW,NEW HAVEN,CT 06520; PENN STATE UNIV,COLL MED,HERSHEY,PA; ALBERT EINSTEIN COLL MED,BRONX,NY 10467; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH; UNIV WASHINGTON,MED CTR,ST LOUIS,MO; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD; HARVARD UNIV,SCH MED,BOSTON,MA; UNIV SO CALIF,SCH MED,LOS ANGELES,CA; CHARLES R DREW UNIV MED & SCI,LOS ANGELES,CA 90059; GEORGETOWN UNIV,CTR LAW,WASHINGTON,DC	Georgetown University; University of Pennsylvania; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Yeshiva University; Albert Einstein College of Medicine; Case Western Reserve University; Washington University (WUSTL); Johns Hopkins University; Harvard University; Harvard Medical School; University of Southern California; Charles R. Drew University of Medicine & Science; Georgetown University	Faden, RR (corresponding author), JOHNS HOPKINS UNIV,INST BIOETH,624 N BROADWAY,HAMPTON HOUSE 511,BALTIMORE,MD 21205, USA.							Advisory Committee on Human Radiation Experiments, 1996, HUM RAD EXP FIN REP; [Anonymous], 1986, HIST THEORY INFORM C; BEESON P, 1994, ACHRE RES PROJECT SE, P16; Bujorian G A, 1988, Oncol Nurs Forum, V15, P779; CASSILETH BR, 1982, JAMA-J AM MED ASSOC, V248, P968, DOI 10.1001/jama.248.8.968; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; DECOSTER G, 1990, ANN ONCOL, V2, P175; ESTEY E, 1986, CANCER TREAT REP, V70, P1105; KASS NE, 1991, FED REG         0618, V56, P28002; KATZ J, 1987, IRB, V9, P5; Katz J., 1972, EXPT HUMAN BEINGS; KING NMP, 1993, HASTINGS CTR REP, V25, P6; LYNOE N, 1991, BRIT MED J, V303, P610, DOI 10.1136/bmj.303.6803.610; MALTBY JR, 1993, CAN J ANAESTH, V40, P897, DOI 10.1007/BF03009265; Natl. Comm. Prot. Hum. Subj. Biomed. Behav. Res, 1978, BELM REP ETH PRINC G; *NIH, 1953, HHS090794A NIH ACHRE; *NIH, 1954, HHS090794A NIH ACHRE; OCKENE IS, 1991, CLIN RES, V39, P13; Pellegrino E., 1988, PATIENTS GOOD RESTOR; PENMAN DT, 1984, J CLIN ONCOL, V2, P849, DOI 10.1200/JCO.1984.2.7.849; RIECKEN HW, 1982, JAMA-J AM MED ASSOC, V248, P344, DOI 10.1001/jama.248.3.344; SAGAN L, 1994, ACHRE RES PROJECT SE, P13; TANAKANOW RM, 1992, AM J HOSP PHARM, V49, P633; VONHOFF DD, 1991, INVEST NEW DRUG, V9, P115, DOI 10.1007/BF00194562	24	34	34	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					403	409						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ776	8683820				2022-12-24	WOS:A1996UZ77600023
J	Chamovitz, DA; Wei, N; Osterlund, MT; vonArnim, AG; Staub, JM; Matsui, M; Deng, XW				Chamovitz, DA; Wei, N; Osterlund, MT; vonArnim, AG; Staub, JM; Matsui, M; Deng, XW			The COP9 complex, a novel multisubunit nuclear regulator involved in light control of a plant developmental switch	CELL			English	Article							MEDIATED DEVELOPMENT; ARABIDOPSIS; PROTEIN; GENE; ENCODES	Arabidopsis COP9 is a component of a large protein complex that is essential for the light control of a developmental switch and whose conformation or size is modulated by light. The complex is acidic, binds heparin, and is localized within the nucleus. Biochemical purification of the complex to near homogeneity revealed that it contains 12 distinct subunits. One of the other subunits is COP11, mutations in which result in a phenotype identical to cop9 mutants. The COP9 complex may act to regulate the nuclear abundance of COP1, an established repressor of photomorphogenic development. During the biogenesis of the COP9 complex, a certain degree of prior subunit association is a prerequisite for proper nuclear translocation. Since both COP9 and COP11 have closely related human counterparts, the COP9 complex probably represents a conserved developmental regulator in higher eukaryotes.	YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06520 USA; RIKEN, LAB PHOTOPERCEPT & SIGNAL TRANSDUCT, WAKO, SAITAMA 35101, JAPAN	Yale University; RIKEN			Deng, Xing Wang/ABF-4107-2020; Chamovitz, Daniel/S-5021-2019; Matsui, Minami/A-5235-2016	Chamovitz, Daniel/0000-0002-2815-2909; Matsui, Minami/0000-0001-5162-2668; von Arnim, Albrecht/0000-0003-3472-3357				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BOWLER C, 1994, PLANT CELL, V6, P1529, DOI 10.1105/tpc.6.11.1529; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHAMOVITZ DA, 1995, CELL, V82, P353, DOI 10.1016/0092-8674(95)90423-9; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; Kwok SF, 1996, PLANT PHYSIOL, V110, P731, DOI 10.1104/pp.110.3.731; MATSUI M, 1995, P NATL ACAD SCI USA, V92, P4239, DOI 10.1073/pnas.92.10.4239; MCNELLIS TW, 1995, PLANT CELL, V7, P1749, DOI 10.1105/tpc.7.11.1749; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MCNELLIS TW, 1994, PLANT CELL, V6, P1391, DOI 10.1105/tpc.6.10.1391; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; WEI N, 1994, PLANT CELL, V6, P629, DOI 10.1105/tpc.6.5.629; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9	18	255	271	2	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					115	121		10.1016/S0092-8674(00)80082-3	http://dx.doi.org/10.1016/S0092-8674(00)80082-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689678	hybrid			2022-12-24	WOS:A1996UX93400013
J	Ginsburg, J				Ginsburg, J			Tackling environmental endocrine disrupters	LANCET			English	Editorial Material											Ginsburg, J (corresponding author), UNIV LONDON,ROYAL FREE HOSP & SCH MED,DEPT MED,LONDON,ENGLAND.							Colborn T., 1996, OUR STOLEN FUTURE; *DAN MIN EN ENV, 1995, 290 DAN MIN EN ENV; *I ENV HLTH, 1995, IEH ASS ENV OESTR CO; KAVLOCK RJ, IN PRESS ENV HLTH PE; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; *UMW BUND, 1955, END ACT CHEM ENV; 1995, LANCET, V345, P933	7	12	14	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1501	1502		10.1016/S0140-6736(96)90667-4	http://dx.doi.org/10.1016/S0140-6736(96)90667-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UN473	8684098				2022-12-24	WOS:A1996UN47300006
J	Johansson, A; Hoa, HT; Lap, NT; Diwan, V; Eriksson, B				Johansson, A; Hoa, HT; Lap, NT; Diwan, V; Eriksson, B			Population policies and reproductive patterns in Vietnam	LANCET			English	Article								Background Vietnam's population policy since the 1980s had stipulated a limit on family size to two children, born 3-5 years apart, and recommends a minimum age of 19 for the mother of a first child, We analysed trends in the timing of marriages and births, and in fertility and abortion rates, among women born between 1945 and 1970, to assess the impact of these policies on reproductive patterns. Methods Reproductive histories were recorded in a random sample of 1432 married women aged 15-49 in a rural province in northern Vietnam. Mean age at marriage and at birth of the first child, birth intervals, fertility, and abortion rates were examined in relation to the woman's year of birth. Findings Later-born women married and had their first child at a younger age than women born earlier. Birth intervals had increased among later-born women but 25% still had only a 1-year interval between first and second child, Fertility had gradually decreased while abortion ratios had increased rapidly. Childbearing patterns had become ''earlier, longer, and fewer'' rather than ''later, longer, and fewer'' as stipulated by the policies. The results also show that women with more schooling married and had their first child later, Women involved in farming had shorter spacing between children. Interpretation There are signs that Vietnam's population policy has focused too strongly on contraception and abortion while ignoring the connection between fertility and women's opportunities for education and employment. In these respects, rural women are at particular risk.	HANOI SCH MED,DEPT HYG ENVIRONM & EPIDEMIOL,HANOI,VIETNAM; CTR RES GENDER FAMILY & ENVIRONM DEV,HANOI,VIETNAM; NORD SCH PUBL HLTH,GOTHENBURG,SWEDEN	Hanoi Medical University	Johansson, A (corresponding author), KAROLINSKA INST,IHCAR,DEPT INT HLTH & SOCIAL MED,S-17177 STOCKHOLM,SWEDEN.							Banister J., 1993, VIETNAM POPULATION D; Blackburn J. L., 1993, SOCIAL RES DEV COUNT, P193; BONGAARTS J, 1985, POPUL DEV REV, V4, P586; Cochrane S.H., 1980, POPULATION, V35, P985; COX DR, 1989, ANAL SURVIVAL DATA; Dixon-Muller R., 1993, POPULATION POLICY WO; FONG SM, 1994, GENDER POVERTY VIETN; *GEN STAT OFF, 1992, VIETN POP CENS 1989; GOODKIND A, 1994, STUD FAM PLAN, V26, P342; HENSHAW SK, 1990, INDUCED ABORTIONS S; Hieu Do Trong, 1993, ASIA PACIFIC POP J, V8, P3; HOA HT, IN PRESS BMJ; JOHANSSON A, IN PRESS INT FAM PLA; *KIEN XUONG STAT O, 1995, THAI BINH; LOC N, 1993, J BIOSOC SCI, V25, P303; MARTIN TC, 1995, STUD FAMILY PLANN, V26, P187, DOI 10.2307/2137845; *NAT COMM POP FAM, 1990, VIETN DEM HLTH SURV; NHAN VQ, 1994, VIETNAM SOC SCI REV, V39, P3; RAJARETNAM T, 1993, J FAM WELFARE, V34, P3; RELE JR, 1993, REVOLUTION ASIAN FER; SAN PB, 1992, DEMOGRAPHIC TRANSITI; *STAT PLANN COMM G, 1995, VIETN LIV STAND SURV; *UN, 1992, POP STUD, V120; *UNICEF, 1994, COND WOM CHILDR VIET; VALDELIN J, 1993, 1992 93 SIDA; 1989, POPUL DEV REV, V15, P169	26	6	6	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 1	1996	347	9014					1529	1532		10.1016/S0140-6736(96)90676-5	http://dx.doi.org/10.1016/S0140-6736(96)90676-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UN473	8684107	Bronze			2022-12-24	WOS:A1996UN47300015
J	Gardner, CD; Fortmann, SP; Krauss, RM				Gardner, CD; Fortmann, SP; Krauss, RM			Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STANFORD 5-CITY PROJECT; PLASMA TRIGLYCERIDE CONCENTRATION; HEART-DISEASE; RISK-FACTORS; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; SUBCLASS PATTERNS; FAMILIAL HYPERCHOLESTEROLEMIA; APOLIPOPROTEIN-B; HEPATIC LIPASE	Objective.-To investigate the prospective association of low-density lipoprotein (LDL) particle diameter with the incidence of fatal and nonfatal coronary artery disease (CAD). Design.-A nested case-control study. Setting.-Cases and controls were identified from a population-based sample of men and women combining all of the 5 cross-sectional surveys conducted from 1979 to 1990 of the Stanford Five-City Project (FCP). Participants.-Incident CAD cases were identified through FCP surveillance between 1979 and 1992. Controls were matched by sex, 5-year age groups, survey time point, ethnicity, and FCP treatment condition. The sample included 124 matched pairs: 90 pairs of men and 34 pairs of women. Main Outcome Measures.-LDL peak particle diameter (LDL size) was determined by gradient gel electrophoresis on plasma samples collected during the cross-sectional surveys (stored at 70 degrees C for 5-15 years). Established CAD risk-factor data were available from FCP baseline measurements. Results.-LDL size was smaller among CAD cases than controls (mean+/-SD) (26.17+/-1.00 nm vs 26.68+/-0.90 nm; P<.001). The association was graded across control quintiles of LDL size. The significant case-control difference in LDL size was independent of levels of high-density lipoprotein cholesterol (HDL-C), non-HDL cholesterol (non-HDL-C), triglyceride, smoking, systolic blood pressure, and body mass index, but was not significant after adjusting for the ratio of total cholesterol (TC) to HDL-C (TC:HDL-C). Among all the physiological risk factors, LDL size was the best differentiator of CAD status in conditional logistic regression. However, when added to the physiological parameters above, the TC:HDL-C ratio was found to be a stronger independent predictor of CAD status. Conclusion.-LDL size was significantly smaller in CAD cases than in controls in a prospective, population-based study. These findings support other evidence of a role for small, dense LDL particles in the etiology of atherosclerosis.	STANFORD UNIV, SCH MED, STANFORD CTR RES DIS PREVENT, PALO ALTO, CA 94304 USA; STANFORD UNIV, SCH MED, DEPT MED, PALO ALTO, CA 94304 USA; LAWRENCE BERKELEY NATL LAB, DIV LIFE SCI, BERKELEY, CA USA	Stanford University; Stanford University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory			Adiels, Martin/C-9278-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007034, P01HL018574, R01HL021906] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21906, HL 18574, 5 T32 HL07034] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAD Y, 1992, CIRCULATION, V86, P551; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495; AUWERX JH, 1989, ARTERIOSCLEROSIS, V9, P319, DOI 10.1161/01.ATV.9.3.319; BARAKAT HA, 1990, DIABETES, V39, P1527, DOI 10.2337/diabetes.39.12.1527; CAMEJO G, 1990, CURR OPIN LIPIDOL, V1, P431; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P187, DOI 10.1161/01.ATV.12.2.187; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P1410, DOI 10.1161/01.ATV.12.12.1410; CASTELLI WP, 1983, CIRCULATION, V67, P730, DOI 10.1161/01.CIR.67.4.730; CHAIT A, 1993, AM J MED, V94, P350, DOI 10.1016/0002-9343(93)90144-E; CORESH J, 1993, J LIPID RES, V34, P1687; CROUSE JR, 1985, J LIPID RES, V26, P566; DECKELBAUM RJ, 1984, ARTERIOSCLEROSIS, V4, P225, DOI 10.1161/01.ATV.4.3.225; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; DREON DM, 1994, FASEB J, V8, P121, DOI 10.1096/fasebj.8.1.8299884; FARQUHAR JW, 1985, AM J EPIDEMIOL, V122, P323, DOI 10.1093/oxfordjournals.aje.a114104; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FORTMANN SP, 1986, AM J EPIDEMIOL, V123, P656, DOI 10.1093/oxfordjournals.aje.a114285; FORTMANN SP, 1984, PREV MED, V13, P127, DOI 10.1016/0091-7435(84)90045-8; GRIFFIN BA, 1994, ATHEROSCLEROSIS, V106, P241, DOI 10.1016/0021-9150(94)90129-5; HAINLINE A, 1982, US DHEW PUBLICATION; HAVEL RJ, 1995, NEW ENGL J MED, V332, P1491, DOI 10.1056/NEJM199506013322207; KARPE F, 1994, ATHEROSCLEROSIS, V106, P83, DOI 10.1016/0021-9150(94)90085-X; KINOSHITA M, 1990, J LIPID RES, V31, P701; KINOSIAN B, 1994, ANN INTERN MED, V121, P641, DOI 10.7326/0003-4819-121-9-199411010-00002; KRAUSS RM, 1987, AM HEART J, V113, P578, DOI 10.1016/0002-8703(87)90636-3; KRAUSS RM, 1982, J LIPID RES, V23, P97; KRAUSS RM, 1994, CIRCULATION, V90, P460; Krauss Ronald M., 1994, Current Opinion in Lipidology, V5, P339, DOI 10.1097/00041433-199410000-00005; LAGROST L, 1994, ARTERIOSCLER THROMB, V14, P1327, DOI 10.1161/01.ATV.14.8.1327; LAMONFAVA S, 1989, METABOLISM, V38, P921, DOI 10.1016/0026-0495(89)90243-6; MCKEONE BJ, 1993, J CLIN INVEST, V91, P1926, DOI 10.1172/JCI116411; MCNAMARA JR, 1992, ARTERIOSCLER THROMB, V12, P1284, DOI 10.1161/01.ATV.12.11.1284; MCNAMARA JR, 1987, ARTERIOSCLEROSIS, V7, P483, DOI 10.1161/01.ATV.7.5.483; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NIGON F, 1991, J LIPID RES, V32, P1741; PARKER DJP, 1984, EPIDEMIOLOGY MED PRA; PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; REAVEN GM, 1993, J CLIN INVEST, V92, P141, DOI 10.1172/JCI116541; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; SAKAI N, 1991, ARTERIOSCLER THROMB, V11, P71, DOI 10.1161/01.ATV.11.1.71; SELBY JV, 1993, CIRCULATION, V88, P381, DOI 10.1161/01.CIR.88.2.381; SLYPER AH, 1994, JAMA-J AM MED ASSOC, V272, P305, DOI 10.1001/jama.272.4.305; SUPERKO HR, 1992, ATHEROSCLEROSIS, V95, P69, DOI 10.1016/0021-9150(92)90177-I; SWINKELS DW, 1989, ARTERIOSCLEROSIS, V9, P604, DOI 10.1161/01.ATV.9.5.604; SWINKELS DW, 1989, ATHEROSCLEROSIS, V77, P59, DOI 10.1016/0021-9150(89)90010-5; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; TENG B, 1985, J BIOL CHEM, V260, P5067; THOMPSON GR, 1984, COLOGNE ATHEROSCLERO, V16, P121; TORNVALL P, 1991, ATHEROSCLEROSIS, V90, P67, DOI 10.1016/0021-9150(91)90245-X; TRIBBLE DL, 1992, ATHEROSCLEROSIS, V93, P189, DOI 10.1016/0021-9150(92)90255-F; WILLIAMS PT, 1990, CIRCULATION, V81, P1293, DOI 10.1161/01.CIR.81.4.1293; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; ZAMBON A, 1993, ARTERIOSCLER THROMB, V13, P147, DOI 10.1161/01.ATV.13.2.147	56	695	758	2	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					875	881		10.1001/jama.276.11.875	http://dx.doi.org/10.1001/jama.276.11.875			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782636				2022-12-24	WOS:A1996VF78700030
J	Wilson, RPH; Hatcher, J; Barton, S; Walley, T				Wilson, RPH; Hatcher, J; Barton, S; Walley, T			Influences of practice characteristics on prescribing in fundholding and non-fundholding general practices: An observational study	BRITISH MEDICAL JOURNAL			English	Article							COSTS; ENGLAND	Objective-To investigate the variation in prescribing among general practices by examining the contribution to this variation of fundholding, training status, partnership status, and the level of deprivation in the practice population and to investigate the extent to which fundholding has been responsible for any changes in prescribing. Design-Analysis of prescribing data (PACT) for the years 1990-1 (before fundholding) and 1993-4 (after fundholding). Use of multiple linear regressions to investigate the variation among practices in total prescribing costs (net ingredient cost per prescribing unit), prescribing volume (items per 1000 prescribing units), and mean cost per item in each of the two years and also the change in these variables between years. Setting-Former Mersey region. Subjects-384 practices. Results-The models developed explained the variation in cost per item (43% of variation explained for 1990-1, 38% for 1993-4) and prescribing volume (34% for 1990-1, 38% for 1993-4) better than the variation in total prescribing costs (3% for 1990-1, 7% for 1993-4). The models developed to explain the change in these variables between years did not explain more than 10% of the variation. Most of the explained variation in the change in total prescribing costs was accounted for by fundholding. Of the pound 3.71 saved by first wave fundholders compared with non-fundholders pound 3.57 was attributable to fundholding alone. Conclusion-In neither year did fundholding make a major contribution to the variation in prescribing behaviour among practices, which was better explained by deprivation, training status, and partnership status, but it did seem largely responsible for differences in the rise of total prescribing costs between fundholders and non-fundholders.	UNIV LIVERPOOL,DEPT PHARMACOL & THERAPEUT,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool								*AUD COMM, 1996, WHAT DOCT ORD STUD G; BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; BRITTEN N, 1995, BRIT MED J, V310, P1067, DOI 10.1136/bmj.310.6986.1067c; Department of Health, 1994, EV HOUS COMM HLTH CO; Eachus J, 1996, BMJ-BRIT MED J, V312, P287; FORSTER DP, 1991, BRIT J GEN PRACT, V41, P67; GLENNERSTER H, 1994, EVALUATING NHS REFOR; *GOV STAT SERV, 1995, STAT B GOV  STAT SER; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; HEALEY AT, 1994, HEALTH ECON, V3, P47, DOI 10.1002/hec.4730030107; LLOYD DCEF, 1995, BRIT MED J, V310, P165, DOI 10.1136/bmj.310.6973.165; LLOYD DCEF, 1995, BRIT MED J, V310, P1068, DOI 10.1136/bmj.310.6986.1068b; MARINKER M, 1994, CONTROVERSIES HLTH C; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MORTONJONES T, 1993, BRIT MED J, V306, P1731, DOI 10.1136/bmj.306.6894.1731; PRINGLE M, 1994, BR J GEN PRACT, V44, P543; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; STEWARTBROWN S, 1995, BRIT MED J, V311, P1543, DOI 10.1136/bmj.311.7019.1543; Whynes DK, 1996, BRIT MED J, V312, P488, DOI 10.1136/bmj.312.7029.488; Wilson R, 1995, LANCET, V346, P1710, DOI 10.1016/S0140-6736(95)92877-4; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347; Wilson-Davis K, 1992, PHARMACOEPIDEM DR S, V1, P341, DOI [10.1002/pds.2630010606, DOI 10.1002/PDS.2630010606]; 1996, GP MAGAZINE      FEB	24	35	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					595	599						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806250				2022-12-24	WOS:A1996VG10800019
J	Balakin, AG; Smith, L; Fournier, MJ				Balakin, AG; Smith, L; Fournier, MJ			The RNA world of the nucleolus: Two major families of small RNAs defined by different box elements with related functions	CELL			English	Article							SMALL NUCLEAR RNAS; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; SECONDARY STRUCTURE; YEAST; GENE; MRP; INTRON; RIBONUCLEOPROTEINS; IDENTIFICATION	We have discovered that all known yeast and vertebrate small nucleolar RNAs (snoRNAs), except for the MRP/7-2 RNA, fall into two major classes. One class is defined by conserved boxes C and D and the other by a novel element: a consensus ACA triplet positioned 3 nt before the 3' end of the RNA. A role for the ACA box in snoRNA stability has been established by mutational analysis of a yeast ACA snoRNA (snR11). Full function of the box depends on the integrity of an adjacent upstream stem. All members of the yeast ACA family are associated with the GAR1 protein. Binding of this or another common small nucleolar ribonucleoprotein particle protein is predicted to be a critical entry point to snoRNA posttranscriptional life, including precise formation of the snoRNA 3' end.	UNIV MASSACHUSETTS, DEPT BIOCHEM & MOL BIOL, AMHERST, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst					NIGMS NIH HHS [GM19531] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIS JP, 1991, METHOD ENZYMOL, V194, P735; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BALAKIN AG, 1994, J BIOL CHEM, V269, P739; BALAKIN AG, 1993, NUCLEIC ACIDS RES, V21, P5391, DOI 10.1093/nar/21.23.5391; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; CECCONI F, 1994, NUCLEIC ACIDS RES, V22, P732, DOI 10.1093/nar/22.5.732; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; CLARK MW, 1990, J CELL BIOL, V111, P1741, DOI 10.1083/jcb.111.5.1741; DANDEKAR T, 1993, NUCLEIC ACIDS RES, V21, P5386, DOI 10.1093/nar/21.23.5386; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GOLD HA, 1988, P NATL ACAD SCI USA, V85, P5483, DOI 10.1073/pnas.85.15.5483; HARLOW E, 1988, ANTIBODIES; HUANG GM, 1992, MOL CELL BIOL, V12, P4456, DOI 10.1128/MCB.12.10.4456; Kiss T, 1996, MOL CELL BIOL, V16, P1391; KISS T, 1993, EMBO J, V12, P2913, DOI 10.1002/j.1460-2075.1993.tb05953.x; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; LEVERETTE RD, 1992, CELL, V71, P1215, DOI 10.1016/S0092-8674(05)80069-8; LUBBEN B, 1993, NUCLEIC ACIDS RES, V21, P5377, DOI 10.1093/nar/21.23.5377; LUBBEN B, 1995, J BIOL CHEM, V270, P11549, DOI 10.1074/jbc.270.19.11549; LYGEROU Z, 1994, GENE DEV, V8, P1423, DOI 10.1101/gad.8.12.1423; Lygerou Z, 1996, SCIENCE, V272, P268, DOI 10.1126/science.272.5259.268; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; OCHMAN H, 1989, PCR TECHNOLOGY PRINC, P105; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PECULIS BA, 1994, GENE DEV, V8, P2241, DOI 10.1101/gad.8.18.2241; QU LH, 1995, NUCLEIC ACIDS RES, V23, P2669, DOI 10.1093/nar/23.14.2669; RIEDEL N, 1986, P NATL ACAD SCI USA, V83, P8097, DOI 10.1073/pnas.83.21.8097; RUFF EA, 1993, P NATL ACAD SCI USA, V90, P635, DOI 10.1073/pnas.90.2.635; SAMARSKY DA, 1995, NUCLEIC ACIDS RES, V23, P2548, DOI 10.1093/nar/23.13.2548; Sambrook J., 1989, MOL CLONING; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SCHMITT ME, 1993, FASEB J, V7, P208, DOI 10.1096/fasebj.7.1.7678563; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; TERNS MP, 1995, EMBO J, V14, P4860, DOI 10.1002/j.1460-2075.1995.tb00167.x; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; Watkins NJ, 1996, RNA, V2, P118; WISE JA, 1991, METHOD ENZYMOL, V194, P405; WISE JA, 1983, CELL, V35, P743, DOI 10.1016/0092-8674(83)90107-1; ZUBENKO GS, 1980, GENETICS, V96, P137	47	378	413	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1996	86	5					823	834		10.1016/S0092-8674(00)80156-7	http://dx.doi.org/10.1016/S0092-8674(00)80156-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797828	Bronze			2022-12-24	WOS:A1996VG37200015
J	Hopken, UE; Lu, B; Gerard, NP; Gerard, C				Hopken, UE; Lu, B; Gerard, NP; Gerard, C			The C5a chemoattractant receptor mediates mucosal defence to infection	NATURE			English	Article							PSEUDOMONAS-AERUGINOSA; ANAPHYLATOXIN RECEPTOR; CYSTIC-FIBROSIS; LUNG; MICE; NEUTROPHILS; EXPRESSION; IMMUNE; CELLS	A FAMILY of G-protein-coupled chemoattractant receptors is known to mediate the transport and activation of neutrophils and macrophages. This family includes receptors for chemokines, such as interleukin-8, bacterial formylated peptides, platelet-activating factor, leukotriene B4, and the complement anaphylatoxins(1-3). The apparent redundancy of these receptors suggests that they have an important underlying role in host defence. To isolate the contribution of particular molecules, we disrupted a gene that encodes a single chemoattractant receptor, Here we show that mice deficient in the chemoattractant C5a receptor, in comparison to their wild-type littermates, were unable to clear intrapulmonary-instilled Pseudomonas aeruginosa, despite a marked increase in neutrophil influx, and succumbed to pneumonia, These C5a-receptor-deficient mice challenged with sublethal inocula of Pseudomonas become superinfected with secondary bacterial strains. We conclude that the C5a receptor has a non-redundant function, and is required for mucosal host defence in the lung.	CHILDRENS HOSP,INA SUE PERLMUTTER CYST FIBROSIS LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BETH ISRAEL HOSP,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School								BERGER M, 1989, J CLIN INVEST, V84, P1302, DOI 10.1172/JCI114298; BOZIC CR, 1995, J IMMUNOL, V154, P6048; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CERQUETTI MC, 1986, INFECT IMMUN, V52, P853, DOI 10.1128/IAI.52.3.853-857.1986; CZUPRYNSKI CJ, 1984, J LEUKOCYTE BIOL, V35, P193; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.immunol.12.1.775; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; HORNICK DB, 1990, J CLIN INVEST, V86, P1285, DOI 10.1172/JCI114836; KUDOH I, 1994, AM J PHYSIOL-LUNG C, V267, P551; LARSEN GL, 1982, AM REV RESPIR DIS, V126, P306; Mosser D M, 1994, Immunol Ser, V60, P99; TOEWS GB, 1985, INFECT IMMUN, V50, P207, DOI 10.1128/IAI.50.1.207-212.1985; WILLIAMS JC, 1992, EXP LUNG RES, V18, P155, DOI 10.3109/01902149209020658	17	280	293	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					86	89		10.1038/383086a0	http://dx.doi.org/10.1038/383086a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779720				2022-12-24	WOS:A1996VF29500053
J	Jousilahti, P; Vartiainen, E; Tuomilehto, J; Puska, P				Jousilahti, P; Vartiainen, E; Tuomilehto, J; Puska, P			Symptoms of chronic bronchitis and the risk of coronary disease	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; CHLAMYDIA-PNEUMONIAE INFECTION; HEART-DISEASE; EASTERN FINLAND; STRAIN TWAR; ASSOCIATION; INFLAMMATION; MORTALITY; CELLS	Background Experimental and epidemiological studies show a positive association between coronary various infections in different organs, both bacterial and both acute and chronic. Most attention has been paid to dental infections and infections in the respiratory tract. We have studied how chronic respiratory infection predicts coronary disease. Methods We defined chronic respiratory infection by the occurrence of symptoms of chronic bronchitis. We also analysed whether any association with coronary disease incidence and mortality is independent of the known major cardiovascular risk factors and whether it is similar among persons in different occupations. Our cohort study was a 13-year follow-up of 19 444 randomly selected eastern Finnish men and women born between 1913 and 1947 and examined in either 1972 or 1977. Findings During follow-up, there were 1419 first coronary events, either fatal or non-fatal, and 614 coronary deaths. Among men, the age-adjusted and study-year-adjusted risk ratio of long lasting-symptoms of chronic bronchitis (during as much as 3 months in a year) was 1.52 (95% CI 1.33-1.75) for coronary disease and 1.74 (CI 1.43-2.11) for coronary death. Among women the risk ratios were 1.38 (1.07-1.78) and 1.49 (0.98-2.27), respectively. Inclusion of smoking, serum cholesterol, and systolic blood pressure into the models decreased risk ratios to 1.36 (1.17-1.56) and 1.55 (1.26-1.90) in men and to 1.34 (1.04-1.74) and 1.41 (0.92-2.16) in women, respectively. The risk of coronary disease associated with the symptoms of chronic bronchitis was similar among blue-collar and white-collar workers but the association was not found among farmers. Interpretation Symptoms of chronic bronchitis predicted the risk of coronary disease independently from the known major cardiovascular risk factors. If the observed association is causal, prevention and improved management of chronic infections may have played a role in the decrease in coronary disease mortality observed in eastern Finland in the past two decades.			Jousilahti, P (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, MANNERHEIMINTIE 166, FIN-00300 HELSINKI, FINLAND.							[Anonymous], COMMUNITY CONTROL CA; GODZIK KL, 1995, J CLIN MICROBIOL, V33, P2411, DOI 10.1128/JCM.33.9.2411-2414.1995; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; HUBBARD RC, 1991, LUNG SCI F, P2059; JANG IK, 1993, EUR HEART J, V14, P2; JOUSILAHTI P, 1995, AM J EPIDEMIOL, V141, P50, DOI 10.1093/oxfordjournals.aje.a117345; KARVONEN M, 1993, EPIDEMIOL INFECT, V110, P349, DOI 10.1017/S0950268800068291; KHAW KT, 1995, BRIT MED J, V310, P1559, DOI 10.1136/bmj.310.6994.1559; MATTHAY RA, 1988, CECIL TXB MED, P410; MATTILA K, 1989, THROMB RES, V56, P325, DOI 10.1016/0049-3848(89)90174-6; MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x; MCDONALD K, 1989, AM J CARDIOL, V64, P359, DOI 10.1016/0002-9149(89)90535-3; MENDALL MA, 1994, BRIT HEART J, V71, P437; MENDALL MA, 1995, J INFECTION, V30, P121, DOI 10.1016/S0163-4453(95)80006-9; NIEMINEN MS, 1993, EUR HEART J, V14, P12; ODEH M, 1992, EUR J CLIN MICROBIOL, V11, P885, DOI 10.1007/BF01962368; RICHARDSON SGN, 1979, BRIT J HAEMATOL, V42, P469, DOI 10.1111/j.1365-2141.1979.tb01155.x; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Rose G, 1968, CARDIOVASCULAR SURVE; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SAMMALKORPI K, 1989, J INTERN MED, V225, P15, DOI 10.1111/j.1365-2796.1989.tb00030.x; SAMMALKORPI K, 1988, METABOLISM, V37, P859, DOI 10.1016/0026-0495(88)90120-5; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; SZCZEKLIK A, 1993, CORONARY ARTERY DIS, V4, P1029, DOI 10.1097/00019501-199311000-00012; THOM DH, 1991, ARTERIOSCLER THROMB, V11, P547, DOI 10.1161/01.ATV.11.3.547; TOTANI L, 1994, ARTERIOSCLER THROMB, V14, P125, DOI 10.1161/01.ATV.14.1.125; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; *WHO, 1994, WHO TECH REP SER, V841	30	202	219	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	1996	348	9027					567	572		10.1016/S0140-6736(96)02374-4	http://dx.doi.org/10.1016/S0140-6736(96)02374-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774568				2022-12-24	WOS:A1996VF18600009
J	Kable, ML; Seiwert, SD; Heidmann, S; Stuart, K				Kable, ML; Seiwert, SD; Heidmann, S; Stuart, K			RNA editing: A mechanism for gRNA-specified uridylate insertion into precursor mRNA	SCIENCE			English	Article							MESSENGER-RNA; TRYPANOSOMA-BRUCEI; LEISHMANIA-TARENTOLAE; CRITHIDIA-FASCICULATA; GUIDE RNAS; KINETOPLASTID MITOCHONDRIA; CHIMERA FORMATION; IN-VITRO; DOMAINS; LIGASE	In the mitochondria of trypanosomatid protozoa the precursors of messenger RNAs (pre-mRNAs) have their coding information remodeled by the site-specific insertion and deletion of uridylate (U) residues. Small trans-acting guide RNAs (gRNAs) supply the genetic information for this RNA editing. An in vitro system was developed to study the mechanism of U insertion into pre-mRNA. U-insertion editing occurs through a series of enzymatic steps that begin with gRNA-directed pre-mRNA cleavage. Inserted U's are derived from free uridine triphosphate and are added to the 3' terminus of a 5' pre-mRNA cleavage product. gRNA specifies edited RNA sequence at the subsequent ligation step by base pairing-mediated juxtaposition of the 3' cleavage product and the processed 5' cleavage product. gRNA/pre-mRNA chimeras, purported intermediates, seem to be abortive end products of the same reaction.	SEATTLE BIOMED RES INST,SEATTLE,WA 98109; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	Center for Infectious Disease Research; University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM42188, GM08347] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER BK, 1994, CURR OPIN GENET DEV, V4, P316, DOI 10.1016/S0959-437X(05)80060-7; ARTS GJ, 1993, EMBO J, V12, P1523, DOI 10.1002/j.1460-2075.1993.tb05796.x; ARTS GJ, 1995, MOL BIOCHEM PARASIT, V73, P211, DOI 10.1016/0166-6851(95)00119-L; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1994, EUR J BIOCHEM, V221, P9, DOI 10.1111/j.1432-1033.1994.tb18710.x; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1990, CELL, V62, P391, DOI 10.1016/0092-8674(90)90375-O; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CORELL RA, 1993, NUCLEIC ACIDS RES, V21, P4313, DOI 10.1093/nar/21.18.4313; Corell RA, 1996, MOL CELL BIOL, V16, P1410; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; FRECH GC, 1995, EMBO J, V14, P178, DOI 10.1002/j.1460-2075.1995.tb06988.x; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; KABLE ML, UNPUB; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; MASLOV DA, 1994, MOL BIOCHEM PARASIT, V68, P155, DOI 10.1016/0166-6851(94)00160-X; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; PILLER KJ, 1995, MOL CELL BIOL, V15, P2916; Piller KJ, 1996, J BIOL CHEM, V271, P4613, DOI 10.1074/jbc.271.9.4613; PILLER KJ, 1995, MOL CELL BIOL, V15, P2925; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; READ LK, 1992, J BIOL CHEM, V267, P1123; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; RUSCHE LN, 1995, MOL CELL BIOL, V15, P2933; SABATINI R, 1995, J BIOL CHEM, V270, P7233, DOI 10.1074/jbc.270.13.7233; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; SEIWERT SD, 1995, PARASITOL TODAY, V11, P362, DOI 10.1016/0169-4758(95)80004-2; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; Simpson L, 1993, RNA EDITING ALTERATI, P53; Sollner-Webb B, 1991, CURR OPIN CELL BIOL, V3, P1056, DOI 10.1016/0955-0674(91)90129-M; STUART K, 1993, RNA EDITING ALTERATI, P26; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x	37	157	161	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1189	1195		10.1126/science.273.5279.1189	http://dx.doi.org/10.1126/science.273.5279.1189			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703045				2022-12-24	WOS:A1996VE47600028
J	Zhang, JP; Normark, S				Zhang, JP; Normark, S			Induction of gene expression in Escherichia coli after pilus-mediated adherence	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PROTEINS; URINARY-TRACT INFECTION; OUTER-MEMBRANE PROTEINS; VIRULENCE FACTORS; AEROBACTIN; TRANSPORT; SEQUENCES; RNA	The induction of cascades of virulence factors after contact between bacteria and host cells was investigated. P-pili mediate the binding of uropathogenic Escherichia coli to its host cell receptor, After P-pili binding there was transcriptional activation of a sensor-regulator protein that is essential for the bacterial iron-starvation response, An insertion mutation of the sensor-regulator gene eliminated the ability of uropathogenic E, coli to produce siderophores and their iron-regulated membrane receptors, thereby abolishing their ability to grow in urine, These results suggest that P-pilus-mediated attachment may be an important part of the sensor-regulatory process involved in uropathogenic E. coli urinary tract infection.	WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,ST LOUIS,MO 63110; KAROLINSKA INST,MICROBIOL & TUMORBIOL CTR,S-10521 STOCKHOLM,SWEDEN; SWEDISH INST INFECT DIS CONTROL,S-10521 STOCKHOLM,SWEDEN	Washington University (WUSTL); Karolinska Institutet; Swedish Institute for Infectious Disease Control					NIGMS NIH HHS [5RO1GM44655-05] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044655] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARICO B, 1989, P NATL ACAD SCI USA, V86, P6671, DOI 10.1073/pnas.86.17.6671; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; BULLITT E, 1995, NATURE, V373, P164, DOI 10.1038/373164a0; DEAN CR, 1993, MOL MICROBIOL, V8, P1095, DOI 10.1111/j.1365-2958.1993.tb01654.x; FREE AH, 1975, URINALYSIS CLIN LABO, P13; GIARDINA PC, 1995, J BACTERIOL, V177, P6058, DOI 10.1128/jb.177.21.6058-6063.1995; GRIFFITHS E, 1985, INFECT IMMUN, V47, P808, DOI 10.1128/IAI.47.3.808-813.1985; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; JOHNSON JR, 1991, CLIN MICROBIOL REV, V4, P80, DOI 10.1128/CMR.4.1.80-128.1991; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MELTON AR, 1989, J BACTERIOL, V170, P6206; MONTGOMERIE JZ, 1984, INFECT IMMUN, V46, P835, DOI 10.1128/IAI.46.3.835-838.1984; NAGASAWA S, 1992, MOL MICROBIOL, V6, P799, DOI 10.1111/j.1365-2958.1992.tb01530.x; NAU CD, 1989, J BACTERIOL, V171, P1041, DOI 10.1128/jb.171.2.1041-1047.1989; NEILANDS JB, 1992, CAN J MICROBIOL, V38, P728, DOI 10.1139/m92-119; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OPAL SM, 1990, J INFECT DIS, V161, P794, DOI 10.1093/infdis/161.4.794; ROBERTS JA, 1994, P NATL ACAD SCI USA, V91, P11889, DOI 10.1073/pnas.91.25.11889; ROBLEDO JA, 1990, J UROLOGY, V143, P386, DOI 10.1016/S0022-5347(17)39971-8; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; WILLIS DK, 1990, MOL PLANT MICROBE IN, V1, P80; WONG KK, 1994, P NATL ACAD SCI USA, V91, P639, DOI 10.1073/pnas.91.2.639	26	144	149	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1234	1236		10.1126/science.273.5279.1234	http://dx.doi.org/10.1126/science.273.5279.1234			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703059				2022-12-24	WOS:A1996VE47600042
J	Orentlicher, D				Orentlicher, D			The legalization of physician-assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; DOCTORS; OREGON; KILL				Orentlicher, D (corresponding author), INDIANA UNIV, SCH LAW INDIANAPOLIS, CTR LAW & HLTH, 735 W NEW YORK ST, INDIANAPOLIS, IN 46202 USA.							ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; ANNAS GJ, 1994, NEW ENGL J MED, V331, P1240, DOI 10.1056/NEJM199411033311822; Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BATTIN MP, 1995, ETHICAL ISSUES SUICI, P206; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; CALLAHAN D, 1992, HASTINGS CENT REP, V22, P52, DOI 10.2307/3562566; CARSON R, 1992, HASTINGS CENT REP, V22, P7, DOI 10.2307/3562559; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; generally, 1994, ISSUES LAW MED, V10, P91; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; KASS LR, 1989, PUBLIC INTEREST, P25; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; LESSENBERRY J, 1996, NY TIMES        0504, P10; LEWIN T, 1996, NY TIMES        0521, pA14; MCFADDEN RD, 1985, NY TIMES        0612, pA1; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; ORENTLICHER D, 1994, MED UNBOUND HUMAN BO, P256; Pellegrino E D, 1992, J Clin Ethics, V3, P95; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; RUBENFELD J, 1989, HARVARD LAW REV, V102, P737, DOI 10.2307/1341305; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; 1995, NY TIMES        1005, pD23	30	54	54	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					663	667		10.1056/NEJM199608293350912	http://dx.doi.org/10.1056/NEJM199608293350912			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VD425	8687525				2022-12-24	WOS:A1996VD42500012
J	OKeefe, RT; Norman, C; Newman, AJ				OKeefe, RT; Norman, C; Newman, AJ			The invariant U5 snRNA loop 1 sequence is dispensable for the first catalytic step of pre-mRNA splicing in yeast	CELL			English	Article							BASE-PAIRING INTERACTION; SMALL NUCLEAR-RNA; MESSENGER-RNA; SITE SELECTION; U1 SNRNA; U6 SNRNA; ACTIVE-SITE; SPLICEOSOME; MUTATIONS; INVITRO	We have developed an in vitro reconstitution system to investigate the role of U5 snRNA in the two catalytic steps of pre-mRNA splicing. The invariant U5 loop 1 is known to interact with exon sequences at the 5' splice site before the first catalytic step. Remarkably, analysis of U5 mutations in vitro reveals that the first transesterification occurs accurately in the absence of the U5 loop. Therefore this sequence is not an essential component of the spliceosomal active site for the first catalytic step. The second catalytic step, although strongly dependent on the presence of a U5 loop to tether the exon 1 splicing intermediate, is surprisingly tolerant of mutations in the invariant sequence.			OKeefe, RT (corresponding author), MRC,MOL BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CORTES JJ, 1993, EMBO J, V12, P5181, DOI 10.1002/j.1460-2075.1993.tb06213.x; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JARMOLOWSKI A, 1993, EMBO J, V12, P223, DOI 10.1002/j.1460-2075.1993.tb05648.x; JONES MH, 1990, EMBO J, V9, P2555, DOI 10.1002/j.1460-2075.1990.tb07436.x; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; LAMM GM, 1991, NUCLEIC ACIDS RES, V19, P3193, DOI 10.1093/nar/19.12.3193; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MCPHEETERS DS, 1989, GENE DEV, V3, P2124, DOI 10.1101/gad.3.12b.2124; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Moore M., 1993, RNA WORLD, P303; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; Newman AJ, 1995, RNA, V1, P968; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; Reyes J, 1996, RNA, V2, P213; RYMOND BC, 1992, MOL CELLULAR BIOL YE, V2, P143; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SEGAULT V, 1995, EMBO J, V14, P4010, DOI 10.1002/j.1460-2075.1995.tb00072.x; SERAPHIN B, 1991, NUCLEIC ACIDS RES, V19, P3857, DOI 10.1093/nar/19.14.3857; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; Umen JG, 1995, RNA, V1, P869; VARANI G, 1991, BIOCHEMISTRY-US, V30, P320; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WINKELMANN G, 1989, EMBO J, V8, P3105, DOI 10.1002/j.1460-2075.1989.tb08462.x; WISE JA, 1993, SCIENCE, V262, P1978, DOI 10.1126/science.8266091; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	46	107	108	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					679	689		10.1016/S0092-8674(00)80140-3	http://dx.doi.org/10.1016/S0092-8674(00)80140-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752221	Bronze			2022-12-24	WOS:A1996VE23500017
J	Oelgeschlager, T; Chiang, CM; Roeder, RG				Oelgeschlager, T; Chiang, CM; Roeder, RG			Topology and reorganization of a human TFIID-promoter complex	NATURE			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; TATA-BOX; PREINITIATION COMPLEX; CRYSTAL-STRUCTURE; MINOR-GROOVE; EUKARYOTIC GENES; BINDING PROTEIN; DNA COMPLEX; ELEMENT	TRANSCRIPTION factor TFIID is a multiprotein complex composed of a TATA-box-binding subunit, TBP, and several tightly associated factors (TAFs)(1,2). Human TFIID-promoter interactions are restricted to the TATA-box region on most core promoters(3,4) but extend over a large promoter region downstream of the TATA box and the transcription start site on the Ad2ML promoter(3-6). TFIID downstream interactions are thought to be functionally relevant because they can be induced by transcriptional activators(7-10), which in some cases requires TFIIA(9,10), result in stabilization of the TFIID-promoter complex(9,10), and correlate with increased recruitment of the remaining general transcription factors(8,10). Here we examine the topological organization of human TFIID complexes bound to the Ad2ML promoter. Our data provide insight into the relative disposition of DNA and several TFIID subunits, as well as evidence for DNA wrapping by TFIID, and suggest a direct role of TFIIA in the stable positioning of promoter DNA relative to TAFs.	ROCKEFELLER UNIV,BIOCHEM & MOL BIOL LAB,NEW YORK,NY 10021	Rockefeller University				Oelgeschlager, Thomas/0000-0002-4086-719X				BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BARTHOLOMEW B, 1994, J BIOL CHEM, V269, P18090; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1993, PEPTIDE RES, V6, P62; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; GE H, IN PRESSMETH ENZYM; HIROSE S, 1988, P NATL ACAD SCI USA, V85, P718, DOI 10.1073/pnas.85.3.718; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LORCH Y, 1993, MOL CELL BIOL, V13, P1872, DOI 10.1128/MCB.13.3.1872; MIZUTANI M, 1991, NUCLEIC ACIDS RES, V19, P2907, DOI 10.1093/nar/19.11.2907; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1996, P NATL ACAD SCI USA, V93, P4956; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; TABUCHI H, 1993, BIOCHEM BIOPH RES CO, V192, P1432, DOI 10.1006/bbrc.1993.1576; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	30	151	151	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					735	738		10.1038/382735a0	http://dx.doi.org/10.1038/382735a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751448				2022-12-24	WOS:A1996VD33300056
J	Kaddoura, S; PooleWilson, PA				Kaddoura, S; PooleWilson, PA			Endothelin-1 in heart failure: A new therapeutic target?	LANCET			English	Editorial Material							PLASMA ENDOTHELIN; HYPERTENSION		ROYAL BROMPTON HOSP,LONDON SW3 6LY,ENGLAND	Royal Brompton Hospital	Kaddoura, S (corresponding author), NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.							CODY RJ, 1992, CIRCULATION, V85, P504, DOI 10.1161/01.CIR.85.2.504; HIROE M, 1991, AM J CARDIOL, V68, P1114, DOI 10.1016/0002-9149(91)90511-I; KIOWSKI W, 1995, LANCET, V346, P732, DOI 10.1016/S0140-6736(95)91504-4; KRUM H, 1995, AM J CARDIOL, V75, P1282, DOI 10.1016/S0002-9149(99)80783-8; Krum H, 1996, AM HEART J, V131, P337, DOI 10.1016/S0002-8703(96)90363-4; MARGULIES KB, 1990, CIRCULATION, V82, P2226, DOI 10.1161/01.CIR.82.6.2226; MCMURRAY JJ, 1992, CIRCULATION, V85, P1374, DOI 10.1161/01.CIR.85.4.1374; PACHER R, 1993, AM J CARDIOL, V71, P1293, DOI 10.1016/0002-9149(93)90543-L; Pacher R, 1996, J AM COLL CARDIOL, V27, P633, DOI 10.1016/0735-1097(95)00520-X; STEWART DJ, 1992, CIRCULATION, V85, P510, DOI 10.1161/01.CIR.85.2.510; TEERLINK JR, 1994, CIRCULATION, V90, P2510, DOI 10.1161/01.CIR.90.5.2510; TSUTAMOTO T, 1994, J AM COLL CARDIOL, V23, P1427, DOI 10.1016/0735-1097(94)90387-5; WEI CM, 1994, CIRCULATION, V89, P1580, DOI 10.1161/01.CIR.89.4.1580	13	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					418	419		10.1016/S0140-6736(05)64531-X	http://dx.doi.org/10.1016/S0140-6736(05)64531-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709775				2022-12-24	WOS:A1996VC67300002
J	While, D; Kelly, S; Huang, WY; Charlton, A				While, D; Kelly, S; Huang, WY; Charlton, A			Cigarette advertising and onset of smoking in children: Questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To investigate uptake of smoking in a cohort of 11 to 12 year olds related to awareness of advertised cigarette brands named. Design-Self completed questionnaires administered to whole classes of schoolchildren in June 1993 and June 1994. Setting-Primary, middle, and secondary schools in the north and south of England. Subjects-1450 pupils aged 11 and 12 years at the time of the first survey. Main outcome measures-Onset of smoking and brands smoked by the second survey related to cigarette brands named in the first one. Less advertised brands were used as the: base for calculating odds ratios. Results-Girls who named the most advertised brands-namely, Benson and Hedges alone (odds ratio = 2.50, 95% confidence interval = 1.18 to 5.30) or Benson and Hedges and Silk Cut (2.15, 1.04 to 4.42) in the first survey were at greatest risk of taking up smoking by the second one. The difference was similar but not significant for boys. Boys and girls who named the least advertised brands in the first survey were at no greater risk of taking up smoking by the second survey than those who named no brands (boys odds ratio = 0.49 (0.24 to 1.01); girls 0.79 (0.38 to 1.62)). New smokers were more Likely to smoke any available brand (29.5%) or a less advertised brand such as Embassy (24.6%) than the most advertised ones, Benson and Hedges (19.7%) and Silk Cut (14.8%). Established smokers were more selective, only 15% smoking any available brand and 38.3% smoking Benson and Hedges. Conclusions-Cigarette advertising appears to increase children's awareness of smoking at a generic level and encourages them to take up the behaviour, beginning with any cigarettes which are available and affordable.	UNIV MANCHESTER,SCH EPIDEMIOL & HLTH SCI,CRC EDUC & CHILD STUDIES RES GRP,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester								AITKEN PP, 1990, BRIT J ADDICT, V85, P399; Aitken PP, 1987, HLTH PROMOTION, V2, P219; CHAPMAN S, 1982, AM J PUBLIC HEALTH, V72, P491, DOI 10.2105/AJPH.72.5.491; CHARLTON A, 1989, SOC SCI MED, V29, P813, DOI 10.1016/0277-9536(89)90080-4; Department of Health, 1992, POL REQ AV COMP SPEC; GODDARD E, 1990, WHY CHILDREN START S; GOLDSTEIN AO, 1987, J PEDIATR-US, V110, P488, DOI 10.1016/S0022-3476(87)80523-1; HASTINGS GB, 1994, BRIT MED J, V309, P933, DOI 10.1136/bmj.309.6959.933; MCNEILL AD, 1985, LANCET, V2, P271; *NEILS REG MEAL, 1994, 1993 94 MEAL NIELS R; *TOB ADV COUNC, 1985, CAS TOB ADV; *US SURG GEN, 1994, PREV TOB US YOUNG PE	12	34	34	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					398	399						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VD206	8761227				2022-12-24	WOS:A1996VD20600025
J	Huang, Z; Kunes, S				Huang, Z; Kunes, S			Hedgehog, transmitted along retinal axons, triggers neurogenesis in the developing visual centers of the Drosophila brain	CELL			English	Article							CELL-CELL COMMUNICATION; 1ST OPTIC GANGLION; POLARITY GENE; EARLY DIFFERENTIATION; PATTERN-FORMATION; PATCHED GENE; GLIAL-CELLS; MELANOGASTER; PROTEIN; SEGMENT	The development of the visual centers of the Drosophila brain is tightly regulated by the ingrowth of retinal axons from the developing eye. In the first optic ganglion, the lamina, arriving retinal axons trigger the precursors of their synaptic partners to complete a final cell division and commence neural differentiation. The secreted product of the hedgehog gene regulates the temporal assembly of photoreceptor precursor cells into ommatidial clusters in the compound eye. Here, we show that Hedgehog is transmitted along the retinal axons to serve as the inductive signal in the brain. Hedgehog acts in the first of two retinal axon-mediated steps in the assembly of lamina synaptic cartridges. These observations provide a novel insight into the molecular interactions that orchestrate the assembly of neural precursor cells into precise synaptic circuits.			Huang, Z (corresponding author), HARVARD UNIV,DEPT MOL & CELL BIOL,CAMBRIDGE,MA 02138, USA.				NATIONAL EYE INSTITUTE [R01EY010112] Funding Source: NIH RePORTER; NEI NIH HHS [EY10112] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; DUNINBORKOWSKI OM, 1995, DEV BIOL, V168, P689, DOI 10.1006/dbio.1995.1115; FISCHBACH KF, 1984, DEV BIOL, V104, P219, DOI 10.1016/0012-1606(84)90050-2; GONG QH, 1995, NEURON, V14, P91, DOI 10.1016/0896-6273(95)90243-0; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOFBAUER A, 1990, ROUX ARCH DEV BIOL, V198, P264, DOI 10.1007/BF00377393; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KAPHINGST K, 1994, CELL, V78, P437, DOI 10.1016/0092-8674(94)90422-7; KOLLROS JJ, 1982, J COMP NEUROL, V205, P171, DOI 10.1002/cne.902050208; KUNES S, 1993, J NEUROSCI, V13, P752; Kunes Samuel, 1993, Current Opinion in Neurobiology, V3, P53, DOI 10.1016/0959-4388(93)90035-W; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MACAGNO ER, 1979, DEV BIOL, V73, P206, DOI 10.1016/0012-1606(79)90064-2; MARDON G, 1994, DEVELOPMENT, V120, P3473; Marigo V, 1996, DEVELOPMENT, V122, P1225; Meinertzhagen Ian A., 1993, P1363; MEYEROWITZ EM, 1978, DEV BIOL, V62, P112, DOI 10.1016/0012-1606(78)90096-9; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; MOZER BA, 1994, DEVELOPMENT, V120, P1049; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Perez SE, 1996, J NEUROBIOL, V30, P359, DOI 10.1002/(SICI)1097-4695(199607)30:3<359::AID-NEU5>3.0.CO;2-3; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; Power ME, 1943, J EXP ZOOL, V94, P33, DOI 10.1002/jez.1400940103; RAYMOND PA, 1983, J NEUROSCI, V3, P1092; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; SELLECK SB, 1992, NATURE, V355, P253, DOI 10.1038/355253a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TOLBERT LP, 1990, EXP NEUROL, V109, P19, DOI 10.1016/S0014-4886(05)80005-6; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TREISMAN JE, 1995, DEVELOPMENT, V121, P2835; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; vonBartheld CS, 1996, NATURE, V379, P830, DOI 10.1038/379830a0; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; WINBERG ML, 1992, DEVELOPMENT, V115, P903; Wolff Tanya, 1993, P1277; ZECCA M, 1995, DEVELOPMENT, V121, P2265	54	221	223	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					411	422		10.1016/S0092-8674(00)80114-2	http://dx.doi.org/10.1016/S0092-8674(00)80114-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756723	Bronze			2022-12-24	WOS:A1996VC30900009
J	Matsumoto, M; Lo, SF; Carruthers, CJL; Min, JJ; Mariathasan, S; Huang, GM; Plas, DR; Martin, SM; Geha, RS; Nahm, MH; Chaplin, DD				Matsumoto, M; Lo, SF; Carruthers, CJL; Min, JJ; Mariathasan, S; Huang, GM; Plas, DR; Martin, SM; Geha, RS; Nahm, MH; Chaplin, DD			Affinity maturation without germinal centres in lymphotoxin-alpha-deficient mice	NATURE			English	Article							FOLLICULAR DENDRITIC CELLS; B-CELL; IMMUNE-RESPONSE; SOMATIC HYPERMUTATION; PRIMARY IMMUNIZATION; COMPLEMENT RECEPTOR; ANTIBODY MUTANTS; LYMPHOCYTES-B; T-CELL; CENTERS	AFFINITY maturation by somatic hypermutation is thought to occur within germinal centres(1-4). Mice deficient in lymphotoxin-alpha (LT alpha(-/-) mice) have no lymph nodes or Peyer's patches(5,6), and fail to form germinal centres in the spleen(7). We tested whether germinal centres are essential for maturation of antibody responses to T-cell-dependent antigens. LT alpha(-/-) mice immunized with low doses of (4-hydroxy-3-nitrophenyl)acetyl-ovalbumin (NP-OVA) showed dramatically impaired production of high-affinity anti-NP IgG1. However, LT alpha(-/-) mice immunized with high doses of NP-OVA, even though they failed to produce germinal centres, manifested a high-affinity anti-NP IgG1 response similar to wild-type mice. Furthermore, when LT alpha(-/-) mice were multiply immunized with high doses of NP-OVA, the predominantly expressed anti-NP Vu gene segment VH186.2 showed somatic mutations typical of affinity maturation(8). Thus, B-cell memory and affinity maturation are not absolutely dependent on the presence of germinal centres.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02138	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Harvard University; Harvard Medical School				Nahm, Moon/0000-0002-6922-1042; Chaplin, David/0000-0002-1354-3069				ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; BANKS TA, 1995, J IMMUNOL, V155, P1685; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BLIER PR, 1987, J IMMUNOL, V139, P3996; CERNY A, 1988, CELL TISSUE RES, V254, P449; CLARK EA, 1992, J IMMUNOL, V148, P3327; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; HEBELL T, 1991, SCIENCE, V254, P102, DOI 10.1126/science.1718035; JACK RS, 1977, EUR J IMMUNOL, V7, P559, DOI 10.1002/eji.1830070813; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KAPASI ZF, 1993, J IMMUNOL, V150, P2648; KINOSHITA T, 1988, J IMMUNOL, V140, P3066; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MCHEYZERWILLIAMS MG, 1991, NATURE, V350, P502, DOI 10.1038/350502a0; NEUBERGER MS, 1995, CURR OPIN IMMUNOL, V7, P248, DOI 10.1016/0952-7915(95)80010-7; NOSSAL GJV, 1968, J EXP MED, V127, P263, DOI 10.1084/jem.127.2.263; RAJEWSKY K, 1987, SCIENCE, V238, P1088, DOI 10.1126/science.3317826; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; RYFFEL B, 1993, INT REV EXP PATHOL, V34, P149; SCHRIEVER F, 1992, ADV IMMUNOL, V51, P243, DOI 10.1016/S0065-2776(08)60489-7; SMITH KGC, 1994, IMMUNITY, V1, P803, DOI 10.1016/S1074-7613(94)80022-7; WAGNER SD, 1995, NATURE, V376, P732, DOI 10.1038/376732a0; WEISS U, 1992, EUR J IMMUNOL, V22, P511, DOI 10.1002/eji.1830220233; WEISS U, 1990, J EXP MED, V172, P1681, DOI 10.1084/jem.172.6.1681; YOSHIDA K, 1994, EUR J IMMUNOL, V24, P464, DOI 10.1002/eji.1830240230	29	285	299	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					462	466		10.1038/382462a0	http://dx.doi.org/10.1038/382462a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684487	Bronze			2022-12-24	WOS:A1996VA25100060
J	Buchan, J				Buchan, J			Characteristics of orf in a farming community in mid-Wales	BRITISH MEDICAL JOURNAL			English	Article											Buchan, J (corresponding author), THE SURGERY,CAEHERBERT LANE,POWYS LD6 5ED,WALES.							HIGHET AS, 1992, TXB DERMATOLOGY, P873; Peterkin GAG, 1937, BRIT J DERMATOL SYPH, V49, P492, DOI 10.1111/j.1365-2133.1937.tb11664.x; WILKINSON JD, 1977, BRIT J DERMATOL, V97, P447, DOI 10.1111/j.1365-2133.1977.tb14256.x; YIRRELL DL, 1994, BRIT J DERMATOL, V130, P438, DOI 10.1111/j.1365-2133.1994.tb03375.x	4	32	32	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					203	204		10.1136/bmj.313.7051.203	http://dx.doi.org/10.1136/bmj.313.7051.203			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696196	Green Published			2022-12-24	WOS:A1996VA12600025
J	Alpagut, B; Andrews, P; Fortelius, M; Kappelman, J; Temizsoy, I; Celebi, H; Lindsay, W				Alpagut, B; Andrews, P; Fortelius, M; Kappelman, J; Temizsoy, I; Celebi, H; Lindsay, W			A new specimen of Ankarapithecus meteai from the Sinap Formation of central Anatolia	NATURE			English	Article							HOMINOID EVOLUTION; SIVAPITHECUS	HOMINOID fossils from the Middle and Late Miocene are exceedingly rare, yet such material is necessary for determining hominoid phylogeny, We report here the discovery of a fossil hominoid partial skull from the Upper Miocene Sinap Formation(1,2) of central Turkey that is the most complete known from the period of 18 to 3 Myr. Our fieldwork places the hominoid locality within a precisely dated geochronological and biostratigraphical framework(3) that permits detailed comparisons with other fossil hominoids. Earlier discoveries of more fragmentary remains of Ankarapithecus meteai suggested affinities with the Asian hominoids Sivapithecus and Pongo(4). This new and nearly complete specimen reveals a combination of facial, mandibular, and dental features including a relatively narrow interorbital region, extensive frontal and maxillary sinuses, moderately developed supraorbital tori, square orbits, robust mandibular corpus, and incisor heteromorphy that is not matched in any extant or fossil hominoid. This configuration of features seems to support its placement as a stem member of the great ape and human clade.	UNIV TEXAS,DEPT ANTHROPOL,AUSTIN,TX 78712; NAT HIST MUSEUM,LONDON SW7 5BD,ENGLAND; UNIV HELSINKI,FINNISH MUSEUM NAT HIST,FIN-00014 HELSINKI,FINLAND; ANADOLU MEDENYETLERI MUZESI,ANKARA,TURKEY; ANKARA UNIV,ANKARA,TURKEY	University of Texas System; University of Texas Austin; Natural History Museum London; University of Helsinki; Ministry of Culture & Tourism - Turkey; Ankara University			Klein, Richard G/B-5910-2009	Alpagut, Berna/0000-0002-5640-1036				Agusti J, 1996, J HUM EVOL, V31, P143, DOI 10.1006/jhev.1996.0055; ALPAGUT B, 1989, ARASTIRMA SONUCLAN T, V8, P55; ALPAGUT B, 1993, ARASTIRMA SONUCLAN T, V12, P177; ANDREWS P, 1982, NATURE, V297, P541, DOI 10.1038/297541a0; Andrews P., 1980, Palaeontology (Oxford), V23, P85; Barry J.C., 1986, P93; BEGUN DR, 1995, J HUM EVOL, V29, P169, DOI 10.1006/jhev.1995.1052; BEGUN DR, 1993, J HUM EVOL, V25, P271, DOI 10.1006/jhev.1993.1049; BEGUN DR, 1995, AM J PHYS ANTHR S, V20, P63; BONIS L, 1990, NATURE, V345, P712; Brown B., 1988, P247; CANDE SC, 1995, J GEOPHYS RES-SOL EA, V100, P6093, DOI 10.1029/94JB03098; CAVE AJE, 1940, J ANAT, V72, P493; Coolidge HJ, 1933, AM J PHYS ANTHROPOL, V18, P1, DOI 10.1002/ajpa.1330180113; de Bonis L, 1977, Geobios Lyon, V10, P849, DOI 10.1016/S0016-6995(77)80081-8; DEBONIS L, 1993, J HUM EVOL, V24, P469, DOI 10.1006/jhev.1993.1032; KAPPELMAN J, 1991, J HUM EVOL, V21, P61, DOI 10.1016/0047-2484(91)90036-U; KAPPELMAN J, IN PRESS EVOLUTION W; KELLEY J, 1995, J HUM EVOL, V28, P503, DOI 10.1006/jhev.1995.1039; MARTIN L, 1985, NATURE, V314, P260, DOI 10.1038/314260a0; Moya Sola Salvadoor, 1995, Journal of Human Evolution, V29, P101; MoyaSola S, 1996, NATURE, V379, P156, DOI 10.1038/379156a0; MOYASOLA S, 1993, NATURE, V365, P543, DOI DOI 10.1038/365543A0; Ozansoy F., 1957, Bulletin Mineral Research and Exploration Institute Turkey, VNo. 49, P29; OZANSOY F, 1955, CR HEBD ACAD SCI, V240, P992; SHEA BT, 1985, AM J PHYS ANTHROPOL, V68, P329, DOI 10.1002/ajpa.1330680304; SIMONS EL, 1965, FOLIA PRIMATOL, V3, P81, DOI 10.1159/000155026; Szalay F.S., 1979, EVOLUTIONARY HIST PR, DOI [10.1002/ajpa.1330600122, DOI 10.1002/AJPA.1330600122]; Ward S.C., 1983, P211; Ward S.C., 1986, P413	30	44	45	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					349	351		10.1038/382349a0	http://dx.doi.org/10.1038/382349a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UY950	8684462				2022-12-24	WOS:A1996UY95000050
J	StanhopeBaker, P; Hudson, KM; Shaffer, AL; Constantinescu, A; Schlissel, MS				StanhopeBaker, P; Hudson, KM; Shaffer, AL; Constantinescu, A; Schlissel, MS			Cell type-specific chromatin structure determines the targeting of V(D)J recombinase activity in vitro	CELL			English	Article							PRE-B-CELLS; IMMUNOGLOBULIN GENE REARRANGEMENT; BROKEN DNA-MOLECULES; ALLELIC EXCLUSION; MOUSE THYMOCYTES; BONE-MARROW; TRANSCRIPTION; SEGMENTS; ACTIVATION; MICE	A common V(D)J recombinase that recognizes a conserved recombination signal sequence (RSS) mediates the assembly of immunoglobulin (Ig) and T cell receptor (TCR) genes in B and T cell precursors. The rearrangement of particular Ig and TCR gene segments, however, is tightly regulated with respect to cell lineage and developmental stage. Using an in vitro system, we analyzed recombinase cleavage of RSSs flanking Ig and TCR gene segments in nuclei. We found that both the lineage-specificity and temporal ordering of gene rearrangement is reflected in the accessibility of RSSs within chromatin to in vitro cleavage.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University	StanhopeBaker, P (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205, USA.				NHLBI NIH HHS [R01 HL48702] Funding Source: Medline; NIAID NIH HHS [R01 AI22833, T32-AI07247] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022833, T32AI007247] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLACKWELL TK, 1989, ANNU REV GENET, V23, P605, DOI 10.1146/annurev.ge.23.120189.003133; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; CHANG Y, 1992, EMBO J, V11, P1891, DOI 10.1002/j.1460-2075.1992.tb05241.x; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; FERNEX C, 1995, MOL CELL BIOL, V15, P3217; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; Hiramatsu R, 1995, CELL, V83, P1113, DOI 10.1016/0092-8674(95)90138-8; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Krop I, 1996, EUR J IMMUNOL, V26, P238, DOI 10.1002/eji.1830260137; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PERNIS B, 1965, J EXP MED, V122, P853, DOI 10.1084/jem.122.5.853; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH MG, 1986, EMBO J, V5, P2131, DOI 10.1002/j.1460-2075.1986.tb04476.x; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHLISSEL MS, 1994, J IMMUNOL, V153, P1645; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043	45	259	260	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					887	897		10.1016/S0092-8674(00)81272-6	http://dx.doi.org/10.1016/S0092-8674(00)81272-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681383	hybrid			2022-12-24	WOS:A1996UR60400012
J	Derkinderen, P; Toutant, M; Burgaya, F; LeBert, M; Siciliano, JC; deFranciscis, V; Gelman, M; Girault, JA				Derkinderen, P; Toutant, M; Burgaya, F; LeBert, M; Siciliano, JC; deFranciscis, V; Gelman, M; Girault, JA			Regulation of a neuronal form of focal adhesion kinase by anandamide	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; ENDOGENOUS CANNABINOID ANANDAMIDE; LONG-TERM POTENTIATION; ACETYLCHOLINE-RECEPTOR; MUTANT MICE; BRAIN; PHOSPHORYLATION; EXPRESSION; CHANNEL; IDENTIFICATION	Anandamide is an endogenous ligand for central cannabinoid receptors and is released after neuronal depolarization. Anandamide increased protein tyrosine phosphorylation in rat hippocampal slices and neurons in culture. The action of anandamide resulted from the inhibition of adenylyl cyclase and cyclic adenosine 3',5'-monophosphate-dependent protein kinase. One of the proteins phosphorylated in response to anandamide was an isoform of pp125-focal adhesion kinase (FAK+) expressed preferentially in neurons. Focal adhesion kinase is a tyrosine kinase involved in the interactions between the integrins and actin-based cytoskeleton. Thus, anandamide may exert neurotrophic effects and play a role in synaptic plasticity.	COLL FRANCE,INSERM,CHAIRE NEUROPHARMACOL,U114,F-75231 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France			Girault, Jean-Antoine/F-7518-2013; Le Bert, Marc/AAR-4577-2021; Derkinderen, Pascal/K-2393-2015	Girault, Jean-Antoine/0000-0002-7900-1705; Le Bert, Marc/0000-0002-5945-3800; 				Boxall AR, 1996, NEURON, V16, P805, DOI 10.1016/S0896-6273(00)80100-2; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; Burgaya F, 1996, MOL BRAIN RES, V37, P63, DOI 10.1016/0169-328X(95)00273-U; CHAMAK B, 1987, J NEUROSCI, V7, P3163; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; DERKINDEREN P, UNPUB; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HOWLETT AC, 1995, ANNU REV PHARMACOL, V35, P607, DOI 10.1146/annurev.pharmtox.35.1.607; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Menegoz M, 1995, NEUROREPORT, V7, P125, DOI 10.1097/00001756-199512290-00030; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SICILIANO JC, 1994, J NEUROCHEM, V62, P950; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WARTMANN M, 1995, FEBS LETT, V359, P133, DOI 10.1016/0014-5793(95)00027-7; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0	32	145	151	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1719	1722		10.1126/science.273.5282.1719	http://dx.doi.org/10.1126/science.273.5282.1719			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781236				2022-12-24	WOS:A1996VH40800043
J	Shann, F				Shann, F			How often do children cough?	LANCET			English	Editorial Material											Shann, F (corresponding author), ROYAL CHILDRENS HOSP,INTENS CARE UNIT,MELBOURNE,VIC 3052,AUSTRALIA.		Shann, Frank/C-9510-2011					FALCONER A, 1993, PEDIATR PULM, V15, P209, DOI 10.1002/ppul.1950150405; FULLER RW, 1991, LUNG SCI FDN; Munyard P, 1996, ARCH DIS CHILD, V74, P531, DOI 10.1136/adc.74.6.531; Pio A, 1988, Indian J Pediatr, V55, P197, DOI 10.1007/BF02722181	4	14	16	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					699	700		10.1016/S0140-6736(05)65602-4	http://dx.doi.org/10.1016/S0140-6736(05)65602-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806287				2022-12-24	WOS:A1996VG37400006
J	Tariq, SM; Stevens, M; Matthews, S; Ridout, S; Twiselton, R; Hide, DW				Tariq, SM; Stevens, M; Matthews, S; Ridout, S; Twiselton, R; Hide, DW			Cohort study of peanut and tree nut sensitisation by age of 4 years	BRITISH MEDICAL JOURNAL			English	Article							ENVIRONMENTAL-FACTORS; ALLERGIC DISORDERS; FOOD; CHILDREN	Objective-To determine the prevalence of sensitisation to peanuts and tree nuts in all children born during one year in one geographical area. Design-Birth cohort study with structured review at ages 1, 2, and 4 years. Setting-All children born on the Isle of Wight between January 1989 and February 1990. Subjects-Of 1456 children originally included, 1218 were reviewed at age 4 years, Of these, 981 had skin prick tests. Main outcome measures-Positive skin test results, clinical atopic disease, and risk factors for the development of atopy. Results-15 of 1218 (1.2%) children were sensitised to peanuts or tree nuts (13 to peanuts). Six had had allergic reactions to peanuts (0.5% of the population), one to hazelnuts, and one to cashew nuts; three had had anaphylactic reactions, Seven children had positive skin test results or detectable IgE to peanuts without clinical symptoms. Two children who reacted to peanut in infancy had lost their sensitivity by 4 years. Family history of atopy, allergy to egg (odds ratio 9.9, 95% confidence interval 2.1 to 47.9, and eczema (7.3, 2.1 to 26.1) were important predictors for peanut allergy. Conclusions-IgE mediated allergy to peanuts is common in early childhood. In many the allergy persists but a minority may develop tolerance.	ST MARYS HOSP,DEPT BIOCHEM,NEWPORT PO30 5TG,ISLE OF WIGHT,ENGLAND; ST MARYS HOSP,ASTHMA & ALLERGY RES CTR,NEWPORT PO30 5TG,ISLE OF WIGHT,ENGLAND									ARSHAD SH, 1991, CLIN EXP ALLERGY, V21, P373, DOI 10.1111/j.1365-2222.1991.tb01671.x; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; EBERT W, 1990, INVITRO DIAGNOSTICA, V2, P6; FRIES JH, 1982, ANN ALLERGY, V48, P220; GERRARD JW, 1986, ANN ALLERGY, V56, P351; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; VANASPEREN PP, 1983, ARCH DIS CHILD, V58, P253, DOI 10.1136/adc.58.4.253; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZIMMERMAN B, 1989, J ALLERGY CLIN IMMUN, V83, P764, DOI 10.1016/0091-6749(89)90012-2	11	261	271	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					514	517						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789974	Green Published			2022-12-24	WOS:A1996VF29400014
J	Davies, HD; McGeer, A; Schwartz, B; Green, K; Cann, D; Simor, AE; Low, DE; Fletcher, A; Kaul, R; Scriver, S; Willey, B; Demers, B; Gold, W; Lovgren, M; Talbot, J; Naus, M				Davies, HD; McGeer, A; Schwartz, B; Green, K; Cann, D; Simor, AE; Low, DE; Fletcher, A; Kaul, R; Scriver, S; Willey, B; Demers, B; Gold, W; Lovgren, M; Talbot, J; Naus, M			Invasive group a streptococcal infections in Ontario, Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SHOCK-LIKE SYNDROME; GROUP-A STREPTOCOCCI; CHANGING EPIDEMIOLOGY; WOUND INFECTIONS; NURSING-HOME; PYOGENES; OUTBREAK; CHILDREN; ASSOCIATION; BACTEREMIA	Background Several reports suggest that the incidence of invasive group A streptococcal infections, including streptococcal toxic shock syndrome and necrotizing fasciitis, is increasing. Methods During 1992 and 1993 we conducted prospective, population-based surveillance of invasive group A streptococcal disease in Ontario, Canada. We reviewed clinical and laboratory records, searched for secondary cases of invasive disease, and cultured specimens from household contacts. Results We identified 323 patients with invasive group A streptococcal infections, for an annual incidence of 1.5 cases per 100,000 population. The rates were highest in young children and the elderly. Fifty-six percent of the patients had underlying chronic illness. Risk factors for disease included infection with the human immunodeficiency virus, cancer, diabetes, alcohol abuse, and chickenpox. The most common clinical presentations were soft-tissue infection (48 percent), bacteremia with no septic focus (14 percent), and pneumonia (11 percent). Necrotizing fasciitis occurred in 6 percent of patients, and toxic shock in 13 percent. The mortality rate was 15 percent overall, but it was 29 percent among those over 64 years of age (P<0.001) and 81 percent among those with toxic shock (P<0.001). Fourteen percent of the cases were nosocomial, and 4 percent occurred in nursing home residents, often in association with disease outbreaks. Invasive disease occurred in 2 household contacts of patients with infection, for an estimated risk of 3.2 per 1000 household contacts (95 percent confidence interval, 0.39 to 12 per 1000). Conclusions The elderly and those with underlying medical conditions are at greatest risk for invasive group A streptococcal disease, toxic shock, and necrotizing fasciitis. Invasive streptococcal infection is associated with a substantial risk of transmission in households and health care institutions. (C) 1996, Massachusetts Medical Society.	MT SINAI HOSP,DEPT MICROBIOL,TORONTO,ON M5G 1X5,CANADA; PRINCESS MARGARET HOSP,TORONTO,ON M4X 1K9,CANADA; HOSP SICK CHILDREN,DIV INFECT DIS,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DEPT MICROBIOL,TORONTO,ON M5S 1A1,CANADA; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341; INST PASTEUR,PARIS,FRANCE; TORONTO HOSP,TORONTO,ON M5T 2S8,CANADA; NATL CTR STREPTOCOCCUS,EDMONTON,AB,CANADA; ONTARIO MINIST HLTH,TORONTO,ON M5W 1R5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Centers for Disease Control & Prevention - USA; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Toronto; University Toronto Affiliates; University Health Network Toronto			McGeer, Allison/AAB-6885-2020; mcgeer, allison/H-7747-2014; Low, Donald/B-1726-2012	McGeer, Allison/0000-0001-5647-6137; mcgeer, allison/0000-0001-5647-6137; 				*AM AC PED, 1994, 1994 REDBOOK, P430; ARMITAGE P, 1987, STAT METHODS MED RES, P134; AUERBACH SB, 1992, ARCH INTERN MED, V152, P1017, DOI 10.1001/archinte.152.5.1017; BIBLER MR, 1986, REV INFECT DIS, V8, P941; CLEARY PP, 1992, LANCET, V339, P518, DOI 10.1016/0140-6736(92)90339-5; COLMAN G, 1993, J MED MICROBIOL, V39, P165, DOI 10.1099/00222615-39-3-165; CONE LA, 1987, NEW ENGL J MED, V317, P146, DOI 10.1056/NEJM198707163170305; DAVIES HD, 1994, PEDIATR INFECT DIS J, V13, P49, DOI 10.1097/00006454-199401000-00011; DEMERS B, 1993, CLIN INFECT DIS, V16, P792, DOI 10.1093/clind/16.6.792; DIPERSIO JR, 1995, 95 GEN M AM SOC MICR; FRANCIS J, 1988, Q J MED, V68, P603; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GARNER JS, 1988, AM J INFECT CONTROL, V16, P177; GONZALEZRUIZ A, 1995, CLIN INFECT DIS, V20, P1058, DOI 10.1093/clinids/20.4.1058; Griffith F, 1934, J HYG-CAMBRIDGE, V34, P542, DOI 10.1017/S0022172400043308; HOGE CW, 1993, JAMA-J AM MED ASSOC, V269, P384, DOI 10.1001/jama.269.3.384; HOGE CW, 1993, JAMA-J AM MED ASSOC, V269, P1638; HOLM SE, 1992, J INFECT DIS, V166, P31, DOI 10.1093/infdis/166.1.31; JOHNSON DR, 1992, J INFECT DIS, V166, P374, DOI 10.1093/infdis/166.2.374; MASTRO TD, 1990, NEW ENGL J MED, V323, P968, DOI 10.1056/NEJM199010043231406; MAXTED WR, 1973, J MED MICROBIOL, V6, P83, DOI 10.1099/00222615-6-1-83; *ONT MIN HLTH, 1992, 1990 ONT MIN HLTH; PAUL SM, 1990, INFECT CONT HOSP EP, V11, P643; PREBLUD SR, 1984, PEDIATR INFECT DIS J, V3, P505, DOI 10.1097/00006454-198411000-00004; ROTTA J, 1971, J EXP MED, V134, P1298, DOI 10.1084/jem.134.5.1298; SCHAFFNER W, 1969, NEW ENGL J MED, V280, P1224, DOI 10.1056/NEJM196905292802209; SCHWARTZ B, 1992, INFECT CONT HOSP EP, V13, P742; SCHWARTZ B, 1992, CLIN INFECT DIS, V15, P277, DOI 10.1093/clinids/15.2.277; SCHWARTZ B, 1990, LANCET, V336, P1167, DOI 10.1016/0140-6736(90)92777-F; SINGLE LA, 1992, FEMS MICROBIOL LETT, V91, P85, DOI 10.1111/j.1574-6968.1992.tb05188.x; STAMM WE, 1978, J INFECT DIS, V138, P287, DOI 10.1093/infdis/138.3.287; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STROMBERG A, 1991, J INFECT DIS, V164, P595, DOI 10.1093/infdis/164.3.595; TALKINGTON DF, 1993, INFECT IMMUN, V61, P3369, DOI 10.1128/IAI.61.8.3369-3374.1993; TYLER SD, 1992, J CLIN MICROBIOL, V30, P3127, DOI 10.1128/JCM.30.12.3127-3131.1992; VALENZUELA TD, 1991, ANN EMERG MED, V20, P90, DOI 10.1016/S0196-0644(05)81129-1; VIGLIONESE A, 1991, AM J MED, V91, pS329, DOI 10.1016/0002-9343(91)90391-A; WATANABEOHNISHI R, 1995, J INFECT DIS, V171, P74, DOI 10.1093/infdis/171.1.74; WHEELER MC, 1991, JAMA-J AM MED ASSOC, V266, P533, DOI 10.1001/jama.266.4.533; WILSON GJ, 1995, CLIN INFECT DIS, V20, P1333, DOI 10.1093/clinids/20.5.1333; 1993, JAMA-J AM MED ASSOC, V269, P390; 1976, J INFECT DIS, V134, P201; 1976, JAMA-J AM MED ASSOC, V235, P261	43	519	530	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1996	335	8					547	554		10.1056/NEJM199608223350803	http://dx.doi.org/10.1056/NEJM199608223350803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD302	8684408	Green Published			2022-12-24	WOS:A1996VD30200003
J	Vasen, HFA; vanderLuijt, RB; Slors, JFM; Buskens, E; deRuiter, P; Baeten, CGM; Schouten, WR; Oostvogel, HJM; Kuijpers, JHC; Tops, CMJ; Khan, PM				Vasen, HFA; vanderLuijt, RB; Slors, JFM; Buskens, E; deRuiter, P; Baeten, CGM; Schouten, WR; Oostvogel, HJM; Kuijpers, JHC; Tops, CMJ; Khan, PM			Molecular genetic tests as a guide to surgical management of familial adenomatous	LANCET			English	Article							GERM-LINE MUTATIONS; APC GENE; POLYPOSIS; CANCER; IDENTIFICATION	Background In familial adenomatous polyposis the only curative treatment is colectomy, and the choice of operation lies between restorative proctocolectomy (RPC) and colectomy with ileorectal anastomosis (IRA). The RPC procedure carries a higher morbidity but, unlike IRA, removes the risk of subsequent rectal cancer. Since the course of familial adenomatous polyposis is influenced by the site of mutation in the polyposis gene, DNA analysis might be helpful in treatment decisions. Methods We evaluated the incidence of rectal cancer in polyposis patients who had undergone IRA, and examined whether the requirement for subsequent rectal excision because of cancer or uncontrollable polyps was related to the site of mutation. Findings Between 1956 and mid-1995, 225 patients registered at the Netherlands Polyposis Registry had undergone IRA. In 87 of them, a pathogenetic mutation was detected. 72 patients had a mutation located before codon 1250 and 15 patients after this codon. The cumulative risk of rectal cancer 20 years after surgery was 12%, and at that time 42% had undergone rectal excision. The risk of secondary surgery was higher in patients with mutations in the region after codon 1250 than in patients with mutations before this codon (relative risk 2.7, p<0.05). Interpretation On this evidence, IRA should be the primary treatment for polyposis in patients with mutations before codon 1250, and RPC in those with mutations after this codon.	LEIDEN UNIV HOSP,DEPT GASTROENTEROL,NL-2333 AA LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT HUMAN GENET,MGC,NL-2300 RA LEIDEN,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT SURG,NL-1105 AZ AMSTERDAM,NETHERLANDS; UNIV UTRECHT HOSP,DEPT CLIN EPIDEMIOL,UTRECHT,NETHERLANDS; MED CTR,DEPT SURG,ALKMAAR,NETHERLANDS; UNIV LIMBURG HOSP,DEPT SURG,MAASTRICHT,NETHERLANDS; ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT SURG,ROTTERDAM,NETHERLANDS; ST ELIZABETH HOSP,DEPT SURG,TILBURG,NETHERLANDS; UNIV NIJMEGEN HOSP,DEPT SURG,NL-6500 HB NIJMEGEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center; Maastricht University; Maastricht University Medical Centre (MUMC); Erasmus University Rotterdam; Erasmus MC; Elisabeth-TweeSteden Ziekenhuis (ETZ); Radboud University Nijmegen	Vasen, HFA (corresponding author), LEIDEN UNIV HOSP,NETHERLANDS FDN DETECT HEREDITARY TUMOURS,RIJNSBURGERWEG 10,BLDG 50,NL-2333 AA LEIDEN,NETHERLANDS.			Vasen, Hans/0000-0003-2682-2603				BESS MA, 1980, ARCH SURG-CHICAGO, V115, P460; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; BUSSEY HJR, 1985, BRIT J SURG, V72, pS29, DOI 10.1002/bjs.1800721318; CASPARI R, 1994, LANCET, V343, P629, DOI 10.1016/S0140-6736(94)92634-4; DECOSSE JJ, 1992, BRIT J SURG, V79, P1372, DOI 10.1002/bjs.1800791245; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; GAYTHER SA, 1994, HUM MOL GENET, V3, P53, DOI 10.1093/hmg/3.1.53; GIARDIELLO FM, 1994, GASTROENTEROLOGY, V106, P1542, DOI 10.1016/0016-5085(94)90408-1; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; IWAMA T, 1993, ANN SURG, V217, P101, DOI 10.1097/00000658-199302000-00002; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; NAGASE H, 1992, CANCER RES, V52, P4055; NUGENT KP, 1994, GUT, V35, P1622, DOI 10.1136/gut.35.11.1622; NUGENT KP, 1992, BRIT J SURG, V79, P1204, DOI 10.1002/bjs.1800791136; PAUL P, 1993, HUM MOL GENET, V2, P925, DOI 10.1093/hmg/2.7.925; SPIGELMAN AD, 1994, FAMILIAL ADENOMATOUS; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; VASEN HFA, 1990, DIS COLON RECTUM, V33, P227, DOI 10.1007/BF02134185	20	149	151	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					433	435		10.1016/S0140-6736(96)01340-2	http://dx.doi.org/10.1016/S0140-6736(96)01340-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709782	Green Submitted			2022-12-24	WOS:A1996VC67300010
J	Weaver, SC; Salas, R; RicoHesse, R; Ludwig, GV; Oberste, MS; Boshell, J; Tesh, RB				Weaver, SC; Salas, R; RicoHesse, R; Ludwig, GV; Oberste, MS; Boshell, J; Tesh, RB			Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America	LANCET			English	Article							ENCEPHALITIS COMPLEX; VIRUSES; IDENTIFICATION; ALPHAVIRUSES; ANTIBODY; VACCINE	Background Venezuelan equine encephalomyelitis (VEE) virus has caused periodic epidemics among human beings and equines in Latin America from the 1920s to the early 1970s. The first major outbreak since 1973 occurred in Venezuela and Colombia during 1995, and involved an estimated 75 000 to 100 000 people. We report an and virological investigation of this epidemic. Methods Virus isolates were made in cell culture from human serum, human throat swabs, and brain tissue from aborted and stillborn human fetuses, as well as from horse brain tissue and pooled mosquito collections. Human sera were also tested for VEE-specific antibodies. The serotypes of VEE isolates were identified by antigen assays, and viruses were characterised genetically by sequencing PCR products generated from the E3 and E2 genes. Phylogenetic analyses were done to determine evolutionary relations with respect to previous epidemic/epizootic and enzootic VEE virus isolates. Mosquito collections were made to identify possible vectors, and clinical findings were determined by direct observation of patients visiting hospitals and clinics in affected regions, and by inspecting patient records. Equine vaccination and vector control were used in an attempt to halt the spread of the outbreak. Findings Most affected people had an acute, self-limited febrile illness of 3 to 4 days duration. However, convulsions were often seen in children, and abortions and fetal deaths occurred in pregnant women infected with VEE virus. Antigenic characterisation of 12 virus isolates spanning the temporal and spatial range of the outbreak indicated that all are VEE serotype IC. Phylogenetic analysis revealed that all of the 1995 viruses were closely related to serotype IC viruses isolated during a large VEE outbreak that occurred in the same regions of Colombia and Venezuela from 1962-1964. A 1983 mosquito isolate from north central Venezuela was also closely related to the 1995 isolates. Interpretation This outbreak was remarkably similar to one that occurred in same regions of Venezuela and Colombia during 1962-1964. Symptoms of infected patients, estimated mortality rates, meteorological conditions preceding the epidemic, and seasonal patterns of transmission were all very similar to those reported in the previous outbreak. In addition, viruses isolated during 1995 were antigenically and genetically nearly identifical to those obtained during 1962-1964. These findings suggest that the epidemic resulted from the re-emergence of an epizootic serotype IC VEE virus. Identification of a similar virus isolate in mosquitoes in Venezuela in 1983, 10 years after epidemic/epizootic VEE activity ceased, raises the possibility of a serotype IC enzootic transmission cycle in northern Venezuela.	UNIV TEXAS,MED BRANCH,DEPT PATHOL,GALVESTON,TX 77555; INST NACL HIGIENE RAFAEL RANGEL,CARACAS,VENEZUELA; YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,YALE ARBOVIRUS RES UNIT,NEW HAVEN,CT 06510; USA,MED RES INST INFECT DIS,DIV VIROL,FT DETRICK,MD 21702; INST NACL SALUD,BOGOTA,COLOMBIA	University of Texas System; University of Texas Medical Branch Galveston; Yale University; Instituto Nacional de Salud (Colombia)	Weaver, SC (corresponding author), UNIV TEXAS,MED BRANCH,CTR TROP DIS,GALVESTON,TX 77555, USA.		Rico-Hesse, Rebeca/C-5294-2011; Weaver, Scott C/D-6490-2011; Rico-Hesse, Rebecca/AAW-9501-2021	Rico-Hesse, Rebeca/0000-0001-6216-1000; Weaver, Scott C/0000-0001-8016-8556; 	NIAID NIH HHS [AI 33983, AI 39508, AI 10894] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI039508] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOWEN GS, 1976, J CLIN MICROBIOL, V4, P22; BUNDO K, 1985, J VIROL METHODS, V11, P15, DOI 10.1016/0166-0934(85)90120-X; Calisher C. H., 1988, The arboviruses: epidemiology and ecology. Volume I., P19; ESCALANA AS, 1969, INVEST CLIN, V31, P45; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J., 1990, PHYLIP MANUAL VERSIO; Johnson K M, 1974, Adv Vet Sci Comp Med, V18, P79; KINNEY RM, 1989, VIROLOGY, V170, P19, DOI 10.1016/0042-6822(89)90347-4; KINNEY RM, 1992, J GEN VIROL, V73, P3301, DOI 10.1099/0022-1317-73-12-3301; KINNEY RM, 1983, J GEN VIROL, V64, P135, DOI 10.1099/0022-1317-64-1-135; MARTIN DH, 1972, AM J EPIDEMIOL, V95, P565, DOI 10.1093/oxfordjournals.aje.a121426; RICOHESSE R, 1995, P NATL ACAD SCI USA, V92, P5278, DOI 10.1073/pnas.92.12.5278; RICOHESSE R, 1988, AM J TROP MED HYG, V38, P187, DOI 10.4269/ajtmh.1988.38.187; ROEHRIG JT, 1991, J CLIN MICROBIOL, V29, P630, DOI 10.1128/JCM.29.3.630-631.1991; Rossi A L, 1967, Prog Med Virol, V9, P176; ROVIRA JA, 1964, REV VENEZ SANIDAD AS, V29, P231; Sudia W. D., 1972, Venezuelan encephalitis-proceedings of the workshop-symposium on Venezuelan encephalitis virus., P157; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; TESH RB, 1979, AM J TROP MED HYG, V28, P1053, DOI 10.4269/ajtmh.1979.28.1053; Walton T. E., 1989, The arboviruses: epidemiology and ecology. Volume IV., P203; WALTON TE, 1973, J INFECT DIS, V128, P271, DOI 10.1093/infdis/128.3.271; WEAVER SC, 1992, VIROLOGY, V191, P282, DOI 10.1016/0042-6822(92)90190-Z; WEAVER SC, 1992, CURR TOP MICROBIOL, V176, P99; WEGNER F, 1978, TERAROLOGY, V16, P359; 1995, MMWR-MORBID MORTAL W, V44, P775; 1995, MMWR-MORBID MORTAL W, V44, P721	26	211	219	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 17	1996	348	9025					436	440		10.1016/S0140-6736(96)02275-1	http://dx.doi.org/10.1016/S0140-6736(96)02275-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC673	8709783	hybrid			2022-12-24	WOS:A1996VC67300011
J	Bennett, MJ; Marchant, A; Green, HG; May, ST; Ward, SP; Millner, PA; Walker, AR; Schulz, B; Feldmann, KA				Bennett, MJ; Marchant, A; Green, HG; May, ST; Ward, SP; Millner, PA; Walker, AR; Schulz, B; Feldmann, KA			Arabidopsis AUX1 gene: A permease-like regulator of root gravitropism	SCIENCE			English	Article							THALIANA; ACID; TRANSPORT; EXPRESSION; PROTEINS; SPECIFICITY; RESISTANCE; RESPONSES; MEMBRANE; MUTANTS	The plant hormone auxin regulates various developmental processes including root formation, vascular development, and gravitropism. Mutations within the AUX1 gene confer an auxin-resistant root growth phenotype and abolish root gravitropic curvature. Polypeptide sequence similarity to amino acid permeases suggests that AUX1 mediates the transport of an amino acid-like signaling molecule. Indole-3-acetic acid, the major form of auxin in higher plants, is structurally similar to tryptophan and is a likely substrate for the AUX1 gene product. The cloned AUX1 gene can restore the auxin-responsiveness of transgenic aux1 roots. Spatially, AUX1 is expressed in root apical tissues that regulate root gravitropic curvature.	UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV CAMBRIDGE,DEPT PLANT SCI,CAMBRIDGE CB2 1TN,ENGLAND; UNIV ARIZONA,DEPT PLANT SCI,TUCSON,AZ 85721	University of Leeds; University of Cambridge; University of Arizona	Bennett, MJ (corresponding author), UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.		Bennett, Malcolm/G-4004-2010; Marchant, Alan/I-4395-2012; may, sean t/B-6838-2012; Walker, Mandy/C-4957-2012	Bennett, Malcolm/0000-0003-0475-390X; Marchant, Alan/0000-0002-8293-2332; may, sean t/0000-0001-5282-3250; Walker, Mandy/0000-0002-7596-8484				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; CIAROS M, 1994, CABIOS, V10, P685; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ESTELLE M, 1992, BIOESSAYS, V14, P439, DOI 10.1002/bies.950140703; EVANS ML, 1994, PLANTA, V194, P215, DOI 10.1007/BF01101680; EVANS ML, 1991, PLANT PHYSIOL, V95, P1, DOI 10.1104/pp.95.1.1; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; HASENSTEIN KH, 1988, PLANT PHYSIOL, V86, P890, DOI 10.1104/pp.86.3.890; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; JONES AM, 1994, ANN REV PLANT PHYSL, V45, P394; KWART M, 1993, PLANT J, V4, P993, DOI 10.1046/j.1365-313X.1993.04060993.x; LELANNE EB, 1994, GENETICS, V138, P61; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LOMAX TL, 1992, BIOCHEM SOC T, V20, P64, DOI 10.1042/bst0200064; LOMAX TL, 1994, PLANT HORMONES THEIR, P509; LUDEVID D, 1992, PLANT PHYSIOL, V100, P1633, DOI 10.1104/pp.100.4.1633; MAHER EP, 1980, BIOCHEM GENET, V18, P1041, DOI 10.1007/BF00484337; MAY S, UNPUB; MUDAY GK, 1994, PLANT PHYSIOL BIOCH, V32, P193; NORMANLY J, 1993, P NATL ACAD SCI USA, V90, P10355, DOI 10.1073/pnas.90.21.10355; OKADA K, 1990, SCIENCE, V250, P274, DOI 10.1126/science.250.4978.274; PICKETT FB, 1990, PLANT PHYSIOL, V94, P1462, DOI 10.1104/pp.94.3.1462; RAYLE DL, 1992, PLANT PHYSIOL, V99, P1271, DOI 10.1104/pp.99.4.1271; ROST B, 1995, PROTEIN SCI, V4, P521; RUBERY PH, 1974, PLANTA, V118, P101, DOI 10.1007/BF00388387; SCHULZ B, 1994, PLANT MOL BIOL MANUA; TSURUMI S, 1978, PLANT CELL PHYSIOL, V19, P1195; VESPER MJ, 1990, PLANTA, V182, P486, DOI 10.1007/BF02341022; Ward S., UNPUB; ZETTL R, 1992, P NATL ACAD SCI USA, V89, P480, DOI 10.1073/pnas.89.2.480	33	731	765	5	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					948	950		10.1126/science.273.5277.948	http://dx.doi.org/10.1126/science.273.5277.948			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688077				2022-12-24	WOS:A1996VC67000060
J	Wang, TW; Li, BY; Danielson, PD; Shah, PC; Rockwell, S; Lechleider, RJ; Martin, J; Manganaro, T; Donahoe, PK				Wang, TW; Li, BY; Danielson, PD; Shah, PC; Rockwell, S; Lechleider, RJ; Martin, J; Manganaro, T; Donahoe, PK			The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; SERINE-THREONINE KINASE; PEPTIDYL-PROLYL ISOMERASE; ACTIVIN RECEPTOR; IMMUNOSUPPRESSANT FK506; EXPRESSION CLONING; MAMMALIAN PROTEIN; COMPLEX; CALCINEURIN; RAPAMYCIN	The immunophilin FKBP12 is an evolutionarily conserved abundant protein; however, its physiological roles remain poorly defined. Here we report that FKBP12 is a common cytoplasmic interactor of TGF beta family type I receptors. FKBP12 binds to ligand-free TGF beta type I receptor, from which it is released upon a ligand-induced, type II receptor mediated phosphorylation of the type I receptor. Blocking FKBP12/type I receptor interaction with FK506 nonfunctional derivatives enhances the ligand activity, indicating that FKBP12 binding is inhibitory to the signaling pathways of the TGF beta family ligands. Overexpression of a myristylated FKBP12 in Mv1Lu cell specifically inhibits two separate pathways activated by TGF beta, and two point mutations on FKBP12 (G89P, 190K) abolish the inhibitory activity of FKBP12, suggesting that FKBP12 may dock a cytoplasmic protein to the type I receptors to inhibit TGF beta family mediated signaling.	NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, TW (corresponding author), HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT SURG,PEDIAT SURG RES LAB,BOSTON,MA 02114, USA.				NICHD NIH HHS [P-30 HD07396, HD 32112] Funding Source: Medline; NIGMS NIH HHS [R29 GM53710] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053710] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BECKER JW, 1993, J BIOL CHEM, V268, P11335; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DONAHOE PK, 1977, J SURG RES, V23, P141, DOI 10.1016/0022-4804(77)90202-5; DUMONT FJ, 1992, J EXP MED, V176, P751, DOI 10.1084/jem.176.3.751; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; Jost, 1947, ARCH ANAT MICR MORPH, V36, P271; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; PRICE JM, 1977, AM J ANAT, V149, P353, DOI 10.1002/aja.1001490304; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TRELSTAD RL, 1982, DEV BIOL, V92, P27, DOI 10.1016/0012-1606(82)90147-6; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; YANG D, 1993, J AM CHEM SOC, V115, P819, DOI 10.1021/ja00055a081; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	47	307	319	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					435	444		10.1016/S0092-8674(00)80116-6	http://dx.doi.org/10.1016/S0092-8674(00)80116-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756725	Bronze			2022-12-24	WOS:A1996VC30900011
J	vandenHeuvel, M; Ingham, PW				vandenHeuvel, M; Ingham, PW			smoothened encodes a serpentine protein required for hedgehog signalling	NATURE			English	Article							DROSOPHILA PATCHED GENE; WINGLESS TRANSCRIPTION; POLARITY GENE; EXPRESSION; MUTATIONS; EMBRYOS; LARVAL; PATTERN; CUTICLE; FAMILY	MEMBERS of the Hedgehog family of secreted proteins control a number of important inductive interactions in the development of both vertebrates and Drosophila(1), but little is known about the ways in which their signalling activities are transduced. In Drosophila, hedgehog is one of the segment-polarity genes, mutations of which disrupt the pattern and polarity of individual embryonic segments(2) and their adult derivatives(3); several of these genes have been implicated in transduction of the hedgehog signal(4-6). Here we show that the segment-polarity gene smoothened is required for the response of cells to hedgehog signalling during the development of both the embryonic segments and imaginal discs. Sequence analysis of the smoothened transcription unit reveals a single open reading frame encoding a protein with seven putative transmembrane domains. This structure is typical of G-protein-coupled receptors, suggesting that the Smoothened protein may act as a receptor for the Hedgehog ligand.	IMPERIAL CANC RES FUND,MOL EMBRYOL LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Ingham, Philip W/G-9903-2011; Ingham, Philip W/E-6710-2010; Ingham, Philip William/AAH-5884-2020	Ingham, Philip W/0000-0001-8224-9958; Ingham, Philip William/0000-0001-8224-9958				BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOU TB, 1992, GENETICS, V131, P643; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FORBES AJ, 1993, DEVELOPMENT, P115; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; KALDERON D, 1995, CURR BIOL, V5, P580, DOI 10.1016/S0960-9822(95)00114-X; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; Wang YS, 1996, J BIOL CHEM, V271, P4468; WILLIAMS JA, 1993, BIOESSAYS, V15, P567, DOI 10.1002/bies.950150902; XU T, 1993, DEVELOPMENT, V117, P1223	32	403	420	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					547	551		10.1038/382547a0	http://dx.doi.org/10.1038/382547a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700230				2022-12-24	WOS:A1996VB25800053
J	Greenwood, B				Greenwood, B			Fever and malaria	LANCET			English	Editorial Material							TUMOR-NECROSIS-FACTOR; TOXINS				Greenwood, B (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED PARASITOL,LONDON WC1E 7HT,ENGLAND.							BATE CAW, 1994, INFECT IMMUN, V62, P3086, DOI 10.1128/IAI.62.8.3086-3091.1994; JAKOBSEN PH, 1995, PARASITE IMMUNOL, V17, P223, DOI 10.1111/j.1365-3024.1995.tb01019.x; KARUNAWEERA ND, 1992, P NATL ACAD SCI USA, V89, P3200, DOI 10.1073/pnas.89.8.3200; KWIATKOWSKI D, 1993, Q J MED, V86, P91; MILLER M. J., 1958, TRANS ROY SOC TROP MED AND HYG, V52, P152, DOI 10.1016/0035-9203(58)90036-1; Rogier C, 1996, AM J TROP MED HYG, V54, P613, DOI 10.4269/ajtmh.1996.54.613; SMITH T, 1994, PARASITOLOGY, V109, P539, DOI 10.1017/S0031182000076411; SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					280	281		10.1016/S0140-6736(05)64468-6	http://dx.doi.org/10.1016/S0140-6736(05)64468-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709683				2022-12-24	WOS:A1996VA25000004
J	Donnelly, SC; Strieter, RM; Reid, PT; Kunkel, SL; Burdick, MD; Armstrong, I; Mackenzie, A; Haslett, C				Donnelly, SC; Strieter, RM; Reid, PT; Kunkel, SL; Burdick, MD; Armstrong, I; Mackenzie, A; Haslett, C			The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						cytokines; respiratory distress syndrome, adult; tumor necrosis factor; interleukin-1; interleukin-10	TUMOR-NECROSIS-FACTOR; INHIBITS CYTOKINE PRODUCTION; IL-1; INVIVO; TRAUMA	Objectives: To determine the relation between 1) intraalveolar concentrations of the proinflammatory cytokines (tumor necrosis factor, interleukin-1 beta, and interleukin-8) and the anti-inflammatory cytokines (interleukin-10 and interleukin-1 receptor antagonist) in patients with early adult respiratory distress syndrome (ARDS) and 2) subsequent patient mortality rates. Design: Prospective cohort study. Setting: University medical center. Patients: 28 consecutive patients in whom ARDS was prospectively identified during hospitalization and 9 ventilated controls. Measurements: Concentrations of proinflammatory cytokines and anti-inflammatory cytokines in bronchoalveolar lavage fluid. Results: The concentrations of proinflammatory and anti-inflammatory cytokines within the alveolar air spaces were significantly elevated in patients with ARDS compared with controls (P = 0.01 for tumor necrosis factor [median, 90 pg/mL (range, 0 to 2500 pg/mL) for patients with ARDS; median, 0 pg/mL (range, 0 to 118 pg/mL) for controls]; P = 0.001 for interleukin-1 beta [median, 179 pg/mL (range, 0 to 2200 pg/mL) for patients with ARDS; median, 0 pg/mL (range, 0 to 80 pg/mL) for controls]; P = 0.0001 for interleukin-8 [median, 628 pg/mL (range, 0 to 4700 pg/mL) for patients with ARDS; median, 0 pg/mL (range, 0 to 278 pg/mL) for controls]; P = 0.0005 for interleukin-10 [median, 100 pg/mL (range, 0 to 1600 pg/mL) for patients with ARDS; median, 0 pg/mL (range, 0 to 50 pg/mL) for controls], and P = 0.002 for interleukin-1 receptor antagonist [median, 820 pg/mL (range, 0 to 18 900 pg/mL) for patients with ARDS; median, 50 pg/mL (range, 0 to 240 pg/mL) for controls]). A highly significant correlation was found between low concentrations of anti-inflammatory cytokines and subsequent patient mortality rates (P = 0.003 for interleukin-10 [median, 120 pg/mL (range, 30 to 1600 pg/mL) for survivors; median, 40 pg/mL (range, 0 to 110 pg/mL) for nonsurvivors]; P = 0.008 for interleukin-1 receptor antagonist [median, 1600 pg/mL (range, 80 to 18 900 pg/mL) for survivors; median, 90 pg/mL (range, 0 to 3400 pg/mL) for nonsurvivors. No significant correlation was found between the concentrations of the proinflammatory cytokines and mortality rates. Conclusion: Low concentrations of the anti-inflammatory cytokines interleukin-10 and interleukin-1 receptor antagonist in bronchoalveolar lavage fluid obtained from patients with early ARDS are closely associated with poor prognosis. These findings support the hypothesis that failure to mount a localized intrapulmonary anti-inflammatory response early in the pathogenesis of ARDS contributes to more severe organ injury and worse prognosis. Our findings suggest that augmenting anti-inflammatory cytokine defenses would be a beneficial therapeutic approach to patients with ARDS and other inflammatory diseases.	UNIV EDINBURGH, SCH MED, RAYNE LAB, RESP MED UNIT, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; UNIV MICHIGAN, DEPT MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DIV PULM & CRIT CARE MED, ANN ARBOR, MI 48109 USA; ROYAL INFIRM, EDINBURGH, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	University of Edinburgh; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Royal Infirmary of Edinburgh; University of Edinburgh				Donnelly, Seamas/0000-0001-7145-1843				AREND WP, 1989, J IMMUNOL, V143, P1851; BACHOFEN M, 1974, CHEST, V65, pS14, DOI 10.1378/chest.65.4_Supplement.14S; BALDWIN SR, 1986, LANCET, V1, P11; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DONNELLY SC, 1995, AM J RESP CRIT CARE, V151, P1428, DOI 10.1164/ajrccm.151.5.7735596; DONNELLY SC, 1994, LANCET, V344, P215, DOI 10.1016/S0140-6736(94)92995-5; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; EVANOFF HL, 1992, IMMUNOL INVEST, V21, P39, DOI 10.3109/08820139209069361; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FUKUDA Y, 1987, AM J PATHOL, V126, P171; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HYERS TM, 1991, AM REV RESPIR DIS, V144, P268, DOI 10.1164/ajrccm/144.2.268; LAMY M, 1976, AM REV RESPIR DIS, V114, P267; MACNAUGHTON PD, 1992, LANCET, V339, P469, DOI 10.1016/0140-6736(92)91068-J; MALEFYT RD, 1992, CURR OPIN IMMUNOL, V4, P314, DOI 10.1016/0952-7915(92)90082-P; MCHUGH LG, 1994, AM J RESP CRIT CARE, V150, P90, DOI 10.1164/ajrccm.150.1.8025779; MEDURI GU, 1995, CHEST, V108, P1303, DOI 10.1378/chest.108.5.1303; MILLAR AB, 1989, LANCET, V2, P712, DOI 10.1016/S0140-6736(89)90772-1; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; ROCKER GM, 1989, LANCET, V1, P120; SHANLEY TP, 1995, J IMMUNOL, V154, P3454; SMITH DR, 1994, AM J PATHOL, V145, P18; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; VELDE AAT, 1992, J IMMUNOL, V149, P4048; WARSHAWSKI FJ, 1986, AM REV RESPIR DIS, V133, P797	31	195	210	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1996	125	3					191	+		10.7326/0003-4819-125-3-199608010-00005	http://dx.doi.org/10.7326/0003-4819-125-3-199608010-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ287	8686976				2022-12-24	WOS:A1996UZ28700004
J	Seemuller, E; Lupas, A; Baumeister, W				Seemuller, E; Lupas, A; Baumeister, W			Autocatalytic processing of the 20S proteasome	NATURE			English	Article							MULTICATALYTIC PROTEINASE; THERMOPLASMA-ACIDOPHILUM; COMPLEX; ACYLASE	THE Ntn (N-terminal nucleophile) hydrolases are enzymes with an unusual four-layer alpha \ beta fold(1-5). The amino-terminal residue (cysteine, serine or threonine) of the mature protein is the catalytic nucleophile(6-10), and its side chain is activated nucleophilic attack by transfer of its proton to the free N terminus(2), although other active-site residues may also be involved(4,8). The four currently known Ntn hydrolases (glutamine PRPP amidotransferase(1,6), penicillin acylase(2,7), the 20S proteasome(3,8,9) and aspartylglucosaminidase(4,10)) are encoded as inactive precursors, and are activated by cleavage of the peptide bond preceding the catalytic residue. It has been suggested that autocatalytic processing is a common Feature of Ntn hydrolases, and proceeds by an intramolecular mechanism determined by their common fold(5). Here we show that propeptide processing In the proteasome from Thermoplasma acidophilum is Indeed autocatalytic, but is probably intermolecular. Processing is not required for assembly, is largely unaffected by propeptide length and sequence, and occurs before beta-subunit folding is completed. Although serine is an acceptable active-site nucleophile for proteolysis, and cysteine for processing, only threonine is fully functional in both. This explains why threonine is universally conserved in active proteasome subunits.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society								BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; CHOI KS, 1992, J BACTERIOL, V174, P6270, DOI 10.1128/JB.174.19.6270-6276.1992; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FISHER KJ, 1993, FEBS LETT, V323, P271, DOI 10.1016/0014-5793(93)81355-4; GRZLWA A, 1994, EUR J BIOCHEM, V233, P1061; GRZLWA A, 1991, FEBS LETT, V290, P186; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; HEGERL R, 1991, FEBS LETT, V283, P117, DOI 10.1016/0014-5793(91)80567-M; HILT W, 1995, MOL BIOL REP, V21, P3, DOI 10.1007/BF00990964; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; OLNONEN C, 1995, NAT STRUCT BIOL, V2, P1102; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; SCHAUER TM, 1993, J STRUCT BIOL, V111, P135, DOI 10.1006/jsbi.1993.1044; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; SOUCIET JL, 1988, J BIOL CHEM, V263, P3323; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; TANAKA K, 1995, MOL BIOL REP, V21, P21, DOI 10.1007/BF00990966; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	28	180	182	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					468	470		10.1038/382468a0	http://dx.doi.org/10.1038/382468a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684489				2022-12-24	WOS:A1996VA25100062
J	Connelly, C; Hieter, P				Connelly, C; Hieter, P			Budding yeast SKP1 encodes an evolutionarily conserved kinetochore protein required for cell cycle progression	CELL			English	Article							SACCHAROMYCES-CEREVISIAE KINETOCHORE; CHROMOSOME SEGREGATION; CENTROMERE DNA; CHECKPOINT; SEQUENCE; COMPLEX; GENES; IDENTIFICATION; LOCALIZATION; POLYMERASE	The budding yeast SKP1 gene, identified as a dosage suppressor of a known kinetochore protein mutant, encodes an intrinsic 22.3 kDa subunit of CBF3, a multi-protein complex that binds centromere DNA in vitro. Temperature-sensitive mutations in SKP1 define two distinct phenotypic classes. skp1-4 mutants arrest predominantly as large budded cells with a G2 DNA content and short mitotic spindle, consistent with a role in kinetochore function, skp1-3 mutants, however, arrest predominantly as multiply budded cells with a G1 DNA content, suggesting an additional role during the G1/S phase. Identification of Skp1p homologs from C. elegans, A. thaliana, and H. sapiens indicates that SKP1 is evolutionarily highly conserved. Skp1p therefore represents an intrinsic kinetochore protein conserved throughout eukaryotic evolution and may be directly involved in linking kinetochore function with the cell cycle-regulatory machinery.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA016519, CA16519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOGUSKI MS, 1994, SCIENCE, V265, P1993, DOI 10.1126/science.8091218; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CHEN H, 1995, GENOMICS, V27, P389, DOI 10.1006/geno.1995.1068; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; GORBSKY GJ, 1995, TRENDS CELL BIOL, V5, P143, DOI 10.1016/S0962-8924(00)88968-0; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HEGEMANN JH, 1988, MOL CELL BIOL, V8, P2523, DOI 10.1128/MCB.8.6.2523; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEHN B, 1991, MOL CELL BIOL, V11, P5212, DOI 10.1128/MCB.11.10.5212; JIANG WD, 1993, J CELL BIOL, V121, P513, DOI 10.1083/jcb.121.3.513; KOSHLAND D, 1987, METHOD ENZYMOL, V155, P351; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LU ZQ, 1995, VIROLOGY, V206, P339, DOI 10.1016/S0042-6822(95)80049-2; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; NIEDENTHAL RK, 1993, NUCLEIC ACIDS RES, V21, P4413, DOI 10.1093/nar/21.18.4413; PANGILINAN F, 1996, IN PRESS MOL BIOL CE; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; Rose MD., 1990, METHODS YEAST GENETI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; STEMMANN O, 1996, IN PRESS EMBO J; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; WANG YC, 1995, MOL CELL BIOL, V15, P6838; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; WEST CM, 1995, J BIOL CHEM, V270, P3022; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	50	232	249	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					275	285		10.1016/S0092-8674(00)80099-9	http://dx.doi.org/10.1016/S0092-8674(00)80099-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706132	Green Published, hybrid			2022-12-24	WOS:A1996UZ97200013
J	Cyster, JG; Healy, JI; Kishihara, K; Mak, TW; Thomas, ML; Goodnow, CC				Cyster, JG; Healy, JI; Kishihara, K; Mak, TW; Thomas, ML; Goodnow, CC			Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45	NATURE			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; TRANSGENIC MICE; PHOSPHORYLATION; ELIMINATION; ACTIVATION; EXPRESSION	ELIMINATION of self-reactive B cells must be balanced against the need for B-cell diversity for antibody responses to pathogens. To analyse factors that determine the extent of B cell negative selection, we crossed CD45-deficient mice(1) with mice carrying immunoglobulin transgenes specific for hen egg lysozyme (HEL). CD45 positively regulates antigen-receptor signallingt(2-9) and CD45-deficient HEL-specific B cells gave diminished signalling in response to HEL. Significantly, few mature CD45(-/-) B cells accumulated, despite normal immature B-cell production. Circulating HEL autoantigen mediates negative selection of mature CD45(+/+) HEL binding B cells(10) but, in striking contrast, the autoantigen positively selected CD45(-/-) HEL-binding B cells, promoting their accumulation as long-lived IgD(hi) cells. These findings are consistent with a signal-threshold model for B-cell selection and demonstrate that changes in antigen receptor signalling can cause high-affinity self-reactive B cells to be actively retained instead of eliminated, thus revealing a potential mechanism for inherited susceptibility to autoimmune disease.	STANFORD UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PROGRAM IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,BECKMAN CTR,HOWARD HUGHES MED INST,STANFORD,CA 94305; KYUSHU UNIV,MED RES INST BIOREGULAT,DEPT IMMUNOL,HIGASHI KU,FUKUOKA 812,JAPAN; UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS & BIOREGULAT,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,AMGEN INST,TORONTO,ON M4X 1K9,CANADA; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PATHOL,ST LOUIS,MO 63110	Stanford University; Howard Hughes Medical Institute; Stanford University; Kyushu University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Howard Hughes Medical Institute; Washington University (WUSTL)			Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155				ADELSTEIN S, 1991, SCIENCE, V251, P1223, DOI 10.1126/science.1900950; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUI D, 1994, EMBO J, V13, P798, DOI 10.1002/j.1460-2075.1994.tb06322.x; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1994, INT IMMUNOL, V6, P1417, DOI 10.1093/intimm/6.9.1417; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MALYNN BA, 1990, J EXP MED, V171, P843, DOI 10.1084/jem.171.3.843; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; OGIMOTO M, 1995, EUR J IMMUNOL, V25, P2265, DOI 10.1002/eji.1830250823; PEYRON JF, 1991, INT IMMUNOL, V3, P1357, DOI 10.1093/intimm/3.12.1357; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835	27	207	208	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					325	328		10.1038/381325a0	http://dx.doi.org/10.1038/381325a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692271				2022-12-24	WOS:A1996UM40300057
J	Maquet, P; Peters, JM; Aerts, J; Delfiore, G; Degueldre, C; Luxen, A; Franck, G				Maquet, P; Peters, JM; Aerts, J; Delfiore, G; Degueldre, C; Luxen, A; Franck, G			Functional neuroanatomy of human rapid-eye-movement sleep and dreaming	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; CINGULATE CORTEX; WORKING-MEMORY; AMYGDALA; ORGANIZATION; WAKEFULNESS; PROJECTIONS; STATES; BRAIN; PET	RAPID-EYE-MOVEMENT (REM) sleep is associated with intense neuronal activity, ocular saccades, muscular atonia and dreaming(1,2). The function of REM sleep remains elusive and its neural correlates have not been characterized precisely in man. Here we use positron emission tomography and statistical parametric mapping to study the brain state associated with REM sleep in humans. We report a group study of seven subjects who maintained steady REM sleep during brain scanning and recalled dreams upon awakening. The results show that regional cerebral blood flow is positively correlated with REM sleep in pontine tegmentum, left thalamus, both amygdaloid complexes, anterior cingulate cortex and right parietal operculum. Negative correlations between regional cerebral blood flow and REM sleep are observed bilaterally, in a vast area of dorsolateral prefrontal cortex, in parietal cortex (supramarginal gyrus) as well as in posterior cingulate cortex and precuneus. Given the role of the amygdaloid complexes in the acquisition of emotionally influenced memories, the pattern of activation in the amygdala and the cortical areas provides a biological basis for the processing of some types of memory during REM sleep.	CHU SART TILMAN,DEPT NEUROL,B-4000 LIEGE,BELGIUM	University of Liege	Maquet, P (corresponding author), UNIV LIEGE,CYCLOTRON RES CTR B30,B-4000 LIEGE,BELGIUM.		luxen, andre/C-2116-2009	, Pierre/0000-0003-3106-3357				AGGLETON JP, 1980, BRAIN RES, V190, P347, DOI 10.1016/0006-8993(80)90279-6; AGGLETON JP, 1993, TRENDS NEUROSCI, V16, P328, DOI 10.1016/0166-2236(93)90110-8; AMARAL D G, 1992, P1; AMARAL DG, 1984, J COMP NEUROL, V230, P465, DOI 10.1002/cne.902300402; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; BRAUN A R, 1992, Neurology, V42, P182; BUCHSBAUM MS, 1989, LIFE SCI, V45, P1349, DOI 10.1016/0024-3205(89)90021-0; CALVO JM, 1987, BRAIN RES, V403, P22, DOI 10.1016/0006-8993(87)90118-1; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; Gallagher M, 1996, CURR OPIN NEUROBIOL, V6, P221, DOI 10.1016/S0959-4388(96)80076-6; Hall C., 1966, CONTENT ANAL DREAMS, DOI DOI 10.1192/BJP.112.490.963; Hobson J. Allan, 1988, DREAMING BRAIN; HONG CCH, 1995, SLEEP, V18, P570; JONES BE, 1991, NEUROSCIENCE, V40, P637, DOI 10.1016/0306-4522(91)90002-6; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; LLINAS RR, 1991, NEUROSCIENCE, V44, P521, DOI 10.1016/0306-4522(91)90075-Y; MADSEN PL, 1991, J CEREBR BLOOD F MET, V11, P502, DOI 10.1038/jcbfm.1991.94; MAQUET P, 1990, BRAIN RES, V513, P136, DOI 10.1016/0006-8993(90)91099-3; OLSON CR, 1992, J COMP NEUROL, V324, P237, DOI 10.1002/cne.903240207; Orem J, 1980, PHYSL SLEEP, P315; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Rechtschaffen A., 1968, MANUAL STANDARDIZED; SMITH C, 1995, BEHAV BRAIN RES, V69, P137, DOI 10.1016/0166-4328(95)00024-N; SMITH C, 1991, SLEEP, V14, P325, DOI 10.1093/sleep/14.4.325; Steriade M., 1990, THALAMIC OSCILLATION	29	760	775	2	148	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					163	166		10.1038/383163a0	http://dx.doi.org/10.1038/383163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774879				2022-12-24	WOS:A1996VG14800050
J	Marin, I; Franke, A; Bashaw, GJ; Baker, BS				Marin, I; Franke, A; Bashaw, GJ; Baker, BS			The dosage compensation system of Drosophila is co-opted by newly evolved X chromosomes	NATURE			English	Article							EVOLUTION; GENE; EXPRESSION; PHYLOGENY	IN species where males and females differ in number of sex chromosomes, the expression of sex-linked genes is equalized by a process known as dosage compensation. In Drosophila melanogaster, dosage compensation is mediated by the binding of the products of the male-specific lethal (msl) genes to the single male X chromosome. Here we report that the sex- and chromosome-specific binding of three of the msl proteins (MSLs) occurs in other drosophilid species, spanning four genera. Moreover, we show that MSL binding correlates with the evolution of the sex chromosomes: in species that have acquired a second X chromosome arm because of an X-autosome translocation, we observe binding of the MSLs to the 'new' (previously autosomal) arm of the X chromosome, only when its homologue has degenerated. Moreover, in Drosophila miranda, a Y-autosome translocation has produced a new X chromosome (called neo-X), only some regions of which are dosage compensated. In this neo-X chromosome, the pattern of MSL binding correlates with the known pattern of dosage compensation.			Marin, I (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.		Marin, Ignacio/A-9524-2009	Marin, Ignacio/0000-0002-1315-8961				ABRAHAM I, 1974, GENETICS, V78, P119; BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; Bull J. J., 1983, EVOLUTION SEX DETERM; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; DAS M, 1982, CHROMOSOMA, V87, P373, DOI 10.1007/BF00327180; Dobzhansky T, 1935, GENETICS, V20, P0377; GORMAN M, 1995, DEVELOPMENT, V121, P463; GRIMALDI DA, 1990, B AM MUS NAT HIST, V197, P1; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KWIATOWSKI J, 1994, J MOL EVOL, V38, P443, DOI 10.1007/BF00178844; RUSSO CAM, 1995, MOL BIOL EVOL, V12, P391; Steinemann M, 1996, CHROMOSOME RES, V4, P185, DOI 10.1007/BF02254957; STROBEL E, 1978, P NATL ACAD SCI USA, V75, P931, DOI 10.1073/pnas.75.2.931; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	17	86	86	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					160	163		10.1038/383160a0	http://dx.doi.org/10.1038/383160a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774878				2022-12-24	WOS:A1996VG14800049
J	Becraft, PW; Stinard, PS; McCarty, DR				Becraft, PW; Stinard, PS; McCarty, DR			CRINKLY4: A TNFR-like receptor kinase involved in maize epidermal differentiation	SCIENCE			English	Article							SEQUENCE; CELLS; GENE	The maize crinkly4 (cr4) mutation affects leaf epidermis differentiation such that cell size and morphology are altered, and surface functions are compromised, allowing graft-like fusions between organs. In the seed, loss of cr4 inhibits aleurone formation in a pattern that reflects the normal progression af differentiation over the developing endosperm surface. The cr4 gene was Isolated by transposon tagging and found to encode a putative receptor kinase. The extracellular domain contains a cysteine-rich region similar to the ligand binding domain in mammalian tumor necrosis factor receptors (TNFRs) and seven copies of a previously unknown 39-amino acid repeat. The results suggest a role for cr4 in a differentiation signal.	IOWA STATE UNIV,DEPT AGRON,AMES,IA 50011; ARS,USDA,URBANA,IL 61801; UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611	Iowa State University; United States Department of Agriculture (USDA); State University System of Florida; University of Florida	Becraft, PW (corresponding author), IOWA STATE UNIV,DEPT ZOOL & GENET,AMES,IA 50011, USA.			Becraft, Philip/0000-0002-3299-2126				BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BARKER RF, 1984, NUCLEIC ACIDS RES, V12, P5955, DOI 10.1093/nar/12.15.5955; BECRAFT PW, UNPUB; Braun DM, 1996, TRENDS BIOCHEM SCI, V21, P70, DOI 10.1016/S0968-0004(96)80185-X; BRUCK DK, 1985, AM J BOT, V72, P1602, DOI 10.2307/2443311; BRUCK DK, 1988, CAN J BOT, V67, P303; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Freeling Michael, 1994, P17; KOHORN BD, 1992, P NATL ACAD SCI USA, V89, P10989, DOI 10.1073/pnas.89.22.10989; Lee HS, 1996, PLANT J, V9, P613, DOI 10.1046/j.1365-313X.1996.9050613.x; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOLLE SJ, 1992, DEV BIOL, V152, P383, DOI 10.1016/0012-1606(92)90145-7; McClintock B., 1978, CLONAL BASIS DEV, P217; MOORE R, 1984, CAN J BOT, V62, P2476, DOI 10.1139/b84-338; NASRALLAH JB, 1994, PLANT J, V5, P373, DOI 10.1111/j.1365-313X.1994.00373.x; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; Randolph LF, 1936, J AGRIC RES, V53, P0881; SATINA S, 1940, AM J BOT, V44, P311; SIEGEL BA, 1989, SCIENCE, V244, P580, DOI 10.1126/science.244.4904.580; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; STEWART RN, 1979, AM J BOT, V66, P47, DOI 10.2307/2442624; Stinard P. S., 1987, Maize Genetics Cooperation Newsletter, P7; STINARD PS, 1992, MAIZE GENET COOP NEW, V66, P3; STINARD PS, 1991, MAIZE GENET COOP NEW, V65, P17; Tilney-Bassett RA., 1986, PLANT CHIMERAS; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; UPTON C, 1987, VIROLOGY, V160, P20, DOI 10.1016/0042-6822(87)90039-0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALKER DB, 1985, CAN J BOT, V63, P2129, DOI 10.1139/b85-300	29	283	313	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1406	1409		10.1126/science.273.5280.1406	http://dx.doi.org/10.1126/science.273.5280.1406			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703079				2022-12-24	WOS:A1996VF61000048
J	ColeStrauss, A; Yoon, KG; Xiang, YF; Byrne, BC; Rice, MC; Gryn, J; Holloman, WK; Kmiec, EB				ColeStrauss, A; Yoon, KG; Xiang, YF; Byrne, BC; Rice, MC; Gryn, J; Holloman, WK; Kmiec, EB			Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide	SCIENCE			English	Article							BETA-S-GLOBIN; ERYTHROID-CELLS; GENE; LOCUS	A chimeric oligonucleotide composed of DNA and modified RNA residues was used to direct correction of the mutation in the hemoglobin beta(S) allele. After introduction of the chimeric molecule into lymphoblastoid cells homozygous for the beta(S) mutation, there was a detectable level of gene conversion of the mutant allele to the normal sequence. The efficient and specific conversion directed by chimeric molecules may hold promise as a therapeutic method for the treatment of genetic diseases.	THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,DEPT PHARMACOL,PHILADELPHIA,PA 19107; COOPER HOSP UNIV MED CTR,UNIV MED CTR,DEPT MED,DIV HEMATOL ONCOL,CAMDEN,NJ 08103; CORNELL UNIV,SCH MED,DEPT MICROBIOL,NEW YORK,NY 10021	Jefferson University; Rutgers State University Camden; Cornell University								ALLISON AC, 1954, BRIT MED J, V1, P290, DOI 10.1136/bmj.1.4857.290; CHANG JC, 1982, NEW ENGL J MED, V307, P30, DOI 10.1056/NEJM198207013070105; GREEVER RF, 1981, P NATL ACAD SCI USA, V78, P5081; INGRAM VM, 1956, NATURE, V178; Kawasaki E. S., 1990, PCR PROTOCOLS GUIDE, P146; KMIEC EB, 1994, MOL CELL BIOL, V14, P7163, DOI 10.1128/MCB.14.11.7163; LIBER HL, 1982, MUTAT RES, V94, P467, DOI 10.1016/0027-5107(82)90308-6; MAROTTA CA, 1977, J BIOL CHEM, V252, P5040; MILLER JL, 1994, P NATL ACAD SCI USA, V91, P10183, DOI 10.1073/pnas.91.21.10183; NEEL JV, 1956, ANN HUM GENET, V21, P1, DOI 10.1111/j.1469-1809.1971.tb00262.x; ORKIN SH, 1982, NEW ENGL J MED, V307, P32, DOI 10.1056/NEJM198207013070106; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; PLAVEC I, 1993, BLOOD, V81, P1384; SHESELY EG, 1991, P NATL ACAD SCI USA, V88, P4294, DOI 10.1073/pnas.88.10.4294; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS, P66; WILSON JT, 1982, P NATL ACAD SCI-BIOL, V79, P3628, DOI 10.1073/pnas.79.11.3628; Yoon K, 1996, P NATL ACAD SCI USA, V93, P2071, DOI 10.1073/pnas.93.5.2071	18	285	352	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1386	1389		10.1126/science.273.5280.1386	http://dx.doi.org/10.1126/science.273.5280.1386			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703073				2022-12-24	WOS:A1996VF61000042
J	Hecht, A; StrahlBolsinger, S; Grunstein, M				Hecht, A; StrahlBolsinger, S; Grunstein, M			Spreading of transcriptional repressor SIR3 from telomeric heterochromatin	NATURE			English	Article							SILENT MATING LOCI; SACCHAROMYCES-CEREVISIAE; HISTONE H3; YEAST; COMPLEX; RAP1; PROTEINS; DOMAINS; TERMINUS	TELOMERIC genes and the HM loci in Saccharomyces cerevisiae are transcriptionally repressed and adopt a heterochromatin-like structure(1,2). The trans-acting factors RAP1, SIR3 and SIR4 are required for telomeric and HM silencing(3-5): and are thought to be chromosomal(6-8), but how they contribute to histone-dependent repression of adjacent chromatin(9-11) is unclear. SIR3 suppresses silencing defects in histones(10), is limiting for silencing adjacent to telomeres(12), and interacts with the H3 and H4 amino termini in vitro(13), Here we show that SIR3 co-immunoprecipitates SIR4, RAP1 and histones from cellular extracts, suggesting the presence of large chromatin-associated protein complexes. Crosslinking experiments show that SIR3 is present at HMRa, HML alpha and telomeres in vivo, and that it spreads from telomeric regions into adjacent chromatin when overexpressed. Thus SIR3 is a structural component of yeast heterochromatin, repressing adjacent genes as it spreads along the chromosome.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles				Hecht, Andreas/0000-0003-2262-2575				APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Harlow E, 1988, ANTIBODIES LAB MANUA; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KURTZ S, 1991, GENE DEV, V5, P618; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LIU C, 1994, GENETICS, V138, P1025; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; MOORE GD, 1983, GENETICS, V105, P327; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; TARTOF KD, 1990, DEVELOPMENT S, V120, P35; TASAKA K, 1984, ACTA HISTOCHEM CYTOC, V17, P283, DOI 10.1267/ahc.17.283; THOMPSON JS, 1993, COLD SPRING HARB SYM, V58, P247, DOI 10.1101/SQB.1993.058.01.029; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	26	438	447	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					92	96		10.1038/383092a0	http://dx.doi.org/10.1038/383092a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779721				2022-12-24	WOS:A1996VF29500055
J	Zhou, YF; Leon, MB; Waclawiw, MA; Popma, JJ; Yu, ZX; Finkel, T; Epstein, SE				Zhou, YF; Leon, MB; Waclawiw, MA; Popma, JJ; Yu, ZX; Finkel, T; Epstein, SE			Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL-CELLS; ANGIOPLASTY; SURFACE; VIRUS; ATHEROSCLEROSIS; FIBROBLASTS; ADHESION	Background Restenosis occurs commonly after coronary angioplasty and atherectomy, but the causes of restenosis are poorly understood. Recently, it has been found that cytomegalovirus (CMV) DNA is present in restenotic lesions from atherectomy specimens. This and other evidence suggest that CMV may have a role in the process of restenosis. Methods We prospectively studied 75 consecutive patients undergoing directional coronary atherectomy for symptomatic coronary artery disease. Before atherectomy was performed, we measured blood levels of anti-CMV IgG antibodies to determine whether previous exposure to CMV increased the risk of restenosis, as determined by coronary angiography performed six months after atherectomy. Results After atherectomy, the mean (+/-SD) minimal luminal diameter of the target vessel was greater in the 49 patients who were seropositive for CMV than in the 26 patients who were seronegative (3.18+/-0.51 mm vs. 2.89+/-0.45 mm, P=0.01). After six months, however, the seropositive patients had a greater reduction in the luminal diameter (1.24+/-0.83 mm vs, 0.68+/-0.69 mm, P=0.003), resulting in a significantly higher rate of restenosis in the seropositive patients (43 percent vs. 8 percent, P=0.002). In a multivariable logistic-regression model, CMV seropositivity and the CMV titer were independently predictive of restenosis (odds ratios, 12.9 and 8.1, respectively). There was no evidence of acute infection, since the titer of anti-CMV IgG antibodies did not increase over time and tests for anti-CMV IgM antibodies were negative in all patients. Conclusions Prior infection with CMV is a strong independent risk factor for restenosis after coronary atherectomy. If confirmed, these findings may help identify patients at risk for restenosis. (C) 1996, Massachusetts Medical Society.	NHLBI, CARDIOL BRANCH, BETHESDA, MD 20892 USA; WASHINGTON HOSP CTR, WASHINGTON, DC 20010 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); MedStar Washington Hospital Center								ALCAMI J, 1991, J GEN VIROL, V72, P2765, DOI 10.1099/0022-1317-72-11-2765; BACH R, 1994, THROMB RES, V74, pS55; BANKS TA, 1992, CLIN INFECT DIS, V14, P933, DOI 10.1093/clinids/14.4.933; BRUGGEMAN CA, 1993, VIRCHOWS ARCH B, V64, P325, DOI 10.1007/BF02915131; DZAVIK V, 1995, AM J CARDIOL, V75, P936, DOI 10.1016/S0002-9149(99)80691-2; ETINGIN OR, 1990, CELL, V61, P657, DOI 10.1016/0092-8674(90)90477-V; ETINGIN OR, 1993, P NATL ACAD SCI USA, V90, P5153, DOI 10.1073/pnas.90.11.5153; FAXON DP, 1995, ANN NY ACAD SCI, V748, P419; FOLEY DP, 1994, CIRCULATION, V90, P1239, DOI 10.1161/01.CIR.90.3.1239; GEIST LJ, 1991, AM J RESP CELL MOL, V5, P292, DOI 10.1165/ajrcmb/5.3.292; GONCZOL E, 1984, J GEN VIROL, V65, P1833, DOI 10.1099/0022-1317-65-10-1833; GRUNDY JE, 1993, IMMUNOLOGY, V78, P405; HERMANS WRM, 1993, J CARDIOVASC PHARM, V22, pS45, DOI 10.1097/00005344-199322004-00007; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; JORDAN MC, 1973, ANN INTERN MED, V79, P153, DOI 10.7326/0003-4819-79-2-153; KLACSMANN P, 1977, DEL MED J, V49, P399; KOWALIK TF, 1993, IMMUNOLOGY, V78, P405; LEFEUVRE C, 1994, AM J CARDIOL, V73, P840, DOI 10.1016/0002-9149(94)90806-0; MELNICK JL, 1993, EUR HEART J, V14, P30; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; PRYZDIAL ELG, 1994, BLOOD, V84, P3749, DOI 10.1182/blood.V84.11.3749.bloodjournal84113749; SCHULMAN LL, 1991, ARCH INTERN MED, V151, P1118, DOI 10.1001/archinte.151.6.1118; SERRUYS PW, 1988, CIRCULATION, V77, P361, DOI 10.1161/01.CIR.77.2.361; SOUTHERN P, 1986, NEW ENGL J MED, V314, P359, DOI 10.1056/NEJM198602063140606; SPAN AHM, 1991, EUR J CLIN INVEST, V21, P331, DOI 10.1111/j.1365-2362.1991.tb01378.x; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; STEIN B, 1995, CIRCULATION, V91, P979, DOI 10.1161/01.CIR.91.4.979; VANDAMMIERAS MCE, 1992, THROMB HAEMOSTASIS, V68, P364; ZHOU H, 1995, J VIROL, V69, P7960; ZHOU YF, 1995, J AM COLL CARDIOL, V25, pA242; ZHOU YF, 1995, CIRCULATION S1, V92, P162	31	400	427	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					624	630		10.1056/NEJM199608293350903	http://dx.doi.org/10.1056/NEJM199608293350903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD425	8687516				2022-12-24	WOS:A1996VD42500003
J	Yuzaki, M; Forrest, D; Curran, T; Connor, JA				Yuzaki, M; Forrest, D; Curran, T; Connor, JA			Selective activation of calcium permeability by aspartate in Purkinje cells	SCIENCE			English	Article							CEREBELLAR CLIMBING FIBERS; ACID RECEPTOR CHANNELS; METHYL-D-ASPARTATE; CA2+ PERMEABILITY; GLUTAMATE; RAT; NEURONS; PERMEATION; NEUROTRANSMITTER; RELEASE	Glutamate and aspartate are endogenous excitatory amino acid neurotransmitters widely distributed in the mammalian central nervous system, Aspartate was shown to induce a large membrane current sensitive to N-methyl-D-aspartate (NMDA) and non-NMDA receptor antagonists in Purkinje cells from mice lacking functional NMDA receptors (NR1(-/-)). This response was accompanied by high permeability to calcium, in contrast, no current was induced by aspartate in hippocampal neurons and cerebellar granule cells from NR1(-/-) mice, Several other glutamate receptor agonists failed to evoke this response. Thus, in Purkinje cells, aspartate activates a distinct response capable of contributing to synaptic plasticity through calcium permeability.	CUNY MT SINAI SCH MED, DEPT HUMAN GENET, NEW YORK, NY 10029 USA; LOVELACE INST, ALBUQUERQUE, NM 87108 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Lovelace Respiratory Research Institute	Yuzaki, M (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Curran, Thomas/AAE-7631-2019; Curran, Tom/F-5234-2018; Curran, Tom/C-1164-2008; Yuzaki, Michisuke/K-5328-2013; Curran, Tom/D-7515-2011	Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Yuzaki, Michisuke/0000-0002-5750-3544; 	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJIMA A, 1991, NEUROSCI RES, V12, P281, DOI 10.1016/0168-0102(91)90117-H; BRORSON JR, 1994, J NEUROSCI, V14, P187; CREPEL F, 1983, BRAIN RES, V279, P311, DOI 10.1016/0006-8993(83)90200-7; EGEBJERG J, 1993, P NATL ACAD SCI USA, V90, P755, DOI 10.1073/pnas.90.2.755; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; GILBERTSON TA, 1991, SCIENCE, V251, P1613, DOI 10.1126/science.1849316; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KIMURA H, 1985, J PHYSIOL-LONDON, V365, P103, DOI 10.1113/jphysiol.1985.sp015761; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MURASE K, 1990, BRAIN RES, V525, P84, DOI 10.1016/0006-8993(90)91323-9; NADI NS, 1977, J NEUROCHEM, V28, P661, DOI 10.1111/j.1471-4159.1977.tb10439.x; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; PITZER KS, 1973, J PHYS CHEM-US, V77, P2300, DOI 10.1021/j100638a009; ROSEMUND C, 1992, J NEUROPHYSIOL, V68, P1901, DOI 10.1152/jn.1992.68.5.1901; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; VOLLENWEIDER FX, 1990, J NEUROCHEM, V54, P1533, DOI 10.1111/j.1471-4159.1990.tb01201.x; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WIKLUND L, 1982, SCIENCE, V216, P78, DOI 10.1126/science.6121375; YUZAKI M, 1992, J NEUROSCI, V12, P4253; Yuzaki M, 1996, J NEUROSCI, V16, P4651	25	34	36	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 23	1996	273	5278					1112	1114		10.1126/science.273.5278.1112	http://dx.doi.org/10.1126/science.273.5278.1112			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688099				2022-12-24	WOS:A1996VD42800040
J	Chavis, P; Fagni, L; Lansman, JB; Bockaert, J				Chavis, P; Fagni, L; Lansman, JB; Bockaert, J			Functional coupling between ryanodine receptors and L-type calcium channels in neurons	NATURE			English	Article							CEREBELLAR GRANULE CELLS; PROTEIN-KINASE-C; GLUTAMATE RECEPTORS; CA2+ CHANNEL; DEPRESSION; INDUCTION; RELEASE; TOXIN	IN skeletal muscle, L-type Ca2+ channels act as voltage sensors to control ryanodine-sensitive Ca2+ channels in the sarcoplasmic reticulum(1). It has recently been demonstrated that these ryanodine receptors generate a retrograde signal that modifies L-type Ca2+-channel activity(2). Here we demonstrate a tight functional coupling between ryanodine receptors and L-type Ca2+ channel in neurons, In cerebellar granule cells, activation of the type-1 metabotropic glutamate receptor (mGluR1) induced a large, oscillating increase of the L-type Ba2+ current. Activation occurred independently of inositol 1,4,5-trisphosphate and classical protein kinases, but was mimicked by caffeine and blocked by ryanodine, The kinetics of this blockade were dependent on the frequency of Ba2+ current stimulation, Both mGluR1- and caffeine-induced increase in L-type Ca2+-channel activity persisted in inside-out membrane patches, In these excised patches, ryanodine suppressed both the mGluR1- and caffeine-activated L-type Ca2+ channels. These results demonstrate a novel mechanism for Ca2+-channel modulation in neurons.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT CELLULAR & MOL PHARMACOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Chavis, P (corresponding author), CNRS,UPR 9023,CCIPE,141 RUE CARDONILLE,F-34094 MONTPELLIER 05,FRANCE.		Chavis, Pascale/M-8312-2016	Chavis, Pascale/0000-0002-3038-1014; Lansman, Jeffry/0000-0002-8279-4064				CHAVIS P, 1994, J NEUROSCI, V14, P7067; CHAVIS P, 1995, NEUROPHARMACOLOGY, V34, P929, DOI 10.1016/0028-3908(95)00082-H; CHAVIS P, 1995, J NEUROSCI, V15, P135; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; DEWAARD M, 1992, NEURON, V9, P497, DOI 10.1016/0896-6273(92)90187-I; FAGNI L, 1992, BRIT J PHARMACOL, V105, P973, DOI 10.1111/j.1476-5381.1992.tb09087.x; HALL KE, 1995, J NEUROSCI, V15, P6069; IRVING AJ, 1992, J PHYSIOL-LONDON, V456, P667, DOI 10.1113/jphysiol.1992.sp019360; KOHDA K, 1995, J NEUROPHYSIOL, V74, P2184, DOI 10.1152/jn.1995.74.5.2184; LAMBERT RC, 1995, J NEUROSCI, V15, P6014; LINDEN DJ, 1993, NEURON, V11, P1093, DOI 10.1016/0896-6273(93)90222-D; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; MANZONI O, 1990, MOL PHARMACOL, V38, P1; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANVLIET BJ, 1989, J NEUROCHEM, V52, P1229; WHITHAM EM, 1991, EUR J PHARM-MOLEC PH, V206, P181, DOI 10.1016/S0922-4106(05)80017-3	19	270	274	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					719	722		10.1038/382719a0	http://dx.doi.org/10.1038/382719a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751443				2022-12-24	WOS:A1996VD33300051
J	Gossop, M; Griffiths, P; Powis, B; Williamson, S; Strang, J				Gossop, M; Griffiths, P; Powis, B; Williamson, S; Strang, J			Frequency of non-fatal heroin overdose: Survey of heroin users recruited in non-clinical settings	BRITISH MEDICAL JOURNAL			English	Article							DEPENDENCE				Gossop, M (corresponding author), NATL ADDICT CTR,DRUG TRANSIT STUDY,LONDON SE5 8AF,ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725				Darke S, 1996, ADDICTION, V91, P405, DOI 10.1111/j.1360-0443.1996.tb02289.x; GHODSE AH, 1977, BRIT MED J, V1, P1381, DOI 10.1136/bmj.1.6073.1381; GOSSOP M, 1995, ADDICTION, V90, P607, DOI 10.1111/j.1360-0443.1995.tb02199.x; GRIFFITHS P, 1993, ADDICTION, V88, P1617, DOI 10.1111/j.1360-0443.1993.tb02036.x; *NAT I DRUG AB, 1992, DHHS PUBL NAT I DRUG	5	140	143	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					402	402						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VD206	8761230				2022-12-24	WOS:A1996VD20600028
J	Pisacane, A; Sansone, R; Impagliazzo, N; Coppola, A; Rolando, P; DApuzzo, A; Tregrossi, C				Pisacane, A; Sansone, R; Impagliazzo, N; Coppola, A; Rolando, P; DApuzzo, A; Tregrossi, C			Iron deficiency anaemia and febrile convulsions: Case-control study in children under 2 years	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEIZURES		OSPED CASTELLAMMARE STABIA, DIV PEDIAT, NAPLES, ITALY		Pisacane, A (corresponding author), UNIV NAPLES, DIPARTIMENTO PEDIAT, VIA PANSINI 5, I-80131 NAPLES, ITALY.							CASSANO PA, 1990, AM J EPIDEMIOL, V132, P462, DOI 10.1093/oxfordjournals.aje.a115681; NELSON KB, 1990, ANN NEUROL, V27, P127, DOI 10.1002/ana.410270206; PARKS YA, 1989, ACTA PAEDIAT SC S361, V55, P71; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; WALTER T, 1989, PEDIATRICS, V84, P7	5	48	50	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 10	1996	313	7053					343	343		10.1136/bmj.313.7053.343	http://dx.doi.org/10.1136/bmj.313.7053.343			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760744	Green Published			2022-12-24	WOS:A1996VC30000022
J	Zhu, CM; Bogue, MA; Lim, DS; Hasty, P; Roth, DB				Zhu, CM; Bogue, MA; Lim, DS; Hasty, P; Roth, DB			Ku86-deficient mice exhibit severe combined immunodeficiency and defective processing of V(D)J recombination intermediates	CELL			English	Article							STRAND-BREAK-REPAIR; DEPENDENT PROTEIN-KINASE; COMBINED IMMUNE-DEFICIENCY; DNA END-BINDING; CELL RECEPTOR-GAMMA; PRE-B CELLS; KU-AUTOANTIGEN; MAMMALIAN-CELLS; SCID MICE; MOUSE THYMOCYTES	Ku is a heterodimeric DNA end binding complex composed of 70 and 86 kDa subunits. Here, we show that Ku86 is essential for normal V(D)J recombination in vivo, as Ku86-deficient mice are severely defective for formation of coding joints. Unlike severe combined immunodeficient (scid) mice, Ku8B-deficient mice are also defective for signal joint formation. Both hairpin coding ends and blunt full-length signal ends accumulate. Contrary to expectation, Ku86 is evidently not required for protection of either type of V(D)J recombination intermediate. Instead, V(D)J recombination appears to be arrested after the cleavage step in Ku86-deficient mice. We suggest that Ku86 may be required to remodel or disassemble DNA-protein complexes containing broken ends, making them available for further processing and joining.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	Zhu, CM (corresponding author), BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030, USA.		Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555; Hasty, Paul/0000-0003-3046-0131	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036420] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-36420] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Aldaz H, 1996, CELL, V85, P257, DOI 10.1016/S0092-8674(00)81102-2; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chen FQ, 1996, MUTAT RES-DNA REPAIR, V362, P9, DOI 10.1016/0921-8777(95)00026-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; Errami A, 1996, MOL CELL BIOL, V16, P1519; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HENDRICKSON EA, 1991, MOL CELL BIOL, V11, P3155, DOI 10.1128/MCB.11.6.3155; HENDRICKSON EA, 1990, MOL CELL BIOL, V10, P5397, DOI 10.1128/MCB.10.10.5397; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; KIENKER LJ, 1991, J IMMUNOL, V147, P4351; KIM D, 1995, J BIOL CHEM, V270, P15277, DOI 10.1074/jbc.270.25.15277; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; KRUKLITIS R, 1994, J BIOL CHEM, V269, P16469; LEBER R, 1996, IN PRESS VET IMMUNOL; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LEWIS SM, 1994, P NATL ACAD SCI USA, V91, P1332, DOI 10.1073/pnas.91.4.1332; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MIELKE C, 1995, TRENDS GENET, V11, P258, DOI 10.1016/S0168-9525(00)89069-1; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; MURPHY WJ, 1994, J IMMUNOL, V153, P1004; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PENNYCOOK JL, 1993, J EXP MED, V178, P1007, DOI 10.1084/jem.178.3.1007; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; Savilahti H, 1996, CELL, V85, P271, DOI 10.1016/S0092-8674(00)81103-4; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHULER W, 1990, EUR J IMMUNOL, V20, P545, DOI 10.1002/eji.1830200313; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; STAUNTON JE, 1994, MOL CELL BIOL, V14, P3876, DOI 10.1128/MCB.14.6.3876; Steen SB, 1996, GENES CELLS, V1, P543; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	79	372	381	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					379	389		10.1016/S0092-8674(00)80111-7	http://dx.doi.org/10.1016/S0092-8674(00)80111-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756720	Bronze			2022-12-24	WOS:A1996VC30900006
J	Shields, PL; LowBeer, TS				Shields, PL; LowBeer, TS			Patients' awareness of adverse relation between Crohn's disease and their smoking: Questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							RECURRENCE		SELLY OAK HOSP,DEPT MED,BIRMINGHAM B29 6JD,W MIDLANDS,ENGLAND									COTTONE M, 1994, GASTROENTEROLOGY, V106, P643, DOI 10.1016/0016-5085(94)90697-1; LINDBERG E, 1992, GUT, V33, P779, DOI 10.1136/gut.33.6.779; PERSSON PG, 1990, GUT, V31, P1377, DOI 10.1136/gut.31.12.1377; SUTHERLAND LR, 1990, GASTROENTEROLOGY, V98, P1123, DOI 10.1016/0016-5085(90)90324-T	4	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					265	266		10.1136/bmj.313.7052.265	http://dx.doi.org/10.1136/bmj.313.7052.265			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704536	Green Published			2022-12-24	WOS:A1996VA90300025
J	Dick, TP; Ruppert, T; Groettrup, M; Kloetzel, PM; Kuehn, L; Koszinowski, UH; Stevanovic, S; Schild, H; Rammensee, HG				Dick, TP; Ruppert, T; Groettrup, M; Kloetzel, PM; Kuehn, L; Koszinowski, UH; Stevanovic, S; Schild, H; Rammensee, HG			Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; INTERFERON-GAMMA; 20S PROTEASOME; HOMOLOGOUS SUBUNITS; PROTEIN-DEGRADATION; 20-S PROTEASOME; PEPTIDES; ACTIVATOR; PURIFICATION	The eukaryotic 20S proteasome is known to associate with the IfN gamma-inducible regulator PA28. We analyzed the kinetics of product generation by 20S proteasomes with and without PA28. In the absence of PA28, the 20S proteasome rapidly generates peptides that have been cleaved only once, while internal fragments accumulate only slowly. In the presence of PA28, products generated by two flanking cleavages appear immediately as main products while the generation of single-cleavage products is strongly reduced. Kinetic data support a PA28-induced, coordinated double-cleavage mechanism. In particular, degradation of peptides derived from mouse cytomegalovirus pp89 and JAK1 kinase in the presence of PA28 leads to strongly enhanced production of the respective major histocompatibility complex ligands and potential precursors. These results show that PA28 profoundly alters the cleavage mechanism of the proteasome and appears to optimize the generation of dominant T-cell epitopes.	GERMAN CANC RES CTR,DEPT TUMORVIRUS IMMUNOL,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT VIROL,D-69120 HEIDELBERG,GERMANY; HUMBOLDT UNIV BERLIN,FAC MED,INST BIOCHEM,D-10115 BERLIN,GERMANY; DIABET RES INST,D-40225 DUSSELDORF,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Humboldt University of Berlin			Ruppert, Thomas/AAC-2467-2021	Ruppert, Thomas/0000-0001-9152-2266				AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; DEVAL M, 1991, CELL, V66, P1145; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DICK LR, 1994, J IMMUNOL, V152, P3884; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; HARPUR AG, 1993, IMMUNOL LETT, V35, P235, DOI 10.1016/0165-2478(93)90188-8; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KUCKELKORN U, 1995, EUR J IMMUNOL, V25, P2605, DOI 10.1002/eji.1830250930; Kuehn L, 1996, ARCH BIOCHEM BIOPHYS, V329, P87, DOI 10.1006/abbi.1996.0195; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1992, J BIOL CHEM, V267, P10515; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MOTT JD, 1994, J BIOL CHEM, V269, P31466; NEEFJES J, 1995, EUR J IMMUNOL, V25, P1133, DOI 10.1002/eji.1830250444; NIEDERMANN G, 1995, IMMUNITY, V2, P289, DOI 10.1016/1074-7613(95)90053-5; NIESIG A, 1995, J IMMUNOL, V154, P1273; Oldstone M B, 1994, Curr Top Microbiol Immunol, V189, P1; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Stein RL, 1996, BIOCHEMISTRY-US, V35, P3899, DOI 10.1021/bi952262x; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	32	245	251	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					253	262		10.1016/S0092-8674(00)80097-5	http://dx.doi.org/10.1016/S0092-8674(00)80097-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706130	Bronze			2022-12-24	WOS:A1996UZ97200011
J	GalatiusJensen, S; Launbjerg, J; Mortensen, LS; Hansen, JF				GalatiusJensen, S; Launbjerg, J; Mortensen, LS; Hansen, JF			Sex related differences in short and long term prognosis after acute myocardial infarction: 10 year follow up of 3073 patients in database of first Danish verapamil infarction trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONFIRMED DIAGNOSIS; HEART-DISEASE; RISK-FACTORS; WOMEN; MORTALITY; SURVIVAL; MEN; MORBIDITY; GENDER; ENDOTHELIN	Objective-To re-examine the prevailing hypothesis that women fare worse than m Design-10 year follow up of all patients with confirmed acute myocardial infarction registered in the database of the Danish verapamil infarction trial in 1979-81. Setting-16 coronary care units, covering a fifth of the total Danish population. Patients-3073 consecutive patients with acute myocardial infarction, 738 (24%) women and 2335 (76%) men. Main outcome measures-Early mortality (before day 15). For patients alive on day 15: mortality, cause of death, admission with recurrent infarction, and mortality after reinfarction. Results-Early mortality increased significantly with age (P<0.0001) but was not significantly related to sex, with a 15 day mortality of 17% in women and 16% in men. Adjustment for age and sex simultaneously revealed a significant interaction (P=0.02) between these variables, with a greater increase with age in early mortality for men than for women (early mortality was equal for the two sexes at age 64 years). Ten year mortality in patients alive on day 15 was 58.8%. The overall age adjusted hazard ratio (95% confidence interval) for women versus men was 0.90 (0.80 to 1.01); 0.90 (0.78 to 1.04) for 10 year reinfarction (48.8%); and 0.98 (0.82 to 1.16) for 10 year mortality after reinfarction (82.3%). No difference in cause of death was found between the sexes. With a follow up of up to 10 years for patients alive on day 15 mortality, rate of reinfarction, and mortality after reinfarction increased with increasing age (P<0.0001). Conclusion-Sex by itself is not a risk factor after acute myocardial infarction.	UNI C, DANISH COMP CTR RES & EDUC, AARHUS, DENMARK; HVIDOVRE UNIV HOSP, DEPT CARDIOL, DK-2650 HVIDOVRE, DENMARK	University of Copenhagen	GalatiusJensen, S (corresponding author), NATL UNIV HOSP, RIGSHOSP, DEPT CARDIOL B, BLEGDAMSVEJ 9, DK-2100 COPENHAGEN, DENMARK.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BUENO H, 1995, CIRCULATION, V92, P1133, DOI 10.1161/01.CIR.92.5.1133; CHAMBERLAIN DA, 1988, LANCET, V1, P545; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; DONAHUE RP, 1993, J CLIN EPIDEMIOL, V46, P245, DOI 10.1016/0895-4356(93)90072-9; EDWARDS BS, 1991, AM J CARDIOL, V67, P782, DOI 10.1016/0002-9149(91)90545-V; EVERY NR, 1995, CIRCULATION, V92, P124; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HANSEN JF, 1984, EUR HEART J, V5, P516; ISLES CG, 1992, LANCET, V339, P702, DOI 10.1016/0140-6736(92)90599-X; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KARLSON BW, 1994, AM HEART J, V128, P477, DOI 10.1016/0002-8703(94)90620-3; LAUNBJERG J, 1993, CORONARY ARTERY DIS, V4, P195, DOI 10.1097/00019501-199302000-00010; LAUNBJERG J, 1991, AM HEART J, V122, P1270, DOI 10.1016/0002-8703(91)90565-Y; LAUNBJERG J, 1992, CARDIOLOGY, V80, P294, DOI 10.1159/000175015; LERMAN A, 1991, CIRCULATION, V83, P1808, DOI 10.1161/01.CIR.83.5.1808; MADSEN EB, 1984, AM J CARDIOL, V53, P47, DOI 10.1016/0002-9149(84)90682-9; MURABITO JM, 1993, CIRCULATION, V88, P2548, DOI 10.1161/01.CIR.88.6.2548; NAYLOR CD, 1994, J AM COLL CARDIOL, V24, P1431, DOI 10.1016/0735-1097(94)90136-8; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; Rose GA, 1982, WHO MONOGRAPH SERIES; SAITO M, 1987, AM HEART J, V113, P891, DOI 10.1016/0002-8703(87)90049-4; THOMSEN BL, 1988, 885317 U COP STAT RE; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097; WILCOX RG, 1988, LANCET, V2, P525; WILKINSON P, 1994, BRIT MED J, V309, P566, DOI 10.1136/bmj.309.6954.566; WILSON PWF, 1985, NEW ENGL J MED, V313, P1038, DOI 10.1056/NEJM198510243131702	35	27	27	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	1996	313	7050					137	140		10.1136/bmj.313.7050.137	http://dx.doi.org/10.1136/bmj.313.7050.137			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UY921	8688773	Green Published			2022-12-24	WOS:A1996UY92100015
J	Pante, N; Aebi, U				Pante, N; Aebi, U			Sequential binding of import ligands to distinct nucleopore regions during their nuclear import	SCIENCE			English	Article							PORE COMPLEX; PROTEIN IMPORT; IDENTIFICATION; LOCALIZATION; TRANSPORT; ENVELOPE; TRANSLOCATION; ARCHITECTURE; MICROSCOPY; RAN/TC4	Protein import into nuclei is mediated by the nuclear pore complex (NPC) and by cellular factors. To structurally characterize this process, nuclear import of gold-labeled nucleoplasmin was followed by electron microscopy to identify NPC components interacting with the import ligand complex in vivo. Before translocation into the nucleus, nucleoplasmin sequentially bound to two distinct regions. first to the distal part of the cytoplasmic filaments and then at the cytoplasmic entry to the central gated channel, Evidence that the delivery of the import ligand from the first to the second binding region occurred by bending of the cytoplasmic filaments is presented here.			Pante, N (corresponding author), UNIV BASEL, BIOZENTRUM, ME MULLER INST MICROSCOPY, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND.		Pante, Nelly/GVR-8478-2022					ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AZUMA Y, 1995, P NATL ACAD SCI USA, V92, P5159, DOI 10.1073/pnas.92.11.5159; BASCHONG W, 1990, J ELECTRON MICR TECH, V14, P313, DOI 10.1002/jemt.1060140405; BOULIKAS T, 1993, CRIT REV BIOCH, V62, P219; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GORLICH D, IN PRESS EMBO J; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Pante N, 1995, INT REV CYTOL, V162B, P225; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; PANTE N, 1994, CURR OPIN STRUC BIOL, V4, P187, DOI 10.1016/S0959-440X(94)90307-7; Pante N, 1995, J CELL SCI, P1; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143	32	118	119	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1996	273	5282					1729	1732		10.1126/science.273.5282.1729	http://dx.doi.org/10.1126/science.273.5282.1729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781239				2022-12-24	WOS:A1996VH40800046
J	Ewald, D; Li, MG; Efrat, S; Auer, G; Wall, RJ; Furth, PA; Hennighausen, L				Ewald, D; Li, MG; Efrat, S; Auer, G; Wall, RJ; Furth, PA; Hennighausen, L			Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen	SCIENCE			English	Article							SV40-TRANSFORMED CELLS; GENE-EXPRESSION; ONCOGENES; PROMOTER; PROTEIN; CANCER; GROWTH	The role of viral oncoprotein expression in the maintenance of cellular transformation was examined as a function of time through controlled expression of simian virus 40 T antigen (TAg), Expression of TAg in the submandibular gland of transgenic mice from the time of birth induced cellular transformation and extensive ductal hyperplasia by 4 months of age, The hyperplasia was reversed when TAg expression was silenced for 3 weeks, When TAg expression was silenced after 7 months, however, the hyperplasia persisted even though TAg was absent, Although the polyploidy of ductal cells could be reversed at 4 months of age, cells at 7 months of age remained polyploid even in the absence of TAg, These results support a model of time-dependent multistep tumorigenesis, in which virally transformed cells eventually lose their dependence on the viral oncoprotein for maintenance of the transformed state.	UNIV MARYLAND,SCH MED,DEPT MED,DIV INFECT DIS,BALTIMORE,MD 21201; INST HUMAN VIROL,BALTIMORE,MD 21201; ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461; KAROLINSKA INST,DEPT PATHOL & ONCOL,S-17176 STOCKHOLM,SWEDEN; ARS,USDA,BELTSVILLE,MD 20705; NIDDKD,BIOCHEM & METAB LAB,NIH,BETHESDA,MD 20892	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Yeshiva University; Albert Einstein College of Medicine; Karolinska Institutet; United States Department of Agriculture (USDA); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Efrat, Shimon/0000-0001-5987-232X; Hennighausen, Lothar/0000-0001-8319-9841				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; ELSON A, 1995, ONCOGENE, V11, P181; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; FURTH PA, UNPUB; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; HENNINGHAUSEN L, UNPUB; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PASCALL JC, 1994, J MOL ENDOCRINOL, V12, P313, DOI 10.1677/jme.0.0120313; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TZENG YJ, 1993, ONCOGENE, V8, P1965; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x	21	202	206	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1384	1386		10.1126/science.273.5280.1384	http://dx.doi.org/10.1126/science.273.5280.1384			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703072				2022-12-24	WOS:A1996VF61000041
J	Yang, NN; Venugopalan, M; Hardikar, S; Glasebrook, A				Yang, NN; Venugopalan, M; Hardikar, S; Glasebrook, A			Identification of an estrogen response element activated by metabolites of 17 beta-estradiol and raloxifene	SCIENCE			English	Article							CARDIOVASCULAR RISK-FACTORS; POSTMENOPAUSAL WOMEN; BREAST-CANCER; RECEPTOR; GROWTH; GENE; BONE; TRANSCRIPTION; PROMOTER; CELLS	17 beta-Estradiol modulates gene transcription through the estrogen receptor and the estrogen response element in DNA. The human transforming growth factor-beta 3 gene was shown to be activated by the estrogen receptor in the presence of estrogen metabolites or estrogen antagonists, Activation was mediated by a polypurine sequence, termed the raloxifene response element, and did not require the DNA binding domain of the estrogen receptor, Interaction of the estrogen receptor with the raloxifene response element appears to require a cellular adapter protein, The observation that individual estrogens modulate multiple DNA response elements may explain the tissue-selective estrogen agonist or antagonist activity of compounds such as raloxifene.			Yang, NN (corresponding author), ELI LILLY & CO,LILLY CORP CTR,ENDOCRINE RES,MAIL DROP 0444,INDIANAPOLIS,IN 46285, USA.							ANDERSON JE, 1984, BIOL REGUL DEV, V3, P169; ARRICK BA, 1994, MOL CELL BIOL, V14, P619, DOI 10.1128/MCB.14.1.619; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P8270, DOI 10.1021/bi00399a038; Draper MW, 1996, J BONE MINER RES, V11, P835; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISHMAN J, 1981, J ENDOCRINOL S, V89, P59; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; GLASEBROOK AL, UNPUB; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; JONES CD, 1984, J MED CHEM, V27, P1057, DOI 10.1021/jm00374a021; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KRAUS WL, 1993, ENDOCRINOLOGY, V132, P2371, DOI 10.1210/en.132.6.2371; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; LIEBERMAN S, 1986, J ENDOCRINOL, V111, P519, DOI 10.1677/joe.0.1110519; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; MACLUSKY NJ, 1981, J STEROID BIOCHEM, V15, P111, DOI 10.1016/0022-4731(81)90265-X; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NEDIVI E, 1992, J NEUROSCI, V12, P691; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WAKELING AE, 1988, J STEROID BIOCHEM, V31, P645, DOI 10.1016/0022-4731(88)90014-3; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075; YOUNG MF, 1989, J BIOL CHEM, V264, P450	31	370	388	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1222	1225		10.1126/science.273.5279.1222	http://dx.doi.org/10.1126/science.273.5279.1222			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703055				2022-12-24	WOS:A1996VE47600038
J	Abenhaim, L; Moride, Y; Brenot, F; Rich, S; Benichou, J; Kurz, X; Higenbottam, T; Oakley, C; Wouters, E; Aubier, M; Simonneau, G; Begaud, B				Abenhaim, L; Moride, Y; Brenot, F; Rich, S; Benichou, J; Kurz, X; Higenbottam, T; Oakley, C; Wouters, E; Aubier, M; Simonneau, G; Begaud, B			Appetite-suppressant drugs and the risk of primary pulmonary hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FENFLURAMINE; INFECTION	Background Recently in France, primary pulmonary hypertension developed in a cluster of patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents), which are used for weight control. We investigated the potential role of anorexic agents and other suspected risk factors for primary pulmonary hypertension. Methods In a case-control study, we assessed 95 patients with primary pulmonary hypertension from 35 centers in France, Belgium, the United Kingdom, and the Netherlands and 355 controls recruited from general practices and matched to the patients' sex and age. Results The use of anorexic drugs (mainly derivatives of fenfluramine) was associated with an increased risk of primary pulmonary hypertension (odds ratio with any anorexic-drug use, 6.3; 95 percent confidence interval, 3.0 to 13.2). For the use of anorexic agents in the preceding year, the odds ratio was 10.1 (95 percent confidence interval, 3.4 to 29.9). When anorexic drugs were used for a total of more than three months, the odds ratio was 23.1 (95 percent confidence interval, 6.9 to 77.7). We also confirmed an association with several previously identified risk factors: a family history of pulmonary hypertension, infection with the human immunodeficiency virus, cirrhosis, and use of cocaine or intravenous drugs. Conclusions The use of anorexic drugs was associated with the development of primary pulmonary hypertension. Active surveillance for this disease should be considered, particularly since the use of anorexic drugs is expected to increase in the near future. (C) 1996, Massachusetts Medical Society.	MCGILL UNIV,CTR CLIN EPIDEMIOL & COMMUNITY STUDIES,MONTREAL,PQ H3T 1E2,CANADA; ANTOINE BECLERE HOSP,SERV PNEUMOL,CLAMART,FRANCE; UNIV ILLINOIS,DEPT SURG,CARDIOL SECT,CHICAGO,IL 60680; NCI,ROCKVILLE,MD; CHU LIEGE,INST PATHOL,PHARMACOL LAB,LIEGE,BELGIUM; UNIV SHEFFIELD,SECT RESP MED,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; HAMMERSMITH HOSP,DEPT CARDIOL,LONDON,ENGLAND; UNIV HOSP MAASTRICHT,DEPT PULMONOL,MAASTRICHT,NETHERLANDS; HOP XAVIER BICHAT,SERV PNEUMOL,PARIS,FRANCE; PELLEGRIN HOSP,CTR PHARMACOVIGILANCE,BORDEAUX,FRANCE	McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Liege; University of Sheffield; Imperial College London; Maastricht University; Maastricht University Medical Centre (MUMC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux	Abenhaim, L (corresponding author), SIR MORTIMER B DAVIS JEWISH HOSP,CTR CLIN EPIDEMIOL & COMMUNITY STUDIES,MONTREAL,PQ H3T 1E2,CANADA.		Wouters, Emiel/ABD-6200-2021; Simonneau, Gerald/ABE-6614-2020					ABENHAIM L, 1994, CHEST, V105, pS37; BRENOT F, 1993, BRIT HEART J, V70, P537; BRENOT F, 1994, CHEST, V105, pS33, DOI 10.1378/chest.105.2_Supplement.33S; COLLINS E, 1989, MED J AUSTRALIA, V150, P331, DOI 10.5694/j.1326-5377.1989.tb136497.x; DAWKINS KD, 1986, CHEST, V89, P383, DOI 10.1378/chest.89.3.383; DOUGLAS JG, 1981, BMJ-BRIT MED J, V283, P881, DOI 10.1136/bmj.283.6296.881; FAHLEN M, 1973, BRIT HEART J, V35, P824; GURTNER HP, 1985, COR VASA, V27, P160; HADENGUE A, 1991, GASTROENTEROLOGY, V100, P520, DOI 10.1016/0016-5085(91)90225-A; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; KLEIGER RE, 1976, CHEST, V69, P143, DOI 10.1378/chest.69.2.143; LANGLEBEN D, 1994, CHEST, V105, pS13, DOI 10.1378/chest.105.2_Supplement.13S; LEGOUX B, 1990, AM J MED, V89, P122, DOI 10.1016/0002-9343(90)90113-R; MASI AT, 1976, CHEST, V69, P451; MCDONNELL PJ, 1983, AM REV RESPIR DIS, V127, P437, DOI 10.1164/arrd.1983.127.4.437; MCMURRAY J, 1986, BRIT MED J, V293, P51, DOI 10.1136/bmj.293.6538.51-d; MICHELAKIS ED, 1995, AM J RESP CRIT CAR S, V151, pA725; NAEIJE R, 1995, AM J RESP CRIT CARE, V151, P692; OAKLEY CW, 1994, CHEST, V105, pS29, DOI 10.1378/chest.105.2_Supplement.29S; PETITPRETZ P, 1994, CIRCULATION, V89, P2722, DOI 10.1161/01.CIR.89.6.2722; POUWELS HMM, 1990, EUR RESPIR J, V3, P606; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RUBIN LJ, 1993, CHEST, V104, P236, DOI 10.1378/chest.104.1.236; RUBIN LJ, 1990, ANN INTERN MED, V112, P485, DOI 10.7326/0003-4819-112-7-485; RUSSELL L A, 1992, American Review of Respiratory Disease, V145, pA717; SCHAIBERGER PH, 1993, CHEST, V104, P614, DOI 10.1378/chest.104.2.614	27	885	914	0	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 29	1996	335	9					609	616		10.1056/NEJM199608293350901	http://dx.doi.org/10.1056/NEJM199608293350901			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD425	8692238				2022-12-24	WOS:A1996VD42500001
J	Markram, H; Tsodyks, M				Markram, H; Tsodyks, M			Redistribution of synaptic efficacy between neocortical pyramidal neurons	NATURE			English	Article							LONG-TERM POTENTIATION; TRANSMISSION; HIPPOCAMPUS; LTP	EXPERIENCE-dependent potentiation and depression of synaptic strength has been proposed to subserve learning and memory by changing the gain of signals conveyed between neurons(1,2). Here we examine synaptic plasticity between individual neocortical layer-5 pyramidal neurons, We show that an increase in the synaptic response, induced by pairing action-potential activity in pre- and postsynaptic neurons, was only observed when synaptic input occurred at low frequencies. This frequency-dependent increase in synaptic responses arises because of a redistribution of the available synaptic efficacy and not because of an increase in the efficacy. Redistribution of synaptic efficacy could represent a mechanism to change the content, rather than the gain, of signals conveyed between neurons.			Markram, H (corresponding author), WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL.		tsodyks, misha/J-4430-2013	Tsodyks, Misha/0000-0002-5661-4349				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BARNES CA, 1995, NEURON, V15, P751, DOI 10.1016/0896-6273(95)90166-3; BASHIR ZI, 1991, NATURE, V349, P156, DOI 10.1038/349156a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; JONES HC, 1987, J PHYSL LOND P, V64; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; MARKRAM H, 1995, SOC NEUR ABSTR; MARKRAM H, 1995, EUROPEAN NEUROSCIENC; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; STEVENS CF, 1993, NEURON S, V10, P55; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TEYLER TJ, 1984, BRAIN RES REV, V7, P15, DOI 10.1016/0165-0173(84)90027-4; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X	16	600	614	0	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					807	810		10.1038/382807a0	http://dx.doi.org/10.1038/382807a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752273				2022-12-24	WOS:A1996VE34700046
J	Yan, J; Suga, N				Yan, J; Suga, N			Corticofugal modulation of time-domain processing of biosonar information in bats	SCIENCE			English	Article							COMBINATION-SENSITIVE NEURONS; MEDIAL GENICULATE-BODY; AUDITORY-CORTEX; INFERIOR COLLICULUS; MUSTACHED BAT; TARGET RANGE; MOUSTACHED BAT; CONNECTIONS; PROJECTIONS; STIMULATION	The Jamaican mustached bar has delay-tuned neurons in the inferior colliculus, medial geniculate body, and auditory cortex. The responses of these neurons to an echo are facilitated by a biosonar pulse emitted by the bat when the echo returns with a particular delay from a target located at a particular distance. Electrical stimulation of cortical delay-tuned neurons increases the delay-tuned responses of collicular neurons tuned to the same echo delay as the cortical neurons and decreases those of collicular neurons tuned to different echo delays, Cortical neurons improve information processing in the inferior colliculus by way of the corticocollicular projection.			Yan, J (corresponding author), WASHINGTON UNIV, DEPT BIOL, 1 BROOKINGS DR, ST LOUIS, MO 63130 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000175] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC 00175] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ANDERSEN P, 1973, BRAIN BEHAV EVOLUT, V6, P170, DOI 10.1159/000123705; ANDERSEN RA, 1980, J COMP NEUROL, V191, P479, DOI 10.1002/cne.901910310; CARRASCAL E, 1991, Society for Neuroscience Abstracts, V17, P305; FELICIANO M, 1995, J NEUROCHEM, V65, P1348; Feliciano M., 1995, AUDIT NEUROSCI, V1, P287; GAMES KD, 1988, HEARING RES, V34, P1, DOI 10.1016/0378-5955(88)90047-0; HERBERT H, 1991, J COMP NEUROL, V304, P103, DOI 10.1002/cne.903040108; HORIKAWA J, 1994, HEARING RES, V76, P45, DOI 10.1016/0378-5955(94)90085-X; HUFFMAN RF, 1990, BRAIN RES REV, V15, P295, DOI 10.1016/0165-0173(90)90005-9; KELLY JP, 1981, BRAIN RES, V212, P1, DOI 10.1016/0006-8993(81)90027-5; LUETHKE LE, 1989, J COMP NEUROL, V285, P487, DOI 10.1002/cne.902850406; MASSOPUST LC, 1962, EXP NEUROL, V6, P465, DOI 10.1016/0014-4886(62)90072-9; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; MITANI A, 1983, NEUROSCI LETT, V42, P185, DOI 10.1016/0304-3940(83)90404-4; MITTMANN DH, 1995, EHAR RES, V90, P185; MOREL A, 1992, J COMP NEUROL, V318, P27, DOI 10.1002/cne.903180104; OJIMA H, 1996, CEREB CORTEX, V6, P646; OLSEN JF, 1991, J NEUROPHYSIOL, V65, P1275, DOI 10.1152/jn.1991.65.6.1275; OLSEN JF, 1986, THESIS WASHINGTON U; ONEILL WE, 1982, J NEUROSCI, V2, P17; RYUGO DK, 1976, EXP NEUROL, V51, P377, DOI 10.1016/0014-4886(76)90262-4; Saldana E, 1996, J COMP NEUROL, V371, P15, DOI 10.1002/(SICI)1096-9861(19960715)371:1<15::AID-CNE2>3.0.CO;2-O; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; SUGA N, 1990, NEURAL NETWORKS, V3, P3, DOI 10.1016/0893-6080(90)90043-K; SUGA N, 1979, SCIENCE, V206, P351, DOI 10.1126/science.482944; SUGA N, 1983, J NEUROPHYSIOL, V49, P1573, DOI 10.1152/jn.1983.49.6.1573; SUGA N, 1986, J NEUROPHYSIOL, V55, P776, DOI 10.1152/jn.1986.55.4.776; Suga N, 1984, DYNAMIC ASPECTS NEOC, P315; SUGA N, 1995, ACTIVE HEARING, P13; SUN X, 1989, BRAIN RES, V495, P1, DOI 10.1016/0006-8993(89)91212-2; SYKA J, 1984, NEUROSCI LETT, V51, P235, DOI 10.1016/0304-3940(84)90557-3; VATER M, 1992, J COMP NEUROL, V325, P183, DOI 10.1002/cne.903250205; VILLA AEP, 1991, EXP BRAIN RES, V86, P506, DOI 10.1007/BF00230524; WATANABE T, 1966, EXP BRAIN RES, V2, P302; Yan J, 1996, HEARING RES, V93, P102, DOI 10.1016/0378-5955(95)00209-X	35	160	165	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 23	1996	273	5278					1100	1103		10.1126/science.273.5278.1100	http://dx.doi.org/10.1126/science.273.5278.1100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688095				2022-12-24	WOS:A1996VD42800036
J	Desbois, C; Rousset, R; Bantignies, F; Jalinot, P				Desbois, C; Rousset, R; Bantignies, F; Jalinot, P			Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I tax oncoprotein	SCIENCE			English	Article							VIRUS TYPE-I; T-CELL LEUKEMIA; RETINOBLASTOMA GENE-PRODUCT; LARGE TUMOR-ANTIGEN; RAR-ALPHA; PROTEINS; TRANSFORMATION; LOCALIZATION; LYMPHOCYTES; ASSOCIATION	The Tax transactivator of the human T cell leukemia virus type I (HTLV-I) exhibits oncogenic properties. A screen for proteins interacting with Tax yielded a complementary DNA (cDNA) encoding the human Int-6 protein, In mice, the Int-6 gene can be converted into a putative dominant negative oncogene after retroviral insertion. Here, Int-6 was localized in the cell nucleus to give a speckled staining pattern superposed to that of the promyelocytic leukemia (PML) protein. The binding of Tax to Int-6 caused its redistribution from the nuclear domains to the cytoplasm. Thus, Int-6 is a component of the PML nuclear bodies and Tax disrupts its normal cellular localization by binding to it.	ECOLE NORMALE SUPER LYON,LAB BIOL MOL & CELLULAIRE,CNRS,UMR49,F-69364 LYON 07,FRANCE	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet			Rousset, Raphael/E-5908-2017; Morris, Christelle/M-8168-2014	Rousset, Raphael/0000-0002-4999-403X; Morris, Christelle/0000-0003-1575-4609				ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DETHE H, 1991, SCIENCE, V254, P1371; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GESSAIN A, 1985, LANCET, V2, P407; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STUURMAN N, 1992, J CELL SCI, V101, P773; SUGAWARA M, 1994, MOL CELL BIOL, V14, P8438, DOI 10.1128/MCB.14.12.8438; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TERRIS B, 1995, CANCER RES, V55, P1590; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	31	132	142	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					951	953		10.1126/science.273.5277.951	http://dx.doi.org/10.1126/science.273.5277.951			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688078				2022-12-24	WOS:A1996VC67000061
J	Hilgemann, DW; Ball, R				Hilgemann, DW; Ball, R			Regulation of cardiac Na+,Ca2+ exchange and K-ATP potassium channels by PIP2	SCIENCE			English	Article							SODIUM-CALCIUM EXCHANGE; PHOSPHOLIPASE-C; NA+-CA2+ EXCHANGER; DIACYLGLYCEROL KINASE; SULFONYLUREA RECEPTOR; CA2+-BINDING DOMAIN; MEMBRANE PATCHES; BACILLUS-CEREUS; PROTEIN-KINASE; INHIBITION	Cardiac Na+,Ca2+ exchange is activated by a mechanism that requires hydrolysis of adenosine triphosphate (ATP) but is not mediated by protein kinases. In giant cardiac membrane patches, ATP acted to generate phosphatidylinositol-4,5-bisphosphate (PIP2) from phosphatidylinositol (PI). The action of ATP was abolished by a PI-specific phospholipase C (PLC) and recovered after addition of exogenous PI; it was reversed by a PIP2-specific PLC; and it was mimicked by exogenous PIP2. High concentrations of free Ca2+ (5 to 20 mu M) accelerated reversal oi the ATP effect, and PLC activity in myocyte membranes was activated with a similar Ca2+ dependence, Aluminum reversed the ATP effect by binding with high affinity to PIP2. ATP-inhibited potassium channels (K-ATP) were also sensitive to PIP2, whereas Na+,K+ pumps and Na+ channels were not. Thus, PIP2 may be an important regulator oi both ion transporters and channels.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hilgemann, DW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049993] Funding Source: NIH RePORTER; NHLBI NIH HHS [5-R1-HL51323-03] Funding Source: Medline; NIGMS NIH HHS [GM49993] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; BIRCHALL JD, 1988, CLIN CHEM, V34, P265; BUSER CA, 1995, MOL MEMBR BIOL, V12, P69, DOI 10.3109/09687689509038498; CHOQUETTE D, 1984, BIOCHEM BIOPH RES CO, V125, P908, DOI 10.1016/0006-291X(84)91369-X; COLLINS A, 1993, PFLUG ARCH EUR J PHY, V423, P347, DOI 10.1007/BF00374927; COLLINS A, 1992, J PHYSL, V454, P37; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; CONNOR J, 1988, BIOCHEMISTRY-US, V27, P848, DOI 10.1021/bi00403a002; FILOTEO AG, 1992, J BIOL CHEM, V267, P11800; Furukawa T, 1996, PFLUG ARCH EUR J PHY, V431, P504, DOI 10.1007/s004240050028; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GILMORE AP, 1996, NATURE, V381, P5311; GOTO K, 1995, P NATL ACAD SCI USA, V50, P235; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hilgemann Donald W., 1995, P307; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; HILGEMANN DW, 1992, J PHYSIOL-LONDON, V454, P59, DOI 10.1113/jphysiol.1992.sp019254; HILGEMANN DW, UNPUB; IKEZAWA H, 1976, BIOCHIM BIOPHYS ACTA, V450, P154; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; KANOH H, 1993, CELL SIGNAL, V5, P495, DOI 10.1016/0898-6568(93)90045-N; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1993, J BIOL CHEM, V268, P11489; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LUCIANI S, 1993, ANN NY ACAD SCI, V639, P156; Martell A. E., 1977, CRITICAL STABILITY C; MARTIN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1194; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MCDONALD LJ, 1995, J LIPID MEDIAT CELL, V11, P81, DOI 10.1016/0929-7855(94)00029-C; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; OHNOSHOSAKU T, 1987, PFLUG ARCH EUR J PHY, V408, P133, DOI 10.1007/BF00581342; REDMAN C, 1995, BIOCHEM PHARMACOL, V50, P235, DOI 10.1016/0006-2952(95)00118-J; REITER M, 1988, PHARMACOL REV, V40, P189; RIBALET B, 1994, J MEMBRANE BIOL, V142, P395; RIBALET B, 1989, J GEN PHYSIOL, V94, P693, DOI 10.1085/jgp.94.4.693; SCHOFL C, 1990, BIOCHEM J, V269, P547, DOI 10.1042/bj2690547; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SHANNON TR, 1994, AM J PHYSIOL, V266, pC1350, DOI 10.1152/ajpcell.1994.266.5.C1350; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TAKANO M, 1990, AM J PHYSIOL, V258, pH45, DOI 10.1152/ajpheart.1990.258.1.H45; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; Tsien R W, 1977, Adv Cyclic Nucleotide Res, V8, P363; VEMURI R, 1988, BIOCHIM BIOPHYS ACTA, V937, P258, DOI 10.1016/0005-2736(88)90248-9; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; WEBER G, 1982, BIOCHIM BIOPHYS ACTA, V694, P1	54	543	555	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					956	959		10.1126/science.273.5277.956	http://dx.doi.org/10.1126/science.273.5277.956			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688080				2022-12-24	WOS:A1996VC67000063
J	Nellis, WJ; Weir, ST; Mitchell, AC				Nellis, WJ; Weir, ST; Mitchell, AC			Metallization and electrical conductivity of hydrogen in Jupiter	SCIENCE			English	Article							GIANT PLANETS; MOLECULAR-HYDROGEN; SOLID HYDROGEN; STATE; PRESSURES; EQUATION; INTERIOR	Electrical conductivities of molecular hydrogen in Jupiter were calculated by scaling electrical conductivities measured at shock pressures in the range of 10 to 180 gigapascals (0.1 to 1.8 megabars) and temperatures to 4000 kelvin, representative of conditions inside Jupiter. Jupiter's magnetic field is caused by convective dynamo motion of electrically conducting fluid hydrogen. The data imply that Jupiter should become metallic at 140 gigapascals in the fluid, and the electrical conductivity in the jovian molecular envelope at pressures up to metallization is about an order of magnitude larger than expected previously. The large magnetic field is produced in the molecular envelope closer to the surface than previously thought.			Nellis, WJ (corresponding author), LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550, USA.		Weir, Samuel/H-5046-2012					ABRIKOSOV AA, 1964, SOV PHYS JETP-USSR, V18, P1399; ASHCROFT NW, 1990, PHYS REV B, V41, P10963, DOI 10.1103/PhysRevB.41.10963; ASHCROFT NW, 1968, PHYS REV LETT, V21, P1748, DOI 10.1103/PhysRevLett.21.1748; CEPERLEY DM, 1987, PHYS REV B, V36, P2092, DOI 10.1103/PhysRevB.36.2092; FREIDLI C, 1977, PHYS REV B, V16, P662; GUILLOT T, 1994, ICARUS, V112, P354, DOI 10.1006/icar.1994.1189; GUILLOT T, 1994, ICARUS, V112, P337, DOI 10.1006/icar.1994.1188; Hensel F, 1996, PHYS WORLD, V9, P43, DOI 10.1088/2058-7058/9/4/25; HIDE R, 1979, NATURE, V280, P42, DOI 10.1038/280042a0; Holmes NC, 1995, PHYS REV B, V52, P15835, DOI 10.1103/PhysRevB.52.15835; HUBBARD WB, 1969, ASTROPHYS J SUPPL S, V18, P297, DOI 10.1086/190192; HUBBARD WB, 1968, ASTROPHYS J, V152, P745, DOI 10.1086/149591; HUBBARD WB, 1981, SCIENCE, V214, P145, DOI 10.1126/science.214.4517.145; HUBBARD WB, 1984, PLANETARY INTERIORS, P141; KIRK RL, 1987, ASTROPHYS J, V316, P836, DOI 10.1086/165248; MIN BI, 1986, PHYS REV B, V33, P6383, DOI 10.1103/PhysRevB.33.6383; MOTT NF, 1971, ELECT PROCESSES NONC, P81; MOTT NF, 1971, PHILOS MAG, V24, P2; NELLIS WJ, 1988, SCIENCE, V240, P779, DOI 10.1126/science.240.4853.779; NELLIS WJ, 1992, PHYS REV LETT, V68, P2937, DOI 10.1103/PhysRevLett.68.2937; NELLIS WJ, 1995, SCIENCE, V269, P1249, DOI 10.1126/science.7652570; ROSS M, 1981, PHILOS T R SOC A, V303, P303, DOI 10.1098/rsta.1981.0204; SAUMON D, 1995, ASTROPHYS J SUPPL S, V99, P713, DOI 10.1086/192204; Smith E. J., 1976, JUPITER, P788; SMOLUCHOWSKI R, 1975, ASTROPHYS J, V200, pL119, DOI 10.1086/181911; STEVENSON DJ, 1977, ASTROPHYS J SUPPL S, V35, P221, DOI 10.1086/190478; STEVENSON DJ, 1983, REP PROG PHYS, V46, P555, DOI 10.1088/0034-4885/46/5/001; STEVENSON DJ, 1974, PHYS REV A, V9, P782, DOI 10.1103/PhysRevA.9.782; STEVENSON DJ, 1982, ANNU REV EARTH PL SC, V10, P257, DOI 10.1146/annurev.ea.10.050182.001353; Weir ST, 1996, PHYS REV LETT, V76, P1860, DOI 10.1103/PhysRevLett.76.1860; Zharkov V. N., 1992, HIGH PRESSURE RES AP, P393; ZHARKOV VN, 1976, JUPITER, P145	32	92	96	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					936	938		10.1126/science.273.5277.936	http://dx.doi.org/10.1126/science.273.5277.936			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688072				2022-12-24	WOS:A1996VC67000055
J	Ekbom, A; Hsieh, CC; Lipworth, L; Wolk, A; Ponten, J; Adami, HO; Trichopoulos, D				Ekbom, A; Hsieh, CC; Lipworth, L; Wolk, A; Ponten, J; Adami, HO; Trichopoulos, D			Perinatal characteristics in relation to incidence of and mortality from prostate cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; MUTATOR PHENOTYPE; PHYSICAL-ACTIVITY; BREAST-CANCER; BIRTH-WEIGHT; RISK; ESTROGENS; PREGNANCY; EPIDEMIOLOGY; VASECTOMY	Objective-To test the hypothesis that factors causing morbidity and mortality from prostate cancer may operate in utero. Design-Matched case-control study of singleton men born between 1874 and 1946 at one hospital. Setting-Uppsala University Hospital. Subjects-250 patients with prostate cancer and 691 controls, including 80 patients who died from prostate cancer and their 196 matched controls. Main outcome measures-Mother's age at menarche, parity, pre-eclampsia or eclampsia before delivery, age at delivery and socioeconomic status; case or control's birth length and weight, placental weight, prematurity derived from gestational age, and presence of jaundice. Results-Both pre-eclampsia (odds ratio 0, 95% confidence interval 0 to 0.71) and prematurity (0.31, 0.09 to 1.04) were inversely associated with incidence of prostate cancer. Among subjects born full term, placental weight, birth weight, and ponderal index (weight/height(3)) showed non-significant positive associations with prostate cancer incidence, and stronger associations with mortality. Conclusion-Prenatal exposures that are likely correlates of pregnancy hormones and other growth factors are important in prostate carcinogenesis and influence the natural course as well as the occurrence of this cancer.	UNIV UPPSALA, DEPT PATHOL, S-75185 UPPSALA, SWEDEN; UNIV MASSACHUSETTS, MED CTR, CTR CANC, WORCESTER, MA 01605 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, CTR CANC PREVENT, BOSTON, MA 02115 USA	Uppsala University; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Ekbom, A (corresponding author), UNIV UPPSALA, DEPT CANC EPIDEMIOL, S-75185 UPPSALA, SWEDEN.				NCI NIH HHS [T32 CA09001-19A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON SO, 1995, CANCER EPIDEM BIOMAR, V4, P187; ANDERSSON SO, 1993, BRIT J CANCER, V68, P97, DOI 10.1038/bjc.1993.293; BARRETTCONNOR E, 1990, CANCER RES, V50, P169; BERNSTEIN L, 1986, J NATL CANCER I, V76, P1035; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; *CANC REG, 1990, CAN INC SWED 1987; CHEVILLE JC, 1995, AM J SURG PATHOL, V19, P1068, DOI 10.1097/00000478-199509000-00011; COFFEY DS, 1981, UROLOGY, V17, P17; DAIKOKU NH, 1979, OBSTET GYNECOL, V54, P211; DRAFTA D, 1982, J STEROID BIOCHEM, V17, P689, DOI 10.1016/0022-4731(82)90572-6; EKBOM A, 1995, INT J CANCER, V61, P177, DOI 10.1002/ijc.2910610206; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GERHARD I, 1987, EUR J OBSTET GYN R B, V26, P313, DOI 10.1016/0028-2243(87)90129-8; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P873, DOI 10.1001/jama.269.7.873; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P1571, DOI 10.1093/jnci/85.19.1571; GREENWALD P, 1982, CANC EPIDEMIOLOGY PR, P9138; HENDERSON BE, 1988, BRIT J CANCER, V57, P216, DOI 10.1038/bjc.1988.46; HSING AW, 1989, AM J EPIDEMIOL, V130, P829; HYNES RB, 1995, JNCI-J NATL CANCER I, V87, P629; JOHN EM, 1995, J NATL CANCER I, V87, P662, DOI 10.1093/jnci/87.9.662; KLOPPER A, 1975, J STEROID BIOCHEM, V6, P651, DOI 10.1016/0022-4731(75)90047-3; LIPWORTH L, 1995, EUR J CANCER PREV, V4, P7, DOI 10.1097/00008469-199502000-00002; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1994, CANCER RES, V54, P5059; LONG PA, 1979, AM J OBSTET GYNECOL, V135, P344, DOI 10.1016/0002-9378(79)90702-6; LUBCHENCO LO, 1966, PEDIATRICS, V37, P403; LUNDE AS, 1980, VITAL HLTH STATIST 2, V84, P5; MCFADYEN IR, 1982, BRIT J OBSTET GYNAEC, V89, P994, DOI 10.1111/j.1471-0528.1982.tb04653.x; NOMURA AMY, 1991, EPIDEMIOL REV, V13, P200, DOI 10.1093/oxfordjournals.epirev.a036069; PANAGIOTOPOULOU K, 1990, CANCER CAUSE CONTROL, V1, P119, DOI 10.1007/BF00053162; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; Petridou E, 1990, Epidemiology, V1, P247, DOI 10.1097/00001648-199005000-00011; POTOSKY AL, 1990, J NATL CANCER I, V82, P1624, DOI 10.1093/jnci/82.20.1624; ROSING U, 1984, GYNECOL OBSTET INVES, V18, P199, DOI 10.1159/000299081; ROSS RK, 1992, LANCET, V339, P887, DOI 10.1016/0140-6736(92)90927-U; ROSS RK, 1994, J NATL CANCER I, V86, P252, DOI 10.1093/jnci/86.4.252; ROTKIN ID, 1977, CANCER TREAT REP, V61, P173; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; THUNE I, 1994, CANCER CAUSE CONTROL, V5, P549, DOI 10.1007/BF01831383; TIBBLIN G, 1995, EPIDEMIOLOGY, V6, P423, DOI 10.1097/00001648-199507000-00017; TOMATIS L, 1990, IARC SCI PUBLICATION, V100; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; TRICHOPOULOS D, 1995, EPIDEMIOLOGY, V6, P347; WANG XB, 1994, INT J EPIDEMIOL, V23, P119, DOI 10.1093/ije/23.1.119; WHITTEMORE AS, 1995, JNCI-J NATL CANCER I, V87, P652, DOI 10.1093/jnci/87.9.652; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8	47	86	86	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 10	1996	313	7053					337	341		10.1136/bmj.313.7053.337	http://dx.doi.org/10.1136/bmj.313.7053.337			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VC300	8760741	Green Published			2022-12-24	WOS:A1996VC30000019
J	Colot, V; Maloisel, L; Rossignol, JL				Colot, V; Maloisel, L; Rossignol, JL			Interchromosomal transfer of epigenetic states in Ascobolus: Transfer of DNA methylation is mechanistically related to homologous recombination	CELL			English	Article							DOUBLE-STRAND BREAKS; WILMS-TUMOR; MEIOTIC RECOMBINATION; SEQUENCE SPECIFICITY; DENOVO METHYLATION; IMMERSUS; MEIOSIS; YEAST; LOCUS; H19	The transfer of methylation between alleles represents a plausible epigenetic mutational mechanism to explain loss of imprinting in mammals and paramutation in plants. Here, we have exploited advantages unique to the fungus Ascobolus immersus to obtain direct experimental evidence that methylation transfer can occur between homologous chromosomes. A methylated allele and an unmethylated allele of the Ascobolus b2 spore color gene were brought together in individual meiotic cells. Frequent transfer of methylation to the unmethylated allele was observed. This transfer was polarized 5' to 3' along the b2 gene, as is gene conversion, and always accompanied the latter process when tested in the same cross. These and other observations strongly suggest that methylation transfer and recombination are mechanistically related.			Colot, V (corresponding author), UNIV PARIS 11,INST GENET & MICROBIOL,F-91405 ORSAY,FRANCE.		Maloisel, Laurent/G-4556-2012	Maloisel, Laurent/0000-0003-0258-0769				BARRY C, 1993, P NATL ACAD SCI USA, V90, P4557, DOI 10.1073/pnas.90.10.4557; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRINK RA, 1973, ANNU REV GENET, V7, P129, DOI 10.1146/annurev.ge.07.120173.001021; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; COLOT V, 1995, GENETICS, V141, P1299; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; EGGLESTON WB, 1995, GENETICS, V141, P347; Esposito MS, 1981, MOL BIOL YEAST SACCH, P341; FEDOROFF NV, 1995, HOMOLOGOUS RECOMBINA, P349; GOYON C, 1989, MOL CELL BIOL, V9, P2818, DOI 10.1128/MCB.9.7.2818; GOYON C, 1994, J MOL BIOL, V240, P42, DOI 10.1006/jmbi.1994.1416; GOYON C, 1996, MOL CELL BIOL, V19, P3054; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; KERMICLE JL, 1990, DEVELOPMENT, P9; KNUDSON AG, 1993, MED PEDIATR ONCOL, V21, P193, DOI 10.1002/mpo.2950210308; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; LEBLON G, 1978, GENETICS, V90, P475; LEBLON G, 1972, MOL GEN GENET, V115, P36, DOI 10.1007/BF00272216; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lichten M, 1995, ANNU REV GENET, V29, P423, DOI 10.1146/annurev.ge.29.120195.002231; MEYER P, 1993, PLANT J, V4, P89, DOI 10.1046/j.1365-313X.1993.04010089.x; MEYER P, 1995, CURR TOP MICROBIOL, V197, P15; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NICOLAS A, 1989, GENOME, V31, P528, DOI 10.1139/g89-101; NICOLAS A, 1987, GENETICS, V116, P33; PAQUETTE N, 1978, CAN J GENET CYTOL, V20, P9, DOI 10.1139/g78-002; PAQUETTE N, 1978, MOL GEN GENET, V163, P313, DOI 10.1007/BF00271961; PATTERSON GI, 1995, GENE SILENCING HIGHE, P121; RADMAN M, 1993, CHROMOSOMA, V102, P369, DOI 10.1007/BF00360400; RAZIN A, 1994, PROG NUCLEIC ACID RE, V48, P53, DOI 10.1016/S0079-6603(08)60853-3; RHOUNIM L, 1992, EMBO J, V11, P4451, DOI 10.1002/j.1460-2075.1992.tb05546.x; ROSSEN JM, 1966, CR TRAV LAB CARLSB, V35, P233; Rossignol J.-L., 1988, RECOMBINATION GENETI, P23; ROSSIGNOL JL, 1979, P NATL ACAD SCI USA, V89, P2871; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; Singer-Sam J., 1993, DNA methylation: molecular biology and biological significance., P358; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; ZICKLER D, 1973, CHROMOSOMA, V40, P401, DOI 10.1007/BF00399431	48	104	106	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					855	864		10.1016/S0092-8674(00)80161-0	http://dx.doi.org/10.1016/S0092-8674(00)80161-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808621	Bronze			2022-12-24	WOS:A1996VJ44300004
J	Braverman, LE				Braverman, LE			Is there one successful antithyroid regimen for Graves' disease?	LANCET			English	Editorial Material							DRUGS				Braverman, LE (corresponding author), UNIV MASSACHUSETTS,MED CTR,DIV ENDOCRINOL,WORCESTER,MA 01655, USA.			Braverman, Lewis/0000-0003-1263-1099				ALLANNIC H, 1990, J CLIN ENDOCR METAB, V70, P675, DOI 10.1210/jcem-70-3-675; McIver B, 1996, NEW ENGL J MED, V334, P220, DOI 10.1056/NEJM199601253340403; MYERGEFNER M, 1994, J ENDOCRINOL INVEST, V17, P29; PASCHKE R, 1995, J CLIN ENDOCR METAB, V80, P2470, DOI 10.1210/jc.80.8.2470; ROMALDINI JH, 1983, J CLIN ENDOCR METAB, V57, P563, DOI 10.1210/jcem-57-3-563; Spencer CA, 1996, CLIN CHEM, V42, P140; WENZEL KW, 1984, J CLIN ENDOCR METAB, V58, P62, DOI 10.1210/jcem-58-1-62; Wilson R, 1996, QJM-INT J MED, V89, P381	8	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					697	698		10.1016/S0140-6736(05)65600-0	http://dx.doi.org/10.1016/S0140-6736(05)65600-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806285				2022-12-24	WOS:A1996VG37400004
J	Skinner, R; Pearson, ADJ; English, MW; Price, L; Wyllie, RA; Coulthard, MG; Craft, AW				Skinner, R; Pearson, ADJ; English, MW; Price, L; Wyllie, RA; Coulthard, MG; Craft, AW			Risk factors for ifosfamide nephrotoxicity in children	LANCET			English	Article							HYPOPHOSPHATEMIC RICKETS; TUBULAR TOXICITY; FANCONI SYNDROME; RENAL-FUNCTION; CANCER	Background Risk factors for long-term nephrotoxicity after ifosfamide for childhood cancers are not fully known. We have studied patient-related and treatment-related risk factors for chronic ifosfamide nephrotoxicity. Methods A group of 23 children who had received ifosfamide at age 2.1-16.2 years (median 6.9) for various cancers were assessed for nephrotoxicity, at 1-28 (2) months after the end of treatment, by renal function testing, laboratory values, and a grading score (none, mild, moderate, severe). No patient had received cisplatin or undergone nephrectomy. 13 children were reassessed at 10-26 (23) months; eight had died and two were not evaluable. The median total ifosfamide dose was 100.8 (9.0-160.4) g/m(2) over a median of 15 courses every 3 weeks as a 48-72 h continuous intravenous infusion (in 22 cases), with mesna and hydration. Findings Glomerular filtration rate was below normal in ten (45%) of 22 evaluable children; their rate was 61-85 mL/min per 1.73 m(2). Proximal tubular toxicity led to hypophosphataemic rickets and/or renal tubular acidosis in six children, and distal tubular toxicity caused nephrogenic diabetes insipidus in one. Of the risk factors analysed by multiple regression, only total ifosfamide dose was associated with proximal tubular toxicity. Only two of ten evaluable patients who received under 100 g/m(2) developed moderate nephrotoxicity, whereas six of ten who received over this dose had moderate or severe nephrotoxicity, Interpretation High total ifosfamide dose was the only risk factor we identified. Although inter-patient variability was high, cumulative doses of 100 g/m(2) or higher should be avoided in children with cancer.			Skinner, R (corresponding author), UNIV NEWCASTLE UPON TYNE, ROYAL VICTORIA INFIRM, SIR JAMES SPENCE INST CHILD HLTH, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND.							ARNDT C, 1994, CANCER CHEMOTH PHARM, V34, P431, DOI 10.1007/s002800050166; ASHRAF MS, 1994, EUR J PEDIATR, V153, P90, DOI 10.1007/BF01959214; BURK CD, 1990, J PEDIATR-US, V117, P331, DOI 10.1016/S0022-3476(05)80557-8; CARON HN, 1992, MED PEDIATR ONCOL, V20, P42, DOI 10.1002/mpo.2950200109; DESCHEPPER J, 1993, ACTA PAEDIATR, V82, P373; HENEY D, 1989, LANCET, V2, P103; MONCRIEFF M, 1989, CANCER CHEMOTH PHARM, V23, P121; NEWBURYECOB RA, 1989, LANCET, V1, P1328; PRATT CB, 1991, J CLIN ONCOL, V9, P1495, DOI 10.1200/JCO.1991.9.8.1495; ROSSI R, 1994, J CLIN ONCOL, V12, P159, DOI 10.1200/JCO.1994.12.1.159; SHAW PJ, 1990, LANCET, V335, P1022, DOI 10.1016/0140-6736(90)91076-M; SKINNER R, 1989, BRIT MED J, V298, P1560, DOI 10.1136/bmj.298.6687.1560; SKINNER R, 1994, MED PEDIATR ONCOL, V22, P153, DOI 10.1002/mpo.2950220219; SKINNER R, 1991, CANCER CHEMOTH PHARM, V28, P81, DOI 10.1007/BF00689694; SKINNER R, 1993, J CLIN ONCOL, V11, P173, DOI 10.1200/JCO.1993.11.1.173; SKINNER R, 1990, ARCH DIS CHILD, V65, P732, DOI 10.1136/adc.65.7.732; SKINNER R, 1992, BRIT J CANCER, V66, pS30; SMEITINK J, 1988, EUR J PEDIATR, V148, P164, DOI 10.1007/BF00445929; VANGOOL S, 1992, MED PEDIATR ONCOL, V20, P254, DOI 10.1002/mpo.2950200316; ZALUPSKI M, 1988, J NATL CANCER I, V80, P556, DOI 10.1093/jnci/80.8.556	20	64	68	2	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	1996	348	9027					578	580		10.1016/S0140-6736(96)03480-0	http://dx.doi.org/10.1016/S0140-6736(96)03480-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774570				2022-12-24	WOS:A1996VF18600011
J	Pless, IB				Pless, IB			Collisions with animals	LANCET			English	Editorial Material											Pless, IB (corresponding author), MCGILL UNIV,DEPT PAEDIAT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA.							Farrell TM, 1996, ARCH SURG-CHICAGO, V131, P377; HAYES P, 1995, DANGEROUS ELK    SEP; PLESS IB, 1996, INJURY PREVENTION, V2, P87; THOMPSON SJ, 1985, ERGONOMICS, V28, P1469, DOI 10.1080/00140138508963271	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 24	1996	348	9026					492	492		10.1016/S0140-6736(05)64668-5	http://dx.doi.org/10.1016/S0140-6736(05)64668-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD427	8757149				2022-12-24	WOS:A1996VD42700007
J	Rossi, AF; Rittenhouse, CD; Paradiso, MA				Rossi, AF; Rittenhouse, CD; Paradiso, MA			The representation of brightness in primary visual cortex	SCIENCE			English	Article							ILLUSORY CONTOURS; RESPONSES; CATS	Although neurons in primary visual cortex are sensitive to the spatial distribution and intensity of light, their responses have not been thought to correlate with the perception of brightness. Indeed, primary visual cortex is often described as an initial processing stage that sends information to higher cortical areas where perception of brightness, color, and form occurs. However, a significant percentage of neurons in primary visual cortex were shown to respond in a manner correlated with perceived brightness, rather than responding strictly to the light level in the receptive fields of the cells. This finding suggests that even at the first stage of visual cortical processing, spatial integration of information yields perceptual qualities that are only indirectly related to the pattern of illumination of the retina.			Rossi, AF (corresponding author), BROWN UNIV, DEPT NEUROSCI, PROVIDENCE, RI 02912 USA.							BRAVO M, 1988, VISION RES, V28, P861, DOI 10.1016/0042-6989(88)90095-8; DEVALOIS RL, 1971, SCIENCE, V171, P694, DOI 10.1126/science.171.3972.694; DEVALOIS RL, 1986, VISION RES, V26, P887, DOI 10.1016/0042-6989(86)90147-1; HERING E, 1878, LEHRE VOM LICHTSINN; HESS C, 1894, GRAEFES ARCH OPHTHAL, V15, P1; HIRSCH J, 1995, P NATL ACAD SCI USA, V92, P6469, DOI 10.1073/pnas.92.14.6469; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; LANDIS C, 1954, PHYSIOL REV, V34, P259, DOI 10.1152/physrev.1954.34.2.259; NEWSOME WT, 1990, COLD SPRING HARB SYM, V55, P697; REDIES C, 1986, EXP BRAIN RES, V61, P469; Rossi AF, 1996, VISION RES, V36, P1391, DOI 10.1016/0042-6989(95)00206-5; SCHEIN SJ, 1990, J NEUROSCI, V10, P3369; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; STONER GR, 1992, NATURE, V358, P412, DOI 10.1038/358412a0; TOOTELL RBH, 1995, NATURE, V375, P139, DOI 10.1038/375139a0; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; ZEKI S, 1980, NATURE, V284, P412, DOI 10.1038/284412a0	17	205	207	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 23	1996	273	5278					1104	1107		10.1126/science.273.5278.1104	http://dx.doi.org/10.1126/science.273.5278.1104			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD428	8688096				2022-12-24	WOS:A1996VD42800037
J	Liu, R; Paxton, WA; Choe, S; Ceradini, D; Martin, SR; Horuk, R; MacDonald, ME; Stuhlmann, H; Koup, RA; Landau, NR				Liu, R; Paxton, WA; Choe, S; Ceradini, D; Martin, SR; Horuk, R; MacDonald, ME; Stuhlmann, H; Koup, RA; Landau, NR			Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection	CELL			English	Article							ERYTHROCYTE CHEMOKINE RECEPTOR; TYPE-1; DISEASE; GENE; FAMILY; REGION; PROGRESSION; REQUIREMENT; EXPRESSION; PHENOTYPE	Rare individuals have been multiply exposed to HIV-1 but remain uninfected. The CD4(+) T-cells of two of these individuals, designated EU2 and EU3, are highly resistant in vitro to the entry of primary macrophage-tropic virus but are readily infectable with transformed T-cell line adapted viruses. We report here on the genetic basis of this resistance. We found that EU2 and EU3 have a homozygous defect in CKR-5, the gene encoding the recently described coreceptor for primary HIV-1 isolates. These individuals appear to have inherited a defective CKR-5 allele that contains an internal 32 base pair deletion. The encoded protein is severely truncated and cannot be detected at the cell surface. Surprisingly, this defect has no obvious phenotype in the affected individuals. Thus, a CKR-5 allele present in the human population appears to protect homozygous individuals from sexual transmission of HIV-1. Heterozygous individuals are quite common (similar to 20%) in some populations. These findings indicate the importance of CKR-5 in HIV-1 transmission and suggest that targeting the HIV-1-CKR-5 interaction may provide a means of preventing or slowing disease progression.	BERLEX BIOSCI, DEPT IMMUNOL, RICHMOND, CA 94080 USA; MASSACHUSETTS GEN HOSP, MOL NEUROGENET UNIT, CHARLESTOWN, MA 02129 USA; CUNY MT SINAI SCH MED, BROOKDALE CTR MOL BIOL, NEW YORK, NY 10029 USA	Harvard University; Massachusetts General Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Liu, R (corresponding author), ROCKEFELLER UNIV, AARON DIAMOND AIDS RES CTR, 1230 YORK AVE, NEW YORK, NY 10016 USA.		paxton, william/R-9747-2019	Paxton, William/0000-0001-5200-0801; Stuhlmann, Heidi/0000-0001-7217-768X; Paxton, William/0000-0002-2654-5186	NCI NIH HHS [R01CA72149] Funding Source: Medline; NIAID NIH HHS [R01AI35522, R29AI36057] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035522, R29AI036057] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; COCCHI F, 1996, SCIENCE, V720, P1811; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FISHER AG, 1988, NATURE, V334, P444, DOI 10.1038/334444a0; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; HE JL, 1995, J VIROL, V69, P4587, DOI 10.1128/JVI.69.7.4587-4592.1995; HEXTER A, 1968, SCIENCE, V160, P436, DOI 10.1126/science.160.3826.436; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085; LENBURG ME, 1993, J VIROL, V67, P7238, DOI 10.1128/JVI.67.12.7238-7245.1993; LOCKE PA, 1993, SOMAT CELL MOLEC GEN, V19, P95, DOI 10.1007/BF01233958; MACDONALD ME, 1992, NAT GENET, V1, P99, DOI 10.1038/ng0592-99; MACDONALD ME, 1991, AM J HUM GENET, V49, P723; MALLINSON G, 1995, BRIT J HAEMATOL, V90, P823, DOI 10.1111/j.1365-2141.1995.tb05202.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naylor SL, 1996, CYTOGENET CELL GENET, V72, P90, DOI 10.1159/000134170; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SPIRA AI, 1995, J VIROL, V69, P422, DOI 10.1128/JVI.69.1.422-429.1995; TANZI R E, 1988, Genomics, V3, P129, DOI 10.1016/0888-7543(88)90143-7; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	45	2423	2550	1	140	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1996	86	3					367	377		10.1016/S0092-8674(00)80110-5	http://dx.doi.org/10.1016/S0092-8674(00)80110-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756719	Bronze			2022-12-24	WOS:A1996VC30900005
J	Roberts, JM				Roberts, JM			Preventing pre-eclampsia	LANCET			English	Editorial Material							PREGNANCY-INDUCED HYPERTENSION; PREECLAMPSIA				Roberts, JM (corresponding author), UNIV PITTSBURGH,MAGEE WOMENS RES INST,DEPT OBSTET & GYNAECOL,PITTSBURGH,PA 15213, USA.		Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207				BAKER PN, 1994, OBSTET GYNECOL, V83, P745; Conde-Agudelo A, 1994, Obstet Gynecol Surv, V49, P210, DOI 10.1097/00006254-199403000-00027; FRIEDMAN SA, 1991, CLIN PERINATOL, V18, P661, DOI 10.1016/S0095-5108(18)30490-1; KYLE PM, 1995, AM J OBSTET GYNECOL, V173, P865, DOI 10.1016/0002-9378(95)90356-9; MACGILLIVRAY I, 1976, IS J MED SCI, V112, P500; Millar JGB, 1996, BRIT J OBSTET GYNAEC, V103, P421, DOI 10.1111/j.1471-0528.1996.tb09767.x; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	8	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					281	282		10.1016/S0140-6736(05)64469-8	http://dx.doi.org/10.1016/S0140-6736(05)64469-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709684				2022-12-24	WOS:A1996VA25000005
J	Whincup, PH; Cook, DG; Adshead, F; Taylor, S; Papacosta, O; Walker, M; Wilson, V				Whincup, PH; Cook, DG; Adshead, F; Taylor, S; Papacosta, O; Walker, M; Wilson, V			Cardiovascular risk factors in British children from towns with widely differing adult cardiovascular mortality	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; BLOOD-PRESSURE; SOCIOECONOMIC-STATUS; GLUCOSE-TOLERANCE; BODY-MASS; CHILDHOOD; WEIGHT; GROWTH; BIRTH; FETAL	Objective-To examine whether cardiovascular risk factors differ in children from towns in England and Wales with widely differing adult cardiovascular death rates. Design-School based survey conducted during 1994 in 10 towns, five with exceptionally high adult cardiovascular mortality (standardised mortality ratio 131-143) and five with exceptionally low adult cardiovascular mortality (64-75). Towns were surveyed in high-low pairs. Subjects-3415 white children aged 8-11 years with physical measurements (response rate 75%), including 1287 with blood samples (response rate 64%), of whom 515 had blood samples taken 30 minutes after a glucose load. Results-Children in towns with high cardiovascular mortality were on average shorter than those in towns with low mortality (mean difference 1.2 cm; 95% confidence interval 0.3 to 2.1 cm; P = 0.02) and had a higher ponderal index (0.34 kg/m(3); 0.16 to 0.52 kg/m(3); P = 0.006). Mean systolic pressure was higher in high mortality towns, particularly after adjustment for height (2.0 mm Hg; 0.8 to 3.2 mm Hg; P = 0.009). Mean waist:hip ratio, total cholesterol concentration, and 30 minute post-load glucose measurements were similar in high and low mortality towns. The differences in height and blood pressure between high and low mortality towns were unaffected by standardisation for birth weight. Conclusions-The differences in height, ponderal index, and blood pressure between towns with high and low cardiovascular mortality, if persistent, may have important future public health implications. Their independence of birth weight suggests that the childhood environment rather than the intrauterine environment is involved in their development.	UNIV LONDON ST GEORGES HOSP, SCH MED,DEPT PUBL HLTH SCI, LONDON SW17 0RE, ENGLAND	St Georges University London	Whincup, PH (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PRIMARY CARE & POPULAT SCI, LONDON NW3 2PF, ENGLAND.		TAYLOR, STEPHANIE/GYV-4768-2022	Whincup, Peter/0000-0002-5589-4107; Cook, Derek/0000-0002-9723-5759; Papacosta, Olia/0000-0001-8781-6747; Taylor, Stephanie/0000-0001-7454-6354	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AZAD K, 1994, ANN CLIN BIOCHEM, V31, P233, DOI 10.1177/000456329403100303; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Bennett N, 1995, HLTH SURVEY ENGLAND; BRUCE NG, 1990, J CLIN EPIDEMIOL, V43, P385, DOI 10.1016/0895-4356(90)90124-8; CHINN S, 1992, EUR J CLIN NUTR, V46, P489; DESWIET M, 1992, BRIT MED J, V304, P23, DOI 10.1136/bmj.304.6818.23; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; FREEMAN W, 1990, ARCH DIS CHILD, V65, P78, DOI 10.1136/adc.65.1.78; FROHLICH ED, 1988, CIRCULATION, V77, pA502; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HAMMOND J, 1994, ARCH DIS CHILD, V70, P367, DOI 10.1136/adc.70.5.367; LAW CM, 1993, J EPIDEMIOL COMMUN H, V47, P255, DOI 10.1136/jech.47.4.255; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; *OFF POP CENS SURV, 1990, OFF POP CENS SURV DS, V9; *POL STUD I, 1994, URB TRENDS, V2; PRINEAS RJ, 1980, HYPERTENSION, V2, pI24, DOI 10.1161/01.HYP.2.4_Pt_2.I24; RAMSEY M, 1979, MED BIOL ENG COMPUT, V17, P11, DOI 10.1007/BF02440948; *SAS I, 1985, SAS US GUID; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1984, BRIT MED BULL, V40, P366, DOI 10.1093/oxfordjournals.bmb.a072006; VOORS AW, 1977, AM J EPIDEMIOL, V106, P101, DOI 10.1093/oxfordjournals.aje.a112439; WALKER M, 1989, INT J EPIDEMIOL, V18, P602, DOI 10.1093/ije/18.3.602; WANNAMETHEE G, 1989, BRIT MED J, V299, P1497, DOI 10.1136/bmj.299.6714.1497; WHINCUP PH, 1988, LANCET, V2, P890; WHINCUP PH, 1992, J EPIDEMIOL COMMUN H, V46, P164, DOI 10.1136/jech.46.2.164; WHINCUP PH, 1992, J EPIDEMIOL COMMUN H, V46, P396, DOI 10.1136/jech.46.4.396; WHINCUP PH, 1992, ARCH DIS CHILD, V67, P1423, DOI 10.1136/adc.67.12.1423; WHINCUP PH, 1991, THESIS U LONDON	38	49	51	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	1996	313	7049					79	84		10.1136/bmj.313.7049.79	http://dx.doi.org/10.1136/bmj.313.7049.79			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688758	Green Published			2022-12-24	WOS:A1996UX69800021
J	Schedl, A; Ross, A; Lee, M; Engelkamp, D; Rashbass, P; vanHeyningen, V; Hastie, ND				Schedl, A; Ross, A; Lee, M; Engelkamp, D; Rashbass, P; vanHeyningen, V; Hastie, ND			Influence of PAX6 gene dosage on development: Overexpression causes severe eye abnormalities	CELL			English	Article							HOMEOBOX-CONTAINING GENE; PAIRED BOX GENE; INSITU HYBRIDIZATION; WAARDENBURG SYNDROME; POINT MUTATION; NEURAL-TUBE; ANIRIDIA; MOUSE; DEFECTS; EXPRESSION	Aniridia in man and Small eye in mice are semidominant developmental disorders caused by mutations within the paired box gene PAX6. Whereas heterozygotes suffer from iris hypoplasia, homozygous mice lack eyes and nasal cavities and exhibit brain abnormalities. To investigate the role of gene dosage in more detail, we have generated yeast artificial chromosome transgenic mice carrying the human PAX6 locus. When crossed onto the Small eye background, the transgene rescues the mutant phenotype. Strikingly, mice carrying multiple copies on a wild-type background show specific developmental abnormalities of the eye, but not of other tissues expressing the gene. Thus, at least five different eye phenotypes are associated with changes in PAX6 expression. We provide evidence that not only reduced, but also increased levels of transcriptional regulators can cause developmental defects.			Schedl, A (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Schedl, Andreas/F-8823-2015; Schedl, Andreas/GOP-3427-2022; VAN HEYNINGEN, Veronica/GYE-0531-2022; van Heyningen, Veronica/B-8039-2008	Schedl, Andreas/0000-0001-9380-7396; van Heyningen, Veronica/0000-0003-0359-0141	Medical Research Council [MC_U127527199] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [MC_U127527199] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; Bateman J B, 1984, Int Ophthalmol Clin, V24, P87, DOI 10.1097/00004397-198402410-00008; BEEBE DC, 1986, T OPHTHAL SOC UK, V105, P123; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; FALK RE, 1973, AM J MENT DEF, V77, P383; FANTES J, 1995, HUM MOL GENET, V4, P415, DOI 10.1093/hmg/4.3.415; FANTES JA, 1992, AM J HUM GENET, V51, P1286; GENISGAL.JM, 1966, NATURE, V210, P209, DOI 10.1038/210209a0; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HODGSON SV, 1980, J MED GENET, V17, P478, DOI 10.1136/jmg.17.6.478; HOGAN B, 1994, MANIPULATION MOUSE E; HOGAN BLM, 1988, DEVELOPMENT, V103, P115; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; LAMB BT, 1995, CURR OPIN GENET DEV, V5, P342, DOI 10.1016/0959-437X(95)80049-2; LAVEDAN C, 1989, CYTOGENET CELL GENET, V50, P70, DOI 10.1159/000132726; LURIE IW, 1994, BRIT J OPHTHALMOL, V78, P415, DOI 10.1136/bjo.78.5.415; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; PALMER CG, 1976, HUM GENET, V31, P219, DOI 10.1007/BF00296149; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; PLAZA S, 1995, MOL CELL BIOL, V15, P892; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; READ AP, 1995, NAT GENET, V9, P333, DOI 10.1038/ng0495-333; SANCHEZ O, 1974, HUMANGENETIK, V22, P59, DOI 10.1007/BF00338135; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SCHEDL A, 1993, NATURE, V362, P258, DOI 10.1038/362258a0; SCHMAHL W, 1993, ACTA NEUROPATHOL, V86, P126, DOI 10.1007/BF00334879; SMITH DJ, 1995, GENOMICS, V27, P425, DOI 10.1006/geno.1995.1073; SPELEMAN F, 1991, CYTOGENET CELL GENET, V56, P129, DOI 10.1159/000133068; STROBEL RJ, 1980, AM J MED GENET, V7, P15, DOI 10.1002/ajmg.1320070105; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TON CCT, 1992, GENOMICS, V13, P251, DOI 10.1016/0888-7543(92)90239-O; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WALTHER C, 1991, DEVELOPMENT, V113, P1435	45	358	365	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					71	82		10.1016/S0092-8674(00)80078-1	http://dx.doi.org/10.1016/S0092-8674(00)80078-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689689	Bronze			2022-12-24	WOS:A1996UX93400009
J	Jiang, F; Kumar, RA; Jones, RA; Patel, DJ				Jiang, F; Kumar, RA; Jones, RA; Patel, DJ			Structural basis of RNA folding and recognition in an AMP-RNA aptamer complex	NATURE			English	Article							RIBOSOMAL-RNA; SELECTION; SEQUENCE; INVITRO; LOOPS; DNA	THE catalytic properties of RNA(1,2) and its well known role in gene expression and regulation are the consequence of its unique solution structures, Identification of the structural determinants of ligand recognition by]RNA molecules is of fundamental importance for understanding the biological functions of RNA, as well as for the rational design of RNA sequences with specific catalytic activities(3-6). Towards this latter end, Szostak et al(7,8) used in vitro selection techniques to isolate RNA sequences ('aptamers') containing a high-affinity binding site for ATP, the universal currency of cellular energy, and then used this motif to engineer ribozymes with polynucleotide kinase activity, Here we present the solution structure, as determined by multidimensional NMR spectroscopy and molecular dynamics calculations, of both uniformly and specifically C-13-, N-15-labelled 40-mer RNA containing the ATP-binding motif complexed with AMP, The aptamer adopts an L-shaped structure with two nearly orthogonal stems, each capped proximally by a G . G mismatch pair, binding the AMP ligand at their junction in a GNRA-like motif.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021; RUTGERS STATE UNIV,DEPT CHEM,PISCATAWAY,NJ 08855	Memorial Sloan Kettering Cancer Center; Rutgers State University New Brunswick			Jones, Roger A./GRY-0637-2022	Jones, Roger A./0000-0002-6835-6615				ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; Battiste JL, 1995, J BIOMOL NMR, V6, P375; Brunger A. T., 1992, X PLOR SYSTEM X RAY; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ELLINGTON A, 1990, NATURE, V346, P812; Fan P, 1996, J MOL BIOL, V258, P480, DOI 10.1006/jmbi.1996.0263; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; KOLE R, 1981, BIOCHEMISTRY-US, V20, P1902, DOI 10.1021/bi00510a028; Koshland D E Jr, 1971, Harvey Lect, V65, P33; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4508; ORITA M, 1993, NUCLEIC ACIDS RES, V21, P5670, DOI 10.1093/nar/21.24.5670; Pardi A, 1995, METHOD ENZYMOL, V261, P350; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; YE X, 1995, J CHEM BIOL, V2, P827	28	225	237	3	94	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					183	186		10.1038/382183a0	http://dx.doi.org/10.1038/382183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700212				2022-12-24	WOS:A1996UW67200055
J	Xu, QL; Alldus, G; Macdonald, R; Wilkinson, DG; Holder, N				Xu, QL; Alldus, G; Macdonald, R; Wilkinson, DG; Holder, N			Function of the Eph-related kinase rtk1 in patterning of the zebrafish forebrain	NATURE			English	Article							TYROSINE KINASE; BRAIN; INDUCTION; MESODERM	EARLY during its development, the vertebrate brain is subdivided into regions that have distinct fates and correlate with the expression domains of regulatory genes(1,2), but little is known about the cell-cell interactions that establish this spatial pattern. Candidates for regulating such interactions are the Eph-related receptor tyrosine kinases (RTKs) which have spatially restricted expression in the developing brain(2-6). These RTKs may mediate cell-contact-dependent signalling by interacting with membrane-bound ligands, and have been implicated in axon repulsion(8,9) and the segmental restriction of gene expression in the hindbrain(10), but nothing is known regarding their function in the rostral neural epithelium. Here we use a dominant-negative approach in the zebrafish embryo to interfere with the function of Rtk1, an Eph-related RTK expressed in the developing diencephalon. We find that expression of a truncated receptor leads to expansion of the eye field into diencephalic territory and loss of diencephalic structures, indicating a role for Rtk1 in patterning the developing forebrain.	UNIV LONDON KINGS COLL,RANDALL INST,DBRC,LONDON WC2B 5RL,ENGLAND; NATL INST MED RES,DIV DEV NEUROBIOL,LONDON NW7 1AA,ENGLAND	University of London; King's College London; MRC National Institute for Medical Research				Wilkinson, David/0000-0001-6757-7080				ALLENDE ML, 1994, DEV BIOL, V166, P509, DOI 10.1006/dbio.1994.1334; ALVARADOMALLART RM, 1990, DEV BIOL, V139, P75, DOI 10.1016/0012-1606(90)90280-V; AMAYA E, 1991, CELL, V66, P256; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHUNG SH, 1975, NATURE, V258, P126, DOI 10.1038/258126a0; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Irving C, 1996, DEV BIOL, V173, P26, DOI 10.1006/dbio.1996.0004; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; NAKAMURA H, 1986, CELL DIFFER DEV, V19, P187, DOI 10.1016/0045-6039(86)90095-3; NIETO MA, 1992, DEVELOPMENT, V116, P1137; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PAPALOPULU N, 1995, PERSPECT DEV NEUROBI, V3, P39; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; RUBENSTEIN JLR, 1994, CURR TOP DEV BIOL, V29, P1, DOI 10.1016/S0070-2153(08)60546-3; SCHMITT EA, 1994, J COMP NEUROL, V344, P532, DOI 10.1002/cne.903440404; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WOO K, 1995, DEVELOPMENT, V121, P2595; XU QL, 1994, DEVELOPMENT, V120, P287; Xu QL, 1995, DEVELOPMENT, V121, P4005	28	109	111	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					319	322		10.1038/381319a0	http://dx.doi.org/10.1038/381319a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692269				2022-12-24	WOS:A1996UM40300055
J	Vlieghe, D; VanMeervelt, L; Dautant, A; Gallois, B; Precigoux, G; Kennard, O				Vlieghe, D; VanMeervelt, L; Dautant, A; Gallois, B; Precigoux, G; Kennard, O			Parallel and antiparallel (G center dot GC)(2) triple helix fragments in a crystal structure	SCIENCE			English	Article							BASE TRIPLETS; NUCLEIC-ACIDS; DNA TRIPLER; TRANSCRIPTION; RECOMBINATION; RECOGNITION; STABILITY; DATABASE; PACKAGE	Nucleic acid triplexes are formed by sequence-specific interactions between single-stranded polynucleotides and the double helix. These triplexes are implicated in genetic recombination in vivo and have application to areas that include genome analysis and antigene therapy. Despite the importance of the triple helix, only limited high-resolution structural information is available. The x-ray crystal structure of the oligonucleotide d(GGCGAATTGG) is described; it was designed to contain the d(G . GC)(2) fragment and thus provide the basic repeat unit oi a DNA triple helix. Parameters derived from this crystal structure have made it possible to construct models of both parallel and antiparallel triple helices.	CAMBRIDGE CRYSTALLOG DATA CTR, CAMBRIDGE CB2 1EZ, ENGLAND; KATHOLIEKE UNIV LEUVEN, DEPT CHEM, B-3001 HEVERLEE, BELGIUM; UNIV BORDEAUX 2, UNITE BIOPHYS STRUCT, EP CNRS, F-33405 TALENCE, FRANCE	University of Cambridge; KU Leuven; UDICE-French Research Universities; Universite de Bordeaux			Van Meervelt, Luc/AAD-2878-2022	Van Meervelt, Luc/0000-0003-2186-5209				ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BERMAN HM, 1992, BIOPHYS J, V63, P751, DOI 10.1016/S0006-3495(92)81649-1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETTS L, 1995, SCIENCE, V270, P1838, DOI 10.1126/science.270.5243.1838; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DERVAN PB, 1992, NATURE, V359, P87, DOI 10.1038/359087a0; DIEKMANN S, 1989, EMBO J, V8, P1; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; JIANG SP, 1994, J BIOMOL STRUCT DYN, V12, P383, DOI 10.1080/07391102.1994.10508747; KOHWI Y, 1992, J MOL BIOL, V223, P817, DOI 10.1016/0022-2836(92)90242-C; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEBRET M, 1991, J CHIM PHYS PCB, V88, P2489, DOI 10.1051/jcp/1991882489; LEONARD GA, 1995, ACTA CRYSTALLOGR D, V51, P136, DOI 10.1107/S0907444994004713; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, P50; LIU KL, 1994, NAT STRUCT BIOL, V1, P11, DOI 10.1038/nsb0194-11; MAHLER LJ, 1989, SCIENCE, V245, P725; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PIRIOU JM, 1994, BIOPHYS CHEM, V50, P323, DOI 10.1016/0301-4622(93)E0103-C; RADHAKRISHNAN I, 1993, STRUCTURE, V1, P135, DOI 10.1016/0969-2126(93)90028-F; RADHAKRISHNAN I, 1994, BIOCHEMISTRY-US, V33, P11405, DOI 10.1021/bi00204a001; RAGHUNATHAN G, 1993, BIOCHEMISTRY-US, V32, P455, DOI 10.1021/bi00053a009; RAO BJ, 1994, P NATL ACAD SCI USA, V91, P6161, DOI 10.1073/pnas.91.13.6161; SHCHYOLKINA AK, 1995, FEBS LETT, V367, P81, DOI 10.1016/0014-5793(95)00519-F; Sheldrick G.M., 2015, ACTA CRYSTALLOGR, VC71, P3; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; SUN JS, 1993, CURR OPIN STRUC BIOL, V3, P345, DOI 10.1016/S0959-440X(05)80105-8; VANMEERVELT L, 1995, NATURE, V374, P742, DOI 10.1038/374742a0; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362	34	74	74	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1996	273	5282					1702	1705		10.1126/science.273.5282.1702	http://dx.doi.org/10.1126/science.273.5282.1702			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781231				2022-12-24	WOS:A1996VH40800038
J	Moqtaderi, Z; Bai, Y; Poon, D; Weil, PA; Struhl, K				Moqtaderi, Z; Bai, Y; Poon, D; Weil, PA; Struhl, K			TBP-associated factors are not generally required for transcriptional activation in yeast	NATURE			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; GENE; HOLOENZYME; PROMOTER; COMPLEX; RECRUITMENT; REPRESSION	THE transcription factor TFIID, a central component of the eukaryotic RNA polymerase II (Pol II) transcription apparatus, comprises the TATA-binding protein (TBP) and approximately ten TBP-associated factors (TAFs)(1). Although the essential role of TBP in all eukaryotic transcription has been extensively analysed in vivo and in vitro(2,3), the function of the TAFs is less clear. In vitro, TAFs are dispensable for basal transcription but are required for the response to activators(1). In addition, specific TAFs may act as molecular bridges between particular activators and the general transcription machinery(4,5). In vivo, TAFs are required for yeast(6,7) and mammalian(8) cell growth, but little is known about their specific transcriptional functions. Using conditional alleles created by a new double-shutoff method, we show here that TAF depletion in yeast cells fan reduce transcription from some promoters lacking conventional TATA elements. However, TAF depletion has surprisingly little effect on transcriptional enhancement by several activators, indicating that TAFs are not generally required for transcriptional activation in yeast.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; VANDERBILT UNIV,MED CTR,DEPT MOL PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Harvard University; Harvard Medical School; Vanderbilt University								ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN W, 1985, EMBO J, V4, P3272; CORMACK BP, 1994, GENE DEV, V8, P1335, DOI 10.1101/gad.8.11.1335; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; HERNANDEZ N, 1993, GENE DEV, V7, P4291; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; IYER V, 1995, MOL CELL BIOL, V15, P7059; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LEE M, 1995, MOL CELL BIOL, V15, P5461; MARTENS JA, 1994, J BIOL CHEM, V269, P15661; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; RAY BL, 1991, CURR GENET, V20, P25, DOI 10.1007/BF00312761; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	30	247	253	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					188	191		10.1038/383188a0	http://dx.doi.org/10.1038/383188a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774887				2022-12-24	WOS:A1996VG14800058
J	Jorgensen, HL; Scholler, J; Sand, JC; Bjuring, M; Hassager, C; Christiansen, C				Jorgensen, HL; Scholler, J; Sand, JC; Bjuring, M; Hassager, C; Christiansen, C			Relation of common allelic variation at vitamin D receptor locus to bone mineral density and postmenopausal bone loss: Cross sectional and longitudinal population study	BRITISH MEDICAL JOURNAL			English	Article							X-RAY ABSORPTIOMETRY; PHOTON ABSORPTIOMETRY; GENE POLYMORPHISMS; OSTEOPOROTIC WOMEN; SINGLE-PHOTON; LUMBAR-SPINE; FRACTURES; MASS; GENOTYPE; TWIN	Objective-To determine whether common allelic variation at the vitamin D receptor locus is related to bose mineral density and postmenopausal bone loss. Design-Cross sectional and longitudinal population study. Setting-Outpatient clinic in research centre. Subjects-599 healthy women aged 27 to 72 and 125 women with low bone mass aged 55-77 had bone mineral density measured once in the cross sectional study. 136 women aged 45-54 were followed up for 18 years in the longitudinal study. Main outcome measures-Bone mineral density measured at the lumbar spine, hip, and forearm and rate of bone loss at different times over 18 years in relation to vitamin D receptor genotype as defined by the endonucleases ApaI, BsmI, and TaqI. Results-Vitamin D receptor genotype was not related to bone mineral density at any site. The maximum difference between homozygotes was 1.3% (P = 0.33, n = 723). Women with low bone mineral density had almost the same genotype frequencies as the women with normal bone mineral densities. Vitamin D receptor genotype was not related to early postmenopausal bone loss from age 51 to 53 (mean (SD) total loss at the lower forearm -3.6% (3.6%)), late postmenopausal bone loss from age 63 to 69 (at the hip -6.2% (8.7%)), or to long term postmenopausal loss from age 51 to 69 (at the lower forearm -24.5% (11.4%)). Conclusion-Common allelic variation at the vitamin D receptor locus as defined by the endonucleases ApaI, BsmI, and TaqI is related neither to bone mineral density nor to the rate of bone loss in healthy postmenopausal Danish women.			Jorgensen, HL (corresponding author), CTR CLIN & BASIC RES,BALLERUP BYVEJ 222,DK-2750 BALLERUP,DENMARK.		Jorgensen, Henrik/ABI-8236-2020	Jorgensen, Henrik Lovendahl/0000-0001-6374-761X				BORG J, 1995, OSTEOPOROSIS INT, V5, P377, DOI 10.1007/BF01622260; CHRISTIANSEN C, 1980, EUR J CLIN INVEST, V10, P273, DOI 10.1111/j.1365-2362.1980.tb00033.x; CHRISTIANSEN C, 1987, Lancet, V1, P1105; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; FERRARI S, 1995, LANCET, V345, P423, DOI 10.1016/S0140-6736(95)90404-2; FLEET JC, 1995, J BONE MINER RES, V10, P985; HANSEN MA, 1990, J NUCL MED, V31, P1156; HUSMEYER FG, 1994, J CLIN INVEST, V94, P2130; KEEN RW, 1995, LANCET, V345, P990, DOI 10.1016/S0140-6736(95)90740-8; KELLY TL, 1994, CALCIFIED TISSUE INT, V54, P212, DOI 10.1007/BF00301681; KRALL EA, 1995, J BONE MINER RES, V10, P978; LOONEY JE, 1995, J CLIN ENDOCR METAB, V80, P2158, DOI 10.1210/jc.80.7.2158; MELTON LJ, 1993, BONE, V14, pS1; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; NILAS L, 1985, J NUCL MED, V26, P1257; OVERGAARD K, 1992, CALCIFIED TISSUE INT, V50, P30, DOI 10.1007/BF00297294; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; RIGGS BL, 1995, J BONE MINER RES, V10, P991; *SAS I, 1987, SAS STAT GUID PERS C; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SPECTOR TD, 1995, BRIT MED J, V310, P1357, DOI 10.1136/bmj.310.6991.1357; Uitterlinden A. G., 1995, Calcified Tissue International, V56, P474; 1993, JAMA-J AM MED ASSOC, V94, P646	24	59	61	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					586	590						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806247	Green Published			2022-12-24	WOS:A1996VG10800016
J	Bouwmeester, T; Kim, SH; Sasai, Y; Lu, B; DeRobertis, EM				Bouwmeester, T; Kim, SH; Sasai, Y; Lu, B; DeRobertis, EM			Cerberus is a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer	NATURE			English	Article							XENOPUS-LAEVIS EMBRYOS; HOMEO-BOX GENE; NEURAL INDUCTION; BLASTOPORE LIP; GASTRULATION; MESODERM; CLONING; DOMAIN; NOGGIN; AXIS	An abundant cDNA enriched in Spemann's organizer, cerberus, was isolated by differential screening. It encodes a secreted protein that is expressed in the anterior endomesoderm. Microinjection of cerberus mRNA into Xenopus embryos induces ectopic heads, and duplicated hearts and livers. The results suggest a role for a molecule expressed in the anterior endoderm in the induction of head structures in the vertebrate embryo.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869				ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Adelmann HB, 1936, Q REV BIOL, V11, P284, DOI 10.1086/394509; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; BLITZ IL, 1995, DEVELOPMENT, V121, P993; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DALE L, 1987, DEVELOPMENT, V99, P527; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; DEROBERTIS EM, 1995, NATURE, V374, P407, DOI 10.1038/374407a0; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; GERHART J, 1989, DEVELOPMENT, V107, P37; GONT LK, 1993, DEVELOPMENT, V119, P991; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HAUSEN P, 1991, EARLY DEV XENOPUS; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HOLTPRETER J., 1938, WILHELM RAUX ARCH ENTWICKLUNGSMECH ORGAN, V138, P522, DOI 10.1007/BF00573814; JONES CM, 1995, DEVELOPMENT, V121, P3651; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KELLER R, 1991, METHOD CELL BIOL, V36, P61; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MOOS M, 1995, DEVELOPMENT, V121, P4239; NASCONE N, 1995, DEVELOPMENT, V121, P515; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; Nieuwkoop P. D., 1950, Archives de Biologie Liege, V61, P113; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; PANNESE M, 1995, DEVELOPMENT, V121, P707; PASTEELS J., 1949, ARCH BIOL, V60, P235; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SASAI Y, IN PRESS EMBO J; SATER AK, 1990, DEVELOPMENT, V108, P461; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SIVE HL, 1989, CELL, V58, P170; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SPEMANN H, 1931, ROUX ARCH ENTW MECH, V123, P389; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; VODICKA MA, 1995, DEVELOPMENT, V121, P3505; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; ZARAISKY AG, 1995, DEVELOPMENT, V121, P3839	48	617	647	1	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					595	601		10.1038/382595a0	http://dx.doi.org/10.1038/382595a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757128				2022-12-24	WOS:A1996VC30300043
J	Curnow, AW; Ibba, M; Soll, D				Curnow, AW; Ibba, M; Soll, D			tRNA-dependent asparagine formation	NATURE			English	Letter							TRANSFER-RNA-SYNTHETASE				Curnow, AW (corresponding author), YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,POB 6666,NEW HAVEN,CT 06520, USA.							Baron Christian, 1995, P529; BAYLEY ST, 1971, METHOD MOL BIOL, V1, P89; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; DOOLITTLE RF, 1995, P NATL ACAD SCI USA, V92, P2421, DOI 10.1073/pnas.92.7.2421; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GUPTA R, 1984, J BIOL CHEM, V259, P9461; Hong KW, 1996, EMBO J, V15, P1983, DOI 10.1002/j.1460-2075.1996.tb00549.x; JimenezSanchez A, 1995, J MOL EVOL, V41, P712; Kim SI, 1996, NUCLEIC ACIDS RES, V24, P2648, DOI 10.1093/nar/24.14.2648; SCHON A, 1988, BIOCHIMIE, V70, P391, DOI 10.1016/0300-9084(88)90212-X; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WHITE BN, 1972, CAN J BIOCHEM CELL B, V50, P600, DOI 10.1139/o72-082; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229	17	139	144	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					589	590		10.1038/382589b0	http://dx.doi.org/10.1038/382589b0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757127				2022-12-24	WOS:A1996VC30300034
J	Fink, GR; Halligan, PW; Marshall, JC; Frith, CD; Frackowiak, RSJ; Dolan, RJ				Fink, GR; Halligan, PW; Marshall, JC; Frith, CD; Frackowiak, RSJ; Dolan, RJ			Where in the brain does visual attention select the forest and the trees?	NATURE			English	Article							HUMANS; CORTEX; AREAS; ORGANIZATION; STIMULI; V2	THE perceptual world is organized hierarchically: the forest consists of trees, which in turn have leaves, Visual attention can emphasize the overall picture (global form) or the focal details of a scene (local components)(1). Neuropsychological studies have indicated that the left hemisphere is biased towards local and the right towards global processing, The underlying attentional and perceptual mechanisms are maximally impaired by unilateral lesions to the temporal and parietal cortex(2,3). We measured brain activity of normal subjects during two experiments using 'hierarchically' organized figures, In a directed attention task, early visual processing (prestriate) areas were activated: attention to the global aspect of the figures activated the right lingual gyrus whereas locally directed attention activated the left inferior occipital cortex. In a subsequent divided attention task, the number of target switches from local to global (and vice versa) covaried with temporal-parietal activation, The findings provide direct evidence for hemispheric specialization in global and local perception; furthermore, they indicate that temporal-parietal areas exert attentional control over the neural transformations occurring in prestriate cortex.	INST NEUROL,WELLCOME DEPT COGNIT NEUROL,LONDON WC1N 3BG,ENGLAND; RIVERMEAD REHABIL CTR,OXFORD OX1 4XD,ENGLAND; RADCLIFFE INFIRM,UNIV DEPT CLIN NEUROL,NEUROPSYCHOL UNIT,OXFORD OX2 6HE,ENGLAND; ROYAL FREE HOSP,SCH MED,LONDON NW3 2PF,ENGLAND	University of London; University College London; Radcliffe Infirmary; University of Oxford; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Fink, Gereon R./AFW-9377-2022; Frackowiak, Richard/H-4383-2011; Fink, Gereon R./E-1616-2012; Frackowiak, Richard S/I-1809-2013; Halligan, Peter W/A-1669-2010; Frith, Chris D/A-2171-2009	Fink, Gereon R./0000-0002-8230-1856; Frackowiak, Richard/0000-0002-3151-822X; Fink, Gereon R./0000-0002-8230-1856; Halligan, Peter W/0000-0003-2784-6690; Frith, Chris D/0000-0002-8665-0690; Dolan, Ray/0000-0001-9356-761X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CLARKE S, 1994, EUR J NEUROSCI, V6, P725, DOI 10.1111/j.1460-9568.1994.tb00984.x; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; Friston K, 1995, HUM BRAIN MAPP, V2, P1; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; Hellige J. B., 1993, HEMISPHERIC ASYMMETR; MARSHALL JC, 1995, NATURE, V373, P521, DOI 10.1038/373521a0; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; POLSTER MR, 1994, CORTEX, V30, P487, DOI 10.1016/S0010-9452(13)80344-9; Rafal Robert, 1995, P625; ROBERTSON LC, 1988, J NEUROSCI, V8, P3757; ROBERTSON LC, 1991, COGNITIVE PSYCHOL, V23, P299, DOI 10.1016/0010-0285(91)90012-D; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; SHIPP S, 1995, NEUROIMAGE, V2, P125, DOI 10.1006/nimg.1995.1015; SILBERSWEIG DA, 1993, J CEREBR BLOOD F MET, V13, P617, DOI 10.1038/jcbfm.1993.80; Talairach J., 1988, COPLANAR STEREOTAXIC; TIPPER SP, 1994, Q J EXP PSYCHOL-A, V47, P809, DOI 10.1080/14640749408401098	19	503	514	6	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					626	628		10.1038/382626a0	http://dx.doi.org/10.1038/382626a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VC303	8757132	Green Submitted			2022-12-24	WOS:A1996VC30300052
J	Sorensen, TIA				Sorensen, TIA			Which patients may be harmed by good treatments?	LANCET			English	Editorial Material							METAANALYSIS; CIRRHOSIS; TRIALS				Sorensen, TIA (corresponding author), UNIV COPENHAGEN HOSP,INST PREVENT MED,COPENHAGEN TRIAL UNIT,DK-2100 COPENHAGEN,DENMARK.							CHRISTENSEN E, 1985, GASTROENTEROLOGY, V88, P156, DOI 10.1016/S0016-5085(85)80148-7; Horwitz RI, 1996, J CLIN EPIDEMIOL, V49, P395, DOI 10.1016/0895-4356(95)00058-5; LAU J, 1995, J CLIN EPIDEMIOL, V48, P45, DOI 10.1016/0895-4356(94)00106-Z; MOLLER S, 1992, J HEPATOL, V15, P184, DOI 10.1016/0168-8278(92)90034-M; PAGLIARO L, 1992, ANN INTERN MED, V117, P59, DOI 10.7326/0003-4819-117-1-59; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; 1974, NEW ENGL J MED, V291, P271	7	13	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					351	352		10.1016/S0140-6736(05)64988-4	http://dx.doi.org/10.1016/S0140-6736(05)64988-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709730				2022-12-24	WOS:A1996VB42600006
J	Bergan, JJ				Bergan, JJ			New technology and recurrent varicose veins	LANCET			English	Editorial Material											Bergan, JJ (corresponding author), SCRIPPS CLIN & HOSP,LA JOLLA,CA 92037, USA.							BRADBURY AW, 1994, BRIT J SURG, V81, P373, DOI 10.1002/bjs.1800810316; BRADBURY AW, 1993, BRIT J SURG, V80, P373; DARKE SG, 1992, EUR J VASCULAR SURG, V6, P512, DOI 10.1016/S0950-821X(05)80626-7; JAKOBSEN BH, 1979, BRIT J SURG, V66, P182, DOI 10.1002/bjs.1800660313; Khaira HS, 1996, ANN ROY COLL SURG, V78, P139; Labropoulos N, 1996, SURGERY, V119, P406, DOI 10.1016/S0039-6060(96)80140-1; MUNN SR, 1981, BRIT J SURG, V68, P426, DOI 10.1002/bjs.1800680621; ODONNELL TF, 1977, ARCH SURG-CHICAGO, V112, P31; PHILLIPS GWL, 1995, CLIN RADIOL, V50, P20, DOI 10.1016/S0009-9260(05)82960-5; Sales CM, 1996, ANN VASC SURG, V10, P186, DOI 10.1007/BF02000764; Walsh J C, 1994, Ann Vasc Surg, V8, P566, DOI 10.1007/BF02017413	11	15	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 27	1996	348	9022					210	211		10.1016/S0140-6736(05)65541-9	http://dx.doi.org/10.1016/S0140-6736(05)65541-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ286	8684195				2022-12-24	WOS:A1996UZ28600005
J	vonKries, R; Gobel, U; Hachmeister, A; Kaletsch, U; Michaelis, J				vonKries, R; Gobel, U; Hachmeister, A; Kaletsch, U; Michaelis, J			Vitamin K and childhood cancer: A population based case-control study in Lower Saxony, Germany	BRITISH MEDICAL JOURNAL			English	Article								Objective-To confirm or refute a possible association of parenteral vitamin K prophylaxis and childhood cancer. Design-Population based case-control study. Comparison of vitamin K exposure in children with leukaemia or other common tumours with two control groups. Setting-State of Lower Saxony (north western part of Germany); case recruitment from the German childhood cancer registry. Subjects-272 children with leukaemia, nephroblastoma, neuroblastoma, rhabdomyosarcoma, and tumours of the central nervous system diagnosed between 1 July 1988 and 30 June 1993; children were aged between 30 days and 15 years at diagnosis. 334 population based controls without diagnoses of cancer matched to the leukaemia cases for age and sex. Main exposure measures-Parenteral vitamin K prophylaxis (intramuscular and subcutaneous) versus oral and no vitamin K prophylaxis. Results-An association between parenteral vitamin K exposure and childhood cancer (leukaemias and other tumours combined) could not be confirmed (odds ratio 1.04, 95% confidence interval 0.74 to 1.48). For leukaemias the observed odds ratio was only 0.98 (0.64 to 1.50) (comparison of leukaemia cases with local controls 1.24 (0.68 to 2.25); state controls 0.82 (0.50 to 1.36)). These odds ratios remained almost unchanged when several potential confounders were considered in the logistic regression model. Conclusions-This population based study adds substantial evidence that there is no association between parenteral vitamin K and childhood cancer.	UNIV DUSSELDORF,KINDERKLIN,D-40225 DUSSELDORF,GERMANY; UNIV MAINZ,INST MED STAT & DOKUMENTAT,D-55131 MAINZ,GERMANY	Heinrich Heine University Dusseldorf; Johannes Gutenberg University of Mainz								DRAPER G, 1994, BRIT MED J, V308, P867, DOI 10.1136/bmj.308.6933.867; DRAPER GJ, 1992, BRIT MED J, V305, P709, DOI 10.1136/bmj.305.6855.709; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; KAATSCH P, 1995, EUR J CANCER, V31A, P993, DOI 10.1016/0959-8049(95)00091-7; KAATSCH P, IN PRESS CLIN PAEDIA; KALETSCH U, 1995, FALLKONTROLL STUDIE; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; MILLER RW, 1992, BMJ-BRIT MED J, V305, P1016, DOI 10.1136/bmj.305.6860.1016-c; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; PASSMORE SJ, 1993, BRIT MED J, V307, P1140, DOI 10.1136/bmj.307.6912.1140; *SAS I, 1992, P229 SAS STAT; SAS Institute, 1990, SAS STAT US GUID, V2; 1986, DTSCH ARZTEBLATT, V83, P3380	14	36	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 27	1996	313	7051					199	203		10.1136/bmj.313.7051.199	http://dx.doi.org/10.1136/bmj.313.7051.199			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA126	8696195	Green Published			2022-12-24	WOS:A1996VA12600024
J	Pontieri, FE; Tanda, G; Orzi, F; DiChiara, G				Pontieri, FE; Tanda, G; Orzi, F; DiChiara, G			Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs	NATURE			English	Article							CEREBRAL GLUCOSE-UTILIZATION; FREELY MOVING RATS	THE question of whether nicotine, the neuroactive compound of tobacco, is addictive has been open to considerable scientific and public discussion. Although it can serve as a positive reinforcer in several animal species, including man, nicotine is thought to be a weak reinforcer in comparison with addictive drugs such as cocaine and heroin(1,2), and has been argued to be habit forming but not addictive(3,4). Here we report that intravenous nicotine in the rat, at doses known to maintain self-administration, stimulates local energy metabolism, as measured by 2-deoxyglucose autoradiography, and dopamine transmission, as estimated by brain microdialysis, in the shell of the nucleus accumbens. These neurochemical and metabolic effects are qualitatively similar to those of other drugs, such as cocaine, amphetamine and morphine, which have strong addictive properties(5-7). Our results provide functional and neurochemical evidence that there are specific neurobiological commonalities between nicotine and addictive drugs.	UNIV CAGLIARI, DEPT TOXICOL, I-09126 CAGLIARI, ITALY; UNIV ROMA LA SAPIENZA, DEPT NEUROSCI, I-00185 ROME, ITALY; INM NEUROMED, POZILLI, IS, ITALY	University of Cagliari; Sapienza University Rome; IRCCS Neuromed			Di Chiara, Gaetano/I-7835-2013; Tanda, Gianluigi/B-3318-2009; Tanda, Gianluigi/Q-4976-2019; PONTIERI, FRANCESCO ERNESTO/K-4232-2018	Tanda, Gianluigi/0000-0001-9526-9878; Tanda, Gianluigi/0000-0001-9526-9878; PONTIERI, FRANCESCO ERNESTO/0000-0002-8693-8432; Orzi, Francesco/0000-0003-1048-4662				ALHEID GF, 1988, NEUROSCIENCE, V27, P1, DOI 10.1016/0306-4522(88)90217-5; CORRIGALL WA, 1989, PSYCHOPHARMACOLOGY, V99, P473, DOI 10.1007/BF00589894; CORRIGALL WA, 1991, ADV PHAR SC, P423; CRANE AM, 1989, BRAIN RES, V499, P87, DOI 10.1016/0006-8993(89)91137-2; DAMSMA G, 1989, EUR J PHARMACOL, V168, P368; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DICHIARA G, 1990, TRENDS PHARMACOL SCI, V11, P116, DOI 10.1016/0165-6147(90)90197-G; DICHIARA G, 1995, DRUG ALCOHOL DEPEN, V38, P95, DOI 10.1016/0376-8716(95)01118-I; GRUNWALD F, 1987, BRAIN RES, V400, P232, DOI 10.1016/0006-8993(87)90622-6; HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y; HENNINGFIELD JE, 1995, PSYCHOPHARMACOLOGY, V117, P11, DOI 10.1007/BF02245089; IMPERATO A, 1986, EUR J PHARMACOL, V132, P337, DOI 10.1016/0014-2999(86)90629-1; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LONDON ED, 1988, J NEUROSCI, V8, P3920; MCNAMARA D, 1990, J CEREBR BLOOD F MET, V10, P48, DOI 10.1038/jcbfm.1990.7; ORZI F, IN PRESS EUR J PHARM; PAXINOS G, 1987, RAT BRAIN STEREOTAXI; Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304; PONTIERI FE, 1994, NEUROREPORT, V5, P2561, DOI 10.1097/00001756-199412000-00039; PORRINO LJ, 1993, PSYCHOPHARMACOLOGY, V112, P343, DOI 10.1007/BF02244931; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P397, DOI 10.1007/BF02247412; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STOLERMAN IP, 1987, HDB PSYCHOPHARMACOLO, P421; SWEDBERG MDB, 1990, NICOTINE PSYCHOPHARM, P38; TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147; Ungerstedt U, 1984, MEASUREMENT NEUROTRA, P81; WARBURTON DM, 1989, PHARM NICOTINE, P359; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469	28	844	874	1	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					255	257		10.1038/382255a0	http://dx.doi.org/10.1038/382255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717040				2022-12-24	WOS:A1996UX79000050
J	Riek, R; Hornemann, S; Wider, G; Billeter, M; Glockshuber, R; Wuthrich, K				Riek, R; Hornemann, S; Wider, G; Billeter, M; Glockshuber, R; Wuthrich, K			NMR structure of the mouse prion protein domain PrP(121-231)	NATURE			English	Article							DISEASES	THE 'protein only' hypothesis(1) states that a modified form of normal prion protein triggers infectious neurodegenerative diseases, such as bovine spongiform encephalopathy (BSE), or Creutzfeldt-Jakob disease (CJD) in humans(2-4). Prion proteins are thought to exist in two different conformations(5): the 'benign' PrPC form, and the infections 'scrapie form', PrPSc. Knowledge of the three-dimensional structure of PrPC is essential for understanding the transition to PrPSc. The nuclear magnetic resonance (NMR) structure of the autonomously folding PrP domain comprising residues 121-231 (ref. 6) contains a two-stranded antiparallel beta-sheet and three alpha-helices. This domain contains most of the point-mutation sites that have been linked, in human PrP, to the occurrence of familial prion diseases(7). The NMR structure shows that these mutations occur within, or directly adjacent to, regular secondary structures, The presence of a beta-sheet in PrP(121-231) is in contrast with model predictions of an all-helical structure of PrPC (ref. 8), and may be important for the initiation of the transition from PrPC to PrPSc.	ETH HONGGERBERG,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich			Billeter, Martin/A-8293-2010	Wider, Gerhard/0000-0001-9366-7645; Riek, Roland/0000-0002-6333-066X				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Cavanagh J., 1996, PROTEIN NMR SPECTROS; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; CORNELL, 1995, J AM CHEM SOC, V117, P5179; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HORNEMANN S, IN PRESS J MOL BIOL; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, ARCH NEUROL-CHICAGO, V50, P1129, DOI 10.1001/archneur.1993.00540110011002; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; SCHATZL HM, 1995, J MOL BIOL, V245, P362, DOI 10.1006/jmbi.1994.0030; STAHL N, 1991, FASEB J, V5, P2799, DOI 10.1096/fasebj.5.13.1916104; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; WEISSMANN C, 1995, NATURE, V375, P628, DOI 10.1038/375628a0; Weissmann Charles, 1994, Trends in Cell Biology, V4, P10, DOI 10.1016/0962-8924(94)90032-9; Wuthrich K., 1986, NMR PROTEINS NUCL AC	26	1021	1044	1	122	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					180	182		10.1038/382180a0	http://dx.doi.org/10.1038/382180a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700211				2022-12-24	WOS:A1996UW67200054
J	Rieder, HL				Rieder, HL			Repercussions of the Karonga prevention trial for tuberculosis control	LANCET			English	Editorial Material											Rieder, HL (corresponding author), INT UNION AGAINST TB & LUNG DIS,68 BLVD ST MICHEL,F-75006 PARIS,FRANCE.							[Anonymous], 1995, Wkly Epidemiol Rec, V70, P229; Baily G V, 1980, Indian J Med Res, V72 Suppl, P1; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; 1980, LANCET, V1, P73	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					4	4		10.1016/S0140-6736(05)64349-8	http://dx.doi.org/10.1016/S0140-6736(05)64349-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691932				2022-12-24	WOS:A1996UV92300004
J	Rousset, R; Desbois, C; Bantignies, F; Jalinot, P				Rousset, R; Desbois, C; Bantignies, F; Jalinot, P			Effects on NF-kappa B1/p105 processing of the interaction between the HTLV-1 transactivator tax and the proteasome	NATURE			English	Article							NF-KAPPA-B; THERMOPLASMA-ACIDOPHILUM; PRECURSOR P105; EXPRESSION; PROTEINS; PRODUCT; SUBUNIT; YEAST; GENE; LOCALIZATION	THE viral Tax protein, which is encoded by human T-cell leukaemia virus HTLV-I, activates nuclear translocation of the NF-kappa B/Rel transcription factors and relieves cytoplasmic sequestration of RelA and Rel by heterodimerizatian with NF-kappa B1/p105 (refs 1,2). Proleolytic maturation of this precursor protein is performed by the proteasome complex(3,4). Here we show that Tax binds specifically to two subunits of the 20S proteasome, HsN3 and HC9. This Interaction is weakened with HsN3 and last for HC9 when a mutant of Tax is substituted that is selectively defective for NF-kappa B activation. Immunoprecipitation shows that p105 binds weakly to HC9 and that this interaction is reinforced by Tax. No bridging function of Tax between p105 and HsN3 was observed. From these results, we propose that Tax accelerates the proteolytic maturation of p105 by favouring its anchorage to the proteasome.	ECOLE NORMALE SUPER LYON,CNRS,UMR 49,F-69364 LYON 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)			Rousset, Raphael/E-5908-2017; Morris, Christelle/M-8168-2014	Rousset, Raphael/0000-0002-4999-403X; Morris, Christelle/0000-0003-1575-4609				BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CRENON I, 1993, ONCOGENE, V8, P867; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; HIRAI H, 1992, ONCOGENE, V7, P1737; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOPP F, 1995, J MOL BIOL, V248, P264; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Miller J.H., 1972, EXPT MOL GENETICS; MUNOZ E, 1994, J VIROL, V68, P8035; NOTHWANG HG, 1994, BBA-GENE STRUCT EXPR, V1219, P361, DOI 10.1016/0167-4781(94)90060-4; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; WATANABE M, 1993, ONCOGENE, V8, P2949; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79	30	125	129	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					328	331		10.1038/381328a0	http://dx.doi.org/10.1038/381328a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692272				2022-12-24	WOS:A1996UM40300058
J	Gold, DR; Wang, XB; Wypij, D; Speizer, FE; Ware, JH; Dockery, DW				Gold, DR; Wang, XB; Wypij, D; Speizer, FE; Ware, JH; Dockery, DW			Effects of cigarette smoking on lung function in adolescent boys and girls	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY-FUNCTION GROWTH; CHILDREN; SMOKERS; SPLINES; HEALTH; AGE; ADULTS	Background Little is known about the sex-specific effects of cigarette smoking on the level and growth of lung function in adolescence, when 71 percent of people in the United States who smoke tried their first cigarette. Methods We studied the effects of cigarette smoking on the level and rate of growth of pulmonary function in a cohort of 5158 boys and 4902 girls 10 to 18 years of age, examined annually between 1974 and 1989 in six cities in the United States. Results We found a dose-response relation between smoking and lower levels of both the ratio of forced expiratory volume in one second to forced vital capacity (FEV(1)/FVC) and the forced expiratory flow between 25 and 75 percent of FVC (FEF(25-75)). Each pack per day of smoking was associated with a 3.2 percent reduction in FEF(25-75) for girls (P=0.01) and a 3.5 percent reduction in FEF(25-75) for boys (P=0.007). Whereas the FVC level was elevated in smokers, the rate of growth of FVC and FEV(1) was reduced. Among adolescents of the same sex, smoking five or more cigarettes a day, as compared with never smoking, was associated with 1.09 percent slower growth of FEV(1) per year in girls (95 percent confidence interval, 0.70 to 1.47 percent) and 0.20 percent slower growth in boys (95 percent confidence interval, -0.16 to 0.56 percent), and with 1.25 percent slower growth of FEF(25-75) per year in girls (95 percent confidence interval, 0.38 to 2.13 percent) and 0.93 percent slower growth in boys (95 percent confidence interval, 0.21 to 1.65 percent). Whereas girls who did not smoke reached a plateau in lung function at 17 to 18 years of age, girls of the same age who smoked had a decline of FEV(1) and FEF(25-75). Conclusions Cigarette smoking is associated with evidence of mild airway obstruction and slowed growth of lung function in adolescents. Adolescent girls may be more vulnerable than boys to the effects of smoking on the growth of lung function.	HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Gold, DR (corresponding author), BRIGHAM & WOMENS HOSP,CHANNING LAB,DEPT MED,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		, dwdockery/AAO-7272-2021	Wypij, David/0000-0001-8367-8711; Dockery, Douglas/0000-0002-6052-4880	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES001108] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES01108] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON DO, 1965, CAN MED ASSOC J, V92, P1066; CHALON J, 1971, J AMER MED ASSOC, V218, P1928, DOI 10.1001/jama.218.13.1928; CHEN Y, 1991, AM REV RESPIR DIS, V143, P1224, DOI 10.1164/ajrccm/143.6.1224; *DEP HLTH HUM SERV, 1989, DHHS PUBL; *DEP HLTH HUM SERV, 1994, PREV TOB US YOUNG PE; *DEP HLTH HUM SERV, 1980, HLTH CONS SMOK WOM R; DOCKERY DW, 1988, AM REV RESPIR DIS, V137, P286, DOI 10.1164/ajrccm/137.2.286; FERRIS BG, 1979, AM REV RESPIR DIS, V120, P767; FERRIS BG, 1968, ARCH ENVIRON HEALTH, V16, P541, DOI 10.1080/00039896.1968.10665102; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10, DOI 10.1164/ajrccm/148.1.10; HAYASHI M, 1977, AM REV RESPIR DIS, V115, P595; HAYASHI M, 1978, CHEST, V73, P515, DOI 10.1378/chest.73.4.515; KANNER RE, 1994, AM J RESP CRIT CARE, V150, P956, DOI 10.1164/ajrccm.150.4.7921469; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MACKLEM PT, 1974, AM REV RESPIR DIS, V109, P567; PETERS JM, 1967, AM REV RESPIR DIS, V95, P774; SMITH PL, 1979, AM STAT, V33, P57, DOI 10.2307/2683222; TAGER IB, 1985, AM REV RESPIR DIS, V131, P752; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; WALTER S, 1979, AM REV RESPIR DIS, V119, P717; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204; WANG XB, 1993, AM REV RESPIR DIS, V148, P1502, DOI 10.1164/ajrccm/148.6_Pt_1.1502; WANG XB, 1994, AM J RESP CRIT CARE, V149, P1420, DOI 10.1164/ajrccm.149.6.8004293; WARE JH, 1984, AM REV RESPIR DIS, V129, P366; WEGMAN EJ, 1983, J AM STAT ASSOC, V78, P351, DOI 10.2307/2288640; WRIGHT JL, 1992, AM REV RESPIR DIS, V146, P240, DOI 10.1164/ajrccm/146.1.240; WYPIJ D, 1993, STAT SINICA, V3, P329; XU XP, 1992, AM REV RESPIR DIS, V146, P1345, DOI 10.1164/ajrccm/146.5_Pt_1.1345; ZAMEL N, 1983, J ASTHMA, V20, P307, DOI 10.3109/02770908309077089	29	319	330	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1996	335	13					931	937		10.1056/NEJM199609263351304	http://dx.doi.org/10.1056/NEJM199609263351304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK148	8782500	Bronze			2022-12-24	WOS:A1996VK14800004
J	Dale, N; Gilday, D				Dale, N; Gilday, D			Regulation of rhythmic movements by purinergic neurotransmitters in frog embryos	NATURE			English	Article							SWIMMING MOTOR PATTERN; XENOPUS-EMBRYOS; SPINAL-CORD; RESPONSES; STIMULATION; GENERATION; INVITRO	MANY rhythmic motor behaviours, including swimming(1), walking(2) scratching(3), swallowing(4), micturition(5) and sexual climax(6), are episodic: even in the absence of sensory inputs they exhibit a gradual run-down in frequency before spontaneously terminating. We have investigated whether the purinergic transmitters, ATP and adenosine, control run-down of swimming in the Xenopus embryo(7). By using specific agonists and antagonists for the purinergic receptors, we have shown that ATP (or a related substance) is released during swimming and activates P2y receptors to reduce voltage-gated K+ currents and cause an increase in the excitability of the spinal motor circuits. Adenosine is also produced during motor activity, possibly through the actions of ectonucleotidases. The activation by adenosine of P1 receptors reduces the voltage-gated Ca2+ currents, lowers excitability of the motor circuits, and so opposes the actions of ATP. A gradually changing balance between ATP and adenosine therefore seems to underlie the run-down of the motor pattern for swimming in Xenopus. We believe this to be the first time that ATP and adenosine have been found to be involved in motor pattern these two may offer a general feedback mechanism that underlies run down of all episodic motor patterns in vertebrates.	UNIV BRISTOL, SCH BIOL SCI, BRISTOL BS8 1UG, AVON, ENGLAND	University of Bristol	Dale, N (corresponding author), UNIV ST ANDREWS, SCH BIOL & MED SCI, BUTE MED BLDG, ST ANDREWS KY16 9RU, FIFE, SCOTLAND.		Dale, Nicholas/C-7772-2011	Dale, Nicholas/0000-0003-2196-2949				Dale N, 1995, J PHYSIOL-LONDON, V489, P489, DOI 10.1113/jphysiol.1995.sp021067; DALE N, 1991, EUR J NEUROSCI, V3, P1025, DOI 10.1111/j.1460-9568.1991.tb00039.x; Dale N, 1995, J PHYSIOL-LONDON, V489, P473, DOI 10.1113/jphysiol.1995.sp021066; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GORDON EL, 1986, J BIOL CHEM, V261, P5496; HOYLE CHV, 1990, BRIT J PHARMACOL, V99, P617, DOI 10.1111/j.1476-5381.1990.tb12979.x; IWAHARA T, 1991, SOMATOSENS MOT RES, V8, P281, DOI 10.3109/08990229109144751; JEAN A, 1984, J AUTONOM NERV SYST, V10, P225, DOI 10.1016/0165-1838(84)90017-1; KAHN JA, 1982, J EXP BIOL, V99, P185; LAMBRECHT G, 1992, EUR J PHARMACOL, V217, P217, DOI 10.1016/0014-2999(92)90877-7; MCCLELLAN AD, 1983, BRAIN RES, V269, P237, DOI 10.1016/0006-8993(83)90133-6; MCKENNA KE, 1991, AM J PHYSIOL, V261, pR1276, DOI 10.1152/ajpregu.1991.261.5.R1276; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; ROBERTSON GA, 1985, J NEUROPHYSIOL, V53, P1517, DOI 10.1152/jn.1985.53.6.1517; SHEFCHYK SJ, 1989, NEUROSCI LETT, V99, P175, DOI 10.1016/0304-3940(89)90285-1; WALL MJ, 1994, J NEUROPHYSIOL, V72, P337, DOI 10.1152/jn.1994.72.1.337; WALL MJ, 1995, J PHYSIOL-LONDON, V487, P557, DOI 10.1113/jphysiol.1995.sp020900	17	107	108	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 19	1996	383	6597					259	263		10.1038/383259a0	http://dx.doi.org/10.1038/383259a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805702				2022-12-24	WOS:A1996VH31500054
J	Knight, SC; Patterson, S				Knight, SC; Patterson, S			AIDS - Beyond helper T cells	LANCET			English	Editorial Material							RESPONSES				Knight, SC (corresponding author), NORTHWICK PK INST MED RES,UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,HARROW HA1 3UJ,MIDDX,ENGLAND.							HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Knight SC, 1996, AIDS, V10, P807, DOI 10.1097/00002030-199607000-00003; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; ROWLANDJONES SL, 1995, CURR OPIN IMMUNOL, V7, P448, DOI 10.1016/0952-7915(95)80087-5; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; ZINKERNAGEL RM, 1995, CURR OPIN IMMUNOL, V7, P462, DOI 10.1016/0952-7915(95)80089-1	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					631	631		10.1016/S0140-6736(05)65070-2	http://dx.doi.org/10.1016/S0140-6736(05)65070-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782750				2022-12-24	WOS:A1996VF60900005
J	Conley, KE; Lindstedt, SL				Conley, KE; Lindstedt, SL			Minimal cost per twitch in rattlesnake tail muscle	NATURE			English	Article							INSECT MUSCLE; P-31 NMR; FLIGHT; ENERGETICS; MORPHOLOGY; EFFICIENCY; FREQUENCY; CAPACITY; OXYGEN; POWER	SOUND production is one of the most energetically costly activities in animals(1), Minimizing contraction costs is one means of achieving the high activation rates necessary for sound production (20-550 Hz) (refs 1-3) without exceeding energy supplies. Rattlesnakes produce a sustained, high-frequency warning sound by extremely rapid contraction of their tailshaker muscles (20-90 Hz) (refs 4, 5), The ATP cost per twitch is only 0.015 pmol ATP per g muscle per twitch during rattling, as measured by in vivo magnetic resonance. The reduced volume density of myofibre (32%) in tailshaker muscle is consistent with contraction cost being minimized (crossbridge cycling), in contrast to the con tractile costs of vertebrate locomotory and asynchronous insect flight muscle, Thus tailshaker muscle is an example of sound-producing muscle designed for 'high frequency, minimal cost'. The high rates of rattling are achieved by minimizing contractile use of ATP, which reduces the cost per twitch to among the lowest found for striated muscle.	UNIV WASHINGTON,MED CTR,CTR BIOENGN,SEATTLE,WA 98195; NO ARIZONA UNIV,DEPT BIOL SCI,PHYSIOL & FUNCT MORPHOL GRP,FLAGSTAFF,AZ 86011	University of Washington; University of Washington Seattle; Northern Arizona University	Conley, KE (corresponding author), UNIV WASHINGTON,MED CTR,DEPT RADIOL,BOX 357115,SEATTLE,WA 98195, USA.							ADAMS GR, 1990, J APPL PHYSIOL, V69, P968, DOI 10.1152/jappl.1990.69.3.968; BARTHOLOMEW GA, 1978, J EXP BIOL, V76, P11; BLEI ML, 1993, J PHYSIOL-LONDON, V465, P203, DOI 10.1113/jphysiol.1993.sp019673; Casey T. M., 1989, ENERGY TRANSFORMATIO, P200; CASEY TM, 1985, J EXP BIOL, V116, P271; CHADWICK LE, 1954, SCIENCE, V119, P442, DOI 10.1126/science.119.3092.442; DICKINSON MH, 1995, SCIENCE, V268, P87, DOI 10.1126/science.7701346; ELLINGTON CP, 1991, J EXP BIOL, V160, P71; FOLEY JM, 1993, NMR BIOMED, V6, P32, DOI 10.1002/nbm.1940060106; GILMOUR KM, 1993, J EXP BIOL, V183, P101; HEINEMAN FW, 1990, J CLIN INVEST, V85, P843, DOI 10.1172/JCI114511; HOPPELER H, 1987, RESP PHYSIOL, V69, P27, DOI 10.1016/0034-5687(87)90099-5; JOSEPHSON RK, 1985, J EXP BIOL, V117, P357; JOSEPHSON RK, 1981, J EXP BIOL, V91, P219; JOSEPHSON RK, 1985, J EXP BIOL, V118, P185; JOSEPHSON RK, 1991, J PHYSIOL-LONDON, V442, P413, DOI 10.1113/jphysiol.1991.sp018800; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; KUSMERICK MJ, 1976, J PHYSIOL-LONDON, V254, P711; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; PRESTWICH KN, 1994, AM ZOOL, V34, P625, DOI 10.1093/icb/34.6.625; Rall J A, 1985, Exerc Sport Sci Rev, V13, P33; Schaeffer PJ, 1996, J EXP BIOL, V199, P351; SCHULTZ E, 1980, TISSUE CELL, V12, P323, DOI 10.1016/0040-8166(80)90008-7; SCHWERZMANN K, 1989, P NATL ACAD SCI USA, V86, P1583, DOI 10.1073/pnas.86.5.1583; STEVENS ED, 1977, PHYSIOL ZOOL, V50, P31, DOI 10.1086/physzool.50.1.30155713; STOKES DR, 1975, J EXP ZOOL, V194, P379, DOI 10.1002/jez.1401940205; TEAGUE WE, 1992, J BIOL CHEM, V267, P14084; TREGEAR R, 1993, HDB PHYSL SKELETAL M, P487	28	29	29	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					71	72		10.1038/383071a0	http://dx.doi.org/10.1038/383071a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779716				2022-12-24	WOS:A1996VF29500048
J	Xing, J; Ginty, DD; Greenberg, ME				Xing, J; Ginty, DD; Greenberg, ME			Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase	SCIENCE			English	Article							SERUM RESPONSE FACTOR; RIBOSOMAL S6 KINASE; C-FOS PROMOTER; PROTEIN-KINASE; IN-VIVO; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION; SEQUENCE; SPECIFICITY	A signaling pathway has been elucidated whereby growth factors activate the transcription factor cyclic adenosine monophosphate response element-binding protein (CREB), a critical regulator of immediate early gene transcription. Growth factor-stimulated CREB phosphorylation at serine-133 is mediated by the RAS-mitogen-activated protein kinase (MAPK) pathway. MAPK activates CREB kinase, which in turn phosphorylates and activates CREB. Purification, sequencing, and biochemical characterization of CREB kinase revealed that it is identical to a member of the pp90(RSK) family, RSK2. RSK2 was shown to mediate growth factor induction of CREB serine-133 phosphorylation both in vitro and in vivo. These findings identify a cellular function for RSK2 and define a mechanism whereby growth factor signals mediated by RAS and MAPK are transmitted to the nucleus to activate gene expression.	CHILDRENS HOSP,DEPT NEUROL,DIV NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02115; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Johns Hopkins University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034814, R01NS034814, R37NS034814] Funding Source: NIH RePORTER; NCI NIH HHS [CA43855] Funding Source: Medline; NICHD NIH HHS [P30-HD18655] Funding Source: Medline; NINDS NIH HHS [NS34814-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BJORBAEK C, 1995, DIABETES, V44, P90, DOI 10.2337/diabetes.44.1.90; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; Sambrook J., 1989, MOL CLONING; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; XING J, UNPUB; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	36	1062	1085	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					959	963		10.1126/science.273.5277.959	http://dx.doi.org/10.1126/science.273.5277.959			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688081				2022-12-24	WOS:A1996VC67000064
J	Murphy, FA				Murphy, FA			The public health risk of animal organ and tissue transplantation into humans	SCIENCE			English	Editorial Material							XENOTRANSPLANTATION				Murphy, FA (corresponding author), UNIV CALIF DAVIS, SCH VET MED, DAVIS, CA 95616 USA.							Altman L. K. (, 1994, NY TIMES, pA1; Buchmeier M., 1995, ARCH VIROL, V10, P350; CHAPMAN LE, 1995, NEW ENGL J MED, V333, P1498, DOI 10.1056/NEJM199511303332211; HOKE F, 1995, SCIENTIST, V9, P11; Institute of Medicine Committee on Xenograft Transplantation, 1996, XEN SCI ETH PUBL POL; MICHAELS MG, 1994, TRANSPLANTATION, V57, P1, DOI 10.1097/00007890-199401000-00001; MICHAELS MG, 1994, TRANSPLANTATION, V57, P1462, DOI 10.1097/00007890-199405270-00011; Michler RE, 1996, EMERG INFECT DIS, V2, P64, DOI 10.3201/eid0201.960111; OBrien C, 1996, SCIENCE, V271, P1357; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	18	41	43	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 9	1996	273	5276					746	747		10.1126/science.273.5276.746	http://dx.doi.org/10.1126/science.273.5276.746			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8701323				2022-12-24	WOS:A1996VB42900024
J	Nussenzweig, A; Chen, CH; Soares, VD; Sanchez, M; Sokol, K; Nussenzweig, MC; Li, GC				Nussenzweig, A; Chen, CH; Soares, VD; Sanchez, M; Sokol, K; Nussenzweig, MC; Li, GC			Requirement for Ku80 in growth and immunoglobulin V(D)J recombination	NATURE			English	Article							STRAND-BREAK-REPAIR; DEPENDENT PROTEIN-KINASE; DNA END-BINDING; CATALYTIC SUBUNIT; CELL-LINE; GENE; MICE; MUTANT; AUTOANTIGEN; SENSITIVITY	THE DNA-dependent protein kinase (DNA-PK) is a mammalian serine/threonine kinase that is implicated in the repair of DNA double-strand breaks(1-4), DNA replication(1,5), transcription(6-8), and V(D)J recombination(9-12). To determine the role of the DNA-binding subunit of DNA-PK in vivo, we targeted Ku80 in mice. In mutant mice, T and B lymphocyte development is arrested at early progenitor stages and there is a profound deficiency in V(D)J rearrangement. Although Ku80(-/-) mice are viable and reproduce, they are 40-60% of the size of littermate controls. Consistent with this growth defect, fibroblasts derived from Ku80(-/-) embryos showed an early loss of proliferating cells, a prolonged doubling time, and intact cell-cycle checkpoints that prevented cells with damaged DNA from entering the cell-cycle. The unexpected growth phenotype suggests a new and important link between Ku80 and growth control.	MEM SLOAN KETTERING CANC CTR,DEPT MED PHYS,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT RADIAT ONCOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,LAB MOL IMMUNOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,LAB ANIM RES CTR,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Nussenzweig, Michel/AAE-7292-2019					ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CARROLL AM, 1991, GENE DEV, V5, P1357, DOI 10.1101/gad.5.8.1357; CARROLL AM, 1993, MOL CELL BIOL, V13, P3623; Chen FQ, 1996, MUTAT RES-DNA REPAIR, V362, P9, DOI 10.1016/0921-8777(95)00026-7; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; Errami A, 1996, MOL CELL BIOL, V16, P1519; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GETTS RC, 1994, J BIOL CHEM, V269, P15981; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LI GC, 1995, P NATL ACAD SCI USA, V92, P4512, DOI 10.1073/pnas.92.10.4512; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WEIRICHSCHWAIGER H, 1994, MUTAT RES, V316, P37, DOI 10.1016/0921-8734(94)90006-X; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	29	551	564	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					551	555		10.1038/382551a0	http://dx.doi.org/10.1038/382551a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700231				2022-12-24	WOS:A1996VB25800054
J	Guo, S; Kemphues, KJ				Guo, S; Kemphues, KJ			A non-muscle myosin required for embryonic polarity in Caenorhabditis elegans	NATURE			English	Article							HEAVY-CHAIN FUNCTION; C-ELEGANS; CYTOPLASMIC LOCALIZATION; PROTEIN; GENES; DROSOPHILA; SEQUENCE; ENCODES; IDENTIFICATION; MICROFILAMENTS	DAUGHTER cells with distinct fates can arise through intrinsically asymmetrical divisions'. Before such divisions, factors crucial for determining cell fates become asymmetrically localized in the mother cell(2,3). In Caenorhabditis elegans, PAR proteins are required for the early asymmetrical divisions that establish embryonic polarity(4,8), and are asymmetrically localized in early blastomeres(9,10), although the mechanism of their distribution is not known. Here we report the identification in C. elegans of a nonmuscle myosin II heavy chain (designated NMY-2) by means of its interaction with the PAR-1 protein, a putative Ser/Thr protein kinase. Furthermore, injections of nmy-2 antisense RNA into ovaries of adult worms cause embryonic partitioning defects and lead to mislocalization of PAR proteins. We therefore conclude that NMY-2 is required for establishing cellular polarity in C. elegans embryos.	CORNELL UNIV,GENET & DEV SECT,ITHACA,NY 14853	Cornell University								BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; CHENG NN, 1995, GENETICS, V139, P549; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HILL DP, 1990, DEVELOPMENT, V108, P159; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KETCHUM AS, 1990, P NATL ACAD SCI USA, V87, P6316, DOI 10.1073/pnas.87.16.6316; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MORTON DG, 1992, GENETICS, V130, P771; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPUDICH JA, 1989, CELL REGUL, V1, P1; SULSTON J, 1983, DEV BIOL, V100, P67; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOUNG PE, 1993, GENE DEV, V7, P29, DOI 10.1101/gad.7.1.29	26	219	229	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					455	458		10.1038/382455a0	http://dx.doi.org/10.1038/382455a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684486				2022-12-24	WOS:A1996VA25100058
J	Heald, R; Tournebize, R; Blank, T; Sandaltzopoulos, R; Becker, P; Hyman, A; Karsenti, E				Heald, R; Tournebize, R; Blank, T; Sandaltzopoulos, R; Becker, P; Hyman, A; Karsenti, E			Self-organization of microtubules into bipolar spindles around artificial chromosomes in Xenopus egg extracts	NATURE			English	Article							CYTOPLASMIC DYNEIN; IDENTIFICATION; CENTROSOMES; KINESIN; LOCALIZATION; KINETOCHORES; CHROMATIN; POLARITY; MOTILITY; MITOSIS	Functional nuclei and mitotic spindles are shown to assemble around DNA-coated beads incubated in Xenopus egg extracts. Bipolar spindles assemble in the absence of centrosomes and kinetochores, indicating that bipolarity is an intrinsic property of microtubules assembling around chromatin in a mitotic cytoplasm. Microtubules nucleated at dispersed sites with random polarity rearrange into two arrays of uniform polarity. Spindle-pole formation requires cytoplasmic dynein-dependent translocation of microtubules across one another. It is proposed that spindles form in the absence of centrosomes by motor-dependent sorting of microtubules according to their polarity.	EUROPEAN MOLEC BIOL LAB, GENE EXPRESS PROGRAM, D-69117 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)	Heald, R (corresponding author), EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, MITOT SPINDLE GRP, MEYERHOFSTR 1, D-69117 HEIDELBERG, GERMANY.		Hyman, Tony/F-1923-2011; Tournebize, Regis/K-7847-2018	Tournebize, Regis/0000-0003-3718-3130; Heald, Rebecca/0000-0001-6671-6528				Albertson DG, 1993, CHROMOSOME RES, V1, P15, DOI 10.1007/BF00710603; BAJER AS, 1981, COLD SPRING HARB SYM, V46, P263; DOTEROM M, 1996, J CELL BIOL, V133, P125; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; HYMAN AA, 1991, J CELL SCI, P125; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; KARSENTI E, 1984, J CELL BIOL, V99, pS47, DOI 10.1083/jcb.99.1.47s; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lambert Anne Marie, 1994, V13, P325; LOURIM D, 1993, J CELL BIOL, V123, P501, DOI 10.1083/jcb.123.3.501; MCINTOSH JR, 1984, J CELL BIOL, V98, P525, DOI 10.1083/jcb.98.2.525; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; PELLMAN D, 1995, J CELL BIOL, V130, P1373, DOI 10.1083/jcb.130.6.1373; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; SANDALTZOPOULOS R, 1994, EMBO J, V13, P373, DOI 10.1002/j.1460-2075.1994.tb06271.x; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SHPETNER HS, 1988, J CELL BIOL, V107, P1001, DOI 10.1083/jcb.107.3.1001; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SWANSON CP, 1981, CYTOGENETICS, P494; TELZER BR, 1981, J CELL BIOL, V89, P373, DOI 10.1083/jcb.89.2.373; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VEMOS I, 1996, CURR OPIN CELL BIOL, V8, P4; VEMOS I, 1995, TRENDS CELL BIOL, V5, P297; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; ZHANG DH, 1995, J CELL BIOL, V129, P1287, DOI 10.1083/jcb.129.5.1287	34	772	778	2	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 1	1996	382	6590					420	425		10.1038/382420a0	http://dx.doi.org/10.1038/382420a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684481				2022-12-24	WOS:A1996VA25100047
J	Tian, GL; Huang, Y; Rommelaere, H; Vandekerckhove, J; Ampe, C; Cowan, NJ				Tian, GL; Huang, Y; Rommelaere, H; Vandekerckhove, J; Ampe, C; Cowan, NJ			Pathway leading to correctly folded beta-tubulin	CELL			English	Article							MICROTUBULE-MEDIATED PROCESSES; T-COMPLEX POLYPEPTIDE-1; FUNCTION IN-VIVO; CYTOPLASMIC CHAPERONIN; ALPHA-TUBULIN; PROTEIN; GROEL; SUBUNITS; RELEASE; TRANSLATION	We describe the complete beta-tubulin folding pathway. Folding intermediates produced via ATP-dependent interaction with cytosolic chaperonin undergo a sequence of interactions with four proteins (cofactors A, D, E, and C). The postchaperonin steps in the reaction cascade do not depend on ATP or GTP hydrolysis, although GTP plays a structural role in tubulin folding. Cofactors A and D function by capturing and stabilizing beta-tubulin in a quasi-native conformation. Cofactor E binds to the cofactor D-beta-tubulin complex; interaction with cofactor C then causes the release of beta-tubulin polypeptides that are committed to the native state. Sequence analysis identifies yeast homologs of cofactors D (cin1) and E (pac2), characterized by mutations that affect microtubule function.	NYU, MED CTR, DEPT BIOCHEM, NEW YORK, NY 10016 USA; STATE UNIV GHENT VIB, B-9000 GHENT, BELGIUM	New York University; Flanders Institute for Biotechnology (VIB); Ghent University			Ampe, Christophe/B-5534-2012					ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; ARCHER JE, 1995, CELL, V82, P425, DOI 10.1016/0092-8674(95)90431-X; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; CLEVELAND DW, 1978, CELL, V15, P1021, DOI 10.1016/0092-8674(78)90286-6; DETRICH HW, 1978, BIOCHEMISTRY-US, V17, P3900, DOI 10.1021/bi00612a002; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; FARR GW, 1990, P NATL ACAD SCI USA, V87, P5041, DOI 10.1073/pnas.87.13.5041; FONTALBA A, 1993, J CELL SCI, V106, P627; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; Lewis SA, 1996, J CELL BIOL, V132, P1, DOI 10.1083/jcb.132.1.1; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; MURPHY DB, 1977, BIOCHEMISTRY-US, V16, P2598, DOI 10.1021/bi00631a004; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PACIUCCI R, 1994, BIOCHEM J, V301, P105, DOI 10.1042/bj3010105; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; STEARNS T, 1990, GENETICS, V124, P251; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; YAFFE MB, 1988, J BIOL CHEM, V263, P16023; YAFFE MB, 1989, J BIOL CHEM, V264, P19045; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZABALA JC, 1992, CELL MOTIL CYTOSKEL, V23, P222, DOI 10.1002/cm.970230306	43	228	236	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					287	296		10.1016/S0092-8674(00)80100-2	http://dx.doi.org/10.1016/S0092-8674(00)80100-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706133	hybrid			2022-12-24	WOS:A1996UZ97200014
J	Wagner, N; Lohler, J; Kunkel, EJ; Ley, K; Leung, E; Krissansen, G; Rajewsky, K; Muller, W				Wagner, N; Lohler, J; Kunkel, EJ; Ley, K; Leung, E; Krissansen, G; Rajewsky, K; Muller, W			Critical role for beta 7 integrins in formation of the gut-associated lymphoid tissue	NATURE			English	Article							MUCOSAL IMMUNE-SYSTEM; ALPHA-CHAIN; DEFICIENT MICE; LYMPHOCYTES; POPULATIONS; ADHESION; CELLS; EXPRESSION; GENERATION; RECEPTOR	IMMUNE defence against pathogens entering the gut is accomplished by lymphocytes in the gut-associated lymphoid tissue (GALT), a major compartment of the immune system(1). The GALT, comprising Peyer's patches, lamina propria lymphocytes and intra-epithelial lymphocytes of the intestine, is populated by lymphocytes that migrate there from the vasculature(2,3). Here we report that, in mice deficient for the beta 7 integrin subfamily of adhesion molecules, the formation of the GALT is severely impaired. This is probably due to a failure of beta 7(-/-) lymphocytes to arrest and adhere to the vasculature at the site of transmigration into the GALT.	UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY; UNIV VIRGINIA, DEPT BIOMED ENGN, CHARLOTTESVILLE, VA 22908 USA; UNIV AUCKLAND, DEPT MOLEC MED, AUCKLAND, NEW ZEALAND	Heinrich Pette Institute; University of Hamburg; University of Virginia; University of Auckland	Wagner, N (corresponding author), UNIV COLOGNE, INST GENET, D-50937 COLOGNE, GERMANY.		Muller, Werner/B-9044-2008; Leung, Euphemia/D-2642-2009	Muller, Werner/0000-0002-1297-9725; Leung, Euphemia/0000-0002-6932-3188; Rajewsky, Klaus/0000-0002-6633-6370				ANDREW DP, 1994, J IMMUNOL, V153, P3847; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Arroyo AG, 1996, CELL, V85, P997, DOI 10.1016/S0092-8674(00)81301-X; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BRANDTZAEG P, 1989, CURR TOP MICROBIOL, V146, P13; BUTCHER EC, 1979, J IMMUNOL, V123, P1996; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARLOS TM, 1994, BLOOD, V84, P2068; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CERFBENSUSSAN N, 1992, EUR J IMMUNOL, V22, P273, DOI 10.1002/eji.1830220140; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; Griebel PJ, 1996, IMMUNOL TODAY, V17, P30, DOI 10.1016/0167-5699(96)80566-4; GUYGRAND D, 1992, EUR J IMMUNOL, V22, P505, DOI 10.1002/eji.1830220232; HAMANN A, 1994, J IMMUNOL, V152, P3282; Hirsch E, 1996, NATURE, V380, P171, DOI 10.1038/380171a0; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; KILSHAW PJ, 1991, EUR J IMMUNOL, V21, P2591, DOI 10.1002/eji.1830211041; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PODOLSKY DK, 1993, J CLIN INVEST, V92, P372, DOI 10.1172/JCI116575; ROCHA B, 1994, J EXP MED, V180, P681, DOI 10.1084/jem.180.2.681; SIM GK, 1994, INT IMMUNOL, V6, P1287, DOI 10.1093/intimm/6.9.1287; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUNDBERG JP, 1994, GASTROENTEROLOGY, V107, P1726, DOI 10.1016/0016-5085(94)90813-3; ZOU YR, 1993, EMBO J, V12, P811, DOI 10.1002/j.1460-2075.1993.tb05721.x	30	456	464	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 25	1996	382	6589					366	370		10.1038/382366a0	http://dx.doi.org/10.1038/382366a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684468				2022-12-24	WOS:A1996UY95000056
J	Mattingly, RR; Macara, IG				Mattingly, RR; Macara, IG			Phosphorylation-dependent activation of the Ras-GRF/CDC25(Mm) exchange factor by muscarinic receptors and G-protein beta gamma subunits	NATURE			English	Article							NUCLEOTIDE-RELEASING-FACTOR; MAP KINASE; RAS; PATHWAY; TRANSFORMATION; FIBROBLASTS; STIMULATION; HYPERTROPHY; P21(RAS); CLONING	MUSCARINIC receptors activate Ras through a pathway distinct(1,2) from that mediated through translocation of the exchange factor mSos1 by receptor tyrosine kinases(3'4). Here we report that muscarinic receptors can activate another Ras exchange factor, CDC25(Mm), or p140(Ras-GRF) (refs 5,6). In NIH-3T3 cells expressing subtype 1 human muscarinic receptors (hm1), the agonist carbachol selectively increased the specific activity and phosphorylation state of epitope-tagged Ras-GRF. This stimulation nas reversed by protein phosphatase 1 (PP1), and prevented by transducin alpha-subunits. Carbachol treatment of neonatal rat brain explants increased Ras exchange factor activity and the phosphorylation state of endogenous Ras-GRF. In COS-7 cells, cotransfection of hm1 or hm2 receptors with Ras-GRF conferred carbachol-dependent increases in exchange-factor activity, whereas cotransfection with G protein beta gamma subunits caused a constitutive activation that was sensitive to PP1. These results demonstrate a G-protein-coupled mechanism for Ras activation, mediated by p140R(Ras-GRF).	UNIV VERMONT,COLL MED,DEPT MICROBIOL & MOLEC GENET,BURLINGTON,VT 05405; VERMONT COMPREHENS CANC CTR,BURLINGTON,VT 05405	University of Vermont	Mattingly, RR (corresponding author), UNIV VERMONT,COLL MED,DEPT PATHOL,BURLINGTON,VT 05405, USA.							BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GRABER SG, 1992, J BIOL CHEM, V267, P13123; Guerrero C, 1996, ONCOGENE, V12, P1097; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HANLEY MR, 1989, NATURE, V340, P97, DOI 10.1038/340097a0; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LINNEMANN D, 1989, DISSECTION TISSUE CU, P75; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATTINGLY RR, 1992, J BIOL CHEM, V267, P7470; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAMIREZ MT, 1995, J BIOL CHEM, V270, P8446, DOI 10.1074/jbc.270.15.8446; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; THORBURN A, 1993, J BIOL CHEM, V268, P2244; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	30	155	157	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					268	272		10.1038/382268a0	http://dx.doi.org/10.1038/382268a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717044				2022-12-24	WOS:A1996UX79000054
J	Barlow, C; Hirotsune, S; Paylor, R; Liyanage, M; Eckhaus, M; Collins, F; Shiloh, Y; Crawley, JN; Ried, T; Tagle, D; WynshawBoris, A				Barlow, C; Hirotsune, S; Paylor, R; Liyanage, M; Eckhaus, M; Collins, F; Shiloh, Y; Crawley, JN; Ried, T; Tagle, D; WynshawBoris, A			Atm-deficient mice: A paradigm of ataxia telangiectasia	CELL			English	Article							WILD-TYPE P53; DOUBLE-STRAND BREAKS; CELL-CYCLE; P53-DEFICIENT MICE; GENE AMPLIFICATION; MOLECULAR ANALYSIS; GAMMA-IRRADIATION; DNA; RADIATION; TRANSLOCATION	A murine model of ataxia telangiectasia was created by disrupting the Atm locus via gene targeting. Mice homozygous for the disrupted Atm allele displayed growth retardation, neurologic dysfunction, male and female infertility secondary to the absence of mature gametes, defects in T lymphocyte maturation, and extreme sensitivity to gamma-irradiation. The majority of animals developed malignant thymic lymphomas between 2 and 4 months of age. Several chromosomal anomalies were detected in one of these tumors. Fibroblasts from these mice grew slowly and exhibited abnormal radiation-induced G1 checkpoint function. Atm-disrupted mice recapitulate the ataxia telangiectasia phenotype in humans, providing a mammalian model in which to study the pathophysiology of this pleiotropic disorder.	NATL INST HLTH,NATL CTR HUMAN GENOME RES,LAB GENE TRANSFER,BETHESDA,MD 20892; NATL INST HLTH,NATL CTR HUMAN GENOME RES,DIAGNOST DEV BRANCH,BETHESDA,MD 20892; NIMH,EXPTL THERAPEUT BRANCH,SECT BEHAV NEUROPHARMACOL,NATL INST HLTH,BETHESDA,MD 20892; NATL INST HLTH,NATL CTR RES RESOURCES,VET RESOURCES PROGRAM,BETHESDA,MD 20892; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 RAMAT AVIV,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; Tel Aviv University; Sackler Faculty of Medicine	Barlow, C (corresponding author), NATL INST HLTH,NATL CTR HUMAN GENOME RES,LAB GENET DIS RES,BETHESDA,MD 20892, USA.							ARTUSO M, 1995, ONCOGENE, V11, P1427; BAKER BS, 1972, GENETICS, V71, P255; BLOCHER D, 1991, INT J RADIAT BIOL, V60, P791, DOI 10.1080/09553009114552601; Boder E, 1975, Birth Defects Orig Artic Ser, V11, P255; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CARBONARI M, 1990, NEW ENGL J MED, V322, P73, DOI 10.1056/NEJM199001113220201; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; CLARKE AR, 1994, ONCOGENE, V9, P1767; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; COQUERELLE TM, 1987, INT J RADIAT BIOL, V51, P209, DOI 10.1080/09553008714550711; COX R, 1986, MOL BIOL MED, V3, P229; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; Harlow E, 1988, ANTIBODIES LAB MANUA; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; HEPPELL A, 1988, HUM GENET, V79, P360; Hogan B, 1994, MANIPULATING MOUSE E; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIU N, 1994, INT J RADIAT BIOL, V66, pS115, DOI 10.1080/09553009414551941; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luna L.G., 1992, HISTOPATHOLOGICAL ME; METCALFE JA, 1991, CYTOGENET CELL GENET, V56, P91, DOI 10.1159/000133057; MEYN MS, 1995, CANCER RES, V55, P5991; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; PECKER I, 1996, IN PRESS GENOMICS; POWELL S, 1993, MUTAT RES, V294, P9, DOI 10.1016/0921-8777(93)90053-J; PURDIE CA, 1994, ONCOGENE, V9, P603; RABBITTS P, 1995, NAT GENET, V9, P369, DOI 10.1038/ng0495-369; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Schrock E, 1996, HUM GENET, V97, P256, DOI 10.1007/BF02265277; SCHROCK E, 1996, IN PRESS SCIENCE; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; SHERRINGTON PD, 1994, ONCOGENE, V9, P2377; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; STERN MH, 1989, BLOOD, V74, P2076; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; TAYLOR AMR, 1981, INT J CANCER, V27, P311, DOI 10.1002/ijc.2910270309; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; THICK J, 1992, GENE CHROMOSOME CANC, V5, P321, DOI 10.1002/gcc.2870050407; TSUKADA T, 1993, ONCOGENE, V8, P3313; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	69	1203	1219	2	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1996	86	1					159	171		10.1016/S0092-8674(00)80086-0	http://dx.doi.org/10.1016/S0092-8674(00)80086-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689683	Bronze			2022-12-24	WOS:A1996UX93400017
J	DSouza, T; Dryer, SE				DSouza, T; Dryer, SE			A cationic channel regulated by a vertebrate intrinsic circadian oscillator	NATURE			English	Article							CHICK PINEAL CELLS; MELATONIN RHYTHM; PHOTOENDOCRINE TRANSDUCTION; CALCIUM INFLUX; CYCLIC-AMP; GLAND; LIGHT; GMP; PACEMAKER; CULTURE	SECRETORY cells of the chicken pineal gland exhibit light sensitive circadian rhythms in melatonin release that persist in vitro(1-12). Melatonin secretion is positively regulated by cyclic AMP and intracellular Ca2+ (refs 8, 10-15), Cyclic AMP analogues are more effective at stimulating melatonin secretion during the circadian night owing in part to increased Ca2+ influx at those times(12), However, this cannot be attributed to increased activity of L-type Ca2+ channels(12). Here we describe an unusual 40-pS cationic channel (I-LOT) in cultured chicken pineal cells that is permeable to Ca2+ and active in the night but not during the day, I-LOT is not voltage- or stretch-activated, it has a characteristically long open time, and its gating persists in excised inside-out patches in the absence of Ca2+ or cyclic nucleotides. Daily rhythms in I-LOT gating are also observed in previously entrained chicken pineal cells free-running under constant dark conditions. Nighttime I-LOT activity is not suppressed by brief Light pulses.	FLORIDA STATE UNIV, DEPT BIOL SCI, PROGRAM NEUROSCI, TALLAHASSEE, FL 32306 USA	State University System of Florida; Florida State University								DEGUCHI T, 1979, NATURE, V282, P94, DOI 10.1038/282094a0; DRYER SE, 1991, NATURE, V353, P756, DOI 10.1038/353756a0; DRYER SE, 1993, J COMP PHYSIOL A, V172, P271, DOI 10.1007/BF00216609; DSOUZA T, 1994, BRAIN RES, V656, P85, DOI 10.1016/0006-8993(94)91369-2; HARRISON NL, 1989, J NEUROSCI, V9, P2462; MICHEL S, 1993, SCIENCE, V259, P239, DOI 10.1126/science.8421785; NIKAIDO SS, 1989, NEURON, V3, P609, DOI 10.1016/0896-6273(89)90271-7; NIKAIDO SS, IN PRESS BRAIN RES; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROBERTSON LM, 1988, J NEUROSCI, V8, P22; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6; ZATZ M, 1989, BRAIN RES, V477, P14, DOI 10.1016/0006-8993(89)91389-9; ZATZ M, 1988, BRAIN RES, V463, P305; ZATZ M, 1988, BRAIN RES, V438, P199, DOI 10.1016/0006-8993(88)91339-X; ZATZ M, 1992, J BIOL RHYTHM, V7, P301, DOI 10.1177/074873049200700404; ZATZ M, 1988, BRAIN RES, V453, P51, DOI 10.1016/0006-8993(88)90142-4; ZATZ M, 1988, BRAIN RES, V450, P137, DOI 10.1016/0006-8993(88)91553-3; ZAWILSKA JB, 1990, NEUROSCI LETT, V118, P17, DOI 10.1016/0304-3940(90)90238-5	19	40	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	1996	382	6587					165	167		10.1038/382165a0	http://dx.doi.org/10.1038/382165a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700206				2022-12-24	WOS:A1996UW67200049
J	Cole, AP; Root, DE; Mukherjee, P; Solomon, EI; Stack, TDP				Cole, AP; Root, DE; Mukherjee, P; Solomon, EI; Stack, TDP			Trinuclear intermediate in the copper-mediated reduction of O-2: Four electrons from three coppers	SCIENCE			English	Article							MAGNETIC CIRCULAR-DICHROISM; ACTIVE-SITE; NATIVE LACCASE; ASCORBATE OXIDASE; DIOXYGEN; REACTIVITY; COMPLEXES; HEMOCYANIN; PROTEINS; PEROXIDE	The reaction of metal complexes with dioxygen (O-2) generally proceeds in 1:1, 2:1, or 4:1 (metal:O-2) stoichiometry. A discrete, structurally characterized 3:1 product is presented. This mixed-valence trinuclear copper cluster, which contains copper in the highly oxidized trivalent oxidation state, exhibits O-2 bond scission and intriguing structural, spectroscopic, and redox properties. The relevance of this synthetic complex to the reduction of O-2 at the trinuclear active sites of multicopper oxidases is discussed.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Stanford University				Solomon, Edward/0000-0003-0291-3199	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031450, R01DK031450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050730, R01GM050730] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31450] Funding Source: Medline; NIGMS NIH HHS [GM50730] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLENDORF MD, 1985, P NATL ACAD SCI USA, V82, P3063, DOI 10.1073/pnas.82.10.3063; BALDWIN MJ, 1992, J AM CHEM SOC, V114, P10421, DOI 10.1021/ja00052a043; CHANG D, 1984, INORG CHEM, V23, P817, DOI 10.1021/ic00175a006; CHAUDHURI P, 1985, ANGEW CHEM INT EDIT, V24, P57, DOI 10.1002/anie.198500571; CLARK PA, 1992, J AM CHEM SOC, V114, P1108, DOI 10.1021/ja00029a061; COLE JL, 1990, J AM CHEM SOC, V112, P9534, DOI 10.1021/ja00182a013; COLE JL, 1990, J AM CHEM SOC, V112, P2243, DOI 10.1021/ja00162a025; Comarmond J., 1985, CHEM COMMUN, V74; EVANS DF, 1959, J CHEM SOC, P2003, DOI 10.1039/jr9590002003; FUJISAWA K, 1994, J AM CHEM SOC, V116, P12079, DOI 10.1021/ja00105a069; HARATA M, 1994, J AM CHEM SOC, V116, P10817, DOI 10.1021/ja00102a070; HESTERMANN K, 1969, Z ANORG ALLG CHEM, V367, P249, DOI 10.1002/zaac.19693670506; Karlin K.D., 1993, BIOINORGANIC CHEM CO; KARLIN KD, 1995, ACTIVE OXYGEN BIOCH, V3, P188; KITAJIMA N, 1994, CHEM REV, V94, P737, DOI 10.1021/cr00027a010; LEVANDA C, 1977, J AM CHEM SOC, V99, P2964, DOI 10.1021/ja00451a019; LYNCH WE, 1994, J AM CHEM SOC, V116, P11030, DOI 10.1021/ja00103a019; MAGNUS KA, 1994, CHEM REV, V94, P727, DOI 10.1021/cr00027a009; MAHAPATRA S, 1994, J AM CHEM SOC, V116, P9785, DOI 10.1021/ja00100a068; MESSERSCHMIDT A, 1993, J MOL BIOL, V230, P997, DOI 10.1006/jmbi.1993.1215; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; RYDEN L, 1976, BIOCHEMISTRY-US, V15, P3411, DOI 10.1021/bi00661a003; SCHATZ PN, 1978, MOL PHYS, V35, P1537, DOI 10.1080/00268977800101151; Shin W, 1996, J AM CHEM SOC, V118, P3202, DOI 10.1021/ja953621e; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; SOLOMON EI, 1993, SCIENCE, V259, P1575, DOI 10.1126/science.8384374; SORRELL TN, 1995, INORG CHEM, V34, P952, DOI 10.1021/ic00108a030; SPIRASOLOMON DJ, 1986, J AM CHEM SOC, V108, P5318, DOI 10.1021/ja00277a043; YOUNGBLOOD MP, 1980, INORG CHEM, V19, P3068, DOI 10.1021/ic50212a048; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	30	247	248	2	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1848	1850		10.1126/science.273.5283.1848	http://dx.doi.org/10.1126/science.273.5283.1848			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791587				2022-12-24	WOS:A1996VJ71300041
J	Mauriege, P; Bouchard, C				Mauriege, P; Bouchard, C			Trp65Arg mutation in beta 3-adrenoceptor gene of doubtful significance for obesity and insulin resistance	LANCET			English	Editorial Material							BETA(3)-ADRENERGIC-RECEPTOR GENE; RECEPTOR; WEIGHT; GAIN				Mauriege, P (corresponding author), UNIV LAVAL,PHYS ACT SCI LAB,QUEBEC CITY,PQ G1K 7P4,CANADA.		Bouchard, Claude/AAE-2035-2019; Bouchard, Claude/A-7637-2009	Bouchard, Claude/0000-0002-0048-491X				ARCH JRS, 1993, MED RES REV, V13, P663, DOI 10.1002/med.2610130604; Bouchard C, 1996, OBES RES, V4, P81, DOI 10.1002/j.1550-8528.1996.tb00516.x; CLEMENT K, 1995, NEW ENGL J MED, V333, P352, DOI 10.1056/NEJM199508103330605; EMORINE L, 1994, TRENDS PHARMACOL SCI, V15, P3, DOI 10.1016/0165-6147(94)90118-X; Fujisawa T, 1996, DIABETOLOGIA, V39, P349, DOI 10.1007/s001250050452; GAGNON J, IN PRESS J CLIN INVE; KADOWAKI H, 1995, BIOCHEM BIOPH RES CO, V215, P555, DOI 10.1006/bbrc.1995.2500; LAFONTAN M, 1994, CELL SIGNAL, V6, P363, DOI 10.1016/0898-6568(94)90085-X; Li LS, 1996, DIABETOLOGIA, V39, P857, DOI 10.1007/s001250050521; LONNQVIST F, 1995, J CLIN INVEST, V95, P1109, DOI 10.1172/JCI117758; MAURIEGE P, 1995, J LIPID RES, V36, P672; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603; WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604; ZURLO F, 1990, AM J PHYSIOL, V259, P650	15	35	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					698	699		10.1016/S0140-6736(05)65601-2	http://dx.doi.org/10.1016/S0140-6736(05)65601-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806286				2022-12-24	WOS:A1996VG37400005
J	Cheng, K; Smyth, RL; Govan, JRW; Doherty, C; Winstanley, C; Denning, N; Heaf, DP; vanSaene, H; Hart, CA				Cheng, K; Smyth, RL; Govan, JRW; Doherty, C; Winstanley, C; Denning, N; Heaf, DP; vanSaene, H; Hart, CA			Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic	LANCET			English	Article							BURKHOLDERIA CEPACIA; CF-CENTER; COMMUNICABILITY; MICROBIOLOGY; COLONIZATION; INFECTIONS	Background Pseudomonas aeruginosa colonisation of the airways of patients with cystic fibrosis (CF) is associated with considerable respiratory morbidity. Although segregation of colonised patients from non-colonised patients to prevent cross-infection has been recommended, there is little evidence that such cross-infection is widespread. We observed that a high proportion of children attending our CF clinic were colonised with P aeruginosa that was resistant to ceftazidime and other beta-lactam antibiotics. We used two genomic fingerprinting techniques to see whether this may have arisen from epidemic spread of a single strain. Methods The prevalence of P aeruginosa colonisation and the antibiotic susceptibility of the organisms was determined from review of laboratory reports in the case-notes of 120 children with CF. Isolates were cultured from the sputum of 65 children colonised with ceftazidime-resistant P aeruginosa. Polymorphisms in total bacterial DNA from 92 isolates were analysed with two molecular fingerprinting techniques-pulsed-field gel electrophoresis after restriction enzyme digestion and assessment of flagellin gene polymorphisms by amplification of the whole gene and restriction enzyme digestion. Results 92 (76.7%) of 120 children were colonised with P aeruginosa, and 65 of the 92 harboured isolates that were resistant to ceftazidime. Only three of the 92 children had never been treated with ceftazidime. The results of the two molecular-fingerprinting techniques were concordant and showed that 55 of 65 children harboured the same epidemic strain. This strain was resistant to ceftazidime, azlocillin, and imipenem, and sensitive to tobramycin and ciprofloxacin. Interpretation This study provides the first molecular evidence of a long-term outbreak of P aeruginosa in a CF centre. We suggest that careful surveillance of the prevalence of antibiotic resistance in CF centres should be instituted with measures to prevent cross-infection. We believe that antipseudomonal monotherapy should be considered with caution.	UNIV LIVERPOOL,DEPT MED MICROBIOL & GENITOURINARY MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT CHILD HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV EDINBURGH,DEPT MED MICROBIOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; COVENTRY UNIV,SCH NAT & ENVIRONM SCI,COVENTRY,W MIDLANDS,ENGLAND	University of Liverpool; University of Liverpool; University of Edinburgh; Coventry University				Winstanley, Craig/0000-0002-2662-8053				BINGEN E, 1993, EPIDEMIOLOGY PULMONA; BUTLER SL, 1995, J CLIN MICROBIOL, V33, P1001, DOI 10.1128/JCM.33.4.1001-1004.1995; CHEN HY, 1995, J MED MICROBIOL, V43, P300, DOI 10.1099/00222615-43-4-300; CIOFU O, 1994, APMIS, V102, P674, DOI 10.1111/j.1699-0463.1994.tb05219.x; DALZELL AM, 1991, THORAX, V46, P239, DOI 10.1136/thx.46.4.239; GILLIGAN PH, 1991, CLIN MICROBIOL REV, V4, P35, DOI 10.1128/CMR.4.1.35-51.1991; GOVAN JRW, 1993, LANCET, V342, P15, DOI 10.1016/0140-6736(93)91881-L; GOVAN JRW, 1992, BRIT MED BULL, V48, P912, DOI 10.1093/oxfordjournals.bmb.a072585; GOVAN JRW, 1996, PRACTICAL MED MICROB, P413; GROTHUES D, 1988, J CLIN MICROBIOL, V26, P1973, DOI 10.1128/JCM.26.10.1973-1977.1988; HOOGKAMPKORSTANJE JAA, 1980, A VAN LEEUW J MICROB, V46, P100, DOI 10.1007/BF00422237; National Committee for Clinical Laboratory Standards, 1990, M7A2 NCCLS; PADOAN R, 1987, PEDIATR INFECT DIS J, V6, P648, DOI 10.1097/00006454-198707000-00006; PEDERSEN SS, 1986, J ANTIMICROB CHEMOTH, V17, P505, DOI 10.1093/jac/17.4.505; SPEERT DP, 1987, J HOSP INFECT, V9, P11, DOI 10.1016/0195-6701(87)90089-2; SPEERT DP, 1982, J PEDIATR-US, V101, P227, DOI 10.1016/S0022-3476(82)80127-3; SPEERT DP, 1989, J PEDIATR-US, V114, P1068, DOI 10.1016/S0022-3476(89)80476-7; SUN L, 1995, NAT MED, V1, P661, DOI 10.1038/nm0795-661; Thomassen M J, 1985, Pediatr Pulmonol, V1, P40, DOI 10.1002/ppul.1950010110; TUMMLER B, 1991, J CLIN MICROBIOL, V29, P1265; Winstanley C, 1996, MICROBIOL-UK, V142, P2145, DOI 10.1099/13500872-142-8-2145; WOLZ C, 1989, EPIDEMIOL INFECT, V102, P205, DOI 10.1017/S0950268800029873; 1994, J INFECT DIS, V169, P134	23	329	330	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					639	642		10.1016/S0140-6736(96)05169-0	http://dx.doi.org/10.1016/S0140-6736(96)05169-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782753				2022-12-24	WOS:A1996VF60900008
J	Reilly, KM; Melton, DA				Reilly, KM; Melton, DA			Short-range signaling by candidate morphogens of the TGF beta family and evidence for a relay mechanism of induction	CELL			English	Article							GROWTH-FACTOR-BETA; XENOPUS-LAEVIS; MESODERM INDUCTION; VG1 PROTEIN; DROSOPHILA EMBRYO; MESSENGER-RNAS; EARLY RESPONSE; REQUIRES FGF; II RECEPTOR; C-ELEGANS	The specification and patterning of cell fates by a morphogen gradient is a unifying theme of developmental biology, yet little evidence exists for the presence of gradients in vivo or to show how such putative gradients form. Vg1 and activin are candidate morphogens involved in Xenopus mesoderm induction. This study suggests that these TGF beta family members act on adjacent cells but do not travel through the intact extracellular space to induce distant cells directly. Moreover, we present evidence for the presence of secondary inducing signals that could be involved in relaying signals to distant cells. These results suggest that if a localized cellular source of an inducer acts to pattern mesodermal cells at a distance in Xenopus embryos, it does so by a relay mechanism.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute	Reilly, KM (corresponding author), HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.		Reilly, Karlyne/V-4475-2019; Young, Richard A/F-6495-2012	Reilly, Karlyne/0000-0001-9109-4409; Young, Richard A/0000-0001-8855-8647				ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; BAUER DV, 1994, DEVELOPMENT, V120, P1179; BHUSHAN A, 1994, MOL CELL BIOL, V14, P4280, DOI 10.1128/MCB.14.6.4280; COOKE J, 1987, DEVELOPMENT, V101, P893; CORNELL RA, 1994, DEVELOPMENT, V120, P453; CORNELL RA, 1995, DEVELOPMENT, V121, P2429; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1987, DEVELOPMENT, V99, P527; DOHRMANN CE, 1993, DEV BIOL, V157, P474, DOI 10.1006/dbio.1993.1150; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GARNER LW, 1995, DEV BIOL, V171, P240; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GRUNZ H, 1986, ROUX ARCH DEV BIOL, V195, P467, DOI 10.1007/BF00375751; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Henry GL, 1996, DEVELOPMENT, V122, P1007; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; ITOH K, 1994, DEVELOPMENT, V120, P2703; KALT MR, 1971, J EMBRYOL EXP MORPH, V26, P37; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; KENYON C, 1995, CELL, V82, P171, DOI 10.1016/0092-8674(95)90302-X; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KOGA M, 1995, DEVELOPMENT, V121, P2655; KONDAIAH P, 1988, J BIOL CHEM, V263, P18313; Korc Murray, 1993, P751; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LABONNE C, 1994, DEVELOPMENT, V120, P463; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Mangold O, 1927, ROUX ARCH DEV BIOL, V111, P341; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PENG HB, 1991, XENOPUS LAEVIS PRACT, P657; REBAGLIATI MR, 1993, DEV BIOL, V159, P574, DOI 10.1006/dbio.1993.1265; REPRESA J, 1989, International Journal of Developmental Biology, V33, P397; SIMKE JS, 1995, NATURE, V375, P142; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SLACK JMW, 1987, TRENDS BIOCHEM SCI, V12, P200, DOI 10.1016/0968-0004(87)90094-6; SLACK JMW, 1991, DEVELOPMENT, V113, P661; Smith J, 1996, NATURE, V381, P367, DOI 10.1038/381367a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SUDARWAT.S, 1971, ROUX ARCH DEV BIOL, V166, P189, DOI 10.1007/BF00650029; SYMES K, 1994, DEVELOPMENT, V120, P2339; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VODICKA MA, 1995, DEVELOPMENT, V121, P3505; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	63	88	90	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					743	754		10.1016/S0092-8674(00)80149-X	http://dx.doi.org/10.1016/S0092-8674(00)80149-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797821	Bronze			2022-12-24	WOS:A1996VG37200008
J	Chakravarti, D; LaMorte, VJ; Nelson, MC; Nakajima, T; Schulman, IG; Juguilon, H; Montminy, M; Evans, RM				Chakravarti, D; LaMorte, VJ; Nelson, MC; Nakajima, T; Schulman, IG; Juguilon, H; Montminy, M; Evans, RM			Role of CBP/P300 in nuclear receptor signalling	NATURE			English	Article							THYROID-HORMONE RECEPTOR; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; RETINOIC ACID; CO-REPRESSOR; PROTEIN; SUPERFAMILY; MEDIATOR; PATHWAYS; BINDING	THE nuclear receptor superfamily includes receptors for steroids, retinoids, thyroid hormone and vitamin D, as well as many related proteins(1-3). An important feature of the action of the lipophilic hormones and vitamins is that the maintenance of homeostatic function requires both intrinsic positive and negative regulation(4,5). Here we provide in vitro and in vivo evidence that identifies the CREB-binding protein (CBP) and its homologue P300 (refs 6, 7) as cofactors mediating nuclear-receptor-activated gene transcription. The role of CBP/P300 in the transcriptional response to cyclic AMP, phorbol esters, serum, the lipophilic hormones and as the target of the E1A oncoprotein suggests they may serve as integrators of extracellular and intracellular signalling pathways.	SALK INST BIOL STUDIES,GENE EXPRESS LAB,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Salk Institute; Salk Institute; Howard Hughes Medical Institute; Salk Institute			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAUR EV, 1995, EMBO J, V15, P110; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; ORIATE SA, 1995, SCIENCE, V270, P1354; Parker D, 1996, MOL CELL BIOL, V16, P694; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y	26	823	860	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					99	103		10.1038/383099a0	http://dx.doi.org/10.1038/383099a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779723				2022-12-24	WOS:A1996VF29500057
J	Schipani, E; Langman, CB; Parfitt, AM; Jensen, GS; Kikuchi, S; Kooh, SW; Cole, WG; Juppner, H				Schipani, E; Langman, CB; Parfitt, AM; Jensen, GS; Kikuchi, S; Kooh, SW; Cole, WG; Juppner, H			Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MESSENGER RIBONUCLEIC-ACIDS; FOLLOW-UP; GENE; DYSPLASIA; TISSUES; PROTEIN	Background An activating mutation of the receptor for parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) was recently found in a patient with Jansen's metaphyseal chondrodysplasia, a rare form of short-limbed dwarfism associated with hypercalcemia and normal or low serum concentrations of the two hormones. To investigate this and other activating mutations and to refine the classification of this unusual disorder, we analyzed genomic DNA from six additional patients with Jansen's disease. Methods Exons encoding the PTH-PTHrP receptor were amplified by the polymerase chain reaction (PCR), and the products were analyzed by gel electrophoresis or direct nucleotide-sequence analysis. Nucleotide changes were confirmed by restriction-enzyme digestion of genomic DNA or the PCR products. Results The previously reported mutation, which changes a histidine at position 223 to arginine (H223R), was found in genomic DNA from three of the six patients but not in DNA from their healthy relatives or 45 unrelated normal subjects. A novel missense mutation that changes a threonine in the receptor's sixth membrane-spanning region to proline (T410P) was identified in another patient but not in 62 normal subjects. In two patients with radiologic evidence of Jansen's metaphyseal chondrodysplasia but less severe hypercalcemia, no receptor mutations were detected. In COS-7 cells expressing PTH-PTHrP receptors with the T410P or H223R mutation, basal cyclic AMP accumulation was four to six times higher than in cells expressing wild-type receptors. Conclusions The expression of constitutively active PTH-PTHrP receptors in kidney, bone, and growth-plate chondrocytes provides a plausible genetic explanation for mineral-ion abnormalities and metaphyseal changes in patients with Jansen's disease. (C) 1996, Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,DEPT MED,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CHILDRENS SERV,BOSTON,MA 02114; NORTHWESTERN UNIV,SCH MED,PEDIAT NEPHROL & MINERAL METAB UNIT,CHICAGO,IL; CHILDRENS MEM HOSP,CHICAGO,IL 60614; HENRY FORD HOSP,BONE & MINERAL RES LAB,DETROIT,MI 48202; FUKUSHIMA MED COLL,FUKUSHIMA,JAPAN; HOSP SICK CHILDREN,DEPT ORTHOPAED SURG & ENDOCRINOL,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,TORONTO,ON M5S 1A1,CANADA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Henry Ford Health System; Henry Ford Hospital; Fukushima Medical University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto					PHS HHS [R01 46718] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CAMERON JAP, 1954, J BONE JOINT SURG BR, V36, P622, DOI 10.1302/0301-620X.36B4.622; CHARROW J, 1984, AM J MED GENET, V18, P321, DOI 10.1002/ajmg.1320180216; de Haas W H, 1969, J Bone Joint Surg Br, V51, P290; Frame B, 1980, PEDIAT DIS RELATED C, P269; GORDON SL, 1976, PEDIATRICS, V58, P556; GRAM PB, 1959, J BONE JOINT SURG AM, V41, P951, DOI 10.2106/00004623-195941050-00015; Holthusen W, 1975, Pediatr Radiol, V3, P137, DOI 10.1007/BF01006898; IWAMOTO M, 1994, J BIOL CHEM, V269, P17245; Jaffe HL, 1972, METABOLIC DEGENERATI, P222; Jansen M, 1934, Z ORTHOP CHIR, V61, P253; Jikko A, 1996, ENDOCRINOLOGY, V137, P122, DOI 10.1210/en.137.1.122; Juppner H, 1994, Curr Opin Nephrol Hypertens, V3, P371; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KESSEL D, 1992, PEDIATR RADIOL, V22, P470, DOI 10.1007/BF02013518; KIKUCHI S, 1976, J BONE JOINT SURG BR, V58, P102, DOI 10.1302/0301-620X.58B1.1270485; KRUSE K, 1993, EUR J PEDIATR, V152, P912, DOI 10.1007/BF01957529; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE K, 1994, ENDOCRINOLOGY, V134, P441, DOI 10.1210/en.134.1.441; Lee KC, 1996, AM J PHYSIOL-RENAL, V270, pF186, DOI 10.1152/ajprenal.1996.270.1.F186; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LENZ WD, 1969, BIRTH DEFECTS, V5, P71; Rao DS, 1979, VITAMIN D BASIC RES, P1173; REED A, 1990, J PEDIATR-US, V116, P574, DOI 10.1016/S0022-3476(05)81605-1; REN Q, 1994, J BIOL CHEM, V269, P1566; REN Q, 1993, J BIOL CHEM, V268, P16483; SCHIPANI E, 1994, HUM MOL GENET, V3, P1210, DOI 10.1093/hmg/3.7.1210-a; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SCHIPANI E, 1995, J CLIN ENDOCR METAB, V80, P1611, DOI 10.1210/jc.80.5.1611; SILVERTHORN KG, 1987, PEDIATR RADIOL, V17, P119, DOI 10.1007/BF02388087; TIAN J, 1993, AM J NEPHROL, V13, P210, DOI 10.1159/000168620; URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617; WEIR E, 1995, J BONE MINER RES, V10, pS157; WYSOLMERSKI JJ, 1995, DEVELOPMENT, V121, P3539	33	192	194	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1996	335	10					708	714		10.1056/NEJM199609053351004	http://dx.doi.org/10.1056/NEJM199609053351004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH266	8703170				2022-12-24	WOS:A1996VH26600004
J	Gelb, BD; Shi, GP; Chapman, HA; Desnick, RJ				Gelb, BD; Shi, GP; Chapman, HA; Desnick, RJ			Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency	SCIENCE			English	Article							MOLECULAR-CLONING; PROTEINASE-INHIBITORS; TISSUE DISTRIBUTION; CYSTEINE PROTEASE; TOULOUSE-LAUTREC; BONE-RESORPTION; OSTEOCLASTOMAS; LOCALIZATION; COLLAGEN; CELLS	Pycnodysostosis, an autosomal recessive osteochondrodysplasia characterized by osteosclerosis and short stature, maps to chromosome 1q21. Cathepsin K, a cysteine protease gene that is highly expressed in osteoclasts, localized to the pycnodysostosis region. Nonsense, missense, and stop codon mutations in the gene encoding cathepsin K were identified in patients. Transient expression of complementary DNA containing the stop codon mutation resulted in messenger RNA but no immunologically detectable protein. Thus, pycnodysostosis results from gene defects in a lysosomal protease with highest expression in osteoclasts. These findings suggest that cathepsin K is a major protease in bone resorption, providing a possible rationale for the treatment of disorders such as osteoporosis and certain forms of arthritis.	MT SINAI SCH MED,DIV PEDIAT CARDIOL,NEW YORK,NY 10029; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gelb, BD (corresponding author), MT SINAI SCH MED,DEPT HUMAN GENET,BOX 1203,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.				NHLBI NIH HHS [R01 HL44816] Funding Source: Medline; NIDDK NIH HHS [R01 DK31775, R37 DK34045] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031775, R37DK034045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREN L., 1962, ACTA CHIR SCAND, V124, P496; BISHOP DF, 1982, J BIOL CHEM, V256, P1307; BLAIR HC, 1993, CLIN ORTHOP RELAT R, V294, P7; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; DEBARI K, 1995, CALCIFIED TISSUE INT, V56, P566, DOI 10.1007/BF00298591; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Drake FH, 1996, J BIOL CHEM, V271, P12511, DOI 10.1074/jbc.271.21.12511; EVERTS V, 1988, CALCIFIED TISSUE INT, V43, P172, DOI 10.1007/BF02571316; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; EVERTS V, 1985, CALCIFIED TISSUE INT, V37, P25, DOI 10.1007/BF02557674; FREY JB, 1995, NAT GENET, V10, P128, DOI 10.1038/ng0695-128; Gelb BD, 1996, HUM GENET, V98, P141, DOI 10.1007/s004390050177; GELB BD, 1995, NAT GENET, V10, P235, DOI 10.1038/ng0695-235; GELB BD, UNPUB; GOTO T, 1994, HISTOCHEMISTRY, V101, P33, DOI 10.1007/BF00315829; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KIRSCHKE H, 1994, METHOD ENZYMOL, V244, P500; LI YP, 1995, J BONE MINER RES, V10, P1197; MAROTEAUX P, 1962, PRESSE MED, V70, P999; MAROTEAUX P, 1965, J AMER MED ASSOC, V191, P715, DOI 10.1001/jama.1965.03080090029007; MAROTEAUX P, 1993, PRESSE MED, V22, P1635; MUNGER JS, 1995, BIOCHEM J, V311, P299, DOI 10.1042/bj3110299; POLYMEROPOULOS MH, 1995, NAT GENET, V10, P238, DOI 10.1038/ng0695-238; SHI GP, 1992, J BIOL CHEM, V267, P7258; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; SHI GP, 1994, J BIOL CHEM, V269, P11530; TEZUKA K, 1994, J BIOL CHEM, V269, P1106	30	792	821	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1236	1238		10.1126/science.273.5279.1236	http://dx.doi.org/10.1126/science.273.5279.1236			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703060				2022-12-24	WOS:A1996VE47600043
J	Valaskovic, GA; Kelleher, NL; McLafferty, FW				Valaskovic, GA; Kelleher, NL; McLafferty, FW			Attomole protein characterization by capillary electrophoresis mass spectrometry	SCIENCE			English	Article							MULTIPLY-CHARGED IONS; ELECTROSPRAY-IONIZATION; LARGE BIOMOLECULES; LARGE MOLECULES; SENSITIVITY; PEPTIDES; SPECTRA; IDENTIFICATION; CELLS	Electrospray ionization with an ultralow flow rate (less than or equal to 4 nanoliters per minute) was used to directly couple capillary electrophoresis with tandem mass spectrometry for the analysis and identification of biomolecules in mixtures. A Fourier transform mass spectrometer provided full spectra (>30 kilodaltons) at a resolving power of approximate to 60,000 for injections of 0.7 x 10(-18) to 3 x 10(-18) mole of 8- to 29-kilodalton proteins with errors of <1 dalton in molecular mass. Using a crude isolate from human blood, a value of 28,780.6 daltons (calculated, 28,780.4 daltons) was measured for carbonic anhydrase, representing 1 percent by weight of the protein in a single red blood cell. Dissociation of molecular ions from 9 x 10(-18) mole of carbonic anhydrase gave nine sequence-specific fragment ions, more data than required for unique retrieval of this enzyme from the protein database.	CORNELL UNIV,BAKER LAB,DEPT CHEM,ITHACA,NY 14853	Cornell University					NIGMS NIH HHS [08-T2GM07273, GM16609] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016609, R37GM016609] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEU SC, 1993, J AM SOC MASS SPECTR, V4, P557, DOI 10.1016/1044-0305(93)85017-R; CURL RF, 1988, SCIENCE, V242, P1017, DOI 10.1126/science.242.4881.1017; EMMETT MR, 1994, J AM SOC MASS SPECTR, V5, P605, DOI 10.1016/1044-0305(94)85001-1; EWING AG, 1992, ACCOUNTS CHEM RES, V25, P440, DOI 10.1021/ar00022a002; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FISHMAN HA, 1995, P NATL ACAD SCI USA, V92, P7877, DOI 10.1073/pnas.92.17.7877; Flaming K.T., 1986, ADV MICROPIPETTE TEC; FOSKETT JK, 1990, NONINVASIVE TECHNIQU, V9; Herman B., 1990, OPTICAL MICROSCOPY B, V1st; Hofstadler SA, 1996, RAPID COMMUN MASS SP, V10, P919, DOI 10.1002/(SICI)1097-0231(19960610)10:8<919::AID-RCM597>3.0.CO;2-8; HOFSTADLER SA, 1993, J AM CHEM SOC, V115, P6983, DOI 10.1021/ja00068a070; JORGENSON JW, 1983, SCIENCE, V222, P266, DOI 10.1126/science.6623076; KARGER BL, 1995, ANNU REV BIOPH BIOM, V24, P579, DOI 10.1146/annurev.bb.24.060195.003051; KELLEHER NL, 1995, J AM SOC MASS SPECTR, V6, P981, DOI 10.1016/1044-0305(95)00584-Z; KENNEDY RT, 1989, SCIENCE, V246, P57, DOI 10.1126/science.2675314; LINDSKOG S, 1960, BIOCHIM BIOPHYS ACTA, V39, P218, DOI 10.1016/0006-3002(60)90156-6; LITTLE DP, IN PRESS J AM CHEM S; LOO JA, 1991, ANAL CHEM, V63, P2488, DOI 10.1021/ac00021a018; LOO JA, 1994, ANAL CHEM, V66, P3659, DOI 10.1021/ac00093a020; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MCLAFFERTY FW, 1994, ACCOUNTS CHEM RES, V27, P379, DOI 10.1021/ar00047a009; Mortz E, 1996, P NATL ACAD SCI USA, V93, P8264, DOI 10.1073/pnas.93.16.8264; Pennell R.B., 1974, RED BLOOD CELL, V1, P93; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SAKMANN B, 1983, SINGLE CHANNEL RECOR; SAUER K, 1995, METHOD ENZYMOL, V246, P1; SENKO MW, 1995, J AM SOC MASS SPECTR, V6, P52, DOI 10.1016/1044-0305(94)00091-D; SENKO MW, 1995, J AM SOC MASS SPECTR, V6, P229, DOI 10.1016/1044-0305(95)00017-8; SMITH RD, 1993, ANAL CHEM, V65, pA574, DOI 10.1021/ac00061a001; SPEIR JP, 1995, J MASS SPECTROM, V30, P39, DOI 10.1002/jms.1190300108; VALASKOVIC GA, 1995, ANAL CHEM, V67, P3802, DOI 10.1021/ac00116a030; Valaskovic GA, 1996, RAPID COMMUN MASS SP, V10, P825; WAHL JH, 1993, ELECTROPHORESIS, V14, P448, DOI 10.1002/elps.1150140170; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9; YEUNG ES, 1994, ACCOUNTS CHEM RES, V27, P409, DOI 10.1021/ar00048a004	36	327	333	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1199	1202		10.1126/science.273.5279.1199	http://dx.doi.org/10.1126/science.273.5279.1199			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703047				2022-12-24	WOS:A1996VE47600030
J	Brennan, P; Harrison, B; Barrett, E; Chakravarty, K; Scott, D; Silman, A; Symmons, D				Brennan, P; Harrison, B; Barrett, E; Chakravarty, K; Scott, D; Silman, A; Symmons, D			A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: Prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							JOINT DESTRUCTION; PROGRESSION; DISEASE; DAMAGE; GOLD	Objective-To produce a practical algorithm to predict which patients with early rheumatoid arthritis will develop radiological erosions. Design-Primary care based prospective cohort study. Setting-All general practices in the Norwich Health Authority, Norfolk Subjects-175 patients notified to the Norfolk Arthritis Register were visited by a metrologist soon after they had presented to their general practitioners with inflammatory polyarthritis, and again after a further 12 months. All the patients satisfied the American Rheumatism Association's 1987 criteria for rheumatoid arthritis and were seen by a metrologist within six months of the onset of symptoms. The study population was randomly split into a prediction sample (n = 105) for generating the algorithm and a validation sample (n = 70) for testing it. Main outcome measures-Predictor variables measured at baseline included rheumatoid factor status, swelling of specific joint areas, duration of morning stiffness, nodules, disability score, age, sex, and disease duration when the patient first presented. The outcome variable was the presence of radiological erosions in the hands or feet, or both, after 12 months. Results-A simple algorithm based on a combination of three variables-a positive rheumatoid factor test, swelling of at least two large joints, and a disease duration of more than three months-was best able to predict erosions. When the accuracy of this algorithm was tested with the validation sample, the erosion status of 79% of patients was predicted correctly. Conclusions-A simple algorithm based on three easily measured items of information can predict which patients are at high risk and which are at low risk of developing radiological erosions.	ST MICHAELS HOSP,NORFOLK ARTHRIT REGISTER,AYLSHAM,NORFOLK,ENGLAND		Brennan, P (corresponding author), UNIV MANCHESTER,SCH MED,ARTHRIT & RHEUMATISM EPIDEMIOL RES UNIT,MANCHESTER M13 9PT,LANCS,ENGLAND.			Symmons, Deborah/0000-0002-8625-1200				ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BROOK A, 1977, ANN RHEUM DIS, V36, P71, DOI 10.1136/ard.36.1.71; CARUSO I, 1990, J RHEUMATOL, V17, P1263; DAWES PT, 1986, ANN RHEUM DIS, V45, P945, DOI 10.1136/ard.45.11.945; DECARVALHO A, 1980, ACTA RADIOL DIAGN, V21, P551, DOI 10.1177/028418518002100419; EBERHARDT KB, 1990, RHEUMATOL INT, V10, P135, DOI 10.1007/BF02274837; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; Kaarela K, 1985, Scand J Rheumatol Suppl, V57, P1; KAY EA, 1992, BRIT J RHEUMATOL, V31, P477; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; LARSEN A, 1977, ACTA RADIOL DIAGN, V18, P481, DOI 10.1177/028418517701800415; LUUKKAINEN R, 1983, CLIN EXP RHEUMATOL, V1, P295; LUUKKAINEN R, 1977, SCAND J RHEUMATOL, V6, P189, DOI 10.3109/03009747709095448; MOTTONEN TT, 1988, ANN RHEUM DIS, V47, P648, DOI 10.1136/ard.47.8.648; SHARP JT, 1989, ARTHRITIS RHEUM-US, V32, P221, DOI 10.1002/anr.1780320218; SJOBLOM KG, 1984, SCAND J RHEUMATOL, V13, P21; *STAT CORP, 1995, STAT STAT SOFTW REL; SUAREZALMAZOR ME, 1994, J RHEUMATOL, V21, P1438; SYMMONS DPM, 1994, BRIT J RHEUMATOL, V33, P735; TEITSSON I, 1984, ANN RHEUM DIS, V43, P673, DOI 10.1136/ard.43.5.673; VANDERHEIDE A, 1995, ARTHRITIS RHEUM, V38, P1466; VANDERHEIJDE DMF, 1988, SEMIN ARTHRITIS RHEU, V17, P284; VANZEBEN D, 1993, J RHEUMATOL, V20, P1288; WESTEDT ML, 1986, ANN RHEUM DIS, V45, P809, DOI 10.1136/ard.45.10.809; YOUNG A, 1988, BRIT J RHEUMATOL, V27, P94	25	86	88	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					471	476						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776318				2022-12-24	WOS:A1996VE08000025
J	Arason, VA; Kristinsson, KG; Sigurdsson, JA; Stefansdottir, G; Molstad, S; Gudmundsson, S				Arason, VA; Kristinsson, KG; Sigurdsson, JA; Stefansdottir, G; Molstad, S; Gudmundsson, S			Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STREPTOCOCCUS-PNEUMONIAE; ANTIBIOTIC-RESISTANCE; ICELAND; SPAIN	Objective-To study the correlation of antimicrobial consumption with the carriage rate of penicillin resistant and multiresistant pneumococci in children. Design-Cross sectional and analytical prevalence study. Setting-Five different communities in Iceland. Main outcome measure-Prevalence of nasopharyngeal carriage of penicillin resistant pneumococci in children aged under 7 years in relation to antibiotic use as determined by information from parents, patient's records, and total sales of antimicrobials from local pharmacies in four study areas. Results-Total antimicrobial sales for children (6223 prescriptions) among the four areas for which data were available ranged from 9.6 to 23.2 defined daily doses per 1000 children daily (1.1 to 2.6 courses yearly per child). Children under 2 consumed twice as much as 2-6 year olds (20.5 v 10.9 defined daily doses per 1000 children daily). Nasopharyngeal specimens were obtained from 919 children, representing 15-38% of the peer population groups in the different areas. Pneumococci were carried by 484 (52.7%) of the children, 47 (9.7%) of the isolates being resistant to penicillin or multiresistant. By multivariate analysis age (<2 years), area (highest antimicrobial consumption), and individual use of antimicrobials significantly influenced the odds of carrying penicillin resistant pneumococci. By univariate analysis, recent antimicrobial use (two to seven weeks) and use of co-trimoxazole were also significantly associated with carriage of penicillin resistant pneumococci. Conclusions-Antimicrobial use, with regard to both individual use and total antimicrobial consumption in the community, is strongly associated with nasopharyngeal carriage of penicillin resistant pneumococci in children. Control measures to reduce the prevalence of penicillin resistant pneumococci should include reducing the use of antimicrobials in community health care.	LANDSPITALINN UNIV HOSP, DEPT MICROBIOL, IS-101 REYKJAVIK, ICELAND; BORGARSPITALINN REYKJAVIK CITY HOSP, MICROBIOL LAB, IS-108 REYKJAVIK, ICELAND; HOOR HLTH CTR, S-24330 HOOR, SWEDEN; LANDSPITALINN, DEPT INTERNAL MED, IS-101 REYKJAVIK, ICELAND	Landspitali National University Hospital	Arason, VA (corresponding author), UNIV ICELAND, SOLVANGUR HLTH CTR, DEPT FAMILY MED, IS-220 HAFNARFJORDUR, ICELAND.			Sigurdsson, Johann Agust/0000-0002-5646-6411				APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77; AUSTRIAN R, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_A.35; Bro F, 1986, Scand J Prim Health Care, V4, P101, DOI 10.3109/02813438609014811; GESLIN P, 1992, CLIN INFECT DIS, V15, P95, DOI 10.1093/clinids/15.1.95; GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; HOSMER DW, 1989, APPLIED LOGISTIC REG, P83; JACOBY GA, 1991, NEW ENGL J MED, V324, P601, DOI 10.1056/NEJM199102283240906; Kristinsson KG, 1995, MICROB DRUG RESIST, V1, P121, DOI 10.1089/mdr.1995.1.121; KRISTINSSON KG, 1992, LANCET, V339, P1606, DOI 10.1016/0140-6736(92)91868-9; KRONVALL G, 1973, J MED MICROBIOL, V6, P187, DOI 10.1099/00222615-6-2-187; KUNIN CM, 1990, PRINCIPLES PRACTICE, P427; LINARES J, 1992, CLIN INFECT DIS, V15, P99, DOI 10.1093/clinids/15.1.99; MARTON A, 1991, J INFECT DIS, V163, P542, DOI 10.1093/infdis/163.3.542; MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033; MIETTINEN OS, 1976, AM J EIDEMIOL, V104, P425; MOLSTAD S, 1992, Scandinavian Journal of Primary Health Care, V10, P16, DOI 10.3109/02813439209014029; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; *NORD LAK, 1993, NLN PUBL, V34; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; Ruoff Kathryn L., 1995, P299; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; SOARES S, 1993, J INFECT DIS, V168, P158, DOI 10.1093/infdis/168.1.158; SWENSON JM, 1986, J CLIN MICROBIOL, V24, P749, DOI 10.1128/JCM.24.5.749-752.1986; *WHO, 1992, AN THER CHEM ACT CLA; Woods Gail L., 1995, P1327	26	412	418	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 17	1996	313	7054					387	391						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761224				2022-12-24	WOS:A1996VD20600022
J	Miller, PM; Plant, M				Miller, PM; Plant, M			Drinking, smoking, and illicit drug use among 15 and 16 year olds in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine patterns of self reported drinking, smoking, and illicit drug use among a representative United Kingdom sample of people born in 1979. Design-Cross sectional, single phase survey based on a stratified cluster sample of 70 United Kingdom secondary schools during March and April 1995. Pupils completed a 406 item standardised questionnaire under examination conditions. Setting-United Kingdom state and private secondary schools. Subjects-7722 pupils aged 15 and 16. Main outcome measures-Reported use of alcohol, tobacco, and illicit drugs. Results-Almost all the pupils had drunk alcohol, 36% (2772/7689) had smoked cigarettes in the past 30 days, and 42.3% (3264/7722) had at some time used illicit drugs, mainly cannabis. 43% (1546/3546) of boys and 38% (1529/4009) of girls had tried cannabis, Higher levels of smoking were associated with poorer school performance (20.4% (783/3840) with average performance v 44.1% (214/486) with below average performance, F = 79.06, P<0.01), Levels of drug use in 15 and 16 year olds in 1995 were higher in Scotland than in England, Wales, or Northern ireland. Conclusions-Drug experimentation was high among 15 and 16 year olds, and use of cannabis was particularly high among smokers. Cigarette smoking was more common among girls than boys.			Miller, PM (corresponding author), UNIV EDINBURGH,DEPT PSYCHIAT,ALCOHOL & HLTH RES GRP,EDINBURGH EH10 5HF,MIDLOTHIAN,SCOTLAND.							Aldridge J., 1995, DRUGS FUTURES CHANGI; ANDERSON J, 1995, ALCOHOL TOBACCO ILLI; *FIF HLTH RES, 1996, REP STUD YOUNG PEOPL; GODDARD E, 1996, TEENAGE DRINKING 199; *HOM OFF, 1995, 1994 HOM OFF; *HOM OFF, 1995, 1993 HOM OFF; *IOW STAT U, 1989, MAN PEC; JOHNSTON LD, 1994, SURVEYING STUDENT DR; LORETTO WA, 1994, DRUG-EDUC PREV POLIC, V1, P143, DOI 10.3109/09687639409017379; MAY C, 1992, ALCOHOL ALCOHOLISM, V27, P109; Plant M., 1992, RISK TAKERS ALCOHOL; RUDAT K, 1992, TOMORROWS YOUNG ADUL; Rudat K, 1992, TODAYS YOUNG ADULTS	13	160	163	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					394	397						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761226				2022-12-24	WOS:A1996VD20600024
J	Ghosh, P; Shabat, D; Kumar, S; Sinha, SC; Grynszpan, F; Li, J; Noodleman, L; Keinan, E				Ghosh, P; Shabat, D; Kumar, S; Sinha, SC; Grynszpan, F; Li, J; Noodleman, L; Keinan, E			Using antibodies to perturb the coordination sphere of a transition metal complex	NATURE			English	Article							DENSITY-FUNCTIONAL CALCULATIONS; ELECTRONIC-STRUCTURE; COPPER(I) COMPLEXES; ENERGIES; DERIVATIVES	METAL ions in the active sites of many metalloenzymes exhibit distinctive spectral and chemical features which are different from those of small inorganic complexes(1,2). These features are the result of the unusual geometric and electronic constraints that are imposed on the metal ion within the protein environment(3). Much effort has been invested to try to mimic this feature of metalloenzymes in synthetic systems, but this remains a formidable task Here we show that one of the key lessons learned from the science of catalytic antibodies-that binding energy can be converted into chemical energy(4)-can be exploited to 'fine-tune' the physicochemical properties of a metal complex. We show that an antibody's binding site can reversibly perturb the coordination geometry of a metal ion, and can stabilize a high-energy coordinated species(5). Specifically, antibodies designed to bind the organosilicon compound 1 (Fig, 1) also bind the geometrically similar Cu(I) complex 2. However, the antibody binds a slightly compressed form of 2, which is closer in size to 1. This distortion is manifested by a spectral shift-an 'immunochromic' effect.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; TECHNION ISRAEL INST TECHNOL, DEPT CHEM, IL-32000 HAIFA, ISRAEL	Scripps Research Institute; Technion Israel Institute of Technology			Kumar, Sandeep/E-5140-2012; Grynszpan, Flavio/V-5379-2019; noodleman, louis/A-3750-2008; Grynszpan, Flavio/P-2107-2014; KUMAR, SANDEEP/GZA-7182-2022	Grynszpan, Flavio/0000-0003-2445-5416; noodleman, louis/0000-0001-8176-4448; Kumar, Sandeep/0000-0003-4789-5158				Baerends E. J., 1992, J COMPUT PHYS, V99, P84, DOI DOI 10.1016/0021-9991(92)90277-6; BARD AJ, 1983, ENCY ELECTROCHEMIS A, V9, P172; BECKE AD, 1986, J CHEM PHYS, V84, P4524, DOI 10.1063/1.450025; FOLEY J, 1994, J CHEM SOC DA, V1, P1; Hathway B. J., 1987, COMPREHENSIVE COORDI, V5, P533; JOHNSON JE, 1971, J CHEM SOC A, P1371, DOI 10.1039/j19710001371; JONES DH, 1993, INORG CHEM, V32, P2092, DOI 10.1021/ic00062a035; KARLIN KD, 1984, INORG CHEM, V23, P1184, DOI 10.1021/ic00177a003; KEINAN E, 1992, INORG CHEM, V31, P5433, DOI 10.1021/ic00052a019; KITAGAWA S, 1981, INORG CHEM, V20, P2261, DOI 10.1021/ic50221a064; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LEWIS C, 1991, SCIENCE, V253, P1019, DOI 10.1126/science.1887215; LEWIS C, 1993, J AM CHEM SOC, V115, P1410, DOI 10.1021/ja00057a025; NABESHIMA T, 1993, INORG CHEM, V32, P1407, DOI 10.1021/ic00060a015; NOODLEMAN L, 1984, J AM CHEM SOC, V106, P2316, DOI 10.1021/ja00320a017; PALMER RA, 1966, INORG CHEM, V5, P864, DOI 10.1021/ic50039a034; PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822; ROSA A, 1994, INORG CHEM, V33, P584, DOI 10.1021/ic00081a029; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHABAT D, 1995, NATURE, V374, P143, DOI 10.1038/374143a0; SHOKAT KM, 1988, ANGEW CHEM INT EDIT, V27, P1172, DOI 10.1002/anie.198811721; SOLOMON EI, 1993, SCIENCE, V259, P1575, DOI 10.1126/science.8384374; STEWARD MW, 1983, ANTIBODY AFFINITY TH, P76; VALLEE BL, 1968, P NATL ACAD SCI USA, V59, P498, DOI 10.1073/pnas.59.2.498; VOSKO SH, 1980, CAN J PHYS, V58, P1200, DOI 10.1139/p80-159; WILLIAMS RJP, 1955, J CHEM SOC, P137, DOI 10.1039/jr9550000137; WILLIAMS RJP, 1995, EUR J BIOCHEM, V234, P363, DOI 10.1111/j.1432-1033.1995.363_b.x; ZEIGLER T, 1995, CAN J CHEM, V73, P743; ZIEGLER T, 1977, THEOR CHIM ACTA, V43, P261, DOI 10.1007/BF00551551	29	26	26	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					339	341		10.1038/382339a0	http://dx.doi.org/10.1038/382339a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684461				2022-12-24	WOS:A1996UY95000046
J	Yuan, ZM; Huang, YY; Whang, Y; Sawyers, C; Weichselbaum, R; Kharbanda, S; Kufe, D				Yuan, ZM; Huang, YY; Whang, Y; Sawyers, C; Weichselbaum, R; Kharbanda, S; Kufe, D			Role for c-Abl tyrosine kinase in growth arrest response to DNA damage	NATURE			English	Article							RETINOBLASTOMA PROTEIN; INHIBITION; BINDING; P53	THE c-Abl protein tyrosine kinase is activated by certain DNA-damaging agents', and its overexpression causes arrest in the G1 phase of the cell cycle by a mechanism dependent on the tumour-suppressor protein p53 (refs 2-4). Here we investigate the possible role of c-Abl in growth arrest induced by DNA damage. Transient transfection experiments using wild-type or inactivated c-Abl show that both induce expression of p21, an effector of p53, but only wild-type c-Abl downregulates the activity of the cyclin-dependent kinase Cdk2 and causes growth arrest. Exposure to ionizing radiation of cells that stably express active or inactive c-Abl is associated with induction of c-Abl/p53 complexes and p21 expression. However, cells expressing the dominant-negative c-Abl mutant and cells lacking the c-abl gene are impaired in their ability to downregulate Cdk2 or undergo G1 arrest in response to ionizing radiation. We also show that expression of c-Abl kinase in p21(-/-), but not in p53(-/-), cells results in downregulation of Cdk2. Our results suggest that c-Abl kinase contributes to the regulation of growth arrest induced by ionizing radiation by a p53-dependent, p21-independent mechanism.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90095; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Chicago			Whang, Young/AAK-7435-2021; Sawyers, Charles/G-5327-2016	Whang, Young/0000-0002-1621-6661				BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARTEK J, 1992, ONCOGENE, V7, P101; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOGA A, 1995, ONCOGENE, V11, P791; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MATTIONI T, 1995, ONCOGENE, V10, P1325; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041	18	214	222	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					272	274		10.1038/382272a0	http://dx.doi.org/10.1038/382272a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717045				2022-12-24	WOS:A1996UX79000055
J	Fahey, TP; Peters, TJ				Fahey, TP; Peters, TJ			What constitutes controlled hypertension? Patient based comparison of hypertension guidelines	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; MANAGEMENT; CLUSTER; TRIALS	Objectives-To investigate and quantify the extent to which variations in guidelines influence assessment of control of hypertension. Design-Cross sectional study. Selected patients had hypertension assessed as controlled or uncontrolled with guidelines from New Zealand, Canada, the United States, Britain, and the World Health Organisation. Setting-18 general practices in Oxfordshire. Subjects-876 patients with diagnosed hypertension and taking antihypertensive drugs. Main outcome measures-Proportion of patients with controlled hypertension according to each set of guidelines. Results-The proportion of patients with controlled hypertension varied from 17.5% to 84.6% with the different guidelines after adjustment for the sampling method. All five sets of guidelines agreed on the classification for 31% (277) of the patients. The New Zealand guidelines calculate an absolute risk of a cardiovascular event. When this was taken as the standard half of the patients with uncontrolled hypertension by the United States criteria would be treated unnecessarily and 31% of those classified as having controlled hypertension by the Canadian guidelines would be denied beneficial treatment. Conclusions-Hypertension guidelines are inconsistent in their recommendations and need to make clear the absolute benefits and risks of treatment.			Fahey, TP (corresponding author), UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND.		Fahey, Tom/C-9367-2012	Fahey, Tom/0000-0002-5896-5783; Peters, Tim/0000-0003-2881-4180				ALDERMAN MH, 1993, ANN INTERN MED, V119, P329, DOI 10.7326/0003-4819-119-4-199308150-00013; [Anonymous], 1991, JAMA, V265, P3255; Armitage P., 1987, STAT METHODS MED RES; COLLINS R, 1994, TXB HYPERTENSION, P1156; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DONNER A, 1994, AM J EPIDEMIOL, V140, P279, DOI 10.1093/oxfordjournals.aje.a117247; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; EGGER M, 1995, J HYPERTENS, V13, P813, DOI 10.1097/00004872-199507000-00014; EVANS JBT, 1995, BRIT J GEN PRACT, V45, P15; FAHEY T, 1995, J PUBLIC HEALTH MED, V17, P57; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Grol R, 1992, Qual Health Care, V1, P184, DOI 10.1136/qshc.1.3.184; GROVER SA, 1995, BRIT MED J, V310, P975, DOI 10.1136/bmj.310.6985.975; GROVER SA, 1995, JAMA-J AM MED ASSOC, V274, P801, DOI 10.1001/jama.274.10.801; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HOES AW, 1995, J HYPERTENS, V13, P805; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; LEVY D, 1995, LANCET, V346, P1112, DOI 10.1016/S0140-6736(95)91792-6; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; MYERS MG, 1989, CAN MED ASSOC J, V140, P1141; Payer L., 1988, MED CULTURE VARIETIE; SACKETT DL, 1994, BMJ-BRIT MED J, V309, P755, DOI 10.1136/bmj.309.6957.755; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; SMITH WCS, 1990, BRIT MED J, V300, P981, DOI 10.1136/bmj.300.6730.981; SWALES JD, 1994, LANCET, V344, P380; SWALES JD, 1993, J HYPERTENS, V11, P899, DOI 10.1097/00004872-199309000-00003; ZANCHETTI A, 1993, BMJ-BRIT MED J, V307, P1541, DOI 10.1136/bmj.307.6918.1541	30	80	80	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 13	1996	313	7049					93	96		10.1136/bmj.313.7049.93	http://dx.doi.org/10.1136/bmj.313.7049.93			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX698	8688763	Green Published			2022-12-24	WOS:A1996UX69800026
J	Grewal, SIS; Klar, AJS				Grewal, SIS; Klar, AJS			Chromosomal inheritance of epigenetic states in fission yeast during mitosis and meiosis	CELL			English	Article							MATING-TYPE REGION; SWITCHING GENE SWI6; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTIONAL STATES; MEIOTIC RECOMBINATION; EXPRESSION; LOCI; CASSETTES; CHROMATIN; METHYLATION	Inheritance of the active and inactive states of gene expression by individual cells is crucial for development. In fission yeast, mating-type region consists of three loci called mat1, mat2, and mat3. Transcriptionally silent mat2 and mat3 loci are separated by a 15 kb interval, designated the K-region, and serve as donors of information for transcriptionally active mat1 interconversion. In a strain carrying replacement of 7.5 kb of the K-region with the ura4 gene, we discovered that ura4 silencing and efficiency of mating-type switching were covariegated and were regulated by an epigenetic mechanism. Genetic analyses demonstrated that epigenetic states were remarkably stable not only in mitosis but also in meiosis and were linked to the mating-type region. This study indicates that different epigenetic states are heritable forms of chromatin organization at the mat region.			Grewal, SIS (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, GENE REGULAT & CHROMOSOME BIOL LAB, FREDERICK, MD 21702 USA.			Grewal, Shiv/0000-0002-4552-9261	NCI NIH HHS [N01-CO-46000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; ANTEQUERA F, 1984, J BIOL CHEM, V259, P8033; BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; BEACH DH, 1984, EMBO J, V3, P603, DOI 10.1002/j.1460-2075.1984.tb01855.x; BENDER J, 1995, CELL, V83, P725, DOI 10.1016/0092-8674(95)90185-X; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; BRUTNELL TP, 1994, GENETICS, V138, P213; COLOT V, 1995, GENETICS, V141, P1299; EGEL R, 1984, CURR GENET, V8, P199, DOI 10.1007/BF00417816; EGEL R, 1989, CURR GENET, V15, P407, DOI 10.1007/BF00376796; EISSENBERG JC, 1995, CHROMATIN STRUCTURE, P147; EKWALL K, 1994, GENETICS, V136, P53; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; KLAR AJS, 1991, GENETICS, V129, P1033; KLAR AJS, 1992, MOL CELLULAR BIOL YE, P745; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LORENTZ A, 1992, MOL GEN GENET, V233, P436, DOI 10.1007/BF00265441; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; McClintock B, 1987, DISCOVERY CHARACTERI; MIYATA H, 1981, J GEN APPL MICROBIOL, V27, P365, DOI 10.2323/jgam.27.365; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PATTERSON GI, 1993, GENETICS, V135, P881; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; SABL JF, 1992, AM J HUM GENET, V50, P1171; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SINGER MJ, 1995, GENE SILENCING HIGHE, P165; THON G, 1993, GENETICS, V134, P1045; THON G, 1992, GENETICS, V131, P287; THON G, 1994, GENETICS, V138, P29; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604	39	194	199	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					95	101		10.1016/S0092-8674(00)80080-X	http://dx.doi.org/10.1016/S0092-8674(00)80080-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689692	Bronze			2022-12-24	WOS:A1996UX93400011
J	Liu, XS; Kim, CN; Yang, J; Jemmerson, R; Wang, XD				Liu, XS; Kim, CN; Yang, J; Jemmerson, R; Wang, XD			Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c	CELL			English	Article							MITOCHONDRIAL-DNA; BCL-2 PROTEIN; DEATH; GENE; LOCALIZATION; DEFICIENCY; CLEAVAGE; ENCODES; CED-3	A cell-free system based on cytosols of normally growing cells is established that reproduces aspects of the apoptotic program in vitro. The apoptotic program is initiated by addition of dATP. Fractionation of cytosol yielded a 15 kDa protein that is required for in vitro apoptosis. The absorption spectrum and protein sequence revealed that this protein is cytochrome c. Elimination of cytochrome c from cytosol by immunodepletion, or inclusion of sucrose to stabilize mitochondria during cytosol preparation, diminished the apoptotic activity. Adding back cytochrome c to the cytochrome c-depleted extracts restored their apoptotic activity. Cells undergoing apoptosis in vivo showed increased release of cytochrome c to their cytosol, suggesting that mitochondria may function in apoptosis by releasing cytochrome c.	EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA; UNIV MINNESOTA, SCH MED, DEPT MICROBIOL, MINNEAPOLIS, MN 55455 USA	Emory University; University of Minnesota System; University of Minnesota Twin Cities				Wang, Xiaodong/0000-0001-9885-356X				BENVENISTE P, 1995, P NATL ACAD SCI USA, V92, P8373, DOI 10.1073/pnas.92.18.8373; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; DEJONG D, 1994, CANCER RES, V54, P256; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; EEARI M, 1995, EMBO J, V14, P5201; EVANS MJ, 1988, P NATL ACAD SCI USA, V85, P9625, DOI 10.1073/pnas.85.24.9625; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GODAY A, 1985, BIOCHEM PHARMACOL, V34, P3561, DOI 10.1016/0006-2952(85)90734-8; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; HAYAKAWA M, 1993, MOL CELL BIOCHEM, V119, P95, DOI 10.1007/BF00926859; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, PHILOS T R SOC B, V345, P243, DOI 10.1098/rstb.1994.0100; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JEMMERSON R, 1991, EUR J IMMUNOL, V21, P143, DOI 10.1002/eji.1830210122; JEMMERSON R, 1991, P NATL ACAD SCI USA, V88, P4428, DOI 10.1073/pnas.88.10.4428; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Margoliash E, 1967, METHOD ENZYMOL, V10, P339; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pai JT, 1996, P NATL ACAD SCI USA, V93, P5437, DOI 10.1073/pnas.93.11.5437; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WAKADE AR, 1995, J BIOL CHEM, V270, P17986, DOI 10.1074/jbc.270.30.17986; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	48	4226	4452	11	237	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					147	157		10.1016/S0092-8674(00)80085-9	http://dx.doi.org/10.1016/S0092-8674(00)80085-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689682	Bronze			2022-12-24	WOS:A1996UX93400016
J	Hartwig, WC; Cartelle, C				Hartwig, WC; Cartelle, C			A complete skeleton of the giant South American primate Protopithecus	NATURE			English	Article								A COMPLETE Skeleton of a large-bodied New World monkey has been found in Pleistocene cave deposits in the Brazilian state of Bahia. It demonstrates an unprecedented combination of body size, locomotor and cranial morphology. Skeletal features indicate an animal of approximately 25 kg, more than twice the mass of any living South American monkey. We refer the specimen to Protopithecus brasiliensis Lund, 1838, a large Pleistocene primate originally represented by only a proximal femur and distal humerus(1-4). The skeleton resembles species of two distinct New World monkey lineages. The cranium is modified for an enlarged vocal sac typical of living howler monkeys(5-7), and the postcranium includes suspensory and brachiating components of locomotion as seen in living spider and woolly spider monkeys(8). This skeleton confirms that adaptive diversity in neotropical primates was greater in the recent past, and that current interpretations of how their distinctive adaptations evolved should be revised.	UNIV FED MINAS GERAIS,INST GEOCIENCIAS,BELO HORIZONT,MG,BRAZIL; GEORGE WASHINGTON UNIV,DEPT ANTHROPOL,WASHINGTON,DC 20052	Universidade Federal de Minas Gerais; George Washington University								CARTELLE C, 1994, ACTA GEOL LEOPOLD, V17, P411; CARTELLE C, 1993, NEOTROPICAL PRIMATES, V1, P8; Erikson, 1963, S ZOOL SOC LOND, V10, P135; Fleagle JG, 1988, PRIMATE ADAPTATION E; HARTWIG WC, 1995, J HUM EVOL, V28, P189, DOI 10.1006/jhev.1995.1013; HARTWIG WC, 1996, HIST PHIL LIFE SCI, V17, P3; LUND PW, 1838, DET KONG DANSKE VIDE, V8, P61; Martin PS, 1984, QUATERNARY EXTINCTIO; MENDEL F, 1976, FOLIA PRIMATOL, V26, P36, DOI 10.1159/000155728; PERES CA, 1994, J HUM EVOL, V26, P245, DOI 10.1006/jhev.1994.1014; ROSENBERGER AL, 1989, J HUM EVOL, V18, P717, DOI 10.1016/0047-2484(89)90102-4; Ruff C., 1990, P119; SCHON MA, 1971, FOLIA PRIMATOL, V15, P117, DOI 10.1159/000155371; Schon Ybarra MA, 1976, S DEV BAS, P664; YBARRA MAS, 1984, AM J PHYS ANTHROPOL, V63, P65, DOI 10.1002/ajpa.1330630109	15	65	68	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					307	311		10.1038/381307a0	http://dx.doi.org/10.1038/381307a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UM403	8692267				2022-12-24	WOS:A1996UM40300052
J	Bozic, CR; Lu, B; Hopken, UE; Gerard, C; Gerard, NP				Bozic, CR; Lu, B; Hopken, UE; Gerard, C; Gerard, NP			Neurogenic amplification of immune complex inflammation	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; PASSIVE ARTHUS REACTION; MAST-CELLS; SUBSTANCE-P; FC-RECEPTORS; MICE; NEUROPEPTIDES; MOUSE; INVOLVEMENT; PERITONITIS	The formation of intrapulmonary immune complexes in mice generates a vigorous inflammatory response characterized by microvascular permeability and polymorphonuclear neutrophil influx. Gene-targeted disruption of the substance P receptor (NK-1R) protected the lung from immune complex injury, as did disruption of the C5a anaphylatoxin receptor. Immunoreactive substance P was measurable in fluids lining the lung at time points before neutrophil influx and may thus be involved in an early step in the inflammatory response to immune complexes in the lung.	CHILDRENS HOSP,INA SUE PERLMUTTER LAB,BOSTON,MA 02115	Harvard University; Boston Children's Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036162, R01HL051366, R37HL036162] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51366, HL36162] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANSEL JC, 1993, J IMMUNOL, V150, P4478; Arthus M, 1903, CR SOC BIOL, V55, P817; BALUK P, 1996, AM J RESP CRIT CARE, V153, pA161; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; BOOMSMA JD, 1992, CHEST, V101, pS389, DOI 10.1378/chest.101.6_Supplement.389S; BOST K L, 1992, Regional Immunology, V4, P105; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BUCKLEY TL, 1994, J IMMUNOL, V153, P4169; BUNNETT N, COMMUNICATION; COCHRANE CG, 1974, INFLAMMATORY PROCESS, V3, pCH3; DAVIES KA, 1994, SPRINGER SEMIN IMMUN, V15, P397, DOI 10.1007/BF01837367; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; HOPKEN UE, IN PRESS NATURE; INOUE H, 1993, BRIT J PHARMACOL, V110, P1614, DOI 10.1111/j.1476-5381.1993.tb14009.x; LARSEN GL, 1981, AM REV RESPIR DIS, V123, P434; LUBERNAROD J, 1994, J IMMUNOL, V152, P819; MANTIONE CR, 1990, BRIT J PHARMACOL, V99, P516, DOI 10.1111/j.1476-5381.1990.tb12960.x; MAZUMDAR S, 1992, AM J GASTROENTEROL, V87, P176; PASCUAL DW, 1990, IMMUNOLOGY, V71, P52; RAMOS BF, 1994, J IMMUNOL, V152, P1380; RAMOS BF, 1992, EUR J IMMUNOL, V22, P2381, DOI 10.1002/eji.1830220930; RAMOS BF, 1990, J IMMUNOL, V145, P1868; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; WARREN JS, 1989, J CLIN INVEST, V84, P1873, DOI 10.1172/JCI114374; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922; ZHANG Y, 1991, J CLIN INVEST, V88, P841, DOI 10.1172/JCI115385	27	282	287	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1722	1725		10.1126/science.273.5282.1722	http://dx.doi.org/10.1126/science.273.5282.1722			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781237				2022-12-24	WOS:A1996VH40800044
J	Valcarcel, J; Gaur, RK; Singh, R; Green, MR				Valcarcel, J; Gaur, RK; Singh, R; Green, MR			Interaction of U2AF(65) RS region with pre-mRNA of branch point and promotion base pairing with U2 snRNA	SCIENCE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; PROTEIN-PROTEIN INTERACTIONS; RNA-BINDING PROTEINS; SPLICING FACTOR U2AF; MESSENGER-RNA; PREMESSENGER RNA; CONSERVED FAMILY; AUXILIARY FACTOR; SITE SELECTION; RECOGNITION	The mammalian splicing factor U2AF(65) binds to the polypyrimidine tract adjacent to the 3' splice site and promotes assembly of U2 small nuclear ribonucleoprotein on the upstream branch point, an interaction that involves base pairing with U2 small nuclear RNA(snRNA). U2AF(65) contains an RNA binding domain, required for interaction with the polypyrimidine tract, and an arginine-serine-rich (RS) region, required for U2 snRNP recruitment and splicing, Here it is reported that binding of U2AF(65) to the polypyrimidine tract directed the RS domain to contact the branch point and promoted U2 snRNA-branch point base pairing even in the absence of other splicing factors. Analysis of RS domain mutants indicated that the ability ol U2AF(65) to contact the branch point, to promote the U2 snRNA-branch point interaction, and to support splicing are related activities, requiring only a few basic amino acids. Thus, the U2AF(65) RS domain plays a direct role in modulating spliceosomal RNA-RNA interactions.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOL MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester			Valcarcel, Juan/O-9814-2014	Valcarcel, Juan/0000-0001-5398-3571				AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; ERICSON G, 1988, ANAL BIOCHEM, V174, P215, DOI 10.1016/0003-2697(88)90538-6; FEUGHELMAN M, 1955, NATURE, V175, P834, DOI 10.1038/175834a0; FLECKNER J, UNPUB; GAUR RK, 1995, RNA, V1, P407; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; HODGES PE, 1994, CURR BIOL, V4, P264, DOI 10.1016/S0960-9822(00)00061-0; KLEINSCHMIDT AM, 1989, NUCLEIC ACIDS RES, V17, P4817, DOI 10.1093/nar/17.12.4817; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LEE CG, 1993, J BIOL CHEM, V268, P13472; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MIRFAKHRAI M, 1993, NUCLEIC ACIDS RES, V21, P3591, DOI 10.1093/nar/21.15.3591; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; ONO W, 1994, MOL CELL BIOL, V14, P7611, DOI 10.1128/MCB.14.11.7611; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PATTON JR, 1987, MOL CELL BIOL, V7, P4030, DOI 10.1128/MCB.7.11.4030; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TEARE J, 1990, NUCLEIC ACIDS RES, V18, P855, DOI 10.1093/nar/18.4.855; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VALCARCEL J, UNPUB; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	46	232	233	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1996	273	5282					1706	1709		10.1126/science.273.5282.1706	http://dx.doi.org/10.1126/science.273.5282.1706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781232				2022-12-24	WOS:A1996VH40800039
J	Battiste, JL; Mao, HY; Rao, NS; Tan, RY; Muhandiram, DR; Kay, LE; Frankel, AD; Williamson, JR				Battiste, JL; Mao, HY; Rao, NS; Tan, RY; Muhandiram, DR; Kay, LE; Frankel, AD; Williamson, JR			alpha helix-RNA major groove recognition in an HIV-1 Rev peptide RRE RNA complex	SCIENCE			English	Article							PROTEIN SECONDARY STRUCTURE; IMMUNODEFICIENCY-VIRUS TAT; CHEMICAL-SHIFT INDEX; NMR-SPECTROSCOPY; CRYSTAL-STRUCTURE; BINDING-SITE; RESPONSIVE ELEMENT; MESSENGER-RNA; SIDE-CHAIN; BASE-PAIRS	The solution structure of a human immunodeficiency virus type-1 (HIV-1) Rev peptide bound to stem-loop IIB of the Rev response element (RRE) RNA was solved by nuclear magnetic resonance spectroscopy. the Rev peptide has an alpha-helical conformation and binds in the major groove of the RNA near a purine-rich internal loop. Several arginine side chains make base-specific contacts, and an asparagine residue contacts a G . A base pair. The phosphate backbone adjacent to a G . G base pair adopts an unusual structure that allows the peptide to access a widened major groove. The structure formed by the two purine-purine base pairs of the RRE creates a distinctive binding pocket that the peptide can use for specific recognition.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; UNIV TORONTO,DEPT MED GENET,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT CHEM,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,PROT ENGN CTR EXCELLENCE,TORONTO,ON M5S 1A8,CANADA; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Massachusetts Institute of Technology (MIT); University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of California System; University of California San Francisco			Williamson, James R/B-2891-2009; Rao, Nageswara/H-8707-2019; Williamson, James/AAL-2104-2021	Williamson, James R/0000-0002-8772-468X; Williamson, James/0000-0002-8772-468X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039589, R01GM053320] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39589, GM-53320, GM-08344] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Battiste JL, 1995, J BIOMOL NMR, V6, P375; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; BATTISTE JL, UNPUB; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRUNGER AT, 1992, X PLOR USER MANUAL V; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GRONENBORN AM, 1994, J BIOMOL NMR, V4, P455; Harada K, 1996, NATURE, V380, P175, DOI 10.1038/380175a0; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; LOGAN TM, 1992, FEBS LETT, V314, P413, DOI 10.1016/0014-5793(92)81517-P; LYU PC, 1993, BIOCHEMISTRY-US, V32, P421, DOI 10.1021/bi00053a006; MILHOLLEN MA, UNPUB; MONTELIONE GT, 1992, J AM CHEM SOC, V114, P10974, DOI 10.1021/ja00053a051; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P201; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; PRITCHARD CE, 1994, NUCLEIC ACIDS RES, V22, P2592, DOI 10.1093/nar/22.13.2592; PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; STALEY JP, 1994, PROTEIN SCI, V3, P1822, DOI 10.1002/pro.5560031021; TAN RY, 1994, BIOCHEMISTRY-US, V33, P14579, DOI 10.1021/bi00252a025; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6; YEN R, 1995, P NATL ACAD SCI USA, V92, P5282; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734	48	537	546	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1996	273	5281					1547	1551		10.1126/science.273.5281.1547	http://dx.doi.org/10.1126/science.273.5281.1547			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8703216				2022-12-24	WOS:A1996VG59700040
J	Imbert, V; Rupec, RA; Livolsi, A; Pahl, HL; Traenckner, EBM; MuellerDieckmann, C; Farahifar, D; Rossi, B; Auberger, P; Baeuerle, PA; Peyron, JF				Imbert, V; Rupec, RA; Livolsi, A; Pahl, HL; Traenckner, EBM; MuellerDieckmann, C; Farahifar, D; Rossi, B; Auberger, P; Baeuerle, PA; Peyron, JF			Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha	CELL			English	Article							SIGNAL-INDUCED PHOSPHORYLATION; REL-ASSOCIATED PP40; T-CELL ACTIVATION; TRANSCRIPTION FACTORS; KINASE; PROTEIN; INHIBITOR; TRANSDUCTION; RECEPTOR; DISSOCIATION	The transcription factor NF-kappa B regulates genes participating in immune and inflammatory responses. In T lymphocytes, NF-kappa B is sequestered in the cytosol by the inhibitor I kappa B-alpha and released after serine phosphorylation of I kappa B-alpha that regulates its ubiquitin-dependent degradation. We report an alternative mechanism of NF-kappa B activation. Stimulation of Jurkat T cells with the protein tyrosine phosphatase inhibitor and T cell activator pervanadate led to NF-kappa B activation through tyrosine phosphorylation but not degradation of I kappa B-alpha. Pervanadate-induced I kappa B-alpha phosphorylation and NF-kappa B activation required expression of the T cell tyrosine kinase p56(lck). Reoxygenation of hypoxic cells appeared as a physiological effector of I kappa B-alpha tyrosine phosphorylation. Tyrosine phosphorylation of I kappa B-alpha represents a proteolysis-independent mechanism of NF-kappa B activation that directly couples NF-kappa B to cellular tyrosine kinase.	UNIV FREIBURG, INST BIOCHEM, D-79104 FREIBURG, GERMANY	University of Freiburg	Imbert, V (corresponding author), FAC MED PASTEUR, INSERM U364, F-06107 NICE 02, FRANCE.		Peyron, Jean-Francois/M-5682-2016; Jean-Francois, Peyron/AAA-9496-2022; Pahl, Heike/AGM-5260-2022; AUBERGER, Patrick/G-1491-2013; Imbert, Véronique/I-6093-2016	Peyron, Jean-Francois/0000-0001-6113-916X; Jean-Francois, Peyron/0000-0001-6113-916X; AUBERGER, Patrick/0000-0002-2481-8275; Imbert, Véronique/0000-0003-2103-6718				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DRUKER BJ, 1994, J BIOL CHEM, V269, P5387; EICHER DM, 1994, J IMMUNOL, V152, P2710; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Imbert V, 1996, J INFLAMM, V46, P65; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; KOONG AC, 1994, CANCER RES, V54, P1425; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	618	638	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1996	86	5					787	798		10.1016/S0092-8674(00)80153-1	http://dx.doi.org/10.1016/S0092-8674(00)80153-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797825	Bronze			2022-12-24	WOS:A1996VG37200012
J	Lee, SL; Sadovsky, Y; Swirnoff, AH; Polish, JA; Goda, P; Gavrilina, G; Milbrandt, J				Lee, SL; Sadovsky, Y; Swirnoff, AH; Polish, JA; Goda, P; Gavrilina, G; Milbrandt, J			Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1)	SCIENCE			English	Article							GONADOTROPIN-RELEASING-HORMONE; RAT PITUITARY-CELLS; GENE-EXPRESSION; BETA-SUBUNIT; TRANSGENIC MICE; GROWTH; RECEPTOR; PROTEIN; DNA; NUCLEAR	The immediate-early transcription factor NGFl-A (also called Egr-1, zif/268, or Krox-24) is thought to couple extracellular signals to changes in gene expression, Although activins and inhibins regulate follicle-stimulating hormone (FSH) synthesis, no factor has been identified that exclusively regulates luteinizing hormone (LH) synthesis. An analysis of NGFl-A-deficient mice derived from embryonic stem cells demonstrated female infertility that was secondary to LH-beta deficiency. Ovariectomy led to increased amounts of FSH-beta but not LH-beta messenger RNA, which suggested a pituitary defect. A conserved, canonical NGFl-A site in the LH-beta promoter was required for synergistic activation by NGFl-A and steroidogenic factor-1 (SF-1). NGFl-A apparently influences female reproductive capacity through its regulation of LH-beta transcription.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Milbrandt, Jeffrey/0000-0002-5477-7689	NCI NIH HHS [CA53524] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA053524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beamer W. G., 1983, The mouse in biomedical research. Volume III. Normative biology, immunology, and husbandry, P165; CATTANACH BM, 1977, NATURE, V269, P338, DOI 10.1038/269338a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CLAYTON RN, 1991, MOL CELL ENDOCRINOL, V80, P193, DOI 10.1016/0303-7207(91)90156-M; CLAYTON RN, 1993, HUM REPROD, V8, P29, DOI 10.1093/humrep/8.suppl_2.29; DALKIN AC, 1993, ENDOCRINOLOGY, V132, P1297, DOI 10.1210/en.132.3.1297; DAY ML, 1990, J BIOL CHEM, V265, P15253; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GREEN ED, 1986, MOL CELL BIOCHEM, V72, P81; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JAMESON L, 1984, J BIOL CHEM, V259, P5474; KERI RA, 1994, MOL ENDOCRINOL, V8, P1807, DOI 10.1210/me.8.12.1807; KIM KE, 1990, MOL CELL ENDOCRINOL, V74, P101, DOI 10.1016/0303-7207(90)90112-L; LALA DS, 1995, STEROIDS, V60, P10, DOI 10.1016/0039-128X(94)00002-T; Lee S. A., UNPUB; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; RUGH R, 1990, MOUSE ITS REPRODUCTI, P7; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SAADE G, 1989, ENDOCRINOLOGY, V124, P1744, DOI 10.1210/endo-124-4-1744; SAADE G, 1989, J MOL ENDOCRINOL, V2, P213, DOI 10.1677/jme.0.0020213; SHUPNIK MA, 1989, J BIOL CHEM, V264, P80; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; WATSON MA, 1990, DEVELOPMENT, V110, P173; WEISS J, 1992, ENDOCRINOLOGY, V130, P415, DOI 10.1210/en.130.1.415; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	31	418	423	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1219	1221		10.1126/science.273.5279.1219	http://dx.doi.org/10.1126/science.273.5279.1219			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703054				2022-12-24	WOS:A1996VE47600037
J	Anderson, RM; Donnelly, CA; Ferguson, NM; Woolhouse, MEJ; Watt, CJ; Udy, HJ; MaWhinney, S; Dunstan, SP; Southwood, TRE; Wilesmith, JW; Ryan, JBM; Hoinville, LJ; Hillerton, JE; Austin, AR; Wells, GAH				Anderson, RM; Donnelly, CA; Ferguson, NM; Woolhouse, MEJ; Watt, CJ; Udy, HJ; MaWhinney, S; Dunstan, SP; Southwood, TRE; Wilesmith, JW; Ryan, JBM; Hoinville, LJ; Hillerton, JE; Austin, AR; Wells, GAH			Transmission dynamics and epidemiology of BSE in British cattle	NATURE			English	Article							BOVINE SPONGIFORM ENCEPHALOPATHY; SCRAPIE; SHEEP; OPTIMIZATION; MICE; PRP; VARIABLES; GENE	A comprehensive analysis of the bovine spongiform encephalopathy (BSE) epidemic in cattle in Great Britain assesses past, present and future patterns in the incidence of infection and disease, and allows a critical appraisal of different culling policies for eradication of the disease.	UNIV COLORADO, HLTH SCI CTR, DEPT PREVENT MED & BIOMETR, DENVER, CO 80262 USA; CENT VET LAB, ADDLESTONE KT15 3NB, SURREY, ENGLAND; INST ANIM HLTH, COMPTON NG20 7NN, BERKS, ENGLAND	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute	Anderson, RM (corresponding author), UNIV OXFORD, DEPT ZOOL, CTR EPIDEMIOL INFECT DIS, OXFORD OX1 3PS, ENGLAND.		Ferguson, Neil/B-8578-2008	Ferguson, Neil/0000-0002-1154-8093; Donnelly, Christl/0000-0002-0195-2463; Anderson, Roy/0000-0002-9528-3175	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; Asher D M, 1976, Ann Clin Lab Sci, V6, P84; BACCHETTI P, 1993, STAT SCI, V8, P82, DOI 10.1214/ss/1177010994; *BOV SPONG ENC ORD, 1988, 1039 BOV SPONG ENC O; BROOKMEYER R, 1988, J AM STAT ASSOC, V83, P301, DOI 10.2307/2288844; Caughley G, 1980, ANAL VERTEBRATE POPU; DAWSON M, 1991, CURRENT TOPICS VET M, P25; *DEP AGR FISH SCOT, 1981, 1980 1989 DEP AGR FI; *DEP AGR FISH SCOT, 1975, 1974 1979 DEP AGR FI; DICKINSON AG, 1974, J COMP PATHOL, V84, P19, DOI 10.1016/0021-9975(74)90023-1; Dickinson AG., 1979, SLOW TRANSMISSIBLE D, P13; DORRELL S, 1996, COMMUNICATION   0320; ESSLEMONT RJ, 1995, DAISY; FOSTER JD, 1993, VET REC, V133, P339, DOI 10.1136/vr.133.14.339; Foster JD, 1996, VET REC, V138, P546, DOI 10.1136/vr.138.22.546; FRASER H, 1992, J GEN VIROL, V73, P1891, DOI 10.1099/0022-1317-73-8-1891; GOLDMANN W, 1994, J GEN VIROL, V75, P989, DOI 10.1099/0022-1317-75-5-989; HALL JG, 1986, RUMINANT IMMUNE SYST; HOINVILLE LJ, 1995, VET REC, V136, P312, DOI 10.1136/vr.136.13.312; HUNTER N, 1994, VET REC, V135, P400, DOI 10.1136/vr.135.17.400; HUNTER N, 1989, VET REC, V124, P364, DOI 10.1136/vr.124.14.364; Jacobs D. A. H., 1977, STATE ART NUMERICAL; KIMBERLIN RH, 1993, INTERVIROLOGY, V35, P208, DOI 10.1159/000150311; KIMBERLIN RH, 1988, CIBA F SYMP, V135, P37; KIMBERLIN RH, 1994, ANN NY ACAD SCI, V724, P210, DOI 10.1111/j.1749-6632.1994.tb38911.x; KIRKPATRICK S, 1984, J STAT PHYS, V34, P975, DOI 10.1007/BF01009452; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; Madge D. S., 1975, MAMMALIAN ALIMENTARY; *MAFF, 1989, REP WORK PART BOV SP; MARTIN T, 1991, P EUR SOC VET VIR SE, P148; MCKAY MD, 1979, TECHNOMETRICS, V21, P239, DOI 10.2307/1268522; MCKINLEY MP, 1989, NEUROLOGY, V39, P1319, DOI 10.1212/WNL.39.10.1319; MIDDLETON DJ, 1993, VET REC, V132, P545, DOI 10.1136/vr.132.22.545; *MILK MARK BOARD N, 1991, MONTHL STAT MILK REC; *MIN AGR FISH FOOD, 1992, 1991 1994 AGR CENS S; *MIN AGR FISH FOOD, 1975, 1974 1989 MIN AGR FI; *MIN AGR FISH FOOD, 1996, SPONG ENNC GREAT BRI; OUTRAM GW, 1973, NATURE, V241, P536, DOI 10.1038/241536a0; PRESS WH, 1992, NUMEICAL RECIPES C; Prusiner SB, 1996, SEMIN VIROL, V7, P159, DOI 10.1006/smvy.1996.0021; RICHARDS MS, 1993, P SOC VET EP PREV ME, P70; *SCOTT OFF EC, 1991, 1990 1994 SCOTT OFF; *SPONG ENC ADV COM, 1995, TRANSM SPONG ENC SUM; Stekel DJ, 1996, NATURE, V381, P119, DOI 10.1038/381119a0; VANDERBILT D, 1984, J COMPUT PHYS, V56, P259, DOI 10.1016/0021-9991(84)90095-0; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0; WELLS GAH, 1994, VET REC, V135, P40, DOI 10.1136/vr.135.2.40; WILESMITH JW, 1992, VET REC, V130, P90, DOI 10.1136/vr.130.5.90; WILESMITH JW, 1994, PHILOS T R SOC B, V343, P357, DOI 10.1098/rstb.1994.0029; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; WILESMITH JW, 1993, VET REC, V132, P300, DOI 10.1136/vr.132.12.300; WILESMITH JW, UNPUB NATURE; WILESMITH JW, SERONO S; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; 1996, PROGRAMME ERADICATE	55	496	513	1	62	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 29	1996	382	6594					779	788		10.1038/382779a0	http://dx.doi.org/10.1038/382779a0			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752271				2022-12-24	WOS:A1996VE34700038
J	Beltman, FW; Heesen, WF; Kok, RHJ; Smit, AJ; May, JF; deGraeff, PA; Havinga, TK; Schuurman, FH; vanderVeur, E; Lie, KI; MeyboomdeJong, B				Beltman, FW; Heesen, WF; Kok, RHJ; Smit, AJ; May, JF; deGraeff, PA; Havinga, TK; Schuurman, FH; vanderVeur, E; Lie, KI; MeyboomdeJong, B			Predictive value of ambulatory blood pressure shortly after withdrawal of antihypertensive drugs in primary care patients	BRITISH MEDICAL JOURNAL			English	Article							THERAPY	Objective-To determine whether ambulatory blood pressure eight weeks after withdrawal of antihypertensive medication is a more sensitive measure than seated blood pressure to predict blood pressure in the long term. Design-Patients with previously untreated diastolic hypertension were treated with antihypertensive drugs for one year; these were withdrawn in patients with well controlled blood pressure, who were then followed for one year. Setting-Primary care. Subjects-29 patients fulfilling the criteria for withdrawal of antihypertensive drugs. Main outcome measures-Sensitivity, specificity, and positive and negative predictive value of seated and ambulatory blood pressure eight weeks after withdrawal of antihypertensive drugs. Results-Eight weeks after withdrawal of medication, mean diastolic blood pressure returned to the pretreatment level on ambulatory measurements but not on seated measurements. One;year after withdrawal of medication, mean diastolic blood pressure had returned to the pretreatment revel both for seated and ambulatory blood pressure. For ambulatory blood pressure, the sensitivity and the positive predictive value eight weeks after withdrawal of medication were superior to those for seated blood pressure; specificity and negative predictive value were comparable for both types of measurement. Receiver operating characteristic curves showed that the results were not dependent on the cut off vales that were used. Conclusion-Ambulatory blood pressure eight weeks after withdrawal of antihypertensive drugs predicts long term blood pressure better than measurements made when the patient is seated.	UNIV GRONINGEN HOSP,DEPT CARDIOL,NL-9700 RB GRONINGEN,NETHERLANDS; GRONINGEN HYPERTENS SERV,GEN PRACTITIONERS LAB,NL-9713 EC GRONINGEN,NETHERLANDS	University of Groningen	Beltman, FW (corresponding author), UNIV GRONINGEN,DEPT GEN PRACTICE,ANT DEUSINGLAAN 4,NL-9713 AW GRONINGEN,NETHERLANDS.							APPEL LJ, 1993, ANN INTERN MED, V118, P867, DOI 10.7326/0003-4819-118-11-199306010-00008; DORFMAN DD, 1969, J MATH PSYCHOL, V6, P487, DOI 10.1016/0022-2496(69)90019-4; FLETCHER AE, 1988, J HYPERTENS, V6, P431, DOI 10.1097/00004872-198806000-00001; METZ CE, 1986, INVEST RADIOL, V21, P720, DOI 10.1097/00004424-198609000-00009; SCHMIEDER RE, 1990, CARDIOVASC DRUG THER, V4, P1487, DOI 10.1007/BF02026496; STAESSEN J, 1990, J HYPERTENS, V8, pS57; STAESSEN JA, 1993, J HYPERTENS, V11, P1289; STANTON A, 1992, HYPERTENSION, V19, P93, DOI 10.1161/01.HYP.19.1.93	8	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 17	1996	313	7054					404	406						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761232				2022-12-24	WOS:A1996VD20600030
J	Fuchs, SC; Victora, CG; Martines, J				Fuchs, SC; Victora, CG; Martines, J			Case-control study of risk of dehydrating diarrhoea in infants in vulnerable period after full weaning	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OTITIS-MEDIA; YOUNG-CHILDREN; BRAZIL; DISEASES; DEATHS	Objectives-To investigate risk factors for dehydrating diarrhoea in infants, with special interest in the weaning period. Design-Case-control study. Setting-Metropolitan area of Porto Alegre, Brazil. Subjects-Cases were 192 children aged 0-23 months hospitalised with acute diarrhoea and moderate to severe dehydration. Controls were 192 children matched for age and neighbourhood who did not have diarrhoea in the previous week. Main outcome measures-Associations between dehydrating diarrhoea and child's age, type of milk consumed, time since breast feeding stopped, and breast feeding status. Results-In infants aged <12 months the risk of dehydrating diarrhoea was significantly higher in the first 9 months of life (P<0.001), and in those aged 12-23 months the risk was again greater in younger children (12-17 months) (P = 0.03). The type of milk consumed before start of diarrhoea episode was strongly associated with dehydration independent of socioeconomic, environmental, maternal reproductive, demographic, and health services factors. Compared with infants exclusively breast fed, bottle fed infants were at higher risk (odds ratio (95% confidence interval) for cow's milk 6.0 (1.8 to 19.8), for formula milk 6.9 (1.4 to 33.3)). Compared with those still breast feeding, children who stopped in the previous two months were more likely to develop dehydrating diarrhoea (odds ratio 8.4 (2.4 to 29.6)). This risk decreased with time since breast feeding stopped. Conclusion-These results confirm the protective effect of breast feeding and suggest there is a vulnerable period soon after breast feeding is stopped, which may be of relevance for developing preventive strategies.	UNIV FED PELOTAS, SCH MED, MESTRADO EPIDEMIOL, PELOTAS, RS, BRAZIL; WHO, DIARRHOEAL DIS CONTROL PROGRAMME, GENEVA, SWITZERLAND	Universidade Federal de Pelotas; World Health Organization	Fuchs, SC (corresponding author), UNIV FED RIO GRANDE SUL, SCH MED, DEPT SOCIAL MED, R RAMIRO BARCELOS 2600, SALA 415, BR-90035003 PORTO ALEGRE, RS, BRAZIL.		Fuchs, Sandra C/T-2670-2019; Victora, Cesar Gomes/Y-2455-2019; Victora, Cesar G/D-4476-2013	Victora, Cesar Gomes/0000-0002-2465-2180; Victora, Cesar G/0000-0002-2465-2180				ANIANSSON G, 1994, PEDIATR INFECT DIS J, V13, P183, DOI 10.1097/00006454-199403000-00003; BARAHAVIT Z, 1980, INFECT IMMUN, V29, P417; BARROS FC, 1990, 3 POP COUNC; BLACK RE, 1989, AM J EPIDEMIOL, V129, P785, DOI 10.1093/oxfordjournals.aje.a115193; Breslow N, 1980, STATISTICAL METHODS, V32; DUNCAN B, 1993, PEDIATRICS, V91, P867; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; GIUGLIANI ERJ, 1992, ACTA PAEDIATR, V81, P484, DOI 10.1111/j.1651-2227.1992.tb12279.x; GLASS RI, 1989, ACTA PAEDIATR SCAND, P131; HANSON LA, 1985, PEDIATRICS, V75, P172; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; LODINOVAZADNIKOVA R, 1991, PEDIATR RES, V29, P396, DOI 10.1203/00006450-199104000-00013; MAHMOOD DA, 1989, B WORLD HEALTH ORGAN, V67, P701; NARAYANAN I, 1989, ACTA PAEDIATR SCAND, P126; SASSEN ML, 1994, AM J OTOLARYNG, V15, P351, DOI 10.1016/0196-0709(94)90134-1; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SNYDER JD, 1982, B WORLD HEALTH ORGAN, V60, P605; VICTORA CG, 1989, AM J EPIDEMIOL, V129, P1032, DOI 10.1093/oxfordjournals.aje.a115207; VICTORA CG, 1994, PEDIATRICS, V93, P977; VICTORA CG, 1992, B WORLD HEALTH ORGAN, V70, P467; VICTORA CG, 1987, LANCET, V2, P319; World Health Organization, 1991, WHOCDDSER9114	22	27	28	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 17	1996	313	7054					391	394						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD206	8761225	Green Published			2022-12-24	WOS:A1996VD20600023
J	Wasan, HS; Goodlad, RA				Wasan, HS; Goodlad, RA			Fibre-supplemented foods may damage your health	LANCET			English	Editorial Material							CHAIN FATTY-ACIDS; DIETARY FIBER; CELL-DIVISION; GERM-FREE; CANCER; COLON		IMPERIAL CANC RES FUND, HISTOPATHOL UNIT, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	Wasan, HS (corresponding author), IMPERIAL CANC RES FUND, CANC GENET LAB, LONDON WC2A 3PX, ENGLAND.			Goodlad, Robert/0000-0002-7660-4287				ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BURKITT DP, 1969, LANCET, V2, P1229, DOI 10.1016/S0140-6736(69)90757-0; Goodlad R. A., 1995, P97; GOODLAD RA, 1989, GUT, V30, P820, DOI 10.1136/gut.30.6.820; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; HEATON KW, 1990, ROY SOC CH, V83, P3, DOI 10.1533/9781845698195.1.3; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; KRIPKE SA, 1989, JPEN-PARENTER ENTER, V13, P109, DOI 10.1177/0148607189013002109; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; PELL JD, 1995, GASTROENTEROLOGY, V108, P1745, DOI 10.1016/0016-5085(95)90136-1; Peterson K, 1996, SCIENCE, V271, P441; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; ROBERFROID MB, 1993, ROY SOC CH, P255, DOI 10.1533/9781845698256.5.255; SAKATA T, 1984, Q J EXP PHYSIOL CMS, V69, P639, DOI 10.1113/expphysiol.1984.sp002850; THOMAS RD, 1995, ENVIRON HEALTH PERSP, V103, P45, DOI 10.2307/3432344	18	53	54	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					319	320		10.1016/S0140-6736(96)01401-8	http://dx.doi.org/10.1016/S0140-6736(96)01401-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709694				2022-12-24	WOS:A1996VA25000016
J	Wise, R				Wise, R			Global paradox	LANCET			English	Editorial Material											Wise, R (corresponding author), CITY HOSP NHS TRUST,DUDLEY RD,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							Ford CW, 1996, ANTIMICROB AGENTS CH, V40, P1508, DOI 10.1128/AAC.40.6.1508; SLEE AM, 1987, ANTIMICROB AGENTS CH, V31, P1791, DOI 10.1128/AAC.31.11.1791; *WHO, 1996, 1996 WORLD HEALTH; 1996, ECONOMIST       0525, P17	4	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 3	1996	348	9023					282	282		10.1016/S0140-6736(05)64470-4	http://dx.doi.org/10.1016/S0140-6736(05)64470-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA250	8709685				2022-12-24	WOS:A1996VA25000006
J	Omont, A; Petitjean, P; Guilloteau, S; McMahon, RG; Solomon, PM; Pecontal, E				Omont, A; Petitjean, P; Guilloteau, S; McMahon, RG; Solomon, PM; Pecontal, E			Molecular gas and dust around a radio-quiet quasar at redshift 4.69	NATURE			English	Article							GALAXY IRAS 10214+4724; EMISSION; MASS; F10214+4724	GALAXIES are believed to have formed a large proportion of their stars in giant bursts of star formation early in their lives, but when and how this took place are still very uncertain. The presence(1-6) of large amounts of dust in quasars and radio galaxies at redshifts z > 4 shows that some synthesis of heavy elements had already occurred at this time. This implies that molecular gas-the building material of stars-should also be present, as it is in galaxies at lower redshifts (z approximate to 2.5, refs 7-10). Here we report the detection of emission from dust and carbon monoxide in the radio-quiet quasar BR1202 - 0725, at redshift z = 4.69. Maps of these emissions reveal two objects, separated by a few are seconds, which could indicate either the presence of a companion to the quasar of gravitational lensing of the quasar itself. Regardless of the precise interpretation of the maps, the detection of carbon monoxide confirms the presence of a large mass of molecular gas in one of the most distant galaxies known, and shows that conditions conducive to huge bursts of star formation existed in the very early Universe.	OBSERV PARIS,DAEC,CNRS,URA 173,F-92195 MEUDON,FRANCE; INST RADIO ASTRON MILLIMETR,F-38460 ST MARTIN DHERES,FRANCE; INST ASTRON,CAMBRIDGE CB3 0HA,ENGLAND; SUNY STONY BROOK,ASTRON PROGRAM,STONY BROOK,NY 11794; CTR RECH ASTRON LYON,CNRS,UMR 142,F-69561 ST GENIS LAVAL,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; University of Cambridge; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Centre National de la Recherche Scientifique (CNRS)	Omont, A (corresponding author), CNRS,INST ASTROPHYS,98BIS BD ARAGO,F-75014 PARIS,FRANCE.		McMahon, Richard/G-4260-2012	McMahon, Richard/0000-0001-8447-8869				BARVAINIS R, 1994, NATURE, V371, P586, DOI 10.1038/371586a0; BARVAINIS R, IN PRESS COLD GAS HI; BROADHURST T, 1995, ASTROPHYS J, V450, pL41, DOI 10.1086/316774; BROWN RL, 1992, ASTROPHYS J, V397, pL19, DOI 10.1086/186534; CHINI R, 1994, ASTRON ASTROPHYS, V288, pL33; DJORGOVSKI S, 1992, MON NOT R ASTRON SOC, V257, P240, DOI 10.1093/mnras/257.2.240; Djorgovski S. G., 1995, Science with VLT. Proceedings of the ESO Workshop, P351; DOWNES D, 1992, ASTROPHYS J, V398, pL25, DOI 10.1086/186568; DOWNES D, 1993, ASTROPHYS J, V414, pL13, DOI 10.1086/186984; DOWNES D, 1995, ASTROPHYS J, V453, pL65, DOI 10.1086/309754; DUNLOP JS, 1994, NATURE, V370, P347, DOI 10.1038/370347a0; Eisenhardt PR, 1996, ASTROPHYS J, V461, P72, DOI 10.1086/177038; Elston R, 1996, ASTROPHYS J, V456, pL13, DOI 10.1086/309853; FONTANA A, IN PRESS MON NOT R A; FRANCESCHINI A, UNPUB MON NOT R ASTR; HAEHNELT MG, 1993, MON NOT R ASTRON SOC, V263, P168, DOI 10.1093/mnras/263.1.168; Hu EM, 1996, ASTROPHYS J, V459, pL53, DOI 10.1086/309958; ISAAK KG, 1994, MON NOT R ASTRON SOC, V269, pL28, DOI 10.1093/mnras/269.1.L28; IVISON RJ, 1995, MON NOT R ASTRON SOC, V275, pL33, DOI 10.1093/mnras/275.1.L33; Lu LM, 1996, ASTROPHYS J, V457, pL1; MAGAIN P, 1988, NATURE, V334, P325, DOI 10.1038/334325a0; MCMAHON RG, 1994, MON NOT R ASTRON SOC, V267, pL9, DOI 10.1093/mnras/267.1.L9; OMONT A, IN PRESS ASTR ASTROP; Petitjean P, 1996, NATURE, V380, P411, DOI 10.1038/380411a0; SCOVILLE NZ, IN PRESS COLD GAS HI; SOLOMON PM, 1992, ASTROPHYS J, V398, pL29, DOI 10.1086/186569; SOLOMON PM, IN PRESS ASTROPHYS J; STORRIELOMBARDI LJ, IN PRESS ASTROPHYS J; VARVAINIS R, 1995, ASTROPHYS J, V451, pL9; WAMPLER EJ, IN PRESS ASTR ASTROP	30	237	237	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					428	431		10.1038/382428a0	http://dx.doi.org/10.1038/382428a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684483	Green Submitted			2022-12-24	WOS:A1996VA25100049
J	Berger, D; Fukunishi, I				Berger, D; Fukunishi, I			Psychiatric drug development in Japan	SCIENCE			English	Editorial Material									ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine	Berger, D (corresponding author), TOKYO INST PSYCHIAT, SETAGAYA KU, 2-1-8 KAMIKITAZAWA, TOKYO 156, JAPAN.							ALVIR JMJ, 1993, NEW ENGL J MED, V329, P162, DOI 10.1056/NEJM199307153290303; FUKUSHIMA M, 1989, NATURE, V342, P850, DOI 10.1038/342850a0; HAYASHI K, 1995, MED ASAHI, V24, P43; LIN KM, 1988, J CLIN PSYCHOPHARM, V8, P195; MIZUSHIMA Y, 1995, NIHON ENSHOU GAKKAI, V15, P93; MIZUSHIMA Y, 1995, NIHON ENSHOU GAKKAI, V15, P193; OKADA F, 1993, HUM PSYCHOPHARM CLIN, V8, P371, DOI 10.1002/hup.470080512; OKADA F, 1995, ANN PHARMACOTHER, V29, P432, DOI 10.1177/106002809502900419; PICKAR D, 1995, JAMA-J AM MED ASSOC, V274, P981; 1996, ASAHI SHINBUN   0229, P39; 1995, ASAHI SHINBUN   1107, P2; 1994, NATURE, V371, P89	12	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 19	1996	273	5273					318	319		10.1126/science.273.5273.318	http://dx.doi.org/10.1126/science.273.5273.318			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UY202	8685717				2022-12-24	WOS:A1996UY20200025
J	Salmeron, JM; Oldroyd, GED; Rommens, CMT; Scofield, SR; Kim, HS; Lavelle, DT; Dahlbeck, D; Staskawicz, BJ				Salmeron, JM; Oldroyd, GED; Rommens, CMT; Scofield, SR; Kim, HS; Lavelle, DT; Dahlbeck, D; Staskawicz, BJ			Tomato Prf is a member of the leucine-rich repeat class of plant disease resistance genes and lies embedded within the Pto kinase gene cluster	CELL			English	Article							SELF-INCOMPATIBILITY LOCUS; CLADOSPORIUM-FULVUM; BRASSICA-OLERACEA; PROTEIN; CLONING; ARABIDOPSIS; RECEPTOR; SENSITIVITY; DROSOPHILA; EXPRESSION	In tomato, resistance to Pseudomonas syringae pv. tomato (Pst) strains expressing the avirulence gene avrPto requires the presence of at least two host genes, designated Pto and Prf. Here we report that Prf encodes a protein with leucine-zipper, nucleotide-binding, and leucine-rich repeat motifs, as are found in a number of resistance gene products from other plants. prf mutant alleles (4) were found to carry alterations within the Prf coding sequence. A genomic fragment containing Prf complemented a prf mutant tomato line both for resistance to Pst strains expressing avrPto and for sensitivity to the insecticide Fenthion. Prf resides in the middle of the Pto gene cluster, 24 kb from the Pto gene and 500 bp from the Fen gene.	UNIV CALIF BERKELEY, DEPT PLANT BIOL, BERKELEY, CA 94720 USA; CIBA GEIGY CORP, AGR BIOTECHNOL, RES TRIANGLE PK, NC 27709 USA; NATL SCI FDN, CTR ENGN PLANTS RESISTANCE AGAINST PATHOGENS, DAVIS, CA 95616 USA	University of California System; University of California Berkeley; National Science Foundation (NSF)			Scofield, Steven/C-3868-2016; Oldroyd, Giles/ABD-8143-2021; Oldroyd, Giles/ABA-7501-2020	Oldroyd, Giles/0000-0002-5245-6355; 				Ausubel FM, 1992, CURRENT PROTOCOLS MO; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; BOYES DC, 1993, MOL GEN GENET, V236, P369, DOI 10.1007/BF00277135; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CARLAND FM, 1993, MOL GEN GENET, V239, P17, DOI 10.1007/BF00281596; Dangl J L, 1994, Curr Top Microbiol Immunol, V192, P99; DANLG J, 1995, CELL, V80, P383; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LATEROTT H, 1995, TOMATO GENET RES COO, V35, P6; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; MARTIN GB, 1993, MOL PLANT MICROBE IN, V6, P26, DOI 10.1094/MPMI-6-026; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; Pitblado R. E., 1983, Canadian Journal of Plant Pathology, V5, P251; REARDON JT, 1987, GENETICS, V115, P323; ROMMENS CMT, 1995, PLANT CELL, V7, P249, DOI 10.1105/tpc.7.3.249; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; RYALS J, 1995, P NATL ACAD SCI USA, V92, P4202, DOI 10.1073/pnas.92.10.4202; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; STOTZ HU, 1994, PLANT MOL BIOL, V25, P607, DOI 10.1007/BF00029600; SUDUPAK MA, 1993, GENETICS, V133, P119; SUN TP, 1992, PLANT CELL, V4, P119, DOI 10.1105/tpc.4.2.119; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	41	439	479	0	38	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1996	86	1					123	133		10.1016/S0092-8674(00)80083-5	http://dx.doi.org/10.1016/S0092-8674(00)80083-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UX934	8689679	hybrid			2022-12-24	WOS:A1996UX93400014
J	Honour, JW				Honour, JW			Testing for drug abuse	LANCET			English	Editorial Material											Honour, JW (corresponding author), UCL, DIV MOL PATHOL, LONDON W1N 8AA, ENGLAND.								0	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					41	43		10.1016/S0140-6736(96)05336-6	http://dx.doi.org/10.1016/S0140-6736(96)05336-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UV923	8691934				2022-12-24	WOS:A1996UV92300016
J	Boldin, MP; Goncharov, TM; Goltsev, YV; Wallach, D				Boldin, MP; Goncharov, TM; Goltsev, YV; Wallach, D			Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death	CELL			English	Article							FAS ANTIGEN; C-ELEGANS; NECROSIS; EXPRESSION; APOPTOSIS; CLEAVAGE; ENZYME; DOMAIN	Fas/APO-1 and p55 tumor necrosis factor (TNF) receptor (p55-R) activate cellular mechanisms that result in cell death. Upon activation of these receptors, Fas/APO-1 binds a protein called MORT1 (or FADD) and p55-R binds a protein called TRADD. MORT1 and TRADD can also bind to each other. We have cloned a novel protein, MACH, that binds to MORT1. This protein exists in multiple isoforms, some of which contain a region that has proteolytic activity and shows marked sequence homology to proteases of the ICE/CED-3 family. Cellular expression of the proteolytic MACH isoforms results in cell death. Expression of MACH isoforms that contain an incomplete ICE/CEDE region provides effective protection against the cytotoxicity induced by Fas/APO-1 or p55-R triggering. These findings suggest that MACH is the most upstream enzymatic component in the Fas/APO-1- and p55-R-induced cell death signaling cascades.			Boldin, MP (corresponding author), WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL.		Roszak, Joanna/F-4003-2010	Boldin, Mark/0000-0003-4593-0669				ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GRELL M, 1994, EUR J IMMUNOL, V24, P2563, DOI 10.1002/eji.1830241045; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WEITZEN M, 1980, J IMMUNOL, V125, P719; WONG GHW, 1994, J IMMUNOL, V152, P1751; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	56	2054	2148	2	33	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					803	815		10.1016/S0092-8674(00)81265-9	http://dx.doi.org/10.1016/S0092-8674(00)81265-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681376	Bronze			2022-12-24	WOS:A1996UR60400005
J	Walter, JH				Walter, JH			Two ''new'' treatable inherited biosynthetic disorders	LANCET			English	Editorial Material											Walter, JH (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,WILLINK BIOCHEM GENET UNIT,MANCHESTER M27 4HA,LANCS,ENGLAND.							Isbrandt D, 1995, BBA-GENE STRUCT EXPR, V1264, P265, DOI 10.1016/0167-4781(95)00184-0; Jaeken J, 1996, ARCH DIS CHILD, V74, P542, DOI 10.1136/adc.74.6.542; STOCKLER S, 1994, PEDIATR RES, V36, P409; STOCKLER S, 1996, AM J HUM GENET, V59, P914	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					558	559		10.1016/S0140-6736(05)64790-3	http://dx.doi.org/10.1016/S0140-6736(05)64790-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774561				2022-12-24	WOS:A1996VF18600002
J	Cutler, S; Ghassemian, M; Bonetta, D; Cooney, S; McCourt, P				Cutler, S; Ghassemian, M; Bonetta, D; Cooney, S; McCourt, P			A protein farnesyl transferase involved in abscisic acid signal transduction in Arabidopsis	SCIENCE			English	Article							GUARD-CELLS; GENE-EXPRESSION; PLASMA-MEMBRANE; RAS PROTEINS; ACTIVATION; CALCIUM; YEAST; FARNESYLTRANSFERASE; ISOPRENYLATION; PHOSPHATASE	The hormone abscisic acid (ABA) modulates a variety of developmental processes and responses to environmental stress in higher plants. A collection of mutations, designated era, in Arabidopsis thaliana that confer an enhanced response to exogenous ABA includes mutations in the Era1 gene, which encodes the beta subunit of a protein farnesyl transferase. In yeast and mammalian systems, farnesyl transferases modify several signal transduction proteins for membrane localization. The era1 mutants suggest that a negative regulator of ABA sensitivity must be acted on by a farnesyl transferase to function.	UNIV TORONTO, DEPT BOT, TORONTO, ON M5S 3B2, CANADA	University of Toronto			Cutler, Sean R/D-6617-2011					BASKIN JM, 1971, CAN J BOT, V50, P277; BLATT MR, 1990, NATURE, V346, P766, DOI 10.1038/346766a0; CASEY PJ, 1995, BIOCHEM SOC T, V23, P161, DOI 10.1042/bst0230161; CHANDLER PM, 1994, ANNU REV PLANT PHYS, V45, P113, DOI 10.1146/annurev.pp.45.060194.000553; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; Cutler S. J., UNPUB; FINKELSTEIN RR, 1994, PLANT J, V5, P765, DOI 10.1046/j.1365-313X.1994.5060765.x; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; IRVING HR, 1992, P NATL ACAD SCI USA, V89, P1790, DOI 10.1073/pnas.89.5.1790; Koornneef M., 1994, ARABIDOPSIS, VVolume 27, P313; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; RANDALL SK, 1993, PLANT CELL, V5, P433, DOI 10.1105/tpc.5.4.433; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHROEDER JI, 1990, P NATL ACAD SCI USA, V87, P9305, DOI 10.1073/pnas.87.23.9305; SHIRLEY BW, 1992, PLANT CELL, V4, P333, DOI 10.1105/tpc.4.3.333; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; YANG ZB, 1993, PLANT PHYSIOL, V101, P667, DOI 10.1104/pp.101.2.667; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255	27	321	340	3	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1996	273	5279					1239	1241		10.1126/science.273.5279.1239	http://dx.doi.org/10.1126/science.273.5279.1239			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703061				2022-12-24	WOS:A1996VE47600044
J	Kasid, U; Suy, S; Dent, P; Ray, S; Whiteside, TL; Sturgill, TW				Kasid, U; Suy, S; Dent, P; Ray, S; Whiteside, TL; Sturgill, TW			Activation of Raf by ionizing radiation	NATURE			English	Article							MAP KINASE-KINASE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; GROWTH-FACTORS; PROTOONCOGENE; SENSITIVITY; PHOSPHATASE	THE critical pathways through which ionizing radiation induces malignant transformation and cell death are not well defined. Raf-1, a cytoplasmic serine-threonine protein kinase, mediates the transmission of mitogenic signals initiated at the cell membrane to the nucleus, resulting in the activation of transcription factors that regulate cell growth and proliferation(1,2). Moreover, Raf-1 overexpression and activation increases the survival response of mammalian cells to the toxic effects of ionizing radiation by an as-yet unknown mechanism (refs 3, 4 and V. Soldatenkov et al.; manuscript submitted), Somewhat analogous to mitogen-induced signalling, radiation stimulates protein-tyrosine kinase(s) and transcription factors(5,6). No direct biochemical link has been established, however, between radiation-stimulated protein tyrosine phosphorylation and downstream signals. Here we report a series of radiation-responsive events in which protein-tyrosine phosphorylation is followed by membrane recruitment, then tyrosine phosphorylation and activation of Raf-1 in vivo. Our results show that radiation-stimulated protein-tyrosine kinase(s) modify Raf-1, and implicate Raf-1 in the ionizing-radiation signal-transduction pathway.	GEORGETOWN UNIV,LOMBARDI CANC CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007; UNIV VIRGINIA,HOWARD HUGHES MED INST,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,MARKEY CTR CELL SIGNALING,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,MARKEY CTR CELL SIGNALING,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV PITTSBURGH,PITTSBURGH CANC INST,DEPT PATHOL,PITTSBURGH,PA 15261	Georgetown University; Howard Hughes Medical Institute; University of Virginia; University of Virginia; University of Virginia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Kasid, U (corresponding author), GEORGETOWN UNIV,LOMBARDI CANC CTR,DEPT RADIAT MED,WASHINGTON,DC 20007, USA.							CHAE HP, 1993, CANCER RES, V53, P447; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HEO DS, 1989, CANCER RES, V49, P5167; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KASID U, 1993, ADV CANCER RES, V61, P195, DOI 10.1016/S0065-230X(08)60959-8; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARAIS R, 1995, EMBO J, V14, P3169; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WITTE L, 1989, CANCER RES, V49, P5066; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	29	149	156	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					813	816		10.1038/382813a0	http://dx.doi.org/10.1038/382813a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752275				2022-12-24	WOS:A1996VE34700048
J	Hylek, EM; Skates, SJ; Sheehan, MA; Singer, DE				Hylek, EM; Skates, SJ; Sheehan, MA; Singer, DE			An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; WARFARIN; STROKE; COMPLICATIONS; OUTPATIENTS; PREVENTION; THROMBOSIS; ASPIRIN; THERAPY; SMOKING	Background To avert major hemorrhage, physicians need to know the lowest intensity of anticoagulation that is effective in preventing stroke in patients with atrial fibrillation. Since the low rate of stroke has made it difficult to perform prospective studies to resolve this issue, we conducted a case-control study. Methods We studied 74, consecutive patients with atrial fibrillation who were admitted to our hospital from 1989 through 1994 after having an ischemic stroke while taking warfarin. For each patient with stroke, three controls with nonrheumatic atrial fibrillation who were treated as our patients were randomly selected from the 1994 registry of the anticoagulant-therapy unit (222 controls). We used the international normalized ratio (INR) to measure the intensity of anticoagulation. For The patients with stroke, we used the INR at admission; for the controls, we selected the INR that was measured closest to the month and day of the matched case patient's hospital admission. Results The risk of stroke rose steeply at INRs below 2.0. At an INR of 1.7, the adjusted odds ratio for stroke, as compared with the risk at an INR of 2.0, was 2.0 (95 percent confidence interval, 1.6 to 2.4); at an INR of 1.5, it was 3.3 (95 percent confidence interval, 2.4 to 4.6); and at an INR of 1.3, it was 6.0 (95 percent confidence interval, 3.6 to 9.8). Other independent risk factors were previous stroke (odds ratio, 10.4; 95 percent confidence interval, 4.4 to 24.5), diabetes mellitus (odds ratio, 2.9; 95 percent confidence interval, 1.3 to 6.5), hypertension (odds ratio, 2.5; 95 percent confidence interval, 1.1 to 5.7), and current smoking (odds ratio, 5.7; 95 percent confidence Interval, 1.4 to 24.0). Conclusions Among patients with atrial fibrillation, anticoagulant prophylaxis is effective at INRs of 2.0 or greater. Since previous studies have indicated that the risk of hemorrhage rises rapidly at INRs greater than 4.0 to 5.0, tight control of anticoagulant therapy to maintain the INR between 2.0 and 3.0 is a better strategy than targeting lower, less effective levels of anticoagulation. (C) 1996. Massachusetts Medical Society.	MASSACHUSETTS GEN HOSP, DEPT MED, CLIN EPIDEMIOL UNIT, DIV GEN INTERNAL MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Hylek, Elaine/0000-0001-8263-8304				[Anonymous], 1994, ARCH INTERN MED, V154, P2254; [Anonymous], 1996, INT CLASSIFICATION D; ANSELL JE, 1995, ARCH INTERN MED, V155, P2185, DOI 10.1001/archinte.155.20.2185; BERN MM, 1986, SURGERY, V99, P216; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; EZEKOWITZ MD, 1993, NEW ENGL J MED, V328, P148; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; HOSMER DW, 1989, APPL LOGISTIC REGRES, P187; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; KAWACHI I, 1993, JAMA-J AM MED ASSOC, V269, P232, DOI 10.1001/jama.269.2.232; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; LANDEFELD CS, 1989, AM J MED, V87, P144; LAUPACIS A, 1995, CHEST, V108, pS352, DOI 10.1378/chest.108.4_Supplement.352S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCCRORY DC, 1995, ARCH INTERN MED, V155, P277, DOI 10.1001/archinte.155.3.277; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; PETERSEN P, 1989, LANCET, V1, P175; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; *STATSC, 1993, S PLUS REF MAN VERS; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; 1995, STROKE, V26, P1978; 1993, LANCET, V342, P1255; 1995, STROKE, V26, P1981	32	648	688	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1996	335	8					540	546		10.1056/NEJM199608223350802	http://dx.doi.org/10.1056/NEJM199608223350802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VD302	8678931				2022-12-24	WOS:A1996VD30200002
J	Swinbanks, D				Swinbanks, D			Japan shuns radishes after 'possible link' to E-coli	NATURE			English	News Item																		1996, NATURE, V382, P290	1	19	19	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1996	382	6592					567	567		10.1038/382567b0	http://dx.doi.org/10.1038/382567b0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757116	Bronze			2022-12-24	WOS:A1996VC30300008
J	Ekland, EH; Bartel, DP				Ekland, EH; Bartel, DP			RNA-catalysed RNA polymerization using nucleoside triphosphates	NATURE			English	Article							COMPLEMENTARY-STRAND RNA; SELF-SPLICING RNA; TETRAHYMENA RIBOZYME; REPLICATION; POLYMERASE; TEMPLATE; LIFE; ORIGINS; MODEL; VIRUS	THE hypothesis that certain RNA molecules may be able to catalyse RNA replication is central to current theories of the early evolution of life(1-6). In support of this idea, we describe here an RNA that synthesizes RNA using the same reaction as that employed by protein enzymes that catalyse RNA polymerization. In the presence of the appropriate template RNA and nucleoside triphosphates, the ribozyme extends an RNA primer by successive addition of up to six mononucleotides. The added nucleotides are joined to the growing RNA chain by 3',5'-phosphodiester linkages. The ribozyme shows marked template fidelity: extension by nucleotides complementary to the template is up to 1,000 times more efficient than is extension by mismatched nucleotides.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute								BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BARTEL DP, 1991, MOL CELL BIOL, V11, P3390, DOI 10.1128/MCB.11.6.3390; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CHAPMAN KB, 1995, CHEM BIOL, V2, P325, DOI 10.1016/1074-5521(95)90051-9; CHOWRIRA BM, 1993, EMBO J, V12, P3599, DOI 10.1002/j.1460-2075.1993.tb06033.x; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; EKLAND EH, 1995, NUCLEIC ACIDS RES, V23, P3231, DOI 10.1093/nar/23.16.3231; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; JOSHI RL, 1983, EMBO J, V2, P1123, DOI 10.1002/j.1460-2075.1983.tb01556.x; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; Joyce GF., 1993, COLD SPRING HARB MON, V24, P1; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MORL M, 1992, CELL, V70, P803, DOI 10.1016/0092-8674(92)90313-2; MUELLER MW, 1993, SCIENCE, V261, P1035, DOI 10.1126/science.8351516; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; PACE NR, 1985, ORIGINS LIFE EVOL B, V16, P97, DOI 10.1007/BF01809465; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; RAO ALN, 1989, P NATL ACAD SCI USA, V86, P5335, DOI 10.1073/pnas.86.14.5335; SAVILLE BJ, 1991, P NATL ACAD SCI USA, V88, P8826, DOI 10.1073/pnas.88.19.8826; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; STEINHAUER DA, 1986, J VIROL, V57, P219, DOI 10.1128/JVI.57.1.219-228.1986; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; VANTOL H, 1991, VIROLOGY, V180, P23, DOI 10.1016/0042-6822(91)90005-V; WARD CD, 1992, J VIROL, V66, P3784, DOI 10.1128/JVI.66.6.3784-3793.1992; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	30	169	179	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 25	1996	382	6589					373	376		10.1038/382373a0	http://dx.doi.org/10.1038/382373a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684470				2022-12-24	WOS:A1996UY95000058
J	Loomis, CA; Harris, E; Michaud, J; Wurst, W; Hanks, M; Joyner, AL				Loomis, CA; Harris, E; Michaud, J; Wurst, W; Hanks, M; Joyner, AL			The mouse Engrailed-1 gene and ventral limb patterning	NATURE			English	Article							PROTO-ONCOGENE INT-1; ECTODERMAL CONTROL; EXPRESSION; SUGGEST; EMBRYO; BMP-2A; EN-1	DURING vertebrate limb development, positional information must be specified along three distinct axes. Although much progress has been made in our understanding of the molecular interactions involved in anterior-posterior and proximal-distal limb patterning, less is known about dorsal-ventral patterning(1-3). The genes Wnt-7a and Lmx-1,which are expressed in dorsal limb ectoderm and mesoderm, respectively, are thought to be important regulators of dorsal limb differentiation(4-6). Whether a complementary set of molecules controls ventral limb development has not been clear. Here we report that Engrailed-1, a homeodamain-containing transcription factor expressed in embryonic central limb ectoderm(7,8), is essential for ventral limb patterning. Loss of Engrailed-1 function in mice results in dorsal transformations of ventral paw structures, and in subtle alterations along the proximal-distal limb ads. Engrailed-1 seems to act in part by repressing dorsal differentiation induced by Wnt-7a, and is essential for proper formation of the apical ectodermal ridge.	NYU,SCH MED,SKIRBALL INST BIOMOL MED,DEV GENET PROGRAM,NEW YORK,NY 10016; NYU,SCH MED,RONALD PERELMAN DEPT DERMATOL,NEW YORK,NY 10016; NYU,SCH MED,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,SCH MED,DEPT PHYSIOL & NEUROSCI,NEW YORK,NY 10016; COLL FRANCE,INST EMBRYOL CELLULAIRE & MOLEC,F-94736 NOGENT SUR MARNE,FRANCE; CNRS,INST EMBRYOL CELLULAIRE & MOLEC,F-94736 NOGENT SUR MARNE,FRANCE; GSF MUNICH,RES CTR,D-85758 MUNICH,GERMANY	New York University; New York University; New York University; New York University; UDICE-French Research Universities; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health				Wurst, Wolfgang/0000-0003-4422-7410				CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; GEDUSPAN JS, 1987, DEV BIOL, V124, P398, DOI 10.1016/0012-1606(87)90492-1; GEDUSPAN JS, 1989, ANAT REC, V224, P79, DOI 10.1002/ar.1092240110; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MARTIN GR, 1995, NATURE, V374, P410, DOI 10.1038/374410a0; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; PATAU MP, 1977, VERTEBRATE LIMB SOMI, P257; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; SANICOLA M, 1995, GENETICS, V139, P745; TABATA T, 1995, DEVELOPMENT, V121, P3359; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WURST W, 1994, DEVELOPMENT, V120, P2065; ZECCA M, 1995, DEVELOPMENT, V121, P2265	23	237	243	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					360	363		10.1038/382360a0	http://dx.doi.org/10.1038/382360a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684466				2022-12-24	WOS:A1996UY95000054
J	Anda, P; SanchezYebra, W; Vitutia, MD; Pastrana, EP; Rodriguez, I; Miller, NS; Backenson, PB; Benach, JL				Anda, P; SanchezYebra, W; Vitutia, MD; Pastrana, EP; Rodriguez, I; Miller, NS; Backenson, PB; Benach, JL			A new Borrelia species isolated from patients with relapsing fever in Spain	LANCET			English	Article							LYME BORRELIOSIS; SP-NOV; DISEASE; BURGDORFERI; EVOLUTION	Background Lyme disease and tick-borne relapsing fever are worldwide systemic borrelioses caused by several Borrelia species transmitted by hard ticks (family Ixodidae) and soft ticks (family Argasidae), respectively. A previous seroepidemiological study of Lyme borreliosis showed several serologically reactive patients with clinically atypical presentations, and this discovery led to the hypothesis that some of the cases of Lyme borreliosis had been caused by another borrelia organism. Methods Blood from patients in southern Spain who had suspected Lyme disease or relapsing-fever borreliosis was cultured before treatment began, isolates of Borrelia spp were inoculated into several strains of mice of different ages. The 16S rRNA and flagellin genes of Borrelia spp were sequenced by PCR and assessed by phylogenetic analyses. Findings We isolated a species of Borrelia from three patients with relapsing fever and from Ornithodorus spp ticks in southern Spain. This organism (refractory to in-vitro cultivation) caused a relapsing spirochaetaemia with multiple organ involvement in laboratory mice that recreated the human disease. Phylogenetic analysis showed that this organism is a previously unrecognised species. Interpretation We have discovered a new borrelia pathogen that is closely related to the other tick-borne agents of relapsing fever in Europe and Africa, and which causes a relapsing systemic disease with serological similarities to Lyme borreliosis.	HOSP GEN BASICO,MALAGA,SPAIN; SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794; SUNY STONY BROOK,NEW YORK STATE DEPT HLTH,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Anda, P (corresponding author), INST SALUD CARLOS III,CTR NACL MICROBIOL VIROL & INMUNOL SANIT,E-28220 MAJADAHONDA,MADRID,SPAIN.		Anda, Pedro/V-8436-2019	Anda, Pedro/0000-0001-9081-8188; Miller, Nancy/0000-0001-5878-0896; Sanchez-Yebra Romera, Waldo/0000-0001-8546-1989	PHS HHS [A1-27044] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDA P, 1993, CLIN INFECT DIS, V16, P310, DOI 10.1093/clind/16.2.310; AZNAR Pedro, 1926, Arch. Inst. Nac. Higiene de Alfonso XIII, V4, P121; BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; Barbour AG, 1996, J INFECT DIS, V173, P403, DOI 10.1093/infdis/173.2.403; BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARTHOLD SW, 1991, AM J PATHOL, V139, P263; BERNEDO JU, 1977, ACTA DERMOSIFILOG, V68, P109; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; CANICA MM, 1993, SCAND J INFECT DIS, V25, P441, DOI 10.3109/00365549309008525; DEBUEN E, 1931, B TECN DIR SAN, V6, P193; DELOPE ML, 1985, MED CLIN-BARCELONA, V85, P111; FELSENFELD O, 1965, BACTERIOL REV, V29, P46, DOI 10.1128/MMBR.29.1.46-74.1965; FELSENSTEIN J, 1994, PHYLIP VERSION 3 5C; FUKUNAGA M, 1995, INT J SYST BACTERIOL, V45, P804, DOI 10.1099/00207713-45-4-804; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; LOPEZCORTES L, 1989, J INFECT DIS, V159, P804, DOI 10.1093/infdis/159.4.804; MONCO JCG, 1991, MED CLIN-BARCELONA, V98, P89; MONCO JCG, 1995, ANN NEUROL, V37, P691; NOPPA L, 1995, MICROBIOL-UK, V141, P85, DOI 10.1099/00221287-141-1-85; PORTO AS, 1991, ENFERM INFEC MICR CL, V9, P125; SCHWARTZ JJ, 1992, J BACTERIOL, V174, P3757, DOI 10.1128/JB.174.11.3757-3765.1992; SOUTHERN PM, 1969, MEDICINE, V48, P129, DOI 10.1097/00005792-196903000-00002; Swofford D, 1993, PHYLOGENETIC ANAL US; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	25	57	60	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 20	1996	348	9021					162	165		10.1016/S0140-6736(96)02332-X	http://dx.doi.org/10.1016/S0140-6736(96)02332-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UX789	8684157				2022-12-24	WOS:A1996UX78900012
J	Arlt, H; Tauer, R; Feldmann, H; Neupert, W; Langer, T				Arlt, H; Tauer, R; Feldmann, H; Neupert, W; Langer, T			The YTA10-12 complex, an AAA protease with chaperone-like activity in the inner membrane of mitochondria	CELL			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; DEPENDENT PROTEASES; PROTEOLYSIS; YEAST; BIOGENESIS; BACTERIAL; PRODUCTS; MUTANTS; MEMBER	The mitochondrial members of the highly conserved AAA family, Yta10p and Yta12p, constitute a membrane-embedded complex of about 850 kDa. As an ATP dependent metallopeptidase (AAA protease), the YTA10-12 complex mediates the degradation of nonassembled inner membrane proteins. In contrast to nucleotide-dependent complex formation and substrate binding, proteolysis of bound polypeptides depends on the hydrolysis of ATP and the metallopeptidase activity of both subunits. Independent of its proteolytic function, the chaperone-like activity of the YTA10-12 complex is required for assembly of the membrane-associated ATP synthase. We propose that proteolytic and chaperone-like activities in the YTA10-12 complex mediate assembly and degradation processes of membrane protein complexes and thereby exert key functions in the maintenance of membrane integrity.			Arlt, H (corresponding author), UNIV MUNICH,INST PHYSIOL CHEM,GOETHESTR 33,D-80336 MUNICH,GERMANY.			Langer, Thomas/0000-0003-1250-1462				AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; CAMPBELL CL, 1994, MOL BIOL CELL, V5, P899, DOI 10.1091/mbc.5.8.899; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GRIVELL LA, 1989, EUR J BIOCHEM, V182, P477, DOI 10.1111/j.1432-1033.1989.tb14854.x; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; HADIKUSUMO RG, 1988, BIOCHIM BIOPHYS ACTA, V933, P212, DOI 10.1016/0005-2728(88)90072-2; Harlow E, 1988, ANTIBODIES LAB MANUA; HEMMANN JM, 1994, J CELL BIOL, V127, P893; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; HUGUENEY P, 1995, P NATL ACAD SCI USA, V92, P5630, DOI 10.1073/pnas.92.12.5630; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KALNOV SL, 1979, BIOCHEM J, V182, P195, DOI 10.1042/bj1820195; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Langer T, 1995, METHOD ENZYMOL, V260, P495, DOI 10.1016/0076-6879(95)60161-9; LEONHARD K, 1996, IN PRESS EMBO J; LOWE J, 1995, SCIENCE, V268, P633; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; PEARCE DA, 1995, J BIOL CHEM, V270, P1; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SHERMAN MY, 1992, EMBO J, V11, P71; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; TZAGOLOFF A, 1972, J BIOL CHEM, V247, P6517; VANDYCK L, 1994, J BIOL CHEM, V269, P238; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOJTKOWIAK D, 1993, J BIOL CHEM, V268, P22609; YASUHARA T, 1994, J BIOCHEM-TOKYO, V115, P1166, DOI 10.1093/oxfordjournals.jbchem.a124474	47	236	244	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1996	85	6					875	885		10.1016/S0092-8674(00)81271-4	http://dx.doi.org/10.1016/S0092-8674(00)81271-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UR604	8681382	Bronze			2022-12-24	WOS:A1996UR60400011
J	Hsich, G; Kinney, K; Gibbs, CJ; Lee, KH; Harrington, MG				Hsich, G; Kinney, K; Gibbs, CJ; Lee, KH; Harrington, MG			The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; GROWTH-HORMONE THERAPY; 2-DIMENSIONAL ELECTROPHORESIS; 14-3-3-PROTEINS; DIAGNOSIS; KINASE; ACTIVATION; TISSUE; GELS; RAF	Background There is no practical and reliable premortem test for Creutzfeldt-Jakob disease and the related transmissible spongiform encephalopathies. Two proteins, designated 130 and 131, which have been detected in low concentrations in cerebrospinal fluid from patients with Creutzfeldt-Jakob disease, appear to be sensitive and specific markers for the disease. Attempts to identify these proteins, however, have been unsuccessful. We hypothesized that they may be present in the normal brain. Methods We detected proteins 130 and 131 in normal human brain, partially sequenced their amino acids, and found that they matched the brain protein known as 14-3-3. We then developed a simple, rapid immunoassay for this protein and tested it in cerebrospinal fluid samples from 71 humans and 30 animals with spongiform encephalopathies and in control samples from 186 humans and 94 animals. Results The immunoassay detected the 14-3-3 protein in cerebrospinal fluid from 68 of the 71 patients with Creutzfeldt-Jakob disease (96 percent; 95 percent confidence interval, 92 to 99 percent). Among 94 patients with other dementias, the specificity was 96 percent. If one excludes the three patients with dementia who had had strokes within one month before testing, the specificity was 99 percent. The test was positive in 12 of 24 patients with viral encephalitis. In animals the sensitivity of the assay was 87 percent and the specificity was 99 percent. Conclusions In patients with dementia, a positive immunoassay for the 14-3-3 brain protein in cerebrospinal fluid strongly supports a diagnosis of Creutzfeldt-Jakob disease. This finding, however, does not support the use of the test in patients without clinically evident dementia.	NIH,CENT NERVOUS SYST STUDIES LAB,BASIC NEUROSCI PROGRAM,DIV INTRAMURAL RES,BETHESDA,MD 20892; CALTECH,DIV BIOL,PASADENA,CA 91125	National Institutes of Health (NIH) - USA; California Institute of Technology			Lee, Kelvin H/A-4673-2010; Crozier, Laura/C-2170-2011	Lee, Kelvin H/0000-0003-0908-2981; Harrington, Michael/0000-0002-7923-8032	NIA NIH HHS [AG05131, P30AG1230] Funding Source: Medline; NINDS NIH HHS [NS30531] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030531] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBERSOLD RH, 1988, ELECTROPHORESIS, V9, P520, DOI 10.1002/elps.1150090912; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; Asher D. M., 1986, LABORATORY SAFETY PR, P59; AWERBUCH G, 1988, INT J NEUROSCI, V42, P1, DOI 10.3109/00207458808985754; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1375, DOI 10.1002/elps.11501401212; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1357, DOI 10.1002/elps.11501401209; BLISARD KS, 1990, J NEUROL SCI, V99, P75, DOI 10.1016/0022-510X(90)90201-W; BOSTON PF, 1982, J NEUROCHEM, V38, P1466, DOI 10.1111/j.1471-4159.1982.tb07927.x; BOSTON PF, 1982, J NEUROCHEM, V38, P1475, DOI 10.1111/j.1471-4159.1982.tb07928.x; BROWN P, 1986, NEW ENGL J MED, V314, P547, DOI 10.1056/NEJM198602273140904; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; BROWN P, 1994, NEURODEGENER DIS, P839; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CROXSON M, 1988, NEUROLOGY, V38, P1128, DOI 10.1212/WNL.38.7.1128; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GAJDUSEK DC, 1996, FIELDS VIROLOGY, V2, P2851; HARRINGTON M G, 1991, Methods (Orlando), V3, P98, DOI 10.1016/S1046-2023(05)80201-4; HARRINGTON MG, 1986, NEW ENGL J MED, V315, P279, DOI 10.1056/NEJM198607313150502; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JIMI T, 1992, CLIN CHIM ACTA, V211, P37, DOI 10.1016/0009-8981(92)90103-W; MACARIO ME, 1991, BRIT MED J, V302, P1149, DOI 10.1136/bmj.302.6785.1149; MANAKA H, 1992, NEUROSCI LETT, V139, P47, DOI 10.1016/0304-3940(92)90854-Z; MARZEWSKI DJ, 1988, NEUROLOGY, V38, P1131, DOI 10.1212/WNL.38.7.1131; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; PRUSINER SB, 1996, FIELDS VIROLOGY, V2, P2901; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; SOLOMON JE, 1993, COMPUT APPL BIOSCI, V9, P133; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; ZERR I, 1995, LANCET, V345, P1609, DOI 10.1016/S0140-6736(95)90118-3	37	523	543	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1996	335	13					924	930		10.1056/NEJM199609263351303	http://dx.doi.org/10.1056/NEJM199609263351303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK148	8782499				2022-12-24	WOS:A1996VK14800003
J	Espinoza, FH; Farrell, A; ErdjumentBromage, H; Tempst, P; Morgan, DO				Espinoza, FH; Farrell, A; ErdjumentBromage, H; Tempst, P; Morgan, DO			A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK	SCIENCE			English	Article							TRANSCRIPTION FACTOR TFIIH; RING FINGER PROTEIN; CATALYTIC SUBUNIT; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; P40(MO15); MO15; PHOSPHORYLATION; ASSOCIATION; P34(CDC2)	Progress through the cell cycle is governed by the cyclin-dependent kinases (CDKs), the activation oi which requires phosphorylation by the CDK-activating kinase (CAK). In vertebrates, CAK is a trimeric enzyme containing CDK7, cyclin H, and MAT1. CAK from the budding yeast Saccharomyces cerevisiae was identified as an unusual 44-kilodalton protein kinase, Cak1, that is only distantly related to CDKs. Cak1 accounted for most CAK activity in yeast cell lysates, and its activity was constant throughout the cell cycle. The CAK1 gene was essential for cell viability. Thus, the major CAK in S. cerevisiae is distinct from the vertebrate enzyme, suggesting that budding yeast and vertebrates may have evolved different mechanisms of CDK activation.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOL BIOL, NEW YORK, NY 10021 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center				Erdjument-Bromage, Hediye/0000-0003-0224-3594; Morgan, David/0000-0001-8753-4416; Espinoza, Francisco/0000-0002-1855-1914				BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; Buck V, 1995, EMBO J, V14, P6173, DOI 10.1002/j.1460-2075.1995.tb00308.x; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; ESPINOZA FH, UNPUB; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RA, UNPUB; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316	34	139	142	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1996	273	5282					1714	1717		10.1126/science.273.5282.1714	http://dx.doi.org/10.1126/science.273.5282.1714			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781234				2022-12-24	WOS:A1996VH40800041
J	Halm, EA; Browner, WS; Tubau, JF; Tateo, IM; Mangano, DT				Halm, EA; Browner, WS; Tubau, JF; Tateo, IM; Mangano, DT			Echocardiography for assessing cardiac risk in patients having noncardiac surgery	ANNALS OF INTERNAL MEDICINE			English	Article							PERIOPERATIVE MYOCARDIAL-INFARCTION; PERIPHERAL VASCULAR-SURGERY; ABDOMINAL AORTIC-ANEURYSM; DOBUTAMINE STRESS ECHOCARDIOGRAPHY; EJECTION FRACTION; DIAGNOSTIC-TEST; RADIONUCLIDE ANGIOGRAPHY; VENTRICULAR ARRHYTHMIAS; NONVASCULAR SURGERY; MEDICAL LITERATURE	Background: Cardiac complications after noncardiac surgery are a serious cause of illness and death. Echocardiography is being used before noncardiac surgery to assess risk for cardiac complications, but its role remains undefined. Objective: To examine the prognostic value and operating characteristics of transthoracic echocardiography for assessing cardiac risk before noncardiac surgery. Design: Prospective cohort study. Setting: University-affiliated Veterans Affairs medical center. Patients: 339 consecutive men who were known to have or were suspected of having coronary artery disease and were scheduled for major noncardiac surgery. Measurements: Information from detailed histories, physical examinations, and electrocardiographic and laboratory studies was routinely collected. Transthoracic echocardiography was done before surgery to assess ejection fraction, wall motion abnormalities (reported as the wall motion score [range, 5 to 25 points]), and left ventricular hypertrophy. Main Outcome Measures: Postoperative ischemic events (cardiac-related death, nonfatal myocardial infarction, and unstable angina), congestive heart failure, and ventricular tachycardia. Results: 10 patients (3%) had ischemic events; 26 (8%) had congestive heart failure; and 29 (8%) had ventricular tachycardia. No echocardiographic measurements were associated with ischemic events. In univariate analyses, an ejection fraction less than 40% was associated with all cardiac outcomes combined (odds ratio, 3.5 [95% CI, 1.8 to 6.7]), congestive heart failure (odds ratio, 3.0 [CI, 1.2 to 7.4]), and ventricular tachycardia (odds ratio, 2.6 [CI, 1.1 to 6.2]). In multivariable analyses that adjusted for known clinical risk factors, an ejection fraction less than 40% was a significant predictor of ail outcomes combined (odds ratio, 2.5 [CI, 1.2 to 5.0]) but not congestive heart failure (odds ratio, 2.1 [CI, 0.7 to 6.0]) and ventricular ejection fraction (odds ratio, 1.8 [CI, 0.7 to 4.7]). Wall motion score was a univariate predictor of all cardiac outcomes (odds ratio for each 3-unit increase, 1.6 [CI, 1.3 to 2.1]) and ventricular tachycardia (odds ratio, 1.6 [CI, 1.2 to 2.2]) but was only a multivariable risk factor for all events (odds ratio, 1.3 [CI, 1.0 to 1.7]). An ejection fraction less than 40% had a sensitivity of 0.28 to 0.31 and a specificity of 0.87 to 0.89 for all categories of adverse outcomes. Likelihood ratios for ejection fraction had poor operating characteristics. Adding echocardiographic information to predictive models that contained known clinical risk factors did not alter sensitivity, specificity, or predictive values in clinically important ways. Conclusions: The data did not support the use of transthoracic echocardiography for the assessment of cardiac risk before noncardiac surgery. Echocardiographic measurements had limited prognostic value and suboptimal operating characteristics.	VET AFFAIRS MED CTR, SAN FRANCISCO, CA 94121 USA; VET AFFAIRS MED CTR, DEPT ANESTHESIA, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Halm, EA (corresponding author), MASSACHUSETTS GEN HOSP, MED PRACTICES EVALUAT CTR, 50 STANIFORD ST, 9TH FLOOR, BOSTON, MA 02114 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36744] Funding Source: Medline; BHP HRSA HHS [PE 11001-08] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BHP HRSA HHS		ADAMS JE, 1994, NEW ENGL J MED, V330, P670, DOI 10.1056/NEJM199403103301003; ASHBURN WL, 1980, RADIOL CLIN N AM, V18, P467; ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; BARON JF, 1994, NEW ENGL J MED, V330, P663, DOI 10.1056/NEJM199403103301002; BERNING J, 1990, AM J CARDIOL, V65, P567, DOI 10.1016/0002-9149(90)91032-2; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; Bodenheimer MM, 1996, ANN INTERN MED, V124, P763, DOI 10.7326/0003-4819-124-8-199604150-00010; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; BROWNER WS, 1991, CLIN RES, V39, P7; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CHAITMAN BR, 1979, CIRCULATION, V59, P560, DOI 10.1161/01.CIR.59.3.560; COHN JN, 1993, CIRCULATION, V87, P1; COLEY CM, 1992, AM J CARDIOL, V69, P1280, DOI 10.1016/0002-9149(92)91221-O; *CRIT COMM NEW YOR, 1979, NOM CRIT DIAGN DIS H, V94; DAVILAROMAN VG, 1993, J AM COLL CARDIOL, V21, P957, DOI 10.1016/0735-1097(93)90353-3; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; Dudley JC, 1996, AM HEART J, V131, P245, DOI 10.1016/S0002-8703(96)90348-8; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; FRANCO CD, 1989, J VASC SURG, V10, P656, DOI 10.1067/mva.1989.16173; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HOLLENBERG M, 1992, JAMA-J AM MED ASSOC, V268, P205, DOI 10.1001/jama.268.2.205; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KAZMERS A, 1988, J VASC SURG, V8, P128, DOI 10.1067/mva.1988.avs0080128; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; LONDON MJ, 1990, ANESTHESIOLOGY, V73, P644, DOI 10.1097/00000542-199010000-00010; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1992, JAMA-J AM MED ASSOC, V268, P233, DOI 10.1001/jama.268.2.233; MANGANO DT, 1991, CIRCULATION, V84, P493, DOI 10.1161/01.CIR.84.2.493; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MANTHA S, 1994, ANESTH ANALG, V79, P422; MCCANN RL, 1989, J VASC SURG, V10, P240; MCENROE CS, 1990, J VASC SURG, V11, P497, DOI 10.1067/mva.1990.18756; MCPHAIL NV, 1990, CAN J SURG, V33, P224; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; OKELLY B, 1992, JAMA-J AM MED ASSOC, V268, P217, DOI 10.1001/jama.268.2.217; Ouriel K, 1995, J VASC SURG, V22, P671, DOI 10.1016/S0741-5214(95)70057-9; PASTERNACK PF, 1984, J VASC SURG, V1, P320, DOI 10.1067/mva.1984.avs0010320; PASTERNACK PF, 1985, CIRCULATION, V72, P13; POLDERMANS D, 1993, CIRCULATION, V87, P1506, DOI 10.1161/01.CIR.87.5.1506; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; TAKASE B, 1993, AM HEART J, V126, P1099, DOI 10.1016/0002-8703(93)90660-2; TISCHLER MD, 1991, AM J CARDIOL, V68, P593, DOI 10.1016/0002-9149(91)90349-P; WONG T, 1992, ANN INTERN MED, V116, P743, DOI 10.7326/0003-4819-116-9-743	50	143	146	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					433	441		10.7326/0003-4819-125-6-199609150-00001	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779454				2022-12-24	WOS:A1996VF88200003
J	Wei, Y; Lukashev, M; Simon, DI; Bodary, SC; Rosenberg, S; Doyle, MV; Chapman, HA				Wei, Y; Lukashev, M; Simon, DI; Bodary, SC; Rosenberg, S; Doyle, MV; Chapman, HA			Regulation of integrin function by the urokinase receptor	SCIENCE			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; SMOOTH-MUSCLE CELLS; ROUS-SARCOMA VIRUS; ADHESION; EXPRESSION; INHIBITOR; VITRONECTIN; FIBROBLASTS; CANCER; DEGRADATION	Integrin function is central to inflammation, immunity, and tumor progression. The urokinase-type plasminogen activator receptor (uPAR) and integrins formed stable complexes that both inhibited native integrin adhesive function and promoted adhesion to vitronectin via a ligand binding site on uPAR. Interaction of soluble uPAR with the active conformer of integrins mimicked the inhibitory effects of membrane uPAR. Both uPAR-mediated adhesion and altered integrin function were blocked by a peptide that bound to uPAR and disrupted complexes. These data provide a paradigm for regulation of integrins in which a nonintegrin membrane receptor interacts with and modifies the function of activated integrins.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, DEPT STOMATOL, SAN FRANCISCO, CA 94143 USA; GENENTECH INC, S SAN FRANCISCO, CA 94080 USA; CHIRON CORP, EMERYVILLE, CA 94608 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; Roche Holding; Genentech; Novartis					NHLBI NIH HHS [HL 02768, HL44712] Funding Source: Medline; NICHD NIH HHS [HD 26732] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD026732] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; BIANCHI E, 1994, CANCER RES, V54, P861; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BODARY SC, UNPUB; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BRAKENHOFF RH, 1995, J CELL BIOL, V129, P1677, DOI 10.1083/jcb.129.6.1677; BURCHILL SA, 1994, BIOESSAYS, V16, P225, DOI 10.1002/bies.950160403; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; CONFORTI G, 1994, BLOOD, V83, P994; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FONG S, UNPUB; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kindzelskii AL, 1996, J IMMUNOL, V156, P297; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; LI H, 1994, J BIOL CHEM, V269, P8153; LI R, 1995, J CELL BIOL, V129, P1143, DOI 10.1083/jcb.129.4.1143; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; PEDERSEN H, 1994, CANCER RES, V54, P4671; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; RAO NK, 1995, J CLIN INVEST, V96, P465, DOI 10.1172/JCI118057; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; SCHLECHTE W, 1989, CANCER RES, V49, P6064; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SIMON DI, 1993, BLOOD, V82, P2414; SIMON DI, IN PRESS BLOOD; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; SKINNER MP, 1994, AM J PATHOL, V145, P1070; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; TIVERON MC, 1994, J CELL SCI, V107, P1783; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; WANG N, 1995, AM J PHYSIOL-CELL PH, V268, pC1062, DOI 10.1152/ajpcell.1995.268.4.C1062; WEBER MJ, 1977, CELL, V10, P45, DOI 10.1016/0092-8674(77)90138-6; WEI Y, 1994, J BIOL CHEM, V269, P32380; XUE W, 1994, J IMMUNOL, V152, P4630; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	52	692	716	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 13	1996	273	5281					1551	1555		10.1126/science.273.5281.1551	http://dx.doi.org/10.1126/science.273.5281.1551			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8703217				2022-12-24	WOS:A1996VG59700041
J	Ormo, M; Cubitt, AB; Kallio, K; Gross, LA; Tsien, RY; Remington, SJ				Ormo, M; Cubitt, AB; Kallio, K; Gross, LA; Tsien, RY; Remington, SJ			Crystal structure of the Aequorea victoria green fluorescent protein	SCIENCE			English	Article							CHROMOPHORE; MUTATIONS; PROGRAM	The green fluorescent protein (GFP) from the Pacific Northwest jellyfish Aequorea victoria has generated intense interest as a marker for gene expression and localization of gene products, The chromophore, resulting from the spontaneous cyclization and oxidation of the sequence -Ser(65) (or Thr(65))-Tyr(66)-Gly(67)-, requires the native protein fold for both formation and fluorescence emission. The structure of Thr(65) GFP has been determined at 1.9 angstrom resolution, The protein fold consists of an 11-stranded beta barrel with a coaxial helix, with the chromophore forming from the central helix. Directed mutagenesis of one residue adjacent to the chromophore, Thr(203), to Tyr or His results in significantly red-shifted excitation and emission maxima.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, HOWARD HUGHES MED INST 0647, LA JOLLA, CA 92093 USA; AURORA BIOSCI, LA JOLLA, CA 92037 USA; UNIV OREGON, INST MOL BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Oregon; University of Oregon								BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; CHALFIE M, 1995, PHOTOCHEM PHOTOBIOL, V62, P651, DOI 10.1111/j.1751-1097.1995.tb08712.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; *DAR LAB SCI ENG R, 1979, CCP4 SUIT PROGR PROT; DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151; Dopf J, 1996, GENE, V173, P39, DOI 10.1016/0378-1119(95)00692-3; EHRIG T, 1995, FEBS LETT, V367, P163, DOI 10.1016/0014-5793(95)00557-P; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; INOUYE S, 1994, FEBS LETT, V351, P211, DOI 10.1016/0014-5793(94)00859-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MINOR W, 1993, XDISPLAYF; MORIN JG, 1971, J CELL PHYSIOL, V77, P313, DOI 10.1002/jcp.1040770305; MORISE H, 1974, BIOCHEMISTRY-US, V13, P2656, DOI 10.1021/bi00709a028; OTWINOWSKI Z, 1991, DATA COLLECTION PROC, P56; PEROZZO MA, 1988, J BIOL CHEM, V263, P7713; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; RAO BDN, 1980, BIOPHYS J, V32, P630, DOI 10.1016/S0006-3495(80)84999-X; SanPietro R. M., 1993, PHOTOCHEM PHOTOBIOL, V57, p63s; SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302; STEIGEMANN W, 1974, THESIS TU MUNICH; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Ward W.W., 1979, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V4, P1; WARD WW, 1982, BIOCHEMISTRY-US, V21, P4535, DOI 10.1021/bi00262a003; WARD WW, 1982, PHOTOCHEM PHOTOBIOL, V35, P803, DOI 10.1111/j.1751-1097.1982.tb02651.x; Ward WW., 1981, BIOLUMINESCENCE CHEM, DOI 10.1016/b978-0-12-208820-9.50035-5; YANG F, IN PRESS NATURE BIOT	39	1823	1939	19	604	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 6	1996	273	5280					1392	1395						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703075				2022-12-24	WOS:A1996VF61000044
J	Burston, SG; Weissman, JS; Farr, GW; Fenton, WA; Horwich, AL				Burston, SG; Weissman, JS; Farr, GW; Fenton, WA; Horwich, AL			Release of both native and non-native proteins from a cis-only GroEL ternary complex	NATURE			English	Article							CHAPERONIN GROEL; ESCHERICHIA-COLI; ATP HYDROLYSIS; CYCLE; BINDING; POLYPEPTIDE; MECHANISM	PROTEIN folding by the double-ring chaperonin GroEL is initiated in cts ternary complexes, in which polypeptide is sequestered in the central channel of a GroEL ring, capped by the co-chaperonin GroES(1-3), The cis ternary complex is dissociated (half-life of similar to 15 s) by trans-sided ATP hydrolysis, which triggers release of GroES(4-6). For the substrate protein rhodanese, only similar to 15% of cis-localized molecules attain their native form before hydrolysis(2,7). A major question concerning the GroEL mechanism is whether both native and non-native forms are released from the cis complex, Here we address this question using a 'cis-only' mixed-ring GroEL complex that binds polypeptide and GroES on only one of its two rings, This complex mediates refolding of rhodanese but, as with wild-type GroEL, renaturation is quenched by addition of mutant GroEL 'traps', which bind but do not release polypeptide substrate(7,8), This indicates that nonnative forms are released from the cis complex, Quenching of refolding by traps was also observed under physiological conditions, both in undiluted Xenopus oocyte extract and in intact oocytes, We conclude that release of non-native forms from GroEL in vivo allows a kinetic partitioning among various chaperones and proteolytic components, which determines both the conformation and lifetime of a protein.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,BOYER CTR,NEW HAVEN,CT 06510; YALE UNIV,DEPT GENET,BOYER CTR,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University				Burston, Steven/0000-0003-1848-1853; Weissman, Jonathan/0000-0003-2445-670X				Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCKBERGER A, IN PRESS J MOL BIOL; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KANDROR O, 1994, J BIOL CHEM, V269, P23575; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; TANDON S, 1989, J BIOL CHEM, V264, P9859; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	23	82	84	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					96	99		10.1038/383096a0	http://dx.doi.org/10.1038/383096a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779722				2022-12-24	WOS:A1996VF29500056
J	Tanaka, N; Ishihara, M; Lamphier, MS; Nozawa, H; Matsuyama, T; Mak, TW; Aizawa, S; Tokino, T; Oren, M; Taniguchi, T				Tanaka, N; Ishihara, M; Lamphier, MS; Nozawa, H; Matsuyama, T; Mak, TW; Aizawa, S; Tokino, T; Oren, M; Taniguchi, T			Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage	NATURE			English	Article							TRANSCRIPTION FACTOR IRF-1; CYCLIN-DEPENDENT KINASES; APOPTOSIS; INDUCTION; ARREST; CELLS; P21; CHECKPOINT; INHIBITORS; ACTIVATION	NORMALLY growing cells promptly cease DNA synthesis when exposed to genotoxic stresses, such as radiation, and this cell-cycle arrest prevents the accumulation of mutations(1,2). The transcription factor interferon regulatory factor (IRF)-1 is essential for the regulation of the interferon system(3-5), inhibits cell growth, and manifests tumour-suppressor activities(6,7). Here we show that mouse embryonic fibroblasts (EFs) lacking LRF-1 are deficient in their ability to undergo DNA-damage-induced cell-cycle arrest. A similar phenotype has been observed in EFs lacking the tumour suppressor p53 (refs 8, 9), although the expression of IRF-1 and p53 are independent of one another. Furthermore, we show that transcriptional induction of the gene encoding p21 (WAF1, CIP1)(10-12), a cell-cycle inhibitor, by gamma-irradiation is dependent on both p53 and IRF-1, and that the p21 promoter is activated, either directly or indirectly, by both in a transient cotransfection assay. These two tumour-suppressor transcription factors therefore converge functionally to regulate the cell cycle through the activation of a common target genes.	NARA INST SCI & TECHNOL,NARA 6301,JAPAN; RES DEV CORP JAPAN,PRECURSORY RES PROGRAM EMBRYON SCI & TECHNOL,KYOTO 61902,JAPAN; ONTARIO CANC INST,AMGEN INST,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,DEPT IMMUNOL & MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,KUMAMOTO 860,JAPAN; UNIV TOKYO,INST MED SCI,MOL MED LAB,MINATO KU,TOKYO 108,JAPAN; WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Nara Institute of Science & Technology; Japan Science & Technology Agency (JST); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Kumamoto University; University of Tokyo; Weizmann Institute of Science	Tanaka, N (corresponding author), UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,HONGO 7-3-1,TOKYO 113,JAPAN.		Tokino, Takashi/AAI-9887-2021	Tanaka, Nobuyuki/0000-0002-6373-2220				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KASTAN MB, 1991, CANCER RES, V51, P6304; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	30	297	305	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 29	1996	382	6594					816	818		10.1038/382816a0	http://dx.doi.org/10.1038/382816a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE347	8752276				2022-12-24	WOS:A1996VE34700049
J	Zwaal, RR; Ahringer, J; vanLuenen, HGAM; Rushforth, A; Anderson, P; Plasterk, RHA				Zwaal, RR; Ahringer, J; vanLuenen, HGAM; Rushforth, A; Anderson, P; Plasterk, RHA			G proteins are required for spatial orientation of early cell cleavages in C. elegans embryos	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; BETA-GAMMA-DIMERS; SIGNAL-TRANSDUCTION; VULVAR INDUCTION; GENE-EXPRESSION; ALPHA-SUBUNITS; DIVISION AXES; GTP-BINDING; POLARITY; SPINDLE	Heterotrimeric G proteins are signal-transducing molecules activated by seven transmembrane domain receptors. In C. elegans, gpb-1 encodes the sole G beta subunit; therefore, its inactivation should affect all heterotrimeric G protein signaling. When maternal but no zygotic gpb-1 protein (GPB-1) is present, development proceeds until the first larval stage, but these larvae show little muscle activity and die soon after hatching. When, however, the maternal contribution of GPB-1 is also reduced, spindle orientations in early cell divisions are randomized. Cell positions in these embryos are consequently abnormal, and the embryos die with the normal number of cells and well-differentiated but abnormally distributed tissues. These results indicate that maternal G proteins are important for orientation of early cell division axes, possibly by coupling a membrane signal to centrosome position.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 3EH,ENGLAND; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706	University of Cambridge; MRC Laboratory Molecular Biology; University of Wisconsin System; University of Wisconsin Madison	Zwaal, RR (corresponding author), NETHERLANDS CANC INST,DIV MOL BIOL,PLESMANLAAN 121,NL-1066 CX AMSTERDAM,NETHERLANDS.			van Luenen, Henri/0000-0002-5584-7968; Ahringer, Julie/0000-0002-7074-4051	NCRR NIH HHS [5 R01 RR10082-02] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR010082] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BRENNER S, 1974, GENETICS, V77, P71; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOWNEY GP, 1994, CURR OPIN IMMUNOL, V6, P113, DOI 10.1016/0952-7915(94)90042-6; DRUBIN DG, 1996, CELL, V84, P401; ETAMADMOGHADAM B, 1995, CELL, V83, P743; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSTEIN B, 1995, J CELL BIOL, V129, P1071, DOI 10.1083/jcb.129.4.1071; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HERMAN RK, 1976, GENETICS, V83, P91; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; HODGKIN J, 1979, GENETICS, V91, P67; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KOGA M, 1995, DEVELOPMENT, V121, P2655; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LIN CT, 1992, LAB INVEST, V67, P770; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MELLO C, 1995, CAENORHABDITIS ELEGA, P452; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; RUSHFORTH AM, 1993, MOL CELL BIOL, V13, P902, DOI 10.1128/MCB.13.2.902; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SILVA IF, 1990, J MOL BIOL, V215, P483, DOI 10.1016/S0022-2836(05)80160-3; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; STINCHCOMB DT, 1985, MOL CELL BIOL, V5, P3484, DOI 10.1128/MCB.5.12.3484; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; VANDERVOORN L, 1990, J MOL BIOL, V213, P17, DOI 10.1016/S0022-2836(05)80118-4; White J, 1996, CELL, V84, P195, DOI 10.1016/S0092-8674(00)80974-5; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	55	132	134	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1996	86	4					619	629		10.1016/S0092-8674(00)80135-X	http://dx.doi.org/10.1016/S0092-8674(00)80135-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VE235	8752216	Bronze			2022-12-24	WOS:A1996VE23500012
J	Dickinson, TA; White, J; Kauer, JS; Walt, DR				Dickinson, TA; White, J; Kauer, JS; Walt, DR			A chemical-detecting system based on a cross-reactive optical sensor array	NATURE			English	Article							PATTERN-RECOGNITION ANALYSIS; NILE-RED; ELECTRONIC NOSE; OLFACTORY-BULB; ODOR; VAPORS; MIXTURES; DISCRIMINATION; SALAMANDER; RESPONSES	THE vertebrate olfactory system has long been recognized for its extraordinary sensitivity and selectivity for odours. Chemical sensors have been developed recently that are based on analogous distributed sensing properties(1-4), but although an association between artificial devices and the olfactory system has been made explicit in some previous studies(4,5) none has incorporated comparable mechanisms into the mode of detection. Here we describe a multi-analyte fibre-optic sensor modelled directly on the olfactory system, in the sense that complex, time-dependent signals from an array of sensors provide a 'signature' of each analyte, In our system, polymer-immobilized dye molecules on the fibre tips give different fluorescent response patterns (including spectral shifts, intensity changes, spectral shape variations(6) and temporal responses) on exposure to organic vapours, depending on the physical and chemical nature (for example, polarity, shape and size) of both the vapour and the polymer, We use video images of temporal responses of the multi-fibre tip as the input signals to train a neural network for vapour recognition, The system is able to identify individual vapours at different concentrations with great accuracy. 'Artificial noses' such as this should have wide potential application, most notably in environmental and medical monitoring.	TUFTS UNIV,DEPT CHEM,MAX TISHLER LAB ORGAN CHEM,MEDFORD,MA 02155; TUFTS UNIV,SCH MED,DEPT NEUROSCI,BOSTON,MA 02111	Tufts University; Tufts University								BARNARD SM, 1991, ENVIRON SCI TECHNOL, V25, P1301, DOI 10.1021/es00019a012; CAREY W, 1988, ANAL CHEM, V60, P2801; CAREY WP, 1987, ANAL CHEM, V59, P1529, DOI 10.1021/ac00138a010; DABAN JR, 1991, ANAL BIOCHEM, V199, P162, DOI 10.1016/0003-2697(91)90084-7; DEYE JF, 1990, ANAL CHEM, V62, P615, DOI 10.1021/ac00205a015; FREUND MS, 1995, P NATL ACAD SCI USA, V92, P2652, DOI 10.1073/pnas.92.7.2652; GARDNER JW, 1994, SENSOR ACTUAT B-CHEM, V18, P211; GRATE JW, 1991, ANAL CHEM, V63, P1719, DOI 10.1021/ac00017a013; GREENSPAN P, 1993, INT J BIOCHEM, V25, P987, DOI 10.1016/0020-711X(93)90111-Q; HAMILTON KA, 1989, J NEUROPHYSIOL, V62, P609, DOI 10.1152/jn.1989.62.3.609; HATFIELD JV, 1994, SENSOR ACTUAT B-CHEM, V18, P221, DOI 10.1016/0925-4005(94)87086-1; HILDEBRAND JG, 1995, P NATL ACAD SCI USA, V92, P67, DOI 10.1073/pnas.92.1.67; KAUER JS, 1991, TRENDS NEUROSCI, V14, P79, DOI 10.1016/0166-2236(91)90025-P; KAUER JS, 1977, J PHYSIOL-LONDON, V272, P495, DOI 10.1113/jphysiol.1977.sp012056; Lakowicz J. R., 1982, PRINCIPLES FLUORESCE; LUNDSTROM I, 1991, NATURE, V352, P47, DOI 10.1038/352047a0; MEREDITH M, 1978, J GEN PHYSIOL, V71, P615, DOI 10.1085/jgp.71.6.615; ORELLANA G, 1995, ANAL CHEM, V67, P2231, DOI 10.1021/ac00109a050; PERSAUD K, 1982, NATURE, V299, P352, DOI 10.1038/299352a0; POSCH HE, 1988, TALANTA, V35, P89, DOI 10.1016/0039-9140(88)80044-4; REVIAL MF, 1982, CHEM SENSES, V7, P175, DOI 10.1093/chemse/7.2.175; RONOT C, 1993, SENSOR ACTUAT B-CHEM, V11, P375, DOI 10.1016/0925-4005(93)85277-H; ROSEPEHRSSON SL, 1988, ANAL CHEM, V60, P2801, DOI 10.1021/ac00175a032; RUVINOV SB, 1995, J BIOL CHEM, V270, P6357, DOI 10.1074/jbc.270.11.6357; SARDZEWSKI R, 1908, TALANTA, V35, P95; STETTER JR, 1986, ANAL CHEM, V58, P860, DOI 10.1021/ac00295a047; THUNDAT T, 1995, ANAL CHEM, V67, P519, DOI 10.1021/ac00099a006; VAUTHEY E, 1993, CHEM PHYS LETT, V216, P530, DOI 10.1016/0009-2614(93)90138-Q; White J, 1996, ANAL CHEM, V68, P2191, DOI 10.1021/ac9511197; ZELL A, 1994, STUTTGART NEURAL NET; ZELLERS ET, 1995, ANAL CHEM, V67, P1092, DOI 10.1021/ac00102a012	31	332	372	2	141	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1996	382	6593					697	700		10.1038/382697a0	http://dx.doi.org/10.1038/382697a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VD333	8751439				2022-12-24	WOS:A1996VD33300043
J	Hardwick, KG; Weiss, E; Luca, FC; Winey, M; Murray, AW				Hardwick, KG; Weiss, E; Luca, FC; Winey, M; Murray, AW			Activation of the budding yeast spindle assembly checkpoint without mitotic spindle disruption	SCIENCE			English	Article							POLE BODY DUPLICATION; CELL-CYCLE ARREST; PROTEIN-KINASE; MITOSIS; ENCODES; MPS1	The spindle assembly checkpoint keeps cells with defective spindles from initiating chromosome segregation. The protein kinase Mps1 phosphorylates the yeast protein Mad1p when this checkpoint is activated, and the overexpression of Mps1p induces modification of Mad1p and arrests wild-type yeast cells in mitosis with morphologically normal spindles. Spindle assembly checkpoint mutants overexpressing Mps1p pass through mitosis without delay and can produce viable progeny, which demonstrates that the arrest of wild-type cells results from inappropriate activation of the checkpoint in cells whose spindle is fully functional. Ectopic activation of cell-cycle checkpoints might be used to exploit the differences in checkpoint status between normal and tumor cells and thus improve the selectivity of chemotherapy.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV COLORADO,DEPT MOL CELLULAR & DEV BIOL,BOULDER,CO 80309	University of California System; University of California San Francisco; University of Colorado System; University of Colorado Boulder				Hardwick, Kevin/0000-0002-6462-1047				Byers B, 1981, MOL BIOL YEAST SACCH, P59; BYERS B, 1991, METHOD ENZYMOL, V194, P608; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; HARDWICK KG, UNPUB; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; LAUZE E, 1995, EMBO J, V14, P1655, DOI 10.1002/j.1460-2075.1995.tb07154.x; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; POCH O, 1994, MOL GEN GENET, V243, P641, DOI 10.1007/BF00279573; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; WINEY M, 1995, J CELL BIOL, V129, P1601, DOI 10.1083/jcb.129.6.1601; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745	22	284	296	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1996	273	5277					953	956		10.1126/science.273.5277.953	http://dx.doi.org/10.1126/science.273.5277.953			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC670	8688079				2022-12-24	WOS:A1996VC67000062
J	Boisaubin, EV				Boisaubin, EV			Treatment for obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							TRIAL				Boisaubin, EV (corresponding author), UNIV TEXAS,MED BRANCH,DEPT MED,GALVESTON,TX 77550, USA.							ADKINSON RL, 1994, AM J CLIN NUTR, V60, P153; BLAIR SN, 1993, ANN INTERN MED, V119, P702, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00015; BRAY GA, 1979, NATL I HLTH PUBLICAT; GOLDSTEIN DJ, 1994, INT J OBESITY, V18, P129; OCONNOR HT, 1995, INT J OBESITY, V19, P181; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P581, DOI 10.1038/clpt.1992.68; 1996, AM MED NEWS     0603, P14; [No title captured]	9	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 14	1996	276	6					445	445						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA863	8691540				2022-12-24	WOS:A1996VA86300010
J	Pais, P; Pogue, J; Gerstein, H; Zachariah, E; Savitha, D; Jayprakash, S; Nayak, PR; Yusuf, S				Pais, P; Pogue, J; Gerstein, H; Zachariah, E; Savitha, D; Jayprakash, S; Nayak, PR; Yusuf, S			Risk factors for acute myocardial infarction in Indians: A case-control study	LANCET			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; INSULIN RESISTANCE; ADIPOSE-TISSUE; MORTALITY; DESCENT; LONDON; WOMEN; MEN; LIPOPROTEIN	Background South Asians who have settled overseas and Chose in urban India have an increased risk of ischaemic heart disease (IHD). Reasons for this increased risk are unclear. Most studies have been based on migrants to western nations. so their findings may not apply to most south Asians, who live in their own countries, Therefore, we assessed the relative importance of risk factors for IHD among South Asians in Bangalore, India. Methods We conducted a prospective hospital-based case-control study of 200 Indian patients with a first acute myocardial infarction (AMI) and 200 age and sex matched controls. We recorded prevalence of the following risk factors for IHD: diet, smoking, alcohol use. socioeconomic status, waist to hip ratio (WHR), blood glucose, serum insulin, oral glucose tolerance test, and lipid profile. Findings The most important predictor of AMI was current smoking (odds ratio [OR] 3.6, p<0.001) of cigarettes or beedis (a local form of tobacco), with individuals who currently smoked 10 or more per day having an OR of 6.7 (p<0.001). History of hypertension and of overt diabetes mellitus were also independent risk factors (OR 2.69 [p=0.001] and 2.64 [p=0.004]. respectively). Among all individuals, fasting blood glucose was a strong predictor of risk over the entire range, including al values usually regarded as normal (OR adjusted for smoking, hypertension, and WHR 1.62 for 1 SD increase, p<0.001). Abdominal obesity (as measured by WHR) was also a strong independent predictor across the entire range of measures (OR adjusted for smoking, hypertension, and blood glucose 2.24 for 1 SD increase; p<0.001). Compared with individuals with no risk factors, individuals with multiple risk factors had greatly increased risk of AMI leg, OR of 10.6 far the group with smoking and elevated glucose), Lipid profile was not associated with AMI. In univariate analyses, higher socioeconomic (income) status (OR 0.32, p=0.005 highest vs lowest: OR 0.75 middle vs lowest) and vegetarianism (OR=0.55, p=0.006), seemed to be protective. The impact of vegetarianism was closely correlated with blood glucose and WHR. Interpretation Smoking cessation, treatment of hypertension. and reduction in blood glucose and central obesity (perhaps through dietary modification) may be important in preventing IHD in Asian Indians.	MCMASTER UNIV,DIV CARDIOL,HAMILTON,ON L8L 2X2,CANADA; MCMASTER UNIV,DIV ENDOCRINOL,HAMILTON,ON L8L 2X2,CANADA; HAMILTON GEN HOSP,HAMILTON CIV HOSP,RES CTR,HAMILTON,ON L8L 2X2,CANADA; ST JOHNS MED COLL,EPIDEMIOL RES & TRAINING CTR,DEPT MED,BANGALORE 560034,KARNATAKA,INDIA; ST JOHNS MED COLL,EPIDEMIOL RES & TRAINING CTR,DEPT CARDIOL,BANGALORE 560034,KARNATAKA,INDIA	McMaster University; McMaster University; McMaster University; St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Medical College			Gerstein, Hertzel C/B-1235-2013; Gerstein, Hertzel/ABB-8781-2020	Gerstein, Hertzel C/0000-0001-8072-2836; Gerstein, Hertzel/0000-0001-8072-2836; Yusuf, Salim/0000-0003-4776-5601				BECKLES GLA, 1986, LANCET, V1, P1298; CEREMUZYNSKI L, 1981, CIRC RES, V48, P767, DOI 10.1161/01.RES.48.6.767; CHADHA SL, 1992, INDIAN J MED RES-B, V96, P115; CHADHA SL, 1990, INDIAN J MED RES-B, V92, P424; DHAWAN J, 1991, BRIT HEART J, V66, P81; ENAS EA, 1992, AM J CARDIOL, V70, P945, DOI 10.1016/0002-9149(92)90744-J; FARMER JA, 1992, HEART DISEASE, P1125; FRAYN KN, 1992, CLIN SCI, V82, P1, DOI 10.1042/cs0820001; GORE JM, 1984, AM J CARDIOL, V54, P722, DOI 10.1016/S0002-9149(84)80197-6; GUPTA R, 1994, BRIT MED J, V307, P1332; JACOBSON MS, 1987, LANCET, V2, P656, DOI 10.1016/S0140-6736(87)92443-3; KVIST H, 1988, AM J CLIN NUTR, V48, P1351, DOI 10.1093/ajcn/48.6.1351; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LEIDIG GA, 1994, AM J CARDIOL, V74, P47, DOI 10.1016/0002-9149(94)90490-1; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MCKEIGUE PM, 1985, LANCET, V2, P1086; MCKEIGUE PM, 1989, CLIN EPIDEMIOL, V42, P579; MCKEIGUE PM, 1994, CORONARY HEART DISEA; MILLER GJ, 1989, INT J EPIDEMIOL, V18, P808, DOI 10.1093/ije/18.4.808; MILLER GJ, 1988, ATHEROSCLEROSIS, V70, P63, DOI 10.1016/0021-9150(88)90100-1; RAMCHANDRAN A, 1988, BRIT MED J, V297, P587; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REDDY S, 1992, ATHEROSCLEROSIS, V95, P223, DOI 10.1016/0021-9150(92)90025-C; RYDER REJ, 1984, BRIT MED J, V289, P1651, DOI 10.1136/bmj.289.6459.1651; SARVOTHAM SG, 1968, CIRCULATION, V37, P939, DOI 10.1161/01.CIR.37.6.939; SEEDAT YK, 1990, S AFR MED J, V78, P447; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; THOMAS I, 1986, ATHEROSCLEROSIS, V61, P99, DOI 10.1016/0021-9150(86)90068-7; VETTER NJ, 1974, LANCET, V1, P284; 1986, LANCET, V1, P1307	33	198	205	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 10	1996	348	9024					358	363		10.1016/S0140-6736(96)02507-X	http://dx.doi.org/10.1016/S0140-6736(96)02507-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709733				2022-12-24	WOS:A1996VB42600009
J	Trauger, JW; Baird, EE; Dervan, PB				Trauger, JW; Baird, EE; Dervan, PB			Recognition of DNA by designed ligands at subnanomolar concentrations	NATURE			English	Article							SEQUENCE-SPECIFIC RECOGNITION; DOUBLE-HELICAL DNA; COVALENT PEPTIDE DIMERS; MINOR-GROOVE; ZINC FINGERS; BINDING SPECIFICITY; 2-DIMENSIONAL NMR; DISTAMYCIN; SELECTION; MOTIF	SMALL molecules that specifically bind with high affinity to any predetermined DNA sequence in the human genome would be useful tools in molecular biology and potentially in human medicine. Simple rules have been developed to control rationally the sequence specificity of minor-groove-binding polyamides containing N-methylimidazole and N-methylpyrrole amino acids. Two eight-ring pyrrole-imidazole polyamides differing in sequence by a single amino acid bind specifically to respective six-base-pair target sites which differ in sequence by a single base pair. Binding is observed at subnanomolar concentrations of ligand. The replacement of a single nitrogen atom with a C-H regulates affinity and specificity by two orders of magnitude, The broad range of sequences that can be specifically targeted with pyrrole-imidazole polyamides, coupled with an efficient solid-phase synthesis methodology, identify a powerful class of small molecules for sequence-specific recognition of double-helical DNA.			Trauger, JW (corresponding author), CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125, USA.							Baird EE, 1996, J AM CHEM SOC, V118, P6141, DOI 10.1021/ja960720z; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; CHEN YH, 1994, J AM CHEM SOC, V116, P6995, DOI 10.1021/ja00095a001; CHO JY, 1995, P NATL ACAD SCI USA, V92, P10389, DOI 10.1073/pnas.92.22.10389; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DWYER TJ, 1993, J AM CHEM SOC, V115, P9900, DOI 10.1021/ja00075a005; FOX KR, 1984, NUCLEIC ACIDS RES, V12, P9271, DOI 10.1093/nar/12.24.9271; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GEIERSTANGER BH, 1993, J AM CHEM SOC, V115, P4474, DOI 10.1021/ja00064a009; GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P3055, DOI 10.1021/bi00176a039; GEIERSTANGER BH, 1994, SCIENCE, V266, P646, DOI 10.1126/science.7939719; IVERSON BL, 1987, NUCLEIC ACIDS RES, V15, P7823, DOI 10.1093/nar/15.19.7823; JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; Maxam A M, 1980, Methods Enzymol, V65, P499; MRKSICH M, 1994, J AM CHEM SOC, V116, P3663, DOI 10.1021/ja00087a088; MRKSICH M, 1993, J AM CHEM SOC, V115, P9892, DOI 10.1021/ja00075a004; MRKSICH M, 1995, J AM CHEM SOC, V117, P3325, DOI 10.1021/ja00117a002; MRKSICH M, 1993, J AM CHEM SOC, V115, P2572, DOI 10.1021/ja00060a004; MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586; MRKSICH M, 1994, J AM CHEM SOC, V116, P7983, DOI 10.1021/ja00097a004; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; PELTON JG, 1990, J AM CHEM SOC, V112, P1393, DOI 10.1021/ja00160a016; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; WADE WS, 1992, J AM CHEM SOC, V114, P8783, DOI 10.1021/ja00049a006; WADE WS, 1993, BIOCHEMISTRY-US, V32, P11385, DOI 10.1021/bi00093a015	30	382	406	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1996	382	6591					559	561		10.1038/382559a0	http://dx.doi.org/10.1038/382559a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB258	8700233				2022-12-24	WOS:A1996VB25800056
J	Pell, J; Pell, A; Morrison, C; Blatchford, O; Dargie, H				Pell, J; Pell, A; Morrison, C; Blatchford, O; Dargie, H			Retrospective study of influence of deprivation on uptake of cardiac rehabilitation	BRITISH MEDICAL JOURNAL			English	Article									STOBHILL GEN HOSP,DEPT CARDIOL,GLASGOW G21 3UW,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT CARDIOL,GLASGOW G11 6NT,LANARK,SCOTLAND	University of Glasgow	Pell, J (corresponding author), GREATER GLASGOW HLTH BOARD,DEPT PUBL HLTH,GLASGOW G1 1ET,LANARK,SCOTLAND.							DAVEYSMITH G, 1990, BRIT MED J, V301, P373; McLoone P., 1994, CARSTAIRS SCORES SCO; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE N, 1991, AM J CARDIOL, V67, P1084, DOI 10.1016/0002-9149(91)90870-Q; Tunstall-Pedoe H, 1986, Health Bull (Edinb), V44, P153	5	64	64	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 3	1996	313	7052					267	268		10.1136/bmj.313.7052.267	http://dx.doi.org/10.1136/bmj.313.7052.267			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VA903	8704538	Green Published			2022-12-24	WOS:A1996VA90300027
J	Barbosa, MDFS; Nguyen, QA; Tchernev, VT; Ashley, JA; Detter, JC; Blaydes, SM; Brandt, SJ; Chotai, D; Hodgman, C; Solari, RCE; Lovett, M; Kingsmore, SF				Barbosa, MDFS; Nguyen, QA; Tchernev, VT; Ashley, JA; Detter, JC; Blaydes, SM; Brandt, SJ; Chotai, D; Hodgman, C; Solari, RCE; Lovett, M; Kingsmore, SF			Identification of the homologous beige and Chediak-Higashi syndrome genes	NATURE			English	Article							PROTEIN SECONDARY STRUCTURE; POLYMORPHONUCLEAR LEUKOCYTES; STRUCTURE PREDICTION; DOWN-REGULATION; CAP FORMATION; KINASE-C; MOUSE; MICE; CONCANAVALIN; MUTATION	VESICULAR transport to and from the lysosome and late endosome is defective in patients with Chediak-Higashi syndrome (CHS) and in mutant beige (bg) mice(1-4). CHS and bg cells have giant, perinuclear vesicles with characteriscs of late endosomes and lysosomes that arise from dysregulated homotypic fusion(3-5). CHS and bg lysosomes also exhibit compartmental missorting of proteins, such as elastase, glucuronidase and cathepsin G(2,3,6,7) Lyst, a candidate gene for bg, was identified by direct complementary DNA selection from a yeast artificial chromosome (YAC) clone containing a 650-kilobase segment of the bg-critical region on mouse chromosome 13. Lyst is disrupted by a 5-kilobase deletion in bg(11J) mice, and Lyst messenger RNA is markedly reduced in bg(2J) homozygotes. The homologous human gene, LYST, is highly conserved with mouse Lyst, and contains a frame-shift mutation at nucleotides 117-118 of the coding domain in a CHS patient. Thus bg mice and human CHS patients have homologous disorders associated with Lyst mutations. Lyst encodes a protein with a carboxy-terminal prenylation motif and multiple potential phosphorylation sites. Lyst protein is predicted to form extended helical domains, and has a region of sequence similar to stathmin, a coiled coil phosphoprotein thought to act as a relay integrating cellular signal response coupling(8-10).	UNIV FLORIDA,DEPT MED,GAINESVILLE,FL 32610; UNIV FLORIDA,DEPT PATHOL,GAINESVILLE,FL 32610; UNIV FLORIDA,CTR MAMMALIAN GENET,GAINESVILLE,FL 32610; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR,DALLAS,TX 75235; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232; GLAXO WELLCOME MED RES CTR,CELL BIOL UNIT,STEVENAGE SG1 2NY,HERTS,ENGLAND; GLAXO WELLCOME MED RES CTR,ADV TECHNOL UNIT,STEVENAGE SG1 2NY,HERTS,ENGLAND; GLAXO WELLCOME MED RES CTR,INFORMAT UNIT,STEVENAGE SG1 2NY,HERTS,ENGLAND	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University; Vanderbilt University; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline				Hodgman, Charlie/0000-0001-5862-8296; Kingsmore, Stephen/0000-0001-7180-2527; kingsmore, stephen/0000-0002-3758-4631	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U19HD077693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI039824] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI039824, P01 AI039824-050002] Funding Source: Medline; NICHD NIH HHS [U19 HD077693] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAETZ K, 1995, J IMMUNOL, V154, P6122; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BLUME RS, 1972, MEDICINE, V51, P247, DOI 10.1097/00005792-197207000-00001; BRANDT EJ, 1975, J CELL BIOL, V67, P774, DOI 10.1083/jcb.67.3.774; BURKHARDT JK, 1993, J EXP MED, V178, P1845, DOI 10.1084/jem.178.6.1845; CLARKE SA, REV BIOCH, V61, P355; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; GALLIN JI, 1974, BLOOD, V43, P201, DOI 10.1182/blood.V43.2.201.201; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GRIBRAT JF, 1987, J MOL BIOL, V198, P425; Holcombe R F, 1994, Immunodeficiency, V5, P131; ITO M, 1989, BIOCHEM BIOPH RES CO, V160, P433, DOI 10.1016/0006-291X(89)92451-0; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; KINGSMORE SF, IN PRESS MAMM GENOME; KINGSMORE SF, IN PRESS J INVEST ME; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; OLIVER JM, 1975, NATURE, V253, P471, DOI 10.1038/253471a0; OLIVER JM, 1976, J CLIN INVEST, V57, P1239, DOI 10.1172/JCI108392; PEROU CM, 1993, SOMAT CELL MOLEC GEN, V19, P459, DOI 10.1007/BF01233251; PIERCE JC, 1992, P NATL ACAD SCI USA, V89, P2056, DOI 10.1073/pnas.89.6.2056; RODER J, 1979, NATURE, V278, P451, DOI 10.1038/278451a0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SATO A, 1990, J LEUKOCYTE BIOL, V48, P377, DOI 10.1002/jlb.48.5.377; SAXENA RK, 1982, NATURE, V295, P240, DOI 10.1038/295240a0; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; SWANK RT, 1978, AM J PATHOL, V92, P755; WILLINGHAM MC, 1981, EXP CELL RES, V136, P157, DOI 10.1016/0014-4827(81)90047-1; ZHAO HQ, 1994, LAB INVEST, V71, P25	30	383	404	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 18	1996	382	6588					262	265		10.1038/382262a0	http://dx.doi.org/10.1038/382262a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UX790	8717042	Green Accepted			2022-12-24	WOS:A1996UX79000052
J	Saunders, AM; Hulette, C; WelshBohmer, KA; Schmechel, DE; Crain, B; Burke, JR; Alberts, MJ; Strittmatter, WJ; Breitner, JCS; Rosenberg, C; Scott, SV; Gaskell, PC; PericakVance, MA; Roses, AD				Saunders, AM; Hulette, C; WelshBohmer, KA; Schmechel, DE; Crain, B; Burke, JR; Alberts, MJ; Strittmatter, WJ; Breitner, JCS; Rosenberg, C; Scott, SV; Gaskell, PC; PericakVance, MA; Roses, AD			Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease	LANCET			English	Article							ADRDA WORK GROUP; CLINICAL-DIAGNOSIS; TYPE-4 ALLELE; FREQUENCY; CRITERIA	Background We aimed to determine the specificity, sensitivity, and predictive value of apolipoprotein E(APOE) genotyping in 67 consecutive Patients with clinical diagnoses of sporadic Alzheimer's disease (AD) who underwent necropsy. Methods We studied patients who attended the Duke Memory Disorders Clinic and were diagnosed as having probable AD. These patients were followed up until they died, APOE genotyping was done during life in most cases, but in some brain tissue obtained at necropsy was used. Members of known AD families were excluded. Findings After neuropathological examination 57 (85%) of 67 of our patients were confirmed as having AD including all 43 who had at least one APOE-is an element of 4 allele. None of the patients found not to have AD carried an is an element of 4 allele, In this series, the specificity of the is an element of 4 allele was 100%, the sensitivity 75%, the positive predictive value 100%, and the negative predictive value 42%. In this necropsy-confirmed series, the is an element of 4/is an element of 4 genotype predicted AD with 100% accuracy. The is an element of 3/is an element of 4 and is an element of 2/is an element of 4 genotypes were also unexpectedly highly specific for AD. Interpretation Data from hundreds of necropsy-confirmed non-AD patients in other longitudinal necropsy series will allow the predictive value oi APOE genotypes to be assessed with useful confidence limits.	DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZHEIMERS DIS RES CTR,DEPT MED NEUROL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PSYCHIAT,DURHAM,NC 27710	Duke University; Duke University; Duke University			Welsh-Bohmer, Kathleen/AAA-3178-2020; Burke, James R/E-4245-2016	Burke, James R/0000-0002-3408-7787	NATIONAL INSTITUTE ON AGING [P50AG005128] Funding Source: NIH RePORTER; NIA NIH HHS [5P50 AG-05128] Funding Source: Medline; NINDS NIH HHS [NS-31135] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIRD TD, 1995, ANN NEUROL, V38, P2, DOI 10.1002/ana.410380103; Breitner JCS, 1996, LANCET, V347, P1184, DOI 10.1016/S0140-6736(96)90642-X; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; ELSTON RC, 1994, ESSENTIAL BIOSTATIST; FARRER LA, 1995, JAMA-J AM MED ASSOC, V274, P1627, DOI 10.1001/jama.1995.03530200063039; GEARING M, 1995, NEUROLOGY, V45, P461, DOI 10.1212/WNL.45.3.461; HENDRIE HC, 1995, ANN NEUROL, V37, P118, DOI 10.1002/ana.410370123; HIXSON JE, 1990, J LIPID RES, V31, P545; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; NALBANTOGLU J, 1994, ANN NEUROL, V36, P889, DOI 10.1002/ana.410360614; OSUNTOKUN BO, 1995, ANN NEUROL, V38, P463, DOI 10.1002/ana.410380319; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; REBECK GW, 1994, NEUROLOGY, V44, P1513, DOI 10.1212/WNL.44.8.1513; Relkin NR, 1996, LANCET, V347, P1091, DOI 10.1016/S0140-6736(96)90284-6; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; ROSES AD, 1995, EMERY RIMOINS PRINCI; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; SESHADRI S, 1995, ARCH NEUROL-CHICAGO, V52, P1074, DOI 10.1001/archneur.1995.00540350068018; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TIERNEY MC, 1988, NEUROLOGY, V38, P359, DOI 10.1212/WNL.38.3.359; UEKI A, 1993, NEUROSCI LETT, V163, P166, DOI 10.1016/0304-3940(93)90373-S; VANDUIJN CM, 1995, ANN NEUROL, V37, P605, DOI 10.1002/ana.410370510; YOSHIZAWA T, 1994, ANN NEUROL, V36, P656, DOI 10.1002/ana.410360416	33	214	221	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 13	1996	348	9020					90	93		10.1016/S0140-6736(96)01251-2	http://dx.doi.org/10.1016/S0140-6736(96)01251-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UW673	8676723				2022-12-24	WOS:A1996UW67300011
J	Fox, PT; Ingham, RJ; Ingham, JC; Hirsch, TB; Downs, JH; Martin, C; Jerabek, P; Glass, T; Lancaster, JL				Fox, PT; Ingham, RJ; Ingham, JC; Hirsch, TB; Downs, JH; Martin, C; Jerabek, P; Glass, T; Lancaster, JL			A PET study of the neural systems of stuttering	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN-BRAIN; LOCALIZATION; IMAGES	THE cause of stuttering is unknown(1). Failure to develop left-hemispheric dominance for speech is a long-standing theory(1) although others implicate the motor system more broadly(2), often postulating hyperactivity of the right (language nondominant) cerebral hemisphere(3). As knowledge of motor circuitry has advanced(4), theories of stuttering have become more anatomically specific, postulating hyperactivity of premotor cortex, either directly(5) or through connectivity with the thalamus and basal ganglia(6), Alternative theories target the auditory(7) and speech productions(8,9) systems. By contrasting stuttering with fluent speech using positron emission tomography combined with chorus reading to induce fluency, we found support for each of these hypotheses, Stuttering induced widespread over-activations of the motor system in both cerebrum and cerebellum, with right cerebral dominance. Stuttered reading lacked left-lateralized activations of the auditory system, which are thought to support the self-monitoring of speech, and selectively deactivated a frontal-temporal system implicated in speech production, Induced fluency decreased or eliminated the overactivity in most motor areas, and largely reversed the auditory-system underactivations and the deactivation of the speech production system. Thus stuttering is a disorder affecting the multiple neural systems used for speaking.	UNIV TEXAS, HLTH SCI CTR, DEPT RADIOL, SAN ANTONIO, TX 78284 USA; UNIV CALIF SANTA BARBARA, DEPT SPEECH & HEARING SCI, SANTA BARBARA, CA 93106 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Santa Barbara	Fox, PT (corresponding author), UNIV TEXAS, HLTH SCI CTR, RES IMAGING CTR, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.		Fox, Peter/B-4725-2010; Lancaster, Jack L/F-2994-2010	Fox, Peter/0000-0002-0465-2028; 				ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Bloodstein O., 1995, HDB STUTTERING; CARUSO AJ, 1991, INT CONGR SER, V950, P101; CORDES AK, 1995, J SPEECH HEAR RES, V38, P33, DOI 10.1044/jshr.3801.33; Fairbanks G, 1954, J SPEECH HEAR DISORD, V19, P133, DOI 10.1044/jshd.1902.133; FOX PT, 1985, J NEUROPHYSIOL, V54, P348, DOI 10.1152/jn.1985.54.2.348; FOX PT, 1984, J CEREBR BLOOD F MET, V4, P329, DOI 10.1038/jcbfm.1984.49; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1989, J NUCL MED, V30, P141; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FRISTON KJ, 1991, P ROY SOC B-BIOL SCI, V244, P101, DOI 10.1098/rspb.1991.0057; FRITH CD, 1991, NEUROPSYCHOLOGIA, V29, P1137, DOI 10.1016/0028-3932(91)90029-8; GRAFTON ST, 1994, ANN NEUROL, V36, P3, DOI 10.1002/ana.410360103; INGHAM RJ, 1993, J SPEECH HEAR RES, V36, P1168, DOI 10.1044/jshr.3606.1168; INGHAM RJ, 1979, J SPEECH HEAR RES, V22, P784, DOI 10.1044/jshr.2204.784; INGHAM RJ, 1984, STUTTERING BEHAV; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; Pardo Jose V., 1993, Human Brain Mapping, V1, P57, DOI 10.1002/hbm.460010107; PERKINS WH, 1991, J SPEECH HEAR RES, V34, P734, DOI 10.1044/jshr.3404.734; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; Stromsta C., 1986, ELEMENTS STUTTERING; Talairach J., 1988, COPLANAR STEREOTAXIC; Van Riper C., 1955, STUTTERING CHILDREN, P199; Webster WG, 1993, NEUROPSYCHOLOGY STUT, P73; Wingate M. E., 1988, STRUCTURE STUTTERING; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; YEUDALL LT, 1985, SEMINARS SPEECH LANG, V6, P197; ZIMMERMANN G, 1980, J SPEECH HEAR RES, V23, P122, DOI 10.1044/jshr.2301.122; ZIMMERMANN G, 1984, NATURE TREATMENT STU, P131	30	326	337	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					158	162		10.1038/382158a0	http://dx.doi.org/10.1038/382158a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UW672	8700204				2022-12-24	WOS:A1996UW67200047
J	Gerald, C; Walker, MW; Criscione, L; Gustafson, EL; BatzlHartmann, C; Smith, KE; Vaysse, P; Durkin, MM; Laz, TM; Linemeyer, DL; Schaffhauser, AO; Whitebread, S; Hofbauer, KG; Taber, RI; Branchek, TA; Weinshank, RL				Gerald, C; Walker, MW; Criscione, L; Gustafson, EL; BatzlHartmann, C; Smith, KE; Vaysse, P; Durkin, MM; Laz, TM; Linemeyer, DL; Schaffhauser, AO; Whitebread, S; Hofbauer, KG; Taber, RI; Branchek, TA; Weinshank, RL			A receptor subtype involved in neuropeptide-Y-induced food intake	NATURE			English	Article							PROTEIN-COUPLED RECEPTOR; PEPTIDE-YY; GENE; EXPRESSION; CLONING; BINDING	NEUROPEPTIDE Y (NPY) is a powerful stimulant of food intake and is proposed to activate a hypothalamic 'feeding' receptor distinct from previously cloned Y-type receptors(1). This receptor was first suggested to explain a feeding response to NPY and related peptides, including NPY2-36, that differed from their activities at the Y1 receptor(2), Here we report the expression cloning of a novel Y-type receptor from rat hypothalamus, which we name Y5, The complementary DNA encodes a 456-amino-acid protein with less than 35% overall identity to known Y-type receptors, The messenger RNA is found primarily in the central nervous system, including the paraventricular nucleus of the hypothalamus. The extent to which selected peptides can Inhibit adenylate cyclase through the Y5 receptor and stimulate food intake in rats correspond well, Our data support the idea that the Y5 receptor is the postulated 'feeding' receptor, and may provide a new method for the study and treatment of obesity and eating disorders.	CIBA GEIGY LTD,DIV PHARMACEUT,METAB RISK FACTOR DEPT,CH-4002 BASEL,SWITZERLAND	Novartis	Gerald, C (corresponding author), SYNAPT PHARMACEUT CORP,215 COLL RD,PARAMUS,NJ 07652, USA.							BALASUBRAMANIAM A, 1994, J MED CHEM, V37, P811, DOI 10.1021/jm00032a015; BALL HJ, 1995, J BIOL CHEM, V270, P27272, DOI 10.1074/jbc.270.45.27272; BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; BARD JA, 1995, Patent No. 17906; BLOMQVIST AG, 1995, BBA-GENE STRUCT EXPR, V1261, P439, DOI 10.1016/0167-4781(95)00051-H; COX HM, 1995, BRIT J PHARMACOL, V116, P2673, DOI 10.1111/j.1476-5381.1995.tb17225.x; DURKIN MM, 1995, MOL BRAIN RES, V33, P7, DOI 10.1016/0169-328X(95)00101-W; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; GERALD C, 1995, EMBO J, V14, P2806, DOI 10.1002/j.1460-2075.1995.tb07280.x; GERALD C, 1995, Patent No. 21245; HARRIGAN MT, 1991, MOL ENDOCRINOL, V5, P1331, DOI 10.1210/mend-5-9-1331; HERZOG H, 1993, J BIOL CHEM, V268, P6703; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; KRAUSE J, 1992, MOL PHARMACOL, V41, P817; KRSTENANSKY JL, 1989, P NATL ACAD SCI USA, V86, P4377, DOI 10.1073/pnas.86.12.4377; LABURTHE M, 1986, ENDOCRINOLOGY, V118, P1910, DOI 10.1210/endo-118-5-1910; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LARSEN PJ, 1993, EUR J NEUROSCI, V5, P1622, DOI 10.1111/j.1460-9568.1993.tb00231.x; LUNDELL I, 1995, J BIOL CHEM, V270, P29123, DOI 10.1074/jbc.270.49.29123; Rimland JM, 1996, MOL PHARMACOL, V49, P387; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; RUDOLF K, 1994, EUR J PHARMACOL, V271, pR11, DOI 10.1016/0014-2999(94)90822-2; SCHWARTZ TW, 1983, GASTROENTEROLOGY, V85, P1411; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309	28	807	841	0	33	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					168	171		10.1038/382168a0	http://dx.doi.org/10.1038/382168a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700207				2022-12-24	WOS:A1996UW67200050
J	FritzWolf, K; Schnyder, T; Wallimann, T; Kabsch, W				FritzWolf, K; Schnyder, T; Wallimann, T; Kabsch, W			Structure of mitochondrial creatine kinase	NATURE			English	Article							FORMS OCTAMERIC STRUCTURES; MUSCLE; SITE; CRYSTALLIZATION; CRYSTALS	CREATINE kinase (CK; EC 2.7.3.2), an enzyme important for energy metabolism in cells of high and fluctuating energy requirements, catalyses the reversible transfer of a phosphoryl goup from phosphocreatine to ADP(1-3). We have solved the structure of the octameric mitochondrial isoform, Mi(b)-CK, which is located in the intermembrane compartment and along the cristae membranes. Mi(b)-CK consumes ATP produced in the mitochondria for the production of phosphocreatine, which is then exported into the cytosol for fast regeneration of ATP by the cytosolic CK isoforms. The octamer has 422 point-group symmetry, and appear as a cube of side length of 93 Angstrom with a channel 20 Angstrom wide extending along the four-fold axis. Positively charged amino acids at the four-fold faces of the octamer possible interact with negatively charged mitochondrial membranes. Each monomer consists of a small alpha-helical domain and a large domain containing an eight-stranded antiparallel beta-sheet flanked by seven alpha-helices. The conserved residues of the CK family form a compact cluster that covers the active site between the domains.	MAX PLANCK INST MED RES,BIOPHYS ABT,D-69028 HEIDELBERG,GERMANY; ETH ZURICH,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND	Max Planck Society; Swiss Federal Institutes of Technology Domain; ETH Zurich			Wallimann, Theo/C-6047-2008	Wallimann, Theo/0000-0003-4957-5836				BRUNGER AT, 1992, X PLOR VERSION 3 1; BUECHTER DD, 1992, J BIOL CHEM, V267, P2173; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1204, DOI 10.1021/bi00508a023; GROSS M, 1995, BIOCHEMISTRY-US, V34, P6660, DOI 10.1021/bi00020a011; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; HOSSLE JP, 1988, BIOCHEM BIOPH RES CO, V151, P408, DOI 10.1016/0006-291X(88)90608-0; JAMES P, 1990, FEBS LETT, V273, P139, DOI 10.1016/0014-5793(90)81069-Z; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KALDIS P, 1994, BIOCHEMISTRY-US, V33, P952, DOI 10.1021/bi00170a014; KENYON GL, 1983, ADV ENZYMOL RAMB, V54, P367; MILNERWH.EJ, 1971, BIOCHEM J, V122, P727, DOI 10.1042/bj1220727; MUHLEBACH SM, 1994, MOL CELL BIOCHEM, V133, P245, DOI 10.1007/BF01267958; OLCOTT MC, 1994, BIOCHEMISTRY-US, V33, P19935; ROJO M, 1991, J BIOL CHEM, V266, P20290; ROSEVEAR PR, 1981, BIOCHEMISTRY-US, V20, P6155, DOI 10.1021/bi00524a038; SCHLEGEL J, 1988, J BIOL CHEM, V263, P16942; SCHNYDER T, 1991, J BIOL CHEM, V266, P5318; SCHNYDER T, 1990, J MOL BIOL, V216, P809, DOI 10.1016/S0022-2836(99)80002-3; SCHNYDER T, 1991, J CELL BIOL, V112, P95, DOI 10.1083/jcb.112.1.95; SCHNYDER T, 1994, J STRUCT BIOL, V112, P136, DOI 10.1006/jsbi.1994.1015; SCHNYDER T, 1988, J BIOL CHEM, V263, P16954; TAYLOR JS, 1969, P NATL ACAD SCI USA, V64, P219, DOI 10.1073/pnas.64.1.219; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VASAK M, 1979, BIOCHEMISTRY-US, V18, P5050, DOI 10.1021/bi00590a004; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; WATTS DC, 1973, ENZYMES, V8, P383; WYSS M, 1993, BIOCHEMISTRY-US, V32, P10727, DOI 10.1021/bi00091a025	30	257	267	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 23	1996	381	6580					341	345		10.1038/381341a0	http://dx.doi.org/10.1038/381341a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692275				2022-12-24	WOS:A1996UM40300061
J	Zecevic, D				Zecevic, D			Multiple spike-initiation zones in single neurons revealed by voltage-sensitive dyes	NATURE			English	Article							POTENTIALS; DENDRITES; GANGLION	THE primary function of the nerve cell is to process electrical signals. Over the past fifteen years(1) there has beers renewed Interest in the detailed spatial analysis of signalling in individual neurons owing to experimental evidence that the regional electrical properties of neurons are complex. Thus the behaviour of many nerve cells cannot be understood on the basis of microelectrode measurements from the soma. Regional electrical properties of neurons have been studied using sharp microelectrode(1) and patch-electrode(2,3) recordings from neuronal processes, high-resolution multisite optical recordings of Ca2+ concentration changes(4,5), and by using models to predict the distribution of membrane potential in the entire neoronal arborization(6). Additional direct evidence about electrical signalling in neuronal processes in situ tan now he obtained by recording membrane potential changes using voltage-sensitive dyes(7,21). Here I demonstrate the existence of multiple action potential trigger zones in separate regions of the neuronal arborization of an indentified molluscan neuron.			Zecevic, D (corresponding author), YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, 333 CEDAR ST, NEW HAVEN, CT 06520 USA.		Zecevic, Dejan/A-9824-2008	Zecevic, Dejan/0000-0002-8917-5784				ANTIC S, 1995, J NEUROSCI, V15, P1392; Cohen L B, 1986, Soc Gen Physiol Ser, V40, P71; COHEN LB, 1978, REV PHYSIOL BIOCH P, V83, P35, DOI 10.1007/3-540-08907-1_2; COMBES D, 1993, J PHYSIOL-LONDON, V460, P581, DOI 10.1113/jphysiol.1993.sp019488; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; GRINVALD A, 1987, BIOPHYS J, V51, P643, DOI 10.1016/S0006-3495(87)83389-1; GRINVALD A, 1994, J NEUROSCI, V14, P2545; GUPTA RK, 1981, J MEMBRANE BIOL, V58, P123, DOI 10.1007/BF01870975; HEITLER WJ, 1978, J EXP BIOL, V76, P63; HUGUENARD JR, 1994, J SOC NEUR ABSTR, V20, P1527; KANDEL ER, 1965, J PHYSL, V183, P269; KOGAN A, 1995, BRAIN RES, V700, P235, DOI 10.1016/0006-8993(95)00956-Q; KORN H, 1971, BRAIN RES, V27, P169, DOI 10.1016/0006-8993(71)90379-9; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; MIDTGAARD J, 1993, J NEUROPHYSIOL, V70, P2455, DOI 10.1152/jn.1993.70.6.2455; REGEHR W, 1993, NEURON, V11, P145, DOI 10.1016/0896-6273(93)90278-Y; ROSS WN, 1984, J NEUROSCI, V4, P659; ROSS WN, 1993, JPN J PHYSIOL, V43, pS83; SALZBERG BM, 1993, JPN J PHYSIOL, V43, pS37; STUART G, 1994, NEURON, V13, P703, DOI 10.1016/0896-6273(94)90037-X; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; TAUC L, 1962, J GEN PHYSIOL, V45, P1077, DOI 10.1085/jgp.45.6.1077; TAUC L., 1963, JOUR GEN PHYSIOL, V46, P533; TRAUB RD, 1994, J PHYSIOL-LONDON, V481, P79, DOI 10.1113/jphysiol.1994.sp020420; Wu J.-Y., 1993, FLUORESCENT LUMINESC, P389; ZECEVIC D, 1989, J NEUROSCI, V9, P3681	26	81	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 23	1996	381	6580					322	325		10.1038/381322a0	http://dx.doi.org/10.1038/381322a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UM403	8692270				2022-12-24	WOS:A1996UM40300056
J	Kuo, MH; Brownell, JE; Sobel, RE; Ranalli, TA; Cook, RG; Edmondson, DG; Roth, SY; Allis, CD				Kuo, MH; Brownell, JE; Sobel, RE; Ranalli, TA; Cook, RG; Edmondson, DG; Roth, SY; Allis, CD			Transcription-linked acetylation by Gcn5p of histones H3 and H4 at specific lysines	NATURE			English	Article							SITE-SPECIFIC ANTIBODIES; TETRAHYMENA MACRONUCLEI; ADA2; ACETYLTRANSFERASE; FREQUENCY; ADAPTER; DOMAINS	THE yeast transcriptional adaptor(1-3), Gcn5p, is a catalytic subunit of a nuclear (type A) histone acetyltransferase linking histone acetylation to gene activation(4-6). Here we report that Gcn5p acetylates histones H3 and H4 non-randomly at specific lysines in the amino-terminal domains. Lysine 14 of H3 and lysines 8 and 16 of H4 are highly preferred acetylation sites for Gcn5p. We also demonstrate that lysine 9 is the preferred position of acetylation in newly synthesized yeast H3 in vivo. This finding, along with the fact that lysines 5 and 12 in H4 are predominant acetylation sites during chromatin assembly of many organisms(7-11), indicates that Gcn5p acetylates a distinct set of lysines that do not overlap with those sites characteristically used by type B histone acetyltransferases for histone deposition and chromatin assembly.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Rochester; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center				Dent, Sharon/0000-0002-4824-3269; Edmondson, Diane/0000-0003-3702-9715				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1996, J BIOL CHEM, V271, P5237; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; CLARKE DJ, 1993, BIOCHEM J, V294, P557, DOI 10.1042/bj2940557; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HORIUCHI K, 1975, ANAL BIOCHEM, V69, P491, DOI 10.1016/0003-2697(75)90151-7; MUNKS RJL, 1991, FEBS LETT, V284, P245, DOI 10.1016/0014-5793(91)80695-Y; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; VAVRA KJ, 1982, J BIOL CHEM, V257, P2591; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	23	465	476	1	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					269	272		10.1038/383269a0	http://dx.doi.org/10.1038/383269a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805705				2022-12-24	WOS:A1996VH31500057
J	Schumacher, A; Faust, C; Magnuson, T				Schumacher, A; Faust, C; Magnuson, T			Positional cloning of a global regulator of anterior-posterior patterning in mice	NATURE			English	Article							EXTRA-SEX-COMBS; MOUSE CHROMOSOME-7; HOX EXPRESSION; GENE; DROSOPHILA; PROTEIN; EMBRYOS; EED; TRANSFORMATION; SEQUENCES	ANTERIOR-POSTERIOR (A-P) patterning is of fundamental importance throughout vertebrate embryonic development. Murine members of the trithorax (trx) and Polycomb group (Pc-G) of genes regulate A-P patterning of segmented axial structures(1-4), demonstrating conserved upstream regulation of homeotic pathways between Drosophila and mouse. Here we report the positional cloning of a classical mouse mutation, eed (for embryonic ectoderm development), which is the highly conserved homologue of the Drosophila Pc-G gene esc (for extra sex combs), a long-term repressor of homeotic genes(5). Mutants homozygous for a null allele of eed display disrupted A-P patterning of the primitive streak during gastrulation. Mutant embryos lack a node, notochord and somites, and there is no neural induction(6). In contrast to absence of anterior structures, extra-embryonic mesoderm is abundant. Mice carrying a hypomorphic eed mutation exhibit posterior transformations along the axial skeleton. These results indicate that eed is required globally for A-P patterning throughout embryogenesis.	CASE WESTERN RESERVE UNIV,DEPT GENET,CLEVELAND,OH 44106	Case Western Reserve University								Ahringer J, 1996, GENE DEV, V10, P1120, DOI 10.1101/gad.10.9.1120; Akasaka T, 1996, DEVELOPMENT, V122, P1513; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; ALTABA ARI, 1991, DEV GROWTH DIFFER, V33, P651; ANG SL, 1994, DEVELOPMENT, V120, P2979; BARRO O, 1995, DEV GENET, V17, P117, DOI 10.1002/dvg.1020170204; DESCHAMPS J, 1993, DEV BIOL, V156, P473, DOI 10.1006/dbio.1993.1093; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUSH MK, 1992, DEV BIOL, V151, P273, DOI 10.1016/0012-1606(92)90232-6; FAUST C, 1995, DEVELOPMENT, V121, P273; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; HOLDENER BC, 1995, GENOMICS, V27, P447, DOI 10.1006/geno.1995.1076; HOLDENER BC, 1995, MAMM GENOME, V6, P474, DOI 10.1007/BF00360658; KORNFELD R, 1987, ANN REV BIOCH, V56, P615; LAWSON KA, 1991, DEVELOPMENT, V113, P891; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; RINCHIK EM, 1993, MAMM GENOME, V4, P349, DOI 10.1007/BF00360583; RINCHIK EM, 1990, P NATL ACAD SCI USA, V87, P896, DOI 10.1073/pnas.87.3.896; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SATHE SS, 1995, MECH DEVELOP, V52, P77, DOI 10.1016/0925-4773(95)00392-E; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; STITES WE, 1995, PROTEINS, V22, P132, DOI 10.1002/prot.340220206; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	30	188	191	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					250	253		10.1038/383250a0	http://dx.doi.org/10.1038/383250a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805699				2022-12-24	WOS:A1996VH31500051
J	Bosch, JLHR; Groen, J				Bosch, JLHR; Groen, J			Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients	LANCET			English	Article							ELECTRICAL-STIMULATION; BLADDER	Background Urge urinary incontinence in multiple sclerosis patients is usually due to detrusor hyperreflexia. Patients who do not respond to conservative measures such as anticholinergics, with or without clean intermittent catheterisation, are difficult to manage. Methods We applied electrical stimulation to the S3 sacral spinal nerves with the aim of activating afferent somatic nerve fibres. Stimulation of these fibres can inhibit the micturition reflex. An S3 electrode coupled to a subcutaneously placed pulse generator was implanted in four women who had shown a good response during temporary stimulation via a percutaneously placed wire electrode. All patients were followed for at least 2 years. Findings The number of leakage episodes decreased from a mean of 4 to 0.3 per 24 h. Two patients were completely dry. The hyperreflexia disappeared in one, improved in two, and got worse in one patient. The urodynamic result in the last patient may be explained by clinical progression of the multiple sclerosis. Interpretation Chronic stimulation of the S3 sacral spinal nerve by an implantable neuroprosthesis is a promising treatment option for selected multiple sclerosis patients with refractory urge incontinence.	ERASMUS UNIV ROTTERDAM,DEPT UROL,NL-3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	Bosch, JLHR (corresponding author), ACAD ZIEKENHUIS ROTTERDAM DIJKZIGT,DEPT UROL,H-1073,DR MOLEWATERPLEIN 40,NL-3015 GD ROTTERDAM,NETHERLANDS.							ABRAMS P, 1991, CLIN NEUROUROLOGY, P651; *AG HLTH CAR POL R, 1992, 920038 AG HLTH CAR P, P38; BETTS CD, 1993, J NEUROL NEUROSUR PS, V56, P245, DOI 10.1136/jnnp.56.3.245; BOSCH JLHR, 1995, J UROLOGY, V154, P504, DOI 10.1016/S0022-5347(01)67086-1; DEGROAT WC, 1990, J AUTONOM NERV SYST, V30, pS71, DOI 10.1016/0165-1838(90)90105-R; FALL M, 1991, UROL CLIN N AM, V18, P393; FOWLER CJ, 1994, J NEUROL NEUROSUR PS, V57, P169, DOI 10.1136/jnnp.57.2.169; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lindstrom S, 1989, NEUROUROL URODYNAM, V8, P392; MUNDY AR, 1985, UROL CLIN N AM, V12, P317; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; SCHMIDT RA, 1990, UROLOGY, V35, P388, DOI 10.1016/0090-4295(90)80078-2; VODUSEK DB, 1986, NEUROUROL URODYNAM, V5, P381, DOI 10.1002/nau.1930050404; VODUSEK DB, 1988, NEUROUROL URODYNAM, V6, P389	14	71	75	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					717	719		10.1016/S0140-6736(96)04437-6	http://dx.doi.org/10.1016/S0140-6736(96)04437-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806291	Green Submitted			2022-12-24	WOS:A1996VG37400011
J	Parving, HH; Jacobsen, P; Tarnow, L; Rossing, P; Lecerf, L; Poirier, O; Cambien, F				Parving, HH; Jacobsen, P; Tarnow, L; Rossing, P; Lecerf, L; Poirier, O; Cambien, F			Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: Observational follow up study	BRITISH MEDICAL JOURNAL			English	Article							GLOMERULAR-FILTRATION RATE; INSULIN-DEPENDENT DIABETICS; ARTERIAL BLOOD-PRESSURE; IGA NEPHROPATHY; KIDNEY-FUNCTION; IDDM PATIENTS; MICROALBUMINURIA; CAPTOPRIL; ALBUMINURIA; ENALAPRIL	Objective-To evaluate the concept that an insertion/deletion polymorphism of the angiotensin converting enzyme gene predicts the therapeutic efficacy of inhibition of angiotensin converting enzyme on progression of diabetic nephropathy. Design-Observational follow up study of patients with insulin dependent diabetes and nephropathy who had been treated with captopril for a median of 7 years (range 3-9 years). Setting-Outpatient diabetic clinic in a tertiary referral centre. Patients-35 patients with insulin dependent diabetes and nephropathy were investigated during captopril treatment (median 75 mg/day (range 12.5 to 150 mg/day)) that was in many cases combined with a loop diuretic. 11 patients were homozygous for the deletion allele and 24 were heterozygous or homozygous for the insertion allele of the angiotensin converting enzyme gene. Main outcome measures-Albuminuria, arterial blood pressure, and glomerular filtration rate according to insertion/deletion polymorphism. Results-The two groups had comparable glomerular filtration rate, albuminuria, blood pressure, and haemoglobin A,, concentration at baseline. Captopril induced nearly the same reduction in mean blood pressure in the two groups-to 103 (SD 5) mm Hg in the group with the deletion and 102 (8) mm Hg in the group with the insertion-and in geometric mean albumin excretion-573 (antilog SE 1.3) mu g/min and 470 (1.2) mu g/min, respectively. The rate of decline in glomerular filtration rate (linear regression of all glomerular filtration rate measurements during antihypertensive treatment) was significantly steeper in the group homozygous for the double deletion allele than in the other group (mean 5.7 (3.7) ml/min/year and 2.6 (2.8) ml/min/year, respectively; P = 0.01). Multiple Linear regression analysis showed that haemoglobin A(1c) concentration, albuminuria, and the double deletion genotype independently influenced the sustained rate of decline in glomerular filtration rate (R(2) (adjusted) = 0.51). Conclusion-The deletion polymorphism in the angiotensin converting enzyme gene reduces the long term beneficial effect of angiotensin converting enzyme inhibition on the progression of diabetic nephropathy in patients with insulin dependent diabetes.	INSERM,SC7,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	Parving, HH (corresponding author), STENO DIABET CTR,NIELS STEENSENS VEJ 2,DK-2820 GENTOFTE,DENMARK.		Jacobsen, Peter Karl/AAK-7609-2021; rossing, peter/AAZ-3415-2021; Cambien, Francois/AAP-9751-2020; rossing, peter/AAH-7879-2021	Jacobsen, Peter Karl/0000-0002-1520-8774; rossing, peter/0000-0002-1531-4294; Tarnow, Lise/0000-0002-8735-966X; LECERF, LAURE/0000-0001-8342-5298				BJORCK S, 1992, BMJ-BRIT MED J, V304, P339, DOI 10.1136/bmj.304.6823.339; BREYER J, 1993, J AM SOC NEPHROL, V4, P301; BROCHNERMORTENSEN J, 1976, SCAND J CLIN LAB INV, V36, P35, DOI 10.3109/00365517609068016; BROCHNERMORTENSEN J, 1985, CLIN PHYSIOL, V5, P1, DOI 10.1111/j.1475-097X.1985.tb00742.x; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; HARDEN PN, 1995, LANCET, V345, P1540, DOI 10.1016/S0140-6736(95)91088-3; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; LEVEY AS, 1991, J AM SOC NEPHROL, V1, P1087; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MILES DW, 1970, SCAND J CLIN LAB INV, V26, P5, DOI 10.3109/00365517009049206; PARVING HH, 1981, DIABETOLOGIA, V20, P457; PARVING HH, 1983, LANCET, V1, P1175; PARVING HH, 1995, AM J KIDNEY DIS, V26, P99, DOI 10.1016/0272-6386(95)90162-0; PARVING HH, 1988, BRIT MED J, V297, P1086, DOI 10.1136/bmj.297.6656.1086; PARVING HH, 1996, KIDNEY, P1864; ROSSING P, 1993, DIABETES, V42, P715, DOI 10.2337/diabetes.42.5.715; TARNOW L, 1995, DIABETES, V44, P489, DOI 10.2337/diabetes.44.5.489; UEDA S, 1995, HYPERTENSION, V25, P1266, DOI 10.1161/01.HYP.25.6.1266; vanEssen GG, 1996, LANCET, V347, P94, DOI 10.1016/S0140-6736(96)90213-5; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; YOSHIDA H, 1995, J CLIN INVEST, V96, P2162, DOI 10.1172/JCI118270	23	179	182	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					591	594						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806248				2022-12-24	WOS:A1996VG10800017
J	Brook, WJ; Cohen, SM				Brook, WJ; Cohen, SM			Antagonistic interactions between Wingless and decapentaplegic responsible for dorsal-ventral pattern in the Drosophila leg	SCIENCE			English	Article							SEGMENT-POLARITY GENE; PROTEIN-KINASE-A; IMAGINAL DISKS; SIGNAL-TRANSDUCTION; EXPRESSION; HEDGEHOG; COMPARTMENTS; MELANOGASTER; AXIS; APPENDAGE	Subdivision of the limb primordia of Drosophila into anterior and posterior compartments triggers cell interactions that pattern the legs and wings. A comparable compartment-based mechanism is used to pattern the dorsal-ventral axis of the wing. Evidence is presented here for a mechanism based on cell interaction, rather than on compartment formation, that distinguishes dorsal from ventral in the leg. Mutual repression by Wingless and Decapentaplegic signaling systems generates a stable regulatory circuit by which each gene maintains its own expression in a spatially restricted domain. Compartment-independent patterning mechanisms may be used by other organisms during development.	EUROPEAN MOL BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163				BAKER NE, 1988, DEVELOPMENT, V102, P489; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BLAIR SS, 1995, BIOESSAYS, V17, P299, DOI 10.1002/bies.950170406; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROOK WJ, 1993, DEVELOPMENT, V117, P1287; BROOK WJ, UNPUB; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; COHEN B, 1993, DEVELOPMENT, V117, P597; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; HELD LI, 1994, ROUX ARCH DEV BIOL, V203, P310, DOI 10.1007/BF00457802; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Lawrence PA, 1995, DEVELOPMENT, V121, P4303; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PFLUGFELDER GO, 1992, BIOCHEM BIOPH RES CO, V186, P918, DOI 10.1016/0006-291X(92)90833-7; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; THEISEN H, 1994, DEVELOPMENT, V120, P347; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WILDER EL, 1995, DEVELOPMENT, V121, P477; ZECCA M, 1995, DEVELOPMENT, V121, P2265	42	276	279	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1373	1377		10.1126/science.273.5280.1373	http://dx.doi.org/10.1126/science.273.5280.1373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8703069				2022-12-24	WOS:A1996VF61000038
J	Mao, XQ; Shirakawa, T; Yoshikawa, T; Yoshikawa, K; Kawai, M; Sasaki, S; Enomoto, T; Hashimoto, T; Furuyama, J; Hopkin, JM; Morimoto, K				Mao, XQ; Shirakawa, T; Yoshikawa, T; Yoshikawa, K; Kawai, M; Sasaki, S; Enomoto, T; Hashimoto, T; Furuyama, J; Hopkin, JM; Morimoto, K			Association between genetic variants of mast-cell chymase and eczema	LANCET			English	Article							BETA-SUBUNIT; ATOPY; RECEPTOR	Background Atopy is a common syndrome underlying asthma, rhinitis, and eczema, and is characterised by high immunoglobulin E (IgE) responses to common antigens. IgE and mast-cell chymase (MCC-a serine protease secreted by skin mast cells) have a key role in atopic or allergic inflammation of the skin. The gene for MCC is located within a cluster of genes for cellular proteases on chromosome 14q11.2. We aimed to identify variants of MCC and another gene within this complex, and assess whether there is a genetic association between variants of MCC and atopic disorders-particularly eczema. Methods We randomly selected 100 controls and recruited patients-100 in each group-with atopic asthma, nonatopic asthma, atopic rhinitis, and atopic eczema. PCR amplification was used to test genomic DNA for an association between allelic polymorphisms in MCC and a flanking gene (CGL1, for the cathepsin-G-like protein) on chromosome 14q11 and asthma, rhinitis, and eczema. Findings We found a significant association between a BstXI polymorphism in MCC and eczema (odds ratio 2.17 [95% CI 1.21-3.88], p=0.009), but no association with atopic asthma, rhinitis, or non-atopic asthma. There was no association between an Mboll polymorphism in CGL1 and any of the atopic disorders. Interpretation These findings suggest that variants of MCC may be one source of genetic risk for eczema.	OSAKA UNIV, SCH MED, DEPT HYG & PREVENT MED, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT DERMATOL, SUITA, OSAKA 565, JAPAN; CHURCHILL HOSP, OSLER CHEST UNIT, LUNG RES LAB, OXFORD OX3 7LJ, ENGLAND; KYOTO PREVENT MED CTR, KYOTO, JAPAN; OSAKA MED COLL, DEPT PEDIAT, TAKATSUKI, OSAKA 569, JAPAN; WAKAYAMA RED CROSS HOSP, DEPT OTORHINOLARYNGOL, WAKAYAMA, JAPAN; HYOGO MED UNIV, DEPT GENET, NISHINOMIYA, HYOGO, JAPAN	Osaka University; Osaka University; University of Oxford; Osaka Medical College; Hyogo College of Medicine; University of Hyogo								CAUGHEY GH, 1993, GENOMICS, V15, P614, DOI 10.1006/geno.1993.1115; CAUGHEY GH, 1991, J BIOL CHEM, V266, P12956; COLEMAN R, 1993, LANCET, V341, P1121, DOI 10.1016/0140-6736(93)93130-S; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; HADDAD P, 1990, GENE, V87, P265, DOI 10.1016/0378-1119(90)90311-E; HANAFIN JM, 1980, ACTA DERM-VENEREOL, V92, P44; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; UEHARA M, 1986, ACTA DERM-VENEREOL, V66, P404	11	118	122	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	1996	348	9027					581	583		10.1016/S0140-6736(95)10244-2	http://dx.doi.org/10.1016/S0140-6736(95)10244-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774571				2022-12-24	WOS:A1996VF18600012
J	Puliyel, JM; Hughes, A; Chiswick, ML; Mughal, MZ				Puliyel, JM; Hughes, A; Chiswick, ML; Mughal, MZ			Adverse local reactions from accidental BCG overdose in infants	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,DEPT PAEDIAT,MANCHESTER M13 0JH,LANCS,ENGLAND	University of Manchester			MUGHAL, Zulf/AAA-1230-2021; Hughes, Alun David/N-3781-2013	Hughes, Alun David/0000-0001-5432-5271				Farries J S, 1980, Community Med, V2, P312, DOI 10.1007/BF02549415; MILSTIEN JB, 1990, B WORLD HEALTH ORGAN, V68, P93; OBRIEN KL, 1995, PEDIATRICS, V95, P914	3	11	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					528	529						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789978	Green Published			2022-12-24	WOS:A1996VF29400018
J	Pettersson, J; Nordfelth, R; Dubinina, E; Bergman, T; Gustafsson, M; Magnusson, KE; WolfWatz, H				Pettersson, J; Nordfelth, R; Dubinina, E; Bergman, T; Gustafsson, M; Magnusson, KE; WolfWatz, H			Modulation of virulence factor expression by pathogen target cell contact	SCIENCE			English	Article							YERSINIA-PSEUDOTUBERCULOSIS; EPITHELIAL-CELLS; FUNCTIONAL CONSERVATION; SALMONELLA-TYPHIMURIUM; POLARIZED TRANSFER; SHIGELLA-FLEXNERI; IPA INVASINS; SECRETION; PROTEINS; ENTEROCOLITICA	Upon contact with the eukaryotic cell, Yersinia pseudotuberculosis increased the rate of transcription of virulence genes (yop), as determined by in situ monitoring of light emission from individual bacteria expressing luciferase under the control of the yopE promoter, The microbe-host interaction triggered export of LcrQ, a negative regulator of Yop expression, via the Yop-type III secretion system. The intracellular concentration of LcrQ was thereby lowered, resulting in increased expression of Yops. These results suggest a key role for the type III secretion system of pathogenic bacteria to coordinate secretion with expression of virulence factors after physical contact with the target cell.	LINKOPING UNIV,DEPT MED MICROBIOL,S-58185 LINKOPING,SWEDEN	Linkoping University	Pettersson, J (corresponding author), UMEA UNIV,DEPT MOL & CELL BIOL,S-90187 UMEA,SWEDEN.			Magnusson, Karl-Eric/0000-0002-7809-8437				BERGMAN T, 1994, J BACTERIOL, V176, P2619, DOI 10.1128/JB.176.9.2619-2626.1994; Cornelis G., 1992, SGM S, V49, P231; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; FORSBERG A, 1987, MICROB PATHOGENESIS, V2, P123, DOI 10.1016/0882-4010(87)90104-5; FORSBERG A, 1991, MOL MICROBIOL, V5, P977, DOI 10.1111/j.1365-2958.1991.tb00773.x; FORSBERG A, 1993, INFECT AGENT DIS, V2, P275; Forsberg Ake, 1994, Trends in Microbiology, V2, P14, DOI 10.1016/0966-842X(94)90339-5; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; Hakansson S, 1996, MOL MICROBIOL, V20, P593, DOI 10.1046/j.1365-2958.1996.5251051.x; HERMANT D, 1995, MOL MICROBIOL, V17, P781, DOI 10.1111/j.1365-2958.1995.mmi_17040781.x; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; MENARD R, 1994, EMBO J, V13, P5293, DOI 10.1002/j.1460-2075.1994.tb06863.x; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; Milton DL, 1996, J BACTERIOL, V178, P1310, DOI 10.1128/jb.178.5.1310-1319.1996; NORDFELTH R, UNPUB; OLSSON O, 1988, MOL GEN GENET, V215, P1, DOI 10.1007/BF00331295; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; RIMPILAINEN M, 1992, J BACTERIOL, V174, P3355, DOI 10.1128/jb.174.10.3355-3363.1992; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; ROSQVIST R, 1986, MICROB PATHOGENESIS, V1, P229, DOI 10.1016/0882-4010(86)90047-1; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; STRALEY SC, 1993, MOL MICROBIOL, V8, P1005, DOI 10.1111/j.1365-2958.1993.tb01644.x; STRALEY SC, 1993, INFECT IMMUN, V61, P3105, DOI 10.1128/IAI.61.8.3105-3110.1993; WATARAI M, 1995, EMBO J, V14, P2461, DOI 10.1002/j.1460-2075.1995.tb07243.x	26	331	336	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1231	1233		10.1126/science.273.5279.1231	http://dx.doi.org/10.1126/science.273.5279.1231			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703058				2022-12-24	WOS:A1996VE47600041
J	Richman, AD; Uyenoyama, MK; Kohn, JR				Richman, AD; Uyenoyama, MK; Kohn, JR			Allelic diversity and gene genealogy at the self-incompatibility locus in the solanaceae	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; LYCOPERSICON-PERUVIANUM; POPULATION-GENETICS; PAPAVER RHOEAS; S-ALLELES; NATURAL-POPULATIONS; SOLANUM-CHACOENSE; POLYMORPHISM; RIBONUCLEASE; VARIABILITY	The self-incompatibility (S) locus of flowering plants offers an example of extreme polymorphism maintained by balancing selection. Estimates of recent and long-term effective population size (N-e) were determined for two solanaceous species by examination of S-allele diversity. Estimates of recent N-e in two solanaceous species differed by an order of magnitude, consistent with difference in the species' ecology. In one species, the evidence was consistent with historical population restriction despite a large recent N-e. In the other, no severe bottleneck was indicated over millions of years. Bottlenecks are integral to founder-event speciation, and loci that are subject to balancing selection can be used to evaluate the frequency of this mode of speciation.	DUKE UNIV,DEPT ZOOL,DURHAM,NC 27708	Duke University	Richman, AD (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.			Uyenoyama, Marcy/0000-0001-8249-1103	NIGMS NIH HHS [GM 37841] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AI YJ, 1992, PLANT MOL BIOL, V19, P523, DOI 10.1007/BF00023404; AI YJ, 1990, SEX PLANT REPROD, V3, P130, DOI 10.1007/BF00198857; CHUNG IK, 1994, PLANT MOL BIOL, V26, P757, DOI 10.1007/BF00013760; CLARK AG, 1993, MECHANISMS OF MOLECULAR EVOLUTION, P79; CLARK AG, 1991, P NATL ACAD SCI USA, V88, P9823, DOI 10.1073/pnas.88.21.9823; CLARK KR, 1990, PLANT CELL, V2, P815, DOI 10.1105/tpc.2.8.815; Emerson S, 1939, GENETICS, V24, P524; FELSENSTEIN J, 1993, PHYLIP 3 5; HINATA K, 1995, GENETICS, V140, P1099; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; IDE H, 1991, FEBS LETT, V284, P161, DOI 10.1016/0014-5793(91)80675-S; IOERGER TR, 1990, P NATL ACAD SCI USA, V87, P9732, DOI 10.1073/pnas.87.24.9732; IOERGER TR, 1991, SEX PLANT REPROD, V4, P81; JOST W, 1991, EUR J BIOCHEM, V198, P1, DOI 10.1111/j.1432-1033.1991.tb15978.x; KAUFMANN H, 1991, MOL GEN GENET, V226, P457, DOI 10.1007/BF00260659; KHEYRPOUR A, 1990, SEX PLANT REPROD, V3, P88, DOI 10.1007/BF00198851; KLEIN D, 1993, NATURE, V364, P330, DOI 10.1038/364330a0; KLEIN J, 1993, J MED PRIMATOL, V22, P57; Kumar S, 1993, MOL EVOLUTIONARY GEN; LANE MD, 1993, HEREDITY, V71, P596, DOI 10.1038/hdy.1993.184; LAWRENCE MJ, 1993, HEREDITY, V71, P581, DOI 10.1038/hdy.1993.182; LEVIN DA, 1993, HEREDITY, V71, P193, DOI 10.1038/hdy.1993.124; LEWIS D, 1951, HEREDITY, V5, P399, DOI 10.1038/hdy.1951.39; MANTEL N, 1974, BIOMETRICS, V30, P355; NEI M, 1989, MOL BIOL EVOL, V6, P290; ODONNELL S, 1993, HEREDITY, V71, P591, DOI 10.1038/hdy.1993.183; OLMSTEAD RG, 1994, SYST BIOL, V43, P467, DOI 10.2307/2413546; PAXMAN GJ, 1963, GENETICS, V48, P1029; RICHMAN AD, 1995, HEREDITY, V75, P405, DOI 10.1038/hdy.1995.153; RICHMAN AD, IN PRESS HEREDITY; ROYO J, 1994, P NATL ACAD SCI USA, V91, P6511, DOI 10.1073/pnas.91.14.6511; ROYO J, 1994, PLANT PHYSIOL, V105, P751, DOI 10.1104/pp.105.2.751; SABAELLEIL MK, 1994, PLANT MOL BIOL, V24, P571, DOI 10.1007/BF00023555; TAKAHATA N, 1990, P NATL ACAD SCI USA, V87, P2419, DOI 10.1073/pnas.87.7.2419; TAKAHATA N, 1990, GENETICS, V124, P967; TAKAHATA N, 1993, MOL BIOL EVOL, V10, P2; TAKAHATA N, 1990, P NATL ACAD SCI USA, V87, P1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UYENOYAMA MK, 1995, GENETICS, V139, P975; VEKEMANS X, 1994, GENETICS, V137, P1157; WRIGHT S, 1960, BIOMETRICS, V16, P61, DOI 10.2307/2527956; Wright S, 1939, GENETICS, V24, P538; XU BB, 1990, MOL GEN GENET, V224, P341, DOI 10.1007/BF00262427; YOKOYAMA S, 1982, HEREDITY, V48, P299, DOI 10.1038/hdy.1982.35	44	133	134	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1212	1216		10.1126/science.273.5279.1212	http://dx.doi.org/10.1126/science.273.5279.1212			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8703052				2022-12-24	WOS:A1996VE47600035
J	Ramsay, LE; Haq, IU; Jackson, PR; Yeo, WW; Pickin, DM; Payne, JN				Ramsay, LE; Haq, IU; Jackson, PR; Yeo, WW; Pickin, DM; Payne, JN			Targeting lipid-lowering drug therapy for primary prevention of coronary disease: An updated Sheffield table	LANCET			English	Article							HEART-DISEASE; RISK		SHEFFIELD CTR HLTH & RELATED RES, MED CARE RES UNIT, SHEFFIELD, S YORKSHIRE, ENGLAND; SHEFFIELD HLTH, DEPT PUBL HLTH, SHEFFIELD, S YORKSHIRE, ENGLAND	University of Sheffield	Ramsay, LE (corresponding author), ROYAL HALLAMSHIRE HOSP, DEPT MED & PHARMACOL, SECT CLIN PHARMACOL & THERAPEUT, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND.		Payne, Nick/A-3073-2010	Yeo, Wilfred/0000-0001-9554-5203				GROVER SA, 1995, JAMA-J AM MED ASSOC, V274, P801, DOI 10.1001/jama.274.10.801; HAQ IU, 1995, LANCET, V346, P1467, DOI 10.1016/S0140-6736(95)92477-9; HAQ IU, IN PRESS CLIN SCI; PEDERSEN TR, 1994, LANCET, V344, P1383; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001	5	122	123	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 10	1996	348	9024					387	388		10.1016/S0140-6736(96)05516-X	http://dx.doi.org/10.1016/S0140-6736(96)05516-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VB426	8709740				2022-12-24	WOS:A1996VB42600016
J	PerezMartin, J; deLorenzo, V				PerezMartin, J; deLorenzo, V			ATP binding to the sigma(54)-dependent activator XyIR triggers a protein multimerization cycle catalyzed by UAS DNA	CELL			English	Article							INTEGRATION HOST FACTOR; TRANSCRIPTIONAL REGULATOR XYLR; RHIZOBIUM-MELILOTI DCTD; AMINO-TERMINAL DOMAIN; ESCHERICHIA-COLI; RNA-POLYMERASE; PSEUDOMONAS-PUTIDA; TOL PLASMID; AROMATIC-COMPOUNDS; TRUNCATED FORM	The events that take place at the prokaryotic enhancer of the Po promoter of Pseudomonas putida prior to the engagement of the sigma(54)-RNA polymerase (sigma(54)-RNAP) have been studied in vitro. ATP hydrolysis by XylR, the cognate regulator of the system, is preceded by the multimerization of XylR at the enhancer, which is itself triggered by the sole allosteric effect of ATP binding to the protein. Since ADP is unable to support multimerization, ATP hydrolysis might be followed by a return to the nonmultimerized state. This notion is supported further by the properties of mutant proteins that seem to be frozen, in either the nonmultimerized or the multimerized state, respectively. These results support a cyclic mechanism of ATP-dependent association/dissociation of XylR at the promoter UAS that precedes any involvement of the polymerase in transcription initiation.	CSIC,CTR INVEST BIOL,E-28049 MADRID,SPAIN; CSIC,CTR NACL BIOTECNOL,E-28049 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)			Perez-Martin, Jose/K-5117-2014	Perez-Martin, Jose/0000-0001-9849-7382; de Lorenzo, Victor/0000-0002-6041-2731				ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; AUSTIN S, 1990, EUR J BIOCHEM, V187, P353, DOI 10.1111/j.1432-1033.1990.tb15312.x; AUSTIN S, 1994, J BIOL CHEM, V269, P18141; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BERGER DK, 1994, P NATL ACAD SCI USA, V91, P103, DOI 10.1073/pnas.91.1.103; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P2212, DOI 10.1073/pnas.88.6.2212; DELGADO A, 1994, J BIOL CHEM, V269, P8059; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; FERNANDEZ S, 1995, MOL MICROBIOL, V16, P205, DOI 10.1111/j.1365-2958.1995.tb02293.x; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GU BH, 1994, MOL MICROBIOL, V13, P51, DOI 10.1111/j.1365-2958.1994.tb00401.x; HOOPER S, 1994, J BIOL CHEM, V269, P19597; HOOPER S, 1995, J BACTERIOL, V177, P2798; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KLOSE KE, 1993, J MOL BIOL, V232, P67, DOI 10.1006/jmbi.1993.1370; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; LEE HS, 1993, P NATL ACAD SCI USA, V90, P2266, DOI 10.1073/pnas.90.6.2266; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; LEE JH, 1994, J BIOL CHEM, V269, P20401; MARQUES S, 1993, MOL MICROBIOL, V9, P923, DOI 10.1111/j.1365-2958.1993.tb01222.x; Maxam A M, 1980, Methods Enzymol, V65, P499; METTKE I, 1995, J BACTERIOL, V177, P5056, DOI 10.1128/jb.177.17.5056-5061.1995; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; PerezMartin J, 1996, J MOL BIOL, V258, P562, DOI 10.1006/jmbi.1996.0269; PEREZMARTIN J, 1994, J BIOL CHEM, V269, P22657; PEREZMARTIN J, 1995, J BACTERIOL, V177, P3758, DOI 10.1128/jb.177.13.3758-3763.1995; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P9392, DOI 10.1073/pnas.92.20.9392; PerezMartin J, 1996, J MOL BIOL, V258, P575, DOI 10.1006/jmbi.1996.0270; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Porter SC, 1995, 2 COMPONENT SIGNAL T, P147; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGTH S, 1988, CELL, V62, P945; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Shingler V, 1996, MOL MICROBIOL, V19, P409, DOI 10.1046/j.1365-2958.1996.388920.x; SHINGLER V, 1994, J BACTERIOL, V176, P1555, DOI 10.1128/jb.176.6.1555-1560.1994; SHINGLER V, 1995, MOL MICROBIOL, V17, P505, DOI 10.1111/j.1365-2958.1995.mmi_17030505.x; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; WEBB MR, 1992, PHILOS T ROY SOC B, V336, P19, DOI 10.1098/rstb.1992.0039; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WOOTTON JC, 1989, PROTEIN ENG, V2, P535, DOI 10.1093/protein/2.7.535; XIAO YX, 1994, J BACTERIOL, V176, P1025, DOI 10.1128/JB.176.4.1025-1036.1994	55	75	75	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1996	86	2					331	339		10.1016/S0092-8674(00)80104-X	http://dx.doi.org/10.1016/S0092-8674(00)80104-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706137	Bronze			2022-12-24	WOS:A1996UZ97200018
J	Yang, XJ; Ogryzko, VV; Nishikawa, J; Howard, BH; Nakatani, Y				Yang, XJ; Ogryzko, VV; Nishikawa, J; Howard, BH; Nakatani, Y			A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A	NATURE			English	Article							NUCLEAR-PROTEIN CBP; TRANSCRIPTIONAL ADAPTERS; ACTIVATION; YEAST; CREB; DNA; NUCLEOSOME; DOMAINS; CELLS; P300	The adenoviral oncoprotein E1A induces progression through the cell cycle by binding to the products of the p300/CBP and retinoblastoma gene families. A new cellular p300/CBP-associated factor (P/CAF) having intrinsic histone acetylase activity has been identified that competes with E1A. Exogenous expression of P/CAF in HeLa cells inhibits cell-cycle progression and counteracts the mitogenic activity of E1A. E1A disturbs the normal cellular interaction between p300/CBP and its associated histone acetylase.	NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389				ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANISTER AJ, 1995, EMBO J, V14, P4758; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOWNELL JE, 1996, CELL, V84, P843; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1996, MOL CELL BIOL, V16, P593; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GIORDANO T, 1991, EXP CELL RES, V192, P193, DOI 10.1016/0014-4827(91)90175-T; Harlow E, 1988, ANTIBODIES LAB MANUA; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2063; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; OGRYZKO VV, 1994, J VIROL, V68, P3724, DOI 10.1128/JVI.68.6.3724-3732.1994; ROCHETTEEGLY C, 1990, GENE DEV, V5, P1200; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1	36	1302	1340	1	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1996	382	6589					319	324		10.1038/382319a0	http://dx.doi.org/10.1038/382319a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UY950	8684459				2022-12-24	WOS:A1996UY95000041
J	Barker, S				Barker, S			Brain science benefits from budget plan	NATURE			English	News Item																		1995, NATURE, V378, P227	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 11	1996	382	6587					105	105		10.1038/382105a0	http://dx.doi.org/10.1038/382105a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UW672	8700193	Bronze			2022-12-24	WOS:A1996UW67200015
J	Grewal, IS; Foellmer, HG; Grewal, KD; Xu, JC; Hardardottir, F; Baron, JL; Janeway, CA; Flavell, RA				Grewal, IS; Foellmer, HG; Grewal, KD; Xu, JC; Hardardottir, F; Baron, JL; Janeway, CA; Flavell, RA			Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis	SCIENCE			English	Article							DENDRITIC CELLS; IMMUNE-RESPONSES; TRANSGENIC MICE; ANTIGEN; EXPRESSION; RECEPTOR	The mechanism of CD40 ligand (CD40L)-mediated in vivo activation of CD4(+) T cells was examined by investigation of the development of experimental allergic encephalomyelitis (EAE) in CD40L-deficient mice that carried a transgenic T cell receptor specific for myelin basic protein. These mice failed to develop EAE after priming with antigen, and CD4(+) T cells remained quiescent and produced no inteferon-gamma (IFN-gamma). T cells were primed to make IFN-gamma and induce EAE by providing these mice with B7.1(+) antigen-presenting cells (APCs). Thus, CD40L is required to induce costimulatory activity on APCs for in vivo activation of CD4(+) T cells to produce IFN-gamma and to evoke autoimmunity.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,YALE NEUROTRANSPLANT PROGRAM,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University				Grewal, Iqbal S/0000-0002-4775-055X				Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Griggs ND, 1996, J EXP MED, V183, P801, DOI 10.1084/jem.183.3.801; HARDARDOTTIR F, 1995, P NATL ACAD SCI USA, V92, P354, DOI 10.1073/pnas.92.2.354; Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323; INABA K, 1994, J EXP MED, V180, P1849, DOI 10.1084/jem.180.5.1849; Jaiswal AI, 1996, INT IMMUNOL, V8, P275, DOI 10.1093/intimm/8.2.275; Kamanaka M, 1996, IMMUNITY, V4, P275, DOI 10.1016/S1074-7613(00)80435-5; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KEARNEY ER, 1995, J IMMUNOL, V155, P1032; Kennedy MK, 1996, EUR J IMMUNOL, V26, P370, DOI 10.1002/eji.1830260216; KUCHROO VK, 1994, J EXP MED, V179, P1659, DOI 10.1084/jem.179.5.1659; LUDEWING B, 1995, EUR J IMMUNOL, V22, P2855; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; MOUDGIL KD, 1993, J EXP MED, V178, P2131, DOI 10.1084/jem.178.6.2131; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; PEGUETNAVARRO J, 1995, J IMMUNOL, V155, P4241; ROY M, 1995, EUR J IMMUNOL, V25, P596, DOI 10.1002/eji.1830250243; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SCHEICHER C, 1995, EUR J IMMUNOL, V25, P1566, DOI 10.1002/eji.1830250615; SETHNA MP, 1994, IMMUNITY, V1, P415, DOI 10.1016/1074-7613(94)90072-8; SHU U, 1995, EUR J IMMUNOL, V25, P1125, DOI 10.1002/eji.1830250442; Stout RD, 1996, J IMMUNOL, V156, P8; Stuber E, 1996, J EXP MED, V183, P693, DOI 10.1084/jem.183.2.693; WU Y, 1995, CURR BIOL, V5, P1303, DOI 10.1016/S0960-9822(95)00257-0; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	28	369	380	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1864	1867		10.1126/science.273.5283.1864	http://dx.doi.org/10.1126/science.273.5283.1864			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791592				2022-12-24	WOS:A1996VJ71300046
J	Vandenberghe, R; Price, C; Wise, R; Josephs, O; Frackowiak, RSJ				Vandenberghe, R; Price, C; Wise, R; Josephs, O; Frackowiak, RSJ			Functional anatomy of a common semantic system for words and pictures	NATURE			English	Article							MEANING SYSTEMS; VISUAL AGNOSIA; OPTIC APHASIA; OBJECT; COMPREHENSION; VISION; BRAIN	THE relationship between the semantic processing of words and of pictures is a matter of debate among cognitive scientists(1,2). We studied the functional anatomy of such processing by using positron-emission tomography (PET). We contrasted activity during two semantic tasks (probing knowledge of associations between concepts, and knowledge of the visual attributes of these concepts) and a baseline task (discrimination of physical stimulus size), performed either with words or with pictures. Modality-specific activations unrelated to semantic processing occurred in the left inferior parietal lobule for words, and the right middle occipital gyrus for pictures. A semantic network common to both words and pictures extended from the left superior occipital gyrus through the middle and inferior temporal cortex to the inferior frontal gyrus. A picture-specific activation related to semantic tasks occurred in the left posterior inferior temporal sulcus, and word-specific activations related to semantic tasks were localized to the left superior temporal sulcus, left anterior middle temporal gyrus, and left inferior frontal sulcus. Thus semantic tasks activate a distributed semantic processing system shared by both words and pictures, with a few specific areas differentially active for either words or pictures.	INST NEUROL, WELLCOME DEPT COGNIT NEUROL, LONDON WC1N 3BG, ENGLAND	University of London; University College London			Vandenberghe, Rik/K-2145-2014; Frackowiak, Richard/H-4383-2011; Vandenberghe, Rik/AAR-7485-2020; Frackowiak, Richard S/I-1809-2013	Vandenberghe, Rik/0000-0001-6237-2502; Frackowiak, Richard/0000-0002-3151-822X; Vandenberghe, Rik/0000-0001-6237-2502; Price, Catherine/0000-0001-7448-4835	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERT ML, 1979, NEUROLOGY, V29, P876, DOI 10.1212/WNL.29.6.876; BEAUVOIS MF, 1982, PHILOS T R SOC B, V298, P35, DOI 10.1098/rstb.1982.0070; BUB DN, 1988, COGN NEUROPSYCHOL, V5, P27, DOI 10.1080/02643298808252926; BUTTERWORTH B, 1984, NEUROPSYCHOLOGIA, V22, P409, DOI 10.1016/0028-3932(84)90036-8; CAPTAN D, 1992, LANGUAGE STRUCTURE P, P63; CARAMAZZA A, 1990, COGNITIVE NEUROPSYCH, V7, P161, DOI 10.1080/02643299008253441; COLTHEART V, 1994, Q J EXP PSYCHOL-A, V47, P917, DOI 10.1080/14640749408401102; Damasio H, 1996, NATURE, V380, P499, DOI 10.1038/380499a0; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; Farah M.J., 1990, VISUAL AGNOSIA DISOR; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; GLASER WR, 1992, COGNITION, V42, P61, DOI 10.1016/0010-0277(92)90040-O; GOMORI AJ, 1984, NEUROLOGY, V34, P947, DOI 10.1212/WNL.34.7.947; Howard D., 1992, PYRAMIDS PALM TREES; LINDE J, 1982, J EXP PSYCHOL LEARN, V8, P584; MACK JL, 1977, NEUROPSYCHOLOGIA, V15, P345, DOI 10.1016/0028-3932(77)90044-6; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; Martin A, 1996, NATURE, V379, P649, DOI 10.1038/379649a0; MCCARTHY RA, 1988, NATURE, V334, P428, DOI 10.1038/334428a0; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; Price CJ, 1996, CEREB CORTEX, V6, P62, DOI 10.1093/cercor/6.1.62; Price CJ, 1996, NEUROIMAGE, V3, P40, DOI 10.1006/nimg.1996.0005; RIDDOCH MJ, 1987, COGN NEUROPSYCHOL, V4, P131, DOI 10.1080/02643298708252038; Shallice T., 1987, COGNITIVE NEUROPSYCH, P111; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; WARRINGTON EK, 1994, NEUROPSYCHOLOGIA, V32, P1465, DOI 10.1016/0028-3932(94)90118-X; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	30	962	979	4	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 19	1996	383	6597					254	256		10.1038/383254a0	http://dx.doi.org/10.1038/383254a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VH315	8805700	Green Accepted			2022-12-24	WOS:A1996VH31500052
J	Risch, N; Merikangas, K				Risch, N; Merikangas, K			The future of genetic studies of complex human diseases	SCIENCE			English	Editorial Material							TRAITS				Risch, N (corresponding author), STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305, USA.							LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; RISCH N, 1990, AM J HUM GENET, V46, P229; RISCH N, 1987, AM J HUM GENET, V40, P1; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506	4	3843	4038	17	281	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1996	273	5281					1516	1517		10.1126/science.273.5281.1516	http://dx.doi.org/10.1126/science.273.5281.1516			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8801636				2022-12-24	WOS:A1996VG59700028
J	Spina, M; MerloPich, E; Chan, RKW; Basso, AM; Rivier, J; Vale, W; Koob, GF				Spina, M; MerloPich, E; Chan, RKW; Basso, AM; Rivier, J; Vale, W; Koob, GF			Appetite-suppressing effects of urocortin, a CRF-related neuropeptide	SCIENCE			English	Article							CORTICOTROPIN-RELEASING-FACTOR; FACTOR-RECEPTOR; FUNCTIONAL EXPRESSION; EXPLORATORY-BEHAVIOR; FACTOR ANTAGONIST; BETA-ENDORPHIN; RAT-BRAIN; STRESS; SECRETION; PITUITARY	The neuropeptide corticotropin-releasing factor (CRF) is well known to act on the central nervous system in ways that mimic stress and result in decreases in exploration, increases in sympathetic activity, decreases in parasympathetic outflow, and decreases in appetitive behavior. Urocortin, a neuropeptide related to CRF, binds with high affinity to the CRF(2) receptor, is more potent than CRF in suppressing appetite, but is less potent than CRF in producing anxiety-like effects and activation. Doses as low as 10 nanograms injected intracerebroventricularly were effective in decreasing food intake in food-deprived and free-feeding rats. These results suggest that urocortin may be an endogenous CRF-like factor in the brain responsible for the effects of stress on appetite.	Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, NEURONAL STRUCT & FUNCT LAB, LA JOLLA, CA 92037 USA; SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Salk Institute; Salk Institute					FIC NIH HHS [1 F05 TW05262] Funding Source: Medline; NIDDK NIH HHS [DK 26741] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW005262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1994, SEMIN NEUROSCI; ANTONI FA, 1990, J ENDOCRINOL, V125, P175, DOI 10.1677/joe.0.1250175; BALDWIN HA, 1991, PSYCHOPHARMACOLOGY, V103, P227, DOI 10.1007/BF02244208; BERRIDGE CW, 1989, PHARMACOL BIOCHEM BE, V34, P517, DOI 10.1016/0091-3057(89)90551-0; BRITTON KT, 1986, LIFE SCI, V39, P1281, DOI 10.1016/0024-3205(86)90189-X; BRITTON KT, 1985, PSYCHOPHARMACOLOGY, V86, P170, DOI 10.1007/BF00431704; BURTON MJ, 1981, BRIT J PHARMACOL, V72, P621, DOI 10.1111/j.1476-5381.1981.tb09142.x; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Donaldson CJ, 1996, ENDOCRINOLOGY, V137, P2167, DOI 10.1210/en.137.5.2167; DUNN AJ, 1990, BRAIN RES REV, V15, P71, DOI 10.1016/0165-0173(90)90012-D; EAVES M, 1985, PEPTIDES, V6, P923, DOI 10.1016/0196-9781(85)90323-7; FISHER LA, 1983, REGUL PEPTIDES, V5, P153, DOI 10.1016/0167-0115(83)90123-4; FISHER LA, 1989, AM J PHYSIOL, V256, pH949, DOI 10.1152/ajpheart.1989.256.4.H949; GOSNELL BA, 1983, PHARMACOL BIOCHEM BE, V19, P771, DOI 10.1016/0091-3057(83)90078-3; GRINKER JA, 1980, PHARMACOL BIOCHEM BE, V12, P265, DOI 10.1016/0091-3057(80)90367-6; HEINRICHS SC, 1992, PEPTIDES, V13, P879, DOI 10.1016/0196-9781(92)90044-4; HEINRICHS SC, 1993, BRAIN RES, V611, P18, DOI 10.1016/0006-8993(93)91771-J; HEINRICHS SC, 1992, BRAIN RES, V581, P190, DOI 10.1016/0006-8993(92)90708-H; HENKE PG, 1991, DIGEST DIS SCI, V36, P1633, DOI 10.1007/BF01296409; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; KRAHN DD, 1986, BRAIN RES BULL, V17, P285, DOI 10.1016/0361-9230(86)90233-9; Lederis K., 1985, Recent Progress in Hormone Research, V41, P553; LENZ HJ, 1985, AM J PHYSIOL, V249, pR85; LEVINE AS, 1983, NEUROPHARMACOLOGY, V22, P337, DOI 10.1016/0028-3908(83)90249-6; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; MENZAGHI F, 1994, J PHARMACOL EXP THER, V269, P564; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; PERRIN MH, 1993, ENDOCRINOLOGY, V133, P3058, DOI 10.1210/en.133.6.3058; PICH EM, 1993, PSYCHONEUROENDOCRINO, V18, P495; PLOTSKY PM, 1991, J NEUROENDOCRINOL, V3, P1, DOI 10.1111/j.1365-2826.1991.tb00231.x; POTTER E, 1992, P NATL ACAD SCI USA, V89, P4192, DOI 10.1073/pnas.89.9.4192; RIVIER C, 1982, ENDOCRINOLOGY, V110, P272, DOI 10.1210/endo-110-1-272; SPINA ME, UNPUB; SUTTON RE, 1982, NATURE, V297, P331, DOI 10.1038/297331a0; TAKAHASHI LK, 1989, BEHAV NEUROSCI, V103, P648, DOI 10.1037/0735-7044.103.3.648; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V	40	513	519	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1996	273	5281					1561	1564		10.1126/science.273.5281.1561	http://dx.doi.org/10.1126/science.273.5281.1561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8703220				2022-12-24	WOS:A1996VG59700044
J	Zhang, Y; Feng, XH; Wu, RY; Derynck, R				Zhang, Y; Feng, XH; Wu, RY; Derynck, R			Receptor-associated Mad homologues synergize as effectors of the TGF-beta response	NATURE			English	Article							GROWTH-FACTOR-BETA; II RECEPTOR; PROTEIN; CLONING; COMPLEX; KINASE; CELLS; DPP	TRANSFORMING growth factor-beta TGP-Beta is the prototype for a family of extracellular proteins that affect cell proliferation and tissue differentiation(1-3). TGF-beta-related factors, including BMP-2/4, Dpp and activin, act through two types of serine/threonine kinase receptors which can form a heteromeric complex(3,4). However, the mechanism of signal transduction by these receptors is largely unknown. In Drosophila, Mad is required for signalling by Dpp(5). We have isolated complementary DNAs for four human Mad homologues, one of which, hMAD-4, is identical to DPC-4, a candidate tumour suppressor(6). hMAD-3 and -4 synergized to induce strong ligand-independent TGF-beta-like responses. When truncated at their carboxy termini, hMAD-3 and -4 act as dominant-negative inhibitors of the normal TGF-beta response. The activity of hMAD-3 and -4 was regulated by the TGF-beta receptors, and hMAD-3 but not hMAD-4 was phosphorylated and associated with the ligand-bound receptor complex. These results define hMAD-3 and -4 as effecters of the TGF-beta response and demonstrate a function for DPC-4/hMAD-4 as a tumour suppressor.	UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ARARA K, 1995, CELL, V81, P781; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1994, CYTOKINE HDB, P319; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HHOODLESS PA, 1996, CELL, V85, P489; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIKE B, 1986, J BIOL CHEM, V261, P3426; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P105, DOI 10.1016/0167-4781(92)90472-C; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P243; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	33	753	801	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					168	172		10.1038/383168a0	http://dx.doi.org/10.1038/383168a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774881				2022-12-24	WOS:A1996VG14800052
J	Macias, MJ; Hyvonen, M; Baraldi, E; Schultz, J; Sudol, M; Saraste, M; Oschkinat, H				Macias, MJ; Hyvonen, M; Baraldi, E; Schultz, J; Sudol, M; Saraste, M; Oschkinat, H			Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide	NATURE			English	Article							NMR-SPECTROSCOPY; IDENTIFICATION; DYSTROPHIN; RESONANCE; MODULES; SITE	THE WW domain is a new protein module with two highly conserved tryptophans that binds proline-rich peptide motifs in vitro. It is present in a number of signalling and regulatory proteins, often in several copies(1-3). Here we investigate the solution structure of the WW domain of human YAP65 (for Yes kinase-associated protein) in complex with proline-rich peptides containing the core motif PPxY (ref. 4). The structure of the domain with the bound peptide GTPPPPYTVG is a slightly curved, three-stranded, antiparallel beta-sheet. Two prolines pack against the first tryptophan, forming a hydrophobic buckle on the convex side of the sheet. The concave side has three exposed hydrophobic residues (tyrosine, tryptophan and leucine) which form the binding site for the ligand, A non-conserved isoleucine in the amino-terminal flanking region covers a hydrophobic patch and stabilizes the WW domain of human YAP65 irt vitro. The structure of the WW domain differs from that of the SH3 domain and reveals a new design for a protein module that uses stacked aromatic surface residues to arrange a binding site for proline-rich peptides.	EUROPEAN MOL BIOL LAB, D-69117 HEIDELBERG, GERMANY; FORSCHUNGSINST MOL PHARMAKOL, D-10315 BERLIN, GERMANY; MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA	European Molecular Biology Laboratory (EMBL); Icahn School of Medicine at Mount Sinai			baraldi, elena/I-7863-2012; Macias, Maria J/K-3898-2014	baraldi, elena/0000-0001-9496-0093; Macias, Maria J/0000-0002-6915-963X; Oschkinat, Hartmut/0000-0002-4384-9544				ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; BRUNGER AT, 1992, X PLOR 3 1 MANUAL; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; Gamier L, 1996, NATURE, V381, P744, DOI 10.1038/381744a0; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HOFMANN K, 1995, FEBS LETT, V358, P153, DOI 10.1016/0014-5793(94)01415-W; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAY LE, 1990, J MAGN RESON, V89, P496, DOI 10.1016/0022-2364(90)90333-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OTTING G, 1989, J MAGN RESON, V85, P586, DOI 10.1016/0022-2364(89)90249-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	27	362	371	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 15	1996	382	6592					646	649		10.1038/382646a0	http://dx.doi.org/10.1038/382646a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VC303	8757138				2022-12-24	WOS:A1996VC30300058
J	DiLaurenzio, L; WysockaDiller, J; Malamy, JE; Pysh, L; Helariutta, Y; Freshour, G; Hahn, MG; Feldmann, KA; Benfey, PN				DiLaurenzio, L; WysockaDiller, J; Malamy, JE; Pysh, L; Helariutta, Y; Freshour, G; Hahn, MG; Feldmann, KA; Benfey, PN			The SCARECROW gene regulates an asymmetric cell division that is essential for generating the radial organization of the Arabidopsis root	CELL			English	Article							PLANT GENES; TRANSCRIPTION; EXPRESSION; THALIANA; PROTEINS; MERISTEM; MARKERS	In the Arabidopsis root meristem, initial cells undergo asymmetric divisions to generate the cell lineages of the root. The scarecrow mutation results in roots that are missing one cell layer owing to the disruption of an asymmetric division that normally generates cortex and endodermis. Tissue-specific markers indicate that a heterogeneous cell type is formed in the mutant. The deduced amino acid sequence of SCARECROW (SCR) suggests that it is a member of a novel family of putative transcription factors. SCR is expressed in the cortex/endodermal initial cells and in the endodermal cell lineage. Tissue-specific expression is regulated at the transcriptional level. These results indicate a key role for SCR in regulating the radial organization of the root.	NYU, DEPT BIOL, NEW YORK, NY 10003 USA; UNIV GEORGIA, COMPLEX CARBOHYDRATE RES CTR, ATHENS, GA 30602 USA; UNIV ARIZONA, DEPT PLANT SCI, TUCSON, AZ 85721 USA	New York University; University System of Georgia; University of Georgia; University of Arizona			Hahn, Michael/AHC-5847-2022; Helariutta, Yrjo/AAE-8149-2020	Helariutta, Yrjo/0000-0002-7287-8459; Hahn, Michael/0000-0003-2136-5191	NIGMS NIH HHS [R01-GM43778] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043778] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AESCHBACHER RA, 1995, GENE DEV, V9, P330, DOI 10.1101/gad.9.3.330; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENFEY PN, 1993, DEVELOPMENT, V119, P57; BERRY JO, 1985, MOL CELL BIOL, V5, P2238, DOI 10.1128/MCB.5.9.2238; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DOLAN L, 1993, DEVELOPMENT, V119, P71; Esau K., 1977, Anatomy of seed plants.; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Freshour G, 1996, PLANT PHYSIOL, V110, P1413, DOI 10.1104/pp.110.4.1413; HEIDECKER G, 1986, ANNU REV PLANT PHYS, V37, P439, DOI 10.1146/annurev.arplant.37.1.439; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HURST HC, 1994, PROTEIN PROFILE, V1, P123; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; JARVIS P, 1994, PLANT MOL BIOL, V24, P685, DOI 10.1007/BF00023565; JOHNSON PF, 1993, J NUTR BIOCHEM, V4, P386, DOI 10.1016/0955-2863(93)90069-9; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KNOX JP, 1990, PLANTA, V181, P512, DOI 10.1007/BF00193004; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; Maniatis T., 1982, MOL CLONING; MAYER U, 1993, DEVELOPMENT, V117, P149; MeloOliveira R, 1996, P NATL ACAD SCI USA, V93, P4718, DOI 10.1073/pnas.93.10.4718; MOGEN BD, 1990, PLANT CELL, V2, P1261; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; PUHLMANN J, 1994, PLANT PHYSIOL, V104, P699, DOI 10.1104/pp.104.2.699; SCHERES B, 1995, DEVELOPMENT, V121, P53; TORRESRUIZ RA, 1994, DEVELOPMENT, V120, P2967; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213	31	763	811	6	108	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1996	86	3					423	433		10.1016/S0092-8674(00)80115-4	http://dx.doi.org/10.1016/S0092-8674(00)80115-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756724	hybrid			2022-12-24	WOS:A1996VC30900010
J	Li, ZW; Deutscher, MP				Li, ZW; Deutscher, MP			Maturation pathways for E-coli tRNA precursors: A random multienzyme process in vivo	CELL			English	Article							TRANSFER-RNA PRECURSORS; ESCHERICHIA-COLI; 3' TERMINUS; EXORIBONUCLEASES; ORGANIZATION; TRANSCRIPT; VIABILITY; GENES; K-12; PH	tRNA maturation consists of the specific removal of precursor sequences from both the 5' and 3' termini of an initial RNA transcript. How this is accomplished has heretofore not been ascertained in any system. Using Northern analysis of RNA isolated from a variety of RNase-deficient E. coli strains, we have identified the processing intermediates that accumulate in the absence of specific processing nucleases. From this information we have established the maturation pathways for 12 different E. coli tRNAs including the specific role of each of the relevant RNases in the process. The surprising conclusion from this work is that tRNA maturation is a stochastic process that lacks a defined order and that can proceed with a variety of alternative 3' processing nucleases.	UNIV CONNECTICUT,CTR HLTH,DEPT BIOCHEM,FARMINGTON,CT 06030	University of Connecticut					NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1987, MOL BIOL RNA NEW PER, P3; Altman Sidney, 1995, P67; AN G, 1980, GENE, V12, P13; BASL M, 1991, NUCLEIC ACIDS RES, V19, P5863; BIKOFF EK, 1975, J BIOL CHEM, V250, P6240; Coburn GA, 1996, J BIOL CHEM, V271, P1048, DOI 10.1074/jbc.271.2.1048; CUDNY H, 1980, P NATL ACAD SCI-BIOL, V77, P837, DOI 10.1073/pnas.77.2.837; DEUTSCHE.MP, 1974, J BACTERIOL, V118, P621, DOI 10.1128/JB.118.2.621-627.1974; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; Deutscher Murray P., 1995, P51; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; FOURNIER MJ, 1985, MICROBIOL REV, V49, P379, DOI 10.1128/MMBR.49.4.379-397.1985; KELLY KO, 1992, J BIOL CHEM, V267, P17153; KELLY KO, 1992, J BACTERIOL, V174, P6682, DOI 10.1128/JB.174.20.6682-6684.1992; KELLY KO, 1992, J BIOL CHEM, V267, P16015; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883; LI ZW, 1994, J BIOL CHEM, V269, P6064; REUVEN NB, 1993, FASEB J, V7, P143, DOI 10.1096/fasebj.7.1.8422961; ROSSI J, 1981, CELL, V26, P305, DOI 10.1016/0092-8674(81)90199-9; SCHEDL P, 1976, CELL, V8, P581, DOI 10.1016/0092-8674(76)90226-9; SEKIYA T, 1979, J BIOL CHEM, V254, P5802	25	156	157	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					503	512		10.1016/S0092-8674(00)80123-3	http://dx.doi.org/10.1016/S0092-8674(00)80123-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756732	hybrid			2022-12-24	WOS:A1996VC30900018
J	Molenaar, M; vandeWetering, M; Oosterwegel, M; PetersonMaduro, J; Godsave, S; Korinek, V; Roose, J; Destree, O; Clevers, H				Molenaar, M; vandeWetering, M; Oosterwegel, M; PetersonMaduro, J; Godsave, S; Korinek, V; Roose, J; Destree, O; Clevers, H			XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos	CELL			English	Article							WINGLESS SIGNALING PATHWAY; HMG-BOX; ALPHA-ENHANCER; EXPRESSION CLONING; CYTOPLASMIC DOMAIN; ACTIVATION DOMAIN; SPEMANN ORGANIZER; CELL-ADHESION; E-CADHERIN; GENE	XTcf-3 is a maternally expressed Xenopus homolog of the mammalian HMG box factors Tcf-1 and Lef-1 The N-terminus of XTcf-3 binds to beta-catenin. Microinjection of XTcf-3 mRNA in embryos results in nuclear translocation of beta-catenin. The beta-catenin-XTcf-3 complex activates transcription in a transient reporter gene assay, while XTcf-3 by itself is silent. N-terminal deletion of XTcf-3 (Delta N) abrogates the interaction with beta-catenin, as well as the consequent transcription activation. This dominant-negative Delta N mutant suppresses the induction of axis duplication by microinjected Delta-catenin. It also suppresses endogenous axis specification upon injection into the dorsal blastomeres of a 4-cell-stage embryo. We propose that signaling by beta-catenin involves complex formation with XTcf-3, followed by nuclear translocation and activation of specific XTcf-3 target genes.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Molenaar, M (corresponding author), UNIV UTRECHT HOSP,DEPT IMMUNOL,POB 85500,NL-3508 GA UTRECHT,NETHERLANDS.		Korinek, Vladimir/G-6348-2014	Korinek, Vladimir/0000-0002-9777-4664; Roose, Jeroen/0000-0003-4746-2811				BEUMER TL, 1995, TRENDS GENET, V11, P9, DOI 10.1016/S0168-9525(00)88978-7; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CASTROP J, 1995, BLOOD, V86, P3050, DOI 10.1182/blood.V86.8.3050.bloodjournal8683050; CASTROP J, 1992, NUCLEIC ACIDS RES, V20, P611, DOI 10.1093/nar/20.3.611; CASTROP J, 1992, EUR J IMMUNOL, V22, P1327; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DESTREE OHJ, 1992, DEV BIOL, V153, P141, DOI 10.1016/0012-1606(92)90098-2; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GAO ZM, 1994, ONCOGENE, V9, P573; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Huelsken Joerg, 1994, Journal of Cell Biology, V127, P2061; Joore J, 1996, MECH DEVELOP, V55, P3, DOI 10.1016/0925-4773(95)00481-5; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KINTNER CR, 1987, DEVELOPMENT, V99, P311; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SOKOL SY, 1995, DEVELOPMENT, V121, P3487; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VEENSTRA GJC, 1995, MECH DEVELOP, V50, P103, DOI 10.1016/0925-4773(94)00328-K; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656	41	1575	1638	1	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1996	86	3					391	399		10.1016/S0092-8674(00)80112-9	http://dx.doi.org/10.1016/S0092-8674(00)80112-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VC309	8756721	Green Submitted, Bronze			2022-12-24	WOS:A1996VC30900007
J	Smith, PG; Cousens, SN				Smith, PG; Cousens, SN			Is the new variant of Creutzfeldt-Jakob disease from mad cows?	SCIENCE			English	Editorial Material											Smith, PG (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		smith, peter/ABH-9627-2020	smith, peter/0000-0003-0080-7560				ALLEN IV, 1993, BR MED B, V49; BRADLEY R, 1993, BRIT MED BULL, V49, P932, DOI 10.1093/oxfordjournals.bmb.a072654; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; *MIN AGR FOOD FISH, 1989, REP WORK PART BOV SP; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	6	5	5	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1996	273	5276					748	748		10.1126/science.273.5276.748	http://dx.doi.org/10.1126/science.273.5276.748			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VB429	8701324				2022-12-24	WOS:A1996VB42900025
J	Mallonee, S; Shariat, S; Stennies, G; Waxweiler, R; Hogan, D; Jordan, F				Mallonee, S; Shariat, S; Stennies, G; Waxweiler, R; Hogan, D; Jordan, F			Physical injuries and fatalities resulting from the Oklahoma City bombing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLAST INJURY; TERRORIST; CASUALTIES; EXPLOSION	Objective.-To provide an epidemiologic description of physical injuries and fatalities resulting from the April 19, 1995, bombing of the Alfred P. Murrah Federal Building in Oklahoma City. Design and Setting.-Descriptive epidemiologic study of all persons injured by the bombing and of all at-risk occupants of the federal building and 4 adjacent buildings. Data were gathered from hospital emergency and medical records departments, medical examiner records. and surveys of area physicians. building occupants, and survivors. Study Population.-All persons known to have been exposed to the blast. Main Outcome Measures.-Characteristics of fatalities and injuries, injury maps, and injury rates by building location. Results.-A total of 759 persons sustained injuries. 167 persons died. 83 survivors were hospitalized, and 509 persons were treated as outpatients, Of the 361 persons who were in the federal building, 319 (88%) were injured, of whom 163 (45%) died. including 19 children. Persons in the collapsed part of the federal building were significantly more likely to die (153/175, 87%) than those in other parts of the building (10/186, 5%) (risk ratio [RR], 16.3, 95% confidence interval [CI], 8.9-29.8). In 4 adjacent buildings, injury rates varied from 38% to 100%; 3 persons in these buildings and 1 person in an outdoor location died. The mast frequent cause of death was multiple injuries. Among survivors, soft tissue injuries, fractures, sprains, strains, and head injuries were most common: these injuries were most often caused by flying glass and other debris and collapsed ceilings. Conclusions.-The Oklahoma City bombing resulted in the largest number of fatalities of any terrorist act in the United Stales, and there were 4 times as many nonfatal injuries as fatalities, Disaster management plans should include the possibility of terrorist bombing, and medical preparedness should anticipate that most injuries will be nonfatal, The role of building collapse in fatal injuries and the role of glass and other flying debris in minor to moderate injuries should be considered in the design of buildings at high risk of being bombed so as to reduce injuries.	CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341; UNIV OKLAHOMA,COLL MED,OKLAHOMA CITY,OK; OFF CHIEF MED EXAMINER,OKLAHOMA CITY,OK	Centers for Disease Control & Prevention - USA; University of Oklahoma System; University of Oklahoma Health Sciences Center	Mallonee, S (corresponding author), OKLAHOMA DEPT HLTH,INJURY PREVENT SERV 0307,1000 NE 10TH ST,OKLAHOMA CITY,OK 73177, USA.							ADLER J, 1983, ISRAEL J MED SCI, V19, P189; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; *AUT INC, 1994, AUT REL 13; BELLAMY RF, 1991, CONVENTIONAL WARFA 1, V5, P2; Boffard K D, 1993, Surg Annu, V25 Pt 1, P29; BRYSMAR B, 1982, J TRAUMA, V22, P216; COOPER GJ, 1983, J TRAUMA, V23, P955, DOI 10.1097/00005373-198311000-00001; *CTR DIS CONTR PRE, 1994, EPI INF VERS 6; *FED BUR INV, 1995, 1994 BOMB SUMM; FRYKBERG ER, 1989, AM SURGEON, V55, P134; FRYKBERG ER, 1988, ANN SURG, V28, P569; HADDEN WA, 1978, BRIT J SURG, V65, P525, DOI 10.1002/bjs.1800650802; HILL JF, 1979, ANN ROY COLL SURG, V61, P4; HULL J B, 1992, Journal of Audiovisual Media in Medicine, V15, P121, DOI 10.3109/17453059209018366; KARMYJONES R, 1994, MIL MED, V159, P536, DOI 10.1093/milmed/159.7.536; KATZ E, 1989, ANN SURG, V209, P484, DOI 10.1097/00000658-198904000-00016; MCMANAMY R, 1995, ENG NEWS RECORD 0501, P10; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; Mellor S G, 1988, Br J Hosp Med, V39, P536; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; National Research Council, 1995, PROT BUILD BOMB DAM; Phillips Y.Y., 1991, CONVENTIONAL WARFARE, P221; SCOTT BA, 1986, NEUROSURGERY, V18, P107, DOI 10.1227/00006123-198601000-00020; STAPCZYNSKI JS, 1992, ANN EMERG MED, V11, P687; WHITE CS, 1968, ANN NY ACAD SCI, V152, P89, DOI 10.1111/j.1749-6632.1968.tb11969.x; WOLF M, 1991, MIL MED, V156, P651, DOI 10.1093/milmed/156.12.651	26	174	177	2	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 7	1996	276	5					382	387		10.1001/jama.276.5.382	http://dx.doi.org/10.1001/jama.276.5.382			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UZ776	8683816				2022-12-24	WOS:A1996UZ77600019
J	Ducy, P; Desbois, C; Boyce, B; Pinero, G; Story, B; Dunstan, C; Smith, E; Bonadio, J; Goldstein, S; Gundberg, C; Bradley, A; Karsenty, G				Ducy, P; Desbois, C; Boyce, B; Pinero, G; Story, B; Dunstan, C; Smith, E; Bonadio, J; Goldstein, S; Gundberg, C; Bradley, A; Karsenty, G			Increased bone formation in osteocalcin-deficient mice	NATURE			English	Article							MATRIX GLA PROTEIN; RAT BONE; MOUSE; EXPRESSION; GENE; INTERLEUKIN-6; OSTEOPONTIN; OSTEOCLASTS; MARKER; FORM	VERTEBRATES constantly remodel bone. The resorption of preexisting bone by osteoclasts and the formation of new hone by osteoblasts is strictly coordinated to maintain bone mass within defined limits. A fen molecular determinants of bone remodelling that affect osteoclast activity(1-3) have been characterized, bot the molecular determinants of osteoblast activity are unknown. To investigate the role of osteocalcin, the most abundant osteoblast-specific non-collagenous protein(4) we have generated osteocalcin-deficient mice. These mice develop a phenotype marked by higher bone mass and bones of Improved functional quality. Histomorphometric studies done before and after ovariectomy showed that the absence of osteocalcin leads to an increase in bone formation without impairing bone resorption. To our knowledge, this study provides the first evidence that osteocalcin is a determinant of bone formation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284; UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; UNIV TEXAS,DENT BRANCH,DEPT BASIC SCI,HOUSTON,TX 77030; UNIV MICHIGAN,SCH MED,DEPT ORTHOPAED,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; YALE UNIV,SCH MED,DEPT ORTHOPAED,NEW HAVEN,CT 06510; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Yale University; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine			Dunstan, Colin/G-6214-2013; Morris, Christelle/M-8168-2014	Dunstan, Colin/0000-0001-7586-4071; Morris, Christelle/0000-0003-1575-4609; Bradley, Allan/0000-0002-2349-8839				ANDERSSON GN, 1989, J HISTOCHEM CYTOCHEM, V37, P115, DOI 10.1177/37.1.2461980; BAIN SD, 1993, J BONE MINER RES, V8, P435; BOIVIN G, 1990, VIRCHOWS ARCH A, V417, P505, DOI 10.1007/BF01625731; BONADIO J, 1990, P NATL ACAD SCI USA, V87, P7145, DOI 10.1073/pnas.87.18.7145; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; GRIGORIADIS AE, 1994, SCIENCE, V266, P143; GUNDBERG CM, 1984, METHOD ENZYMOL, V107, P516; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; LUO GB, 1995, J BONE MINER RES, V10, P325; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096; PARFITT AM, 1988, OSTEOPOROSIS ETIOLOG, P501; Partlow D. P., 1987, Journal of Materials Research, V2, P595, DOI 10.1557/JMR.1987.0595; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; SONANO P, 1991, CELL, V64, P693; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; VIGNERY A, 1980, ANAT REC, V196, P191, DOI 10.1002/ar.1091960210; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WEINREB M, 1990, J BONE MINER RES, V5, P831	25	1255	1319	1	107	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 1	1996	382	6590					448	452		10.1038/382448a0	http://dx.doi.org/10.1038/382448a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VA251	8684484	Green Submitted			2022-12-24	WOS:A1996VA25100056
J	Alcedo, J; Ayzenzon, M; VonOhlen, T; Noll, M; Hooper, JE				Alcedo, J; Ayzenzon, M; VonOhlen, T; Noll, M; Hooper, JE			The Drosophila smoothened gene encodes a seven-pass membrane protein, a putative receptor for the hedgehog signal	CELL			English	Article							SEGMENT-POLARITY GENE; KINASE-A; CELL FATE; WINGLESS TRANSCRIPTION; TRANSMEMBRANE DOMAINS; LARVAL CUTICLE; NERVOUS-SYSTEM; IMAGINAL DISKS; PATCHED GENE; ZYGOTIC LOCI	smoothened(smo) is a segment polarity gene required for correct patterning of every segment in Drosophila. The earliest defect in smo mutant embryos is loss of expression of the Hedgehog-responsive gene wingless between 1 and 2 hr after gastrulation. Since smo mutant embryos cannot respond to exogenous Hedgehog (Hh) but can respond to exogenous Wingless, the Smo product functions in Hh signaling. Smo acts downstream of or in parallel to Patched, an antagonist of the Hh signal. The smo gene encodes an integral membrane protein with characteristics of G protein-coupled receptors and shows homology to the Drosophila Frizzled protein. Based on its predicted physical characteristics and on its position in the Hh signaling pathway, we suggest that smo encodes a receptor for the Hh signal.	UNIV COLORADO, HLTH SCI CTR, DEPT CELLULAR & STRUCT BIOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Alcedo, J (corresponding author), UNIV ZURICH, INST MOL BIOL 2, CH-8057 ZURICH, SWITZERLAND.			Alcedo, Joy/0000-0002-5279-6640	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045396, R01GM045396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS AM, 1988, DEVELOPMENT, V103, P157; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; FORBES AJ, 1993, DEVELOPMENT, P115; FREI E, 1985, EMBO J, V4, P979, DOI 10.1002/j.1460-2075.1985.tb03727.x; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GLASS DB, 1986, J BIOL CHEM, V261, P2987; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; Harlow E, 1988, ANTIBODIES LAB MANUA; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HIDALGO A, 1991, MECH DEVELOP, V35, P77, DOI 10.1016/0925-4773(91)90059-F; HIDALGO A, 1990, DEVELOPMENT, V110, P291; Hofmann K., 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOOPER JE, 1994, NATURE, V372, P461, DOI 10.1038/372461a0; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JIANG J, 1991, GENE DEV, V5, P265, DOI 10.1101/gad.5.2.265; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Johnson RL, 1995, DEVELOPMENT, V121, P4161; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; LIMBOURGBOUCHON B, 1991, DEVELOPMENT, V112, P417; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Maniatis T., 1982, MOL CLONING; MARTINEZARIAS A, 1985, NATURE, V313, P639, DOI 10.1038/313639a0; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PARK WJ, 1994, MECH DEVELOP, V45, P127, DOI 10.1016/0925-4773(94)90026-4; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; PIRROTTA V, 1988, VECTORS SURVEY MOL C; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; PREAT T, 1993, GENETICS, V135, P1047; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAMPEDRO J, 1991, NATURE, V353, P187, DOI 10.1038/353187a0; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; SCHUSKE K, 1994, DEV BIOL, V164, P300, DOI 10.1006/dbio.1994.1200; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Small S, 1991, CURR OPIN GENET DEV, V1, P255, DOI 10.1016/S0959-437X(05)80079-6; STJOHNSTON D, 1992, CELL, V68, P201; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; VANDENHEUVEL M, 1993, DEVELOPMENT, P105; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wang YS, 1996, J BIOL CHEM, V271, P4468; WILDER EL, 1995, DEVELOPMENT, V121, P477; YOFFE KB, 1995, DEV BIOL, V170, P636, DOI 10.1006/dbio.1995.1243; ZHANG Y, 1994, DEVELOPMENT, V120, P1151; ZHAO ZY, 1995, GENOMICS, V27, P370, DOI 10.1006/geno.1995.1060	86	474	513	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 26	1996	86	2					221	232		10.1016/S0092-8674(00)80094-X	http://dx.doi.org/10.1016/S0092-8674(00)80094-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UZ972	8706127	Bronze			2022-12-24	WOS:A1996UZ97200008
J	Ortiz, Z; Tugwell, P				Ortiz, Z; Tugwell, P			Raised ESR in polymyalgia rheumatica no longer a sine qua non?	LANCET			English	Editorial Material							GIANT-CELL ARTERITIS; MANAGEMENT				Ortiz, Z (corresponding author), OTTAWA GEN HOSP,DEPT MED,OTTAWA,ON K1H 8LG,CANADA.		Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556				AYOUB WT, 1985, AM J MED, V79, P309, DOI 10.1016/0002-9343(85)90309-2; BYRON M, 1983, OXFORD TXB MED, P27; CHUANG T, 1985, ANN INTERN MED, V97, P672; COHEN MD, 1990, RHEUM DIS CLIN N AM, V16, P325; ELLIS ME, 1983, ANN RHEUM DIS, V42, P168, DOI 10.1136/ard.42.2.168; HAMILTON CR, 1971, MEDICINE, V50, P1, DOI 10.1097/00005792-197101000-00001; Helfgott SM, 1996, ARTHRITIS RHEUM, V39, P304, DOI 10.1002/art.1780390220; JONES JG, 1981, ANN RHEUM DIS, V40, P1, DOI 10.1136/ard.40.1.1; SUEIRO JLF, 1994, ARTHRITIS RHEUM S9, V37, P410; ZLONIS M, 1993, CLIN LAB MED, V13, P787, DOI 10.1016/S0272-2712(18)30408-6	10	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 6	1996	348	9019					4	5		10.1016/S0140-6736(05)64350-4	http://dx.doi.org/10.1016/S0140-6736(05)64350-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UV923	8691933				2022-12-24	WOS:A1996UV92300005
